{"title": "PDF", "author": "PDF", "url": "https://gredos.usal.es/bitstream/10366/139786/1/REDUCIDA_Anticuerpos.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "\u00a0\n\u00a0\n\u00a0Departamento\u00a0de\u00a0Medicina\u00a0\nCentro\u00a0de\u00a0Investigaci\u00f3n\u00a0del\u00a0C\u00e1ncer\u00a0\nInstituto\u00a0de\u00a0Investigaci\u00f3n\u00a0Biom\u00e9dica\u00a0de\u00a0Salamanca\u00a0\n\u00a0\nDESARROLLO\u00a0DE\u00a0NUEVAS\u00a0ESTRATEGIAS\u00a0\nPARA\u00a0DIAGN\u00d3STICO\u00a0Y\u00a0CLASIFICACI\u00d3N\u00a0DE\u00a0\nINMUNODEFICIENCIAS\u00a0\nPREDOMINANTEMENTE\u00a0DE\u00a0\nANTICUERPOS\u00a0\u00a0\n\u00a0\nElena\u00a0Blanco\u00a0\u00c1lvarez\u00a0\n\u00a0\n\u00a0\nDirectores:\u00a0\nProf.\u00a0Mart\u00edn\u00a0P\u00e9rez\u00a0Andr\u00e9s\u00a0\nProf.\u00a0Alberto\u00a0Orfao\u00a0\u00a0\n\u00a0\n\u00a0\nTesis\u00a0doctoral\u00a0\n2018\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n \n \nDepartamento de Medicina  \nD.\u00a0 Mart\u00edn\u00a0 P\u00e9rez\u00a0 Andr\u00e9s,\u00a0 Doctor\u00a0 en\u00a0 Medicina\u00a0 y\u00a0 Profesor\u00a0 Contratad o\u00a0 Doctor\u00a0 del\u00a0\nDepartamento\u00a0de\u00a0Medicina\u00a0de\u00a0la\u00a0Universidad\u00a0de\u00a0Salamanca.\u00a0\n\u00a0CERTIFICA:\u00a0Que\u00a0el\u00a0trabajo\u00a0de\u00a0tesis\u00a0doctoral\u00a0realizado\u00a0en\u00a0formato\u00a0de\u00a0compen dio\u00a0de\u00a0art\u00edculos\u00a0bajo\u00a0mi\u00a0\ndirecci\u00f3n\u00a0por\u00a0D\u00f1a.\u00a0Elena\u00a0Blanco\u00a0\u00c1lvarez\u00a0y\u00a0titulado\u00a0\u201c Desarrollo\u00a0de\u00a0nuevas\u00a0estrategias\u00a0para\u00a0\ndiagn\u00f3stico\u00a0y\u00a0clasificaci\u00f3n\u00a0de\u00a0inmunodeficiencias\u00a0predominantem ente\u00a0de\u00a0anticuerpos \u201d,\u00a0re\u00fane\u00a0\nlas\u00a0condiciones\u00a0de\u00a0originalidad\u00a0requeridas\u00a0para\u00a0optar\u00a0al\u00a0grado\u00a0 de\u00a0Doctor\u00a0por\u00a0el\u00a0programa\u00a0\n\u201cBiociencias:\u00a0Biolog\u00eda\u00a0y\u00a0Cl\u00ednica\u00a0del\u00a0C\u00e1ncer\u00a0y\u00a0Medicina\u00a0Traslaci onal\u201d\u00a0de\u00a0la\u00a0Universidad\u00a0de\u00a0\nSalamanca.\u00a0\n\u00a0\u00a0\u00a0 Y\u00a0para\u00a0que\u00a0as\u00ed\u00a0conste\u00a0firmo\u00a0la\u00a0presente\u00a0certificaci\u00f3n\u00a0en\u00a0Salam anca\u00a0a\u00a05\u00a0de\u00a0Junio\u00a0de\u00a0\n2018.\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\nFdo.:\u00a0Prof.\u00a0Mart\u00edn\u00a0P\u00e9rez\u00a0Andr\u00e9s\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nDepartamento de Medicina \n\u00a0\nD.\u00a0Jos\u00e9\u00a0Alberto\u00a0Orf \u00e3o\u00a0de\u00a0Matos\u00a0Correia\u00a0e\u00a0Vale,\u00a0Doctor\u00a0en\u00a0Medicina\u00a0y\u00a0Cirug\u00eda\u00a0y\u00a0Cated r\u00e1tico\u00a0\ndel\u00a0Departamento\u00a0de\u00a0Medicina\u00a0d e\u00a0la\u00a0Universidad\u00a0de\u00a0Salamanca\u00a0\n\u00a0\nCERTIFICA:\u00a0\nQue\u00a0el\u00a0trabajo\u00a0de\u00a0tesis\u00a0doctoral\u00a0realizado\u00a0en\u00a0formato\u00a0de\u00a0compen dio\u00a0de\u00a0art\u00edculos\u00a0bajo\u00a0mi\u00a0\ndirecci\u00f3n\u00a0por\u00a0D\u00f1a.\u00a0Elena\u00a0Blanco\u00a0\u00c1lvarez\u00a0y\u00a0titulado\u00a0\u201c Desarrollo\u00a0de\u00a0nuevas\u00a0estrategias\u00a0para\u00a0\ndiagn\u00f3stico\u00a0y\u00a0clasificaci\u00f3n\u00a0de\u00a0inmunodeficiencias\u00a0predominantem ente\u00a0de\u00a0anticuerpos \u201d,\u00a0re\u00fane\u00a0\nlas\u00a0condiciones\u00a0de\u00a0originalidad\u00a0requeridas\u00a0para\u00a0optar\u00a0al\u00a0grado\u00a0 de\u00a0Doctor\u00a0por\u00a0el\u00a0programa\u00a0\n\u201cBiociencias:\u00a0Biolog\u00eda\u00a0y\u00a0Cl\u00ednica\u00a0del\u00a0C\u00e1ncer\u00a0y\u00a0Medicina\u00a0Traslaci onal\u201d\u00a0de\u00a0la\u00a0Universidad\u00a0de\u00a0\nSalamanca.\u00a0\n\u00a0\u00a0\u00a0 Y\u00a0para\u00a0que\u00a0as\u00ed\u00a0conste\u00a0firmo\u00a0la\u00a0presente\u00a0certificaci\u00f3n\u00a0en\u00a0Salam anca\u00a0a\u00a05\u00a0de\u00a0Junio\u00a0de\u00a0\n2018.\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\nFdo.:\u00a0Prof.\u00a0Jos\u00e9\u00a0Alberto\u00a0Orf \u00e3o\u00a0de\u00a0Matos\u00a0Correia\u00a0e\u00a0Vale\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0Esta\u00a0Tesis\u00a0Doctoral\u00a0fue\u00a0desarrollada\u00a0siendo\u00a0Elena\u00a0Blanco\u00a0\u00c1lvare z\u00a0beneficiaria\u00a0de\u00a0una\u00a0 \u201cAyuda\u00a0\nPredoctoral\u00a0de\u00a0la\u00a0Junta\u00a0de\u00a0Castilla\u00a0y\u00a0Le\u00f3n\u201d\u00a0 financiada\u00a0por\u00a0el\u00a0Fondo\u00a0Social\u00a0Europeo\u00a0(JCYL\u2010\nEDU/346/2013).\u00a0\nPara\u00a0el\u00a0desarrollo\u00a0de\u00a0esta\u00a0tesis\u00a0doctoral\u00a0se\u00a0ha\u00a0contado\u00a0con\u00a0el\u00a0 apoyo\u00a0(financiaci\u00f3n\u00a0por\u00a0\nproyectos,\u00a0 utilizaci\u00f3n\u00a0 de\u00a0 infraestructuras\u00a0 y/o\u00a0 cesi\u00f3n\u00a0 de\u00a0 muestr as)\u00a0 de\u00a0 las\u00a0 siguientes\u00a0\ninstituciones:\u00a0\n- Fondo\u00a0de\u00a0Investigaci\u00f3n\u00a0Sanitaria\u00a0(FIS)\u00a0del\u00a0Instituto\u00a0de\u00a0Salud\u00a0C arlos\u00a0III\u00a0(Ministerio\u00a0de\u00a0\nEconom\u00eda,\u00a0 Industria\u00a0 y\u00a0 Competitividad)\u2010FEDER\u00a0 (Fondo\u00a0 Europeo\u00a0 de\u00a0 D esarrollo\u00a0\nRegional):\u00a0PI12/00905.\u00a0\n- CIBERONC\u00a0(Instituto\u00a0de\u00a0Salud\u00a0 Carlos\u00a0III):\u00a0CB16/12/00400.\u00a0\n- Fundaci\u00f3n\u00a0Mutua\u00a0Madrile\u00f1a:\u00a0AP119882013.\u00a0\n- Servicio\u00a0General\u00a0de\u00a0Citometr\u00eda\u00a0( NUCLEUS)\u00a0de\u00a0la\u00a0Universidad\u00a0de\u00a0S alamanca.\u00a0\n- Servicios\u00a0 de\u00a0 Pediatr\u00eda,\u00a0 Alergia,\u00a0 Hematolog\u00eda,\u00a0 Medicina\u00a0 Interna, \u00a0B i o q u \u00ed m i c a \u00a0y \u00a0\nOtorrinolaringolog\u00eda,\u00a0y\u00a0la\u00a0unidad\u00a0de\u00a0Neonatolog\u00eda\u00a0del\u00a0Hospital\u00a0 Cl\u00ednico\u00a0Universitario\u00a0\nde\u00a0Salamanca.\u00a0\n- Consorcio\u00a0 EuroFlow\u2010PID:\u00a0 Departamento\u00a0 de\u00a0 Inmunolog\u00eda,\u00a0 Centro\u00a0 M\u00e9d ico\u00a0 de\u00a0 la\u00a0\nUniversidad\u00a0 Erasmus,\u00a0 Rotterdam,\u00a0 P a \u00ed s e s \u00a0B a j o s ; \u00a0\u00a0D e p a r t a m e n t o \u00a0d e \u00a0 Inmuno\u2010\nHematolog\u00eda\u00a0y\u00a0Transfusi\u00f3n\u00a0de\u00a0Sangre,\u00a0Centro\u00a0M\u00e9dico\u00a0de\u00a0la\u00a0Univer sidad\u00a0de\u00a0Leiden,\u00a0\nUniversidad\u00a0 de\u00a0 Leiden,\u00a0 Leiden,\u00a0 Pa\u00edses\u00a0 bajos;\u00a0 Departamento\u00a0 de\u00a0\nHematolog\u00eda/Oncolog\u00eda,\u00a0 2\u00ba\u00a0 Facultad\u00a0 de\u00a0 Medicina,\u00a0 Universidad\u00a0 Cha rles,\u00a0 Praga,\u00a0\nRep\u00fablica\u00a0Checa;\u00a0Departamento\u00a0de\u00a0Inmunolog\u00eda\u00a0Cl\u00ednica,\u00a0Hospital\u00a0 Universitario\u00a0La\u00a0\nPaz,\u00a0grupo\u00a0de\u00a0Fisiopatolog\u00eda\u00a0de\u00a0Inmunodeficiencias,\u00a0Instituto\u00a0p ara\u00a0la\u00a0investigaci\u00f3n\u00a0de\u00a0\nla\u00a0 Salud\u00a0 IdiPAZ,\u00a0 Madrid,\u00a0 Espa\u00f1a;\u00a0 Instituto\u00a0 de\u00a0 Medicina\u00a0 Molecula r,\u00a0 Facultad\u00a0 de\u00a0\nMedicina,\u00a0Universidad\u00a0de\u00a0Lisboa,\u00a0Lisboa,\u00a0Portugal;\u00a0Departamento \u00a0de\u00a0Inmunolog\u00eda\u00a0\nCl\u00ednica\u00a0y\u00a0Alergia,\u00a0Hospital\u00a0Unive rsitario\u00a0St\u00a0Anne,\u00a0Facultad\u00a0de\u00a0 Medicina,\u00a0Universidad\u00a0\nM a s a r y k , \u00a0B r n o , \u00a0R e p \u00fa b l i c a \u00a0C h e c a ; \u00a0D e p a r t a m e n t o \u00a0d e \u00a0M e d i c i n a \u00a0d e \u00a0L a b oratorio,\u00a0\nHospital\u00a0Universitario\u00a0de\u00a0Gante,\u00a0Gante,\u00a0B\u00e9lgica.\u00a0\n- Centro\u00a0de\u00a0Atenci\u00f3n\u00a0Primaria\u00a0de\u00a0Salud\u00a0Miguel\u00a0Armijo,\u00a0Salamanca.\u00a0\n- Servicio\u00a0de\u00a0Inmunolog\u00eda,\u00a0Funda ci\u00f3n\u00a0Jim\u00e9nez\u00a0D\u00edaz,\u00a0Madrid.\u00a0\n- Servicio\u00a0de\u00a0Hematolog\u00eda,\u00a0Hosp ital\u00a0de\u00a0Navarra,\u00a0Pamplona.\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0La\u00a0presente\u00a0tesis\u00a0doctoral\u00a0inclu ye\u00a0tres\u00a0trabajos\u00a0originales,\u00a0do s\u00a0de\u00a0ellos\u00a0ya\u00a0publicados\u00a0y\u00a0uno\u00a0\nen\u00a0periodo\u00a0de\u00a0revisi\u00f3n\u00a0en\u00a0revist as\u00a0cient\u00edficas\u00a0indexadas\u00a0en\u00a0el\u00a0 Science\u00a0Citation\u00a0Reports ,\u00a0los\u00a0\ncuales\u00a0se\u00a0detallan\u00a0a\u00a0continuaci\u00f3n:\u00a0\n\u00a0\n1.\u00a0Selection\u00a0and\u00a0validation\u00a0of\u00a0antibody\u00a0clones\u00a0against\u00a0IgG\u00a0and\u00a0 IgA\u00a0subclasses\u00a0in\u00a0switched\u00a0\nmemory\u00a0B\u2010cells\u00a0and\u00a0plasma\u00a0cells.\u00a0Elena\u00a0Blanco\n1,\u00a0Martin\u00a0Perez\u2010Andres1,\u00a0Luzalba\u00a0Sanoja\u2010Flores1,\u00a0Marjolein\u00a0Wentink2,\u00a0Ondrej\u00a0\nPelak3,\u00a0Marta\u00a0Mart\u00edn\u2010Ayuso4,\u00a0Georgiana\u00a0Grigore4,\u00a0Juan\u00a0Torres\u2010Canizales5,\u00a0Eduardo\u00a0L\u00f3pez\u2010\nGranados5,\u00a0Tomas\u00a0Kalina3,\u00a0Mirjam\u00a0van\u00a0der\u00a0Burg2,\u00a0Sonia\u00a0Arriba\u2010M\u00e9ndez6,\u00a0Santiago\u00a0Santa\u00a0\nCruz7,\u00a0Noem\u00ed\u00a0Puig8,\u00a0Jacques\u00a0J.M.\u00a0van\u00a0Dongen9\u00a0y\u00a0Alberto\u00a0Orfao1,\u00a0on\u00a0behalf\u00a0of\u00a0the\u00a0EuroFlow\u00a0\nPID\u00a0group.\u00a0\u00a0\nJournal\u00a0of\u00a0Immunological\u00a0Methods ;\u00a02017\u00a0Sep\u00a028.\u00a0doi:\u00a010.1016/j.jim.2017.09.008.\u00a0\n\u00a02.\u00a0Age\u2010associated\u00a0distribution\u00a0of\u00a0normal\u00a0B\u2010cell\u00a0and\u00a0plasma\u00a0cell \u00a0subsets\u00a0in\u00a0peripheral\u00a0\nblood.\u00a0\nElena\u00a0 Blanco\n1,\u00a0 Mart\u00edn\u00a0 P\u00e9rez\u2010Andr\u00e9s1,\u00a0 Sonia\u00a0 Arriba\u2010M\u00e9ndez6,\u00a0 Teresa\u00a0 Contreras\u2010\nSanfeliciano10,\u00a0Ignacio\u00a0Criado1,\u00a0Ondrej\u00a0Pelak3,\u00a0Ana\u00a0Serra\u2010Caetano11,\u00a0Alfonso\u00a0Romero12,\u00a0\nNoem\u00ed\u00a0Puig8,\u00a0Ana\u00a0Remesal6,\u00a0Juan\u00a0Torres\u2010Canizales5,\u00a0Eduardo\u00a0L\u00f3pez\u2010Granados5,\u00a0Tomas\u00a0\nKalina3,\u00a0Ana\u00a0E.\u00a0Sousa11,\u00a0Menno\u00a0van\u00a0Zelm13,\u00a0Mirjam\u00a0van\u00a0der\u00a0Burg2,\u00a0Jacques\u00a0J.M.\u00a0van\u00a0\nDongen9,\u00a0Alberto\u00a0Orfao1,\u00a0on\u00a0behalf\u00a0of\u00a0the\u00a0E uroFlow\u00a0PID\u00a0group.\u00a0\n\u00a0\nJournal\u00a0of\u00a0Allergy\u00a0and\u00a0Clinical\u00a0Immunology ;\u00a02018\u00a0Mar\u00a02.\u00a0doi:\u00a010.10 16/j.jaci.2018.02.017.\u00a0\n\u00a0\n3.\u00a0Dissection\u00a0of\u00a0defects\u00a0in\u00a0memory\u00a0B\u2010cell\u00a0and\u00a0plasma\u00a0cell\u00a0subse ts\u00a0expressing\u00a0different\u00a0\nimmunoglobulin\u00a0subclasses\u00a0provides\u00a0basis\u00a0for\u00a0(new)\u00a0re\u2010classific ation\u00a0of\u00a0CVID\u00a0and\u00a0Ig\u2010\nsubclass\u00a0deficiencies.\u00a0\nElena\u00a0Blanco1\u00a7,\u00a0Mart\u00edn\u00a0P\u00e9rez\u2010Andr\u00e9s1\u00a7,\u00a0Sonia\u00a0Arriba\u2010M\u00e9ndez6,\u00a0Cristina\u00a0Serrano14,\u00a0Luc\u00eda\u00a0del\u00a0\nPino\u2010Molina1,\u00a0\u00a0Susana\u00a0Silva11,\u00a0\u00a0Ignacio\u00a0Criado1,\u00a0Ignacio\u00a0Madruga15,\u00a0Ana\u00a0Serra\u00a0Caetano11,\u00a0\nTeresa\u00a0Contreras\u2010Sanfeliciano10,\u00a0Francisco\u00a0Sala16,\u00a0Alejandro\u00a0Mart\u00edn8,\u00a0Jos\u00e9\u00a0Mar\u00eda\u00a0Bastida8,\u00a0\nF\u00e9lix\u00a0Lorente6,\u00a0Carlos\u00a0Prieto17,\u00a0Ignacio\u00a0D\u00e1vila18,\u00a0Miguel\u00a0Marcos15,\u00a0Tomas\u00a0Kalina3,\u00a0Marcela\u00a0\nVlkova19,\u00a0Carolien\u00a0Bonroy20,\u00a0Jan\u00a0Philipp\u00e920,\u00a0Eduardo\u00a0L\u00f3pez\u2010Granados5,\u00a0Ana\u00a0E.\u00a0da\u00a0Sousa11,\u00a0\nMirjam\u00a0van\u00a0der\u00a0Burg,\u00a0PhD2,\u00a0Jacques\u00a0J.M. \u00a0van\u00a0Dongen9*,\u00a0Alberto\u00a0Orfao1*,\u00a0on\u00a0behalf\u00a0of\u00a0the\u00a0\nEuroFlow\u00a0PID\u00a0group.\u00a0\n\u00a7Both\u00a0authors\u00a0contributed\u00a0equally\u00a0to\u00a0this\u00a0work\u00a0and\u00a0should\u00a0both\u00a0b e\u00a0considered\u00a0as\u00a0first\u00a0author.\u00a0\n*Both\u00a0authors\u00a0contributed\u00a0equally\u00a0to\u00a0this\u00a0work\u00a0and\u00a0should\u00a0both\u00a0 be\u00a0considered\u00a0as\u00a0last\u00a0author.\u00a0\n\u00a0\n(sometido\u00a0para\u00a0publicaci\u00f3n\u00a0y\u00a0en\u00a0revisi\u00f3n\u00a0en\u00a0 Journal\u00a0of\u00a0Allergy\u00a0and\u00a0Clinical\u00a0Immunology )\u00a0\n\u00a0\u00a0\n\u00a01Centro\u00a0de\u00a0Investigaci\u00f3n\u00a0del\u00a0C\u00e1nc er\u00a0(IBMCC,\u00a0USAL\u2010CSIC),\u00a0Departam ento\u00a0de\u00a0Medicina\u00a0y\u00a0\nServicio\u00a0de\u00a0Citometr\u00eda\u00a0(NUCLEUS) ,\u00a0Universidad\u00a0de\u00a0Salamanca,\u00a0IBS AL\u00a0y\u00a0CIBERONC,\u00a0Salamanca,\u00a0\nEspa\u00f1a.\u00a02Departamento\u00a0 de\u00a0 Inmunolog\u00eda,\u00a0 Centro\u00a0 M\u00e9dico\u00a0 de\u00a0 la\u00a0 Universidad\u00a0 Er asmus,\u00a0\nRotterdam,\u00a0 Pa\u00edses\u00a0 Bajos.\u00a03Departamento\u00a0 de\u00a0 Hematolog\u00eda/Oncolog\u00eda,\u00a0 2\u00ba\u00a0 Facultad\u00a0 de\u00a0\nMedicina,\u00a0Universidad\u00a0Charles,\u00a0Praga,\u00a0Rep\u00fablica\u00a0Checa.\u00a04Cytognos\u00a0S.L.,\u00a0Salamanca,\u00a0Espa\u00f1a.\u00a0\n5Departamento\u00a0de\u00a0Inmunolog\u00eda\u00a0Cl\u00edn ica,\u00a0Hospital\u00a0Universitario\u00a0La\u00a0 Paz,\u00a0grupo\u00a0de\u00a0Fisiopatolog\u00eda\u00a0\nde\u00a0Inmunodeficiencias,\u00a0Instituto\u00a0para\u00a0la\u00a0investigaci\u00f3n\u00a0de\u00a0la\u00a0Sa lud\u00a0IdiPAZ,\u00a0Madrid,\u00a0Espa\u00f1a.\u00a0\n6Servicio\u00a0de\u00a0Pediatr\u00eda,\u00a0Hospital\u00a0Universitario\u00a0de\u00a0Salamanca,\u00a0Sal amanca,\u00a0Espa\u00f1a.\u00a07Servicio\u00a0de\u00a0\nOtorrinolaringolog\u00eda,\u00a0Hospital\u00a0Universitario\u00a0de\u00a0Salamanca,\u00a0Sala manca,\u00a0Espa\u00f1a.\u00a08Servicio\u00a0de\u00a0\nHematolog\u00eda,\u00a0Hospital\u00a0Universit ario\u00a0de\u00a0Salamanca,\u00a0Salamanca,\u00a0Es pa\u00f1a.\u00a09Departamento\u00a0de\u00a0\nInmuno\u2010Hematolog\u00eda\u00a0y\u00a0Transfusi\u00f3n\u00a0de\u00a0Sangre,\u00a0Centro\u00a0M\u00e9dico\u00a0de\u00a0la \u00a0Universidad\u00a0de\u00a0Leiden,\u00a0\nUniversidad\u00a0de\u00a0Leiden,\u00a0Leiden,\u00a0Pa\u00edses\u00a0bajos\u00a010Servicio\u00a0de\u00a0Bioqu\u00edmica,\u00a0Hospital\u00a0Universitario\u00a0\nde\u00a0Salamanca,\u00a0Salamanca,\u00a0Espa\u00f1a.\u00a011Instituto\u00a0de\u00a0Medicina\u00a0Molecu lar,\u00a0Facultad\u00a0de\u00a0Medicina,\u00a0\nUniversidad\u00a0de\u00a0Lisboa,\u00a0Lisboa,\u00a0Portugal.\u00a012Centro\u00a0de\u00a0Atenci\u00f3n\u00a0Primaria\u00a0de\u00a0Salud\u00a0Miguel\u00a0\nArmijo,\u00a0 Salamanca,\u00a0 Sanidad\u00a0 de\u00a0 Castilla\u00a0 y\u00a0 Le\u00f3n\u00a0 (SACYL),\u00a0 Castilla \u00a0y \u00a0L e \u00f3 n , \u00a0E s p a \u00f1 a . \u00a0\n13Departamento\u00a0 de\u00a0 Inmunolog\u00eda\u00a0 y\u00a0 Patolog\u00eda,\u00a0 Universidad\u00a0 Monash\u00a0 y\u00a0 H ospital\u00a0 Alfred,\u00a0\nMelbourne,\u00a0Victoria,\u00a0Australia.\u00a014Servicio\u00a0de\u00a0Inmunolog\u00eda,\u00a0Fundaci\u00f3n\u00a0Jim\u00e9nez\u00a0D\u00edaz,\u00a0Madrid,\u00a0\nEspa\u00f1a.\u00a015Servicio\u00a0de\u00a0Medicina\u00a0Interna,\u00a0Hospital\u00a0Universitario\u00a0de\u00a0Salaman ca,\u00a0Salamanca,\u00a0\nEspa\u00f1a.\u00a016Servicio\u00a0de\u00a0Hematolog\u00eda,\u00a0Hospital \u00a0de\u00a0Navarra,\u00a0Pamplona,\u00a0Espa\u00f1a. \u00a017Sevicio\u00a0de\u00a0\nBioinform\u00e1tica\u00a0(NUCLEUS),\u00a0Univer sidad\u00a0de\u00a0Salamanca,\u00a0Salamanca,\u00a0 Espa\u00f1a.\u00a018Servicio\u00a0de\u00a0\nAlergia,\u00a0Hospital\u00a0Universitario\u00a0d e\u00a0Salamanca,\u00a0IBSAL,\u00a0Departamen to\u00a0de\u00a0Ciencia\u00a0Biom\u00e9dica\u00a0y\u00a0\nde\u00a0 Diagn\u00f3stico,\u00a0 Universidad\u00a0 de\u00a0 Salamanca,\u00a0 Salamanca,\u00a0 Espa\u00f1a.\u00a019Departamento\u00a0 de\u00a0\nInmunolog\u00eda\u00a0 Cl\u00ednica\u00a0 y\u00a0 Alergia,\u00a0 Ho spital\u00a0 Universitario\u00a0 St.\u00a0 Anne, \u00a0 Facultad\u00a0 de\u00a0 Medicina,\u00a0\nUniversidad\u00a0Masaryk,\u00a0Brno,\u00a0Rep\u00fablica\u00a0Checa.\u00a020Departamento\u00a0de\u00a0Medicina\u00a0de\u00a0Laboratorio,\u00a0\nHospital\u00a0Universitario\u00a0de\u00a0Gante,\u00a0Gante,\u00a0B\u00e9lgica.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\n\u00a0\n \n \n \n  \nA mis padres. \nA Nacho. \n  \u00a0\n\u00a0  \u00a0\n\u00a0\n\u00a0 \n    \n \n     \n \n \nImagen de portada de \n Miguel \u00c1ngel Blanco Otero \u00a0\n  \u00a0\n\u00a0 \n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n \n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n \n \n \n \n \n \u201cLo m\u00e1s maravilloso de la ciencia es que est\u00e1 viva\u201d \u00a0\nRichard Feynman. \n\u00a0\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0Agradecimientos \nCuando una etapa llega a su fin, es inevit able mirar atr\u00e1s, y aunque el periodo \nde tesis est\u00e1 lleno de altibajos y supone to do un reto (no solamente intelectual) creo \nque con lo que nos tenemos que quedar al final es con las cosas buenas. Y entre \nellas, est\u00e1 toda la gente que me ha ayud ado a llegar hasta aqu\u00ed  y me han hecho el \ncamino m\u00e1s f\u00e1cil. \nEn primer lugar, quiero dar las gracias a mis directores de tesis por la \noportunidad de llevar a cabo este trabajo. Mart\u00edn, gracias por todas las horas \ndedicadas a este proyecto y por tener siem pre tiempo para mis m\u00faltiples llamadas y \ncorreos con dudas, aunque estuvieras hasta arriba de trabajo. Y, sobre todo, gracias \npor ver el vaso medio lleno, cuando yo lo ve\u00eda vac\u00edo del todo. Alberto, gracias por \nser un ejemplo de trabajo y dedicaci\u00f3n a la ciencia, por hacernos pensar y \nplantearnos las cosas desde diferentes pers pectivas, y por todos tus consejos y apoyo \nestos a\u00f1os. Sin vosotros, este trabajo no habr\u00eda sido posible.  \nNunca he sabido en qu\u00e9 momento decid\u00ed dedicarme a la ciencia, pero el \nh e c h o  d e  q u e  a l  f i n a l  e s t \u00e9  a q u \u00ed  h a  s i d o  p o r  e l  \u201c e m p u j \u00f3 n \u201d  d e  m u c h a s  p e r s o n a s .  \nGracias a Gemma, Paco y Don Manuel, por haberme inculcado el cari\u00f1o por la farmacia, que fue el primer pasito. Tambi\u00e9n a mis profesores de grado y m\u00e1ster, por \n\u201cmeterme el gusanillo\u201d de la investigaci\u00f3n, y especialmente a Rafa G\u00f3ngora, ya que \ncontigo empec\u00e9 en el complejo y apasionante mundo de la inmunolog\u00eda. \nTambi\u00e9n quiero dar las gracias a Sonia, ya  que, aunque no hayas dirigido esta \ntesis, sin tu ayuda no habr \u00eda salido adelante. Gracias por contestar a todos mis \ncorreos, whatsapps, llamadas\u2026 siempre con una sonrisa y sin denunciarme por \nacoso. Y, sobre todo, gracias por tu amis tad y apoyo estos a\u00f1os. Gracias tambi\u00e9n a \nlas dem\u00e1s personas del servicio de Pediatr\u00ed a del Hospital Cl\u00ednico, y especialmente a \nCarmen, por hacerme el trabajo mucho m\u00e1s f\u00e1cil. Eduardo, Luc\u00eda, Juan, Nacho y \nCristina, muchas gracias por vuestra colabora ci\u00f3n en la recopila ci\u00f3n de pacientes y \ndatos cl\u00ednicos. Y por supuesto, gracias a todos los pacientes y voluntarios por \nparticipar en el estudio. \n I would also like to thank all the me mbers of the EuroFlow immunodeficiency \nconsortium for your collaboration and fruitf ul discussions (Tomas, Mirjam, Ana\u2026), and \nspecially to Jacques, thank you for your continuous support, review my articles and \nalways have a kind word.  \u00a0\n\u00a0Gracias a todos mis compa\u00f1eros de labo ratorio, a los que est\u00e1n y a los que \nya se han ido. Muchos de vosotros, tras ta ntas horas juntos, os hab\u00e9is convertido en \ngrandes amigos. Hablando de horas en un la boratorio\u2026 \u00a1Cristina! Aunque te hayan \nadoptado en Leiden, sabes que siempre ser\u00e1s del 11, y m\u00e1s concretamente \u201cdel \ncaf\u00e9\u201d. Muchas gracias por haberme ense\u00f1ado tanto, por estar siempre dispuesta a \nechar un mano y por ser sincera cuando hace falta. A\u00fan echo de menos nuestras \ncenas (incluso las de \u201c\u00bfme puede traer un a pizza al Hospital Cl\u00ednico?\u201d). Gracias \ntambi\u00e9n a Albita, la chica m\u00e1s resolutiva del mundo, por haberme facilitado tanto \nlas cosas siempre y por cuidar de todos, au nque ahora sea en la distancia. Paula, \ngracias por tus \u00e1nimos y las risas que nos hemos echado estos a\u00f1os (especialmente \ndisgregando am\u00edgdalas y en alg\u00fan qu e otro congreso y despedida\u2026).  \n\u00a1Y ahora a los del caf\u00e9 que a\u00fan se mantienen fieles a nuestra cita de las 10,30 \ncon Abundio et al.! Gracias Guille por tantas y tantas risas, tantos y tantos caf\u00e9s, y por \nescucharme y ayudarme en mis \u201cbrotes\u201d. Gracias Mayado por estar siempre \npendiente y aconsejarme cuando lo he ne cesitado, y por compartir mi indignaci\u00f3n \ncon los \u201ch\u00e1msters\u201d del mundo. Nacho (zo rro\u2026), gracias por hacernos los caf\u00e9s tan \namenos y elegir tan bien los pinchos. A los ahora usuarios ocasionales del caf\u00e9: Mar\u00eda \nGG, \u00a1mi referente! gracias po r ser una gran maestra Jedi, por ponerte en modo madre \ny hasta insultarme con amor cuando hace fa lta, y por hacerme tanta gracia. M. Jara, \nalias mata-zombis, gracias por tu sitio,  tus recomendaciones de series y tus \nachuchones de osezno ocasionales. Grac ias Dani por acogerme cuando solo era \nuna \u201cpatita\u201d e introducirme en el mundo de la citometr\u00eda. Y tito Sergio, aunque nos \nveamos mucho menos que antes, sigues ha ci\u00e9ndome mucha gracia, gracias por tus \ntontunas.  \nTambi\u00e9n quiero dar las gracias a mis dem\u00e1s compa\u00f1eros del centro del \nc\u00e1ncer. Julia, gracias por escucharme y ay udarme siempre que lo he necesitado, y \npor ser un ejemplo. A Arancha por ser una gran compi de sitio, y ser siempre tan \namable. A Quentin, por toda tu ayuda con infinicyt y Excel, por vigilarme el coche \ncomo buen vecino y por derrotar a Locky. A Manuel, por tener fe  en que alg\u00fan d\u00eda \nser\u00e9 famosa. A mis ex \u2212compis del horno, tambi\u00e9n llamada sala de an\u00e1lisis del I+D+i: \na Lourdes (atempera tu entusiasmo) por ser una gran bestie y las risas que nos hemos \nechado estos a\u00f1os, a Susana por tu ayuda siempre, a Carlos por haberme ense\u00f1ado \ntanto (aunque a\u00fan tengo mucho que aprender), por animarme siempre que me \nve\u00edas de baj\u00f3n y por tu gran empat\u00eda. A Mari Luz, Sheila, Paloma, Javi y Carolina por \nvuestra ayuda y por coger mis muestras si empre con una sonrisa. A Laura por todos \ntus consejos y estar siempre dispuesta a ec har una mano, a Lola por tu amabilidad y \na Andr\u00e9s por estar siempre pendiente de c\u00f3mo vamos y por tus \u00e1nimos. Gracias \u00a0\n\u00a0\n\u00a0tambi\u00e9n al \u201cequipo Cytognos\u201d, Georgiana y Marta, por todo vuestro apoyo estos \na\u00f1os. A los \u201cpredocs\u201d nuevos y no tan nuevos: Alejandro, Noem\u00ed, Blanca, Guille y \nespecialmente \u201cmi heredera\u201d Sara, gracias por coger el relevo y mucho \u00e1nimo, al \nfinal todo sale. Juanito, gracias por tu  paciencia con todas mis dudas y por tus \nense\u00f1anzas de calibraci\u00f3n y compensaci\u00f3n . Gracias Chema por tu sinceridad y tus \nconsejos, y Josito por tu ayuda cuando em pec\u00e9 y la palabra \u201cbulk\u201d me sonaba a \nnombre de fruta. Gracias tambi\u00e9n a las t\u00e9cnicos de citometr\u00eda: Miriam 1, Miriam 2, \nVirginia y Rosana, por vuestra pacienci a cuando os robaba anticuerpos y por \ndejarme \u201ccolarme\u201d en el citometro, A los citometristas m\u00e1s veteranos: gracias Juana \npor todo tu cari\u00f1o y por poner un punto art\u00edstico a todo. Y por supuesto, gracias To\u00f1o \npor haberme transmitido una peque\u00f1a parte de tus conocimientos y por ser una gran \npersona.  \n\u00a1Pero fuera del laboratorio tambi\u00e9n hay vida! Aunque muchas veces se \ncomparta tambi\u00e9n con los coworkers . Gracias Noe por estar siempre pendiente, por \ntodos los detalles que tienes siempre con no sotros y por ser mi compi lectora. Luz \n\u00a1Chama!, gracias por todo tu apoyo y ayuda estos a\u00f1os, y por alegrarte tanto de mis \nlogros como si fueran tuyos. V\u00edtor, eres el mejor padawan y compi yogui que se puede \ntener, gracias por estar siempre dispue sto a ayudarme (si es que somos taaan \nmajos\u2026). Gracias a mi chileno favorito, \u00c1lex , por tu ayuda y tus psicoan\u00e1lisis, y a Mar\u00eda \nTablas y a Pilar, por vuestra alegr\u00eda contagio sa. Gracias tambi\u00e9n, aunque ya no est\u00e9is \npor aqu\u00ed, a Patri y Valentina, por los mo mentos vividos dentro y fuera del labo. \nY ya fuera del mundo cient\u00edfico, quiero dar las gracias a mis farma-charros, \npor todo vuestro apoyo desde que llegu\u00e9 a Salamanca hace ya 12 a\u00f1os y que a\u00fan \nsegu\u00eds d\u00e1ndome, aunque estemos cada uno en una punta del mundo. Gracias \nSantos, Ruth, Domin, Quique, Javi, Pardal, Sandra, Irene, Joanna, Pili, Elia, Alva, Vir, \n\u00c1ngel y especialmente Ana, por ser la mejor compa\u00f1era de piso y amiga que se \npuede tener. Tambi\u00e9n gracias al club de fa ns de Bob Dylan, por poner ese punto de \nlocura que siempre es bien recibido: Miki, Dani, y especialmente gracias Kike por \ntener m\u00e1s confianza en m\u00ed que yo misma, y mi tovarich Jose, por estar ah\u00ed siempre.  \nPor supuesto, gracias tambi\u00e9n a toda mi familia, \u00a1que no os nombro porque \nsois tropecientos! A mis abuelos, por ser una inspiraci\u00f3n para todos nosotros. A mis t\u00edos \ny primos, por echarme la bronca cuando fa lta y por vuestro cari\u00f1o, y especialmente \ngracias a Miguel por la portada, y a Nere, por todo, siempre. \nPor \u00faltimo, quiero dedicar este trabaj o a mis padres, porque sin ellos nunca \nhubiera llegado hasta aqu\u00ed. Mam\u00e1, gracias por escucharme siempre, por todo tu \napoyo y por repetirme hasta la saciedad qu e pod\u00eda conseguirlo (\u201cal toro que es una \u00a0\n\u00a0hormiga\u201d). Pap\u00e1, gracias por ayudarme con todos y cada uno de mis agobios, por \nmuchos agobios que tuvieras t\u00fa tambi\u00e9n, y por todos tus consejos. Gracias tambi\u00e9n \na la subpi\u00f1a de la pi\u00f1a, Patri, David y Manuel, por ser como sois.  \nA Nacho, por ser el mejor compa\u00f1ero de tesis y de vida que se puede tener, \npor tu apoyo, comprensi\u00f3n y cari\u00f1o todos estos a\u00f1os y por el que s\u00e9 que me vas a \nseguir dando. Y sobre todo, gracias por tus sonrisas.  \n \n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n \n \n    \n\u00cdndice general \n\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0INTRODUCCI\u00d3N \u00a0.............................................................. .......................................................\u00a01 \u00a0\n1.\u00a0Inmunoglobulinas \u00a0.............................................................. ..................................................\u00a03 \u00a0\n1.1.\u00a0Caracter\u00edsticas\u00a0generales\u00a0de\u00a0las\u00a0inmunoglobulinas\u00a0........ .............................................\u00a03\u00a0\n1.2.\u00a0Isotipos\u00a0y\u00a0subclase s\u00a0de\u00a0inmunoglobulinas\u00a0................. ..................................................\u00a05\u00a0\n1.2.1.\u00a0IgM\u00a0.................................................... ............................................................... ....\u00a06\u00a0\n1.2.2.\u00a0IgG\u00a0y\u00a0subclases\u00a0de\u00a0IgG\u00a0................................. .........................................................\u00a07\u00a0\n1.2.3.\u00a0IgA\u00a0y\u00a0subclases\u00a0de\u00a0IgA\u00a0................................. .......................................................\u00a010\u00a0\n1.2.4.\u00a0IgD\u00a0.................................................... ............................................................... ...\u00a012\u00a0\n1.2.5.\u00a0IgE\u00a0.................................................... ............................................................... ....\u00a013\u00a0\n2.\u00a0Origen,\u00a0caracter\u00edstica s\u00a0funcionales\u00a0e\u00a0inmu nofenotipo\u00a0de\u00a0los\u00a0lin focitos\u00a0B\u00a0......................\u00a013\u00a0\n2.1.\u00a0Maduraci\u00f3n\u00a0B\u00a0independiente\u00a0de\u00a0ant\u00edgeno\u00a0................... .............................................\u00a014\u00a0\n2.2.\u00a0Maduraci\u00f3n\u00a0B\u00a0dependiente\u00a0de\u00a0ant\u00edgeno\u00a0..................... ..............................................\u00a017\u00a0\n2.2.1.\u00a0Respuesta\u00a0B\u00a0dependiente\u00a0de\u00a0linfocitos\u00a0T\u00a0................ ...........................................\u00a017\u00a0\n2.2.2.\u00a0Respuesta\u00a0B\u00a0independiente\u00a0de\u00a0linfocitos\u00a0T\u00a0.............. ..........................................\u00a021\u00a0\n2.3.\u00a0Poblaciones\u00a0de\u00a0linfocito s\u00a0B\u00a0circulantes\u00a0en\u00a0sangre\u00a0........ .............................................\u00a023\u00a0\n3.\u00a0Desarrollo\u00a0de\u00a0la\u00a0respuesta\u00a0B\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida \u00a0............................................................\u00a02 7\u00a0\n3.1.\u00a0Desarrollo\u00a0de\u00a0los\u00a0 \u00f3rganos\u00a0linfoides\u00a0...................... ......................................................\u00a028\u00a0\n3.2.\u00a0Niveles\u00a0s\u00e9ricos\u00a0de\u00a0inmunoglobulinas\u00a0...................... ...................................................\u00a030\u00a0\n3.3.\u00a0Ontogenia\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0............................ .........................................................\u00a032\u00a0\n3.4.\u00a0Ontogenia\u00a0de\u00a0otros\u00a0componentes\u00a0del\u00a0sistema\u00a0inmune\u00a0........ .....................................\u00a034\u00a0\n4.\u00a0Inmunodeficiencias\u00a0predominantemente\u00a0de\u00a0anticuerpos \u00a0...............................................\u00a035 \u00a0\n4.1.\u00a0Deficiencia\u00a0grave\u00a0de\u00a0todos\u00a0 los\u00a0isotipos\u00a0de\u00a0inmunoglobulina \u00a0con\u00a0ausencia\u00a0o\u00a0\nreducci\u00f3n\u00a0importante\u00a0del\u00a0n\u00famero\u00a0 de\u00a0linfocitos\u00a0B\u00a0(agammaglobulin emias)\u00a0....................\u00a036\u00a0\n4.2.\u00a0Deficiencia\u00a0grave\u00a0de\u00a0al\u00a0menos\u00a0dos\u00a0isotipos\u00a0de\u00a0inmunoglobul ina\u00a0con\u00a0n\u00famero\u00a0\nnormal\u00a0o\u00a0bajo\u00a0de\u00a0linfocitos\u00a0B\u00a0(fenotipo\u00a0de\u00a0inmunodeficiencia\u00a0va riable\u00a0com\u00fan)\u00a0.............\u00a037\u00a0\n4.2.1.\u00a0Diagn\u00f3stico\u00a0de\u00a0la\u00a0inmunodeficiencia\u00a0variable\u00a0com\u00fan\u00a0..... ..................................\u00a037\u00a0\n4.2.2.\u00a0 Epidemiolog\u00eda,\u00a0 caracter\u00eds t i c a s \u00a0c l \u00ed n i c a s \u00a0y \u00a0t r a t a m i e n t o \u00a0d e \u00a0l a \u00a0\ninmunodeficiencia\u00a0variable\u00a0com\u00fan\u00a0.............................. ................................................\u00a040\u00a0\n4.2.3.\u00a0Alteraciones\u00a0gen\u00e9ticas\u00a0en\u00a0la\u00a0inmunodeficiencia\u00a0variable\u00a0 com\u00fan\u00a0......................\u00a042\u00a0\n4.2.4.\u00a0Alteraciones\u00a0de\u00a0poblaciones\u00a0de\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inmun e\u00a0en\u00a0la\u00a0\ninmunodeficiencia\u00a0variable\u00a0com\u00fan\u00a0.............................. ................................................\u00a044\u00a0\n4.2.5.\u00a0Alteraciones\u00a0funcionales\u00a0 B\u00a0asociadas\u00a0a\u00a0inmunodeficiencia \u00a0variable\u00a0com\u00fan\u00a0.....\u00a049\u00a0\n4.3.\u00a0Deficiencia\u00a0grave\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0con\u00a0valores\u00a0normales\u00a0o\u00a0elev ados\u00a0de\u00a0IgM\u00a0y\u00a0\nnormales\u00a0de\u00a0linfocitos\u00a0B\u00a0(s\u00edndromes\u00a0h\u00edper\u2010IgM)\u00a0................ ...............................................\u00a050\u00a0\n4.4.\u00a0Deficiencia\u00a0funcional\u00a0B,\u00a0de \u00a0isotipo\u00a0de\u00a0cadenas\u00a0pesadas\u00a0o\u00a0d e\u00a0cadenas\u00a0ligeras\u00a0\nde\u00a0inmunoglobulina\u00a0............................................ ..............................................................\u00a0 52\u00a0\u00a0\n\u00a04.4.1.\u00a0D\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0............................... ........................................................\u00a052\u00a0\n4.4.1.1.\u00a0Diagn\u00f3stico\u00a0del\u00a0d \u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0............. ...........................................\u00a052\u00a0\n4.4.1.2.\u00a0Epidemiolog\u00eda,\u00a0caracter\u00edsticas\u00a0cl\u00ednicas\u00a0y\u00a0tratamiento\u00a0 del\u00a0 d\u00e9ficit\u00a0\nselectivo\u00a0de\u00a0IgA............................................... ...........................................................\u00a053\u00a0\n4.4.1.3.\u00a0Alteraciones\u00a0gen\u00e9ticas\u00a0 asociadas\u00a0al\u00a0d\u00e9ficit\u00a0selectivo\u00a0 de\u00a0IgA\u00a0........................\u00a054\u00a0\n4.2.1.4.\u00a0Alteraciones\u00a0en\u00a0poblaci ones\u00a0de\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inm une\u00a0en\u00a0el\u00a0\nd\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0...................................... ........................................................\u00a056\u00a0\n4.2.1.5.\u00a0Alteraciones\u00a0funcionale s\u00a0asociadas\u00a0a\u00a0d\u00e9ficit\u00a0selectivo \u00a0de\u00a0IgA\u00a0......................\u00a057\u00a0\n4.4.2.\u00a0D\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0I gG\u00a0asociado\u00a0o\u00a0no\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0I gA\u00a0................................\u00a058\u00a0\n4.4.3.\u00a0Otros\u00a0d\u00e9ficits\u00a0funcionale s\u00a0B,\u00a0de\u00a0isotipo\u00a0IgM\u00a0y\u00a0de\u00a0cadena \u00a0ligera\u00a0kappa\u00a0.............\u00a059\u00a0\nHIP\u00d3TESIS\u00a0DE\u00a0TRABAJO\u00a0Y\u00a0OBJETIVOS \u00a0.............................................................. ...............\u00a063 \u00a0\nMATERIAL,\u00a0M\u00c9TODOS\u00a0Y\u00a0RESULTADOS \u00a0.............................................................. ..............\u00a071 \u00a0\nArt\u00edculo\u00a01: \u00a0\u201cSelecci\u00f3n\u00a0y\u00a0validaci\u00f3n\u00a0de\u00a0clone s\u00a0de\u00a0anticuerpos\u00a0dirigidos\u00a0fre nte\u00a0a\u00a0\nsubclases\u00a0de\u00a0IgA\u00a0e\u00a0IgG\u00a0expresada s\u00a0en\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0 c\u00e9lulas\u00a0plasm\u00e1ticas\u00a0\nque\u00a0presentan\u00a0cambio\u00a0de\u00a0isotipo\u201d\u00a0.............................. ...........................................................\u00a075 \u00a0\nArt\u00edculo\u00a02 :\u00a0\u201cDistribuci\u00f3n\u00a0en\u00a0sangre\u00a0de\u00a0las\u00a0d istintas\u00a0subpoblaciones\u00a0de\u00a0li nfocitos\u00a0B\u00a0y\u00a0\nde\u00a0c\u00e9lulas\u00a0plasm\u00e1ticas\u00a0normale s\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida\u201d\u00a0........ ..................................................\u00a091 \u00a0\nArt\u00edculo\u00a03 :\u00a0\u201cLa\u00a0disecci\u00f3n\u00a0de\u00a0los\u00a0defectos\u00a0de\u00a0 las\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B \u00a0de\u00a0\nmemoria\u00a0 y\u00a0 c\u00e9lulas\u00a0 plasm\u00e1ticas\u00a0 qu e\u00a0 expresan\u00a0 diferentes\u00a0 subclases \u00a0d e \u00a0\ninmunoglobulinas\u00a0proporciona\u00a0una\u00a0base\u00a0s\u00f3lida\u00a0para\u00a0una\u00a0(nueva)\u00a0r e\u2010clasificaci\u00f3n\u00a0de\u00a0\nla\u00a0IDVC\u00a0y\u00a0de\u00a0los\u00a0d\u00e9ficits\u00a0de\u00a0subclases\u00a0de\u00a0inmunoglobulinas\u201d\u00a0... ............................................\u00a0109\u00a0\nDISCUSI\u00d3N \u00a0.............................................................. ............................................................\u00a014 3\u00a0\nCONCLUSIONES \u00a0.............................................................. ...................................................\u00a0169 \u00a0\nANEXO\u00a0I \u00a0.............................................................. ............................................................... ..\u00a0175\u00a0\nANEXO\u00a0II \u00a0.............................................................. ............................................................... \u00a0185\u00a0\nREFERENCIAS\u00a0BIBLIOGR\u00c1FICAS \u00a0.............................................................. ........................\u00a0227 \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0Glosario de Abreviaturas \u00a0\nA\u00a0\nAc:\u00a0anticuerpo.\u00a0\nADN:\u00a0\u00e1cido\u00a0desoxirribonucleico.\u00a0\nAg:\u00a0ant\u00edgeno.\u00a0\nAHI1:  sitio\u00a0de\u00a0integraci\u00f3n\u00a0colaborador \u00a0de\u00a0la\u00a0prote\u00edna\u00a0Abelson\u00a0tipo\u00a01\u00a0 (del\u00a0ingl\u00e9s,\u00a0 Abelson\u00a0\nhelper\u00a0integration\u00a0site\u00a01 ).\u00a0\nAID:\u00a0deaminasa\u00a0de\u00a0citidina\u00a0inducida\u00a0por\u00a0activaci\u00f3n\u00a0(del\u00a0ingl\u00e9s,\u00a0 activation\u2010induced\u00a0cytidine\u00a0\ndeaminase ).\u00a0\nAMBRA1:\u00a0mol\u00e9cula\u00a0activadora\u00a0de\u00a0la\u00a0autofagia\u00a0regulado\u00a0por\u00a0Beclin\u20101\u00a0(de l\u00a0ingl\u00e9s,\u00a0Activating\u00a0\nmolecule\u00a0in\u00a0Beclin\u00a01\u2010regulated\u00a0autophagy ).\u00a0\nAPE:\u00a0endonucleasa\u00a0apur\u00ednica/apirimid\u00ednica\u00a0(del\u00a0ingl\u00e9s,\u00a0 apurinic/apyrimidinic\u00a0endonuclease ).\u00a0\nATG13:\u00a0 gen/prote\u00edna\u00a0 relacionada\u00a0 con\u00a0 la\u00a0 autofagia\u00a0 tipo\u00a0 13\u00a0 (del\u00a0 ingl\u00e9s, \u00a0 Autophagy\u2010\nrelated\u00a0protein\u00a013 ).\u00a0\nARNm:\u00a0\u00e1cido\u00a0ribonucleico\u00a0mensajero.\u00a0\nATP6AP1: \u00a0gen/prote\u00edna\u00a0accesoria\u00a0de\u00a0la\u00a0AT Pasa\u00a0transportadora\u00a0de\u00a0protones \u00a0H+\u00a0tipo\u00a01\u00a0(del\u00a0\ningl\u00e9s,\u00a0ATPase\u00a0H+\u00a0transporting\u00a0accessory\u00a0protein\u00a01 ).\u00a0\nB\u00a0\nBAFF\u2010R:\u00a0receptor\u00a0del\u00a0factor\u00a0de\u00a0activaci\u00f3n\u00a0B\u00a0(del\u00a0ingl\u00e9s,\u00a0 B\u2010cell\u00a0activating\u00a0factor\u00a0receptor).\u00a0\nBCR:\u00a0receptor\u00a0de\u00a0la\u00a0c\u00e9lula\u00a0B\u00a0(del\u00a0ingl\u00e9s,\u00a0 B\u2010cell\u00a0receptor).\u00a0\nBLK:\u00a0tirosina\u00a0quinasa\u00a0de\u00a0c\u00e9lula\u00a0B\u00a0(del\u00a0ingl\u00e9s,\u00a0 B\u2010cell\u00a0lymphocyte\u00a0kinase ).\u00a0\nBlimp\u20101:\u00a0prote\u00edna\u00a0inductora\u00a0de\u00a0maduraci\u00f3n\u00a0del\u00a0linfocito\u00a0B\u00a0tipo\u00a01\u00a0(del\u00a0 ingl\u00e9s,\u00a0B\u00a0lymphocyte\u2010\ninduced\u00a0maturation\u00a0protein\u20101 ).\u00a0\nBLNK:\u00a0gen/prote\u00edna\u00a0de\u00a0uni\u00f3n\u00a0a\u00a0c\u00e9lula\u00a0B\u00a0(del\u00a0ingl\u00e9s,\u00a0 B\u2010cell\u00a0linker\u00a0protein).\u00a0\nBTK:\u00a0gen/prote\u00edna\u00a0kinasa\u00a0de\u00a0Bruton \u00a0(del\u00a0ingl\u00e9s,\u00a0 Bruton\u2019s\u00a0tyrosine\u00a0kinase ).\u00a0\nC\u00a0\nCCR6:\u00a0receptor\u00a0de\u00a0quimiocinas\u00a0tipo\u00a0C\u2010C\u00a06.\u00a0\nCi:\u00a0citoplasm\u00e1tico.\u00a0\u00a0\n\u00a0CD:\u00a0cluster\u00a0(o\u00a0grupo)\u00a0de\u00a0diferenciaci\u00f3n\u00a0(del\u00a0ingl\u00e9s,\u00a0 cluster\u00a0of\u00a0differentiation ).\u00a0\nCDF:\u00a0c\u00e9lula\u00a0dendr\u00edtica\u00a0folicular.\u00a0\nCP:\u00a0c\u00e9lula\u00a0plasm\u00e1tica.\u00a0\nCG:\u00a0centro\u00a0germinal.\u00a0\nCELC16A:\u00a0 gen/prote\u00edna \u00a0A\u00a0de\u00a0la\u00a0familia\u00a016\u00a0de\u00a0prote\u00ednas\u00a0con\u00a0dominio\u00a0tipo\u00a0lectina\u00a0C\u00a0(del \u00a0ingl\u00e9s,\u00a0\nC\u2010type\u00a0lectin\u00a0domain\u00a0family\u00a016\u00a0member\u00a0A ).\u00a0\nCTLA\u20104:\u00a0ant\u00edgeno\u00a0del\u00a0linfocito\u00a0T\u00a0citot\u00f3xico\u00a0tipo\u00a04\u00a0(del\u00a0ingl\u00e9s,\u00a0 cytotoxic\u00a0T\u2010lymphocyte\u00a0antigen\u00a0\n4).\u00a0\u00a0\nD\u00a0\nDCLRE1C:\u00a0gen/prote\u00edna\u00a0de\u00a0reparaci\u00f3n\u00a0de\u00a0uniones\u00a0de\u00a0ADN\u00a0tipo\u00a01C \u00a0(del\u00a0ingl\u00e9s, \u00a0DNA\u00a0cross\u2010\nlink\u00a0repair\u00a01C ).\u00a0\nE\u00a0\nEBF1:\u00a0factor\u00a0de\u00a0transcripci\u00f3n\u00a0B\u00a0temprano\u00a0tipo\u00a01\u00a0(del\u00a0ingl\u00e9s, \u00a0early\u00a0B\u2010cell\u00a0factor\u00a01 )\u00a0\nELISA:\u00a0 ensayo\u00a0 por\u00a0 inmunoabsorci\u00f3n\u00a0 ligado\u00a0 a\u00a0 enzimas\u00a0 (del\u00a0 ingl\u00e9s,\u00a0 enzime\u2010linked\u00a0\nimmunoabsorbent\u00a0assay ).\u00a0\nELISpot:\u00a0ensayo\u00a0de\u00a0puntos \u00a0por\u00a0inmunoabsorci\u00f3n\u00a0ligado\u00a0a\u00a0enzimas\u00a0( del\u00a0ingl\u00e9s,\u00a0enzyme\u2010linked\u00a0\nimmunoSpot\u00a0assay ).\u00a0\nF\u00a0\nFc:\u00a0fragmento\u00a0cristalizable\u00a0de\u00a0mo l\u00e9culas\u00a0de\u00a0inmunoglobulina.\u00a0\nFcR:\u00a0receptor\u00a0del\u00a0fragmento\u00a0crista lizable\u00a0de\u00a0inmunoglobulina.\u00a0\nFcRn:\u00a0receptor\u00a0neonatal\u00a0del\u00a0fragmento\u00a0 cristalizable\u00a0de\u00a0inmunoglobulin a.\u00a0\nH\u00a0\nHLA:\u00a0\u00a0ant\u00edgeno\u00a0leucocitario\u00a0humano\u00a0(del\u00a0ingl\u00e9s,\u00a0 human\u00a0leukocyte\u00a0antigen).\u00a0\nI\u00a0\nICOS:\u00a0gen/prote\u00edna\u00a0 inducible\u00a0 co\u2010estimuladora\u00a0 de\u00a0 c\u00e9lula\u00a0 T\u00a0 (del\u00a0 ingl\u00e9s\u00a0 inducible\u00a0 T\u2010cell\u00a0\ncostimulator).\u00a0\u00a0IDP\u2010Ac:\u00a0inmunodeficiencia\u00a0predominantemente\u00a0de\u00a0anticuerpos.\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0IDP:\u00a0inmunodeficiencia\u00a0primaria. \u00a0\n\u00a0\nIDVC:\u00a0inmunodeficiencia\u00a0variable\u00a0com\u00fan.\u00a0\nIFIH1:\u00a0gen/prote\u00edna\u00a0con\u00a0 dominio\u00a0helicasa\u00a0C\u00a0inducida\u00a0por\u00a0interfer\u00f3n\u00a0tip o\u00a01\u00a0(del\u00a0ingl\u00e9s,\u00a0\ninterferon\u00a0induced\u00a0with\u00a0helicase\u00a0C\u00a0domain\u00a01). \u00a0\n\u00a0Ig:\u00a0inmunoglobulina.\u00a0\nIGH:\u00a0cadena\u00a0pesada\u00a0de\u00a0inmunoglobulina\u00a0(del\u00a0ingl\u00e9s,\u00a0 immunoglobulin\u00a0heavy\u00a0chain ).\u00a0\nIGHC:\u00a0regi\u00f3n\u00a0constante\u00a0de\u00a0la\u00a0cadena\u00a0pesada\u00a0de\u00a0inmunoglobulina \u00a0(del\u00a0ingl\u00e9s,\u00a0 immunoglobulin\u00a0\nheavy\u00a0chain\u00a0constant\u00a0region).\u00a0\nIGL:\u00a0cadena\u00a0ligera\u00a0de\u00a0inmunoglobulina\u00a0(del\u00a0ingl\u00e9s,\u00a0 immunoglobulin\u00a0light\u00a0chain).\u00a0\nIKBA:\u00a0inhibidor\u00a0alfa\u00a0del\u00a0factor\u00a0de\u00a0transcripci\u00f3n\u00a0nuclear\u00a0 \u03baB\u00a0(NF\u03baB).\u00a0\nIL:\u00a0interleucina.\u00a0\n\u00a0IL2RG:\u00a0cadena\u00a0gamma\u00a0del\u00a0receptor\u00a0de\u00a0la\u00a0IL2\u00a0(del\u00a0ingl\u00e9s,\u00a0 interleukin\u00a02\u00a0receptor\u00a0subunit\u00a0\ngamma).\u00a0\n\u00a0\nIRF2BP2:\u00a0\u00a0 gen/prote\u00edna\u00a0de\u00a0uni\u00f3n\u00a0tipo\u00a02\u00a0al\u00a0factor\u00a0regulador\u00a0de\u00a0interfer\u00f3n\u00a0 tipo\u00a02\u00a0(del\u00a0ingl\u00e9s, \u00a0\ninterferon\u00a0regulatory\u00a0factor\u00a02\u00a0binding\u00a0protein\u00a02 ).\u00a0\nIRF\u20104:\u00a0factor\u00a0regulador\u00a0de\u00a0interf er\u00f3n\u00a0tipo\u00a04\u00a0(del\u00a0ingl\u00e9s,\u00a0 Interferon\u00a0regulatory\u00a0factor\u00a04 ).\u00a0\nIUIS:\u00a0Uni\u00f3n\u00a0Internacional\u00a0de\u00a0Sociedades\u00a0de\u00a0Inmunolog\u00eda\u00a0(del\u00a0ingl\u00e9s, \u00a0International\u00a0Union\u00a0of\u00a0\nImmunological \u00a0Societies).\u00a0\nJ\u00a0\nJAK3: gen/prote\u00edna\u00a0 quinasa\u00a0Janus\u00a0tipo\u00a03  (del\u00a0ingl\u00e9s,\u00a0 Janus\u00a0Kinase\u00a03 ).\u00a0\nL\u00a0\nLLC:\u00a0leucemia\u00a0linf\u00e1tica\u00a0cr\u00f3nica. \u00a0\nLRBA:\u00a0 gen/prote\u00edna\u00a0 de\u00a0 anclaje\u00a0 sensible\u00a0 a\u00a0 lipopolisac\u00e1rido \u00a0(del ingl\u00e9s, \u00a0\nlipopolysaccharide\u00a0(LPS)\u2010respon sive\u00a0beige\u2010like\u00a0anchor\u00a0protein ).\u00a0\nM\u00a0\nMALT:\u00a0tejido\u00a0linfoide\u00a0asociado\u00a0a\u00a0mucosa\u00a0(del\u00a0ingl\u00e9s,\u00a0 mucosa\u2010associated\u00a0lymphoid\u00a0tissue ).\u00a0\nMO:\u00a0m\u00e9dula\u00a0\u00f3sea.\u00a0\nMSH6:\u00a0hom\u00f3logo\u00a0de\u00a0mutS\u00a0tipo\u00a06\u00a0(del\u00a0ingl\u00e9s,\u00a0 mutS\u00a0homolog\u00a06 ).\u00a0\u00a0\n\u00a0N\u00a0\nNHEJ:\u00a0uni\u00f3n\u00a0de\u00a0extremos\u00a0no\u00a0hom\u00f3logos\u00a0de\u00a0ADN\u00a0(del\u00a0ingl\u00e9s,\u00a0 non\u2010homologous\u00a0end\u00a0joining ).\u00a0\nNEMO:\u00a0modulador\u00a0esencial\u00a0de\u00a0NF \u03baB\u00a0(del\u00a0ingl\u00e9s,\u00a0 NF\u2010kappa\u2010B\u00a0essential\u00a0modulator ).\u00a0\nNF\u03baB:\u00a0factor\u00a0nuclear\u00a0potenciador\u00a0de\u00a0cadenas\u00a0ligeras\u00a0kappa\u00a0de\u00a0c\u00e9lulas \u00a0B\u00a0activadas\u00a0(del\u00a0ingl\u00e9s,\u00a0\nnuclear\u00a0factor  kappa\u2010light\u2010chain\u2010enhancer\u00a0of\u00a0activated\u00a0B\u00a0cells ).\u00a0\nNK:\u00a0c\u00e9lulas\u00a0asesinas\u00a0naturales\u00a0(del\u00a0ingl\u00e9s,\u00a0n atural\u00a0killer).\u00a0\nNLR:\u00a0receptores\u00a0tipo\u00a0dominio\u00a0de\u00a0oligomerizaci\u00f3n\u00a0de\u00a0nucle\u00f3tidos\u00a0(del \u00a0ingl\u00e9s,\u00a0nucleotide\u00a0\noligomerization\u00a0domain\u2010like\u00a0receptor ).\u00a0\nNu:\u00a0nuclear.\u00a0\nO\u00a0\nOLS:\u00a0\u00f3rgano\u00a0linfoide\u00a0secundario.\u00a0\nOMS:\u00a0Organizaci\u00f3n\u00a0Mundial\u00a0de\u00a0la\u00a0Salud.\u00a0\nP\u00a0\nPax\u20105:\u00a0factor\u00a0de\u00a0transcripci\u00f3n\u00a0tipo\u00a0\u201ccaja\u2010pareada\u201d\u00a05\u00a0(del\u00a0ingl\u00e9s, \u00a0paired\u2010box\u00a0protein\u00a0Pax\u20105 )\u00a0\npIgR:\u00a0receptor\u00a0de\u00a0inmunoglobulina\u00a0polim\u00e9rica.\u00a0\nPIK3CD:\u00a0 subunidad\u00a0 catal\u00edtica\u00a0 delta\u00a0 de\u00a0 la\u00a0 fosfoinositol\u00a0 3\u2010quinasa\u00a0 (del \u00a0 ingl\u00e9s,  \nphosphatidylinositol\u00a03\u2010kinase\u00a0catalytic\u00a0subunit\u00a0delta ).\u00a0\nPIK3R1:\u00a0subunidad\u00a0reguladora\u00a01\u00a0de\u00a0la\u00a0fosfoinositol\u00a03\u2010quinasa\u00a0(del\u00a0ingl \u00e9s, phosphatidylinositol\u00a0\n3\u2010kinase\u00a0regulatory\u00a0subunit\u00a01 ).\u00a0\nPLCG2:\u00a0fosfolipasa\u00a0C\u00a0gamma\u00a02\u00a0(del\u00a0ingl\u00e9s, \u00a0phospholipase\u00a0C\u00a0gamma\u00a0 2).\u00a0\nPRKCD:\u00a0subunidad\u00a0tipo\u00a0delta\u00a0de\u00a0la\u00a0prote\u00edna\u00a0quinasa\u00a0C\u00a0(del\u00a0ingl\u00e9s,  protein\u00a0kinase\u00a0C\u00a0delta\u00a0type ).\u00a0\nR\u00a0\nRAC2:\u00a0sustrato\u00a0de\u00a0la\u00a0toxina\u00a0botul\u00ednica\u00a0relacionada\u00a0con\u00a0Ras\u00a0tipo\u00a02\u00a0(d el\u00a0ingl\u00e9s,\u00a0 Ras\u2010related\u00a0\nC3\u00a0botulinum\u00a0toxin\u00a0substrate\u00a02 ).\u00a0\nRAG1:\u00a0gen/prote\u00edna\u00a0activadora\u00a0de\u00a0recombinaci\u00f3n\u00a0tipo\u00a01\u00a0(del\u00a0ingl\u00e9s, \u00a0recombination\u00a0activating\u00a0\ngene\u00a01).\u00a0\nRAG2:\u00a0gen/prote\u00edna\u00a0activadora\u00a0de\u00a0recombinaci\u00f3n\u00a0tipo\u00a02\u00a0(del\u00a0ingl\u00e9s, \u00a0recombination\u00a0activating\u00a0\ngene\u00a02).\u00a0\u00a0\n\u00a0\n\u00a0S\u00a0\nSEC61A1:\u00a0subunidad\u00a0alfa\u00a01\u00a0del\u00a0complejo\u00a0SEC61\u00a0(del\u00a0ingl\u00e9s,\u00a0 Sec61\u00a0Alpha\u20101 ).\u00a0\nSP:\u00a0sangre\u00a0perif\u00e9rica.\u00a0\u00a0\nSTAT3:\u00a0  transductor\u00a0 de\u00a0 se\u00f1al\u00a0 y\u00a0 activador\u00a0 de\u00a0 la\u00a0 transcripci\u00f3n\u00a0 tipo\u00a0 3\u00a0 (de l\u00a0 ingl\u00e9s,\u00a0 signal\u00a0\ntransducer\u00a0and\u00a0activator\u00a0of\u00a0transcription\u00a03 ).\u00a0\nT\u00a0\nTACI:\u00a0activador\u00a0transmembrana\u00a0modulador\u00a0de\u00a0calcio\u00a0y\u00a0ligando\u00a0de\u00a0la\u00a0ci clofilina\u00a0(del\u00a0ingl\u00e9s,\u00a0\ntransmembrane\u00a0activator\u00a0and\u00a0CAML\u00a0interactor ).\u00a0\nTCR:\u00a0receptor\u00a0del\u00a0linfocito\u00a0T\u00a0(del\u00a0ingl\u00e9s,\u00a0 T\u2010cell\u00a0receptor ).\u00a0\nTLR:\u00a0receptor\u00a0tipo\u00a0 toll\u00a0(del\u00a0ingl\u00e9s,\u00a0 Toll\u2010like\u00a0recepto r).\u00a0\nTHF:\u00a0linfocito\u00a0T\u00a0colaborador\u00a0folicular\u00a0(del\u00a0ingl\u00e9s,\u00a0 follicular\u00a0helper\u00a0T\u2010cell ).\u00a0\nTNF\u03b1:\u00a0factor\u00a0de\u00a0necrosis\u00a0tumoral\u00a0alfa\u00a0(del\u00a0ingl\u00e9s,\u00a0 tumor\u00a0necrosis\u00a0factor\u00a0alpha ).\u00a0\nTRNT1:\u00a0transferasa\u00a0de\u00a0nucle\u00f3tidos\u00a0de\u00a0\u00e1cido\u00a0ribonucleico\u00a0(ARN)\u00a0de\u00a0trans ferencia\u00a0tipo\u00a01 \u00a0(del\u00a0\ningl\u00e9s,\u00a0tRNA\u00a0nucleotidyl\u00a0transferase\u00a01 ).\u00a0\nTTC37:\u00a0dominio\u00a0de\u00a0repetici\u00f3n\u00a0tetratricop\u00e9pt\u00eddico\u00a0tipo\u00a037 \u00a0(del\u00a0ingl\u00e9s,\u00a0 tetratricopeptide\u00a0repeat\u00a0\ndomain\u00a037 ).\u00a0\nTWEAK:\u00a0inductor\u00a0d\u00e9bil\u00a0de\u00a0apoptosis\u00a0de\u00a0ti po\u00a0factor\u00a0de\u00a0necrosis\u00a0tumoral \u00a0(del\u00a0ingl\u00e9s,\u00a0 tumor\u00a0\nnecrosis\u00a0factor\u2010like\u00a0weak\u00a0inducer\u00a0of\u00a0apoptosi s).\u00a0\nU\u00a0\nUNG:\u00a0N\u2010glicosilasa\u00a0de\u00a0uracilo\u00a0(del\u00a0ingl\u00e9s,\u00a0 uracil\u2010N\u2010glycosylase ).\u00a0\nX\u00a0\nXBP\u20101:\u00a0gen/prote\u00edna\u00a0de\u00a0uni\u00f3n\u00a0a\u00a0caja\u2010X\u00a0tipo\u00a01\u00a0(del\u00a0ingl\u00e9s,\u00a0 X\u2010box\u00a0binding\u00a0protein\u00a01) .\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0 \n \n  \n \n  \n \n \n  \u00a0\n\u00a0 \n \n  \n \nIntroducci\u00f3n \n  \u00a0\n\u00a0\n\u00a0 \n \n\u00a0\n\u00a0\u00a0Introducci\u00f3n \n\u2010\u00a03\u00a0\u2010\u00a0\n\u00a01.\u00a0Inmunoglobulinas\u00a0\nLas\u00a0inmunoglobulinas\u00a0(Igs)\u00a0son\u00a0glicoprote\u00ednas\u00a0producidas\u00a0por\u00a0lo s\u00a0linfocitos\u00a0B\u00a0de\u00a0animales\u00a0\nvertebrados\u00a0en\u00a0respuesta\u00a0a\u00a0estructuras\u00a0extra\u00f1as\u00a0conocidas\u00a0como\u00a0 ant\u00edgenos\u00a0(Ags)1.\u00a0Las\u00a0Igs\u00a0\npueden\u00a0presentarse\u00a0en\u00a0dos\u00a0formas:\u00a0i)\u00a0Igs\u00a0solubles\u00a0presentes\u00a0en\u00a0 fluidos\u00a0biol\u00f3gicos\u00a0como\u00a0la\u00a0sangre,\u00a0\nsecreciones\u00a0externas\u00a0y\u00a0l\u00edquido\u00a0cefalorraqu\u00eddeo,\u00a0y\u00a0denominadas\u00a0a nticuerpos\u00a0(Acs);\u00a0y\u00a0ii)\u00a0en\u00a0la\u00a0\nsuperficie\u00a0del\u00a0linfocito\u00a0B\u00a0como\u00a0parte\u00a0del\u00a0receptor\u00a0de\u00a0la\u00a0c\u00e9lula \u00a0B\u00a0para\u00a0Ag\u00a0(BCR;\u00a0del\u00a0ingl\u00e9s,\u00a0 B\u2010cell\u00a0\nreceptor)1,2.\u00a0 Desde\u00a0 el\u00a0 punto\u00a0 de\u00a0 vista\u00a0 funcional\u00a0 estas\u00a0 mol\u00e9culas\u00a0 muestran\u00a0 un a\u00a0 elevada\u00a0\nespecificidad\u00a0por\u00a0un\u00a0Ag\u00a0concreto,\u00a0lo\u00a0que\u00a0les\u00a0permite\u00a0reconocer, \u00a0neutralizar\u00a0y\u00a0eliminar,\u00a0dicho\u00a0Ag3.\u00a0\nEn\u00a0determinadas\u00a0circunstancias\u00a0pueden\u00a0producirse\u00a0Acs\u00a0frente\u00a0a\u00a0A gs\u00a0propios,\u00a0lo\u00a0que\u00a0conducir\u00eda\u00a0\na\u00a0respuestas\u00a0inmunol\u00f3gicas\u00a0frente \u00a0al\u00a0propio\u00a0organismo\u00a0(e.g.\u00a0aut oinmunidad)3,4.\u00a0\u00a0\n\u00a0\n1.1.\u00a0Caracter\u00edsticas\u00a0general es\u00a0de\u00a0las\u00a0inmunoglobulinas \u00a0\nLa\u00a0especificad\u00a0antig\u00e9nica\u00a0y\u00a0la\u00a0funci\u00f3n\u00a0de\u00a0cada\u00a0Ig\u00a0dependen\u00a0de\u00a0s u\u00a0estructura.\u00a0En\u00a0su\u00a0\nconjunto,\u00a0una\u00a0Ig\u00a0est\u00e1\u00a0formada\u00a0por\u00a0cuatro\u00a0cadenas\u00a0polipept\u00eddicas \u00a0id\u00e9nticas\u00a0dos\u00a0a\u00a0dos:\u00a0dos\u00a0\ncadenas\u00a0ligeras\u00a0y\u00a0dos\u00a0cadenas\u00a0pesadas,\u00a0divididas\u00a0en\u00a0dos\u00a0regione s\u00a0estructural\u00a0y\u00a0funcionalmente\u00a0\ndistintas\u00a0 (Figura\u00a0 1):\u00a0 i)\u00a0 la\u00a0 regi\u00f3n\u00a0 variable\u00a0 aminoterminal,\u00a0 que\u00a0 presenta\u00a0 una\u00a0 elevada\u00a0\nheterogeneidad\u00a0en\u00a0su\u00a0secuencia\u00a0d e\u00a0amino\u00e1cidos\u00a0y\u00a0que\u00a0es\u00a0determin ante\u00a0de\u00a0su\u00a0especificidad\u00a0por\u00a0\nel\u00a0Ag;\u00a0y\u00a0ii)\u00a0la\u00a0regi\u00f3n\u00a0constante \u00a0carboxiterminal,\u00a0con\u00a0secuencia s\u00a0de\u00a0amino\u00e1cidos\u00a0altamente\u00a0\nconservadas\u00a0y\u00a0que\u00a0permite\u00a0clasificar\u00a0las\u00a0Igs\u00a0en\u00a0subgrupos\u00a0(isot ipos\u00a0y\u00a0subclases)\u00a0con\u00a0distinta\u00a0\nfunci\u00f3n\u00a0efectora4,5.\u00a0Ambas\u00a0regiones,\u00a0variable\u00a0y\u00a0constante,\u00a0de\u00a0las\u00a0Igs\u00a0se\u00a0organizan \u00a0en\u00a0dominios\u00a0\nestructurales\u00a0que\u00a0se\u00a0estabilizan\u00a0m ediante\u00a0la\u00a0formaci\u00f3n\u00a0de\u00a0puent es\u00a0disulfuro\u00a0entre\u00a0residuos\u00a0de\u00a0\nciste\u00edna,\u00a0confiri\u00e9ndoles\u00a0un\u00a0aspecto\u00a0globular4,5.\u00a0Las\u00a0cadenas\u00a0ligeras\u00a0\u03ba\u00a0y\u00a0\u03bb\u00a0contienen\u00a0dos\u00a0dominios\u00a0\nglobulares,\u00a0uno\u00a0variable\u00a0(VL)\u00a0y\u00a0uno\u00a0constante\u00a0(CL),\u00a0mientras\u00a0qu e\u00a0las\u00a0cadenas\u00a0pesadas\u00a0poseen\u00a0\nadem\u00e1s\u00a0de\u00a0un\u00a0dominio\u00a0variable\u00a0(VH),\u00a0tres\u00a0o\u00a0cuatro\u00a0dominios\u00a0cons tantes\u00a0(CH1,\u00a0CH2,\u00a0CH3,\u00a0CH4),\u00a0\nseg\u00fan\u00a0el\u00a0isotipo\u00a0de\u00a0Ig\u00a0(Figura\u00a01).\u00a0En\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0isotipo s,\u00a0entre\u00a0las\u00a0regiones\u00a0constantes\u00a0CH1\u00a0Introducci\u00f3n \n\u2010\u00a04\u00a0\u2010\u00a0\n\u00a0y\u00a0CH2,\u00a0existe\u00a0una\u00a0zona\u00a0funcional \u00a0denominada\u00a0regi\u00f3n\u00a0bisagra\u00a0(Fig ura\u00a01),\u00a0que\u00a0le\u00a0permite\u00a0a\u00a0la\u00a0\nprote\u00edna\u00a0una\u00a0mayor\u00a0capacidad\u00a0de\u00a0rotaci\u00f3n\u00a0de\u00a0la\u00a0regi\u00f3n\u00a0variable, \u00a0favoreciendo\u00a0el\u00a0acceso\u00a0de\u00a0la\u00a0\nmol\u00e9cula\u00a0al\u00a0Ag.\u00a0La\u00a0existencia\u00a0de\u00a0esta\u00a0regi\u00f3n\u00a0bisagra\u00a0tambi\u00e9n\u00a0pr ovoca\u00a0una\u00a0mayor\u00a0susceptibilidad\u00a0\na\u00a0la\u00a0ruptura\u00a0proteol\u00edtica\u00a0de\u00a0la\u00a0Ig6.\u00a0Aunque\u00a0en\u00a0general\u00a0la\u00a0Ig\u00a0se\u00a0presenta\u00a0como\u00a0mon\u00f3mero,\u00a0algunos\u00a0\nisotipos\u00a0de\u00a0Ig\u00a0pueden\u00a0presentarse\u00a0en\u00a0forma\u00a0de\u00a0d\u00edmero\u00a0(i.e.\u00a0IgA) \u00a0o\u00a0pent\u00e1mero\u00a0(i.e.\u00a0IgM)5.\u00a0Adem\u00e1s,\u00a0\nesta\u00a0estructura\u00a0se\u00a0ve\u00a0modificada\u00a0por\u00a0cadenas\u00a0de\u00a0gl\u00facidos\u00a0que\u00a0se \u00a0unen\u00a0a\u00a0amino\u00e1cidos\u00a0concretos\u00a0\ny\u00a0que\u00a0modulan\u00a0la\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0Ig5.\u00a0\nFigura\u00a01.\u00a0Representaci\u00f3n\u00a0esquem\u00e1tica\u00a0de\u00a0la\u00a0estructura\u00a0de\u00a0los\u00a0di stintos\u00a0isotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs.\u00a0\nLas\u00a0Igs\u00a0se\u00a0componen\u00a0de\u00a0dos\u00a0cadenas\u00a0pesadas,\u00a0con\u00a0tres\u00a0o\u00a0cuatro\u00a0d ominios\u00a0constantes\u00a0(CH1,\u00a0CH2,\u00a0CH3\u00a0y\u00a0CH4)\u00a0y\u00a0uno\u00a0\nvariable\u00a0(VH),\u00a0y\u00a0dos\u00a0cadenas\u00a0ligeras,\u00a0con\u00a0un\u00a0dominio\u00a0constante\u00a0 (CL)\u00a0y\u00a0un\u00a0dominio\u00a0variable\u00a0(VL).\u00a0En\u00a0todos\u00a0los\u00a0isotipos\u00a0\nexcepto\u00a0en\u00a0la\u00a0IgM\u00a0y\u00a0la\u00a0IgE\u00a0exist e\u00a0una\u00a0regi\u00f3n\u00a0bisagra,\u00a0con\u00a0carac ter\u00edsticas\u00a0distintas\u00a0en\u00a0los\u00a0diferentes\u00a0isotipos.\u00a0La\u00a0IgA1\u00a0e\u00a0\nIgA2\u00a0se\u00a0representan\u00a0en\u00a0su\u00a0forma\u00a0monom\u00e9rica\u00a0y\u00a0dim\u00e9rica,\u00a0y\u00a0la\u00a0IgM \u00a0en\u00a0su\u00a0forma\u00a0monom\u00e9rica\u00a0y\u00a0pentam\u00e9rica.\u00a0Fc:\u00a0\nfragmento\u00a0cristalizable\u00a0de\u00a0la\u00a0Ig.\u00a0 \u00a0\nIntroducci\u00f3n \n\u2010\u00a05\u00a0\u2010\u00a0\n\u00a01.2.\u00a0Isotipos\u00a0y\u00a0subclases\u00a0de\u00a0inmunoglobulinas\u00a0\nAunque\u00a0existe\u00a0un\u00a0alto\u00a0grado\u00a0de\u00a0homolog\u00eda\u00a0entre\u00a0los\u00a0distintos\u00a0su btipos\u00a0de\u00a0Igs,\u00a0las\u00a0\nvariaciones\u00a0en\u00a0los\u00a0amino\u00e1cidos\u00a0que\u00a0componen\u00a0la\u00a0regi\u00f3n\u00a0constante \u00a0de\u00a0la\u00a0cadena\u00a0pesada\u00a0(IgH;\u00a0del\u00a0\ningl\u00e9s,\u00a0immunologlubulin\u00a0heavy\u00a0chain ),\u00a0permiten\u00a0distinguir\u00a05\u00a0isotipos\u00a0de\u00a0Igs\u00a0(IgG,\u00a0IgA,\u00a0IgM,\u00a0IgD\u00a0e\u00a0\nIgE),\u00a0subdivididos\u00a0a\u00a0su\u00a0vez\u00a0en\u00a04\u00a0subclases\u00a0de\u00a0IgG\u00a0(IgG1,\u00a0IgG2,\u00a0 IgG3\u00a0e\u00a0IgG4)\u00a0y\u00a0dos\u00a0subclases\u00a0de\u00a0IgA\u00a0\n(IgA1\u00a0e\u00a0IgA2)5,7,8.\u00a0Dichas\u00a0diferencias\u00a0se\u00a0localizan\u00a0fundamentalmente\u00a0en\u00a0el\u00a0llamad o\u00a0fragmento\u00a0\ncristalizable\u00a0(Fc),\u00a0que\u00a0comprende\u00a0todos\u00a0los\u00a0dominios\u00a0CH,\u00a0except o\u00a0CH1,\u00a0y\u00a0parte\u00a0de\u00a0la\u00a0regi\u00f3n\u00a0\nbisagra;\u00a0el\u00a0Fc\u00a0es\u00a0el\u00a0principal\u00a0responsable\u00a0de\u00a0las\u00a0funciones\u00a0efe ctoras\u00a0de\u00a0los\u00a0distintos\u00a0isotipos\u00a0y\u00a0\nsubclases\u00a0de\u00a0Igs5,9.\u00a0\u00a0\nHoy\u00a0conocemos,\u00a0de\u00a0forma\u00a0relativamente\u00a0detallada\u00a0la\u00a0funci\u00f3n\u00a0de\u00a0c ada\u00a0tipo\u00a0de\u00a0Ig\u00a0soluble.\u00a0\nEn\u00a0conjunto,\u00a0los\u00a0Acs\u00a0presentan\u00a0diferentes\u00a0capacidades\u00a0funcional es,\u00a0entre\u00a0las\u00a0que\u00a0merece\u00a0\ndestacar:\u00a0 la\u00a0 neutralizaci\u00f3n\u00a0 de\u00a0 Ag,\u00a0 la\u00a0 capacidad\u00a0 de\u00a0 opsonizaci\u00f3n \u00a0d e \u00a0A g \u00a0y \u00a0d e \u00a0f o r m a r \u00a0\ninmunocomplejos,\u00a0la\u00a0activaci\u00f3n\u00a0del\u00a0sistema\u00a0del\u00a0complemento\u00a0y\u00a0la \u00a0uni\u00f3n\u00a0y\u00a0activaci\u00f3n\u00a0de\u00a0c\u00e9lulas\u00a0\nefectoras\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0receptores\u00a0para\u00a0los\u00a0distintos\u00a0Fc\u00a0de\u00a0las\u00a0I gs\u00a0(FcR).\u00a0\u00a0La\u00a0composici\u00f3n\u00a0y\u00a0estructura\u00a0\ndel\u00a0Fc\u00a0de\u00a0las\u00a0Igs\u00a0tambi\u00e9n\u00a0condiciona\u00a0la\u00a0vida\u00a0media\u00a0del\u00a0Ac,\u00a0su\u00a0p osible\u00a0transporte\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\nplacenta\u00a0(mediante\u00a0el\u00a0FcR\u00a0neonatal\u00a0\u2212FcRn\u2212)\u00a0y\u00a0la\u00a0capacidad\u00a0de\u00a0at ravesar\u00a0las\u00a0membranas\u00a0mucosas\u00a0\n(a\u00a0trav\u00e9s\u00a0del\u00a0receptor\u00a0de\u00a0Ig\u00a0polim\u00e9rica\u00a0\u00a0\u2212pIgR\u2212)5,7,8,10.\u00a0Adem\u00e1s,\u00a0las\u00a0variaciones\u00a0en\u00a0el\u00a0Fc\u00a0de\u00a0la\u00a0zona\u00a0\nconstante\u00a0de\u00a0las\u00a0Igs\u00a0tambi\u00e9n\u00a0condicionan\u00a0una\u00a0distinta\u00a0capacidad \u00a0de\u00a0respuesta\u00a0a\u00a0los\u00a0diferentes\u00a0\ntipos\u00a0de\u00a0Ags\u00a0(i.e.\u00a0prote\u00ednas,\u00a0po lisac\u00e1ridos\u00a0o\u00a0al\u00e9rgenos,\u00a0entre\u00a0 otros)5,7,8,10.\u00a0\nEstas\u00a0diferencias\u00a0en\u00a0la\u00a0funci\u00f3n\u00a0 (biol\u00f3gica)\u00a0efectora\u00a0de\u00a0los\u00a0dis tintos\u00a0isotipos\u00a0y\u00a0subclases\u00a0\nde\u00a0Igs\u00a0hacen\u00a0que\u00a0las\u00a0alteraciones\u00a0de\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0cad a\u00a0Ig\u00a0se\u00a0traduzcan\u00a0en\u00a0distintos\u00a0\npatrones\u00a0de\u00a0enfermedad,\u00a0incluyendo:\u00a0i)\u00a0distintos\u00a0perfiles\u00a0de\u00a0su sceptibilidad\u00a0a\u00a0infecciones\u00a0por\u00a0\ndiferentes\u00a0microorganismos11\u201314\u00a0y\u00a0ii)\u00a0en\u00a0distintas\u00a0localizaciones\u00a0tisulares5,\u00a0iii)\u00a0diferentes\u00a0patrones\u00a0\nd e\u00a0respu est a\u00a0p at ol\u00f3g ic a\u00a0fren t e\u00a0a\u00a0Ag s\u00a0p rop ios\u00a0( e. g .\u00a0c it op en ias,\u00a0 autoinmunidad\u00a0sist\u00e9mica\u00a0 y\u00a0\ntisular)15,16,\u00a0y\u00a0iv)\u00a0diferente\u00a0impacto\u00a0en\u00a0la\u00a0regulaci\u00f3n\u00a0de\u00a0la\u00a0respuesta\u00a0inmu ne,\u00a0por\u00a0ejemplo,\u00a0ante\u00a0\nun\u00a0est\u00edmulo\u00a0cr\u00f3nico\u00a0o\u00a0tras\u00a0inmunoterapia17,18.\u00a0Introducci\u00f3n \n\u2010\u00a06\u00a0\u2010\u00a0\n\u00a0\u00a0Tabla\u00a01.\u00a0Caracter\u00edsticas\u00a0de\u00a0los\u00a0isotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs. \u00a0\na.\u00a0Rango\u00a0de\u00a0referencia\u00a0en\u00a0suero\u00a0de\u00a0adultos\u00a0sanos;\u00a0concentraci\u00f3n \u00a0expresada\u00a0en\u00a0mg/dl.\u00a0\nb.\u00a0Principalmente\u00a0en\u00a0mucosas.\u00a0c.\u00a0Aunque\u00a0cl\u00e1sicamente\u00a0se\u00a0ha\u00a0considerado\u00a0que\u00a0no\u00a0existir\u00eda\u00a0trans porte\u00a0de\u00a0IgA\u00a0e\u00a0IgM\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0placenta,\u00a0\nactualmente\u00a0se\u00a0cree\u00a0que\u00a0podr\u00eda\u00a0ex istir\u00a0cierta\u00a0capacidad\u00a0de\u00a0tran sferencia\u00a0placentaria\u00a0de\u00a0 ambos\u00a0isotipos\u00a0de\u00a0Igs.\u00a0\nFc\u03b3R,\u00a0receptor\u00a0para\u00a0el\u00a0fragmento\u00a0cristalizable\u00a0de\u00a0IgG;\u00a0Fc\u03b1R,\u00a0re ceptor\u00a0para\u00a0el\u00a0fragmento\u00a0cristalizable\u00a0de\u00a0IgA;\u00a0Fc\u03b5R,\u00a0\nreceptor\u00a0para\u00a0el\u00a0fragmento \u00a0cristalizable\u00a0de\u00a0IgE.\u00a0\n\u00a0\n1.2.1.\u00a0IgM\u00a0\nLa\u00a0IgM\u00a0constituye\u00a0el\u00a0primer\u00a0isotipo\u00a0de\u00a0Ig\u00a0que\u00a0se\u00a0produce\u00a0en\u00a0res puesta\u00a0a\u00a0la\u00a0estimulaci\u00f3n\u00a0\nantig\u00e9nica1,2,5.\u00a0Es\u00a0la\u00a0tercera\u00a0Ig\u00a0m\u00e1s\u00a0abundante\u00a0en\u00a0suero\u00a0(5\u201010%\u00a0de\u00a0los\u00a0niveles \u00a0globales\u00a0de\u00a0Igs\u00a0\ns\u00e9ricas)\u00a0con\u00a0una\u00a0concentraci\u00f3n\u00a0de\u00a040\u2010320\u00a0mg/dl4,\u00a0y\u00a0una\u00a0vida\u00a0media\u00a0de\u00a0\u22484\u00a0d\u00edas1,19\u00a0(Tabla\u00a01).\u00a0Los\u00a0\nAcs\u00a0de\u00a0isotipo\u00a0IgM,\u00a0adem\u00e1s\u00a0de\u00a0estar\u00a0presentes\u00a0en\u00a0suero/plasma,\u00a0 se\u00a0encuentran\u00a0tambi\u00e9n\u00a0en\u00a0\nmenor\u00a0concentraci\u00f3n\u00a0en\u00a0otros\u00a0flu idos\u00a0biol\u00f3gicos,\u00a0como\u00a0la\u00a0saliva \u00a0(0,6\u20106\u00a0mg/dl),\u00a0la\u00a0l\u00e1grima\u00a0(0\u20101,8\u00a0\nmg/dl),\u00a0el\u00a0l\u00edquido\u00a0cefalorraqu\u00eddeo\u00a0(0\u20101,3\u00a0mg/dl),\u00a0la\u00a0leche\u00a0mate rna\u00a0(5\u201034\u00a0mg/dl),\u00a0el\u00a0calostro\u00a0(\u224861\u00a0\nmg/dl)\u00a0y\u00a0las\u00a0secreciones\u00a0bro nco\u2010alveolares\u00a0(\u22480,02\u00a0mg/dl)20\u00a0e\u00a0intestinales\u00a0(\u22480,8\u00a0mg/dl)21.\u00a0Su\u00a0\u00a0 IgM\u00a0 IgD\u00a0 IgG1 IgG2 Ig G3 IgG4 IgA1\u00a0 IgA2\u00a0 IgE\nConcentraci\u00f3n\u00a0\nen\u00a0sueroa\u00a040\u2010320\u00a0 0,7\u201013\u00a0 490\u20101.010\u00a0 170\u2010785\u00a0 11\u2010 85\u00a0 3\u2010200\u00a0 75\u2010330\u00a0 7\u2010115\u00a0 <0.03\u00a0\nVida\u00a0media\u00a0en\u00a0\nsuero\u00a0(d\u00edas)\u00a05\u00a0 3\u00a0 21\u00a0 21\u00a0 7\u00a0 21\u00a0 6\u00a0 6\u00a0 3\u00a0\nTama\u00f1o\u00a0de\u00a0regi\u00f3n\u00a0bisagra\u00a0(N\u00ba\u00a0de\u00a0amino\u00e1cidos)\u00a0\n0\u00a0 64\u00a0 15\u00a0 12\u00a0 62\u00a0 12\u00a0 22\u00a0 9\u00a0 0\u00a0\nEstructura\u00a0Mon\u00f3mero/\u00a0\n\u00a0Pent\u00e1mero\u00a0Mon\u00f3mero\u00a0 Mon\u00f3mero\u00a0 Mon\u00f3mero\u00a0 Mon\u00f3mero\u00a0 Mon\u00f3mero\u00a0Mon\u00f3mero/\u00a0\nD\u00edmerob\u00a0Mon\u00f3mero/\u00a0\nD\u00edmerob\u00a0Mon\u00f3mero\u00a0\nTransferencia\u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0la\u00a0\nplacenta\u00a0+/\u2010c\u00a0 \u2010\u00a0 ++++\u00a0 ++\u00a0 ++++\u00a0 +++\u00a0 +/\u2010c\u00a0+ / \u2010c\u00a0\u2010 \u00a0\nTransferencia\u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0la\u00a0mucosa\u00a0 ++\u00a0 +\u00a0 +\u00a0 +\u00a0 +\u00a0 +\u00a0 ++\u00a0 +++\u00a0 \u2010\u00a0\nActividad\u00a0neutralizadora\u00a0+\u00a0 +?\u00a0 ++\u00a0 ++\u00a0 ++\u00a0 ++\u00a0 ++\u00a0 ++\u00a0 \u2010\u00a0\nActivaci\u00f3n\u00a0del\u00a0complemento\u00a0(v\u00eda\u00a0cl\u00e1sica)\u00a0\n++++\u00a0 \u2010\u00a0 ++\u00a0 +\u00a0 +++\u00a0 \u2010\u00a0 \u2010\u00a0 \u2010\u00a0 \u2010\u00a0\nActivaci\u00f3n\u00a0del\u00a0complemento\u00a0\n(via\u00a0alternativa)\u00a0 \u2010\u00a0 \u2010\u00a0 \u2010\u00a0 \u2010\u00a0 \u2010\u00a0 \u2010\u00a0 +?\u00a0 \u2010\u00a0 \u2010\u00a0\nCapacidad\u00a0de\u00a0\nopsonizaci\u00f3n\u00a0+\u00a0 \u2010\u00a0 +\u00a0 +\u00a0 +\u00a0 +\u00a0 \u2010\u00a0 \u2010\u00a0 \u2010\u00a0\nUni\u00f3n\u00a0a\u00a0\nreceptores\u00a0FcR\u00a0\u2010\u00a0 \u2010\u00a0Fc\u03b3R\u00a0I,II,III\u00a0\nFcRn\u00a0Fc\u03b3R\u00a0II\u00a0\nFcRn\u00a0Fc\u03b3R\u00a0I,II,III\u00a0\nFcRn\u00a0Fc\u03b3R\u00a0I,II\u00a0\nFcRn\u00a0Fc\u03b1R\u00a0 Fc\u03b1R\u00a0 Fc\u03b5R\u00a0I,II\u00a0\nRespuesta\u00a0a\u00a0\nprote\u00ednas\u00a0+\u00a0 \u2010\u00a0 ++\u00a0 +/\u2010\u00a0 ++\u00a0 +/\u2010\u00a0 ++\u00a0 +\u00a0 \u2010\u00a0\nRespuesta\u00a0a\u00a0polisac\u00e1ridos\u00a0++\u00a0 \u2010\u00a0 +\u00a0 +++\u00a0 \u2010\u00a0 \u2010\u00a0 +\u00a0 ++\u00a0 \u2010\u00a0\nRespuesta\u00a0a\u00a0al\u00e9rgenos\u00a0\u2010\u00a0 \u2010\u00a0 +\u00a0 \u2010\u00a0 \u2010\u00a0 ++\u00a0 \u2010\u00a0 \u2010\u00a0 +++\u00a0Introducci\u00f3n \n\u2010\u00a07\u00a0\u2010\u00a0\n\u00a0estructura\u00a0 est\u00e1\u00a0 formada\u00a0 por\u00a0 4\u00a0 dominios\u00a0 CH\u00a0 y\u00a0 no\u00a0 posee\u00a0 regi\u00f3n\u00a0 bis agra,\u00a0 encontr\u00e1ndose\u00a0\nhabitualmente\u00a0en\u00a0forma\u00a0de\u00a0pent\u00e1mero,\u00a0con\u00a0las\u00a0mol\u00e9culas\u00a0de\u00a0IgM\u00a0u nidas\u00a0entre\u00a0s\u00ed\u00a0por\u00a0la\u00a0prote\u00edna\u00a0\n\u201cJ\u201d,\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0los\u00a0dominios\u00a0CH45,22\u00a0(Figura\u00a01).\u00a0Esta\u00a0estructura\u00a0pentam\u00e9rica\u00a0incrementa\u00a0la\u00a0avidez\u00a0\nde\u00a0los\u00a0Acs\u00a0IgM\u00a0por\u00a0el\u00a0Ag\u00a0(especialmente\u00a0cuando\u00a0este\u00a0\u00faltimo\u00a0pose e\u00a0varios\u00a0ep\u00edtopos),\u00a0pese\u00a0a\u00a0la\u00a0\nmenor\u00a0afinidad\u00a0por\u00a0Ag\u00a0de\u00a0los\u00a0Acs\u00a0IgM\u00a0respecto\u00a0a\u00a0otros\u00a0isotipos\u00a0 de\u00a0Igs2,5.\u00a0Funcionalmente,\u00a0los\u00a0Acs\u00a0\nde\u00a0tipo\u00a0IgM\u00a0ejercen\u00a0funciones\u00a0efectoras\u00a0basadas\u00a0en\u00a0la\u00a0opsonizac i\u00f3n\u00a0de\u00a0microorganismos\u00a0y\u00a0la\u00a0\nactivaci\u00f3n\u00a0 del\u00a0 complemento\u00a0 por\u00a0 la\u00a0 v\u00eda\u00a0 cl\u00e1sica5,22,\u00a0 mediante\u00a0 su\u00a0 uni\u00f3n\u00a0 a\u00a0 la\u00a0 prote\u00edna\u00a0 del\u00a0\ncomplemento\u00a0C1q;\u00a0esta\u00a0uni\u00f3n\u00a0\u00fanicamente\u00a0ocurre\u00a0cuando\u00a0la\u00a0Ig\u00a0est\u00e1 \u00a0unida\u00a0al\u00a0Ag1,5,\u00a0\u00a0al\u00a0cambiar\u00a0su\u00a0\nforma\u00a0de\u00a0\u201cestrella\u201d\u00a0pentam\u00e9rica\u00a0 a\u00a0la\u00a0denominada\u00a0forma\u00a0de\u00a0\u201ccangr ejo\u201d,\u00a0en\u00a0la\u00a0que\u00a0los\u00a0m\u00faltiples\u00a0\nFc\u00a0de\u00a0las\u00a0IgM\u00a0quedan\u00a0accesibles\u00a0para\u00a0unirse\u00a0a\u00a0la\u00a0prote\u00edna\u00a0C1q\u00a0d el\u00a0sistema\u00a0del\u00a0complemento2.\u00a0\u00a0\n\u00a0\n1.2.2.\u00a0IgG\u00a0y\u00a0subclases\u00a0de\u00a0IgG\u00a0\nCuantitativamente\u00a0la\u00a0IgG\u00a0representa\u00a0el\u00a085%\u00a0de\u00a0las\u00a0Igs\u00a0s\u00e9ricas\u00a0( 700\u20101600\u00a0mg/dl),\u00a0debido\u00a0\na\u00a0que\u00a0es\u00a0el\u00a0isotipo\u00a0producido\u00a0en\u00a0mayor\u00a0cantidad\u00a0por\u00a0las\u00a0c\u00e9lulas \u00a0plasm\u00e1ticas\u00a0(CPs)\u00a0de\u00a0m\u00e9dula\u00a0\u00f3sea\u00a0\n(MO)23\u00a0y\u00a0que\u00a0posee\u00a0una\u00a0vida\u00a0media\u00a0relativamente\u00a0elevada\u00a0(7\u201021\u00a0d\u00edas)1,19\u00a0(Tabla\u00a01).\u00a0Por\u00a0el\u00a0\ncontrario,\u00a0la\u00a0IgG\u00a0no\u00a0suele\u00a0ser\u00a0el\u00a0isotipo\u00a0de\u00a0Ig\u00a0m\u00e1s\u00a0abundante\u00a0e n\u00a0otros\u00a0fluidos\u00a0biol\u00f3gicos.\u00a0As\u00ed,\u00a0en\u00a0\nla\u00a0saliva\u00a0(2,6\u20104,2\u00a0mg/dl),\u00a0en\u00a0la\u00a0l\u00e1grima\u00a0(0\u20101,6\u00a0mg/dl)\u00a0y\u00a0en\u00a0la\u00a0 secreci\u00f3n\u00a0nasal\u00a0(0,8\u201030\u00a0mg/dl),\u00a0su\u00a0\nconcentraci\u00f3n\u00a0es\u00a0inferior\u00a0a\u00a0la\u00a0de\u00a0la\u00a0IgA21,24,\u00a0mientras\u00a0que\u00a0en\u00a0la\u00a0leche\u00a0materna\u00a0(4\u201017\u00a0mg/dl),\u00a0el\u00a0\ncalostro\u00a0(\u224810\u00a0mg/dl)\u00a0y\u00a0el\u00a0fluido\u00a0derivado\u00a0de\u00a0la\u00a0secreci\u00f3n\u00a0intes tinal\u00a0(\u22480,4\u00a0mg/dl)\u00a0su\u00a0concentraci\u00f3n\u00a0\nes\u00a0tambi\u00e9n\u00a0inferior\u00a0a\u00a0la\u00a0concentraci\u00f3n\u00a0de\u00a0IgM21.\u00a0Las\u00a0\u00fanicas\u00a0excepciones\u00a0ser\u00edan\u00a0el\u00a0fluido\u00a0bronco\u2010\nalveolar\u00a0(\u22480,4\u00a0mg/dl)20\u00a0y\u00a0el\u00a0l\u00edquido\u00a0cefalorraqu\u00eddeo\u00a0(0\u20105,5\u00a0mg/dl)24,\u00a0donde\u00a0los\u00a0niveles\u00a0de\u00a0IgG\u00a0son\u00a0\nsimilares\u00a0a\u00a0los\u00a0de\u00a0la\u00a0IgA\u00a0y\u00a0supe riores\u00a0a\u00a0los\u00a0de\u00a0los\u00a0dem\u00e1s\u00a0isoti pos\u00a0de\u00a0Igs,\u00a0respectivamente.\u00a0\nEn\u00a0total,\u00a0existen\u00a04\u00a0subclases\u00a0de\u00a0IgG:\u00a0IgG1\u20104.\u00a0Desde\u00a0el\u00a0punto\u00a0de \u00a0vista\u00a0estructural,\u00a0cada\u00a0\nuna\u00a0de\u00a0las\u00a0cadenas\u00a0pesadas\u00a0de\u00a0las\u00a0distintas\u00a0subclases\u00a0de\u00a0IgG\u00a0co ntienen\u00a0un\u00a0dominio\u00a0variable\u00a0y\u00a03\u00a0\ndominios\u00a0constantes,\u00a0con\u00a0una\u00a0regi\u00f3n\u00a0bisagra\u00a0de\u00a0distinta\u00a0longitu d\u00a0seg\u00fan\u00a0la\u00a0subclase\u00a0de\u00a0IgG;\u00a0todas\u00a0Introducci\u00f3n \n\u2010\u00a08\u00a0\u2010\u00a0\n\u00a0las\u00a0subclases\u00a0de\u00a0IgG\u00a0est\u00e1n\u00a0prese ntes\u00a0de\u00a0forma\u00a0sistem\u00e1tica\u00a0en\u00a0lo s\u00a0distintos\u00a0fluidos\u00a0corporales\u00a0en\u00a0\nforma\u00a0de\u00a0mon\u00f3mer o\u00a0(Figura\u00a01).\u00a0\nFuncionalmente,\u00a0los\u00a0Acs\u00a0de\u00a0isotipo\u00a0IgG\u00a0pueden\u00a0actuar\u00a0de\u00a0forma\u00a0d irecta:\u00a0i)\u00a0activando\u00a0la\u00a0\nv\u00eda\u00a0cl\u00e1sica\u00a0del\u00a0complemento;\u00a0ii) \u00a0neutralizando\u00a0toxinas,\u00a0microor ganismos\u00a0pat\u00f3genos\u00a0y\u00a0otros\u00a0Ags;\u00a0\niii)\u00a0mediante\u00a0la\u00a0opsonizaci\u00f3n\u00a0de\u00a0Ag\u00a0para\u00a0su\u00a0fagocitosis\u00a0por\u00a0c\u00e9l ulas\u00a0del\u00a0sistema\u00a0monocito\u2010\nmacr\u00f3fago\u00a0y\u00a0los\u00a0neutr\u00f3filos;\u00a0y\u00a0iv)\u00a0promoviendo\u00a0la\u00a0degranulaci\u00f3n \u00a0y\u00a0activaci\u00f3n\u00a0de\u00a0c\u00e9lulas\u00a0NK1,5,7,8.\u00a0\nEstas\u00a0dos\u00a0\u00faltimas\u00a0funciones\u00a0son\u00a0mediadas\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0uni\u00f3n\u00a0d e\u00a0la\u00a0IgG\u00a0unida\u00a0a\u00a0Ag,\u00a0a\u00a0los\u00a0\nreceptores\u00a0para\u00a0el\u00a0Fc\u00a0de\u00a0IgG\u00a0(Fc\u03b3R)\u00a0de\u00a0alta\u00a0(Fc\u03b3RI\u00a0o\u00a0CD64),\u00a0int ermedia\u00a0(Fc\u03b3RII\u00a0o\u00a0CD32)\u00a0y\u00a0baja\u00a0\n(Fc\u03b3RIII\u00a0o\u00a0CD16)\u00a0afinidad8,25.\u00a0Adem\u00e1s\u00a0de\u00a0por\u00a0su\u00a0grado\u00a0de\u00a0afinidad\u00a0por\u00a0la\u00a0IgG,\u00a0los\u00a0Fc\u03b3R\u00a0se\u00a0\ndiferencian\u00a0entre\u00a0s\u00ed\u00a0por\u00a0su\u00a0perfil\u00a0de\u00a0expresi\u00f3n\u00a0celular.\u00a0As\u00ed,\u00a0C D32\u00a0se\u00a0expresa\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0\nleucocitos\u00a0incluyendo\u00a0los\u00a0linfoci tos\u00a0B,\u00a0CD64\u00a0se\u00a0expresa\u00a0de\u00a0form a\u00a0constitutiva\u00a0\u00fanicamente\u00a0en\u00a0los\u00a0\nmonocitos,\u00a0macr\u00f3fagos\u00a0y\u00a0granuloc itos\u00a0neutr\u00f3filos,\u00a0y\u00a0la\u00a0expresi\u00f3 n\u00a0de\u00a0CD16\u00a0est\u00e1\u00a0restringida\u00a0a\u00a0los\u00a0\ngranulocitos\u00a0neutr\u00f3filos,\u00a0una\u00a0fracci\u00f3n\u00a0de\u00a0los\u00a0monocitos\u00a0y\u00a0las\u00a0c \u00e9lulas\u00a0NK1,5\u20138.\u00a0Cabe\u00a0se\u00f1alar\u00a0que\u00a0\ntodas\u00a0las\u00a0subclases\u00a0de\u00a0IgG\u00a0tienen\u00a0capacidad\u00a0de\u00a0unirse\u00a0tambi\u00e9n\u00a0a l\u00a0FcRn,\u00a0expresado\u00a0en\u00a0c\u00e9lulas\u00a0\nepiteliales\u00a0y\u00a0c\u00e9lulas\u00a0fagoc\u00edticas,\u00a0y\u00a0que\u00a0es\u00a0responsable\u00a0del\u00a0pas o\u00a0de\u00a0la\u00a0IgG\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0placenta\u00a0a\u00a0\nla\u00a0circulaci\u00f3n\u00a0fetal,\u00a0y\u00a0a\u00a0trav\u00e9s\u00a0 de\u00a0las\u00a0superficies\u00a0mucosas\u00a0a\u00a0l as\u00a0secreciones\u00a0externas5,8.\u00a0\nA\u00a0pesar\u00a0de\u00a0que\u00a0los\u00a0Acs\u00a0de\u00a0isotipo\u00a0IgG\u00a0de\u00a0distintas\u00a0subclases\u00a0pr esentan\u00a0una\u00a0homolog\u00eda\u00a0\nestructural\u00a0>90%,\u00a0existen\u00a0diferencias\u00a0en\u00a0los\u00a0dominios\u00a0funcional es,\u00a0como\u00a0la\u00a0regi\u00f3n\u00a0bisagra\u00a0y/o\u00a0las\u00a0\nzonas\u00a0de\u00a0uni\u00f3n\u00a0a\u00a0la\u00a0prote\u00edna\u00a0C1q\u00a0y\u00a0a\u00a0los\u00a0Fc\u03b3R\u00a0localizadas\u00a0en\u00a0CH 2,\u00a0que,\u00a0adem\u00e1s\u00a0de\u00a0contribuir\u00a0a\u00a0\ndiferenciarlas,\u00a0les\u00a0confieren\u00a0distintas\u00a0funciones5,7,8.\u00a0\u00a0\nIgG1.\u00a0La\u00a0IgG1\u00a0constituye \u00a0la\u00a0subclase\u00a0de\u00a0IgG\u00a0mayoritaria\u00a0en\u00a0suero\u00a0(60\u201075%\u00a0de\u00a0la\u00a0IgG\u00a0total ;\u00a0\n400\u20101.100\u00a0mg/dl\u00a0en\u00a0adultos\u00a0sanos)5,6,23\u00a0con\u00a0una\u00a0vida\u00a0media\u00a0de\u00a0aproximadamente\u00a021\u00a0d\u00edas1,8.\u00a0En\u00a0\notros\u00a0fluidos\u00a0biol\u00f3gicos\u00a0esta\u00a0s ubclase\u00a0de\u00a0IgG\u00a0se\u00a0encuentra\u00a0meno s\u00a0representada\u00a0respecto\u00a0al\u00a0\nconjunto\u00a0de\u00a0las\u00a0IgG,\u00a0representando\u00a0\u224847%\u00a0del\u00a0total\u00a0de\u00a0Acs\u00a0IgG\u00a0en \u00a0la\u00a0leche\u00a0materna,\u00a0\u224846%\u00a0en\u00a0el\u00a0\ncalostro,\u00a0\u224830%\u00a0en\u00a0saliva26\u00a0y\u00a0\u224852%\u00a0en\u00a0l\u00edquido\u00a0cefalorraqu\u00eddeo27.\u00a0La\u00a0IgG1\u00a0posee\u00a0una\u00a0regi\u00f3n\u00a0bisagra\u00a0\nde\u00a015\u00a0amino\u00e1cidos\u00a0que\u00a0le\u00a0proporciona\u00a0gran\u00a0flexibilidad8.\u00a0Tiene\u00a0adem\u00e1s\u00a0una\u00a0a lta\u00a0capacidad\u00a0para\u00a0Introducci\u00f3n \n\u2010\u00a09\u00a0\u2010\u00a0\n\u00a0ser\u00a0transferida\u00a0a\u00a0la\u00a0circulaci\u00f3n\u00a0fetal\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0placenta, \u00a0de\u00a0activar\u00a0el\u00a0complemento\u00a0y\u00a0de\u00a0unirse\u00a0\na\u00a0todos\u00a0los\u00a0tipos\u00a0de\u00a0Fc\u03b3R1,2.\u00a0Los\u00a0Acs\u00a0de\u00a0tipo\u00a0IgG1\u00a0se\u00a0producen\u00a0principalmente\u00a0en\u00a0respuesta\u00a0 a\u00a0Ags\u00a0\nproteicos\u00a0(bacterianos\u00a0y\u00a0v\u00edricos),\u00a0y\u00a0en\u00a0menor\u00a0medida\u00a0tambi\u00e9n,\u00a0e n\u00a0respuesta\u00a0a\u00a0al\u00e9rgenos\u00a0y\u00a0\npolisac\u00e1ridos8.\u00a0Adem\u00e1s,\u00a0con\u00a0relativa\u00a0frecuenci a,\u00a0los\u00a0Acs\u00a0producidos\u00a0frente\u00a0a\u00a0 Ags\u00a0propios\u00a0(auto\u2010\nAcs),\u00a0son\u00a0tambi\u00e9n\u00a0de\u00a0tipo\u00a0IgG116.\u00a0\u00a0\nIgG2.\u00a0La\u00a0IgG2\u00a0es\u00a0la\u00a0segunda\u00a0subclase\u00a0de\u00a0IgG\u00a0m\u00e1s\u00a0representada\u00a0en\u00a0suero \u00a0(20\u201025%\u00a0de\u00a0toda\u00a0\nla\u00a0IgG;\u00a0170\u2010785\u00a0mg/dl\u00a0en\u00a0adultos\u00a0sanos)2,4\u00a0con\u00a0una\u00a0vida\u00a0media\u00a0de\u00a021\u00a0d\u00edas,\u00a0similar\u00a0a\u00a0la\u00a0de\u00a0la\u00a0\nIgG11,5,8.\u00a0En\u00a0otros\u00a0fluidos\u00a0biol\u00f3gicos\u00a0podemos\u00a0encontrar\u00a0niveles\u00a0de\u00a0IgG2 \u00a0similares\u00a0(o\u00a0incluso\u00a0\nsuperiores)\u00a0a\u00a0los\u00a0niveles\u00a0de\u00a0IgG 1,\u00a0representando\u00a0\u224843%\u00a0de\u00a0todos\u00a0 los\u00a0Acs\u00a0IgG\u00a0en\u00a0la\u00a0lecha\u00a0materna\u00a0\ny\u00a0el\u00a0calostro,\u00a0\u224851%\u00a0en\u00a0saliva26\u00a0y\u00a0\u224837%\u00a0en\u00a0l\u00edquido\u00a0cefalorraqu\u00eddeo27.\u00a0Su\u00a0regi\u00f3n\u00a0bisagra\u00a0est\u00e1\u00a0\ncompuesta\u00a0\u00fanicamente\u00a0por\u00a012\u00a0amino\u00e1cidos,\u00a0lo\u00a0que\u00a0junto\u00a0a\u00a0la\u00a0pres encia\u00a0de\u00a0una\u00a0h\u00e9lice\u00a0de\u00a0poli\u2010\nprolinas,\u00a0le\u00a0hace\u00a0mucho\u00a0menos\u00a0flexible\u00a0que\u00a0las\u00a0dem\u00e1s\u00a0subclases\u00a0 de\u00a0IgG8.\u00a0La\u00a0capacidad\u00a0de\u00a0los\u00a0Acs\u00a0\nde\u00a0tipo\u00a0IgG2\u00a0de\u00a0transferencia\u00a0pl acentaria\u00a0y\u00a0de\u00a0activar\u00a0compleme nto\u00a0es\u00a0significativamente\u00a0\ninferior\u00a0a\u00a0la\u00a0de\u00a0IgG1\u00a08;\u00a0adem\u00e1s,\u00a0la\u00a0IgG2\u00a0solamente\u00a0es\u00a0c apaz\u00a0de\u00a0unirse\u00a0a\u00a0algunas\u00a0isofor mas\u00a0de\u00a0\nFc\u03b3RII\u00a0y\u00a0siempre\u00a0de\u00a0forma\u00a0m\u00e1s\u00a0d\u00e9bil\u00a0que\u00a0la\u00a0IgG15,8.\u00a0Desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0funcional,\u00a0la\u00a0IgG2\u00a0\ntiene\u00a0un\u00a0papel\u00a0clave\u00a0en\u00a0la\u00a0respuesta\u00a0inmune\u00a0humoral\u00a0frente\u00a0a\u00a0Ag s\u00a0polisacar\u00eddicos\u00a0de\u00a0origen\u00a0\nbacteriano4,8.\u00a0\nIgG3.\u00a0La\u00a0IgG3\u00a0supone\u00a0\u00fanicamente\u00a0el\u00a05\u201010%\u00a0de\u00a0toda\u00a0la\u00a0IgG\u00a0presente\u00a0en\u00a0s uero\u00a0(11\u201085\u00a0\nmg/dl\u00a0en\u00a0adultos)2,4,\u00a0donde\u00a0tiene\u00a0una\u00a0vida\u00a0media\u00a0de\u00a07\u00a0d\u00edas,\u00a0significativamente\u00a0meno r\u00a0a\u00a0la\u00a0de\u00a0las\u00a0\ndem\u00e1s\u00a0subclases\u00a0de\u00a0 IgG4,8. \u00a0Adem \u00e1s,\u00a0est a\u00a0su b clase\u00a0d e\u00a0IgG\u00a0n o\u00a0se\u00a0d et ect a\u00a0en \u00a0ot ros\u00a0flu idos\u00a0\ncorporales\u00a0 como\u00a0 la\u00a0 leche\u00a0 materna,\u00a0 el\u00a0 calostro\u00a0 y\u00a0 la\u00a0 saliva26,\u00a0 estando\u00a0 presente\u00a0 en\u00a0 l\u00edquido\u00a0\ncefalorraqu\u00eddeo\u00a0en\u00a0niveles\u00a0relativamente\u00a0muy\u00a0bajos\u00a0(\u22487%\u00a0de\u00a0toda \u00a0la\u00a0IgG)27.\u00a0Debido\u00a0a\u00a0que\u00a0se\u00a0trata\u00a0\nde\u00a0 una\u00a0 Ig\u00a0 capaz\u00a0 de\u00a0 generar\u00a0 una\u00a0 potente\u00a0 respuesta\u00a0 pro\u2010inflamator ia,\u00a0 su\u00a0 baja\u00a0 vida\u00a0 media\u00a0\nprobablemente\u00a0responda\u00a0a\u00a0la\u00a0necesidad\u00a0de\u00a0limitar\u00a0respuestas\u00a0inf lamatorias\u00a0excesivas8.\u00a0La\u00a0regi\u00f3n\u00a0\nbisagra\u00a0de\u00a0la\u00a0IgG3\u00a0es\u00a0m\u00e1s\u00a0extens a\u00a0que\u00a0la\u00a0de\u00a0otras\u00a0subclases\u00a0de\u00a0 IgG\u00a0(62\u00a0amino\u00e1cidos),\u00a0lo\u00a0que\u00a0le\u00a0\nproporciona\u00a0una\u00a0gran\u00a0flexibilidad\u00a0para\u00a0unirse\u00a0a\u00a0ep\u00edtopos\u00a0de\u00a0dis tintos\u00a0Ags.\u00a0Sin\u00a0embargo,\u00a0esto\u00a0va\u00a0Introducci\u00f3n \n\u2010\u00a010\u00a0\u2010\u00a0\n\u00a0asociado\u00a0tambi\u00e9n\u00a0a\u00a0un\u00a0mayor\u00a0peso\u00a0molecular\u00a0y\u00a0una\u00a0mayor\u00a0suscepti bilidad\u00a0a\u00a0la\u00a0rotura\u00a0por\u00a0\nenzimas\u00a0proteol\u00edticas,\u00a0posible\u00a0responsable\u00a0\u00faltimo\u00a0de\u00a0su\u00a0corta\u00a0v ida\u00a0media\u00a0en\u00a0suero8.\u00a0Los\u00a0Acs\u00a0de\u00a0\ntipo\u00a0IgG3\u00a0tienen\u00a0una\u00a0elevada\u00a0capacidad\u00a0para\u00a0atravesar\u00a0la\u00a0placen ta,\u00a0activar\u00a0el\u00a0complemento\u00a0y\u00a0\nunirse\u00a0a\u00a0todos\u00a0los\u00a0Fc\u03b3R,\u00a0superando\u00a0la\u00a0capacidad\u00a0funcional\u00a0de\u00a0la \u00a0IgG14,8.\u00a0Al\u00a0igual\u00a0que\u00a0ocurre\u00a0con\u00a0\nla\u00a0 IgG1,\u00a0 la\u00a0 producci\u00f3n\u00a0 de\u00a0 IgG3\u00a0 se\u00a0 induce\u00a0 principalmente\u00a0 en\u00a0 resp uesta\u00a0 a\u00a0 Ags\u00a0 proteicos\u00a0\n(bacterianos\u00a0y\u00a0v\u00edricos),\u00a0detect\u00e1 ndose\u00a0en\u00a0suero\u00a0en\u00a0el\u00a0curso\u00a0de\u00a0u na\u00a0infecci\u00f3n\u00a0antes\u00a0que\u00a0la\u00a0IgG18;\u00a0\ncon\u00a0relativa\u00a0frecuencia\u00a0esta\u00a0subc lase\u00a0de\u00a0IgG\u00a0est\u00e1\u00a0tambi\u00e9n\u00a0invol ucrada\u00a0en\u00a0autoinmunidad16.\u00a0\nIgG4.\u00a0IgG4\u00a0es\u00a0la\u00a0subclase\u00a0de\u00a0IgG\u00a0minoritaria\u00a0en\u00a0suero\u00a0(<5%\u00a0de\u00a0la\u00a0IgG\u00a0 total,\u00a03\u2010200\u00a0mg/dl\u00a0\nen\u00a0suero\u00a0de\u00a0adultos)2,4,\u00a0donde\u00a0presenta\u00a0una\u00a0vida\u00a0media\u00a0de\u00a021\u00a0d\u00edas4,8.\u00a0Adem\u00e1s,\u00a0est\u00e1\u00a0presente\u00a0en\u00a0\npeque\u00f1as\u00a0concentraciones\u00a0en\u00a0la\u00a0leche\u00a0materna\u00a0(\u22486%\u00a0de\u00a0la\u00a0IgG\u00a0tot al),\u00a0el\u00a0calostro\u00a0(\u22486%),\u00a0la\u00a0saliva\u00a0\n(\u22483,7%)26\u00a0y\u00a0el\u00a0l\u00edquido\u00a0cefalorraqu\u00eddeo\u00a0(\u22484%)27.\u00a0Su\u00a0regi\u00f3n\u00a0bisagra\u00a0es\u00a0de\u00a0peque\u00f1o\u00a0tama\u00f1o\u00a0(similar\u00a0\nal\u00a0de\u00a0la\u00a0IgG2)\u00a0con\u00a0solo\u00a012\u00a0amino\u00e1cidos,\u00a0pero\u00a0una\u00a0flexibilidad\u00a0i ntermedia\u00a0entre\u00a0la\u00a0de\u00a0la\u00a0IgG1\u00a0y\u00a0la\u00a0\nde\u00a0la\u00a0IgG28.\u00a0A\u00a0pesar\u00a0de\u00a0no\u00a0ser\u00a0capaz\u00a0de\u00a0activar\u00a0complemento,\u00a0los\u00a0Acs\u00a0de\u00a0ti po\u00a0IgG4\u00a0pueden\u00a0unirse\u00a0\na\u00a0los\u00a0Fc\u03b3RI\u00a0y\u00a0II,\u00a0aunque\u00a0de\u00a0forma\u00a0m\u00e1s\u00a0d\u00e9bil\u00a0que\u00a0la\u00a0IgG1\u00a0e\u00a0IgG3. \u00a0A\u00a0diferencia\u00a0de\u00a0las\u00a0dem\u00e1s\u00a0subclases\u00a0\nde\u00a0IgG,\u00a0la\u00a0IgG4\u00a0suele\u00a0producirse\u00a0en\u00a0respuesta\u00a0a\u00a0exposiciones\u00a0re petidas\u00a0(o\u00a0de\u00a0larga\u00a0duraci\u00f3n)\u00a0a\u00a0\nAg,\u00a0como\u00a0por\u00a0ejemplo,\u00a0en\u00a0individuos\u00a0al\u00e9rgicos\u00a0bajo\u00a0tratamiento\u00a0 con\u00a0inmunoterapia\u00a0al\u00e9rgeno\u2010\nespec\u00edfica28.\u00a0Esto,\u00a0unido\u00a0a\u00a0su\u00a0baja\u00a0efectividad\u00a0para\u00a0llevar\u00a0a\u00a0cabo\u00a0una\u00a0resp uesta\u00a0efectora,\u00a0ha\u00a0\ninducido\u00a0a\u00a0algunos\u00a0autores\u00a0a\u00a0sugerir\u00a0que\u00a0esta\u00a0subclase\u00a0 de\u00a0IgG\u00a0 p ueda\u00a0tener\u00a0una\u00a0funci\u00f3n\u00a0\ntolerog\u00e9nica,\u00a0privando\u00a0del\u00a0Ag\u00a0a\u00a0 otros\u00a0Acs\u00a0pro\u2010inflamatorios\u00a0muc ho\u00a0m\u00e1s\u00a0potentes28.\u00a0\n\u00a0\n1.2.3.\u00a0IgA\u00a0y\u00a0subclases\u00a0de\u00a0IgA\u00a0\nAunque\u00a0la\u00a0concentraci\u00f3n\u00a0de\u00a0IgA\u00a0en\u00a0suero\u00a0es\u00a0inferior\u00a0a\u00a0la\u00a0de\u00a0IgG \u00a0(7\u201015%\u00a0del\u00a0total\u00a0de\u00a0las\u00a0Igs;\u00a0100\u2010\n400\u00a0mg/dl),\u00a0la\u00a0IgA\u00a0es\u00a0la\u00a0Ig\u00a0predom inante\u00a0en\u00a0las\u00a0secreciones\u00a0ext ernas\u00a0(Tabla\u00a01)5,21,29,30.\u00a0As\u00ed,\u00a0su\u00a0\nconcentraci\u00f3n\u00a0en\u00a0l\u00e1grima\u00a0(8\u201040\u00a0 mg/dl),\u00a0saliva\u00a0(10\u201021\u00a0mg/dl),\u00a0le che\u00a0materna\u00a0(47\u2010163\u00a0mg/dl),\u00a0\ncalostro\u00a0(1.234\u20105.380\u00a0mg/dl)\u00a0y\u00a0las \u00a0secreciones\u00a0intestinales\u00a0(\u22481 7mg/dl)\u00a0y\u00a0nasales\u00a0(7\u201085\u00a0mg/dl),\u00a0es\u00a0\nmuy\u00a0superior\u00a0a\u00a0la\u00a0de\u00a0los\u00a0dem\u00e1s\u00a0isotipos\u00a0de\u00a0Igs21.\u00a0Por\u00a0el\u00a0contrario,\u00a0su\u00a0concentraci\u00f3n\u00a0en\u00a0el\u00a0l\u00edquido\u00a0Introducci\u00f3n \n\u2010\u00a011\u00a0\u2010\u00a0\n\u00a0cefalorraqu\u00eddeo\u00a0es\u00a0menor\u00a0que\u00a0la\u00a0de\u00a0IgG\u00a0e\u00a0IgM,\u00a0y\u00a0pr\u00e1cticamente\u00a0i ndetectable\u00a0(0\u20100,06\u00a0mg/dl).\u00a0A\u00a0\npesar\u00a0de\u00a0que\u00a0la\u00a0vida\u00a0media\u00a0de\u00a0los\u00a0Acs\u00a0de\u00a0isotipo\u00a0IgA\u00a0es\u00a0relativ amente\u00a0corta\u00a0(6\u00a0d\u00edas)4,\u00a0la\u00a0elevada\u00a0\nproducci\u00f3n\u00a0de\u00a0IgA\u00a0en\u00a0las\u00a0mucosas\u00a0le\u00a0confiere\u00a0un\u00a0papel\u00a0clave\u00a0en\u00a0 la\u00a0prevenci\u00f3n\u00a0de\u00a0infecciones\u00a0\ngastrointestinales\u00a0y\u00a0respiratorias29,31.\u00a0En\u00a0suero,\u00a0la\u00a0IgA\u00a0suele\u00a0estar\u00a0en\u00a0su\u00a0mayor\u00a0parte\u00a0(\u224885%)\u00a0en\u00a0\nforma\u00a0monom\u00e9rica32,\u00a0mientras\u00a0que\u00a0en\u00a0las\u00a0secrecione s\u00a0externas\u00a0el\u00a050\u201096%\u00a0de\u00a0los\u00a0Acs \u00a0de\u00a0tipo\u00a0IgA\u00a0\nest\u00e1n\u00a0en\u00a0forma\u00a0de\u00a0d\u00edmero\u00a0(e\u00a0incluso\u00a0en\u00a0ocasiones\u00a0formando\u00a0tr\u00edme ros\u00a0y/o\u00a0tetr\u00e1meros5,30)\u00a0gracias\u00a0\na\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0dos\u00a0(o\u00a0m\u00e1s)\u00a0mol\u00e9culas\u00a0IgA\u00a0a\u00a0la\u00a0cadena\u00a0\u201cJ\u201d\u00a0a\u00a0trav\u00e9 s\u00a0de\u00a0sus\u00a0dominios\u00a0CH329\u201331.\u00a0La\u00a0IgA\u00a0\ndim\u00e9rica\u00a0es\u00a0capaz\u00a0de\u00a0unirse\u00a0al\u00a0pIgR\u00a0que\u00a0se\u00a0expresa\u00a0en\u00a0la\u00a0superf icie\u00a0basolateral\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0\nepiteliales\u00a0de\u00a0las\u00a0membranas\u00a0mucosas,\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0uno\u00a0de\u00a0sus\u00a0do s\u00a0dominios\u00a0CH2;\u00a0mediante\u00a0una\u00a0\nvacuola\u00a0de\u00a0endocitosis,\u00a0la\u00a0IgA\u00a0es\u00a0transportada\u00a0hasta\u00a0la\u00a0superfi cie\u00a0apical\u00a0de\u00a0dichas\u00a0c\u00e9lulas\u00a0\nepiteliales.\u00a0Posteriormente,\u00a0el\u00a0d\u00edmero\u00a0de\u00a0IgA\u00a0se\u00a0separa\u00a0del\u00a0pIg R;\u00a0no\u00a0obstante,\u00a0en\u00a0esta\u00a0separaci\u00f3n\u00a0\nquedar\u00e1\u00a0unido\u00a0a\u00a0la\u00a0IgA\u00a0un\u00a0fragmento\u00a0(polip\u00e9ptido)\u00a0de\u00a0dicho\u00a0rece ptor\u00a0llamado\u00a0fragmento\u00a0\nsecretor,\u00a0que\u00a0pasar\u00e1\u00a0a\u00a0formar\u00a0parte\u00a0de\u00a0la\u00a0IgA\u00a0secretada2,29,30,33.\u00a0\nLa\u00a0principal\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0IgA\u00a0es\u00a0la\u00a0neutralizaci\u00f3n\u00a0directa\u00a0de\u00a0 microorganismos\u00a0pat\u00f3genos\u00a0\n(virus,\u00a0bacterias\u00a0y\u00a0par\u00e1sitos)\u00a0y \u00a0de\u00a0sus\u00a0productos\u00a0(toxinas)\u00a0ant es\u00a0de\u00a0que\u00a0entren\u00a0al\u00a0organismo34;\u00a0\nadem\u00e1s,\u00a0la\u00a0IgA\u00a0desarrolla\u00a0un\u00a0importante\u00a0papel\u00a0en\u00a0la\u00a0regulaci\u00f3n\u00a0 de\u00a0las\u00a0bacterias\u00a0comensales\u00a0\npresentes\u00a0en\u00a0el\u00a0intestino34,35.\u00a0As\u00ed\u00a0mismo,\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0la\u00a0IgA\u00a0podr\u00eda\u00a0desarrollar\u00a0otras \u00a0\nfunciones\u00a0relacionadas\u00a0con\u00a0la\u00a0ac tivaci\u00f3n\u00a0de\u00a0la\u00a0respuesta\u00a0mediad a\u00a0por\u00a0su\u00a0uni\u00f3n\u00a0al\u00a0recetor\u00a0Fc\u03b1R\u00a0\n(CD89)29,36,\u00a0\u00a0y/o\u00a0la\u00a0activaci\u00f3n\u00a0del\u00a0complemento\u00a0por\u00a0la\u00a0v\u00eda\u00a0alternativa3,6,37,38;\u00a0sin\u00a0embargo,\u00a0hasta\u00a0\nel\u00a0momento,\u00a0no\u00a0se\u00a0han\u00a0podido\u00a0confirmar\u00a0estas\u00a0funciones\u00a0de\u00a0la\u00a0Ig A\u00a0de\u00a0forma\u00a0definitiva1,30.\u00a0Existen\u00a0\ndos\u00a0subclases\u00a0de\u00a0IgA:\u00a0IgA1\u00a0e\u00a0IgA2.\u00a0\n\u00a0 IgA1.\u00a0La\u00a0IgA1\u00a0constituye\u00a0 la\u00a0subclase\u00a0de\u00a0IgA\u00a0mayoritaria,\u00a0tanto\u00a0en\u00a0suero\u00a0(85\u201090%\u00a0del\u00a0total\u00a0\nde\u00a0la\u00a0IgA;\u00a075\u2010330\u00a0mg/dl\u00a0en\u00a0adultos)5,39\u00a0como\u00a0en\u00a0secreciones\u00a0externas,\u00a0representando\u00a0\u224859%\u00a0de\u00a0la\u00a0\nIgA\u00a0total\u00a0en\u00a0l\u00e1grima,\u00a0\u224863%\u00a0en\u00a0 saliva,\u00a052%\u201065%\u00a0en\u00a0leche\u00a0y\u00a0\u224870%\u00a0e n\u00a0secreciones\u00a0intestinales21.\u00a0\nEstructuralmente,\u00a0la\u00a0IgA1\u00a0se\u00a0caracteriza\u00a0por\u00a0presentar\u00a0una\u00a0regi \u00f3n\u00a0bisagra\u00a0extendida,\u00a0que\u00a0le\u00a0\npermite\u00a0unirse\u00a0simult\u00e1neamente\u00a0a\u00a0dos\u00a0Ags\u00a0relativamente\u00a0separado s\u00a0en\u00a0el\u00a0espacio33,34.\u00a0Sin\u00a0Introducci\u00f3n \n\u2010\u00a012\u00a0\u2010\u00a0\n\u00a0embargo,\u00a0 esta\u00a0 caracter\u00edstica\u00a0 tambi\u00e9n\u00a0 hace\u00a0 que\u00a0 la\u00a0 IgA1\u00a0 sea\u00a0 mucho \u00a0 m\u00e1s\u00a0 vulnerable\u00a0 a\u00a0 ser\u00a0\ndegradada\u00a0por\u00a0enzimas\u00a0proteol\u00edticas\u00a0de\u00a0los\u00a0propios\u00a0pat\u00f3genos29,30.\u00a0Aunque\u00a0se\u00a0detectan\u00a0Acs\u00a0de\u00a0\ntipo\u00a0IgA1\u00a0en\u00a0respuesta\u00a0a\u00a0Ags\u00a0polisac\u00e1ridicos,\u00a0esta\u00a0subclase\u00a0de\u00a0 Ig\u00a0se\u00a0produce\u00a0predominantemente\u00a0\nfrente\u00a0a\u00a0Ags\u00a0proteicos40,41.\u00a0\u00a0\nIgA2.\u00a0Esta\u00a0subclase\u00a0de\u00a0IgA\u00a0se\u00a0encuentr a\u00a0mayoritariamente\u00a0en\u00a0las\u00a0secre ciones\u00a0mucosas,\u00a0\naunque\u00a0tambi\u00e9n\u00a0est\u00e1\u00a0presente\u00a0en\u00a0suero\u00a0(10\u201015%\u00a0de\u00a0la\u00a0IgA\u00a0s\u00e9rica; \u00a07\u2010115\u00a0mg/dl)5,30,39.\u00a0A\u00a0diferencia\u00a0\nde\u00a0la\u00a0IgA1\u00a0contiene\u00a0una\u00a0peque\u00f1a\u00a0regi\u00f3n\u00a0bisagra,\u00a0que\u00a0le\u00a0permite\u00a0 ser\u00a0m\u00e1s\u00a0resistente\u00a0frente\u00a0a\u00a0\nproteasas\u00a0 bacterianas5,29,33,35;\u00a0 esto\u00a0 contribuye\u00a0 a\u00a0 explicar\u00a0 su\u00a0 mayor\u00a0 representaci\u00f3n\u00a0 en\u00a0 las\u00a0\nsecreciones\u00a0mucosas:\u00a0 \u224841%\u00a0de\u00a0la\u00a0IgA\u00a0presente\u00a0en\u00a0l\u00e1grima,\u00a0 \u224837%\u00a0en\u00a0saliva,\u00a0entre\u00a035%\u00a0y\u00a048%\u00a0en\u00a0\nleche\u00a0materna\u00a0y\u00a0 \u224830%\u00a0en\u00a0secreciones\u00a0intestinales5,21,35.\u00a0Al\u00a0contrario\u00a0de\u00a0la\u00a0IgA1,\u00a0la\u00a0IgA2\u00a0predomina\u00a0\nen\u00a0la\u00a0respuesta\u00a0inmune\u00a0frente\u00a0a\u00a0polisac\u00e1ridos,\u00a0aunque\u00a0puede\u00a0pro ducirse\u00a0tambi\u00e9n\u00a0en\u00a0respuesta\u00a0\na\u00a0Ags\u00a0proteicos40,41.\u00a0\n\u00a0\n1.2.4.\u00a0IgD\u00a0\n\u00a0La\u00a0IgD\u00a0\u00fanicamente\u00a0representa\u00a0\u22480,3%\u00a0del\u00a0conjunto\u00a0de\u00a0todas\u00a0las\u00a0I gs\u00a0s\u00e9ricas\u00a0(0,7\u201013\u00a0mg/dl\u00a0\nen\u00a0adultos)\u00a0con\u00a0una\u00a0vida\u00a0media\u00a0corta,\u00a0de\u00a0alrededor\u00a0de\u00a06\u00a0d\u00edas4,42,\u00a0probablemente\u00a0relacionada\u00a0con\u00a0\nel\u00a0tama\u00f1o\u00a0relativamente\u00a0grande\u00a0de\u00a0su\u00a0regi\u00f3n\u00a0bisagra\u00a0(64\u00a0amino\u00e1c idos)\u00a0que\u00a0provoca\u00a0una\u00a0mayor\u00a0\nsensibilidad\u00a0a\u00a0la\u00a0prote\u00f3lisis5,19,43\u00a0(Tabla\u00a01);\u00a0adem\u00e1s,\u00a0los\u00a0Acs\u00a0de\u00a0tipo\u00a0IgD\u00a0tambi\u00e9n\u00a0est\u00e1n\u00a0presentes\u00a0\nen\u00a0 saliva\u00a0 (0,0005\u20100,06\u00a0 mg/dl)\u00a0 y\u00a0 secreciones\u00a0 nasales\u00a0 (0,003\u20100,71 2\u00a0 mg/dl)44.\u00a0 Actualmente,\u00a0\nseguimos\u00a0sin\u00a0conocer\u00a0cu\u00e1l\u00a0es\u00a0el\u00a0verdadero\u00a0papel\u00a0funcional\u00a0de\u00a0la \u00a0IgD,\u00a0aunque\u00a0de\u00a0acuerdo\u00a0con\u00a0los\u00a0\ns\u00edntomas\u00a0que\u00a0presentan\u00a0pacientes\u00a0con\u00a0 s\u00edndrome\u00a0h\u00edper\u2010IgD, \u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0los\u00a0Acs\u00a0de\u00a0tipo\u00a0\nIgD\u00a0podr\u00edan\u00a0favorecer\u00a0la\u00a0liberaci\u00f3n\u00a0de\u00a0mediadores\u00a0proinflamator ios45.\u00a0La\u00a0ausencia\u00a0de\u00a0un\u00a0papel\u00a0\nfuncional\u00a0bien\u00a0definido\u00a0y\u00a0de\u00a0un\u00a0receptor\u00a0espec\u00edfico\u00a0para\u00a0la\u00a0IgD35,46,\u00a0tambi\u00e9n\u00a0han\u00a0llevado\u00a0a\u00a0sugerir\u00a0\nque\u00a0esta\u00a0Ig\u00a0( por\u00a0su\u00a0capacidad\u00a0para\u00a0unirse\u00a0y\u00a0ne utralizar\u00a0a\u00a0bacterias\u00a0pat\u00f3gena s\u00a0como\u00a0M.\u00a0catarrhalis \u00a0\ny\u00a0H.\u00a0influenzae\u00a0 y\u00a0a\u00a0sus\u00a0factores\u00a0virulentos)\u00a0 podr\u00eda\u00a0proteger\u00a0la\u00a0mucosa\u00a0respiratoria45,47.\u00a0Este\u00a0\ndesconocimiento\u00a0sobre\u00a0el\u00a0verdadero\u00a0papel\u00a0funcional\u00a0de\u00a0la\u00a0IgD\u00a0ha ce\u00a0que\u00a0hoy\u00a0por\u00a0hoy\u00a0en\u00a0la\u00a0cl\u00ednica,\u00a0Introducci\u00f3n \n\u2010\u00a013\u00a0\u2010\u00a0\n\u00a0no\u00a0se\u00a0determinen\u00a0sus\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0forma\u00a0rutinaria,\u00a0lo\u00a0cua l\u00a0a\u00a0su\u00a0vez\u00a0dificulta\u00a0el\u00a0avance\u00a0en\u00a0el\u00a0\nconocimiento\u00a0de\u00a0su\u00a0posible\u00a0funci\u00f3n.\u00a0\n\u00a0\n1.2.5.\u00a0IgE\u00a0\nLa\u00a0IgE\u00a0se\u00a0encuentra\u00a0presente\u00a0en\u00a0cantidades\u00a0extremadamente\u00a0bajas \u00a0en\u00a0suero\u00a0(0,02%\u00a0del\u00a0\nconjunto\u00a0de\u00a0las\u00a0Igs\u00a0s\u00e9ricas;\u00a0<0.03\u00a0mg/dl\u00a0en\u00a0adultos\u00a0sin\u00a0patolog \u00eda\u00a0al\u00e9rgica)19\u00a0con\u00a0una\u00a0vida\u00a0media\u00a0\ncorta\u00a0de\u00a03\u00a0d\u00edas4,19\u00a0(Tabla\u00a01).\u00a0En\u00a0t\u00e9rminos\u00a0generales,\u00a0la\u00a0IgE\u00a0tan\u00a0solo\u00a0se\u00a0identifica \u00a0en\u00a0mucosas\u00a0y\u00a0\notros\u00a0fluidos\u00a0de\u00a0pacientes\u00a0al\u00e9rgicos48.\u00a0Estructuralmente,\u00a0posee\u00a0tr es\u00a0dominios\u00a0constantes,\u00a0en\u00a0\nausencia\u00a0de\u00a0zona\u00a0bisagra49.\u00a0A\u00a0pesar\u00a0de\u00a0su\u00a0baja\u00a0concentraci\u00f3n,\u00a0la\u00a0IgE\u00a0muestra\u00a0gran\u00a0actividad \u00a0en\u00a0\nreacciones\u00a0de\u00a0hipersensibilidad,\u00a0 as\u00ed\u00a0como\u00a0en\u00a0la\u00a0respuesta\u00a0inmun e\u00a0frente\u00a0a\u00a0par\u00e1sitos5.\u00a0La\u00a0IgE\u00a0\npuede\u00a0 unirse\u00a0 a\u00a0 su\u00a0 receptor\u00a0 de\u00a0 alta\u00a0 afinidad\u00a0 ( Fc\u03b5RI)\u00a0 expresado\u00a0 de\u00a0 for ma\u00a0 constitutiva\u00a0 en\u00a0\nmastocitos\u00a0y\u00a0bas\u00f3filos,\u00a0y\u00a0en\u00a0eosin\u00f3filos\u00a0activados.\u00a0As\u00ed,\u00a0cuando \u00a0se\u00a0produce\u00a0el\u00a0reconocimiento\u00a0\nantig\u00e9nico\u00a0por\u00a0parte\u00a0de\u00a0Acs\u00a0IgE\u00a0presentes\u00a0en\u00a0la\u00a0superficie\u00a0de\u00a0e stas\u00a0c\u00e9lulas,\u00a0se\u00a0produce\u00a0su\u00a0\ndegranulaci\u00f3n\u00a0 con\u00a0 la\u00a0 liberaci\u00f3n\u00a0 de\u00a0 m\u00faltiples\u00a0 y\u00a0 diversos\u00a0 factore s\u00a0 por\u2010inflamatorios\u00a0 (TNF\u03b1,\u00a0\nhistamina,\u00a0 prostaglandinas\u00a0 y\u00a0 leucotrienos,\u00a0 entre\u00a0 otros)50\u00a0 responsables\u00a0 de\u00a0 los\u00a0 s\u00edntomas\u00a0\ncaracter\u00edsticos\u00a0de\u00a0la\u00a0alergia\u00a0de\u00a0tipo\u00a0I,\u00a0estimulando\u00a0adem\u00e1s\u00a0la\u00a0 expresi\u00f3n\u00a0de\u00a0m\u00e1s\u00a0Fc\u03b5RI\u00a0en\u00a0la\u00a0c\u00e9lula\u00a0\ndiana5.\u00a0Adem\u00e1s\u00a0de\u00a0Fc\u03b5RI,\u00a0existe\u00a0otro\u00a0rec eptor\u00a0de\u00a0IgE\u00a0de\u00a0baja\u00a0afinidad\u00a0( Fc\u03b5RII\u00a0\u00a0o\u00a0CD23)\u00a0con\u00a0dos\u00a0\nisoformas\u00a0y\u00a0una\u00a0funci\u00f3n\u00a0en\u00a0gran\u00a0medida\u00a0desconocida\u00a0a\u00fan:\u00a0i)\u00a0CD23 a\u00a0expresado\u00a0de\u00a0forma\u00a0\nconstitutiva\u00a0en\u00a0linfocitos\u00a0B\u00a0na\u00efve,\u00a0y\u00a0ii)\u00a0CD23b\u00a0expresado\u00a0en\u00a0mo nocitos,\u00a0eosin\u00f3filos,\u00a0plaquetas\u00a0y\u00a0\nc\u00e9lulas\u00a0dendr\u00edticas49.\u00a0\n\u00a0\n2.\u00a0Origen,\u00a0caracter\u00edsticas\u00a0funcio nales\u00a0e\u00a0inmunofenotipo\u00a0de\u00a0los\u00a0\nlinfocitos\u00a0B \u00a0\n\u00a0\nLos\u00a0linfocitos\u00a0B\u00a0son\u00a0las\u00a0c\u00e9lulas\u00a0 del\u00a0sistema\u00a0inmune\u00a0adaptativo\u00a0 responsables\u00a0de\u00a0la\u00a0\nproducci\u00f3n\u00a0de\u00a0Igs\u00a0en\u00a0respuesta\u00a0a\u00a0est\u00edmulos\u00a0antig\u00e9nicos51.\u00a0Dentro\u00a0del\u00a0conjunto\u00a0de\u00a0todas\u00a0las\u00a0\nc\u00e9lulas\u00a0 B,\u00a0 habitualmente\u00a0 se\u00a0 diferencian\u00a0 distintos\u00a0 estadios\u00a0 madu rativos\u00a0 y\u00a0 subpoblaciones\u00a0Introducci\u00f3n \n\u2010\u00a014\u00a0\u2010\u00a0\n\u00a0funcionales,\u00a0que\u00a0corresponden\u00a0a\u00a0dos\u00a0fases\u00a0de\u00a0maduraci\u00f3n\u00a0bien\u00a0di ferenciadas:\u00a0i)\u00a0la\u00a0maduraci\u00f3n\u00a0\nB\u00a0independiente\u00a0de\u00a0Ag,\u00a0que\u00a0se\u00a0produce\u00a0fundamentalmente\u00a0en\u00a0MO52,53;\u00a0y\u00a0ii)\u00a0la\u00a0maduraci\u00f3n\u00a0B\u00a0\ndependiente\u00a0de\u00a0Ag,\u00a0que\u00a0ocurre\u00a0predominantemente\u00a0en\u00a0los\u00a0\u00f3rganos\u00a0 linfoides\u00a0secundarios\u00a0(OLS),\u00a0\nincluidos\u00a0los\u00a0ganglios\u00a0linf\u00e1ticos,\u00a0el\u00a0bazo\u00a0y\u00a0el\u00a0tejido\u00a0linfoide \u00a0asociado\u00a0a\u00a0mucosas\u00a0(MALT;\u00a0del\u00a0ingl\u00e9s,\u00a0\nmucosa\u2010associated\u00a0lymphoid\u00a0tissue )54.\u00a0\n\u00a0\n2.1.\u00a0Maduraci\u00f3n\u00a0B\u00a0independiente\u00a0de\u00a0ant\u00edgeno \u00a0\nTras\u00a0el\u00a0nacimiento,\u00a0la\u00a0maduraci\u00f3n\u00a0B\u00a0independiente\u00a0de\u00a0Ag\u00a0tiene\u00a0l ugar\u00a0en\u00a0la\u00a0MO.\u00a0Su\u00a0\nobjetivo\u00a0 es\u00a0 producir\u00a0 linfocitos\u00a0 B\u00a0 inmunocompetentes,\u00a0 es\u00a0 decir,\u00a0 capaces\u00a0 de\u00a0 reconocer\u00a0 y\u00a0\nresponder\u00a0frente\u00a0a\u00a0Ags\u00a0extra\u00f1os,\u00a0y\u00a0al\u00a0mismo\u00a0tiempo,\u00a0ser\u00a0autotol erantes\u00a0(i.e.\u00a0linfocitos\u00a0B\u00a0na\u00efve).\u00a0\nDurante\u00a0 este\u00a0 proceso\u00a0 de\u00a0 maduraci\u00f3n\u00a0 de\u00a0 los\u00a0 linfocitos\u00a0 B\u00a0 en\u00a0 MO2,55\u00a0 se\u00a0 producir\u00e1\u00a0 el\u00a0\nreordenamiento\u00a0de\u00a0los\u00a0segmentos\u00a0g\u00e9nicos \u00a0que\u00a0forman\u00a0el\u00a0dominio\u00a0variable \u00a0(VH,\u00a0DH\u00a0y\u00a0JH)\u00a0del\u00a0gen\u00a0\nIGH\u00a0que\u00a0codifica\u00a0para\u00a0la\u00a0cadena\u00a0pesada\u00a0de\u00a0Ig,\u00a0y\u00a0de\u00a0los\u00a0segmentos\u00a0d el\u00a0dominio\u00a0variable\u00a0( VL\u00a0y\u00a0JL)\u00a0\ndel\u00a0gen\u00a0IGL\u00a0que\u00a0codifica\u00a0para\u00a0la\u00a0cadena\u00a0ligera\u00a0de\u00a0la\u00a0Ig.\u00a0Este\u00a0proceso\u00a0de\u00a0r ecombinaci\u00f3n\u00a0som\u00e1tica\u00a0\nV(D)J\u00a0de\u00a0IGH\u00a0y\u00a0VJ\u00a0de\u00a0IGL,\u00a0genera\u00a0una\u00a0elevada\u00a0diversidad\u00a0de\u00a0 repertorio\u00a0de\u00a0Igs\u00a0expresadas\u00a0 por\u00a0el\u00a0\nconjunto\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0 na\u00efve\u00a0producidos,\u00a0con\u00a0\u22481014\u00a0versiones\u00a0diferentes\u00a0del\u00a0BCR56.\u00a0\nActualmente\u00a0se\u00a0definen\u00a05\u00a0estadio s\u00a0madurativos\u00a0principales\u00a0en\u00a0la \u00a0maduraci\u00f3n\u00a0de\u00a0los\u00a0precursores\u00a0\nB\u00a0de\u00a0MO,\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0su\u00a0fenotipo\u00a0y\u00a0del\u00a0estado\u00a0del\u00a0reordenamie nto\u00a0de\u00a0los\u00a0genes\u00a0 IGH\u00a0e\u00a0IGL :\u00a0i)\u00a0\nc\u00e9lula\u00a0pro\u2010B,\u00a0ii)\u00a0pre\u2010BI,\u00a0y\u00a0iii)\u00a0pre\u2010BII,\u00a0iv)\u00a0linfocito\u00a0B\u00a0inmad uro\u00a0y\u00a0v)\u00a0linfocito\u00a0B\u00a0na\u00efve\u00a0(Figura\u00a02A).\u00a0La\u00a0\nc\u00e9lula\u00a0pro\u2010B\u00a0se\u00a0origina\u00a0a\u00a0partir\u00a0de\u00a0un\u00a0precursor\u00a0linfoide\u00a0com\u00fan\u00a0B\u00a0y\u00a0T/NK57,58\u00a0por\u00a0la\u00a0inducci\u00f3n\u00a0de\u00a0\nla\u00a0expresi\u00f3n\u00a0de\u00a0los\u00a0factores\u00a0de\u00a0transcripci\u00f3n\u00a0E2A,\u00a0EBF,\u00a0y\u00a0Pax51,57.\u00a0Mediante\u00a0la\u00a0acci\u00f3n\u00a0de\u00a0estos\u00a0\nfactores\u00a0de\u00a0transcripci\u00f3n,\u00a0la\u00a0c\u00e9lula \u00a0Pro\u2010B\u00a0pone\u00a0en\u00a0marcha\u00a0la\u00a0s\u00edntesis\u00a0de\u00a0las\u00a0prote\u00ednas\u00a0y\u00a0enzimas\u00a0\nresponsables\u00a0del\u00a0reordenamiento\u00a0de\u00a0los\u00a0genes\u00a0de\u00a0 IG\u00a0(e.g.\u00a0TdT\u00a0y\u00a0rag1/rag2,\u00a0entre\u00a0otras\u00a0prote\u00ednas)\u00a0\ny\u00a0se\u00a0pone\u00a0en\u00a0marcha\u00a0el\u00a0reordenamiento\u00a0de\u00a0los\u00a0genes\u00a0 IGH.\u00a0Este\u00a0comienza\u00a0por\u00a0el\u00a0reordenamiento\u00a0\nde\u00a0los\u00a0segmentos\u00a0 DH\u00a0y\u00a0JH\u00a0de\u00a0la\u00a0cadena\u00a0pesada56,59,60.\u00a0Fenot\u00edpicamente,\u00a0las\u00a0c\u00e9lulas\u00a0pro\u2010B\u00a0\nmantienen\u00a0la\u00a0expresi\u00f3n\u00a0de\u00a0marcadores\u00a0de\u00a0c\u00e9lula\u00a0precursora\u00a0hemat opoy\u00e9tica\u00a0(CD34++/CD38++),\u00a0Introducci\u00f3n \n\u2010\u00a015\u00a0\u2010\u00a0\n\u00a0aunque\u00a0 muestran\u00a0 ya\u00a0 positividad\u00a0 para\u00a0 las\u00a0 primeras\u00a0 prote\u00ednas\u00a0 cara cter\u00edsticas\u00a0 del\u00a0 precursor\u00a0\nlinfoide\u00a0comprometido\u00a0a\u00a0l\u00ednea\u00a0B\u00a0(Tdt\u00a0nuclear\u00a0\u2212nuTdt\u2212,\u00a0CD22\u00a0y\u00a0CD 79a\u00a0citoplasm\u00e1tico\u00a0\u2212ciCD79a\u2212),\u00a0\nen\u00a0ausencia\u00a0a\u00fan\u00a0del\u00a0marcador\u00a0pan\u2010B\u00a0CD1959.\u00a0En\u00a0la\u00a0etapa\u00a0madurativa\u00a0siguiente,\u00a0la\u00a0c\u00e9lula \u00a0pre\u2010BI\u00a0\nya\u00a0expresa\u00a0CD19\u00a0junto\u00a0con\u00a0CD34,\u00a0CD22,\u00a0CD38,\u00a0nuTdt\u00a0y\u00a0ciCD79a;\u00a0ad em\u00e1s,\u00a0en\u00a0ella\u00a0se\u00a0produce\u00a0el\u00a0\nreordenamiento\u00a0entre\u00a0el\u00a0segmento \u00a0VH\u00a0y\u00a0el\u00a0segmento\u00a0 DH\u2010JH\u00a0ya\u00a0reordenado,\u00a0complet\u00e1ndose\u00a0as\u00ed\u00a0\nel\u00a0reordenamiento\u00a0de\u00a0la\u00a0regi\u00f3n\u00a0variable\u00a0del\u00a0gen\u00a0 IGH59.\u00a0Una\u00a0vez\u00a0reordenado\u00a0el\u00a0gen \u00a0IGH,\u00a0el\u00a0\nprecursor\u00a0 pre\u2010BII\u00a0expresa\u00a0en\u00a0su\u00a0superficie\u00a0el\u00a0pre\u2010BCR,\u00a0formado\u00a0por\u00a0la\u00a0cadena\u00a0pes ada\u00a0Ig\u00b5,\u00a0y\u00a0las\u00a0\ncadenas\u00a0ligeras\u00a0subrogadas\u00a0VpreB\u00a0(CD179a)\u00a0y\u00a0\u03bb5\u00a0(CD179b),\u00a0junto\u00a0 a\u00a0los\u00a0correceptores\u00a0Ig\u03b1/Ig\u03b2\u00a0\n(CD79a/CD79b)53,56,61.\u00a0La\u00a0se\u00f1alizaci\u00f3n\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0pre\u2010BCR\u00a0activa\u00a0la\u00a0proliferaci\u00f3n\u00a0 del\u00a0precursor\u00a0\nB\u00a0 y\u00a0 pone\u00a0 en\u00a0 marcha\u00a0 el\u00a0 reordenamiento\u00a0 de\u00a0 los\u00a0 genes\u00a0 de\u00a0 las\u00a0 cadena s\u00a0 ligeras\u00a0 de\u00a0 Ig1,56,62,\u00a0\ne l i m i n \u00e1 n d o s e \u00a0e n \u00a0e s t a \u00a0e t a p a \u00a0l o s \u00a0p r e c u r s o r e s \u00a0B \u00a0q u e \u00a0n o \u00a0h a n \u00a0s i d o \u00a0c a paces\u00a0 de\u00a0 generar\u00a0 un\u00a0\nreordenamiento\u00a0 IGH\u00a0funcional\u00a0(selecci\u00f3n\u00a0 positiva);\u00a0en\u00a0paralelo,\u00a0la\u00a0se\u00f1alizaci\u00f3n\u00a0v \u00eda\u00a0pre\u2010BCR\u00a0\nbloquea\u00a0el\u00a0reordenamiento\u00a0del\u00a0segundo\u00a0alelo\u00a0de \u00a0IGH,\u00a0evitando\u00a0la\u00a0expresi\u00f3n\u00a0en\u00a0la\u00a0misma\u00a0c\u00e9lula,\u00a0\nde\u00a0dos\u00a0Igs\u00a0con\u00a0distinta\u00a0especificidad\u00a0(exclusi\u00f3n\u00a0al\u00e9lica)56.\u00a0Las\u00a0c\u00e9lulas \u00a0pre\u2010BII\u00a0pierden\u00a0expresi\u00f3n\u00a0\nde\u00a0nuTdt\u00a0y\u00a0CD3463,64,\u00a0pero\u00a0mantienen\u00a0positividad\u00a0para\u00a0CD10,\u00a0CD19,\u00a0CD22,\u00a0y\u00a0CD38++,\u00a0con\u00a0\nexpresi\u00f3n\u00a0heterog\u00e9nea\u00a0de\u00a0CD20+/++.\u00a0Una\u00a0vez\u00a0se\u00a0haya\u00a0realizado\u00a0el \u00a0reordenamiento\u00a0funcional\u00a0de\u00a0\nlos\u00a0genes\u00a0de\u00a0la\u00a0cadena\u00a0ligera,\u00a0el\u00a0 linfocito\u00a0B\u00a0inmaduro/transicional \u00a0expresa\u00a0un\u00a0BCR\u00a0con\u00a0una\u00a0IgM\u00a0\ncompleta,\u00a0al\u00a0reemplazarse\u00a0las\u00a0cadenas\u00a0subrogadas\u00a0por\u00a0las\u00a0cadena s\u00a0ligeras\u00a0reordenadas.\u00a0Junto\u00a0\ncon\u00a0el\u00a0BCR,\u00a0estas\u00a0c\u00e9lulas\u00a0tienen \u00a0expresi\u00f3n\u00a0homog\u00e9nea\u00a0e\u00a0intensa\u00a0 de\u00a0CD20\u00a0y\u00a0CD38,\u00a0junto\u00a0a\u00a0\npositividad\u00a0para\u00a0CD5\u00a0y\u00a0CD24,\u00a0expresi\u00f3n\u00a0d\u00e9bil\u00a0de\u00a0CD10\u00a0y\u00a0reactivi dad\u00a0variable\u00a0para\u00a0CD2153,63\u201365.\u00a0\nEstos\u00a0linfocitos\u00a0B\u00a0inmaduros\u00a0son\u00a0e xpuestos\u00a0a\u00a0Ags\u00a0propios\u00a0con\u00a0el \u00a0fin\u00a0de\u00a0eliminar\u00a0por\u00a0apoptosis,\u00a0o\u00a0\nde\u00a0inducir\u00a0anergia,\u00a0en\u00a0aquellas\u00a0c\u00e9lulas\u00a0que\u00a0presenten\u00a0un\u00a0BCR\u00a0au torreactivo\u00a0(selecci\u00f3n\u00a0negativa),\u00a0\nd\u00e1ndoles\u00a0tambi\u00e9n\u00a0la\u00a0posibilidad\u00a0de\u00a0reordenar\u00a0de\u00a0nuevo\u00a0los\u00a0genes \u00a0de\u00a0cadena\u00a0ligera\u00a0(edici\u00f3n\u00a0del\u00a0\nreceptor)61,66\u201368.\u00a0 Tras\u00a0 pasar\u00a0 esta\u00a0 fase\u00a0 de\u00a0 \u201cselecci\u00f3n\u00a0 negativa\u201d,\u00a0 el\u00a0 linfocito\u00a0 B\u00a0 inmaduro\u00a0 se\u00a0\ndiferencia\u00a0a\u00a0 linfocito\u00a0B\u00a0na\u00efve \u00a0inmunocompetente\u00a0y\u00a0autotolerante, \u00a0con\u00a0fenotipo\u00a0CD5+/\u2010\u00a0CD10\u2010\u00a0\nCD19+\u00a0CD20++\u00a0CD22+\u00a0CD24+d\u00a0CD38\u2010/lo\u00a0IgM+D++\u00a063,64.\u00a0Introducci\u00f3n \n\u2010\u00a016\u00a0\u2010\u00a0\n\u00a0Figura\u00a02. \u00a0Representaci\u00f3n\u00a0esquem\u00e1tica\u00a0de\u00a0la\u00a0maduraci\u00f3n\u00a0B\u00a0ant\u00edgeno\u2010independ iente\u00a0(A)\u00a0y\u00a0\nant\u00edgeno\u2010dependiente\u00a0(B). \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n(A)\u00a0La\u00a0maduraci\u00f3n\u00a0independiente\u00a0d e\u00a0Ag\u00a0tiene\u00a0lugar\u00a0en\u00a0MO,\u00a0distin gui\u00e9ndose\u00a05\u00a0estadios\u00a0principales\u00a0que\u00a0se\u00a0diferencian\u00a0\nen\u00a0el\u00a0estado\u00a0de\u00a0reordenamiento\u00a0de\u00a0los\u00a0genes\u00a0de\u00a0cadena\u00a0pesada\u00a0y\u00a0 cadena\u00a0ligera\u00a0de\u00a0la\u00a0Ig,\u00a0as\u00ed\u00a0como\u00a0en\u00a0la\u00a0expresi\u00f3n\u00a0de\u00a0\ndistintas\u00a0prote\u00ednas\u00a0(inmunofenoti po).\u00a0(B)\u00a0La\u00a0maduraci\u00f3n\u00a0dependi ente\u00a0de\u00a0Ag\u00a0tiene\u00a0lugar\u00a0en\u00a0los\u00a0OLS\u00a0cuando\u00a0el\u00a0linfocito\u00a0\nB\u00a0na\u00efve\u00a0reconoce\u00a0a\u00a0su\u00a0Ag\u00a0de\u00a0forma\u00a0espec\u00edfica,\u00a0y\u00a0puede\u00a0ser\u00a0T\u2010dep endiente,\u00a0con\u00a0la\u00a0formaci\u00f3n\u00a0de\u00a0centros\u00a0germinales,\u00a0o\u00a0\nT\u2010independiente.\u00a0Ambos\u00a0procesos\u00a0dan\u00a0como\u00a0resultado\u00a0la\u00a0formaci\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0efectoras\u00a0(linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0\nCPs).\u00a0Las\u00a0CPs\u00a0emigran\u00a0a\u00a0MO\u00a0y\u00a0las\u00a0mucosas\u00a0donde\u00a0producir\u00e1n\u00a0Acs\u00a0d e\u00a0distinto\u00a0isotipo\u00a0y\u00a0subclase,\u00a0mientras\u00a0que\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0podr\u00edan\u00a0realizar\u00a0uno\u00a0o\u00a0varios\u00a0ciclos\u00a0de \u00a0respuesta\u00a0en\u00a0el\u00a0centro\u00a0germinal\u00a0dando\u00a0lugar\u00a0a\u00a0nuevas\u00a0\nCPs\u00a0y\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria.\u00a0CC,\u00a0centrocito;\u00a0CB,\u00a0centroblasto ;\u00a0OLS,\u00a0\u00f3rgano\u00a0linfoide\u00a0secundario;\u00a0ci,\u00a0citoplasm\u00e1tico;\u00a0\nnu,\u00a0nuclear.\u00a0\nIntroducci\u00f3n \n\u2010\u00a017\u00a0\u2010\u00a0\n\u00a02.2.\u00a0Maduraci\u00f3n\u00a0B\u00a0dependiente\u00a0de\u00a0ant\u00edgeno \u00a0\nLa\u00a0maduraci\u00f3n\u00a0del\u00a0linfocito\u00a0B\u00a0dependiente\u00a0de\u00a0Ag\u00a0se\u00a0produce\u00a0en\u00a0r espuesta\u00a0a\u00a0un\u00a0Ag\u00a0\nespec\u00edfico,\u00a0con\u00a0el\u00a0objetivo\u00a0de\u00a0generar:\u00a0i) \u00a0CPs\u00a0productoras\u00a0de\u00a0Acs19,69;\u00a0y\u00a0ii)\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria \u00a0\nresponsables\u00a0de\u00a0la\u00a0respuesta\u00a0sec undaria\u00a0en\u00a0sucesivos\u00a0encuentros \u00a0con\u00a0el\u00a0Ag70,71(Figura\u00a02A).\u00a0\n\u00a0\n2.2.1.\u00a0Respuesta\u00a0B\u00a0dependiente\u00a0de\u00a0linfocitos\u00a0T\u00a0\n\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0linfocitos\u00a0B\u00a0que\u00a0abandonan\u00a0la\u00a0MO\u00a0presentan\u00a0un\u00a0fen otipo\u00a0na\u00efve,\u00a0aunque\u00a0\nuna\u00a0peque\u00f1a\u00a0fracci\u00f3n\u00a0tienen\u00a0caracter\u00edsticas\u00a0de\u00a0c\u00e9lula\u00a0inmadura/ transicional53,65,72.\u00a0Los\u00a0linfocitos\u00a0\nB\u00a0na\u00efve\u00a0recirculan\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0SP\u00a0y\u00a0los\u00a0OLS,\u00a0y\u00a0se\u00a0activan\u00a0tr as\u00a0el\u00a0reconocimiento\u00a0del\u00a0Ag\u00a0\u2212bien\u00a0en\u00a0\nforma\u00a0soluble\u00a0o\u00a0bien\u00a0retenido\u00a0por\u00a0las\u00a0c\u00e9lulas\u00a0dendr\u00edticas\u00a0folic ulares\u00a0(CDFs)\u2212,\u00a0o\u00a0mueren\u00a0por\u00a0\napoptosis\u00a0al\u00a0cabo\u00a0de\u00a0unas\u00a0semanas53.\u00a0\u00a0\nEl\u00a0reconocimiento\u00a0del\u00a0Ag\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0BCR\u00a0genera\u00a0una\u00a0cascada\u00a0de\u00a0 se\u00f1ales\u00a0que\u00a0inducen\u00a0la\u00a0\nactivaci\u00f3n\u00a0del\u00a0linfocito\u00a0B\u00a0na\u00efve73,74.\u00a0Junto\u00a0con\u00a0el\u00a0BCR,\u00a0el\u00a0linfocito\u00a0B\u00a0na\u00efve\u00a0expresa\u00a0otros\u00a0receptor es\u00a0\nque\u00a0contribuyen\u00a0a\u00a0amplificar\u00a0o\u00a0a \u00a0inhibir\u00a0la\u00a0se\u00f1al\u00a0derivada\u00a0de\u00a0l a\u00a0uni\u00f3n\u00a0BCR\u2010Ag,\u00a0facilitando\u00a0que\u00a0se\u00a0\nalcance\u00a0una\u00a0intensidad\u00a0superior\u00a0al\u00a0umbral\u00a0de\u00a0respuesta\u00a0requerid o.\u00a0Estos\u00a0receptores\u00a0incluyen\u00a0el\u00a0\ncorreceptor\u00a0activador\u00a0de\u00a0c\u00e9lula\u00a0B\u00a0CD19\u2010CD21\u2010CD81\u2010CD225,\u00a0capaz\u00a0d e\u00a0unirse\u00a0a\u00a0inmunocomplejos\u00a0\nde\u00a0C3d/Ag,\u00a0adem\u00e1s\u00a0de\u00a0CD20\u00a0y\u00a0CD4573\u201377\u00a0o\u00a0las\u00a0mol\u00e9culas\u00a0inhibidoras\u00a0CD5\u00a0y\u00a0CD2278\u201380.\u00a0Una\u00a0vez\u00a0\nactivado,\u00a0el\u00a0linfocito\u00a0B\u00a0inte racciona\u00a0con\u00a0linfocitos\u00a0T\u00a0CD4+\u00a0colaboradores\u00a0foliculares\u00a0(linfocitos\u00a0\nTFH;\u00a0del\u00a0ingl\u00e9s,\u00a0 follicular\u00a0helper\u00a0T\u2010cells )\u00a0que\u00a0le\u00a0proporcionan\u00a0las\u00a0se\u00f1ales\u00a0adicionales\u00a0responsables\u00a0\nde\u00a0inducir\u00a0su\u00a0proliferaci\u00f3n\u00a0masiva\u00a0y\u00a0maduraci\u00f3n\u00a0funcional.\u00a0En\u00a0e sta\u00a0interacci\u00f3n\u00a0B\u2010T\u00a0participan\u00a0de\u00a0\nforma\u00a0activa\u00a0las\u00a0mol\u00e9culas\u00a0membrana\u00a0CD80/CD86\u2010CD28,\u00a0CD40\u2010CD40L, \u00a0ICOSL\u2010ICOS,\u00a0HLA\u2010TCR\u00a0y\u00a0\nCD27\u2010CD70,\u00a0adem\u00e1s\u00a0de\u00a0citocinas\u00a0secretadas\u00a0en\u00a0forma\u00a0soluble\u00a0por\u00a0 parte\u00a0del\u00a0linfocito\u00a0T\u00a0como\u00a0la\u00a0\nIL\u20102,\u00a0la\u00a0IL\u20104\u00a0y\u00a0la\u00a0IL\u20102154,81.\u00a0Para\u00a0una\u00a0adecuada\u00a0interacci\u00f3n\u00a0B\u2010T,\u00a0se\u00a0requiere\u00a0la\u00a0formaci\u00f3n\u00a0d e\u00a0una\u00a0\nestructura\u00a0 altamente\u00a0 especializad a\u00a0 \u2212el\u00a0 centro\u00a0 germinal\u00a0 (CG)\u2212\u00a0 en \u00a0e l \u00a0O L S \u00a0d o n d e \u00a0o c u r r e \u00a0l a \u00a0\nrespuesta54,82\u201385.\u00a0Desde\u00a0hace\u00a0tiempo,\u00a0se\u00a0conoce\u00a0la\u00a0existencia\u00a0de\u00a0dos\u00a0zonas\u00a0bien\u00a0 diferenciadas\u00a0en\u00a0Introducci\u00f3n \n\u2010\u00a018\u00a0\u2010\u00a0\n\u00a0el\u00a0CG:\u00a0la\u00a0zona\u00a0oscura\u00a0y\u00a0la\u00a0zona\u00a0clara54,84,85.\u00a0En\u00a0la\u00a0zona\u00a0oscura\u00a0del\u00a0CG\u00a0se\u00a0encuentran\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0\nen\u00a0proliferaci\u00f3n,\u00a0denominadas\u00a0 centroblastos \u00a0(CBs),\u00a0con\u00a0fenotipo\u00a0CD10+\u00a0CD19+\u00a0CD27het\u00a0CD38+\u00a0\nCD44lo\u00a0CD83\u2010\u00a0CD86\u2010\u00a0y\u00a0CXCR4\u00a0(CD184)+\u00a084\u201386;\u00a0al\u00a0proliferar,\u00a0estos\u00a0CBs\u00a0sufren\u00a0mutaciones\u00a0aleatorias\u00a0\nen\u00a0la\u00a0secuencia\u00a0de\u00a0los\u00a0genes\u00a0 VH\u00a0(hipermutaci\u00f3n\u00a0som\u00e1tica;\u00a0HMS),\u00a0inducidas\u00a0por\u00a0la\u00a0enzima\u00a0AID\u00a0\n(deaminasa\u00a0 de\u00a0 citidina\u00a0 inducida\u00a0 por\u00a0 activaci\u00f3n;\u00a0 del\u00a0 ingl\u00e9s,\u00a0 activation\u2010induced\u00a0 cytidine\u00a0\ndeaminase ),\u00a0que\u00a0en\u00a0\u00faltima\u00a0instancia\u00a0van\u00a0a\u00a0modificar\u00a0la\u00a0afinidad\u00a0de\u00a0su\u00a0BC R\u00a0por\u00a0el\u00a0Ag.\u00a0As\u00ed,\u00a0tras\u00a0\nvarias\u00a0rondas\u00a0de\u00a0proliferaci\u00f3n\u2010HM S,\u00a0estas\u00a0c\u00e9lulas\u00a0pasan\u00a0desde\u00a0l a\u00a0zona\u00a0oscura\u00a0a\u00a0la\u00a0zona\u00a0clara\u00a0del\u00a0\nCG,\u00a0donde\u00a0adquieren\u00a0la\u00a0forma\u00a0de\u00a0c\u00e9lulas\u00a0peque\u00f1as\u00a0(centrocitos;\u00a0 CCs)\u00a0que\u00a0siguen\u00a0expresando\u00a0\nCD10+\u00a0CD19+\u00a0CD27het\u00a0CD38+\u00a0y\u00a0CD44lo,\u00a0ahora\u00a0en\u00a0ausencia\u00a0de\u00a0positividad\u00a0por\u00a0CXCR4\u00a0(CD184)\u00a0y\u00a0\nsiendo\u00a0CD83+\u00a0y\u00a0CD86+84\u201386\u00a0(Figura\u00a02B).\u00a0\u00a0El\u00a0CC\u00a0interaccionar\u00e1\u00a0nuevamente\u00a0con\u00a0el\u00a0Ag\u00a0reteni do\u00a0en\u00a0\nla\u00a0superficie\u00a0de\u00a0las\u00a0CDFs,\u00a0seleccion\u00e1ndose\u00a0positivamente\u00a0aquell os\u00a0CCs\u00a0que\u00a0lo\u00a0hayan\u00a0hecho\u00a0y\u00a0por\u00a0\nlo\u00a0tanto,\u00a0que\u00a0hayan\u00a0ganado\u00a0afinidad\u00a0por\u00a0el\u00a0Ag\u00a0como\u00a0consecuencia \u00a0de\u00a0la\u00a0HMS\u00a0(maduraci\u00f3n\u00a0de\u00a0\nafinidad)87.\u00a0Tras\u00a0este\u00a0proceso,\u00a0se\u00a0estima\u00a0 que\u00a010\u201030%\u00a0de\u00a0los\u00a0CCs\u00a0volver\u00e1n\u00a0a \u00a0la\u00a0zona\u00a0oscura\u00a0para\u00a0\nrealizar\u00a0nuevas\u00a0rondas\u00a0de\u00a0HMS,\u00a0mientras\u00a0que\u00a0los\u00a0dem\u00e1s\u00a0CCs\u00a0morir \u00e1n\u00a0por\u00a0apoptosis\u00a0al\u00a0no\u00a0lograr\u00a0\nreconocer\u00a0de\u00a0nuevo\u00a0al\u00a0Ag.\u00a0\nTras\u00a0esta\u00a0respuesta\u00a0B\u00a0frente\u00a0a\u00a0Ag\u00a0(por\u00a0inmunizaci\u00f3n\u00a0o\u00a0infecci\u00f3n ),\u00a0parte\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0\nIgM+IgD+\u00a0activadas,\u00a0cambiar\u00e1n\u00a0el\u00a0isotipo\u00a0de\u00a0la\u00a0IgH\u00a0que\u00a0producen.\u00a0El\u00a0nue vo\u00a0isotipo\u00a0de\u00a0IgH\u00a0puede\u00a0\nser\u00a0una\u00a0subclase\u00a0de\u00a0IgG\u00a0(IgG1,\u00a0IgG2,\u00a0IgG3\u00a0o\u00a0IgG4),\u00a0de\u00a0IgA\u00a0(IgA1 \u00a0o\u00a0IgA2)\u00a0o\u00a0IgE.\u00a0Este\u00a0cambio\u00a0de\u00a0\nisotipo\u00a0modifica\u00a0la\u00a0funci\u00f3n\u00a0efectora\u00a0de\u00a0la\u00a0Ig\u00a0que\u00a0ser\u00e1\u00a0producid a\u00a0por\u00a0la\u00a0futura\u00a0CP,\u00a0sin\u00a0alterar\u00a0su\u00a0\nespecificidad,\u00a0traduci\u00e9ndose\u00a0habitualmente\u00a0en\u00a0una\u00a0mejora\u00a0de\u00a0la\u00a0 capacidad\u00a0de\u00a0los\u00a0futuros\u00a0Acs\u00a0\npara\u00a0eliminar\u00a0el\u00a0pat\u00f3geno\u00a0que\u00a0ha\u00a0desencadenado\u00a0la\u00a0respuesta\u00a0B102.\u00a0\nEl\u00a0cambio\u00a0de\u00a0isotipo\u00a0se\u00a0produce\u00a0por\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0la\u00a0regi\u00f3n\u00a0V(D)J \u00a0del\u00a0gen\u00a0de\u00a0la\u00a0cadena\u00a0\npesada\u00a0con\u00a0un\u00a0segmento\u00a0C\u00a0distinto\u00a0de\u00a0C\u00b5\u00a0(y\u00a0de\u00a0C\u03b4)\u00a0situado\u00a0dista lmente\u00a0a\u00a0nivel\u00a0del\u00a0gen\u00a0 IGHC,\u00a0\nelimin\u00e1ndose\u00a0del\u00a0ADN\u00a0correspondi ente\u00a0a\u00a0dicho\u00a0gen,\u00a0los\u00a0segmentos \u00a0intermedios\u00a0(Figura\u00a03).\u00a0En\u00a0\neste\u00a0proceso\u00a0juegan\u00a0un\u00a0papel\u00a0fundamental\u00a0las\u00a0enzimas\u00a0AID ,\u00a0UNG\u00a0(N\u2010glicosilasa\u00a0de\u00a0uracilos;\u00a0del\u00a0\ningl\u00e9s,\u00a0uracil\u2010N\u2010glycosylase )\u00a0y\u00a0APE\u00a0(endonucleasa\u00a0apur\u00ednic a/apirimid\u00ednica;\u00a0del\u00a0ingl\u00e9s,\u00a0 apurinic\u00a0Introducci\u00f3n \n\u2010\u00a019\u00a0\u2010\u00a0\n\u00a0apyrimidinic/endonuclease ).\u00a0 Cada\u00a0 regi\u00f3n\u00a0 CH\u00a0 del\u00a0 gen\u00a0 IGH\u00a0 (excepto\u00a0 C\u03b4)\u00a0 est\u00e1\u00a0 precedida\u00a0 de\u00a0\nsecuencias\u00a0repetitivas\u00a0ricas\u00a0en\u00a0 citosina\u00a0denominadas\u00a0regiones\u00a0S \u00a0(de\u00a0cambio\u00a0de\u00a0isotipo\u00a0de\u00a0Ig;\u00a0del\u00a0\ningl\u00e9s,\u00a0Ig\u00a0class\u2010switch ).\u00a0La\u00a0enzima\u00a0AID,\u00a0cuya\u00a0transcripci\u00f3n\u00a0es\u00a0inducida\u00a0por\u00a0NF\u2010\u03baB\u00a0(fac tor\u00a0nuclear\u00a0\npotenciador\u00a0de\u00a0cadenas\u00a0ligeras\u00a0kappa\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0activadas;\u00a0de l\u00a0ingl\u00e9s,\u00a0nuclear\u00a0factor  kappa\u2010\nlight\u2010chain\u2010enhancer\u00a0of\u00a0activated\u00a0B\u00a0cells ),\u00a0cambia\u00a0citosinas\u00a0por\u00a0uracilos\u00a0en\u00a0estas\u00a0regiones\u00a0S\u00a0de\u00a0\nlos\u00a0dominios\u00a0CH\u00a0involucrados\u00a0en\u00a0el\u00a0reordenamiento\u00a0 IGHC88\u201390.\u00a0A\u00a0su\u00a0vez,\u00a0los\u00a0uracilos,\u00a0al\u00a0no\u00a0ser\u00a0\nnucle\u00f3tidos\u00a0caracter\u00edsticos\u00a0del\u00a0ADN\u00a0humano,\u00a0son\u00a0eliminados\u00a0por\u00a0 la\u00a0prote\u00edna\u00a0UNG,\u00a0lo\u00a0cual\u00a0implica\u00a0\nla\u00a0generaci\u00f3n\u00a0de\u00a0sitios\u00a0ab\u00e1sicos\u00a0(sin\u00a0nucle\u00f3tido),\u00a0provocando\u00a0q ue\u00a0las\u00a0enzimas\u00a0APE1/2\u00a0generen\u00a0\nrupturas\u00a0en\u00a0la\u00a0secuencia\u00a0del\u00a0ADN .\u00a0Una\u00a0vez\u00a0se\u00a0han\u00a0generado\u00a0estas \u00a0rupturas\u00a0en\u00a0el\u00a0ADN\u00a0de\u00a0las\u00a0\nregiones\u00a0 S\u00a0 de\u00a0 los\u00a0 dos\u00a0 segmentos\u00a0 CH\u00a0 implicados\u00a0 en\u00a0 el\u00a0 reordenamie nto,\u00a0 se\u00a0 produce\u00a0 la\u00a0\nrecombinaci\u00f3n\u00a0del\u00a0ADN\u00a0de\u00a0estas\u00a0regiones\u00a0S\u00a0mediante\u00a0la\u00a0acci\u00f3n\u00a0de \u00a0las\u00a0prote\u00ednas\u00a0implicadas\u00a0en\u00a0la\u00a0\nreparaci\u00f3n\u00a0del\u00a0ADN\u00a0mediante\u00a0mecanismos\u00a0de\u00a0recombinaci\u00f3n\u00a0no\u00a0hom\u00f3 loga\u00a0NHEJ\u00a0(uni\u00f3n\u00a0de\u00a0\nextremos\u00a0no\u00a0hom\u00f3logos\u00a0de\u00a0ADN;\u00a0del\u00a0ingl\u00e9s,\u00a0 non\u2010homologous\u00a0and\u00a0end\u00a0joining ),\u00a0elimin\u00e1ndose\u00a0\nc\u00edrculos\u00a0de\u00a0ADN\u00a0que\u00a0contienen\u00a0los\u00a0segmentos\u00a0eliminados\u00a0de\u00a0la\u00a0se cuencia\u00a0inicial\u00a0de\u00a0ADN,\u00a0situados\u00a0\nentre\u00a0ambas\u00a0regiones\u00a0S\u00a0(e.g.\u00a0C\u00b5\u00a0y\u00a0C\u03b4\u00a0si\u00a0se\u00a0expresa\u00a0la\u00a0siguiente \u00a0regi\u00f3n\u00a0del\u00a0gen\u00a0 IGHC,\u00a0C\u03b33)88,89.\u00a0El\u00a0\nisotipo\u00a0final\u00a0de\u00a0Ig\u00a0producido\u00a0por\u00a0una\u00a0c\u00e9lula\u00a0B\u00a0que\u00a0ha\u00a0llevado\u00a0a \u00a0cabo\u00a0el\u00a0cambio\u00a0de\u00a0isotipo,\u00a0depende\u00a0\nde\u00a0factores\u00a0del\u00a0micromedioambien te\u00a0en\u00a0el\u00a0que\u00a0se\u00a0reconozca\u00a0el\u00a0Ag \u00a0y,\u00a0en\u00a0cierta\u00a0medida\u00a0tambi\u00e9n,\u00a0\ndel\u00a0propio\u00a0Ag.\u00a0As\u00ed,\u00a0las\u00a0citocina s\u00a0producidas\u00a0por\u00a0los\u00a0linfocitos \u00a0TFH\u00a0tienen\u00a0un\u00a0papel \u00a0clave\u00a0a\u00a0la\u00a0hora\u00a0\nde\u00a0determinar\u00a0el\u00a0isotipo\u00a0de\u00a0Ig\u00a0que\u00a0producir\u00e1n\u00a0los\u00a0linfocitos\u00a0B\u00a0 activados.\u00a0En\u00a0este\u00a0sentido,\u00a0la\u00a0\nproducci\u00f3n\u00a0de\u00a0IL\u201010\u00a0se\u00a0ha\u00a0asociado\u00a0con\u00a0los\u00a0isotipos\u00a0IgG1\u00a0e\u00a0IgG391,\u00a0TGF\u2010\u03b2\u00a0con\u00a0IgA92\u00a0y\u00a0la\u00a0IL\u201013\u00a0con\u00a0\nla\u00a0producci\u00f3n\u00a0de\u00a0IgG4/IgE93.\u00a0Recientemente,\u00a0se\u00a0ha\u00a0propuesto\u00a0que\u00a0los\u00a0isotipos\u00a0de\u00a0Igs\u00a0podr\u00eda n\u00a0\nproducirse\u00a0(al\u00a0menos\u00a0en\u00a0parte)\u00a0d e\u00a0forma\u00a0consecutiva,\u00a0siguiendo\u00a0 la\u00a0secuencia\u00a0en\u00a0la\u00a0que\u00a0se\u00a0\nencuentran\u00a0codificados\u00a0en\u00a0el\u00a0gen\u00a0 IGHC94\u201398\u00a0(Figura\u00a03).\u00a0As\u00ed,\u00a0se\u00a0ha\u00a0observado\u00a0la\u00a0existencia\u00a0de\u00a0una\u00a0\nmayor\u00a0tasa\u00a0de\u00a0HMS\u00a0en\u00a0los\u00a0isotipos\u00a0que\u00a0se\u00a0encuentran\u00a0codificados \u00a0por\u00a0los\u00a0segmentos\u00a0de\u00a0ADN\u00a0\nlocalizados\u00a0al\u00a0final\u00a0del\u00a0gen\u00a0 IGHC96,97,\u00a0sugiriendo\u00a0que\u00a0estas\u00a0c\u00e9lulas\u00a0habr\u00edan\u00a0pasado\u00a0por\u00a0un\u00a0mayor\u00a0\nn\u00famero\u00a0de\u00a0rondas\u00a0de\u00a0reconocimiento\u00a0de\u00a0Ag\u00a0en\u00a0el\u00a0CG.\u00a0En\u00a0este\u00a0mism o\u00a0sentido,\u00a0un\u00a0estudio\u00a0reciente\u00a0Introducci\u00f3n \n\u2010\u00a020\u00a0\u2010\u00a0\n\u00a0ha\u00a0demostrado\u00a0que\u00a0en\u00a0las\u00a0regiones\u00a0de\u00a0uni\u00f3n\u00a0S\u00b5\u2010S\u03b32\u00a0del\u00a024%\u00a0de\u00a0la s\u00a0c\u00e9lulas\u00a0B\u00a0con\u00a0cambio\u00a0de\u00a0\nisotipo\u00a0a\u00a0IgG2\u00a0se\u00a0observaban\u00a0remanentes\u00a0de\u00a0secuencias\u00a0S\u03b31,\u00a0S\u03b33\u00a0 y\u00a0S\u03b11,\u00a0mientras\u00a0que\u00a0en\u00a0el\u00a09%\u00a0\nde\u00a0 las\u00a0 que\u00a0 presentaban\u00a0 isotipo\u00a0 IgG1,\u00a0 las\u00a0 regiones\u00a0 de\u00a0 uni\u00f3n\u00a0 S\u00b5\u2010S \u03b31\u00a0 ten\u00edan\u00a0 remantes\u00a0 de\u00a0\nr e o r d e n a m i e n t o \u00a0S \u00b5 \u2010 S \u03b3 3 , \u00a0c o n f i r m a n d o \u00a0l a \u00a0e x i s t e n c i a \u00a0d e \u00a0d o s \u00a0o \u00a0m \u00e1 s \u00a0c ambios\u00a0 de\u00a0 isotipo\u00a0\nconsecutivos\u00a0en\u00a0la\u00a0misma\u00a0c\u00e9lula\u00a0B.\u00a0\nFigura\u00a03.\u00a0Modelo\u00a0hipot\u00e9tico\u00a0que\u00a0explica\u00a0el\u00a0cambio\u00a0consecutivo\u00a0d e\u00a0isotipo\u00a0de\u00a0Ig\u00a0en\u00a0c\u00e9lulas\u00a0B\u00a0\nactivadas.\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nTras\u00a0 el\u00a0 reconocimiento\u00a0 antig\u00e9nico,\u00a0 el\u00a0 linfocito\u00a0 B\u00a0 na\u00efve\u00a0 IgM+D++\u00a0 pueden\u00a0 realizar\u00a0 el\u00a0 cambio\u00a0 de\u00a0 isotipo\u00a0 de\u00a0 Ig,\u00a0\nnormalmente\u00a0a\u00a0isotipos\u00a0que\u00a0se\u00a0encuentran\u00a0m\u00e1s\u00a0cercanos\u00a0a\u00a0la\u00a0regi \u00f3n\u00a0V(D)J\u00a0(e.g.\u00a0a\u00a0IgG3\u00a0o\u00a0IgG1),\u00a0en\u00a0paralelo\u00a0con\u00a0los\u00a0\nprocesos\u00a0de\u00a0HMS\u00a0y\u00a0diferenciaci\u00f3n\u00a0a\u00a0linfocito\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0CP\u00a0 (respuesta\u00a0primaria,\u00a0primer\u00a0cambio\u00a0de\u00a0isotipo).\u00a0Si\u00a0las\u00a0\nc\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0vuelven\u00a0a\u00a0entrar\u00a0en\u00a0contacto\u00a0con\u00a0ese\u00a0mismo \u00a0Ag,\u00a0podr\u00edan\u00a0volver\u00a0a\u00a0sufrir\u00a0un\u00a0segundo\u00a0cambio\u00a0de\u00a0\nisotipo\u00a0a\u00a0un\u00a0isotipo\u00a0que\u00a0se\u00a0encuentre\u00a0m\u00e1s\u00a0alejado\u00a0de\u00a0V(D)J\u00a0(e.g .\u00a0a\u00a0IgG2).\u00a0\n\u00a0\nIntroducci\u00f3n \n\u2010\u00a021\u00a0\u2010\u00a0\n\u00a0En\u00a0un\u00a0principio\u00a0se\u00a0sugiri\u00f3\u00a0que\u00a0e ste\u00a0modelo\u00a0de\u00a0reordenamiento\u00a0co n\u00a0cambio\u00a0a\u00a0>\u00a01\u00a0isotipo\u00a0\ntendr\u00eda\u00a0 lugar\u00a0 \u00fanicamente\u00a0 en\u00a0 el\u00a0 curso\u00a0 de\u00a0 una\u00a0 misma\u00a0 respuesta\u00a0 a\u00a0 A g95,96.\u00a0 Sin\u00a0 embargo,\u00a0\nrecientemente\u00a0se\u00a0ha\u00a0propuesto\u00a0que\u00a0el\u00a0modelo\u00a0secuencial\u00a0podr\u00eda\u00a0o currir\u00a0tambi\u00e9n,\u00a0en\u00a0respuestas\u00a0\nposteriores,\u00a0tras\u00a0sucesivos\u00a0encu entros\u00a0con\u00a0un\u00a0mismo\u00a0Ag,\u00a0a\u00a0lo\u00a0la rgo\u00a0de\u00a0la\u00a0vida97,98.\u00a0\nEn\u00a0paralelo\u00a0con\u00a0estos\u00a0cambios\u00a0en\u00a0el\u00a0gen\u00a0 IGH,\u00a0se\u00a0producen\u00a0cambios\u00a0fenot\u00edpicos\u00a0y\u00a0\nfuncionales\u00a0en\u00a0la\u00a0c\u00e9lula\u00a0B,\u00a0caracter\u00edsticos\u00a0de\u00a0la\u00a0diferenciaci\u00f3 n\u00a0a\u00a0CP\u00a0productora\u00a0de\u00a0Acs\u00a0o\u00a0a\u00a0linfocito\u00a0\nB\u00a0de\u00a0memoria,\u00a0c\u00e9lulas\u00a0que\u00a0pasar\u00e1n \u00a0de\u00a0nuevo\u00a0a\u00a0la\u00a0circulaci\u00f3n\u00a0san gu\u00ednea53.\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0las\u00a0CPs\u00a0\ngeneradas\u00a0en\u00a0respuesta\u00a0a\u00a0Ag\u00a0y\u00a0que\u00a0pasar\u00e1n\u00a0a\u00a0SP,\u00a0se\u00a0eliminar\u00e1n\u00a0p or\u00a0apoptosis\u00a0pasados\u00a0unos\u00a0\nd\u00edas99.\u00a0Sin\u00a0embargo,\u00a0una\u00a0minor\u00eda\u00a0es\u00a0capaz\u00a0de\u00a0instalarse\u00a0en\u00a0nichos\u00a0que \u00a0inducen\u00a0su\u00a0supervivencia,\u00a0\nprincipalmente\u00a0en\u00a0MO\u00a0y\u00a0MALT,\u00a0donde\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0factores\u00a0de\u00a0supe rvivencia\u00a0se\u00a0convierten\u00a0en\u00a0\nCPs\u00a0de\u00a0vida\u00a0larga69,100\u2013103\u00a0capaces\u00a0de\u00a0producir\u00a0y\u00a0secretar\u00a0al\u00a0exterior\u00a0varios\u00a0miles\u00a0de\u00a0mol \u00e9culas\u00a0de\u00a0\nIgs\u00a0por\u00a0segundo19.\u00a0Las\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0permanecen\u00a0durante\u00a0m\u00e1s\u00a0tiempo\u00a0(inclu so\u00a0varias\u00a0\nd\u00e9cadas)104,105\u00a0recirculando\u00a0entre\u00a0la\u00a0SP\u00a0y\u00a0los\u00a0OLS70,\u00a0\u00a0de\u00a0forma\u00a0que\u00a0si\u00a0se\u00a0encuentran\u00a0de\u00a0nuevo\u00a0con\u00a0\nsu\u00a0Ag,\u00a0podr\u00edan\u00a0sufrir\u00a0un\u00a0nuevo\u00a0ciclo\u00a0de\u00a0proliferaci\u00f3n\u00a0en\u00a0el\u00a0CG\u00a0 con\u00a0HMS\u00a0y\u00a0cambio\u00a0de\u00a0isotipo,\u00a0con\u00a0\ndiferenciaci\u00f3n\u00a0a\u00a0CP\u00a0y/o\u00a0a\u00a0una\u00a0nueva\u00a0c\u00e9lula\u00a0B\u00a0de\u00a0memoria106\u00a0.\u00a0\n\u00a0\n2.2.2.\u00a0Respuesta\u00a0B\u00a0independiente\u00a0de\u00a0linfocitos\u00a0T\u00a0\n\u00a0Aunque\u00a0la\u00a0se\u00f1al\u00a0inducida\u00a0por\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0Ags\u00a0es\u00a0insuficie nte\u00a0para\u00a0desencadenar\u00a0\npor\u00a0s\u00ed\u00a0sola\u00a0una\u00a0respuesta\u00a0B,\u00a0algunos\u00a0Ags\u00a0producen\u00a0una\u00a0estimulac i\u00f3n\u00a0lo\u00a0suficientemente\u00a0potente\u00a0\npara\u00a0que\u00a0el\u00a0linfocito\u00a0B\u00a0responda,\u00a0en\u00a0ausencia\u00a0de\u00a0colaboraci\u00f3n\u00a0p or\u00a0parte\u00a0de\u00a0los\u00a0linfocitos\u00a0T106.\u00a0Por\u00a0\nun\u00a0lado,\u00a0estas\u00a0respuestas\u00a0independientes\u00a0de\u00a0c\u00e9lulas\u00a0T\u00a0pueden\u00a0es tar\u00a0mediadas\u00a0por\u00a0receptores\u00a0\ndiferentes\u00a0de\u00a0BCR\u00a0presentes\u00a0en\u00a0los\u00a0linfocitos\u00a0B,\u00a0como\u00a0es\u00a0el\u00a0cas o\u00a0de\u00a0los\u00a0receptores\u00a0TLR\u00a0(receptores\u00a0\ntipo\u00a0Toll;\u00a0del\u00a0ingl\u00e9s,\u00a0 Toll\u2010like\u00a0receptor )\u00a0o\u00a0NLR\u00a0(receptores\u00a0tipo\u00a0dom inio\u00a0de\u00a0oligomerizaci\u00f3n\u00a0de\u00a0\nnucle\u00f3tidos;\u00a0del\u00a0ingl\u00e9s,\u00a0 nucleotide\u2010oligomerization\u00a0domain\u2010like\u00a0receptor )\u00a0capaces\u00a0de\u00a0unirse\u00a0a\u00a0\ndiferentes\u00a0componentes\u00a0de\u00a0microorganismos,\u00a0como\u00a0por\u00a0ejemplo,\u00a0el \u00a0lipopolisac\u00e1rido\u00a0de\u00a0las\u00a0\nbacterias\u00a0Gram\u00a0negativas\u00a0y\u00a0los\u00a0\u00e1cidos\u00a0nucleicos\u00a0de\u00a0origen\u00a0v\u00edric o\u00a0o\u00a0bacteriano\u00a0(respuesta\u00a0B\u00a0Introducci\u00f3n \n\u2010\u00a022\u00a0\u2010\u00a0\n\u00a0independiente\u00a0de\u00a0c\u00e9lulas\u00a0T\u00a0tipo\u00a01)107,108.\u00a0Por\u00a0otra\u00a0parte,\u00a0la\u00a0respuesta\u00a0B\u00a0puede\u00a0llevarse\u00a0a\u00a0cabo\u00a0\ntambi\u00e9n\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0BCR\u00a0de\u00a0forma\u00a0independiente\u00a0de\u00a0linfocitos\u00a0T, \u00a0cuando\u00a0el\u00a0linfocito\u00a0B\u00a0reconoce\u00a0\nAgs\u00a0que\u00a0presentan\u00a0varias\u00a0copias\u00a0de\u00a0un\u00a0mismo\u00a0ep\u00edtopo\u00a0(Ag\u00a0multiva lente);\u00a0esto\u00a0ocurre\u00a0con\u00a0algunos\u00a0\nAgs\u00a0repetitivos\u00a0de\u00a0la\u00a0pared\u00a0de\u00a0bacterias\u00a0encapsuladas,\u00a0o\u00a0cuando \u00a0un\u00a0Ag\u00a0est\u00e1\u00a0presente\u00a0en\u00a0\nconcentraciones\u00a0elevadas\u00a0en\u00a0el\u00a0entorno\u00a0del\u00a0linfocito\u00a0B\u00a0capaz\u00a0de \u00a0reconocerle,\u00a0permitiendo\u00a0la\u00a0\ninteracci\u00f3n\u00a0simult\u00e1nea\u00a0del\u00a0Ag\u00a0con\u00a0m\u00faltiples\u00a0mol\u00e9culas\u00a0de\u00a0BCR\u00a0en \u00a0el\u00a0mismo\u00a0linfocito\u00a0B\u00a0(respuesta\u00a0\nindependiente\u00a0 de\u00a0 c\u00e9lulas\u00a0 T\u00a0 de\u00a0 tipo\u00a0 2)107,108.\u00a0 En\u00a0 la\u00a0 Tabla\u00a0 2\u00a0 se\u00a0 resumen\u00a0 las\u00a0 caracter\u00edsticas\u00a0\nprincipales\u00a0de\u00a0los\u00a0tres\u00a0tipos\u00a0de\u00a0respuesta\u00a0B,\u00a0dependiente\u00a0de\u00a0li nfocitos\u00a0T\u00a0e\u00a0independiente\u00a0de\u00a0\nlinfocitos\u00a0T\u00a0tipo\u00a01\u00a0y\u00a02.\u00a0\nTabla\u00a0 2.\u00a0 Caracter\u00edsticas\u00a0 principales\u00a0 de\u00a0 las\u00a0 respuestas\u00a0 de\u00a0 linfo citos\u00a0 B\u00a0 dependientes\u00a0 e\u00a0\nindependientes\u00a0de\u00a0linfocitos\u00a0T\u00a0\nAg,\u00a0ant\u00edgeno;\u00a0BCR,\u00a0receptor\u00a0de\u00a0c \u00e9lula\u00a0B;\u00a0TLR,\u00a0receptor\u00a0tipo\u00a0tol l;\u00a0NLR:\u00a0receptor\u00a0tipo\u00a0dominio\u00a0de\u00a0oligomerizaci\u00f3n\u00a0de\u00a0\nnucle\u00f3tidos.\u00a0\n\u00a0\nCl\u00e1sicamente,\u00a0la\u00a0activaci\u00f3n\u00a0de\u00a0 linfocitos\u00a0B\u00a0independiente\u00a0de\u00a0c\u00e9 lulas\u00a0T\u00a0se\u00a0ha\u00a0relacionado\u00a0\ncon\u00a0la\u00a0generaci\u00f3n\u00a0de\u00a0CPs\u00a0producto ras\u00a0de\u00a0Igs\u00a0de\u00a0baja\u00a0afinidad\u00a0y\u00a0 de\u00a0tipo\u00a0IgM\u00a0y,\u00a0en\u00a0menor\u00a0medida\u00a0\ntambi\u00e9n\u00a0de\u00a0otros\u00a0isotipos,\u00a0con\u00a0frecuencia\u00a0poliespec\u00edficas\u00a0(solo \u00a0en\u00a0el\u00a0caso\u00a0de\u00a0respuestas\u00a0T\u2010\nindependientes\u00a0de\u00a0tipo\u00a01),\u00a0sin\u00a0que\u00a0dicha\u00a0respuesta\u00a0conlleve\u00a0pro ducci\u00f3n\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0\u00a0 Tipo\u00a0de\u00a0respuesta\u00a0B \u00a0\nCaracter\u00edsticas \u00a0Dependiente\u00a0de\u00a0\nlinfocitos\u00a0T\u00a0Independiente\u00a0de\u00a0\nlinfocitos\u00a0T\u00a0tipo\u00a01\u00a0Independiente\u00a0de\u00a0\nlinfocitos\u00a0T\u00a0tipo\u00a02\u00a0\nTipo\u00a0de\u00a0receptor\u00a0 BCR\u00a0No\u00a0BCR\u00a0\n(e.g.\u00a0TLR,\u00a0NLR,\u00a0CD21)\u00a0BCR\u00a0\nTipo\u00a0de\u00a0est\u00edmulo\u00a0Ags\u00a0comunes\u00a0\u00a0\n(e.g.\u00a0prote\u00ednas)\u00a0Lipopolisac\u00e1rido\u00a0\nbacteriano\u00a0o\u00a0virus\u00a0de\u00a0\nEpstein\u2010Barr\u00a0Ags\u00a0repetitivos\u00a0(e.g.\u00a0pared\u00a0\nde\u00a0bacterias\u00a0encapsuladas)\u00a0\no\u00a0en\u00a0alta\u00a0concentraci\u00f3n\u00a0\nNaturaleza\u00a0de\u00a0la\u00a0respuesta\u00a0Monoclonal\u00a0 Policlonal\u00a0 Monoclonal\u00a0\nCambio\u00a0de\u00a0isotipo\u00a0\nde\u00a0Ig\u00a0Si\u00a0 Minoritario\u00a0 Minoritario\u00a0\nMaduraci\u00f3n\u00a0de\u00a0\nafinidad\u00a0Si\u00a0 No\u00a0 No\u00a0\nGeneraci\u00f3n\u00a0de\u00a0\nMemoria\u00a0Si\u00a0 Minoritaria\u00a0 Minoritaria\u00a0Introducci\u00f3n \n\u2010\u00a023\u00a0\u2010\u00a0\n\u00a0espec\u00edficas\u00a0de\u00a0Ag106,109.\u00a0No\u00a0obstante,\u00a0cabe\u00a0se\u00f1alar\u00a0que\u00a0se\u00a0han\u00a0identificado\u00a0linfocitos\u00a0 B\u00a0con\u00a0cambio\u00a0\nde\u00a0isotipo\u00a0y\u00a0menor\u00a0frecuencia\u00a0de\u00a0HMS,\u00a0en\u00a0pacientes\u00a0con\u00a0defectos \u00a0en\u00a0la\u00a0se\u00f1alizaci\u00f3n\u00a0mediada\u00a0\npor\u00a0 CD40\u2010CD40L,\u00a0 lo\u00a0 cual\u00a0 sugiere\u00a0 que\u00a0 podr\u00edan\u00a0 existir\u00a0 linfocitos\u00a0 B \u00a0d e \u00a0m e m o r i a \u00a0T \u2010\nindependientes110,111,\u00a0tal\u00a0como\u00a0se\u00a0discute\u00a0m\u00e1s\u00a0adelante\u00a0en\u00a0esta\u00a0introducci\u00f3n\u00a0(cap\u00edtu los\u00a02.3\u00a0y\u00a04.3).\u00a0 \u00a0\n\u00a0\n2.3.\u00a0\u00a0 Poblaciones\u00a0de\u00a0linfocitos \u00a0B\u00a0circulantes\u00a0en\u00a0sangre\u00a0\nEl\u00a0desarrollo\u00a0tecnol\u00f3gico\u00a0ocurrido \u00a0en\u00a0las\u00a0\u00faltimas\u00a0d\u00e9cadas,\u00a0espe cialmente\u00a0en\u00a0el\u00a0campo\u00a0de\u00a0\nla\u00a0citometr\u00eda\u00a0de\u00a0flujo,\u00a0ha\u00a0permitido\u00a0aumentar\u00a0nuestro\u00a0conocimie nto\u00a0acerca\u00a0de\u00a0las\u00a0poblaciones\u00a0\nde\u00a0linfocitos\u00a0B\u00a0circulantes\u00a0en\u00a0la\u00a0sangre\u00a0humana53,112.\u00a0As\u00ed,\u00a0en\u00a0t\u00e9rminos\u00a0generales,\u00a0en\u00a0SP\u00a0podemos\u00a0\nidentificar\u00a04\u00a0subpoblaciones\u00a0mayoritarias\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0ac uerdo\u00a0a\u00a0su\u00a0estadio\u00a0madurativo:\u00a0\nlinfocitos\u00a0B\u00a0inmaduros/transiciona les,\u00a0linfocitos\u00a0B\u00a0na\u00efve,\u00a0linf ocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0CPs;\u00a0todos\u00a0\nellos\u00a0comparten\u00a0como\u00a0caracter\u00edstica\u00a0fenot\u00edpica\u00a0com\u00fan\u00a0la\u00a0expresi \u00f3n\u00a0del\u00a0marcador\u00a0pan\u2010B\u00a0CD19.\u00a0\nDe\u00a0acuerdo\u00a0con\u00a0lo\u00a0comentado\u00a0en\u00a0el\u00a0apartado\u00a0anterior\u00a0de\u00a0esta\u00a0int roducci\u00f3n,\u00a0las\u00a0dos\u00a0primeras\u00a0\npoblaciones\u00a0incluyen\u00a0linfocitos\u00a0B\u00a0pre\u2010CG,\u00a0mientras\u00a0que\u00a0las\u00a0dos\u00a0 \u00faltimas\u00a0correspo nden\u00a0a\u00a0c\u00e9lulas\u00a0B\u00a0\nque\u00a0ya\u00a0han\u00a0entrado\u00a0en\u00a0contacto\u00a0co n\u00a0Ag\u00a0y\u00a0han\u00a0respondido\u00a0frente\u00a0a l\u00a0mismo.\u00a0\nLos\u00a0linfocitos\u00a0B\u00a0inmaduros/transicionales\u00a0 de\u00a0SP\u00a0representan\u00a0alrededor\u00a0del\u00a01\u20104%\u00a0de\u00a0\ntodos\u00a0 los\u00a0 linfocitos\u00a0 B\u00a0 de\u00a0 SP\u00a0 de\u00a0 a dultos\u00a0 sanos.\u00a0 Fenot\u00edpicamente, \u00a0 muestran\u00a0 caracter\u00edsticas\u00a0\npr\u00e1cticamente\u00a0 id\u00e9nticas\u00a0 a\u00a0 las\u00a0 de\u00a0 los\u00a0 linfocitos\u00a0 B\u00a0 inmaduros\u00a0 de\u00a0 MO,\u00a0 con\u00a0 una\u00a0 expresi\u00f3n\u00a0\nrelativamente\u00a0alta\u00a0de\u00a0IgM,\u00a0CD38, \u00a0CD24\u00a0y\u00a0CD81,\u00a0y\u00a0positividad\u00a0par a\u00a0CD5,\u00a0CD9,\u00a0CD10,\u00a0CD20,\u00a0CD22,\u00a0\nCD200\u00a0y\u00a0ciTCL1\u00a053,72,113,114.\u00a0Por\u00a0el\u00a0contrario,\u00a0muestran\u00a0expresi\u00f3n\u00a0variable\u00a0de\u00a0las\u00a0prote\u00edna s\u00a0CD21,\u00a0\nCD23,\u00a0CD44\u00a0y\u00a0CD62L,\u00a0y\u00a0son\u00a0CD27\u2010\u00a072,113,115.\u00a0Adem\u00e1s,\u00a0expresan\u00a0niveles\u00a0bajos\u00a0de\u00a0los\u00a0receptores\u00a0de\u00a0\nquimiocinas\u00a0CXCR4\u00a0y\u00a0CXCR572,113,\u00a0lo\u00a0que\u00a0se\u00a0ha\u00a0sugerido\u00a0favorecer\u00eda\u00a0una\u00a0menor\u00a0capacidad\u00a0de\u00a0\nmigraci\u00f3n\u00a0 in\u00a0vitro\u00a0mediada\u00a0por\u00a0CXCL12,\u00a0CXCL13\u00a0y\u00a0CCL21,\u00a0respecto\u00a0a\u00a0la\u00a0de\u00a0las\u00a0c\u00e9lul as\u00a0B\u00a0na\u00efve113.\u00a0\nEsto,\u00a0unido\u00a0a\u00a0la\u00a0expresi\u00f3n\u00a0(relativamente)\u00a0baja\u00a0de\u00a0mol\u00e9culas\u00a0de \u00a0adhesi\u00f3n \u00a0como\u00a0CD44\u00a0y\u00a0CD62L,\u00a0\npodr\u00eda\u00a0estar\u00a0relacionado\u00a0con\u00a0la\u00a0escasa\u00a0presencia\u00a0de\u00a0estos\u00a0linfo citos\u00a0B\u00a0inmaduros\u00a0en\u00a0los\u00a0OLS113.\u00a0\nDesde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0funcional,\u00a0el\u00a0linfocito\u00a0B\u00a0inmaduro\u00a0mues tra\u00a0una\u00a0capacidad\u00a0de\u00a0proliferar\u00a0y\u00a0Introducci\u00f3n \n\u2010\u00a024\u00a0\u2010\u00a0\n\u00a0diferenciarse\u00a0 in\u00a0vitro\u00a0tras\u00a0estimulaci\u00f3n\u00a0mediada\u00a0por\u00a0BCR\u00a0y\u00a0CD40\u00a0relativamente\u00a0limitad a,\u00a0asociada\u00a0\na\u00a0una\u00a0menor\u00a0supervivencia\u00a0en\u00a0cultivo,\u00a0respecto\u00a0a\u00a0la\u00a0del\u00a0linfoci to\u00a0B\u00a0na\u00efve72,113.\u00a0\u00a0\nLos\u00a0linfocitos\u00a0B\u00a0na\u00efve ,\u00a0representan\u00a0aproximadamente\u00a0el\u00a060\u201070%\u00a0de\u00a0todas\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0\nde\u00a0la\u00a0SP\u00a0de\u00a0adultos\u00a0sanos53.\u00a0Al\u00a0igual\u00a0que\u00a0el\u00a0linfocito\u00a0B\u00a0inm aduro,\u00a0el\u00a0linfocito\u00a0B\u00a0na\u00efve\u00a0no \u00a0presenta\u00a0\nsignos\u00a0de\u00a0HMS\u00a0y\u00a0muestra\u00a0un\u00a0fenotipo\u00a0CD19+\u00a0CD20+\u00a0CD22+\u00a0CD200+\u00a0ciTCL1+53,116.\u00a0Sin\u00a0embargo,\u00a0se\u00a0\ndiferencia\u00a0de\u00a0\u00e9l\u00a0por\u00a0presentar\u00a0menor\u00a0expresi\u00f3n\u00a0de\u00a0CD24,\u00a0CD38\u00a0y\u00a0 CD81,\u00a0y\u00a0tener\u00a0mayor\u00a0positividad\u00a0\npara\u00a0CD23,\u00a0CD62L,\u00a0CD22,\u00a0CD44,\u00a0CXCR4\u00a0y\u00a0CXCR553,72,113,114.\u00a0Adem\u00e1s,\u00a0a\u00a0diferencia\u00a0del\u00a0linfocito\u00a0B\u00a0\ninmaduro,\u00a0el\u00a0linfocito\u00a0B\u00a0na\u00efve\u00a0carece\u00a0de\u00a0expresi\u00f3n\u00a0de\u00a0CD9\u00a0y\u00a0CD1 0\u00a0en\u00a0su\u00a0superficie\u00a0y\u00a0muestra\u00a0\nmayor\u00a0expresi\u00f3n\u00a0de\u00a0IgD\u00a0que\u00a0de\u00a0IgM72,117.\u00a0Aunque\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0presentan\u00a0\nmenor\u00a0expresi\u00f3n\u00a0de\u00a0CD5\u00a0que\u00a0la\u00a0observada\u00a0en\u00a0los\u00a0linfocitos\u00a0B\u00a0inm aduros/transicionales,\u00a0el\u00a03\u201016%\u00a0\nd e \u00a0l a s \u00a0c \u00e9 l u l a s \u00a0B \u00a0n a \u00ef v e \u00a0e x p r e s a n \u00a0C D 5 \u00a0e n \u00a0a u s e n c i a \u00a0d e \u00a0o t r o s \u00a0m a r c a d ores\u00a0 de\u00a0 inmadurez,\u00a0\nmanteniendo\u00a0tambi\u00e9n\u00a0una\u00a0capacidad \u00a0funcional\u00a0intermedia\u00a0entre\u00a0la \u00a0del\u00a0linfocito\u00a0B\u00a0na\u00efve\u00a0y\u00a0la\u00a0del\u00a0\nlinfocito\u00a0B\u00a0inmaduro114,118.\u00a0De\u00a0forma\u00a0similar,\u00a0aunque\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0son \u00a0CD21+,\u00a0\nse\u00a0ha\u00a0descrito\u00a0una\u00a0poblaci\u00f3n\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0na\u00efve\u00a0CD21\u2010\u00a0(\u22483%\u00a0del\u00a0conjunto\u00a0de\u00a0todos\u00a0los\u00a0linfocitos\u00a0\nB\u00a0na\u00efve),\u00a0que\u00a0se\u00a0caracteriza\u00a0por\u00a0una\u00a0expresi\u00f3n\u00a0m\u00e1s\u00a0elevada\u00a0de\u00a0l as\u00a0mol\u00e9culas\u00a0CD11c,\u00a0CD19,\u00a0CD20,\u00a0\nCD22\u00a0y\u00a0CD9553,119,120.\u00a0\u00a0\nLos\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria \u00a0constituyen\u00a0el\u00a020\u201030%\u00a0de\u00a0todas\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0SP\u00a0de\u00a0\nadultos\u00a0sanos;\u00a0suelen\u00a0presentar\u00a0 HMS,\u00a0y\u00a0aproximadamente\u00a0la\u00a0mitad \u00a0de\u00a0ellos\u00a0han\u00a0sufrido\u00a0cambio\u00a0\nde\u00a0isotipo\u00a0de\u00a0Ig106,121,122.\u00a0Aunque\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0se\u00a0encuentran\u00a0circulantes\u00a0 en\u00a0SP,\u00a0\nestos\u00a0est\u00e1n\u00a0presentes\u00a0tambi\u00e9n\u00a0en\u00a0los\u00a0\u00f3rganos\u00a0linfoides,\u00a0como\u00a0lo s\u00a0ganglios\u00a0linf\u00e1ticos,\u00a0el\u00a0bazo,\u00a0el\u00a0\nMALT\u00a0y\u00a0la\u00a0MO53,70,71.\u00a0La\u00a0gran\u00a0mayor\u00eda\u00a0(>80%)\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0de\u00a0SP\u00a0p resenta\u00a0un\u00a0\nfenotipo\u00a0 CD5\u2010\u00a0 CD10\u2010\u00a0CD19+\u00a0 CD20+\u00a0 CD21+\u00a0 CD22+\u00a0 CD23\u2010\u00a0 CD25+d\u00a0 CD38\u2010\u00a0 CD200\u2010\u00a0 ciTCL1\u2010,\u00a0 y\u00a0\nCD27+53,106,116,117,121,122,\u00a0constituyendo\u00a0esta\u00a0\u00faltima\u00a0prote\u00edna\u00a0un\u00a0marcador\u00a0cl\u00e1sico,\u00a0utili zado\u00a0para\u00a0\nidentificar\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria121.\u00a0Sin\u00a0embargo,\u00a0cabe\u00a0se\u00f1alar\u00a0que\u00a0existe\u00a0tambi\u00e9n\u00a0una\u00a0\npoblaci\u00f3n\u00a0de\u00a0linfocitos\u00a0B\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u00a0que\u00a0son \u00a0CD27\u2010106,111,123\u2013125.\u00a0Estas\u00a0c\u00e9lulas\u00a0\npresentan\u00a0menos\u00a0antecedentes\u00a0de\u00a0replicaci\u00f3n,\u00a0menor\u00a0frecuencia\u00a0d e\u00a0HMS\u00a0y\u00a0menor\u00a0expresi\u00f3n\u00a0de\u00a0Introducci\u00f3n \n\u2010\u00a025\u00a0\u2010\u00a0\n\u00a0mol\u00e9culas\u00a0asociadas\u00a0a\u00a0la\u00a0cooperaci\u00f3n\u00a0entre\u00a0los\u00a0linfocitos\u00a0T\u00a0y\u00a0B \u00a0(e.g.\u00a0HLADR\u00a0y\u00a0CD40)111,123,125,\u00a0\ncuando\u00a0comparamos\u00a0sus\u00a0caracter\u00eds ticas\u00a0con\u00a0las\u00a0de\u00a0los\u00a0linfocitos \u00a0B\u00a0de\u00a0memoria\u00a0CD27+.\u00a0Todo\u00a0ello,\u00a0\nunido\u00a0 a\u00a0 la\u00a0 presencia\u00a0 de\u00a0 linfocitos\u00a0 B\u00a0 de\u00a0 memoria\u00a0 CD27\u2010\u00a0 en\u00a0 pacientes\u00a0 con\u00a0 defectos\u00a0 en\u00a0 la\u00a0\nse\u00f1alizaci\u00f3n\u00a0 de\u00a0 CD40\u2010CD40L110,111,\u00a0 sugiere\u00a0 un\u00a0 origen\u00a0 T\u2010independiente\u00a0 de\u00a0 las\u00a0 c\u00e9lulas\u00a0 B\u00a0 de\u00a0\nmemoria\u00a0CD27\u2010106,111,123,124.\u00a0A\u00a0pesar\u00a0de\u00a0su\u00a0baja\u00a0frecuencia\u00a0 en\u00a0donantes\u00a0sanos\u00a0(<10%\u00a0de\u00a0toda s\u00a0las\u00a0\nc\u00e9lulas\u00a0B)124,\u00a0estas\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0CD27\u2010\u00a0se\u00a0encuentran\u00a0aumentadas\u00a0en\u00a0enfermedades\u00a0\nautoinmunes\u00a0(e.g.\u00a0lupus\u00a0eritematoso\u00a0sist\u00e9mico)\u00a0y\u00a0en\u00a0infecciones \u00a0v\u00edricas\u00a0cr\u00f3nicas\u00a0(e.g.\u00a0en\u00a0la\u00a0\ninfecci\u00f3n\u00a0por\u00a0el\u00a0virus\u00a0de\u00a0la\u00a0inmunodeficiencia\u00a0humana)124,126.\u00a0De\u00a0forma\u00a0similar,\u00a0existe\u00a0una\u00a0\npeque\u00f1a\u00a0fracci\u00f3n\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0de\u00a0SP\u00a0que\u00a0es\u00a0CD21\u2010\u00a0(\u22484%\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria);\u00a0estas\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0CD21\u2010\u00a0presentan\u00a0una\u00a0expresi\u00f3n\u00a0m\u00e1s\u00a0elevada\u00a0de\u00a0CD11c,\u00a0\nCD19,\u00a0CD22\u00a0y\u00a0CD95120,127,128.\u00a0En\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os\u00a0se\u00a0ha\u00a0descrito\u00a0un\u00a0aumento\u00a0de\u00a0estos\u00a0linfoc itos\u00a0B\u00a0\nde\u00a0memoria\u00a0CD21\u2010\u00a0en\u00a0distintas\u00a0enfermedades\u00a0infecciosas\u00a0(e.g.\u00a0en\u00a0la\u00a0malaria\u00a0o\u00a0la \u00a0hepatitis\u00a0C),\u00a0\nautoinmunes\u00a0 (e.g.\u00a0 la\u00a0 artritis\u00a0 reumatoide)\u00a0 y\u00a0 en\u00a0 inmunodeficienci as\u00a0 primarias\u00a0 (e.g.\u00a0 en\u00a0 la\u00a0\ninmunodeficiencia\u00a0variable\u00a0com\u00fan;\u00a0IDVC),\u00a0por\u00a0lo\u00a0que\u00a0se\u00a0ha\u00a0suger ido\u00a0podr\u00edan\u00a0estar\u00a0relacionados\u00a0\ncon\u00a0procesos\u00a0de\u00a0estimulaci\u00f3n\u00a0cr\u00f3nica127\u2013129.\u00a0\u00a0\nLas\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0en\u00a0su\u00a0conjunto,\u00a0pueden\u00a0expresar\u00a0distin tos\u00a0isotipos\u00a0de\u00a0Igs.\u00a0En\u00a0\nt\u00e9rminos\u00a0generales,\u00a0\u224821%\u00b19%\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0expr esan\u00a0IgA\u00a0y\u00a0\u224823%\u00b110%\u00a0IgG,\u00a0\nmientras\u00a0que\u00a0el\u00a0restante\u00a0\u224850%\u00a0son\u00a0IgM+IgD+53.\u00a0El\u00a0verdadero\u00a0origen\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0\nque\u00a0no\u00a0presentan\u00a0cambio\u00a0de\u00a0isotipo\u00a0(IgM+IgD+)\u00a0ha\u00a0sido\u00a0objeto\u00a0de\u00a0intenso\u00a0debate\u00a0en\u00a0el\u00a0pasado,\u00a0\ndebate\u00a0que\u00a0se\u00a0prolonga\u00a0hasta\u00a0el\u00a0d\u00eda\u00a0de\u00a0hoy.\u00a0Actualmente\u00a0se\u00a0cree \u00a0que\u00a0se\u00a0trata\u00a0de\u00a0una\u00a0poblaci\u00f3n\u00a0\nde\u00a0 c\u00e9lulas\u00a0 B\u00a0 heterog\u00e9nea\u00a0 constituida\u00a0 tanto\u00a0 por\u00a0 linfocitos\u00a0 B\u00a0 der ivados\u00a0 de\u00a0 respuestas\u00a0\ndependientes\u00a0de\u00a0c\u00e9lula\u00a0T\u00a0del\u00a0CG,\u00a0como\u00a0por\u00a0linfocitos\u00a0B\u00a0diferenc iados\u00a0en\u00a0la\u00a0zona\u00a0marginal\u00a0del\u00a0\nbazo\u00a0\u2212y\u00a0potencialmente\u00a0tambi\u00e9n\u00a0en\u00a0otros\u00a0tejidos\u00a0(e.g.\u00a0MALT)\u2212\u00a0de \u00a0forma\u00a0independiente\u00a0de\u00a0las\u00a0\nse\u00f1ales\u00a0derivadas\u00a0de\u00a0los\u00a0linfocitos\u00a0T106,130.\u00a0Los\u00a0estudios\u00a0en\u00a0los\u00a0que\u00a0se\u00a0analiza\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0SP\u00a0seg\u00fan\u00a0la\u00a0subclases\u00a0de\u00a0IgG\u00a0o\u00a0IgA\u00a0que\u00a0expresan ,\u00a0ya\u00a0sea\u00a0por\u00a0citometr\u00eda\u00a0de\u00a0flujo131\u00a0\no\u00a0a\u00a0nivel\u00a0de\u00a0ARNm123,\u00a0son\u00a0muy\u00a0limitados.\u00a0No\u00a0obstante,\u00a0en\u00a0ellos\u00a0se\u00a0sugiere\u00a0una\u00a0mayor \u00a0abundancia\u00a0Introducci\u00f3n \n\u2010\u00a026\u00a0\u2010\u00a0\n\u00a0de\u00a0IgG1,\u00a0seguida\u00a0de\u00a0IgG2\u00a0e\u00a0IgG3\u00a0y\u00a0m\u00e1s\u00a0raramente\u00a0IgG4,\u00a0aunque\u00a0el \u00a0n\u00famero\u00a0de\u00a0individuos\u00a0\nanalizados\u00a0es\u00a0peque\u00f1o.\u00a0Esta\u00a0distribuci\u00f3n\u00a0var\u00eda\u00a0seg\u00fan\u00a0la\u00a0expresi \u00f3n\u00a0de\u00a0CD27,\u00a0con\u00a0un\u00a0mayor\u00a0uso\u00a0de\u00a0\nIGHG3\u00a0en\u00a0la\u00a0poblaci\u00f3n\u00a0CD27\u2010\u00a0y\u00a0de\u00a0IGHG2\u00a0en\u00a0la\u00a0CD27+97,98,106,111,123,131.\u00a0Respecto\u00a0a\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0\nmemoria\u00a0 IgA+\u00a0 de\u00a0 SP,\u00a0 existir\u00eda\u00a0 un\u00a0 predominio\u00a0 de\u00a0 IGHA1\u00a0vs.\u00a0IGHA2132.\u00a0 En\u00a0 paralelo,\u00a0 se\u00a0 ha\u00a0\nidentificado\u00a0la\u00a0presencia\u00a0en\u00a0SP\u00a0de\u00a0adultos\u00a0sanos\u00a0(\u224810%)\u00a0de\u00a0c\u00e9lu las\u00a0de\u00a0memoria\u00a0IgM\u2010IgD+,\u00a0que\u00a0\nsuponen\u00a0menos\u00a0del\u00a00.5%\u00a0de\u00a0todas\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0SP106.\u00a0Estas\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0IgM\u2010IgD+\u00a0se\u00a0\ncaracterizan\u00a0por\u00a0mostrar\u00a0una\u00a0mayor\u00a0frecuencia\u00a0de\u00a0HMS\u00a0que\u00a0otros\u00a0 linfocitos\u00a0B\u00a0de\u00a0memoria,\u00a0junto\u00a0\na\u00a0una\u00a0expresi\u00f3n\u00a0preferencial\u00a0de\u00a0cadenas\u00a0ligeras\u00a0lambda\u00a0y\u00a0de\u00a0det erminadas\u00a0familias\u00a0V(D)J133.\u00a0\nTodo\u00a0ello,\u00a0unido\u00a0a\u00a0la\u00a0capacidad\u00a0de\u00a0la\u00a0IgD\u00a0de\u00a0unirse\u00a0a\u00a0bacterias \u00a0como\u00a0M.\u00a0catarrhalis \u00a0y\u00a0H.\u00a0\ninfluenzae134,\u00a0y \u00a0s u \u00a0a l t a \u00a0p r e v a l e n c i a \u00a0e n \u00a0a m i g d a l i t i s \u00a0r e c u r r e n t e s \u00a0y \u00a0e n \u00a0t e j i d o \u00a0d e\u00a0 adenoides\u00a0\nhiperpl\u00e1sicas135,\u00a0ha\u00a0llevado\u00a0a\u00a0algunos\u00a0autores\u00a0a\u00a0sugerir\u00a0que\u00a0en\u00a0su\u00a0origen,\u00a0esta s\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0\nmemoria\u00a0 podr\u00edan\u00a0 estar\u00a0 relacionadas\u00a0 con\u00a0 la\u00a0 respuesta\u00a0 a\u00a0 Ags\u00a0 bacte rianos\u00a0 y\u00a0 de\u00a0 otro\u00a0 tipo,\u00a0\ncaracter\u00edsticos\u00a0de\u00a0las\u00a0v\u00edas\u00a0respiratorias\u00a0altas133.\u00a0\u00a0\nFinalmente,\u00a0en\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os\u00a0se\u00a0ha\u00a0demostrado\u00a0que\u00a0las\u00a0 CPs\u00a0tambi\u00e9n\u00a0est\u00e1n\u00a0presentes\u00a0\nde\u00a0forma\u00a0sistem\u00e1tica\u00a0en\u00a0la\u00a0SP\u00a0de\u00a0adultos\u00a0sanos,\u00a0aunque\u00a0en\u00a0frecu encias\u00a0muy\u00a0inferiores\u00a0(1\u20103%\u00a0de\u00a0\nlas\u00a0c\u00e9lulas\u00a0B)\u00a0a\u00a0las\u00a0de\u00a0las\u00a0dem\u00e1s\u00a0poblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B,\u00a0lo\u00a0 que\u00a0ha\u00a0dificultado\u00a0enormemente\u00a0su\u00a0\nestudio53,117,136,137.\u00a0Fenot\u00edpicamente,\u00a0las\u00a0CPs\u00a0de\u00a0SP\u00a0se\u00a0caracterizan\u00a0por\u00a0presentar\u00a0 expresi\u00f3n\u00a0\nelevada\u00a0de\u00a0CD38\u00a0y\u00a0CD27,\u00a0positividad\u00a0d\u00e9bil\u00a0para\u00a0CD19\u00a0e\u00a0Ig\u00a0de\u00a0sup erficie,\u00a0junto\u00a0a\u00a0expresi\u00f3n\u00a0parcial\u00a0\nde\u00a0CD20\u00a0y\u00a0CD138,\u00a0en\u00a0ausencia\u00a0de\u00a0CD5,\u00a0CD21,\u00a0CD22,\u00a0CD23,\u00a0CD24,\u00a0CD 200,\u00a0y\u00a0ciTCL153,117,138,139.\u00a0\nAunque\u00a0el\u00a0fenotipo\u00a0de\u00a0las\u00a0CPs\u00a0residentes\u00a0en\u00a0MO\u00a0es\u00a0similar\u00a0al\u00a0de \u00a0las\u00a0CPs\u00a0circulantes\u00a0en\u00a0sangre,\u00a0\nestas\u00a0\u00faltimas\u00a0muestran\u00a0menor\u00a0expresi\u00f3n\u00a0de\u00a0CD38,\u00a0positividad\u00a0con stante\u00a0para\u00a0CD19,\u00a0expresi\u00f3n\u00a0\nd\u00e9bil\u00a0de\u00a0Ig\u00a0de\u00a0superficie\u00a0y\u00a0positividad\u00a0parcial\u00a0para\u00a0CD20\u2010/+.\u00a0Adem\u00e1s,\u00a0mientras\u00a0que\u00a0las\u00a0CPs\u00a0de\u00a0MO\u00a0\nse\u00a0caracterizan\u00a0por\u00a0una\u00a0expresi\u00f3n\u00a0fuerte\u00a0de\u00a0CD138\u00a0y\u00a0positividad \u00a0heterog\u00e9nea\u00a0para\u00a0HLADR\u00a0y\u00a0\nCD45,\u00a0las\u00a0CPs\u00a0de\u00a0SP\u00a0muestran\u00a0una\u00a0expresi\u00f3n\u00a0parcial\u00a0de\u00a0CD138\u2010/+,\u00a0y\u00a0son\u00a0(todas)\u00a0CD45+\u00a0y\u00a0HLADR+117.\u00a0\nEstas\u00a0diferencias\u00a0sugieren\u00a0un\u00a0fenotipo\u00a0m\u00e1s\u00a0inmaduro\u00a0para\u00a0las\u00a0CP s\u00a0de\u00a0SP\u00a0vs.\u00a0MO.\u00a0De\u00a0hecho,\u00a0\nactualmente\u00a0se\u00a0considera\u00a0que\u00a0la\u00a0gran\u00a0mayor\u00eda\u00a0de\u00a0las\u00a0CPs\u00a0de\u00a0SP,\u00a0 son\u00a0c\u00e9lulas\u00a0reci\u00e9n\u00a0generadas\u00a0en\u00a0Introducci\u00f3n \n\u2010\u00a027\u00a0\u2010\u00a0\n\u00a0los\u00a0OLS,\u00a0tras\u00a0una\u00a0respuesta\u00a0inmune,\u00a0ya\u00a0que\u00a06\u20107\u00a0d\u00edas\u00a0tras\u00a0vacuna ci\u00f3n\u00a0se\u00a0puede\u00a0detectar\u00a0una\u00a0\noleada\u00a0de\u00a0CPs\u00a0espec\u00edficas\u00a0del\u00a0Ag\u00a0inoculado\u00a0en\u00a0SP139,140.\u00a0Sin\u00a0embargo,\u00a0se\u00a0ha\u00a0sugerido\u00a0tambi\u00e9n\u00a0que\u00a0\nlas\u00a0CPs\u00a0alojadas\u00a0en\u00a0MO\u00a0podr\u00edan\u00a0recircular\u00a0en\u00a0SP,\u00a0al\u00a0observarse\u00a0 tras\u00a0la\u00a0vacunaci\u00f3n\u00a0un\u00a0aumento\u00a0en\u00a0\nSP\u00a0de\u00a0CPs\u00a0con\u00a0especificidades\u00a0antig\u00e9nicas\u00a0diferentes\u00a0a\u00a0las\u00a0indu cidas\u00a0por\u00a0la\u00a0vacuna,\u00a0asociada\u00a0a\u00a0\nfenotipos\u00a0t\u00edpicos\u00a0de\u00a0CP\u00a0de\u00a0MO\u00a0(e.g.\u00a0menor\u00a0expresi\u00f3n\u00a0de\u00a0HLADR)139,140.\u00a0Esto\u00a0ha\u00a0llevado\u00a0a\u00a0plantear\u00a0\nla\u00a0posibilidad\u00a0de\u00a0que,\u00a0tras\u00a0la\u00a0a ctivaci\u00f3n\u00a0B\u00a0y\u00a0la\u00a0respuesta\u00a0inmu ne,\u00a0las\u00a0CPs\u00a0de\u00a0MO\u00a0 competir\u00edan\u00a0con\u00a0\nlas\u00a0CPs\u00a0reci\u00e9n\u00a0generadas\u00a0procedentes\u00a0de\u00a0 SP,\u00a0por\u00a0 los\u00a0nichos\u00a0medu lares\u00a0de\u00a0 supervivencia,\u00a0\npudiendo\u00a0en\u00a0este\u00a0caso\u00a0abandonar\u00a0la\u00a0MO\u00a0en\u00a0b\u00fasqueda\u00a0de\u00a0nuevos\u00a0nic hos117,138,139.\u00a0Respecto\u00a0a\u00a0la\u00a0\nexpresi\u00f3n\u00a0de\u00a0distintos\u00a0isotipos\u00a0de\u00a0Igs,\u00a0cabe\u00a0se\u00f1alar\u00a0que\u00a0la\u00a0may or\u00eda\u00a0de\u00a0las\u00a0CPs\u00a0de\u00a0SP\u00a0expresan\u00a0IgA\u00a0\n(49%\u00b112%),\u00a0seguida\u00a0de\u00a0IgM\u00a0(18%\u00b1 12%)\u00a0e\u00a0IgG\u00a0(13%\u00b111%),\u00a0y\u00a0solo\u00a0una \u00a0minor\u00eda\u00a0carece\u00a0de\u00a0expresi\u00f3n\u00a0\nde\u00a0Ig\u00a0de\u00a0superficie\u00a0(14%\u00b112%)53,117.\u00a0Esta\u00a0mayor\u00a0proporci\u00f3n\u00a0de\u00a0CPs\u00a0IgA+\u00a0en\u00a0SP\u00a0podr\u00eda\u00a0deberse\u00a0a\u00a0la\u00a0\nexistencia\u00a0de\u00a0una\u00a0estimulaci\u00f3n\u00a0antig\u00e9nica\u00a0continuada\u00a0en\u00a0el\u00a0MALT ,\u00a0especialmente\u00a0en\u00a0el\u00a0intestino,\u00a0\nen\u00a0respuesta\u00a0a\u00a0bacterias\u00a0comensales53,138,141.\u00a0\u00a0\n\u00a0\n3.\u00a0\u00a0Desarrollo\u00a0de\u00a0la\u00a0respuesta\u00a0B\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida\u00a0\nActualmente\u00a0se\u00a0cree\u00a0que\u00a0en\u00a0la\u00a0var iabilidad\u00a0inmunol\u00f3gica\u00a0observa da\u00a0entre\u00a0distintos\u00a0\nindividuos\u00a0sanos\u00a0est\u00e1n\u00a0implicados\u00a0m\u00faltiples\u00a0factores,\u00a0la\u00a0mayor\u00ed a\u00a0de\u00a0los\u00a0cuales\u00a0(50\u201075%)\u00a0ser\u00edan\u00a0\nde\u00a0\u00edndole\u00a0no\u00a0gen\u00e9tica\u00a0o\u00a0ambiental.\u00a0De\u00a0todos\u00a0ellos,\u00a0la\u00a0edad\u00a0se\u00a0c onsidera\u00a0uno\u00a0de\u00a0los\u00a0m\u00e1s\u00a0\nimportantes\u00a0a\u00a0la\u00a0hora\u00a0de\u00a0explicar\u00a0dicha\u00a0variabilidad142\u2013144.\u00a0\u00a0\nDesde\u00a0el\u00a0momento\u00a0del\u00a0nacimiento,\u00a0el\u00a0sistema\u00a0inmune\u00a0se\u00a0desarroll a\u00a0y\u00a0madura\u00a0de\u00a0forma\u00a0\nprogresiva,\u00a0influenciado\u00a0por\u00a0la\u00a0 interacci\u00f3n\u00a0con\u00a0los\u00a0Ags\u00a0del\u00a0ent orno\u00a0del\u00a0individuo,\u00a0modulando\u00a0su\u00a0\ncapacidad\u00a0de\u00a0respuesta145.\u00a0As\u00ed,\u00a0durante\u00a0la\u00a0infancia\u00a0temprana,\u00a0los\u00a0ni\u00f1os\u00a0son\u00a0m\u00e1s\u00a0vulnerab les\u00a0a\u00a0\ninfecciones,\u00a0debido\u00a0fundamentalmente\u00a0a\u00a0la\u00a0inmadurez\u00a0del\u00a0sistema \u00a0inmune,\u00a0que\u00a0provoca\u00a0que\u00a0las\u00a0\nrespuestas\u00a0generadas\u00a0sean\u00a0d\u00e9biles\u00a0y\u00a0de\u00a0corta\u00a0duraci\u00f3n.\u00a0Posterio rmente,\u00a0el\u00a0sistema\u00a0inmune\u00a0va\u00a0\nmadurando\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0infancia\u00a0y\u00a0en\u00a0adultos\u00a0j\u00f3venes\u00a0la\u00a0fre cuencia\u00a0de\u00a0infecciones\u00a0es\u00a0menor145.\u00a0\nEn\u00a0contraposici\u00f3n,\u00a0en\u00a0adultos\u00a0de\u00a0edades\u00a0avanzadas,\u00a0se\u00a0observa\u00a0u n\u00a0mayor\u00a0riesgo\u00a0de\u00a0infecciones\u00a0Introducci\u00f3n \n\u2010\u00a028\u00a0\u2010\u00a0\n\u00a0agudas\u00a0de\u00a0origen\u00a0v\u00edrico\u00a0y\u00a0bacteriano,\u00a0asociado\u00a0a\u00a0una\u00a0mayor\u00a0mort alidad\u00a0por\u00a0causas\u00a0infecciosas,\u00a0y\u00a0\notros\u00a0trastornos\u00a0relacionados\u00a0con\u00a0una\u00a0disfuncionalidad\u00a0de\u00a0la\u00a0re spuesta\u00a0inmune\u00a0o\u00a0una\u00a0respuesta\u00a0\ninmune\u00a0inadecuada\u00a0(enfermedades\u00a0autoinmunes\u00a0y\u00a0c\u00e1ncer);\u00a0esta\u00a0may or\u00a0disfunci\u00f3n\u00a0inmune\u00a0se\u00a0ha\u00a0\nasociado\u00a0a\u00a0un\u00a0deterioro\u00a0progresivo\u00a0de\u00a0la\u00a0respuesta\u00a0inmune\u00a0(\u201cinm unosenescencia\u201d)\u00a0en\u00a0las\u00a0fases\u00a0\nm\u00e1s\u00a0avanzadas\u00a0de\u00a0la\u00a0vida\u00a0(la\u00a0vejez)145\u2013147.\u00a0\u00a0\nEn\u00a0conjunto,\u00a0estos\u00a0cambios\u00a0en\u00a0el\u00a0sistema\u00a0inmune\u00a0y\u00a0en\u00a0la\u00a0respues ta\u00a0inmune\u00a0\u201cprovocados\u201d\u00a0\npor\u00a0la\u00a0edad\u00a0afectan\u00a0de\u00a0forma\u00a0preferente\u00a0a\u00a0la\u00a0inmunidad\u00a0adaptati va145.\u00a0En\u00a0este\u00a0cap\u00edtulo\u00a0nos\u00a0\ncentraremos\u00a0en\u00a0descubrir\u00a0los\u00a0cambios\u00a0que\u00a0ocurren\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0 la\u00a0vida\u00a0en\u00a0los\u00a0\u00f3rganos\u00a0linfoides\u00a0\ny\u00a0en\u00a0los\u00a0elementos\u00a0solubles\u00a0y\u00a0cel ulares\u00a0que\u00a0integran\u00a0la\u00a0respues ta\u00a0B.\u00a0\n\u00a0\n3.1\u00a0Desarrollo\u00a0de\u00a0los\u00a0\u00f3rganos\u00a0linfoides\u00a0\n\u00a0 La\u00a0estructura\u00a0(y\u00a0funci\u00f3n)\u00a0de\u00a0lo s\u00a0\u00f3rganos\u00a0linfoides,\u00a0tanto\u00a0prim arios\u00a0como\u00a0secundarios,\u00a0se\u00a0\nmodifica\u00a0de\u00a0forma\u00a0importante\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida.\u00a0As\u00ed,\u00a0hoy\u00a0se \u00a0conoce\u00a0que\u00a0la\u00a0producci\u00f3n\u00a0de\u00a0\nlinfocitos\u00a0B\u00a0comienza\u00a0en\u00a0etapas\u00a0embrionarias\u00a0en\u00a0el\u00a0saco\u00a0vitelin o,\u00a0desplaz\u00e1ndose\u00a0posteriormente\u00a0\n(entre\u00a0las\u00a0semanas\u00a08\u00a0y\u00a010\u00a0de\u00a0desarrollo)\u00a0a\u00a0tejidos\u00a0blandos\u00a0como \u00a0el\u00a0h\u00edgado\u00a0fetal\u00a0y\u00a0el\u00a0bazo;\u00a0a\u00a0partir\u00a0\nde\u00a0las\u00a0semanas\u00a012\u201015\u00a0de\u00a0gestaci\u00f3n\u00a0la\u00a0linfopoyesis\u00a0B\u00a0se\u00a0establec e\u00a0en\u00a0la\u00a0MO,\u00a0permaneciendo\u00a0la\u00a0\nMO\u00a0como\u00a0\u00fanica\u00a0fuente\u00a0de\u00a0producci \u00f3n\u00a0de\u00a0linfocitos\u00a0B\u00a0humanos,\u00a0des de\u00a0la\u00a0semana\u00a023\u201025\u00a0de\u00a0\ngestaci\u00f3n148,149,\u00a0 aunque\u00a0 algunos\u00a0 autores\u00a0 han\u00a0 sugerido\u00a0 la\u00a0 posibilidad\u00a0 de\u00a0 que\u00a0 exi sta\u00a0\nhematopoyesis\u00a0residual\u00a0en\u00a0el\u00a0h\u00edgado\u00a0de\u00a0ni\u00f1os\u00a0y\u00a0adultos150,151.\u00a0\nE n \u00a0l o s \u00a0p r i m e r o s \u00a0a \u00f1 o s \u00a0d e \u00a0v i d a , \u00a0l a \u00a0m a y o r \u00ed a \u00a0d e \u00a0l o s \u00a0h u e s o s \u00a0c o n t i e n e n\u00a0 m\u00e9dula\u00a0\nhematopoy\u00e9tica\u00a0en\u00a0la\u00a0que\u00a0se\u00a0producen\u00a0de\u00a0forma\u00a0activa\u00a0c\u00e9lulas\u00a0B, \u00a0junto\u00a0a\u00a0otras\u00a0c\u00e9lulas\u00a0del\u00a0\nsistema\u00a0inmune\u00a0y\u00a0de\u00a0la\u00a0sangre.\u00a0En\u00a0adultos,\u00a0el\u00a0ac\u00famulo\u00a0de\u00a0(dep\u00f3s itos\u00a0de)\u00a0grasa\u00a0reduce\u00a0el\u00a0\ncomponente\u00a0hematopoy\u00e9tico\u00a0de\u00a0la\u00a0 MO\u00a0que\u00a0progresivamente\u00a0queda\u00a0re stringido\u00a0a\u00a0las\u00a0v\u00e9rtebras,\u00a0\nestern\u00f3n,\u00a0 cr\u00e1neo,\u00a0 costillas\u00a0 y\u00a0 los \u00a0 extremos\u00a0 de\u00a0 los\u00a0 huesos\u00a0 largos152,153.\u00a0 As\u00ed,\u00a0 el\u00a0 n\u00famero\u00a0 de\u00a0\nprecursores\u00a0de\u00a0c\u00e9lula\u00a0B\u00a0en\u00a0MO\u00a0alcanza\u00a0su\u00a0m\u00e1ximo\u00a0entre\u00a0los\u00a06\u00a0y\u00a02 0\u00a0meses\u00a0de\u00a0vida\u00a0(\u224815\u201020%\u00a0de\u00a0\nla\u00a0celularidad\u00a0global\u00a0de\u00a0MO),\u00a0para\u00a0descender\u00a0bruscamente\u00a0hasta\u00a0 los\u00a0dos\u00a0a\u00f1os\u00a0(\u22484%)\u00a0y\u00a0de\u00a0manera\u00a0Introducci\u00f3n \n\u2010\u00a029\u00a0\u2010\u00a0\n\u00a0m\u00e1s\u00a0gradual\u00a0hasta\u00a0los\u00a0\u224814\u00a0a\u00f1os\u00a0y\u00a0la\u00a0edad\u00a0adulta\u00a0(\u22480.8%)154.\u00a0Adem\u00e1s\u00a0de\u00a0su\u00a0papel\u00a0como\u00a0\u00f3rgano\u00a0\nlinfoide\u00a0primario,\u00a0la\u00a0MO\u00a0es\u00a0responsable\u00a0tambi\u00e9n\u00a0de\u00a0alojar\u00a0las\u00a0C Ps\u00a0de\u00a0larga\u00a0vida\u00a0y\u00a0de\u00a0mantener\u00a0\nuna\u00a0producci\u00f3n\u00a0estable\u00a0de\u00a0Acs\u00a0s\u00e9ricos19,53,100.\u00a0La\u00a0capacidad\u00a0de\u00a0la\u00a0MO\u00a0para\u00a0alojar\u00a0estas\u00a0CPs\u00a0ser\u00eda\u00a0\nmenor\u00a0en\u00a0ni\u00f1os,\u00a0tanto\u00a0por\u00a0la\u00a0inmadurez\u00a0del\u00a0microambiente\u00a0medula r\u00a0en\u00a0edades\u00a0tempranas\u00a0de\u00a0la\u00a0\nvida145,155,156,\u00a0como\u00a0por\u00a0la\u00a0sobreocupaci\u00f3n\u00a0de\u00a0 la\u00a0MO\u00a0por\u00a0precursores\u00a0hematopoy \u00e9ticos154.\u00a0\u00a0\nAl\u00a0igual\u00a0que\u00a0ocurre\u00a0con\u00a0la\u00a0MO,\u00a0los\u00a0OLS\u00a0tambi\u00e9n\u00a0sufren\u00a0modificac iones\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0\nvida,\u00a0especialmente\u00a0en\u00a0lo\u00a0que\u00a0hace\u00a0referencia\u00a0a\u00a0los\u00a0CGs157\u2013159.\u00a0As\u00ed,\u00a0estudios\u00a0morfol\u00f3gicos\u00a0e\u00a0\nhistol\u00f3gicos\u00a0realizados\u00a0en\u00a0muestras\u00a0de\u00a0ganglios\u00a0de\u00a0distintas\u00a0lo calizaciones\u00a0anat\u00f3micas\u00a0y\u00a0en\u00a0bazos\u00a0\nde\u00a0fetos\u00a0y\u00a0de\u00a0reci\u00e9n\u00a0nacidos,\u00a0han\u00a0demostrado\u00a0que\u00a0de\u00a0forma\u00a0siste m\u00e1tica,\u00a0los\u00a0CGs\u00a0est\u00e1n\u00a0ausentes\u00a0\ne n \u00a0O L S \u00a0d e \u00a0f e t o s , \u00a0d e \u00a0n i \u00f1 o s \u00a0p r e m a t u r o s \u00a0y \u00a0d e \u00a0r e c i \u00e9 n \u00a0n a c i d o s \u00a0m e n o r e s\u00a0 de\u00a0 15\u00a0 d\u00edas157,158.\u00a0\nPosteriormente,\u00a0aparecen\u00a0los\u00a0CGs,\u00a0y\u00a0durante\u00a0el\u00a0primer\u00a0a\u00f1o\u00a0de\u00a0vi da\u00a0alcanzan\u00a0mayor\u00a0n\u00famero,\u00a0para\u00a0\nla\u00a0mayor\u00eda\u00a0de\u00a0las\u00a0localizaciones\u00a0analizadas157.\u00a0A\u00a0partir\u00a0de\u00a0los\u00a040\u201060\u00a0a\u00f1os,\u00a0el\u00a0componente\u00a0linfoide\u00a0\nd e \u00a0e s t o s \u00a0t e j i d o s \u00a0( b a z o , \u00a0g a n g l i o s ) \u00a0s e \u00a0r e d u c e , \u00a0d e b i d o \u00a0a l \u00a0a u m e n t o \u00a0 de\u00a0 focos\u00a0 de\u00a0 lipomatosis,\u00a0\nhialinizaci\u00f3n\u00a0y\u00a0fibrosis157,160,161,\u00a0as\u00ed\u00a0como\u00a0por\u00a0la\u00a0reducci\u00f3n\u00a0en\u00a0el\u00a0n\u00famero,\u00a0tama\u00f1o\u00a0y\u00a0celularidad\u00a0 de\u00a0\nlos\u00a0CGs157,161.\u00a0De\u00a0igual\u00a0modo,\u00a0el\u00a0MALT\u00a0tambi\u00e9n\u00a0se\u00a0modifica\u00a0con\u00a0la\u00a0edad,\u00a0lo\u00a0cu al\u00a0es\u00a0debido\u00a0\nfundamentalmente\u00a0a\u00a0la\u00a0colonizaci\u00f3n\u00a0del\u00a0tracto\u00a0gastrointestinal\u00a0 por\u00a0parte\u00a0de\u00a0microorganismos\u00a0\ncomensales\u00a0( B.\u00a0fragilli ,\u00a0C.\u00a0difficile \u00a0y\u00a0especies\u00a0de\u00a0 Bifidobacterius \u00a0y\u00a0Lactobacilli )\u00a0durante\u00a0los\u00a0\nprimeros\u00a0meses\u00a0tras\u00a0el\u00a0nacimiento,\u00a0detectables\u00a0en\u00a0ocasiones\u00a0ya\u00a0 en\u00a0la\u00a0primera\u00a0semana\u00a0de\u00a0\nvida162,163.\u00a0Las\u00a0fuentes\u00a0predominantes\u00a0de\u00a0e stos\u00a0microorganismos\u00a0son\u00a0la\u00a0mic robiota\u00a0materna,\u00a0\nvariable\u00a0seg\u00fan\u00a0un\u00a0parto\u00a0se\u00a0haya\u00a0producido\u00a0de\u00a0forma\u00a0natural\u00a0o\u00a0me diante\u00a0ces\u00e1rea\u00a0(en\u00a0cuyo\u00a0caso\u00a0\nel\u00a0contacto\u00a0ser\u00e1\u00a0con\u00a0diferentes\u00a0microorganismos)164\u2013166,\u00a0y\u00a0la\u00a0dieta\u00a0(leche\u00a0materna\u00a0 vs.\u00a0otra\u00a0fuente\u00a0\nexterna\u00a0de\u00a0leche)166,167,\u00a0pudiendo\u00a0influir\u00a0en\u00a0su\u00a0constituci\u00f3n\u00a0y\u00a0desarrollo\u00a0otros\u00a0factor es\u00a0como\u00a0el\u00a0\nuso\u00a0de\u00a0antibi\u00f3ticos\u00a0y/o\u00a0la\u00a0edad\u00a0gestacional166,167.\u00a0Tanto\u00a0el\u00a0grado\u00a0de\u00a0colonizaci\u00f3n\u00a0de\u00a0la\u00a0mucosa\u00a0\nintestinal\u00a0como\u00a0el\u00a0tipo\u00a0de\u00a0micr oorganismos\u00a0que\u00a0integran\u00a0la\u00a0flor a\u00a0del\u00a0aparato\u00a0digestivo,\u00a0est\u00e1n\u00a0\ndirectamente\u00a0relacionados\u00a0con\u00a0ca mbios\u00a0concretos\u00a0en\u00a0la\u00a0respuesta \u00a0desarrollada\u00a0por\u00a0parte\u00a0de\u00a0las\u00a0\nc\u00e9lulas\u00a0B162,163.\u00a0Estos\u00a0cambios\u00a0en\u00a0los\u00a0tejidos\u00a0linfoides\u00a0asociados\u00a0a\u00a0la\u00a0edad,\u00a0i nfluyen\u00a0l\u00f3gicamente\u00a0Introducci\u00f3n \n\u2010\u00a030\u00a0\u2010\u00a0\n\u00a0e n \u00a0l a \u00a0c o m p o s i c i \u00f3 n \u00a0y \u00a0d i s t r i b u c i \u00f3 n \u00a0d e \u00a0l o s \u00a0A c s \u00a0s \u00e9 r i c o s \u00a0( y \u00a0d e \u00a0l a s \u00a0s ecreciones\u00a0 externas)\u00a0 y\u00a0\nconsecuentemente\u00a0tambi\u00e9n,\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0presentes\u00a0en\u00a0SP\u00a0y \u00a0en\u00a0los\u00a0OLS.\u00a0\n\u00a0\n3.2\u00a0Niveles\u00a0s\u00e9ricos\u00a0 de\u00a0inmunoglobulinas\u00a0 \u00a0\n\u00a0 De\u00a0forma\u00a0previa\u00a0al\u00a0contacto\u00a0con\u00a0pat\u00f3genos\u00a0ambientales,\u00a0el\u00a0neon ato\u00a0ya\u00a0dispone\u00a0de\u00a0Igs\u00a0\ns\u00e9ricas19,\u00a0debido\u00a0fundamentalmente\u00a0a\u00a0la\u00a0transferencia\u00a0de\u00a0IgG\u00a0de\u00a0origen\u00a0m aterno\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0\nplacenta,\u00a0proceso\u00a0que\u00a0se\u00a0inicia\u00a0alrededor\u00a0de\u00a0la\u00a0semana\u00a020\u201022\u00a0de \u00a0gestaci\u00f3n5,19,168.\u00a0Estos\u00a0Acs\u00a0de\u00a0\nisotipo\u00a0IgG\u00a0de\u00a0origen\u00a0materno,\u00a0protegen\u00a0inicialmente\u00a0al\u00a0reci\u00e9n\u00a0 nacido\u00a0de\u00a0infecciones\u00a0con\u00a0las\u00a0que\u00a0\nhaya\u00a0estado\u00a0en\u00a0contacto\u00a0su\u00a0m adre,\u00a0incluso\u00a020\u201030\u00a0a\u00f1os\u00a0atr\u00e1s145.\u00a0Los\u00a0niveles\u00a0de\u00a0IgG\u00a0s\u00e9rica\u00a0del\u00a0\nreci\u00e9n\u00a0nacido\u00a0son\u00a0cuantitativamente\u00a0comparables\u00a0a\u00a0los\u00a0de\u00a0su\u00a0mad re,\u00a0tanto\u00a0en\u00a0t\u00e9rminos\u00a0globales\u00a0\n(426\u20102.080\u00a0mg/dl),\u00a0como\u00a0en\u00a0relaci\u00f3n\u00a0a\u00a0su\u00a0distribuci\u00f3n\u00a0por\u00a0isoti po\u00a0\u2212IgG1\u00a0(240\u20101.066\u00a0mg/dl),\u00a0IgG2\u00a0\n(60\u2010410\u00a0mg/dl),\u00a0IgG3\u00a0(10\u201050\u00a0m g/dl)\u00a0e\u00a0IgG4\u00a0(4\u201056\u00a0mg/dl)168\u2013171\u2212,\u00a0si\u00a0bien\u00a0el\u00a0grado\u00a0de\u00a0transferencia\u00a0\nde\u00a0Acs\u00a0IgG\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0placenta\u00a0depende\u00a0directamente\u00a0del\u00a0tie mpo\u00a0de\u00a0gestaci\u00f3n168,172\u2013174.\u00a0\nAdem\u00e1s\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0en\u00a0condiciones\u00a0normales,\u00a0en\u00a0ausencia\u00a0 de\u00a0inflamaci\u00f3n\u00a0y/o\u00a0infecci\u00f3n,\u00a0\nexistir\u00eda\u00a0tambi\u00e9n\u00a0transferenci a\u00a0de\u00a0Acs\u00a0de\u00a0isotipo\u00a0IgA\u00a0e\u00a0IgM175,176,\u00a0aunque\u00a0los\u00a0niveles\u00a0de\u00a0estas\u00a0Igs\u00a0\nen\u00a0neonatos\u00a0son\u00a0mucho\u00a0m\u00e1s\u00a0bajos\u00a0(IgA,\u00a00\u201011\u00a0mg/dl;\u00a0e\u00a0IgM,\u00a05\u201030\u00a0m g/dl)168,176\u2013178.\u00a0Adem\u00e1s,\u00a0el\u00a0\ntransporte\u00a0de\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0placenta\u00a0aumenta\u00a0en \u00a0aquellos\u00a0casos\u00a0en\u00a0los\u00a0que\u00a0\ncoexisten\u00a0procesos\u00a0inflamatorios\u00a0y/o\u00a0infecciosos\u00a0(e.g.\u00a0rubeola\u00a0 o\u00a0parotiditis)170,175.\u00a0As\u00ed\u00a0mismo,\u00a0es\u00a0\nposible\u00a0que\u00a0al\u00a0menos\u00a0parte\u00a0de\u00a0las\u00a0Igs\u00a0presentes\u00a0en\u00a0el\u00a0suero\u00a0fet al\u00a0y\u00a0del\u00a0reci\u00e9n\u00a0nacido,\u00a0sean\u00a0de\u00a0\norigen\u00a0fetal,\u00a0ya\u00a0que\u00a0se\u00a0ha\u00a0demostrado\u00a0la\u00a0presencia\u00a0de\u00a0IgA\u00a0e\u00a0IgM \u00a0en\u00a0reci\u00e9n\u00a0nacidos\u00a0de\u00a0madres\u00a0\nque\u00a0carecen\u00a0de\u00a0estos\u00a0isotipos\u00a0de\u00a0Igs,\u00a0debido\u00a0a\u00a0que\u00a0son\u00a0portador as\u00a0de\u00a0d\u00e9ficits\u00a0selectivos\u00a0de\u00a0IgA\u00a0\ny/o\u00a0presentan\u00a0hipogammaglobulinemia169,176,\u00a0habi\u00e9ndose\u00a0demostrado\u00a0tambi\u00e9n\u00a0la\u00a0presencia\u00a0de\u00a0\nlinfocitos\u00a0B\u00a0IgA+\u00a0en\u00a0tejidos\u00a0fetales175,179.\u00a0Pocos\u00a0d\u00edas/semanas\u00a0despu\u00e9s\u00a0del\u00a0nacimiento,\u00a0los\u00a0Acs\u00a0\nt r a n s f e r i d o s \u00a0a \u00a0t r a v \u00e9 s \u00a0d e \u00a0l a \u00a0p l a c e n t a \u00a0c o m i e n z a n \u00a0a \u00a0d e g r a d a r s e \u00a0y \u00a0d esaparecer152,\u00a0 siendo\u00a0\nparcialmente\u00a0sustituidos\u00a0por\u00a0Igs\u00a0principalmente\u00a0de\u00a0tipo\u00a0IgA,\u00a0tr ansferidas\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0leche\u00a0\nmaterna19,169,\u00a0y\u00a0por\u00a0las\u00a0Igs\u00a0producidas\u00a0por\u00a0las\u00a0propias\u00a0c\u00e9lulas\u00a0B\u00a0del\u00a0neonat o,\u00a0que\u00a0se\u00a0incrementan\u00a0Introducci\u00f3n \n\u2010\u00a031\u00a0\u2010\u00a0\n\u00a0de\u00a0 forma\u00a0 progresiva\u00a0 durante\u00a0 la\u00a0 infancia170.\u00a0 La\u00a0 baja\u00a0 capacidad\u00a0 proteol\u00edtica\u00a0 del\u00a0 tracto\u00a0\ngastrointestinal\u00a0del\u00a0neonato,\u00a0previene\u00a0la\u00a0degradaci\u00f3n\u00a0de\u00a0la\u00a0IgA \u00a0materna,\u00a0lo\u00a0cual\u00a0alarga\u00a0su\u00a0vida\u00a0\nmedia19.\u00a0 Durante\u00a0 los\u00a0 primeros\u00a0 meses\u00a0 de\u00a0 vida,\u00a0 los\u00a0 niveles\u00a0 s\u00e9ricos\u00a0 de\u00a0 Ig M\u00a0 aumentan\u00a0\nconsiderablemente,\u00a0alcanzando\u00a0alrededor\u00a0de\u00a0los\u00a04\u00a0meses\u00a0el\u00a050%\u00a0d el\u00a0valor\u00a0observado\u00a0en\u00a0adultos,\u00a0\ny\u00a0entre\u00a0el\u00a0primer\u00a0y\u00a0segundo\u00a0a\u00f1o\u00a0de\u00a0vida,\u00a0cifras\u00a0id\u00e9nticas\u00a0a\u00a0las \u00a0detectadas\u00a0en\u00a0adultos\u00a0sanos170,180.\u00a0\nA\u00a0su\u00a0vez,\u00a0los\u00a0niveles\u00a0de\u00a0IgG\u00a0decaen\u00a0tras\u00a0el\u00a0nacimiento,\u00a0(IgG\u00a0to tal\u00a0\u2248350\u00a0mg/dl)\u00a0situ\u00e1ndose\u00a0su\u00a0nadir\u00a0\na\u00a0los\u00a04\u00a0meses\u00a0de\u00a0vida;\u00a0a\u00a0partir\u00a0 de\u00a0esa\u00a0edad,\u00a0las\u00a0cifras\u00a0de\u00a0IgG\u00a0 s\u00e9rica\u00a0se\u00a0recuperan\u00a0parcialmente\u00a0al\u00a0\nfinal\u00a0del\u00a0primer\u00a0a\u00f1o\u00a0(\u2248800\u00a0mg/dl),\u00a0no\u00a0alcanz\u00e1ndose\u00a0valores\u00a0s\u00e9ri cos\u00a0comparables\u00a0a\u00a0los\u00a0de\u00a0adultos\u00a0\nsanos\u00a0hasta\u00a0los\u00a07\u00a0a\u00f1os\u00a0de\u00a0vida170,180.\u00a0Este\u00a0patr\u00f3n\u00a0de\u00a0comportamiento\u00a0global\u00a0de\u00a0los\u00a0Acs\u00a0IgG\u00a0var\u00eda\u00a0\npara\u00a0las\u00a0diferentes\u00a0subclases\u00a0de\u00a0IgG;\u00a0as\u00ed,\u00a0mientras\u00a0que\u00a0tanto\u00a0l a\u00a0IgG1\u00a0como\u00a0la\u00a0IgG3\u00a0alcanzan\u00a0su\u00a0\nvalor\u00a0m\u00e1ximo\u00a0en\u00a0la\u00a0edad\u00a0pedi\u00e1tric a,\u00a0la\u00a0IgG2\u00a0aumenta\u00a0m\u00e1s\u00a0lentame nte\u00a0y\u00a0solo\u00a0alcanza\u00a0su\u00a0nivel\u00a0\nm\u00e1ximo\u00a0en\u00a0suero,\u00a0en\u00a0la\u00a0edad\u00a0adulta181,182.\u00a0De\u00a0forma\u00a0similar,\u00a0los\u00a0niveles\u00a0de\u00a0IgG4\u00a0s\u00e9ricos\u00a0alcanzan\u00a0\nvalores\u00a0m\u00e1ximos\u00a0en\u00a0edades\u00a0m\u00e1s\u00a0avanzadas\u00a0que\u00a0la\u00a0IgG1\u00a0e\u00a0IgG3,\u00a0aun que\u00a0su\u00a0concentraci\u00f3n\u00a0en\u00a0\nsuero\u00a0es\u00a0mucho\u00a0m\u00e1s\u00a0variable\u00a0entre\u00a0distintos\u00a0individuos182.\u00a0\u00a0\nEn\u00a0t\u00e9rminos\u00a0globales,\u00a0los\u00a0nivele s\u00a0de\u00a0IgA\u00a0aumentan\u00a0m\u00e1s\u00a0lentament e\u00a0en\u00a0suero\u00a0que\u00a0los\u00a0de\u00a0\nIgG,\u00a0observ\u00e1ndose\u00a0tambi\u00e9n\u00a0diferencias\u00a0entre\u00a0las\u00a0subclases\u00a0de\u00a0Ig A:\u00a0mientras\u00a0que\u00a0la\u00a0IgA1\u00a0alcanza\u00a0\nsus\u00a0valores\u00a0m\u00e1ximos\u00a0en\u00a0torno\u00a0a\u00a0lo s\u00a020\u00a0a\u00f1os,\u00a0la\u00a0IgA2\u00a0contin\u00faa\u00a0au mentando\u00a0progresivamente\u00a0sus\u00a0\nniveles\u00a0s\u00e9ricos\u00a0durante\u00a0la\u00a0edad\u00a0adulta183.\u00a0Por\u00a0el\u00a0contrario,\u00a0tanto\u00a0la\u00a0IgD\u00a0como\u00a0la\u00a0IgE\u00a0muestran\u00a0\nconcentraciones\u00a0muy\u00a0bajas\u00a0en\u00a0suero5,\u00a0alcanzando\u00a0ambas\u00a0sus\u00a0cifras\u00a0m\u00e1s\u00a0elevadas\u00a0en\u00a0torno\u00a0a\u00a0la\u00a0\nadolescencia184,185.\u00a0Pese\u00a0a\u00a0todos\u00a0los\u00a0cambios\u00a0antes\u00a0referidos,\u00a0cabe\u00a0se\u00f1alar\u00a0que\u00a0lo s\u00a0niveles\u00a0de\u00a0Igs\u00a0\nson\u00a0relativamente\u00a0estables\u00a0en\u00a0la\u00a0edad\u00a0adulta,\u00a0observ\u00e1ndose\u00a0conc entraciones\u00a0similares\u00a0de\u00a0todos\u00a0\nlos\u00a0 isotipos\u00a0 entre\u00a0 adultos\u00a0 j\u00f3venes\u00a0 y\u00a0 personas\u00a0 mayores170,183,186,187,\u00a0 a\u00a0 pesar\u00a0 de\u00a0 la\u00a0 mayor\u00a0\nsusceptibilidad\u00a0de\u00a0estos\u00a0\u00faltimos\u00a0 a\u00a0padecer\u00a0infecciones\u00a0y\u00a0tumore s152.\u00a0\n\u00a0\n\u00a0\u00a0Introducci\u00f3n \n\u2010\u00a032\u00a0\u2010\u00a0\n\u00a03.3.\u00a0Ontogenia\u00a0de\u00a0los\u00a0linfocitos\u00a0B \u00a0\n\u00a0 Durante\u00a0los\u00a0primeros\u00a0d\u00edas\u00a0tras\u00a0el\u00a0nacimiento,\u00a0el\u00a0n\u00famero\u00a0de\u00a0lin focitos\u00a0B\u00a0totales\u00a0en\u00a0SP\u00a0se\u00a0\nmantiene\u00a0relativamente\u00a0bajo,\u00a0aunque\u00a0aumenta\u00a0r\u00e1pidamente\u00a0a\u00a0parti r\u00a0de\u00a0la\u00a0primera\u00a0semana,\u00a0\nduplicando\u00a0sus\u00a0cifras\u00a0a\u00a0los\u00a0dos\u00a0meses\u00a0de\u00a0edad188,\u00a0y\u00a0alcanzan\u00a0su\u00a0valor\u00a0m\u00e1 ximo\u00a0en\u00a0torno\u00a0a\u00a0los\u00a0dos\u00a0\na\u00f1os\u00a0de\u00a0vida.\u00a0A\u00a0partir\u00a0de\u00a0esta\u00a0e dad,\u00a0la\u00a0cifra\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0en\u00a0S P\u00a0desciende\u00a0progresivamente\u00a0hasta\u00a0\nla\u00a0edad\u00a0adulta189\u2013192.\u00a0En\u00a0adultos,\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfo citos\u00a0B\u00a0permanece\u00a0relativamente \u00a0estable117.\u00a0\n\u00a0Pese\u00a0a\u00a0este\u00a0patr\u00f3n\u00a0global,\u00a0la\u00a0c in\u00e9tica\u00a0de\u00a0las\u00a0subpoblaciones\u00a0d e\u00a0linfocitos\u00a0B\u00a0en\u00a0SP\u00a0var\u00eda\u00a0\nsignificativamente\u00a0 seg\u00fan\u00a0 su\u00a0 estadio\u00a0 madurativo.\u00a0 As\u00ed,\u00a0 la\u00a0 expansi \u00f3n\u00a0 global\u00a0 de\u00a0 linfocitos\u00a0 B\u00a0\nobservada\u00a0durante\u00a0los\u00a0primeros\u00a0a\u00f1 os\u00a0de\u00a0vida,\u00a0es\u00a0debida\u00a0fundamen talmente\u00a0a\u00a0una\u00a0producci\u00f3n\u00a0y\u00a0\nliberaci\u00f3n\u00a0masiva\u00a0de\u00a0linfocitos\u00a0B\u00a0inmaduros\u00a0y\u00a0na\u00efve\u00a0(poblacione s\u00a0mayoritarias\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0\ninfancia)\u00a0a\u00a0SP,\u00a0subpoblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0que\u00a0alcanzan\u00a0sus\u00a0va lores\u00a0m\u00e1ximos\u00a0en\u00a0SP\u00a0entre\u00a0los\u00a06\u00a0\nmeses\u00a0y\u00a0el\u00a0a\u00f1o\u00a0de\u00a0vida189,190.\u00a0Posteriormente,\u00a0el\u00a0n\u00famero,\u00a0tan to\u00a0de\u00a0linfocitos\u00a0B\u00a0inmaduros\u00a0co mo\u00a0\nde\u00a0linfocitos\u00a0B\u00a0na\u00efve,\u00a0desciende\u00a0paulatinamente\u00a0hasta\u00a0la\u00a0edad\u00a0a dulta136,\u00a0manteni\u00e9ndose\u00a0sus\u00a0\ncifras\u00a0estables\u00a0a\u00a0partir\u00a0de\u00a0ah\u00ed,\u00a0incluso\u00a0en\u00a0sujetos\u00a0de\u00a0edad\u00a0ava nzada\u00a0(>60\u00a0a\u00f1os)117.\u00a0Esta\u00a0elevada\u00a0\nproporci\u00f3n\u00a0de\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0e\u00a0inmaduros\u00a0existente\u00a0en\u00a0los\u00a0p rimeros\u00a0a\u00f1os\u00a0de\u00a0vida\u00a0(\u224895%\u00a0en\u00a0el\u00a0\nprimer\u00a0mes)193\u00a0explicar\u00eda,\u00a0al\u00a0menos\u00a0en\u00a0parte,\u00a0la\u00a0existencia\u00a0de\u00a0una\u00a0menor\u00a0capa cidad\u00a0de\u00a0respuesta\u00a0\nfrente\u00a0a\u00a0pat\u00f3genos\u00a0y\u00a0vacunas\u00a0en\u00a0la\u00a0infancia152.\u00a0Adem\u00e1s,\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0los\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0\nneonatales,\u00a0podr\u00edan\u00a0tener\u00a0algunas\u00a0diferencias\u00a0fenot\u00edpicas\u00a0con\u00a0l os\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0del\u00a0adulto,\u00a0\nincluyendo\u00a0una\u00a0menor\u00a0expresi\u00f3n\u00a0de\u00a0mol\u00e9culas\u00a0co\u2010estimuladoras\u00a0co mo\u00a0CD40,\u00a0si\u00a0bien\u00a0estas\u00a0\ndiferencias\u00a0no\u00a0han\u00a0podido\u00a0ser\u00a0confirmadas\u00a0por\u00a0el\u00a0momento152,194,195.\u00a0\nEn\u00a0contraposici\u00f3n\u00a0con\u00a0el\u00a0elevado\u00a0n\u00famero\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0pre\u2010CG\u00a0pre sentes\u00a0en\u00a0SP\u00a0durante\u00a0\nlos\u00a0primeros\u00a0meses\u00a0de\u00a0vida,\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0se\u00a0encuent ran\u00a0en\u00a0SP\u00a0en\u00a0cifras\u00a0muy\u00a0bajas\u00a0\nen\u00a0el\u00a0reci\u00e9n\u00a0nacido,\u00a0aumentando\u00a0de\u00a0forma\u00a0exponencial\u00a0hasta\u00a0los\u00a0 5\u00a0a\u00f1os;\u00a0a\u00a0partir\u00a0de\u00a0ah\u00ed,\u00a0\ncomienzan\u00a0 a\u00a0 descender\u00a0 progresivamente\u00a0 hasta\u00a0 los\u00a0 valores\u00a0 normale s\u00a0 observados\u00a0 en\u00a0\nadultos136,144,189,190.\u00a0Los\u00a0adultos\u00a0a\u00a0su\u00a0vez,\u00a0mantienen\u00a0niveles\u00a0estables\u00a0de\u00a0linfocito s\u00a0B\u00a0de\u00a0memoria\u00a0\nen\u00a0SP\u00a0hasta\u00a0alrededor\u00a0de\u00a0los\u00a060\u00a0 a\u00f1os,\u00a0edad\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0cual, \u00a0estos\u00a0vuelven\u00a0a\u00a0disminuir\u00a0de\u00a0forma\u00a0Introducci\u00f3n \n\u2010\u00a033\u00a0\u2010\u00a0\n\u00a0paulatina53,117.\u00a0Algunos\u00a0estudios\u00a0han\u00a0sugerido\u00a0que\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria \u00a0que\u00a0no\u00a0presentan\u00a0\ncambio\u00a0de\u00a0isotipo,\u00a0podr\u00edan\u00a0producirse\u00a0de\u00a0forma\u00a0m\u00e1s\u00a0r\u00e1pida\u00a0que\u00a0l os\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0\ncambio\u00a0de\u00a0isotipo\u00a0de\u00a0Ig136,190;\u00a0sin\u00a0embargo,\u00a0estos\u00a0hallazgos\u00a0no\u00a0han\u00a0podido\u00a0ser\u00a0corroborados\u00a0p or\u00a0\notros\u00a0autores,\u00a0que\u00a0no\u00a0observan\u00a0diferencias\u00a0en\u00a0la\u00a0distribuci\u00f3n\u00a0d e\u00a0ambos\u00a0subtipos\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0\nmemoria\u00a0con\u00a0la\u00a0edad192.\u00a0Estudios\u00a0m\u00e1s\u00a0detallados\u00a0de\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0linfocitos\u00a0B\u00a0de \u00a0memoria\u00a0\ncon\u00a0diferente\u00a0isotipo\u00a0de\u00a0Ig\u00a0han\u00a0demostrado\u00a0la\u00a0presencia,\u00a0ya\u00a0en\u00a0 sangre\u00a0de\u00a0cord\u00f3n\u00a0umbilical,\u00a0de\u00a0\nc\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0IgG+\u00a0e\u00a0IgA+,\u00a0en\u00a0su\u00a0mayor\u00eda\u00a0CD27\u2010,\u00a0aunque\u00a0en\u00a0concentraciones\u00a0muy\u00a0bajas196.\u00a0\nSin\u00a0embargo,\u00a0a\u00a0partir\u00a0del\u00a0nacimiento,\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memor ia\u00a0IgG+\u00a0e\u00a0Ig A+\u00a0 aumentan\u00a0\nsignificativamente\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0los\u00a0primeros\u00a0a\u00f1os\u00a0de\u00a0vida\u00a0y\u00a0al canzan\u00a0su\u00a0pico\u00a0m\u00e1ximo\u00a0antes\u00a0de\u00a0\nlos\u00a05\u00a0a\u00f1os,\u00a0edad\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0cual\u00a0sus\u00a0cifras\u00a0descienden\u00a0sign ificativamente144,190,196.\u00a0\u00a0En\u00a0adultos\u00a0\nj\u00f3venes\u00a0(20\u201060\u00a0a\u00f1os),\u00a0las\u00a0cifras\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0IgA+,\u00a0IgG+\u00a0e\u00a0IgM+\u00a0se\u00a0mantienen\u00a0\nestables,\u00a0disminuyendo\u00a0gradualmente\u00a0las\u00a0IgG+\u00a0e\u00a0IgM+\u00a0a\u00a0partir\u00a0de\u00a0los\u00a060\u00a0a\u00f1os53,117.\u00a0Aunque\u00a0no\u00a0\nexiste\u00a0informaci\u00f3n\u00a0acerca\u00a0de\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0las\u00a0subclases\u00a0d e\u00a0IgG\u00a0e\u00a0IgA\u00a0analizadas\u00a0por\u00a0\ncitometr\u00eda\u00a0de\u00a0flujo,\u00a0los\u00a0datos\u00a0o btenidos\u00a0por\u00a0biolog\u00eda\u00a0molecular \u00a0sugieren\u00a0que\u00a0prevalecer\u00eda\u00a0el\u00a0uso\u00a0\nde\u00a0IgG2/IgG4\u00a0 versus\u00a0IgG1/IgG3\u00a0en\u00a0adultos\u00a0j\u00f3venes\u00a0frente\u00a0a\u00a0ni\u00f1os97,\u00a0as\u00ed\u00a0como\u00a0el\u00a0de\u00a0IgA2\u00a0sobre\u00a0\nIgA1\u00a0y\u00a0el\u00a0de\u00a0IgG2\u00a0sobre\u00a0IgG1/IgG3\u00a0en\u00a0adultos\u00a0de\u00a0m\u00e1s\u00a0edad132,197.\u00a0El\u00a0origen\u00a0de\u00a0estas\u00a0variaciones\u00a0\nen\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0los\u00a0compartimentos\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0que\u00a0expre san\u00a0diferentes\u00a0isotipos\u00a0a\u00a0lo\u00a0largo\u00a0\nde\u00a0la\u00a0vida,\u00a0podr\u00eda\u00a0estar\u00a0relacio nado\u00a0con\u00a0la\u00a0existencia\u00a0de\u00a0cambi os\u00a0consecutivos\u00a0de\u00a0isotipo\u00a0de\u00a0Ig,\u00a0\ndebido\u00a0a\u00a0la\u00a0ocurrencia\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida,\u00a0de\u00a0contactos\u00a0cons ecutivos/repetitivos\u00a0con\u00a0Ag\u00a0por\u00a0\nparte\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0de\u00a0los\u00a0CGs97\u00a0(Figura\u00a03).\u00a0\nFinalmente,\u00a0apenas\u00a0existe\u00a0informaci\u00f3n\u00a0acerca\u00a0de\u00a0la\u00a0cin\u00e9tica\u00a0de\u00a0 las\u00a0CPs\u00a0de\u00a0SP\u00a0en\u00a0la\u00a0\ninfancia,\u00a0debido\u00a0a\u00a0que\u00a0se\u00a0trata\u00a0de\u00a0una\u00a0poblaci\u00f3n\u00a0celular\u00a0minori taria\u00a0y\u00a0a\u00a0que\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0\nestudios\u00a0realizados\u00a0en\u00a0ni\u00f1os\u00a0no\u00a0 alcanzan\u00a0la\u00a0sensibilidad\u00a0necesa ria\u00a0para\u00a0su\u00a0identificaci\u00f3n\u00a0y\u00a0\nrecuento136,144,189.\u00a0Sin\u00a0embargo,\u00a0si\u00a0se\u00a0ha\u00a0observado\u00a0que,\u00a0al\u00a0igual\u00a0que\u00a0las\u00a0c\u00e9lulas \u00a0B\u00a0de\u00a0memoria\u00a0en\u00a0\nadultos,\u00a0las\u00a0CPs\u00a0IgM+,\u00a0IgG+,\u00a0e\u00a0IgA+\u00a0se\u00a0mantienen\u00a0en\u00a0cifras\u00a0relati vamente\u00a0estables\u00a0hasta\u00a0los\u00a060\u00a0\na\u00f1os,\u00a0edad\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0cual\u00a0l as\u00a0tres\u00a0poblaciones\u00a0de\u00a0CPs\u00a0desc ienden\u00a0gradualmente\u00a053,117.\u00a0Introducci\u00f3n \n\u2010\u00a034\u00a0\u2010\u00a0\n\u00a03.4.\u00a0Ontogenia\u00a0de\u00a0otros\u00a0componentes\u00a0del\u00a0sistema\u00a0inmune\u00a0\nEl\u00a0desarrollo\u00a0del\u00a0compartimento\u00a0B\u00a0depende\u00a0de\u00a0otros\u00a0componentes\u00a0 de\u00a0la\u00a0respuesta\u00a0\ninmune,\u00a0y\u00a0en\u00a0particular\u00a0de\u00a0los\u00a0linfocitos\u00a0T;\u00a0esto\u00a0es\u00a0debido\u00a0a\u00a0q ue\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0las\u00a0respuestas\u00a0B\u00a0\nfrente\u00a0a\u00a0Ag\u00a0son\u00a0dependientes\u00a0de\u00a0linfocitos\u00a0T,\u00a0incluyendo\u00a0la\u00a0res puesta\u00a0B\u00a0frente\u00a0a\u00a0Ags\u00a0bacterianos\u00a0\nde\u00a0naturaleza\u00a0proteica,\u00a0polisac\u00e1ridos\u00a0y\u00a0conjugados\u00a0de\u00a0prote\u00edna\u2010 polisac\u00e1rido.\u00a0En\u00a0este\u00a0sentido,\u00a0\nhoy\u00a0se\u00a0sabe\u00a0que\u00a0tras\u00a0el\u00a0nacimiento,\u00a0las\u00a0cifras\u00a0de\u00a0linfocitos\u00a0T\u00a0 CD4+\u00a0y\u00a0T\u00a0CD8+\u00a0en\u00a0sangre\u00a0aumentan\u00a0\nexponencialmente\u00a0durante\u00a0los\u00a0primeros\u00a0meses\u00a0de\u00a0vida,\u00a0debido\u00a0tam bi\u00e9n\u00a0a\u00a0la\u00a0producci\u00f3n\u00a0masiva\u00a0\nde\u00a0linfocitos\u00a0T\u00a0na\u00efve,\u00a0que\u00a0empieza\u00a0a\u00a0declinar\u00a0progresivamente\u00a0e n\u00a0ni\u00f1os\u00a0de\u00a0corta\u00a0edad\u00a0(1\u20102\u00a0\na\u00f1os)198,\u00a0disminuyendo\u00a0en\u00a0paralelo\u00a0tanto\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0T\u00a0CD4+\u00a0como\u00a0el\u00a0de\u00a0linfocitos\u00a0T\u00a0\nCD8+190,191.\u00a0Este\u00a0aumento\u00a0temprano\u00a0del\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0T\u00a0de\u00a0SP\u00a0en\u00a0los \u00a0primeros\u00a0meses/a\u00f1os\u00a0\nde\u00a0vida,\u00a0permitir\u00e1\u00a0rellenar\u00a0los\u00a0OLS\u00a0con\u00a0estas\u00a0c\u00e9lulas\u00a0y\u00a0habilit ar\u00a0as\u00ed,\u00a0la\u00a0generaci\u00f3n\u00a0progresiva\u00a0de\u00a0\nfol\u00edculos\u00a0linfoides\u00a0con\u00a0sus\u00a0respectivos\u00a0CGs.\u00a0Al\u00a0contrario\u00a0de\u00a0lo \u00a0que\u00a0ocurre\u00a0con\u00a0el\u00a0compartimento\u00a0\nB,\u00a0la\u00a0involuci\u00f3n\u00a0del\u00a0timo\u00a0es\u00a0continua,\u00a0de\u00a0forma\u00a0que,\u00a0en\u00a0adultos \u00a0>60\u00a0a\u00f1os\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0\nT\u00a0 na\u00efve\u00a0 en\u00a0 sangre\u00a0 es\u00a0 cerca\u00a0 de\u00a0 6\u00a0 veces\u00a0 menor\u00a0 que\u00a0 en\u00a0 ni\u00f1os\u00a0 de\u00a0 1\u20102 \u00a0 a\u00f1os\u00a0 (1.000\u20102.900\u00a0\nc\u00e9lulas/\u00b5l)198,199.\u00a0Paralelamente\u00a0a\u00a0la\u00a0disminuci\u00f3n\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0T\u00a0CD4+\u00a0na\u00efve,\u00a0se\u00a0produce\u00a0un\u00a0\naumento\u00a0del\u00a0n\u00famero\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0T\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0las\u00a0c\u00e9lulas \u00a0T\u00a0efectoras\u00a0de\u00a0patrones\u00a0T h1,\u00a0\nTh2\u00a0y\u00a0Th17,\u00a0altamente\u00a0espec\u00edficas\u00a0de\u00a0los\u00a0p at\u00f3genos\u00a0encontrados,\u00a0hasta\u00a0igu alar\u00a0en\u00a0n\u00famero\u00a0a\u00a0las\u00a0\nc\u00e9lulas\u00a0T\u00a0na\u00efve145,190,198,200\u2013202.\u00a0Con\u00a0la\u00a0edad,\u00a0no\u00a0solo\u00a0se\u00a0observan\u00a0cambios\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0\nlinfocitos\u00a0 T\u00a0 y\u00a0 sus\u00a0 poblaciones,\u00a0 sino\u00a0 que\u00a0 adem\u00e1s\u00a0 se\u00a0 modifica\u00a0 su\u00a0 capacidad\u00a0 para\u00a0 expresar\u00a0\nmol\u00e9culas\u00a0relevantes\u00a0para\u00a0l a\u00a0respuesta\u00a0B,\u00a0como\u00a0CD40L203,204.\u00a0\u00a0\nAl\u00a0igual\u00a0que\u00a0ocurre\u00a0con\u00a0los\u00a0linfocitos\u00a0T\u00a0y\u00a0B,\u00a0durante\u00a0los\u00a0prime ros\u00a0(3\u201012)\u00a0meses\u00a0de\u00a0vida\u00a0\notros\u00a0elementos\u00a0celulares\u00a0(e.g.\u00a0 los\u00a0neutr\u00f3filos\u00a0y\u00a0los\u00a0monocitos )\u00a0y\u00a0solubles\u00a0(e.g.\u00a0las\u00a0prote\u00ednas\u00a0del\u00a0\nsistema\u00a0del\u00a0complemento)\u00a0de\u00a0la\u00a0respuesta\u00a0inmune\u00a0innata\u00a0se\u00a0encue ntran\u00a0tambi\u00e9n\u00a0reducidos\u00a0en\u00a0\nn\u00famero\u00a0y\u00a0capacidad\u00a0funcional\u00a0(e.g.\u00a0fagoc\u00edtica/oxidativa,\u00a0quimio taxis\u00a0y\u00a0capacidad\u00a0de\u00a0adhesi\u00f3n\u00a0y\u00a0\nbactericida)205\u2013208.\u00a0 A\u00a0 diferencia\u00a0 de\u00a0 lo\u00a0 descrito\u00a0 para\u00a0 el\u00a0 compartimento\u00a0 linfoide,\u00a0 n o\u00a0 se\u00a0 han\u00a0Introducci\u00f3n \n\u2010\u00a035\u00a0\u2010\u00a0\n\u00a0observado\u00a0cambios\u00a0significativos\u00a0 en\u00a0la\u00a0respuesta\u00a0inmune\u00a0innata\u00a0 a\u00a0partir\u00a0del\u00a0primer\u00a0a\u00f1o\u00a0de\u00a0\nvida145.\u00a0\n\u00a0\n4.\u00a0Inmunodeficiencias\u00a0predominantemente\u00a0de\u00a0anticuerpos \u00a0\nLas\u00a0inmunodeficiencias\u00a0predomina ntemente\u00a0de\u00a0anticuerpos\u00a0(IDP\u2010Ac )209\u00a0constituyen\u00a0el\u00a0\ngrupo\u00a0m\u00e1s\u00a0prevalente\u00a0(>50%)\u00a0de\u00a0inmunodeficiencias\u00a0primarias\u00a0(ID P)210,211,\u00a0e\u00a0incluyen\u00a0distintas\u00a0\nentidades\u00a0cl\u00ednicas\u00a0relativamente\u00a0heterog\u00e9neas\u00a0que\u00a0presentan\u00a0en\u00a0 com\u00fan\u00a0un\u00a0defecto\u00a0en\u00a0la\u00a0\nproducci\u00f3n\u00a0de\u00a0uno,\u00a0varios\u00a0o\u00a0todos\u00a0los\u00a0subtipos\u00a0de\u00a0Acs\u00a0s\u00e9ricos211.\u00a0Debido\u00a0a\u00a0que\u00a0los\u00a0Acs\u00a0tienen\u00a0un\u00a0\npapel\u00a0fundamental\u00a0en\u00a0la\u00a0primera\u00a0l\u00ednea\u00a0de\u00a0defensa\u00a0frente\u00a0a\u00a0pat\u00f3g enos,\u00a0la\u00a0principal\u00a0manifestaci\u00f3n\u00a0\ncl\u00ednica\u00a0de\u00a0este\u00a0conjunto\u00a0de\u00a0enfermedades\u00a0son\u00a0las\u00a0infecciones\u00a0re currentes,\u00a0y\u00a0en\u00a0especial\u00a0las\u00a0\ninfecciones\u00a0respiratorias,\u00a0junto\u00a0a\u00a0otras\u00a0complicaciones\u00a0reflejo \u00a0de\u00a0la\u00a0alteraci\u00f3n\u00a0subyacente\u00a0del\u00a0\nsistema\u00a0inmune,\u00a0como\u00a0autoinmunidad,\u00a0linfoproliferaci\u00f3n\u00a0y\u00a0c\u00e1ncer .\u00a0Dependiendo\u00a0de\u00a0la\u00a0gravedad\u00a0\ndel\u00a0defecto\u00a0de\u00a0la\u00a0respuesta\u00a0humoral,\u00a0y\u00a0de\u00a0las\u00a0manifestaciones\u00a0c l\u00ednicas\u00a0asociadas\u00a0al\u00a0mismo,\u00a0esto\u00a0\nconlleva,\u00a0no\u00a0solo\u00a0una\u00a0mayor\u00a0morbilidad\u00a0con\u00a0reducci\u00f3n\u00a0de\u00a0la\u00a0cali dad\u00a0de\u00a0vida,\u00a0sino\u00a0que\u00a0con\u00a0\nfrecuencia\u00a0tambi\u00e9n,\u00a0una\u00a0esperanza\u00a0de\u00a0vida\u00a0significativamente\u00a0m\u00e1 s\u00a0corta212,213.\u00a0Actualmente,\u00a0las\u00a0\nIDP\u2010Ac\u00a0se\u00a0clasifican\u00a0seg\u00fan\u00a0la\u00a0Uni\u00f3n\u00a0Internacional\u00a0de\u00a0Sociedades \u00a0de\u00a0Inmunolog\u00eda\u00a0( International\u00a0\nUnion\u00a0of\u00a0Immunological\u00a0Societies;\u00a0IUIS )\u00a0en\u00a04\u00a0grupos\u00a0mayoritarios209\u00a0asociados\u00a0con\u00a0distinto\u00a0\ncomportamiento\u00a0cl\u00ednico,\u00a0seg\u00fan\u00a0la\u00a0cantidad\u00a0y\u00a0tipo\u00a0de\u00a0Acs\u00a0s\u00e9ricos \u00a0(y\u00a0de\u00a0linfocitos\u00a0B)\u00a0afectados211\u2013\n214:\u00a0i)\u00a0IDP\u2010Ac\u00a0con\u00a0reducci\u00f3n\u00a0severa\u00a0de\u00a0todos\u00a0los\u00a0isotipos\u00a0de\u00a0Igs\u00a0e n\u00a0suero\u00a0asociado\u00a0a\u00a0ausencia\u00a0o\u00a0\ndescenso\u00a0marcado\u00a0de\u00a0linfocitos\u00a0B\u00a0(i.e.\u00a0agammaglobulinemia);\u00a0ii) \u00a0IDP\u2010Ac\u00a0con\u00a0descenso\u00a0grave\u00a0de\u00a0\nal\u00a0menos\u00a0dos\u00a0isotipos\u00a0de\u00a0Igs\u00a0en\u00a0suero,\u00a0y\u00a0un\u00a0n\u00famero\u00a0normal\u00a0o\u00a0baj o\u00a0de\u00a0linfocitos\u00a0B\u00a0(fenotipo\u00a0de\u00a0\ninmunodeficiencia\u00a0variable\u00a0com\u00fan;\u00a0IDVC);\u00a0iii)\u00a0IDP\u2010Ac\u00a0con\u00a0reducc i\u00f3n\u00a0severa\u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0IgG\u00a0\ne\u00a0IgA\u00a0en\u00a0suero\u00a0con\u00a0IgM\u00a0normal/elevada\u00a0y\u00a0un\u00a0n\u00famero\u00a0normal\u00a0de\u00a0lin focitos\u00a0B,\u00a0(s\u00edndromes\u00a0h\u00edper\u2010\nIgM);\u00a0y\u00a0iv)\u00a0d\u00e9ficits\u00a0de\u00a0un\u00a0isotipo\u00a0de\u00a0Ig,\u00a0de\u00a0cadenas\u00a0ligeras\u00a0o\u00a0 d\u00e9ficits\u00a0funcionales\u00a0B,\u00a0habitualmente\u00a0\nasociados\u00a0con\u00a0un\u00a0n\u00famero\u00a0normal\u00a0de\u00a0linfocitos\u00a0B\u00a0en\u00a0sangre.\u00a0A\u00a0con tinuaci\u00f3n,\u00a0resumiremos\u00a0de\u00a0\nforma\u00a0breve\u00a0las\u00a0caracter\u00edsticas\u00a0 de\u00a0cada\u00a0uno\u00a0de\u00a0estos\u00a0cuatro\u00a0sub grupos\u00a0principales\u00a0de\u00a0IDP\u2010Ac.\u00a0 \u00a0Introducci\u00f3n \n\u2010\u00a036\u00a0\u2010\u00a0\n\u00a04.1.\u00a0Deficiencia\u00a0 grave\u00a0 de\u00a0 todos\u00a0 los\u00a0 isotipos\u00a0 de\u00a0 inmunoglobulina\u00a0 con\u00a0\nausencia\u00a0 o\u00a0 reducci\u00f3n\u00a0 importante\u00a0 del\u00a0 n\u00famero\u00a0 de\u00a0 linfocitos\u00a0 B\u00a0\n(agammaglobulinemias)\u00a0\n\u00a0\nLas\u00a0agammaglobulinemias\u00a0se\u00a0caracterizan\u00a0por\u00a0un\u00a0descenso\u00a0severo\u00a0 de\u00a0los\u00a0niveles\u00a0de\u00a0Igs\u00a0\ns\u00e9ricas\u00a0de\u00a0todos\u00a0los\u00a0isotipos,\u00a0en\u00a0ausencia\u00a0(o\u00a0con\u00a0una\u00a0reducci\u00f3n \u00a0muy\u00a0significativa\u00a0del\u00a0n\u00famero)\u00a0de\u00a0\nlinfocitos\u00a0B\u00a0circulantes\u00a0en\u00a0sangre.\u00a0En\u00a0conjunto,\u00a0afectan\u00a0a\u00a01:10 0.000\u2010200.000\u00a0individuos214\u00a0y\u00a0su\u00a0\ndiagn\u00f3stico\u00a0suele\u00a0realizarse\u00a0en\u00a0edades\u00a0tempranas\u00a0de\u00a0la\u00a0vida\u00a0(\u22485 0%\u00a0antes\u00a0del\u00a0primer\u00a0a\u00f1o\u00a0de\u00a0vida\u00a0\ny\u00a0 \u224890%\u00a0 antes\u00a0 de\u00a0 los\u00a0 5\u00a0 a\u00f1os215).\u00a0 En\u00a0 \u224895%216,217\u00a0 de\u00a0 los\u00a0 pacientes\u00a0 que\u00a0 presentan\u00a0\nagammaglobulinemia,\u00a0es\u00a0posible\u00a0identificar\u00a0el\u00a0defecto\u00a0gen\u00e9tico, \u00a0que\u00a0en\u00a0la\u00a0gran\u00a0mayor\u00eda\u00a0(\u224885%)\u00a0\ncorresponde\u00a0a\u00a0alteraciones\u00a0gen\u00e9ticas\u00a0asociadas\u00a0al\u00a0cromosoma\u00a0X,\u00a0 especialmente\u00a0a\u00a0mutaciones\u00a0\nen\u00a0el\u00a0gen\u00a0que\u00a0codifica\u00a0para\u00a0la\u00a0prote\u00edna\u00a0Btk\u00a0(abreviado\u00a0del\u00a0ingl \u00e9s,\u00a0Bruton\u2019s\u00a0tyrosine\u00a0kinase ),\u00a0\nnecesaria\u00a0para\u00a0la\u00a0cascada\u00a0de\u00a0se\u00f1alizaci\u00f3n\u00a0mediada\u00a0por\u00a0el\u00a0pre\u2010BC R;\u00a0este\u00a0defecto\u00a0se\u00a0traduce\u00a0en\u00a0\nun\u00a0 bloqueo\u00a0 de\u00a0 la\u00a0 diferenciaci\u00f3n\u00a0 de\u00a0 c\u00e9lula\u00a0 pro\u2010B\u00a0 a\u00a0 c\u00e9lula\u00a0 pre\u2010BI214,216\u2013219. \u00a0E n \u00a0l a s \u00a0d e m \u00e1 s \u00a0\nagammaglobulinemias,\u00a0las\u00a0alteraciones\u00a0gen\u00e9ticas\u00a0subyacentes\u00a0cau santes\u00a0de\u00a0la\u00a0enfermedad\u00a0\nsuelen\u00a0ser\u00a0debidas\u00a0a\u00a0mutacione s\u00a0autos\u00f3micas\u00a0recesivas\u00a0(10%)216\u00a0que\u00a0afectan\u00a0a\u00a0la\u00a0expresi\u00f3n\u00a0o\u00a0\nse\u00f1alizaci\u00f3n\u00a0del\u00a0pre\u2010BCR,\u00a0como\u00a0mutaciones\u00a0en\u00a0los\u00a0genes\u00a0que\u00a0codi fican\u00a0para\u00a0Ig\u00b5\u00a0(\u22485%\u00a0de\u00a0los\u00a0\npacientes)220,\u00a0para\u00a0las\u00a0cadenas\u00a0ligeras\u00a0subrogadas\u00a0(\u22641%)221,\u00a0CD79a\u00a0(\u22641%)222,\u00a0CD79b\u00a0(\u22641%)223\u00a0o\u00a0\nBLNK\u00a0(\u22641%)224.\u00a0\u00a0\nDesde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0cl\u00ednico,\u00a0los\u00a0pacientes\u00a0que\u00a0presentan\u00a0ag ammaglobulinemia\u00a0se\u00a0\ncaracterizan\u00a0por\u00a0mostrar\u00a0infecciones\u00a0bacterianas\u00a0graves\u00a0y\u00a0recur rentes,\u00a0que\u00a0en\u00a0ocasiones,\u00a0ponen\u00a0\nen\u00a0riesgo\u00a0la\u00a0vida\u00a0del\u00a0paciente214,216,217,225.\u00a0Aunque\u00a0en\u00a0algunos\u00a0casos\u00a0se\u00a0ha\u00a0realizado\u00a0con\u00a0\u00e9xito\u00a0\ntrasplante\u00a0de\u00a0progenitores\u00a0hemat opoy\u00e9ticos,\u00a0e\u00a0incluso\u00a0procedimi entos\u00a0de\u00a0terapia\u00a0g\u00e9nica,\u00a0al\u00a0\ntratarse\u00a0de\u00a0un\u00a0defecto\u00a0restringido\u00a0al\u00a0compartimento\u00a0B,\u00a0el\u00a0trata miento\u00a0temprano\u00a0con\u00a0Igs\u00a0de\u00a0\nsustituci\u00f3n\u00a0permite\u00a0a\u00a0estos\u00a0pacientes\u00a0sobrevivir\u00a0hasta\u00a0la\u00a0edad\u00a0 adulta,\u00a0siendo\u00a0el\u00a0da\u00f1o\u00a0pulmonar\u00a0\npermanente\u00a0la\u00a0principal\u00a0causa\u00a0de \u00a0defunci\u00f3n\u00a0asociada\u00a0a\u00a0este\u00a0subg rupo\u00a0de\u00a0IDP214,216,226\u2013229.\u00a0\n\u00a0Introducci\u00f3n \n\u2010\u00a037\u00a0\u2010\u00a0\n\u00a04.2.\u00a0Deficiencia\u00a0grave\u00a0de\u00a0al\u00a0menos\u00a0dos\u00a0isotipos\u00a0de\u00a0inmunoglobul ina\u00a0con\u00a0\nn\u00famero\u00a0normal\u00a0o\u00a0bajo\u00a0de\u00a0linfocitos\u00a0B\u00a0(fenotipo\u00a0de\u00a0inmunodeficie ncia\u00a0\nvariable\u00a0com\u00fan)\u00a0\n\u00a0\n\u00a0El\u00a0 t\u00e9rmino\u00a0 \u201cinmunodeficiencia\u00a0 variable\u00a0 com\u00fan\u201d\u00a0 fue\u00a0 acu\u00f1ado\u00a0 por\u00a0 l a\u00a0 Organizaci\u00f3n\u00a0\nMundial\u00a0de\u00a0la\u00a0Salud\u00a0(OMS)\u00a0en\u00a01971,\u00a0con\u00a0el\u00a0objetivo\u00a0de\u00a0separar\u00a0e stos\u00a0s\u00edndromes\u00a0con\u00a0d\u00e9ficit\u00a0de\u00a0\nAcs\u00a0s\u00e9ricos\u00a0de\u00a0significado\u00a0incierto,\u00a0de\u00a0los\u00a0que\u00a0muestran\u00a0una\u00a0de scripci\u00f3n\u00a0cl\u00ednica\u00a0m\u00e1s\u00a0homog\u00e9nea\u00a0\nasociada\u00a0a\u00a0una\u00a0herencia\u00a0mendeliana\u00a0bien\u00a0definida180,230.\u00a0De\u00a0hecho,\u00a0actualmente\u00a0sigue\u00a0sin\u00a0existir\u00a0\nuna\u00a0definici\u00f3n\u00a0y/o\u00a0unos\u00a0criterios\u00a0diagn\u00f3sticos\u00a0universalmente\u00a0a ceptados\u00a0para\u00a0este\u00a0grupo\u00a0de\u00a0\nenfermedades,\u00a0que\u00a0a\u00a0su\u00a0vez\u00a0muestran\u00a0un\u00a0espectro\u00a0de\u00a0alteraciones \u00a0inmunol\u00f3gicas\u00a0y\u00a0cl\u00ednicas\u00a0muy\u00a0\nvariable231\u2013235.\u00a0\n\u00a0\n4.2.1.\u00a0Diagn\u00f3stico\u00a0de\u00a0la\u00a0inm unodeficiencia\u00a0variable\u00a0com\u00fan\u00a0\nA\u00a0 pesar\u00a0 de\u00a0 los\u00a0 esfuerzos\u00a0 realizados,\u00a0 actualmente\u00a0 no\u00a0 existe\u00a0 un\u00a0 t est\u00a0 gen\u00e9tico\u00a0 o\u00a0\ninmunol\u00f3gico\u00a0definitivo\u00a0para\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0la\u00a0gran\u00a0mayor\u00eda\u00a0 (\u224890%)\u00a0de\u00a0las\u00a0IDVC214;\u00a0esto\u00a0hace\u00a0\nque\u00a0habitualmente,\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0IDVC\u00a0sea\u00a0m\u00e1s\u00a0un\u00a0diagn\u00f3stic o\u00a0de\u00a0exclusi\u00f3n\u00a0de\u00a0otras\u00a0\nentidades234,236.\u00a0Hasta\u00a02014,\u00a0los\u00a0criterios\u00a0diagn\u00f3sticos\u00a0m\u00e1s\u00a0utilizados\u00a0para\u00a0ID VC\u00a0eran\u00a0los\u00a0criterios\u00a0\npropuestos\u00a0en\u00a01999\u00a0por\u00a0la\u00a0Sociedad\u00a0Europea\u00a0de\u00a0Inmunodeficiencia s\u00a0(European\u00a0Society\u00a0for\u00a0\nImmunodeficiencies ;\u00a0 ESID)\u00a0 junto\u00a0 con\u00a0 el\u00a0 Grupo\u00a0 Panam ericano\u00a0 de\u00a0 Inmunodeficiencias\u00a0 ( Pan\u00a0\nAmerican\u00a0Group\u00a0for\u00a0Immunodeficiencies ;\u00a0PAGID)237,\u00a0y\u00a0que\u00a0inclu\u00edan:\u00a0i)\u00a0la\u00a0existencia\u00a0de\u00a0un\u00a0marcado\u00a0\ndescenso\u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0IgG\u00a0e \u00a0IgA\u00a0o\u00a0IgM\u00a0en\u00a0suero;\u00a0ii)\u00a0el\u00a0ini cio\u00a0de\u00a0la\u00a0inmunodeficiencia\u00a0a\u00a0partir\u00a0\nde\u00a0los\u00a02\u00a0a\u00f1os\u00a0de\u00a0vida;\u00a0iii)\u00a0la\u00a0demostraci\u00f3n\u00a0de\u00a0la\u00a0existencia\u00a0de \u00a0una\u00a0respuesta\u00a0a\u00a0vacunaci\u00f3n\u00a0\ndeficitaria\u00a0o\u00a0ausencia\u00a0de\u00a0isohemaglutininas;\u00a0una\u00a0vez\u00a0iv)\u00a0se\u00a0hub ieran\u00a0excluido\u00a0otras\u00a0causas\u00a0de\u00a0\nhipogammaglobulinemia.\u00a0A\u00a0partir\u00a0d e\u00a0entonces\u00a0se\u00a0han\u00a0propuesto\u00a0ot ras\u00a0clasificaciones\u00a0basadas\u00a0\nen\u00a0la\u00a0combinaci\u00f3n\u00a0de\u00a0estos\u00a0y\u00a0otros\u00a0criterios\u00a0diagn\u00f3sticos;\u00a0las\u00a0 principales\u00a0diferencias\u00a0entre\u00a0la\u00a0\nprimera\u00a0clasificaci\u00f3n\u00a0y\u00a0estas\u00a0\u00fal timas\u00a0clasificaciones,\u00a0se\u00a0resum en\u00a0en\u00a0la\u00a0Tabla\u00a03.\u00a0\n\u00a0\u00a0Introducci\u00f3n \n\u2010\u00a038\u00a0\u2010\u00a0\n\u00a0Tabla\u00a03.\u00a0Principales\u00a0diferencias\u00a0entre\u00a0los\u00a0criterios\u00a0propuestos \u00a0por\u00a0diferentes\u00a0grupos\u00a0para\u00a0el\u00a0\ndiagn\u00f3stico\u00a0de\u00a0IDVC.\u00a0\n\u2191,\u00a0aumento;\u00a0\u2193,\u00a0descenso;\u00a0DS,\u00a0desviaci\u00f3n\u00a0est\u00e1ndar.\u00a0Informaci\u00f3n\u00a0m odificada\u00a0de\u00a0Conley\u00a0 et\u00a0al.\u00a01999237,\u00a0Abinun\u00a0 et\u00a0al.\u00a0201711,\u00a0\nAmeratunga\u00a0 et\u00a0al.\u00a02013238,\u00a0Bertinchamp\u00a0 et\u00a0al.\u00a02016233\u00a0y\u00a0Bonilla\u00a0 et\u00a0al.\u00a02016231.\u00a0Ameratunga\u00a0 et\u00a0al.\u00a0establece\u00a0como\u00a0criterios\u00a0necesarios\u00a0\npara\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0IDVC\u00a0la\u00a0e xistencia\u00a0de\u00a0\u22651\u00a0criterio\u00a0cl\u00ednic o,\u00a0junto\u00a0con\u00a0alteraciones\u00a0histol\u00f3g icas\u00a0o\u00a0\u22653\u00a0criterios\u00a0biol\u00f3gico s.\u00a0ESID,\u00a0\nSociedad\u00a0Europea\u00a0de\u00a0Inmunodeficiencias;\u00a0PAGID,\u00a0Grupo\u00a0Panamerica no\u00a0de\u00a0Inmunodeficiencias ;\u00a0DEFI,\u00a0grupo\u00a0de\u00a0estudio\u00a0franc\u00e9s\u00a0de\u00a0\nadultos\u00a0con\u00a0hipogammaglobulinemia ;\u00a0ICON,\u00a0consenso\u00a0internacional \u00a0para\u00a0la\u00a0definici\u00f3n\u00a0de\u00a0IDVC.\u00a0\u00a0 Criterios\u00a0diagn\u00f3sticos \u00a0\n\u00a0ESID/PAGID\u00a0\n(1999)\u00a0ESID\u00a0\n(2017)\u00a0Ameratunga\u00a0\n(2013)\u00a0DEFI\u00a0\n(2015)\u00a0ICON\u00a0\n(2015)\u00a0\nNiveles\u00a0\ns\u00e9ricos\u00a0de\u00a0Ig \u00a0IgG\u2193\u00a0(<2DS\u00a0seg\u00fan\u00a0\nedad)\u00a0\n\u2193IgA\u00a0o\u00a0IgM\u00a0IgG\u00a0e\u00a0IgA\u2193,\u00a0con\u00a0o\u00a0sin\u2193de\u00a0\nIgM\u00a0(<2DS\u00a0seg\u00fan\u00a0edad)\u00a0IgG<5\u00a0g/l\u00a0\n\u2193de\u00a0IgA\u00a0o\u00a0IgM\u00a0no\u00a0requerido\u00a0\n(apoya\u00a0el\u00a0diagn\u00f3stico)\u00a0IgG\u00a0e\u00a0IgA\u2193,\u00a0con\u00a0o\u00a0sin\u00a0\n\u2193\u00a0de\u00a0IgM\u00a0(<2DS\u00a0seg\u00fan\u00a0\nedad)\u00a0IgG\u2193\u00a0seg\u00fan\u00a0edad\u00a0\n\u2193de\u00a0IgA\u00a0o\u00a0IgM\u00a0\nEdad\u00a0\n(m\u00ednima) \u00a0\u22652\u00a0a\u00f1os\u00a0 \u22654\u00a0a\u00f1os\u00a0 \u22654\u00a0a\u00f1os\u00a0 \u22654\u00a0a\u00f1os\u00a0 \u22654\u00a0a\u00f1os\u00a0\nCaracter\u00edsticas\u00a0\ncl\u00ednicas \u00a0No\u00a0requerido\u00a0\u22651\u00a0de\u00a05\u00a0criterios:\u00a0\n\u00a0\n\u2212Susceptibilidad\u00a0a\u00a0\ninfecciones\u00a0\u2212Autoinmunidad\u00a0\u2212Enfermedad\u00a0\ngranulomatosa\u00a0\n\u2212Linfoproliferaci\u00f3n\u00a0policlonal\u00a0\u2212Antecedentes\u00a0familiares\u00a01)\u00a0\u22651\u00a0de\u00a06\u00a0criterios:\n\u00a0\n\u2212Infecciones\u00a0recurrentes,\u00a0\ninusuales\u00a0o\u00a0graves\u00a0\u2212Pobre\u00a0respuesta\u00a0a\u00a0antibi\u00f3ticos\u00a0\n\u2212Infecciones\u00a0a\u00a0pesar\u00a0del\u00a0uso\u00a0de\u00a0\nantibi\u00f3ticos\u00a0profil\u00e1cticos\u00a0\u2212Infecciones\u00a0a\u00a0pesar\u00a0de\u00a0vacunaci\u00f3n\u00a0\n\u2212Bronquiectasias\u00a0o\u00a0\nenfermedad\u00a0pulmonar\u00a0cr\u00f3nica.\u00a0\u2212Enfermedades\u00a0autoinflamatorias\u00a0o\u00a0\nautoinmunidad\u00a0\n\u00a02)\u00a0Alteraciones\u00a0histol\u00f3gicas\u00a0(e.g.\u00a0hiperplasia,\u00a0granulomas)\u00a0No\u00a0requerido\u00a0Presencia\u00a0de\u00a0\u22651\u00a0\nmanifestaciones\u00a0\ncl\u00ednicas:\u00a0\n\u2212Infecci\u00f3n\u00a0\u2212Autoinmunidad\u00a0\u2212Linfoproliferaci\u00f3n\u00a0\n\u00a0\nNo\u00a0es\u00a0obligado\u00a0si\u00a0se\u00a0cumplen\u00a0los\u00a0dem\u00e1s\u00a0criterios\u00a0\n(especialmente\u00a0en\u00a0\ncasos\u00a0con\u00a0antecedentes\u00a0familiares)\u00a0\nCaracter\u00edsticas\u00a0\nbiol\u00f3gicas \u00a0\u22651\u00a0de\u00a02\u00a0criterios:\u00a0\n\u00a0\n\u2212Pobre\u00a0respuesta\u00a0a\u00a0\nvacunaci\u00f3n\u00a0\u2212Ausencia\u00a0de\u00a0isohemaglutininas\u00a0\u22651\u00a0de\u00a03\u00a0criterios:\u00a0\n\u00a0\u2212Pobre\u00a0respuesta\u00a0a\u00a0vacunaci\u00f3n\u00a0\n\u2212Ausencia\u00a0de\u00a0\nisohemaglutininas\u00a0\u2212C\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u00a0\n<70%\u00a0del\u00a0valor\u00a0normal\u00a0\nseg\u00fan\u00a0edad\u00a0\u22653\u00a0de\u00a08\u00a0criterios:\u00a0\n\u00a0\n\u2212IgA<80mg/dl\u00a0y/o\u00a0IgM<40mg/dl\u00a0\u2212IgG3<20\u00a0mg/dl\u00a0\n\u2212\u2193c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0\ncon\u00a0cambio\u00a0de\u00a0isotipo\u00a0o\u00a0\u2191c\u00e9lulas\u00a0B\u00a0CD21\n\u2010\u00a0\n\u2212Respuesta\u00a0pobre\u00a0a\u00a0vacunaci\u00f3n\u00a0\n\u2212\u00a0Respuesta\u00a0transitoria\u00a0a\u00a0\nvacunaci\u00f3n\u00a0\u2212Ausencia\u00a0de\u00a0isohemaglutininas.\u00a0\n\u2212Presencia\u00a0de\u00a0auto\u2010Ac\u00a0\n\u2212Variantes\u00a0en\u00a0genes\u00a0asociados\u00a0con\u00a0IDVC.\u00a0<10%\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0\nmemoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u00a0\u22651\u00a0de\u00a02\u00a0criterios:\u00a0\n\u00a0\n\u2212Pobre\u00a0respuesta\u00a0\na\u00a0vacunaci\u00f3n\u00a0\u2212Ausencia\u00a0de\u00a0isohemaglutininas\u00a0\nCriterios\u00a0de\u00a0\nexclusi\u00f3n \u00a0ID\u00a0secundaria\u00a0a\u00a0\notra\u00a0causa\u00a01)\u00a0ID\u00a0secundaria\n2)\u00a0Defecto\u00a0en\u00a0c\u00e9lulas\u00a0T\u00a0\n(\u22652\u00a0de\u00a03\u00a0criterios):\u00a0\n\u2212C\u00e9lulas\u00a0CD4/\u00b5l:\u00a0<300\u00a0(2\u22126\u00a0a\u00f1os),\u00a0<250\u00a0(6\u221212\u00a0a\u00f1os),\u00a0<200\u00a0(>12\u00a0a\u00f1os)\u00a0\n\u2212%\u00a0T\u00a0CD4\u00a0na\u00efve:\u00a0<25%\u00a0\n(2\u22126\u00a0a\u00f1os),\u00a0<20%\u00a0(6\u221216\u00a0a\u00f1os),\u00a0<10%\u00a0(>16\u00a0a\u00f1os)\u00a0\u2212Proliferaci\u00f3n\u00a0de\u00a0\nlinfocitos\u00a0T\u00a0ausente\u00a0ID\u00a0secundaria\u00a0a\u00a0otra\u00a0causa\u00a01)\u00a0ID\u00a0secundaria\u00a0\n2)\u00a0Defecto\u00a0en\u00a0c\u00e9lulas\u00a0T\u00a0\n(\u22651\u00a0de\u00a02\u00a0criterios):\u00a0\u2212<20\u00a0T\u00a0CD4+\u00a0na\u00efve/\u00b5l\u00a0\u2212Infecciones\u00a0\noportunistas\u00a0ID\u00a0secundaria\u00a0a\u00a0\notra\u00a0causa\u00a0Introducci\u00f3n \n\u2010\u00a039\u00a0\u2010\u00a0\n\u00a0En\u00a0t\u00e9rminos\u00a0generales,\u00a0uno\u00a0de\u00a0los\u00a0criterios\u00a0diagn\u00f3sticos\u00a0de\u00a0IDV C\u00a0m\u00e1s\u00a0controvertidos,\u00a0es\u00a0\nla\u00a0evaluaci\u00f3n\u00a0de\u00a0la\u00a0respuesta\u00a0de ficitaria\u00a0a\u00a0vacunaci\u00f3n,\u00a0ya\u00a0que\u00a0 ninguna\u00a0clasificaci\u00f3n\u00a0especifica\u00a0\ncu\u00e1les\u00a0son\u00a0las\u00a0vacunas\u00a0y/o\u00a0los\u00a0criterios\u00a0concretos\u00a0que\u00a0deben\u00a0em plearse\u00a0para\u00a0establecer\u00a0dicho\u00a0\nd\u00e9ficit\u00a0(Tabla\u00a03)231,233,238,239.\u00a0No\u00a0obstante\u00a0lo\u00a0anterior,\u00a0si\u00a0 existen\u00a0algunas\u00a0gu\u00edas\u00a0para\u00a0evalua r\u00a0la\u00a0\nrespuesta\u00a0deficitaria\u00a0a\u00a0vacunas240\u2013242,\u00a0sin\u00a0que\u00a0sin\u00a0embargo\u00a0exista\u00a0consenso\u00a0sobre\u00a0(alg\u00fan\u00a0o\u00a0\nalgunos)\u00a0criterios\u00a0que\u00a0puedan\u00a0ser\u00a0uniformes\u00a0y\u00a0objetivos,\u00a0a\u00a0empl ear236.\u00a0Adem\u00e1s,\u00a0la\u00a0interpretaci\u00f3n\u00a0\nde\u00a0 los\u00a0 resultados\u00a0 obtenidos\u00a0 puede\u00a0 resultar\u00a0 problem\u00e1tica,\u00a0 debido \u00a0 fundamentalmente\u00a0 a\u00a0 i)\u00a0\ndiferencias\u00a0en\u00a0la\u00a0respuesta\u00a0inmune\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0edad\u00a0y/o\u00a0la \u00a0administraci\u00f3n\u00a0previa\u00a0de\u00a0vacunas\u00a0\ny\u00a0ii)\u00a0la\u00a0incapacidad\u00a0de\u00a0lograr\u00a0respuestas\u00a0consideradas\u00a0adecuada s,\u00a0en\u00a0donantes\u00a0sanos\u00a0con\u00a0\nelevados\u00a0niveles\u00a0basales\u00a0de\u00a0Acs238.\u00a0Por\u00a0todo\u00a0ello,\u00a0algunos\u00a0autores\u00a0han\u00a0sugerido\u00a0que\u00a0la\u00a0respuesta\u00a0\na\u00a0la\u00a0vacunaci\u00f3n\u00a0pase\u00a0a\u00a0constituir \u00a0un\u00a0criterio\u00a0de\u00a0apoyo\u00a0al\u00a0diagn \u00f3stico,\u00a0y\u00a0que\u00a0no\u00a0sea\u00a0un\u00a0criterio\u00a0de\u00a0\nobligado\u00a0cumplimiento238.\u00a0De\u00a0hecho,\u00a0actualmente\u00a0la\u00a0ESID\u00a0reconoce\u00a0que\u00a0el\u00a0descenso\u00a0en\u00a0el\u00a0\nn\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u00a0en\u00a0SP\u00a0e valuado\u00a0por\u00a0citometr\u00eda\u00a0de\u00a0\nflujo,\u00a0podr\u00eda\u00a0constituir\u00a0una\u00a0alt ernativa\u00a0v\u00e1lida\u00a0a\u00a0la\u00a0evaluaci\u00f3n \u00a0de\u00a0la\u00a0respuesta\u00a0a\u00a0vacunaci\u00f3n11,239.\u00a0\u00a0\nPor\u00a0otro\u00a0lado,\u00a0no\u00a0existe\u00a0un\u00a0\u00fanico\u00a0criterio\u00a0para\u00a0establecer\u00a0un\u00a0d iagn\u00f3stico\u00a0diferencial\u00a0fiable\u00a0\ny\u00a0robusto\u00a0entre\u00a0IDVC\u00a0y\u00a0otras\u00a0IDP\u00a0con\u00a0d\u00e9ficit\u00a0de\u00a0Acs\u00a0s\u00e9ricos.\u00a0En \u00a0este\u00a0sentido,\u00a0aunque\u00a0todas\u00a0las\u00a0\nclasificaciones\u00a0propuestas\u00a0hasta \u00a0la\u00a0fecha\u00a0incluyen\u00a0como\u00a0criteri o\u00a0obligatorio\u00a0el\u00a0descenso\u00a0de\u00a0IgG,\u00a0\nel\u00a0punto\u00a0de\u00a0corte\u00a0establecido\u00a0var\u00eda\u00a0seg\u00fan\u00a0la\u00a0clasificaci\u00f3n231,233,238,239\u00a0(Tabla\u00a03);\u00a0adem\u00e1s,\u00a0solo\u00a0en\u00a0\nalgunas\u00a0clasificaciones\u00a0se\u00a0establece\u00a0como\u00a0criterio\u00a0diagn\u00f3stico\u00a0 obligatorio\u00a0el\u00a0descenso\u00a0de\u00a0IgM\u00a0y/o\u00a0\nIgA231,233,238,239.\u00a0Recientemente\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0aquellos\u00a0pacientes\u00a0que\u00a0prese ntan\u00a0un\u00a0d\u00e9ficit\u00a0\nmarcado\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0T\u00a0en\u00a0SP\u00a0deber\u00edan\u00a0ser\u00a0tratado s\u00a0como\u00a0una\u00a0inmunodeficiencia\u00a0\ncombinada,\u00a0aunque\u00a0el\u00a0criterio\u00a0par a\u00a0establecer\u00a0dicho\u00a0descenso\u00a0ta mpoco\u00a0es\u00a0un\u00e1nime11,233\u00a0(Tabla\u00a0\n3).\u00a0Adem\u00e1s,\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0clasif icaciones\u00a0incluyen\u00a0entre\u00a0los\u00a0cr iterios\u00a0diagn\u00f3sticos\u00a0propuestos\u00a0la\u00a0\npresencia\u00a0de\u00a0manifestaciones\u00a0cl\u00ednicas\u00a0caracter\u00edsticas\u00a0de\u00a0la\u00a0enf ermedad,\u00a0aspecto\u00a0que\u00a0seg\u00fan\u00a0otros\u00a0\nautores\u00a0no\u00a0deber\u00eda\u00a0ser\u00a0considerado,\u00a0al\u00a0sostener\u00a0que\u00a0el\u00a0diagn\u00f3st ico\u00a0de\u00a0IDVC\u00a0podr\u00eda\u00a0y\u00a0deber\u00eda\u00a0\nbasarse\u00a0exclusivamente\u00a0en\u00a0los\u00a0hallazgos\u00a0de\u00a0laboratorio233,\u00a0especialmente\u00a0en\u00a0a quellos\u00a0pacientes\u00a0Introducci\u00f3n \n\u2010\u00a040\u00a0\u2010\u00a0\n\u00a0que\u00a0 presentan\u00a0 antecedentes\u00a0 familiares231.\u00a0 Finalmente,\u00a0 debido\u00a0 a\u00a0 la\u00a0 existencia\u00a0 de\u00a0 una\u00a0\nhipogammaglobulinemia\u00a0transitoria\u00a0durante\u00a0la\u00a0infancia236,243,\u00a0la\u00a0edad\u00a0m\u00ednima\u00a0de\u00a0diagn\u00f3stico\u00a0se\u00a0\nha\u00a0establecido\u00a0en\u00a0los\u00a04\u00a0a\u00f1os,\u00a0a\u00a0 pesar\u00a0de\u00a0que\u00a0en\u00a0aquellos\u00a0pacien tes\u00a0pedi\u00e1tricos\u00a0que\u00a0manifiestan\u00a0\nuna\u00a0cl\u00ednica\u00a0severa,\u00a0deben\u00a0tomarse\u00a0decisiones\u00a0terap\u00e9uticas\u00a0inmed iatas,\u00a0antes\u00a0de\u00a0poder\u00a0confirmar\u00a0\nel\u00a0diagn\u00f3stico\u00a0de\u00a0IDVC235.\u00a0\nAnte\u00a0esta\u00a0situaci\u00f3n,\u00a0y\u00a0la\u00a0ausencia\u00a0de\u00a0unos\u00a0criterios\u00a0diagn\u00f3stic o\u00a0definitivos\u00a0de\u00a0IDVC,\u00a0se\u00a0\nestima\u00a0que\u00a0existe\u00a0un\u00a0retraso\u00a0en\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0la\u00a0enfermedad \u00a0que\u00a0podr\u00eda\u00a0oscilar\u00a0entre\u00a04\u00a0y\u00a09\u00a0\na\u00f1os236,244,245,\u00a0lo\u00a0cual\u00a0aumenta\u00a0considerablemente\u00a0la\u00a0morbilidad\u00a0y\u00a0mortalidad\u00a0 asociada\u00a0a\u00a0la\u00a0\nmisma.\u00a0\n\u00a0\n4.2.2.\u00a0 Epidemiolog\u00eda,\u00a0 caracter\u00edsticas\u00a0 cl\u00ednicas\u00a0 y\u00a0 tratamiento\u00a0 de \u00a0 inmunodeficiencia\u00a0\nvariable\u00a0com\u00fan\u00a0\n\u00a0\nLa\u00a0IDVC\u00a0es\u00a0la\u00a0IDP\u2010Ac\u00a0sintom\u00e1tica\u00a0m\u00e1s\u00a0frecuente\u00a0con\u00a0una\u00a0prevalen cia\u00a0de\u00a01:25.000\u00a0a\u00a0\n1:50.000\u00a0casos\u00a0por\u00a0habitantes,\u00a0en\u00a0pa\u00edses\u00a0occidentales236,246.\u00a0Aunque\u00a0puede\u00a0manifestarse\u00a0a\u00a0\ncualquier\u00a0edad,\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0pacientes\u00a0se\u00a0diagnostican\u00a0ent re\u00a0los\u00a020\u00a0y\u00a040\u00a0a\u00f1os\u00a0de\u00a0vida246\u2013248.\u00a0\u00a0\u00a0\nLos\u00a0pacientes\u00a0con\u00a0IDVC\u00a0presentan\u00a0un\u00a0gran\u00a0abanico\u00a0de\u00a0manifestaci ones\u00a0cl\u00ednicas,\u00a0que\u00a0\npueden\u00a0producir\u00a0da\u00f1o\u00a0permanente\u00a0en\u00a0algunos\u00a0tejidos,\u00a0aumentando\u00a0 el\u00a0riesgo\u00a0global\u00a0de\u00a0muerte\u00a0\nde\u00a0estos\u00a0pacientes\u00a0respecto\u00a0a\u00a0la\u00a0poblaci\u00f3n\u00a0sana\u00a0de\u00a0la\u00a0misma\u00a0eda d;\u00a0as\u00ed,\u00a0tras\u00a040\u00a0a\u00f1os\u00a0de\u00a0\nseguimiento,\u00a0se\u00a0han\u00a0observado\u00a0tasas\u00a0de\u00a0supervivencia\u00a0en\u00a0hombres \u00a0y\u00a0en\u00a0mujeres\u00a0de\u00a058%\u00a0y\u00a0de\u00a0\n51%\u00a0vs.\u00a068%\u00a0y\u00a080%\u00a0en\u00a0donantes\u00a0sanos\u00a0de\u00a0edad\u00a0similar,\u00a0respectivamente247.\u00a0Las\u00a0infecciones\u00a0\nrespiratorias\u00a0constituyen\u00a0la\u00a0manifestaci\u00f3n\u00a0cl\u00ednica\u00a0m\u00e1s\u00a0habitual \u00a0(>90%\u00a0de\u00a0los\u00a0pacientes)247\u2013253;\u00a0\ncon\u00a0relativa\u00a0frecuencia\u00a0son\u00a0debidas\u00a0a\u00a0infecciones\u00a0por\u00a0microorga nismos\u00a0como\u00a0 H.\u00a0influenzae,\u00a0\nseguido\u00a0de \u00a0M.\u00a0catarrhalis\u00a0 y\u00a0S.\u00a0pneumoniae216,236,\u00a0y\u00a0se\u00a0manifiestan\u00a0en\u00a0 forma\u00a0de\u00a0neumon\u00eda,\u00a0\nbronquitis,\u00a0sinusitis\u00a0y\u00a0otitis\u00a0de\u00a0repetici\u00f3n246.\u00a0De\u00a0hecho,\u00a0debido\u00a0a\u00a0la\u00a0elevada\u00a0prevalencia\u00a0y\u00a0\ngravedad\u00a0de\u00a0estas\u00a0infecciones\u00a0respiratorias\u00a0de\u00a0repetici\u00f3n,\u00a0entr e\u00a0el\u00a011%\u00a0y\u00a0el\u00a025%\u00a0de\u00a0los\u00a0pacientes\u00a0\ncon\u00a0IDVC\u00a0padecen\u00a0bronquiectasias244,248,249,251,\u00a0sobre\u00a0todo\u00a0aquellos\u00a0casos\u00a0en\u00a0los\u00a0que\u00a0ocurre\u00a0un\u00a0Introducci\u00f3n \n\u2010\u00a041\u00a0\u2010\u00a0\n\u00a0mayor\u00a0retraso\u00a0en\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0la\u00a0enfermedad244,254.\u00a0Las\u00a0manifestaciones\u00a0gastrointestinales\u00a0\nde\u00a0origen\u00a0infeccioso,\u00a0constituyen\u00a0tambi\u00e9n\u00a0uno\u00a0de\u00a0los\u00a0s\u00edntomas\u00a0m \u00e1s\u00a0frecuentes\u00a0(20\u201060%)\u00a0en\u00a0\npacientes\u00a0con\u00a0IDVC,\u00a0correspondiendo\u00a0con\u00a0relativa\u00a0frecuencia\u00a0a\u00a0p rocesos\u00a0infecciosos\u00a0causados\u00a0\npor\u00a0G.\u00a0lamblia255.\u00a0\nAlrededor\u00a0de\u00a0dos\u00a0tercios\u00a0de\u00a0los\u00a0pacientes\u00a0diagnosticados\u00a0de\u00a0IDV C\u00a0(68\u201071%)\u00a0presentan\u00a0\nadem\u00e1s\u00a0una\u00a0gran\u00a0variedad\u00a0de\u00a0complicaciones\u00a0no\u00a0infecciosas\u00a0de\u00a0di stinta\u00a0\u00edndole234,247,253.\u00a0As\u00ed,\u00a0\nmuestran,\u00a0entre\u00a0otras\u00a0manifestaciones,\u00a0signos\u00a0de\u00a0linfoprolifera ci\u00f3n\u00a0(policlonal),\u00a0reflejada\u00a0en\u00a0\nforma\u00a0de\u00a0organomegalias\u00a0persistentes\u00a0\u2212esplenomegalia\u00a0(26\u201038%)244,249,251,252,\u00a0hepatomegalia\u00a0(7\u2010\n15%)249,256\u00a0y/o\u00a0linfadenopat\u00eda\u00a0(14\u201026%)249,250\u2212\u00a0y/o\u00a0o\u00a0granulomas\u00a0(8\u20109%)244,248,249.\u00a0La\u00a0desregulaci\u00f3n\u00a0\nde\u00a0la\u00a0respuesta\u00a0inmune\u00a0en\u00a0estos\u00a0 sujetos\u00a0se\u00a0ve\u00a0reflejada\u00a0tambi\u00e9n ,\u00a0en\u00a0una\u00a0mayor\u00a0frecuencia\u00a0de\u00a0\nprocesos\u00a0autoinmunes\u00a0(20\u201029%),\u00a0que \u00a0se\u00a0traducen\u00a0tanto\u00a0en\u00a0citopen ias\u00a0autoinmunes\u00a0(sobre\u00a0todo\u00a0\ntrombocitopenia\u00a0y\u00a0anemia\u00a0autoinmune),\u00a0como\u00a0en\u00a0autoinmunidad\u00a0esp ec\u00edfica\u00a0de\u00a0\u00f3rgano\u00a0y/o\u00a0\nsist\u00e9mica\u00a0(e.g.\u00a0enfermedad\u00a0de\u00a0Crohn,\u00a0vit\u00edligo\u00a0y/o\u00a0psoriasis)249,257.\u00a0Otras\u00a0manifestaciones\u00a0cl\u00ednicas\u00a0\nasociadas\u00a0a\u00a0la\u00a0IDVC\u00a0incluyen\u00a0la\u00a0enteropat\u00eda\u00a0(6\u201024%)249,253,256\u00a0y\u00a0el\u00a0desarrollo\u00a0de\u00a0tumores\u00a0malignos,\u00a0\ntanto\u00a0de\u00a0origen\u00a0hematol\u00f3gico\u00a0(2\u20108%;\u00a0fundamentalmente\u00a0linfomas)\u00a0 como\u00a0tumores\u00a0s\u00f3lidos\u00a0(3\u20107%;\u00a0\nprincipalmente\u00a0c\u00e1ncer\u00a0colorrectal,\u00a0g\u00e1strico\u00a0y\u00a0c\u00e1ncer\u00a0de\u00a0mama)244,247,249,251.\u00a0En\u00a0su\u00a0conjunto,\u00a0la\u00a0\npresencia\u00a0de\u00a0complicaciones\u00a0no\u00a0infecciosas\u00a0se\u00a0ha\u00a0asociado\u00a0con\u00a0u na\u00a0supervivencia\u00a0\u224811\u00a0veces\u00a0\nmenor\u00a0en\u00a0pacientes\u00a0con\u00a0IDVC\u00a0(res pecto\u00a0a\u00a0los\u00a0sujetos\u00a0que\u00a0solamen te\u00a0tienen\u00a0infecciones)247,\u00a0\u00a0en\u00a0\nespecial\u00a0en\u00a0aquellos\u00a0casos\u00a0que\u00a0pr esentan\u00a0linfoproliferaci\u00f3n\u00a0pol iclonal\u00a0asociada\u00a0a\u00a0granulomas,\u00a0\nlinfadenopat\u00eda,\u00a0hepatomegalia\u00a0y\u00a0neumon\u00eda\u00a0intersticial\u00a0linfoc\u00edti ca,\u00a0citopenias\u00a0autoinmunes,\u00a0y/o\u00a0\nenteropat\u00eda\u00a0persistente\u00a0e\u00a0inexplicable256.\u00a0\u00a0\nDebido\u00a0a\u00a0que\u00a0no\u00a0existe\u00a0un\u00a0tratamiento\u00a0curativo\u00a0para\u00a0la\u00a0IDVC,\u00a0lo s\u00a0pacientes\u00a0con\u00a0esta\u00a0\nenfermedad\u00a0habitualmente\u00a0requieren\u00a0de\u00a0terapia\u00a0continuada\u00a0con\u00a0Ig s\u00a0de\u00a0sustituci\u00f3n,\u00a0con\u00a0lo\u00a0que\u00a0\nse\u00a0previenen\u00a0las\u00a0infecciones\u00a0y\u00a0se\u00a0reduce\u00a0el\u00a0da\u00f1o\u00a0irreversible\u00a0d e\u00a0distintos\u00a0tejidos.\u00a0Sin\u00a0embargo,\u00a0\nno\u00a0existe\u00a0una\u00a0recomendaci\u00f3n\u00a0clara\u00a0respecto\u00a0al\u00a0uso\u00a0de\u00a0Igs\u00a0de\u00a0sus tituci\u00f3n\u00a0en\u00a0aquellos\u00a0pacientes\u00a0\nque\u00a0presentan\u00a0un\u00a0descenso\u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0Igs\u00a0s\u00e9ricas,\u00a0pero\u00a0e n\u00a0los\u00a0que\u00a0todav\u00eda\u00a0no\u00a0se\u00a0ha\u00a0Introducci\u00f3n \n\u2010\u00a042\u00a0\u2010\u00a0\n\u00a0confirmado\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0IDVC258.\u00a0Adem\u00e1s,\u00a0tampoco\u00a0disponemos \u00a0de\u00a0par\u00e1metros\u00a0validados\u00a0\nque\u00a0permitan\u00a0predecir\u00a0el\u00a0comportamiento\u00a0cl\u00ednico\u00a0y\u00a0la\u00a0evoluci\u00f3n\u00a0 de\u00a0estos\u00a0pacientes,\u00a0lo\u00a0que\u00a0hace\u00a0\nque,\u00a0con\u00a0relativa\u00a0frecuencia,\u00a0en\u00a0el\u00a0momento\u00a0de\u00a0iniciar\u00a0el\u00a0trata miento\u00a0exista\u00a0ya\u00a0da\u00f1o\u00a0tisular\u00a0\nirreversible\u00a0(e.g.\u00a0bronquiectasias)259.\u00a0La\u00a0dosis\u00a0de\u00a0Igs\u00a0requerida\u00a0en\u00a0cada\u00a0paciente\u00a0puede\u00a0variar,\u00a0\naunque\u00a0 la\u00a0 mayor\u00eda\u00a0 de\u00a0 gu\u00edas\u00a0 sugiere\u00a0 empezar\u00a0 con\u00a0 0,4\u20100,5\u00a0 g/kg/mes ,\u00a0 cuando\u00a0 la\u00a0 v\u00eda\u00a0 de\u00a0\nadministraci\u00f3n\u00a0es\u00a0intravenosa,\u00a0y\u00a0 con\u00a00,4\u20100,6\u00a0g/kg/mes,\u00a0cuando\u00a0e sta\u00a0se\u00a0administra\u00a0por\u00a0v\u00eda\u00a0\nsubcut\u00e1nea260.\u00a0Adem\u00e1s,\u00a0en\u00a0aquellos\u00a0pacientes\u00a0que\u00a0padecen\u00a0bronquiectasias,\u00a0es plenomegalia\u00a0o\u00a0\nenteropat\u00eda,\u00a0se\u00a0ha\u00a0sugerido\u00a0la\u00a0utilizaci\u00f3n\u00a0de\u00a0dosis\u00a0m\u00e1s\u00a0elevada s\u00a0(0,6\u20100,8\u00a0g/kg/mes),\u00a0244,251,256\u00a0dado\u00a0\nque\u00a0el\u00a0uso\u00a0de\u00a0dosis\u00a0m\u00e1s\u00a0bajas\u00a0se\u00a0ha\u00a0relacionado\u00a0con\u00a0una\u00a0mayor\u00a0f recuencia\u00a0de\u00a0infecciones\u00a0\nrespiratorias\u00a0y\u00a0peor\u00a0pron\u00f3stico244,261,262.\u00a0En\u00a0este\u00a0contexto,\u00a0cabe\u00a0se\u00f1al ar\u00a0que\u00a0la\u00a0terapia\u00a0con\u00a0Igs\u00a0de\u00a0\nsustituci\u00f3n\u00a0dificulta\u00a0la\u00a0monitor izaci\u00f3n\u00a0de\u00a0los\u00a0pacientes\u00a0una\u00a0ve z\u00a0tratados,\u00a0ya\u00a0que\u00a0los\u00a0niveles\u00a0\ns\u00e9ricos\u00a0 de\u00a0 Acs,\u00a0 y\u00a0 por\u00a0 tanto\u00a0 tambi\u00e9n\u00a0 la\u00a0 evaluaci\u00f3n\u00a0 de\u00a0 la\u00a0 respues ta\u00a0 a\u00a0 vacunaci\u00f3n,\u00a0 se\u00a0 ven\u00a0\nenmascarados\u00a0por\u00a0el\u00a0tratamiento\u00a0administrado.\u00a0\n\u00a0\n4.2.3.\u00a0Alteraciones\u00a0gen\u00e9ticas\u00a0en \u00a0la\u00a0inmunodeficiencia\u00a0variable\u00a0 com\u00fan\u00a0\nAunque\u00a0 la\u00a0 mayor\u00a0 parte\u00a0 de\u00a0 los\u00a0 pacientes\u00a0 diagnosticados\u00a0 de\u00a0 IDVC\u00a0 c arecen\u00a0 de\u00a0\nantecedentes\u00a0familiares\u00a0de\u00a0inmunod eficiencia\u00a0(IDVC\u00a0espor\u00e1dica)\u00a0 se\u00a0estima\u00a0que\u00a0el\u00a010\u201020%\u00a0de\u00a0los\u00a0\ncasos\u00a0se\u00a0asocian\u00a0con\u00a0un\u00a0patr\u00f3n\u00a0de\u00a0herencia\u00a0familiar263\u2013265.\u00a0Sin\u00a0embargo,\u00a0solo\u00a0se\u00a0han\u00a0conseguido\u00a0\nidentificar\u00a0defectos\u00a0monog\u00e9nicos \u00a0en\u00a0el\u00a02\u201010%\u00a0de\u00a0los\u00a0pacientes\u00a0d iagnosticados\u00a0de\u00a0IDVC,\u00a0muchas\u00a0\nveces\u00a0en\u00a0familias\u00a0consangu\u00edneas\u00a0 con\u00a0varios\u00a0miembros\u00a0afectados,\u00a0 mientras\u00a0que\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0\ncasos\u00a0(\u226590%)\u00a0sigue\u00a0sin\u00a0encontrarse\u00a0una\u00a0alteraci\u00f3n\u00a0gen\u00e9tica\u00a0recu rrente\u00a0que\u00a0pueda\u00a0contribuir\u00a0a\u00a0\nexplicar\u00a0el\u00a0fenotipo\u00a0car acter\u00edstico\u00a0de\u00a0la\u00a0IDVC231,265,266.\u00a0\nGlobalmente,\u00a0 los\u00a0 defectos\u00a0 monog\u00e9nicos\u00a0 identificados\u00a0 se\u00a0 encuentr an\u00a0 en\u00a0 genes\u00a0\nrelacionados\u00a0con\u00a0i)\u00a0el\u00a0est\u00edmulo\u00a0 antig\u00e9nico\u00a0mediado\u00a0por\u00a0BCR\u00a0(e.g .\u00a0CD19,\u00a0CD81\u00a0o\u00a0CD21),\u00a0ii)\u00a0los\u00a0\nmecanismos\u00a0involucrados\u00a0en\u00a0el\u00a0cambio\u00a0de\u00a0isotipo\u00a0y\u00a0la\u00a0HMS\u00a0(e.g.\u00a0 ICOS,\u00a0CD27\u00a0o\u00a0NF\u2010 \u03baB1\u00a0y\u00a02),\u00a0iii)\u00a0la\u00a0\nsupervivencia\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0( BAFF\u2010R)\u00a0y\u00a0iv)\u00a0la\u00a0funci\u00f3n\u00a0de\u00a0linfocitos\u00a0T\u00a0( CTLA\u20104\u00a0o\u00a0LRBA)217,265,\u00a0Introducci\u00f3n \n\u2010\u00a043\u00a0\u2010\u00a0\n\u00a0entre\u00a0otros\u00a0(Tabla\u00a0Suplementaria\u00a01\u00a0del\u00a0Anexo\u00a0I).\u00a0Adem\u00e1s\u00a0de\u00a0las\u00a0 mutaciones\u00a0gen\u00e9ticas\u00a0espec\u00edficas\u00a0\nde\u00a0IDVC,\u00a0se\u00a0han\u00a0observado\u00a0tambi\u00e9 n\u00a0en\u00a0pacientes\u00a0con\u00a0IDVC,\u00a0altera ciones\u00a0gen\u00e9ticas\u00a0asociadas\u00a0a\u00a0\notras\u00a0enfermedades,\u00a0entre\u00a0las\u00a0que\u00a0se\u00a0incluyen\u00a0la\u00a0ganancia\u00a0de\u00a0fu nci\u00f3n\u00a0de\u00a0STAT3,\u00a0asociada\u00a0\nhabitualmente\u00a0 a\u00a0 la\u00a0 enfermedad\u00a0 poli\u2010autoinmune\u00a0 de\u00a0 inicio\u00a0 tempran o267,\u00a0 o\u00a0 mutaciones\u00a0\nhipom\u00f3rficas\u00a0en\u00a0genes\u00a0relacionados\u00a0con\u00a0defectos\u00a0combinados\u00a0T\u2010B, \u00a0como\u00a0RAG1268,\u00a0JAK3269,\u00a0\nIL2RG270\u00a0o\u00a0DCLRE1C271,\u00a0y\u00a0que\u00a0se\u00a0ha\u00a0demostrado\u00a0podr\u00edan\u00a0originar\u00a0tambi\u00e9n\u00a0un\u00a0fenotipo\u00a0( cl\u00ednico)\u00a0\nde\u00a0IDVC.\u00a0\n\u00a0Aunque\u00a0algunas\u00a0de\u00a0estas\u00a0alteraciones\u00a0monog\u00e9nicas\u00a0se\u00a0asocian\u00a0a\u00a0 un\u00a0fenotipo\u00a0cl\u00ednico\u00a0\ncaracter\u00edstico\u00a0(e.g.\u00a0 ICOS,\u00a0CD19 \u00a0o\u00a0CD27),\u00a0otras\u00a0(e.g.\u00a0 TACI,\u00a0BAFF\u2010R,\u00a0NFKB1 \u00a0o\u00a0CTLA\u20104)\u00a0tambi\u00e9n\u00a0se\u00a0\nhan\u00a0 detectado\u00a0 posteriormente\u00a0 en\u00a0 familiares\u00a0 con\u00a0 otras\u00a0 IDP\u2010Ac,\u00a0 e\u00a0 incluso\u00a0 en\u00a0 familiares\u00a0\nasintom\u00e1ticos\u00a0 ( Tabla\u00a0 Suplementaria\u00a0 1\u00a0 del\u00a0 Anexo\u00a0 1 ),\u00a0 lo\u00a0 que\u00a0 sugiere\u00a0 podr\u00edan\u00a0 tener\u00a0 una\u00a0\npenetrancia\u00a0parcial265,272\u2013274.\u00a0De\u00a0hecho,\u00a0el\u00a0retraso\u00a0en\u00a0el\u00a0comienzo\u00a0de\u00a0las\u00a0manifestaciones\u00a0cl \u00ednicas\u00a0\nde\u00a0la\u00a0enfermedad231,236,\u00a0hace\u00a0m\u00e1s\u00a0plausible\u00a0la\u00a0posibilidad\u00a0de\u00a0que\u00a0se\u00a0trate\u00a0de\u00a0una\u00a0enfe rmedad\u00a0de\u00a0\norigen\u00a0polig\u00e9nico\u00a0o\u00a0multifactorial\u00a0que\u00a0consecuencia\u00a0de\u00a0una\u00a0alte raci\u00f3n\u00a0gen\u00e9tica\u00a0\u00fanica234,265,266.\u00a0\nAs\u00ed,\u00a0el\u00a0empleo\u00a0de\u00a0t\u00e9cnicas\u00a0de\u00a0secuenciaci\u00f3n\u00a0masiva\u00a0ha\u00a0logrado\u00a0i dentificar\u00a0m\u00faltiples\u00a0regiones\u00a0\ngen\u00f3micas\u00a0asociadas\u00a0con\u00a0el\u00a0desarrollo\u00a0de\u00a0IDCV\u00a0(e.g.\u00a0 HLA,\u00a0MSH5,\u00a0ADAM ),\u00a0apoyando\u00a0la\u00a0naturaleza\u00a0\npolig\u00e9nica\u00a0de\u00a0la\u00a0enfermedad275,276.\u00a0De\u00a0hecho,\u00a0en\u00a0un\u00a0estudio\u00a0realizado\u00a0sobre\u00a031\u00a0pacientes\u00a0sin\u00a0\nantecedentes\u00a0familiares\u00a0de\u00a0inmunodeficiencia,\u00a0se\u00a0identificaron\u00a0 una\u00a0media\u00a0de\u00a09,4\u00a0variantes\u00a0\ng\u00e9nicas\u00a0por\u00a0paciente,\u00a0de\u00a0las\u00a0que\u00a0el\u00a084%\u00a0eran\u00a0compartidas\u00a0entre\u00a0 \u22652\u00a0casos,\u00a0involucrando\u00a0genes\u00a0\npreviamente\u00a0relacionados\u00a0con\u00a0IDVC\u00a0(e.g.\u00a0 TACI,\u00a0BAFF\u2010R,\u00a0IL21R)\u00a0o\u00a0con\u00a0otras\u00a0inmunodeficiencias\u00a0\n(e.g.\u00a0RAG2,\u00a0NHEJ1,\u00a0ATM ),\u00a0y\u00a0en\u00a0genes\u00a0que\u00a0codificaban\u00a0para\u00a0prote\u00ednas\u00a0que\u00a0tienen\u00a0un\u00a0impo rtante\u00a0\npapel\u00a0en\u00a0v\u00edas\u00a0de\u00a0transducci\u00f3n\u00a0y\u00a0en\u00a0funciones\u00a0celulares\u00a0relevant es\u00a0para\u00a0el\u00a0linfocito\u00a0B\u00a0(e.g.\u00a0\nCD79a)277.\u00a0Finalmente\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0en\u00a0la\u00a0patogenia\u00a0de\u00a0la\u00a0IDVC\u00a0podr \u00edan\u00a0estar\u00a0involucrados\u00a0\ntambi\u00e9n\u00a0otros\u00a0factores,\u00a0como\u00a0la\u00a0existencia\u00a0de\u00a0alteraciones\u00a0en\u00a0e l\u00a0patr\u00f3n\u00a0de\u00a0metilaci\u00f3n\u00a0de\u00a0genes\u00a0\nclave\u00a0para\u00a0la\u00a0funci\u00f3n\u00a0de\u00a0los\u00a0linfocitos\u00a0B278.\u00a0\n\u00a0Introducci\u00f3n \n\u2010\u00a044\u00a0\u2010\u00a0\n\u00a04.2.4.\u00a0 Alteraciones\u00a0 de\u00a0 poblaciones\u00a0 de\u00a0 c\u00e9lulas\u00a0 del\u00a0 sistema\u00a0 inmun e\u00a0 en\u00a0 la\u00a0\ninmunodeficiencia\u00a0variable\u00a0com\u00fan\u00a0\n\u00a0\nLa\u00a0 gran\u00a0 heterogeneidad\u00a0 cl\u00ednica\u00a0 y\u00a0 biol\u00f3gica\u00a0 de\u00a0 la\u00a0 IDVC,\u00a0 junto\u00a0 a\u00a0 la\u00a0 informaci\u00f3n\u00a0\nrelativamente\u00a0limitada\u00a0que\u00a0proporcionan\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0 Igs,\u00a0y\u00a0la\u00a0ausencia\u00a0de\u00a0marcadores\u00a0\ngen\u00e9ticos\u00a0bien\u00a0definidos\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0casos,\u00a0ha\u00a0favorec ido\u00a0el\u00a0uso\u00a0de\u00a0la\u00a0citometr\u00eda\u00a0de\u00a0flujo\u00a0\ncomo\u00a0herramienta\u00a0de\u00a0apoyo\u00a0al\u00a0diagn\u00f3stico\u00a0y\u00a0la\u00a0clasificaci\u00f3n\u00a0de\u00a0 la\u00a0IDVC.\u00a0En\u00a0este\u00a0sentido,\u00a0\ndiferentes\u00a0estudios\u00a0muestran\u00a0una\u00a0reducci\u00f3n\u00a0significativa\u00a0del\u00a0n\u00fa mero\u00a0global\u00a0de\u00a0linfocitos\u00a0B\u00a0\ncirculantes\u00a0de\u00a0SP\u00a0en\u00a0el\u00a010\u201018%\u00a0de\u00a0los\u00a0pacientes\u00a0con\u00a0IDVC250,279\u2013281,\u00a0descenso\u00a0que\u00a0se\u00a0relaciona\u00a0con\u00a0\nun\u00a0mayor\u00a0riesgo\u00a0de\u00a0padecer\u00a0esplenomegalia\u00a0(80%\u00a0 vs.\u00a039%)279,\u00a0granulomas\u00a0(33%\u00a0 vs.\u00a06%)280\u00a0y\u00a0\nenteropat\u00eda\u00a0(56%\u00a0 vs.\u00a016%)280,\u00a0tanto\u00a0en\u00a0ni\u00f1os\u00a0como\u00a0en\u00a0adultos284\u2013286.\u00a0Este\u00a0descenso\u00a0anormal\u00a0del\u00a0\nn\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0SP\u00a0se\u00a0ha\u00a0relacionado,\u00a0al\u00a0menos\u00a0en\u00a0par te,\u00a0con\u00a0un\u00a0defecto\u00a0en\u00a0la\u00a0\nmaduraci\u00f3n\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0en\u00a0MO,282,283\u00a0al\u00a0demostrarse\u00a0que\u00a0habitualmente\u00a0se\u00a0debe\u00a0a\u00a0una\u00a0\nd i s m i n u c i \u00f3 n \u00a0d e \u00a0c \u00e9 l u l a s \u00a0n a \u00ef v e \u00a0B \u00a0( 1 1 \u2010 1 5 % \u00a0d e \u00a0l o s \u00a0c a s o s ) \u00a0y / o \u00a0d e \u00a0l i n focitos\u00a0 B\u00a0\ninmaduros/transicionales\u00a0(22\u201025%)284,285.\u00a0\u00a0\nNo\u00a0obstante\u00a0lo\u00a0anterior,\u00a0la\u00a0alteraci\u00f3n\u00a0m\u00e1s\u00a0frecuentemente\u00a0detec tada\u00a0(58%)\u00a0en\u00a0las\u00a0series\u00a0\nm\u00e1s\u00a0largas\u00a0de\u00a0pacientes\u00a0con\u00a0IDVC\u00a0referidos\u00a0en\u00a0la\u00a0bibliograf\u00eda,\u00a0 como\u00a0es\u00a0el\u00a0caso\u00a0del\u00a0estudio\u00a0\nEUROclass\u00a0basado\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0d e\u00a0303\u00a0pacientes\u00a0con\u00a0IDVC,\u00a0es\u00a0l a\u00a0reducci\u00f3n\u00a0significativa\u00a0del\u00a0\nn\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u00a0(linfoc itos\u00a0B\u00a0CD27+IgM\u2010IgD\u2010),\u00a0asociado\u00a0\na\u00a0su\u00a0vez,\u00a0con\u00a0una\u00a0mayor\u00a0frecuencia\u00a0de\u00a0esplenomegalia\u00a0(52%\u00a0 vs.\u00a024%)\u00a0y\u00a0granulomas\u00a0(17%\u00a0 vs.\u00a0\n4%)250.\u00a0Estas\u00a0asociaciones\u00a0coinciden\u00a0c on\u00a0otras\u00a0observaciones\u00a0en\u00a0serie s\u00a0m\u00e1s\u00a0cortas\u00a0d e\u00a0pacientes,\u00a0\nen\u00a0las\u00a0que\u00a056\u201081%\u00a0de\u00a0los\u00a0adultos286\u2013290\u00a0y\u00a020\u201053%\u00a0de\u00a0los\u00a0ni\u00f1os291,292\u00a0presentaban\u00a0un\u00a0descenso\u00a0\nanormal\u00a0del\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0iso tipo\u00a0en\u00a0SP,\u00a0y\u00a0en\u00a0los\u00a0que\u00a0se\u00a0\ndescribe\u00a0un\u00a0mayor\u00a0abanico\u00a0de\u00a0manifestaciones\u00a0cl\u00ednicas\u00a0potencial mente\u00a0asociadas\u00a0con\u00a0esta\u00a0\nalteraci\u00f3n253,289,292:\u00a0citopenias\u00a0autoinmunes\u00a0(21%\u00a0 vs.\u00a00%;\u00a0n=45\u00a0ni\u00f1os)292,\u00a0enfermedad\u00a0pulmonar\u00a0\n(32%\u00a0vs.\u00a00%,\u00a0n=41\u00a0pacientes\u00a0>15\u00a0a\u00f1os)289\u00a0y\u00a0enteropat\u00eda\u00a0(35%\u00a0 vs.\u00a00%;\u00a0n=41\u00a0pacientes\u00a0>15\u00a0a\u00f1os)289.\u00a0\nPese\u00a0 a\u00a0 estos\u00a0 hallazgos,\u00a0 solo\u00a0 en\u00a0 algunos\u00a0 estudios\u00a0 se\u00a0 han\u00a0 analiza do\u00a0 en\u00a0 m\u00e1s\u00a0 detalle\u00a0 estas\u00a0Introducci\u00f3n \n\u2010\u00a045\u00a0\u2010\u00a0\n\u00a0subpoblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo,\u00a0s ubdividi\u00e9ndolas\u00a0seg\u00fan\u00a0el\u00a0tipo\u00a0\nde\u00a0Ig\u00a0(IgG\u00a0o\u00a0IgA)\u00a0que\u00a0expresan;\u00a0as\u00ed,\u00a0se\u00a0ha\u00a0observado\u00a0que,\u00a0aunqu e\u00a0existe\u00a0una\u00a0disminuci\u00f3n\u00a0\nsignificativa\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0que\u00a0expresan\u00a0ambos\u00a0is otipos196,285,\u00a0el\u00a0porcentaje\u00a0de\u00a0\npacientes\u00a0 con\u00a0 este\u00a0 defecto\u00a0 es\u00a0 cl aramente\u00a0 superior\u00a0 cuando\u00a0 el\u00a0 an\u00e1 lisis\u00a0 se\u00a0 restringe\u00a0 a\u00a0 las\u00a0\npoblaciones\u00a0CD27+\u00a0frente\u00a0a\u00a0los\u00a0linfocitos\u00a0CD27\u2010\u00a0(80%\u00a0vs.\u00a060%\u00a0para\u00a0IgG+;\u00a065%\u00a0vs.\u00a010%\u00a0para\u00a0IgA+)196.\u00a0\nFinalmente,\u00a0 los\u00a0 linfocitos\u00a0 B\u00a0 de\u00a0 memoria\u00a0 que\u00a0 no\u00a0 han\u00a0 realizado\u00a0 ca mbio\u00a0 de\u00a0 isotipo\u00a0\n(linfocitos\u00a0B\u00a0CD27+\u00a0IgM++D+)\u00a0tambi\u00e9n\u00a0se\u00a0encuentran\u00a0reducidos\u00a0en\u00a0casi\u00a0un\u00a0tercio\u00a0de\u00a0los\u00a0paci entes\u00a0\ncon\u00a0IDVC\u00a0(25\u201032%),\u00a0aunque\u00a0siempre\u00a0 que\u00a0existe\u00a0alteraci\u00f3n\u00a0de\u00a0esto s\u00a0linfocitos\u00a0B,\u00a0esta\u00a0se\u00a0asocia\u00a0a\u00a0\nun\u00a0descenso\u00a0simult\u00e1neo\u00a0de\u00a0los\u00a0lin focitos\u00a0B\u00a0de\u00a0memoria\u00a0que\u00a0prese ntan\u00a0cambio\u00a0de\u00a0isotipo284,285.\u00a0\u00a0\nOtras\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0que\u00a0se\u00a0ha\u00a0descrito\u00a0est\u00e1n\u00a0alte radas\u00a0en\u00a0la\u00a0SP\u00a0de\u00a0pacientes\u00a0\ncon\u00a0 IDVC\u00a0 incluyen\u00a0 los\u00a0 linfocitos\u00a0 B\u00a0 inmaduros\u00a0 y\u00a0 los\u00a0 linfocitos\u00a0 B \u00a0 CD21\u2010,\u00a0 num\u00e9ricamente\u00a0\naumentados\u00a0en\u00a0el\u00a026\u201053%\u00a0de\u00a0los\u00a0pacientes250,279,286,293\u2013295,\u00a0principalmente\u00a0en\u00a0aquellos\u00a0casos\u00a0que\u00a0\npresentan\u00a0mayor\u00a0frecuencia\u00a0de\u00a0citopenias\u00a0autoinmunes\u00a0(60\u201064 %\u00a0de\u00a0pacientes\u00a0con\u00a0n\u00fameros\u00a0de\u00a0\nCD21\u2010\u00a0aumentados \u00a0v s .\u00a0 5\u201020%\u00a0 de\u00a0 pacientes\u00a0 con\u00a0 n\u00fameros\u00a0 de\u00a0 CD21\u2010\u00a0n o r m a l e s )286,295,296,\u00a0\nesplenomegalia\u00a0(50\u2010100 %\u00a0vs.\u00a010\u201030%)250,286,293,295\u00a0y\u00a0granulomas\u00a0(18\u201028 %\u00a0vs.\u00a00\u20109%)250,295.\u00a0Otras\u00a0\nasociaciones,\u00a0como\u00a0la\u00a0mayor\u00a0frecuencia\u00a0de\u00a0adenopat\u00edas\u00a0en\u00a0pacien tes\u00a0que\u00a0presentan\u00a0un\u00a0aumento\u00a0\nrelativo\u00a0 en\u00a0 el\u00a0 n\u00famero\u00a0 de\u00a0 linfocitos\u00a0 B\u00a0 inmaduros\u00a0 (57%\u00a0 vs.\u00a0 22%)250,\u00a0 se\u00a0 ha\u00a0 comprobado\u00a0\nposteriormente\u00a0son\u00a0realmente\u00a0debidas\u00a0a\u00a0un\u00a0descenso\u00a0en\u00a0el\u00a0n\u00famero \u00a0absoluto\u00a0de\u00a0las\u00a0dem\u00e1s\u00a0\npoblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B284.\u00a0\u00a0\nLa\u00a0reducci\u00f3n\u00a0del\u00a0n\u00famero\u00a0de\u00a0linfo citos\u00a0B\u00a0de\u00a0memoria\u00a0en\u00a0SP,\u00a0estar \u00eda\u00a0tambi\u00e9n\u00a0asociada\u00a0con\u00a0\nuna\u00a0peor\u00a0respuesta\u00a0a\u00a0vacunaci\u00f3n\u00a0frente\u00a0a\u00a0Ags\u00a0proteicos\u00a0y\u00a0polisa car\u00eddicos290,297.\u00a0As\u00ed,\u00a0en\u00a0un\u00a0estudio\u00a0\nrealizado\u00a0sobre\u00a018\u00a0pacientes\u00a0con\u00a0IDVC,\u00a0se\u00a0observ\u00f3\u00a0que\u00a0m\u00e1s\u00a0de\u00a0la \u00a0mitad\u00a0(61%)\u00a0respond\u00edan\u00a0\n(aunque\u00a0habitualmente\u00a0de\u00a0forma\u00a0d\u00e9bil\u00a0y/o\u00a0transitoria)\u00a0a\u00a0alguno\u00a0 de\u00a0los\u00a0Ags\u00a0polipept\u00eddicos\u00a0\nevaluados\u00a0(proteicos:\u00a0hepatitis\u00a0B\u00a0y\u00a0C,\u00a0difteria\u00a0y\u00a0t\u00e9tanos;\u00a0poli sac\u00e1rido+proteico:\u00a0 H.\u00a0influenza \u00a0b\u00a0\nconjugado),\u00a0siendo\u00a0este\u00a0porcenta je\u00a0del\u00a0100%\u00a0(3/3)\u00a0en\u00a0aquellos\u00a0p acientes\u00a0que\u00a0no\u00a0presentaban\u00a0\nalteraciones\u00a0en\u00a0los\u00a0linfocitos\u00a0B\u00a0 de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0isoti po\u00a0y\u00a0solamente\u00a0del\u00a053%\u00a0(8/15)\u00a0Introducci\u00f3n \n\u2010\u00a046\u00a0\u2010\u00a0\n\u00a0en\u00a0pacientes\u00a0con\u00a0defectos\u00a0en\u00a0esta\u00a0poblaci\u00f3n\u00a0B\u00a0de\u00a0SP306.\u00a0En\u00a0este\u00a0mismo\u00a0sentido,\u00a0cabe\u00a0se\u00f1alar\u00a0que\u00a0\nde\u00a0los\u00a0tres\u00a0pacientes\u00a0que\u00a0mostra ron\u00a0adem\u00e1s\u00a0respuesta\u00a0de\u00a0tipo\u00a0Ig G\u00a0frente\u00a0a\u00a0polisac\u00e1ridos\u00a0de\u00a0\nneumococo,\u00a0dos\u00a0pertenec\u00edan\u00a0al\u00a0grupo\u00a0que\u00a0mostraba\u00a0cifras\u00a0normale s\u00a0en\u00a0SP\u00a0de\u00a0linfocitos\u00a0B\u00a0\nmemoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo297.\u00a0De\u00a0acuerdo\u00a0con\u00a0estos\u00a0hallazgos,\u00a0en\u00a0otro\u00a0estudio\u00a0se\u00a0demostr\u00f3\u00a0\nque\u00a0los\u00a0pacientes\u00a0en\u00a0los\u00a0que\u00a0no\u00a0exist\u00eda\u00a0un\u00a0descenso\u00a0del\u00a0n\u00famero\u00a0 total\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0\ncon\u00a0cambio\u00a0de\u00a0isotipo,\u00a0pose\u00edan\u00a0t\u00edtulos\u00a0protectores\u00a0de\u00a0Acs\u00a0frent e\u00a0un\u00a0mayor\u00a0n\u00famero\u00a0de\u00a0serotipos\u00a0\nde\u00a0neumococo,\u00a0que\u00a0aquellos\u00a0que\u00a0mostraban\u00a0d\u00e9ficits\u00a0num\u00e9ricos\u00a0de\u00a0 estas\u00a0c\u00e9lulas\u00a0B\u00a0(mediana\u00a0de\u00a0\n3\u00a0vs.\u00a00.5\u00a0serotipos)290.\u00a0\u00a0\nAlgunos\u00a0autores\u00a0han\u00a0observado\u00a0una\u00a0disminuci\u00f3n\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0C Ps\u00a0presentes\u00a0en\u00a0\nSP284,\u00a0MO283,\u00a0y\u00a0ganglio\u00a0linf\u00e1tico298\u00a0de\u00a0pacientes\u00a0con\u00a0IDVC\u00a0respecto\u00a0 a\u00a0donantes\u00a0sanos;\u00a0no\u00a0obstante,\u00a0\nla\u00a0baja\u00a0frecuencia\u00a0de\u00a0estas\u00a0c\u00e9lulas\u00a0no\u00a0ha\u00a0permitido\u00a0hacer\u00a0estud ios\u00a0m\u00e1s\u00a0detallados\u00a0de\u00a0las\u00a0mismas.\u00a0\nDe\u00a0acuerdo\u00a0con\u00a0estos\u00a0hallazgos,\u00a0se\u00a0ha\u00a0referido\u00a0previamente\u00a0tamb i\u00e9n,\u00a0que\u00a0tanto\u00a0las\u00a0CPs\u00a0como\u00a0\nlos\u00a0 linfocitos\u00a0 B\u00a0 de\u00a0 memoria,\u00a0 podr\u00edan\u00a0 estar\u00a0 reducidos\u00a0 levemente\u00a0 en\u00a0 la\u00a0 SP\u00a0 de\u00a0 familiares\u00a0\nasintom\u00e1ticos\u00a0de\u00a0pacientes\u00a0con\u00a0IDVC,\u00a0apoyando\u00a0de\u00a0este\u00a0modo\u00a0el\u00a0p osible\u00a0origen\u00a0polig\u00e9nico\u00a0de\u00a0la\u00a0\nenfermedad285.\u00a0 En\u00a0 la\u00a0 Tabla\u00a0 4\u00a0 se\u00a0 muestran\u00a0 las\u00a0 alteraciones\u00a0 del\u00a0 compartimento\u00a0 B\u00a0 m\u00e1s\u00a0\ncom\u00fanmente\u00a0observadas\u00a0en\u00a0los\u00a0pr incipales\u00a0subtipos\u00a0de\u00a0IDP\u2010Ac.\u00a0\nBas\u00e1ndose\u00a0en\u00a0las\u00a0alteraciones\u00a0existentes\u00a0en\u00a0las\u00a0poblaciones\u00a0de\u00a0 linfocitos\u00a0B\u00a0de\u00a0SP\u00a0de\u00a0\npacientes\u00a0con\u00a0IDVC,\u00a0especialmente\u00a0en\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memori a\u00a0con\u00a0cambio\u00a0de\u00a0isotipo,\u00a0a\u00a0lo\u00a0\nlargo\u00a0de\u00a0los\u00a0a\u00f1os\u00a0se\u00a0han\u00a0propuesto\u00a0varias\u00a0clasificaciones\u00a0para\u00a0 estos\u00a0pacientes,\u00a0destacando\u00a0por\u00a0\nsu\u00a0amplia\u00a0utilizaci\u00f3n\u00a0las\u00a0clasificaciones\u00a0de\u00a0Friburgo286,\u00a0Par\u00eds287,\u00a0EUROClass250\u00a0y\u00a0Rotterdam284.\u00a0En\u00a0\nla\u00a0Figura\u00a04\u00a0se\u00a0muestra\u00a0un\u00a0resumen\u00a0de\u00a0los\u00a0criterios\u00a0de\u00a0subclasif icaci\u00f3n\u00a0de\u00a0IDVC\u00a0empleados\u00a0en\u00a0\ncada\u00a0una\u00a0de\u00a0ellas.\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0Introducci\u00f3n \n\u2010\u00a047\u00a0\u2010\u00a0\n\u00a0Tabla\u00a04.\u00a0Niveles\u00a0de\u00a0poblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0seg\u00fan\u00a0su\u00a0estadio\u00a0d e\u00a0maduraci\u00f3n\u00a0en\u00a0los\u00a0principales\u00a0\nsubtipos\u00a0de\u00a0IDP\u2010Ac.\u00a0\n\u00a0\u2193\u00a0disminuido.\u00a0N:\u00a0normal;\u00a0ND:\u00a0datos\u00a0no\u00a0disponibles.\u00a0aCifras\u00a0normales\u00a0de\u00a0c\u00e9lulas\u00a0pre\u2010c entro\u00a0germinal\u00a0sin\u00a0informaci\u00f3n\u00a0\ndisponible\u00a0sobre\u00a0linfocitos\u00a0B\u00a0in maduros\u00a0y\u00a0na\u00efve\u00a0por\u00a0separado.\u00a0bSe\u00a0han\u00a0referido\u00a0niveles\u00a0deficitarios\u00a0en\u00a0<15%\u00a0de\u00a0los\u00a0\npacientes.\u00a0cSe\u00a0han\u00a0referido\u00a0niveles\u00a0deficita rios\u00a0en\u00a0<10%\u00a0de\u00a0los\u00a0pacientes .\u00a0\nFinalmente,\u00a0se\u00a0han\u00a0descrito\u00a0tamb i\u00e9n\u00a0en\u00a0pacientes\u00a0con\u00a0IDVC,\u00a0alte raciones\u00a0num\u00e9ricas\u00a0que\u00a0\nafectan\u00a0a\u00a0otras\u00a0poblaciones\u00a0de\u00a0c\u00e9lulas\u00a0de\u00a0la\u00a0respuesta\u00a0inmune,\u00a0 adem\u00e1s\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0y\u00a0las\u00a0\nCPs.\u00a0As\u00ed,\u00a0en\u00a0una\u00a0serie\u00a0de\u00a0473\u00a0pa cientes\u00a0con\u00a0IDVC,\u00a0se\u00a0demostr\u00f3\u00a0q ue\u00a0las\u00a0c\u00e9lulas\u00a0T\u00a0CD4+\u00a0estaban\u00a0\ndisminuidas\u00a0en\u00a0casi\u00a0un\u00a0tercio\u00a0(29%)\u00a0de\u00a0los\u00a0casos247;\u00a0este\u00a0hallazgo\u00a0se\u00a0ha\u00a0confirmado\u00a0en\u00a0series\u00a0m\u00e1s\u00a0\ncortas\u00a0de\u00a0pacientes137,253,\u00a0en\u00a0las\u00a0que\u00a0se\u00a0ha\u00a0asociado\u00a0tambi\u00e9n\u00a0a\u00a0un\u00a0descenso\u00a0de\u00a0las\u00a0c\u00e9lula s\u00a0T\u00a0na\u00efve\u00a0\nCD4+\u00a0y\u00a0 CD8+253,284,299,\u00a0 especialmente\u00a0 en\u00a0 aquellos\u00a0 casos\u00a0 en\u00a0 los\u00a0 que\u00a0 se\u00a0 observan\u00a0 m\u00e1s\u00a0\nmanifestaciones\u00a0cl\u00ednicas\u00a0asociadas\u00a0a\u00a0inmunodeficiencia\u00a0(i.e.\u00a0li nfoproliferaci\u00f3n,\u00a0citopenias\u00a0y\u00a0\nenteropat\u00eda)253.\u00a0Otras\u00a0alteraciones\u00a0descritas\u00a0en\u00a0los\u00a0linfocitos\u00a0de\u00a0SP\u00a0de\u00a0pacie ntes\u00a0con\u00a0IDVC\u00a0\nincluyen:\u00a0el\u00a0descenso\u00a0del\u00a0n\u00famero\u00a0de\u00a0c\u00e9lulas\u00a0T\u00a0reguladoras300,301,\u00a0el\u00a0aumento\u00a0del\u00a0n\u00famero\u00a0de\u00a0\nc\u00e9lulas\u00a0T\u00a0foliculares\u00a0de\u00a0patr\u00f3n\u00a0tipo\u00a0T h1\u00a0(asociado\u00a0a\u00a0aumento\u00a0de\u00a0\u00a0linfocitos\u00a0B\u00a0CD21\u2010)302,\u00a0y\u00a0el\u00a0\ndescenso\u00a0significativo\u00a0del\u00a0n\u00famero\u00a0de\u00a0c\u00e9lulas\u00a0NK,\u00a0asociado\u00a0esta\u00a0 \u00faltima\u00a0alteraci\u00f3n\u00a0con\u00a0un\u00a0menor\u00a0\nn\u00famero\u00a0de\u00a0linfocitos\u00a0T\u00a0CD4+\u00a0na\u00efve,\u00a0T\u00a0CD8+\u00a0y\u00a0de\u00a0linfocitos\u00a0B,\u00a0y\u00a0con\u00a0una\u00a0mayor\u00a0frecuencia\u00a0de\u00a0\ninfecciones\u00a0 bacterianas\u00a0 severas\u00a0 y\u00a0 granuloma303.\u00a0 Adem\u00e1s,\u00a0 otras\u00a0 poblaciones\u00a0 celulares\u00a0 que\u00a0\ndesarrollan\u00a0 funciones\u00a0 importantes\u00a0 en\u00a0 la\u00a0 respuesta\u00a0 inmune,\u00a0 como\u00a0 las\u00a0 c\u00e9lulas\u00a0 dendr\u00edticas,\u00a0\ntambi\u00e9n\u00a0se\u00a0ha\u00a0descrito\u00a0se\u00a0encuentran\u00a0disminuidas\u00a0en\u00a0estos\u00a0pacie ntes285,\u00a0aunque\u00a0no\u00a0ser\u00e1n\u00a0objeto\u00a0\nde\u00a0estudio\u00a0en\u00a0esta\u00a0tesis\u00a0doctoral.\u00a0\u00a0 Subpoblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B \u00a0\nSubtipo\u00a0de\u00a0IDP\u2010Ac \u00a0C\u00e9lula\u00a0B\u00a0\ninmaduras\u00a0Linfocito\u00a0\nB\u00a0na\u00efve\u00a0Linfocito\u00a0B\u00a0de\u00a0\nmemoria\u00a0\nIgM++D+\u00a0CD27+\u00a0Linfocito\u00a0B\u00a0de\u00a0\nmemoria\u00a0\nIgM\u2010D\u2010\u00a0CD27+\u00a0C\u00e9lula\u00a0\nplasm\u00e1tica\u00a0\nAgammaglobulinemia\u00a0 \u2193\u00a0 \u2193\u00a0 \u2193\u00a0 \u2193\u00a0 \u2193\u00a0\nIDVC\u00a0 N/\u2193\u00a0 N/\u2193\u00a0 N/\u2193\u00a0 N/\u2193\u00a0 \u2193\u00a0\nS\u00edndromes\u00a0h\u00edper\u2010IgM\nD\u00e9ficit\u00a0de\u00a0CD40L\u00a0Na\u00a0Na\u00a0N / \u2193 \u00a0\u2193\u00a0\n(IgA+CD27\u2010:\u00a0N)\u00a0ND\u00a0\nS\u00edndromes\u00a0h\u00edper\u2010IgM\nD\u00e9ficit\u00a0de\u00a0AID\u00a0Na\u00a0Na\u00a0N \u00a0 \u2193 \u00a0N D \u00a0\nD\u00e9ficit\u00a0de\u00a0IgA\u00a0 N\u00a0 N\u00a0 N\u00a0 Nb\u00a0N/\u2193\u00a0\nD\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0\n(con\u00a0o\u00a0sin\u00a0d\u00e9ficit\u00a0de\u00a0IgA)\u00a0Nc\u00a0Nc\u00a0 N/\u2193\u00a0 N/\u2193\u00a0 N\u00a0Introducci\u00f3n \n\u2010\u00a048\u00a0\u2010\u00a0\n\u00a0Figura\u00a04.\u00a0\u00a0Esquema\u00a0de\u00a0las\u00a0principales\u00a0clasificaciones\u00a0de\u00a0pacien tes\u00a0con\u00a0IDVC\u00a0basadas\u00a0en\u00a0las\u00a0\nalteraciones\u00a0de\u00a0las\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0SP.\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nLos\u00a0grupos\u00a0establecidos\u00a0por\u00a0las\u00a0clasificaciones\u00a0de\u00a0Friburgo286,\u00a0Par\u00eds287\u00a0y\u00a0EUROClass250\u00a0se\u00a0basan\u00a0en\u00a0el\u00a0descenso\u00a0en\u00a0SP\u00a0\nde\u00a0los\u00a0n\u00fameros\u00a0relativos\u00a0de\u00a0dis tintas\u00a0poblaciones\u00a0de\u00a0linfocitos \u00a0B\u00a0respecto\u00a0a\u00a0puntos\u00a0de\u00a0corte\u00a0establecidos\u00a0para\u00a0cada\u00a0\npoblaci\u00f3n\u00a0celular.\u00a0La\u00a0clasificaci\u00f3 n\u00a0de\u00a0Rotterdam\u00a0se\u00a0basa\u00a0en\u00a0el\u00a0 descenso\u00a0en\u00a0los\u00a0n\u00fameros\u00a0absolutos\u00a0de\u00a0cada\u00a0poblaci\u00f3n\u00a0\nde\u00a0c\u00e9lulas\u00a0B\u00a0por\u00a0debajo\u00a0del\u00a0perc entil\u00a05%\u00a0de\u00a0donantes\u00a0agrupados\u00a0 por\u00a0edad\u00a0(5\u201010\u00a0a\u00f1os;\u00a010\u201016\u00a0a\u00f1os;\u00a0>16\u00a0a\u00f1os)284.\u00a0\nIntroducci\u00f3n \n\u2010\u00a049\u00a0\u2010\u00a0\n\u00a04.2.5.\u00a0Alteraciones\u00a0funcionales\u00a0 B\u00a0asociadas\u00a0a\u00a0inmunodeficiencia \u00a0variable\u00a0com\u00fan\u00a0\nLas\u00a0alteraciones\u00a0detectadas\u00a0en\u00a0los\u00a0distintos\u00a0compartimentos\u00a0mad urativos\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0\nde\u00a0SP\u00a0en\u00a0pacientes\u00a0con\u00a0IDVC,\u00a0no\u00a0se\u00a0restringen\u00a0a\u00a0alteraciones\u00a0nu m\u00e9ricas,\u00a0sino\u00a0que,\u00a0con\u00a0relativa\u00a0\nfrecuencia,\u00a0reflejan\u00a0alteracione s\u00a0funcionales.\u00a0De\u00a0este\u00a0modo,\u00a0Br yant\u00a0et\u00a0al.\u00a0identificaron\u00a0tres\u00a0\ngrupos\u00a0de\u00a0pacientes\u00a0con\u00a0IDVC\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0capacidad\u00a0que\u00a0pre sentaban\u00a0para\u00a0producir\u00a0Acs\u00a0de\u00a0\nt i p o \u00a0I g G \u00a0e \u00a0I g M \u00a0t r a s \u00a0e s t i m u l a c i \u00f3 n \u00a0 in\u00a0 vitro\u00a0 con\u00a0 est\u00edmulos\u00a0 capaces\u00a0 de\u00a0 generar\u00a0 respuesta\u00a0 B\u00a0\nindependiente\u00a0de\u00a0linfocitos\u00a0T304.\u00a0En\u00a0el\u00a0grupo\u00a0A,\u00a0incluyeron\u00a0pacientes\u00a0incapaces\u00a0de\u00a0sintetizar\u00a0I gM\u00a0\no\u00a0IgG\u00a0in\u00a0vitro,\u00a0mientras\u00a0que\u00a0en\u00a0el\u00a0grupo\u00a0B,\u00a0estaba\u00a0constituido\u00a0por\u00a0pacientes\u00a0 capaces\u00a0de\u00a0sintetizar\u00a0\nIgM\u00a0(>4000\u00a0ng/\u00b5l)\u00a0pero\u00a0no\u00a0IgG\u00a0y\u00a0en\u00a0el\u00a0grupo\u00a0C,\u00a0se\u00a0inclu\u00edan\u00a0suje tos\u00a0con\u00a0IDVC\u00a0capaces\u00a0de\u00a0sintetizar\u00a0\nIgM\u00a0e\u00a0IgG\u00a0(>500\u00a0ng/\u00b5l)\u00a0286,304.\u00a0Posteriormente,\u00a0Warnatz\u00a0 et\u00a0al.\u00a0mostraron\u00a0que\u00a0aquellos\u00a0pacientes\u00a0\nque\u00a0presentaban\u00a0en\u00a0SP\u00a0un\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0 cambio\u00a0de\u00a0isotipo\u00a0dentro\u00a0del\u00a0\nrango\u00a0normal\u00a0pertenec\u00edan\u00a0al\u00a0grupo\u00a0C,\u00a0mientras\u00a0que\u00a0aquellos\u00a0que\u00a0 mostraban\u00a0un\u00a0n\u00famero\u00a0reducido\u00a0\nde\u00a0estas\u00a0c\u00e9lulas\u00a0B,\u00a0correspond\u00edan\u00a0a\u00a0pacientes\u00a0de\u00a0los\u00a0grupos\u00a0A\u00a0y \u00a0B286.\u00a0\u00a0M\u00e1s\u00a0recientemente,\u00a0se\u00a0ha\u00a0\nobservado\u00a0mediante\u00a0t\u00e9cnica\u00a0de\u00a0ELISpot\u00a0(ensayo\u00a0de\u00a0puntos\u00a0por\u00a0inm unoadsorci\u00f3n\u00a0ligado\u00a0a\u00a0\nenzimas;\u00a0del\u00a0ingl\u00e9s, \u00a0Enzyme\u2010Linked\u00a0ImmunoSpot\u00a0Assay) \u00a0que\u00a0en\u00a0general,\u00a0los\u00a0pacientes\u00a0con\u00a0IDVC\u00a0\npresentan\u00a0un\u00a0defecto\u00a0f uncional\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0con\u00a0un\u00a0n\u00famero\u00a0r educido\u00a0de\u00a0CPs\u00a0productoras\u00a0de\u00a0\nIgs\u00a0ex\u00a0vivo,\u00a0asociado\u00a0a\u00a0un\u00a0defecto\u00a0en\u00a0la\u00a0diferenciaci\u00f3n\u00a0a\u00a0CP\u00a0tras\u00a0estimula ci\u00f3n\u00a0in\u00a0vitro\u00a0con\u00a0Ags\u00a0T\u2010\nindependientes305.\u00a0En\u00a0este\u00a0estudio\u00a0se\u00a0demostr\u00f3\u00a0adem\u00e1s\u00a0la\u00a0existencia\u00a0de\u00a0una\u00a0relac i\u00f3n\u00a0directa\u00a0\nentre\u00a0esta\u00a0alteraci\u00f3n\u00a0funcional\u00a0y\u00a0el\u00a0descenso\u00a0en\u00a0SP\u00a0del\u00a0n\u00famero\u00a0 de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0\ncambio\u00a0de\u00a0isotipo.\u00a0As\u00ed,\u00a0aquellos\u00a0pacientes\u00a0con\u00a0un\u00a0defecto\u00a0en\u00a0es tas\u00a0c\u00e9lulas\u00a0ten\u00edan\u00a0menos\u00a0CPs\u00a0\nproductoras\u00a0de\u00a0Igs\u00a0 ex\u00a0vivo\u00a0e\u00a0in\u00a0vitro\u00a0que\u00a0aquellos\u00a0que\u00a0mostraban\u00a0cifra s\u00a0normales\u00a0de\u00a0linfocitos\u00a0B\u00a0\nde\u00a0memoria\u00a0con\u00a0cambio\u00a0isot\u00edpico\u00a0circulantes,\u00a0a\u00a0pesar\u00a0de\u00a0que\u00a0den tro\u00a0de\u00a0este\u00a0\u00faltimo\u00a0grupo\u00a0\nexist\u00edan\u00a0tanto\u00a0casos\u00a0con\u00a0respuestas\u00a0funcionales\u00a0indetectables\u00a0c omo\u00a0normales305.\u00a0Sin\u00a0embargo,\u00a0\nestas\u00a0clasificaciones\u00a0funcionale s\u00a0de\u00a0la\u00a0IDVC\u00a0han\u00a0tenido\u00a0menor\u00a0a ceptaci\u00f3n\u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica\u00a0\nque\u00a0 aquellas\u00a0 que\u00a0 est\u00e1n\u00a0 basadas\u00a0 en\u00a0 los\u00a0 hallazgos\u00a0 de\u00a0 la\u00a0 citometr\u00ed a\u00a0 de\u00a0 flujo,\u00a0 debido\u00a0Introducci\u00f3n \n\u2010\u00a050\u00a0\u2010\u00a0\n\u00a0fundamentalmente\u00a0a\u00a0que\u00a0se\u00a0trata\u00a0de\u00a0t\u00e9cnicas\u00a0m\u00e1s\u00a0laboriosas\u00a0y\u00a0di f\u00edciles\u00a0de\u00a0estandarizar\u00a0para\u00a0su\u00a0\naplicaci\u00f3n\u00a0en\u00a0la\u00a0rutina\u00a0diagn\u00f3stica286.\u00a0\n\u00a0\n4.3.\u00a0Deficiencia\u00a0grave\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0con\u00a0valores\u00a0normales\u00a0o\u00a0elev ados\u00a0de\u00a0IgM\u00a0\ny\u00a0normales\u00a0de\u00a0linfocitos\u00a0B\u00a0(s\u00edndromes\u00a0h\u00edper\u2010IgM)\u00a0\nLos\u00a0s\u00edndromes\u00a0h\u00edper\u2010IgM\u00a0son\u00a0un\u00a0conjunto\u00a0de\u00a0inmunodeficiencias\u00a0c aracterizadas\u00a0por\u00a0la\u00a0\nausencia\u00a0o\u00a0descenso\u00a0severo\u00a0de\u00a0IgG\u00a0e\u00a0IgA,\u00a0con\u00a0cifras\u00a0normales\u00a0o\u00a0 elevadas\u00a0de\u00a0IgM,\u00a0debido\u00a0a\u00a0un\u00a0\ndefecto\u00a0en\u00a0el\u00a0cambio\u00a0de\u00a0isotipo\u00a0de\u00a0Ig11,209,306,307.\u00a0Hoy\u00a0se\u00a0conoce\u00a0que\u00a0estos\u00a0defectos\u00a0se\u00a0asocian\u00a0a\u00a0\nmutaciones\u00a0en:\u00a0i)\u00a0prote\u00ednas\u00a0que\u00a0participan\u00a0en\u00a0la\u00a0HMS\u00a0y/o\u00a0cambio \u00a0de\u00a0isotipo\u00a0( AID,\u00a0UNG,\u00a0MSH6,\u00a0\nINO80)306,308,309;\u00a0ii)\u00a0prote\u00ednas\u00a0coestimuladoras\u00a0expresadas\u00a0por\u00a0parte\u00a0de\u00a0los\u00a0lin focitos\u00a0T\u00a0activados\u00a0\n(CD40L)\u00a0o\u00a0por\u00a0los\u00a0linfocitos\u00a0B\u00a0( CD40);\u00a0y\u00a0iii)\u00a0genes\u00a0implicados\u00a0en\u00a0la \u00a0se\u00f1alizaci\u00f3n\u00a0a\u00a0 trav\u00e9s\u00a0de\u00a0NF\u2010\u03baB \u00a0\n(NEMO,\u00a0IKBA )310,311.\u00a0Globalmente,\u00a0la\u00a0incidencia\u00a0de\u00a0s\u00edndromes\u00a0h\u00edper\u2010IgM\u00a0es\u00a0superior \u00a0en\u00a0varones\u00a0\nque\u00a0en\u00a0mujeres,\u00a0debido\u00a0a\u00a0que\u00a0las\u00a0formas\u00a0m\u00e1s\u00a0frecuentes\u00a0de\u00a0estos \u00a0s\u00edndromes\u00a0se\u00a0relacionan\u00a0con\u00a0\ngenes\u00a0codificados\u00a0en\u00a0el\u00a0cromosoma\u00a0X\u00a0( CD40L\u00a0y\u00a0NEMO)306,\u00a0mientras\u00a0que\u00a0las\u00a0formas\u00a0autos\u00f3micas\u00a0\nrecesivas\u00a0( AID312,313,\u00a0UNG314,\u00a0CD40315,\u00a0MSH6308,\u00a0INO80309)\u00a0y\u00a0dominantes\u00a0( IKBA316)\u00a0son\u00a0menos\u00a0\nfrecuentes.\u00a0\u00a0\nEn\u00a0general,\u00a0la\u00a0prevalencia\u00a0de\u00a0los \u00a0s\u00edndromes\u00a0h\u00edper\u2010IgM\u00a0es\u00a0extrem adamente\u00a0baja,\u00a0oscilando\u00a0\nentre\u00a01\u20102/106\u00a0nacimientos\u00a0( CD40L,\u00a0AID)317\u00a0a\u00a0\u2264100\u00a0pacientes\u00a0descritos\u00a0a\u00a0nivel\u00a0mundial\u00a0para\u00a0la\u00a0\nmayor\u00eda\u00a0de\u00a0los\u00a0subtipos\u00a0gen\u00e9ticos:\u00a0 NEMO\u00a0(n\u2248100\u00a0casos),\u00a0 CD40\u00a0(n=16),\u00a0IKBA\u00a0(n=14),\u00a0MSH6\u00a0(n=8),\u00a0\nUNG\u00a0(n=3)\u00a0e\u00a0INO80\u00a0(n=2)216,308,309,314,316,318.\u00a0En\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0casos,\u00a0el\u00a0diagn\u00f3stico\u00a0se\u00a0realiza\u00a0\nantes\u00a0de\u00a0los\u00a05\u00a0a\u00f1os\u00a0de\u00a0edad,\u00a0caracteriz\u00e1ndose\u00a0habitualmente\u00a0est os\u00a0pacientes\u00a0por\u00a0presentar\u00a0\ninfecciones\u00a0respiratorias\u00a0y\u00a0gast rointestinales\u00a0de\u00a0repetici\u00f3n,\u00a0s i\u00a0bien\u00a0las\u00a0manifestaciones\u00a0cl\u00ednicas\u00a0\nvar\u00edan\u00a0de\u00a0forma\u00a0importante\u00a0en\u00a0funci\u00f3n\u00a0del\u00a0defecto\u00a0gen\u00e9tico\u00a0conc reto\u00a0subyacente306,307.\u00a0As\u00ed,\u00a0las\u00a0\ndeficiencias\u00a0de\u00a0 CD40L\u00a0y\u00a0CD40\u00a0afectan\u00a0adem\u00e1s\u00a0de\u00a0a\u00a0la\u00a0producci\u00f3n\u00a0de\u00a0Acs\u00a0de\u00a0tipo\u00a0IgG,\u00a0IgA\u00a0e\u00a0Ig E,\u00a0\u00a0a\u00a0\nla\u00a0inmunidad\u00a0celular306,\u00a0por\u00a0lo\u00a0que\u00a0suelen\u00a0tener\u00a0una\u00a0cl\u00ednica\u00a0m\u00e1s\u00a0severa,\u00a0incluyendo\u00a0ci topenias\u00a0de\u00a0\ndistintas\u00a0l\u00edneas\u00a0(sobre\u00a0todo\u00a0neutropenia)\u00a0asociadas\u00a0a\u00a0infeccion es\u00a0oportunistas317,319.\u00a0De\u00a0igual\u00a0Introducci\u00f3n \n\u2010\u00a051\u00a0\u2010\u00a0\n\u00a0modo,\u00a0las\u00a0mutaciones\u00a0en\u00a0 NEMO\u00a0e\u00a0IKBA\u00a0tambi\u00e9n\u00a0se\u00a0caracterizan\u00a0por\u00a0a sociarse\u00a0a\u00a0infecciones\u00a0por\u00a0\ng\u00e9rmenes\u00a0oportunistas,\u00a0adem\u00e1s\u00a0de\u00a0 alteraciones\u00a0en\u00a0la\u00a0piel\u00a0(e.g.\u00a0 displasia\u00a0ectod\u00e9rmica),\u00a0el\u00a0pelo\u00a0y\u00a0\nlos\u00a0dientes\u00a0(e.g.\u00a0dientes\u00a0c\u00f3nicos)306,307,310.\u00a0Por\u00a0el\u00a0contrario,\u00a0en\u00a0los\u00a0s\u00edndromes\u00a0h\u00edper\u2010IgM\u00a0asociados\u00a0\na\u00a0mutaciones\u00a0en\u00a0los\u00a0genes\u00a0 AID\u00a0y\u00a0UNG,\u00a0las\u00a0alteraciones\u00a0que\u00a0afectan\u00a0a\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inmune \u00a0\ne s t \u00e1 n \u00a0r e s t r i n g i d a s \u00a0a \u00a0l o s \u00a0l i n f o c i t o s \u00a0B , \u00a0a s o c i \u00e1 n d o s e \u00a0c l \u00ed n i c a m e n t e \u00a0a \u00a0i n f e c c i o n e s \u00a0r e s p i r a t o r i a s \u00a0\nrecurrentes,\u00a0linfadenopat\u00eda\u00a0y\u00a0aut oinmunidad,\u00a0siendo\u00a0las\u00a0infecci ones\u00a0por\u00a0g\u00e9rmenes\u00a0oportunistas\u00a0\ny\u00a0la\u00a0neutropenia\u00a0mucho\u00a0menos\u00a0frecuentes307,320.\u00a0Finalmente,\u00a0los\u00a0dos\u00a0pacientes\u00a0identificados\u00a0\nhasta\u00a0 la\u00a0 fecha\u00a0 que\u00a0 presentaban\u00a0 mutaciones\u00a0 en \u00a0 INO80\u00a0s e \u00a0c a r a c t e r i z a b a n \u00a0p o r \u00a0p r e s e n t a r \u00a0\ninfecciones\u00a0bacterianas,\u00a0mientras\u00a0que\u00a0los\u00a0defectos\u00a0en\u00a0el\u00a0gen\u00a0 MSH6\u00a0se\u00a0han\u00a0relacionado\u00a0con\u00a0una\u00a0\nhistoria\u00a0personal\u00a0y/o\u00a0familiar\u00a0de\u00a0c\u00e1ncer307.\u00a0\nEl\u00a0tratamiento\u00a0habitual\u00a0en\u00a0pacientes\u00a0con\u00a0s\u00edndromes\u00a0h\u00edper\u2010IgM\u00a0es \u00a0la\u00a0terapia\u00a0con\u00a0Igs\u00a0de\u00a0\nsustituci\u00f3n,\u00a0y\u00a0en\u00a0funci\u00f3n\u00a0del\u00a0grado\u00a0de\u00a0gravedad\u00a0de\u00a0las\u00a0infeccio nes,\u00a0el\u00a0uso\u00a0profil\u00e1ctico\u00a0de\u00a0\nantibi\u00f3ticos;\u00a0 no\u00a0 obstante,\u00a0 estudios\u00a0 m\u00e1s\u00a0 recientes\u00a0 sugieren\u00a0 que\u00a0 el\u00a0 trasplante\u00a0 de\u00a0 c\u00e9lulas\u00a0\nprogenitoras\u00a0hematopoy\u00e9ticas\u00a0pod r\u00eda\u00a0mejorar\u00a0de\u00a0forma\u00a0significat iva\u00a0la\u00a0supervivencia\u00a0global\u00a0de\u00a0\nestos\u00a0pacientes,\u00a0especialmente\u00a0s i\u00a0se\u00a0realiza\u00a0antes\u00a0de\u00a0los\u00a05\u00a0a\u00f1o s319,321,322.\u00a0\u00a0\nFenot\u00edpicamente,\u00a0los\u00a0pacientes\u00a0con\u00a0s\u00edndrome\u00a0h\u00edper\u2010IgM\u00a0se\u00a0caract erizan\u00a0por\u00a0presentar\u00a0un\u00a0\nn\u00famero\u00a0absoluto\u00a0de\u00a0linfocitos\u00a0B\u00a0en\u00a0SP\u00a0dentro\u00a0de\u00a0los\u00a0valores\u00a0nor males,\u00a0pero\u00a0cifras\u00a0muy\u00a0reducidas\u00a0\nde\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0CD27+\u00a0con\u00a0cambio\u00a0de\u00a0isotipo323.\u00a0La\u00a0distribuci\u00f3n\u00a0de\u00a0las\u00a0dem\u00e1s\u00a0\nsubpoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0var\u00eda\u00a0seg\u00fan\u00a0el\u00a0defect o\u00a0gen\u00e9tico.\u00a0As\u00ed,\u00a0mientras\u00a0que\u00a0\nlos\u00a0pacientes\u00a0con\u00a0deficiencia\u00a0de\u00a0 AID\u00a0tienen\u00a0cifras\u00a0globales\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0CD27+\u00a0\nnormales320,\u00a0 aquellos\u00a0 casos\u00a0 que\u00a0 presentan\u00a0 mutaciones\u00a0 en\u00a0 CD40L\u00a0 generalmente\u00a0 muestran\u00a0\nvalores\u00a0reducidos\u00a0de\u00a0todas\u00a0las\u00a0subpoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0d e\u00a0memoria\u00a0CD27+,\u00a0con\u00a0y\u00a0sin\u00a0\ncambio\u00a0de\u00a0isotipo;\u00a0no\u00a0obstante,\u00a0en\u00a0algunos\u00a0pacientes\u00a0con\u00a0mutaci ones\u00a0en\u00a0CD40L\u00a0se\u00a0han\u00a0descrito\u00a0\ncifras\u00a0normales\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0IgM++D+CD27+324,\u00a0y\u00a0en\u00a0general\u00a0tambi\u00e9n\u00a0presentan\u00a0\ncifras\u00a0normales\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0CD27\u2010\u00a0IgA+110,111.\u00a0\n\u00a0Introducci\u00f3n \n\u2010\u00a052\u00a0\u2010\u00a0\n\u00a04.4.\u00a0Deficiencia\u00a0funcional\u00a0B,\u00a0de\u00a0isotipo\u00a0de\u00a0cadenas\u00a0pesadas\u00a0o\u00a0d e\u00a0cadenas\u00a0\nligeras\u00a0de\u00a0inmunoglobulina\u00a0\nDentro\u00a0de\u00a0este\u00a0grupo\u00a0de\u00a0IDP\u2010Ac\u00a0se\u00a0engloban\u00a0defectos\u00a0restringido s\u00a0a\u00a0un\u00a0isotipo\u00a0y/o\u00a0subclase\u00a0\nconcreta\u00a0de\u00a0Ig,\u00a0una\u00a0cadena\u00a0ligera\u00a0de\u00a0Ig\u00a0en\u00a0particular,\u00a0o\u00a0a\u00a0Acs\u00a0 espec\u00edficos\u00a0de\u00a0un\u00a0determinado\u00a0\npat\u00f3geno,\u00a0siendo\u00a0las\u00a0manifestaci ones\u00a0cl\u00ednicas\u00a0generalmente\u00a0meno s\u00a0severas\u00a0que\u00a0las\u00a0descritas\u00a0\nanteriormente\u00a0para\u00a0otros\u00a0subtipos\u00a0de\u00a0IDP\u2010Ac.\u00a0Habitualmente,\u00a0en\u00a0 estos\u00a0subgrupos\u00a0de\u00a0pacientes\u00a0\nel\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0circul antes\u00a0y\u00a0sus\u00a0principales\u00a0compart imentos\u00a0madurativos,\u00a0est\u00e1n\u00a0\ndentro\u00a0de\u00a0los\u00a0l\u00edmites\u00a0de\u00a0la\u00a0normalidad.\u00a0\n4.4.1.\u00a0D\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA \u00a0\nE l \u00a0d \u00e9 f i c i t \u00a0s e l e c t i v o \u00a0d e \u00a0I g A \u00a0f u e \u00a0d e s c r i t o \u00a0p o r \u00a0p r i m e r a \u00a0v e z \u00a0e n \u00a01 9 6 1\u00a0 en\u00a0 dos\u00a0 individuos\u00a0\ncl\u00ednicamente\u00a0asintom\u00e1ticos,\u00a0lo\u00a0q ue\u00a0llev\u00f3\u00a0a\u00a0la\u00a0conclusi\u00f3n\u00a0de\u00a0que \u00a0la\u00a0IgA\u00a0podr\u00eda\u00a0no\u00a0ser\u00a0necesaria\u00a0en\u00a0\nalgunos\u00a0individuos216,325.\u00a0Sin\u00a0embargo,\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0una \u00a0serie\u00a0m\u00e1s\u00a0amplia\u00a0de\u00a0pacientes \u00a0en\u00a01971,\u00a0\nmostr\u00f3\u00a0 que\u00a0 estos\u00a0 presentaban\u00a0 mayor\u00a0 incidencia\u00a0 de\u00a0 infecciones216,326\u00a0 y\u00a0 de\u00a0 enfermedades\u00a0\nautoinmunes216,327.\u00a0\n4.4.1.1.\u00a0Diagn\u00f3stico\u00a0del\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0\nLa\u00a0ESID\u00a0establece\u00a0como\u00a0criterios\u00a0para\u00a0el\u00a0diagn\u00f3stico\u00a0del\u00a0d\u00e9fici t\u00a0selectivo\u00a0de\u00a0IgA\u00a0 i)\u00a0la\u00a0\npresencia\u00a0de\u00a0mayor\u00a0susceptibilidad\u00a0a\u00a0infecciones\u00a0y/o\u00a0autoinmuni dad,\u00a0o\u00a0la\u00a0existencia\u00a0de\u00a0un\u00a0\nfamiliar\u00a0afectado\u00a0por\u00a0una\u00a0inmunodeficiencia\u00a0similar,\u00a0ii)\u00a0nivele s\u00a0de\u00a0IgA\u00a0s\u00e9rica\u00a0<7\u00a0mg/dl\u00a0con\u00a0\nconcentraciones\u00a0normales\u00a0en\u00a0suero\u00a0de\u00a0IgG\u00a0e\u00a0IgM\u00a0asociados\u00a0a\u00a0iii) \u00a0una\u00a0respuesta\u00a0adecuada\u00a0a\u00a0\nvacunaci\u00f3n,\u00a0 y\u00a0 iv)\u00a0 edad\u00a0 \u22654\u00a0 a\u00f1os,\u00a0 v)\u00a0 una\u00a0 vez\u00a0 se\u00a0 hayan\u00a0 excluido\u00a0 ot ras\u00a0 posibles\u00a0 causas\u00a0 de\u00a0\nhipogammaglobulinemia11.\u00a0Sin\u00a0embargo,\u00a0aunque\u00a0estos\u00a0pacientes\u00a0pueden\u00a0tener\u00a0asociado\u00a0un\u00a0\naumento\u00a0de\u00a0las\u00a0infecciones\u00a0bacte rianas\u00a0y\u00a0de\u00a0las\u00a0enfermedades\u00a0au toinmunes,\u00a0gran\u00a0parte\u00a0de\u00a0ellos\u00a0\nson,\u00a0al\u00a0menos\u00a0aparentemente,\u00a0asintom\u00e1ticos13,328,329.\u00a0As\u00ed,\u00a0a\u00a0diferencia\u00a0de\u00a0la\u00a0ESID,\u00a0la\u00a0IUIS\u00a0no\u00a0\nestablece\u00a0 como\u00a0 requisito\u00a0 para\u00a0 el\u00a0 diagn\u00f3stico\u00a0 de\u00a0 d\u00e9ficit\u00a0 selecti v o \u00a0d e \u00a0I g A \u00a0l a \u00a0e x i s t e n c i a \u00a0d e \u00a0\nmanifestaciones\u00a0cl\u00ednicas\u00a0o\u00a0antecedentes\u00a0familiares,\u00a0si\u00a0bien\u00a0rec onoce\u00a0que\u00a0ambos\u00a0pueden\u00a0estar\u00a0Introducci\u00f3n \n\u2010\u00a053\u00a0\u2010\u00a0\n\u00a0relacionados\u00a0con\u00a0la\u00a0enfermedad209,330.\u00a0En\u00a0la\u00a0Tabla\u00a05\u00a0se\u00a0muestran\u00a0las\u00a0principales\u00a0diferencias\u00a0entre\u00a0\nlos\u00a0criterios\u00a0propuestos\u00a0por\u00a0la\u00a0ESID\u00a0y\u00a0la\u00a0IUIS\u00a0para\u00a0el\u00a0diagn\u00f3st ico\u00a0de\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA.\u00a0\nTabla\u00a05.\u00a0Principales\u00a0diferencias\u00a0entre\u00a0los\u00a0criterios\u00a0propuestos \u00a0por\u00a0la\u00a0ESID\u00a0y\u00a0por\u00a0la\u00a0IUIS\u00a0para\u00a0el\u00a0\ndiagn\u00f3stico\u00a0de\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA.\u00a0\nInformaci\u00f3n\u00a0modificada\u00a0de\u00a0Picard\u00a0et\u00a0al.209\u00a0y\u00a0Abinun\u00a0et\u00a0al.11.\u00a0ESID,\u00a0Sociedad\u00a0Europea\u00a0de\u00a0Inmunodeficiencias;\u00a0IUIS,\u00a0Uni\u00f3n\u00a0\ninternacional\u00a0de\u00a0Sociedades\u00a0de\u00a0Inmunolog\u00eda. \u00a0\n\u00a0\n4.4.1.2.\u00a0Epidemiolog\u00eda,\u00a0caracter \u00edsticas\u00a0cl\u00ednicas\u00a0y\u00a0tratamiento\u00a0 del\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA \u00a0\nEl\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0es\u00a0la\u00a0IDP\u00a0m\u00e1s\u00a0com\u00fan\u00a0en\u00a0los\u00a0pa\u00edses\u00a0o ccidentales,\u00a0afectando\u00a0\naproximadamente\u00a0a\u00a01\u00a0de\u00a0cada\u00a0600\u00a0individuos,\u00a0aunque\u00a0la\u00a0prevalenc ia\u00a0var\u00eda\u00a0entre\u00a0diferentes\u00a0\ngrupos\u00a0\u00e9tnicos,\u00a0desde\u00a01:18.550\u00a0sujetos\u00a0en\u00a0Jap\u00f3n331,332\u00a0hasta\u00a01:163\u00a0en\u00a0Espa\u00f1a332,333.\u00a0En\u00a0este\u00a0\nsentido,\u00a0hay\u00a0que\u00a0tener\u00a0en\u00a0cuenta\u00a0adem\u00e1s\u00a0que,\u00a0debido\u00a0a\u00a0que\u00a0mucho s\u00a0casos\u00a0son\u00a0cl\u00ednicamente\u00a0\nasintom\u00e1ticos\u00a0y\u00a0no\u00a0existen\u00a0programas\u00a0de\u00a0rastreo\u00a0diagn\u00f3stico\u00a0a\u00a0n ivel\u00a0poblacional,\u00a0la\u00a0prevalencia\u00a0\npodr\u00eda\u00a0ser\u00a0a\u00fan\u00a0mayor13.\u00a0En\u00a0t\u00e9rminos\u00a0globales,\u00a0se\u00a0estim a\u00a0que\u00a0hasta\u00a0dos\u00a0tercios\u00a0de\u00a0los\u00a0 sujetos\u00a0que\u00a0\npresentan\u00a0ausencia\u00a0de\u00a0IgA\u00a0en\u00a0suero\u00a0son\u00a0asintom\u00e1ticos,\u00a0lo\u00a0cual\u00a0r esulta\u00a0dif\u00edcil\u00a0de\u00a0explicar\u00a0de\u00a0\nacuerdo\u00a0con\u00a0el\u00a0papel\u00a0de\u00a0los\u00a0Acs\u00a0de\u00a0tipo\u00a0IgA\u00a0en\u00a0la\u00a0defensa\u00a0(inmu ne)\u00a0en\u00a0mucosas.\u00a0Sin\u00a0embargo,\u00a0\nesto\u00a0podr\u00eda\u00a0deberse\u00a0a\u00a0que,\u00a0en\u00a0est os\u00a0sujetos,\u00a0existe\u00a0una\u00a0producc i\u00f3n\u00a0residual\u00a0de\u00a0IgA\u00a0a\u00a0nivel\u00a0de\u00a0las\u00a0\nmucosas13,326,334,\u00a0o\u00a0bien,\u00a0a\u00a0un\u00a0mecanismo\u00a0compensatorio\u00a0mediado\u00a0por\u00a0IgM329.\u00a0De\u00a0hecho,\u00a0varios\u00a0\nestudios\u00a0han\u00a0demostrado\u00a0la\u00a0exist encia\u00a0de\u00a0un\u00a0incremento\u00a0de\u00a0IgM\u00a0e \u00a0IgG\u00a0en\u00a0el\u00a0tejido\u00a0intestinal335\u2013\u00a0 Criterios\u00a0diagn\u00f3sticos \u00a0\n\u00a0ESID\u00a0\n(2017)\u00a0IUIS\u00a0\n(2017)\u00a0\nNiveles\u00a0s\u00e9ricos\u00a0de\u00a0Ig\u00a0IgA\u00a0<7\u00a0mg/dl\u00a0\nIgM\u00a0e\u00a0IgG\u00a0y\u00a0sus\u00a0subclases\u00a0normales\u00a0IgA\u00a0indetectable\u00a0(<7\u00a0mg/dl)\u00a0o\u00a0baja\u00a0\nIgM\u00a0e\u00a0IgG\u00a0y\u00a0sus\u00a0subclases\u00a0normales\u00a0\nEdad\u00a0(minima)\u00a0 \u22654\u00a0a\u00f1os\u00a0 No\u00a0establece\u00a0\nCaracter\u00edsticas\u00a0cl\u00ednicas\u00a0\u22651\u00a0de\u00a03\u00a0criterios:\u00a0\n\u00a0\n\u2212Susceptibilidad\u00a0a\u00a0infecciones\u00a0\n\u2212Autoinmunidad\u00a0\n\u2212Antecedentes\u00a0familiares\u00a0No\u00a0requerido\u00a0\nCaracter\u00edsticas\u00a0biol\u00f3gicas \u00a0Respuesta\u00a0a\u00a0vacunaci\u00f3n\u00a0normal\u00a0 Respuesta\u00a0a\u00a0vacunaci\u00f3n\u00a0normal\u00a0\nCriterios\u00a0de\u00a0exclusi\u00f3n \u00a0 ID\u00a0secundaria\u00a0a\u00a0otra\u00a0causa\u00a0 I D\u00a0secundaria\u00a0a\u00a0otra\u00a0causa\u00a0Introducci\u00f3n \n\u2010\u00a054\u00a0\u2010\u00a0\n\u00a0337,\u00a0las\u00a0secreciones\u00a0nasales44,338,339,\u00a0la\u00a0saliva44,340\u00a0y\u00a0el\u00a0calostro341\u00a0de\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0\nde\u00a0IgA,\u00a0si\u00a0bien\u00a0dicho\u00a0incremento\u00a0no\u00a0se\u00a0ha\u00a0podido\u00a0confirmar\u00a0que\u00a0 est\u00e9\u00a0relacionado\u00a0con\u00a0la\u00a0ausencia\u00a0\nde\u00a0manifestaciones\u00a0cl\u00ednicas338\u2013340,342.\u00a0\n\u00a0 Las\u00a0 infecciones\u00a0 respiratorias\u00a0 son\u00a0 la\u00a0 manifestaci\u00f3n\u00a0 cl\u00ednica\u00a0 m\u00e1s \u00a0f r e c u e n t e \u00a0e n t r e \u00a0l o s \u00a0\npacientes\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA329,343\u2013345,\u00a0estando\u00a0presentes\u00a0en\u00a040\u201090%\u00a0de\u00a0los\u00a0casos\u00a0\nsintom\u00e1ticos13;\u00a0 frecuentemente,\u00a0 estas\u00a0 infecciones\u00a0 est\u00e1n\u00a0 causadas\u00a0 por\u00a0 H.\u00a0 influenzae \u00a0y \u00a0S.\u00a0\npneumoniae\u00a0 y\u00a0suelen\u00a0resolverse\u00a0sin\u00a0complicaciones\u00a0serias,\u00a0si\u00a0bien\u00a0en\u00a0algun os\u00a0casos\u00a0pueden\u00a0\nprovocar\u00a0lesi\u00f3n\u00a0tisular\u00a0(i.e.\u00a0bronquiectasias)346\u2013348.\u00a0As\u00ed\u00a0mismo,\u00a0los\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0de\u00a0IgA\u00a0\npresentan\u00a0tambi\u00e9n\u00a0con\u00a0relativa\u00a0frecuencia\u00a0otras\u00a0infecciones344,349,\u00a0especialmente\u00a0infecciones\u00a0\ngastrointestinales\u00a0causadas\u00a0por \u00a0G.\u00a0lamblia350.\u00a0Recientemente,\u00a0en\u00a0un\u00a0estudio\u00a0retrospectivo\u00a0\nllevado\u00a0a\u00a0cabo\u00a0en\u00a0Suecia\u00a0sobre\u00a02.100\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0sele ctivo\u00a0de\u00a0IgA\u00a0y\u00a018.653\u00a0donantes\u00a0\nsanos,\u00a0se\u00a0observ\u00f3\u00a0que,\u00a0adem\u00e1s\u00a0de\u00a0las\u00a0infecciones\u00a0respiratorias\u00a0 y\u00a0gastrointestinales351,\u00a0estos\u00a0\npacientes\u00a0presentaban\u00a0tambi\u00e9n\u00a0una\u00a0mayor\u00a0frecuencia\u00a0de\u00a0infeccion es\u00a0cut\u00e1neas\u00a0(4,1%\u00a0 vs.\u00a02,2%),\u00a0\ngenitourinarias\u00a0(6,1%\u00a0 vs.\u00a03,4%)\u00a0y\u00a0de\u00a0sepsis\u00a0(1,5%\u00a0 vs.\u00a00,45%)351.\u00a0Otras\u00a0patolog\u00edas\u00a0relacionadas\u00a0con\u00a0\nla\u00a0desregulaci\u00f3n\u00a0del\u00a0sistema\u00a0inmune\u00a0tambi\u00e9n\u00a0se\u00a0detectan\u00a0en\u00a0una\u00a0 frecuencia\u00a0alta,\u00a0como\u00a0son\u00a0la\u00a0\nalergia\u00a0(13\u201043%)343\u2013345,352\u00a0y\u00a0la\u00a0autoinmunidad\u00a0(11\u201027%)343\u2013345,352,\u00a0especialmente\u00a0enfermedad\u00a0\nceliaca,\u00a0diabetes\u00a0mellitus\u00a0tipo\u00a01,\u00a0enfermedad\u00a0inflamatoria\u00a0inte stinal,\u00a0tiroiditis\u00a0y/o\u00a0vit\u00edligo353.\u00a0El\u00a0\ntratamiento\u00a0de\u00a0los\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0es\u00a0ex clusivamente\u00a0sintom\u00e1tico13,\u00a0pero\u00a0\nse\u00a0recomienda\u00a0el\u00a0seguimiento\u00a0aproximadamente\u00a0cada\u00a06\u00a0meses13,\u00a0con\u00a0el\u00a0objetivo\u00a0de\u00a0evaluar\u00a0las\u00a0\nposibles\u00a0complicaciones,\u00a0as\u00ed\u00a0como\u00a0la\u00a0(posible)\u00a0evoluci\u00f3n\u00a0a\u00a0IDVC ,\u00a0observada\u00a0en\u00a0un\u00a0n\u00famero\u00a0\nreducido\u00a0de\u00a0casos354\u2013356.\u00a0\n\u00a0\n4.4.1.3.\u00a0Alteraciones\u00a0gen\u00e9ticas\u00a0 asociadas\u00a0al\u00a0d\u00e9ficit\u00a0selectivo\u00a0 de\u00a0IgA\u00a0\nA\u00a0pesar\u00a0de\u00a0que\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0pacientes\u00a0que\u00a0presentan\u00a0d\u00e9fici t\u00a0selectivo\u00a0de\u00a0IgA\u00a0no\u00a0\nrefieren\u00a0 antecedentes\u00a0 familiares\u00a0 (d\u00e9ficit\u00a0 selectivo\u00a0 de\u00a0 IgA\u00a0 espo r\u00e1dico),\u00a0 se\u00a0 estima\u00a0 que\u00a0 en\u00a0Introducci\u00f3n \n\u2010\u00a055\u00a0\u2010\u00a0\n\u00a0alrededor\u00a0del\u00a020%\u00a0de\u00a0los\u00a0casos\u00a0la\u00a0enfermedad\u00a0ser\u00eda\u00a0heredable,\u00a0s iendo\u00a0el\u00a0riesgo\u00a0de\u00a0padecer\u00a0la\u00a0\nenfermedad\u00a050\u00a0veces\u00a0superior\u00a0cua ndo\u00a0existen\u00a0antecedentes\u00a0famili ares357\u2013360.\u00a0\u00a0\nHasta\u00a0la\u00a0fecha,\u00a0no\u00a0se\u00a0ha\u00a0identificado\u00a0una\u00a0causa\u00a0gen\u00e9tica\u00a0\u00fanica\u00a0 para\u00a0el\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0\nIgA.\u00a0 Sin\u00a0 embargo,\u00a0 se\u00a0 han\u00a0 definido\u00a0 algunos\u00a0 loci\u00a0 relacionados\u00a0 con \u00a0u n a \u00a0m a y o r \u00a0o \u00a0m e n o r \u00a0\nsusceptibilidad\u00a0 a\u00a0 padecer\u00a0 la\u00a0 enfermedad,\u00a0 destacando\u00a0 la\u00a0 asociaci \u00f3n\u00a0 descrita\u00a0 entre\u00a0 d\u00e9ficit\u00a0\nselectivo\u00a0de\u00a0IgA\u00a0y\u00a0genes\u00a0 HLA361\u2013364.\u00a0En\u00a0este\u00a0sentido,\u00a0Ferreira\u00a0et\u00a0al.365\u00a0observaron\u00a0en\u00a0una\u00a0serie\u00a0de\u00a0\n772\u00a0pacientes\u00a0y\u00a01.976\u00a0donantes\u00a0san os\u00a0procedentes\u00a0de\u00a0Espa\u00f1a,\u00a0Isl andia,\u00a0Suecia\u00a0y\u00a0Finlandia,\u00a0que\u00a0\nlos\u00a0haplotipos\u00a0 HLA\u2010DQB1*0201,\u00a0HLA\u2010DRB1*0301 \u00a0y\u00a0HLA\u2010DRB1*0701 \u00a0confieren\u00a0un\u00a0mayor\u00a0riesgo\u00a0\nde\u00a0padecer\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA,\u00a0mientras\u00a0que\u00a0el\u00a0haplotipo\u00a0 HLA\u2010DRB1*1501 \u00a0tiene\u00a0un\u00a0efecto\u00a0\nprotector.\u00a0Curiosamente,\u00a0estos\u00a0haplotipos\u00a0tambi\u00e9n\u00a0se\u00a0han\u00a0relaci onado\u00a0con\u00a0enfermedades\u00a0\nautoinmunes\u00a0(frecuentemente)\u00a0asociadas\u00a0a\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0I gA357,366.\u00a0Adem\u00e1s,\u00a0en\u00a0los\u00a0\u00faltimos\u00a0\na\u00f1os\u00a0se\u00a0han\u00a0identificado\u00a0variantes\u00a0en\u00a0otros\u00a0genes\u00a0a\u00a0parte\u00a0de\u00a0lo s\u00a0genes\u00a0HLA,\u00a0relacionadas\u00a0con\u00a0\nd\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA;\u00a0entre\u00a0ellos\u00a0se\u00a0incluyen\u00a0los\u00a0genes\u00a0 ATG13\u2010AMBRA1 \u00a0y\u00a0AHI1,\u00a0asociados\u00a0a\u00a0\nmayor\u00a0riesgo\u00a0de\u00a0padecer\u00a0la\u00a0enfermedad,\u00a0y\u00a0 IFIH1,\u00a0PVT1 \u00a0y\u00a0CLEC16A,\u00a0con\u00a0un\u00a0efecto\u00a0protector367,368.\u00a0\nTodos\u00a0estos\u00a0genes,\u00a0excepto\u00a0 ATG13\u2010AMBRA1,\u00a0 se\u00a0han\u00a0relacionado\u00a0tambi\u00e9n\u00a0con\u00a0una\u00a0mayor\u00a0o\u00a0\nmenor\u00a0susceptibilidad\u00a0a\u00a0padecer\u00a0 diferentes\u00a0enfermedades\u00a0autoimu nes367.\u00a0\nAl\u00a0igual\u00a0que\u00a0en\u00a0la\u00a0IDVC,\u00a0se\u00a0han\u00a0identificado\u00a0en\u00a0un\u00a0subgrupo\u00a0de\u00a0 pacientes,\u00a0mutaciones\u00a0en \u00a0\nTACI369,370,\u00a0consider\u00e1ndose\u00a0actualmente\u00a0que\u00a0este\u00a0constituye\u00a0un\u00a0gen\u00a0cuya\u00a0alte raci\u00f3n\u00a0favorece\u00a0\nuna\u00a0mayor\u00a0susceptibilidad\u00a0a\u00a0padecer\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA371.\u00a0De\u00a0hecho,\u00a0en\u00a0el\u00a0caso\u00a0del\u00a0d\u00e9ficit\u00a0\nselectivo\u00a0de\u00a0IgA,\u00a0el\u00a0papel\u00a0de\u00a0las\u00a0mutaciones\u00a0de\u00a0 TACI\u00a0es\u00a0muy\u00a0controvertido,\u00a0ya\u00a0que\u00a0se\u00a0cree\u00a0que\u00a0\npodr\u00eda\u00a0estar\u00a0presente\u00a0\u00fanicamente\u00a0en\u00a0aquellos\u00a0casos\u00a0que\u00a0evolucio nar\u00e1n\u00a0a\u00a0IDVC357,372.\u00a0Adem\u00e1s\u00a0de\u00a0\nlas\u00a0mutaciones\u00a0en\u00a0 TACI,\u00a0se\u00a0han\u00a0identificado\u00a0mutaciones\u00a0 en\u00a0otros\u00a0genes\u00a0relacionadas\u00a0con \u00a0otras\u00a0\ninmunodeficiencias,\u00a0como\u00a0los\u00a0genes\u00a0 RAG1373,\u00a0CD27371\u00a0y\u00a0LRBA374;\u00a0no\u00a0obstante,\u00a0el\u00a0seguimiento\u00a0\ncl\u00ednico\u00a0de\u00a0estos\u00a0casos\u00a0ha\u00a0demostrado\u00a0que\u00a0muchos\u00a0de\u00a0ellos,\u00a0en\u00a0re alidad\u00a0correspond\u00edan\u00a0a\u00a0IDP\u2010Ac\u00a0\nm\u00e1s\u00a0severas\u00a0(e.g.\u00a0IDVC)\u00a0que\u00a0debutaban\u00a0como\u00a0un\u00a0d\u00e9ficit\u00a0de\u00a0IgA\u00a0a\u00a0 nivel\u00a0s\u00e9rico.\u00a0Ante\u00a0estos\u00a0hallazgos\u00a0\npodemos\u00a0concluir\u00a0que,\u00a0aunque\u00a0se\u00a0han\u00a0descrito\u00a0algunas\u00a0mutaciones \u00a0en\u00a0genes\u00a0asociados\u00a0a\u00a0otras\u00a0Introducci\u00f3n \n\u2010\u00a056\u00a0\u2010\u00a0\n\u00a0inmunodeficiencias\u00a0en\u00a0pacientes\u00a0que\u00a0aparentemente\u00a0presentan\u00a0d\u00e9f icit\u00a0selectivo\u00a0de\u00a0IgA,\u00a0es\u00a0\nposible\u00a0que\u00a0en\u00a0muchos\u00a0casos\u00a0un\u00a0seguimiento\u00a0cl\u00ednico\u00a0m\u00e1s\u00a0estrecho \u00a0termine\u00a0por\u00a0demostrar\u00a0que\u00a0\nse\u00a0 trata\u00a0 de\u00a0 una\u00a0 IDP\u2010Ac\u00a0 m\u00e1s\u00a0 sever a,\u00a0 quedando\u00a0 por\u00a0 establecer\u00a0 el\u00a0 v erdadero\u00a0 mecanismo\u00a0\n(poli)g\u00e9nico\u00a0de\u00a0esta\u00a0enfermedad.\u00a0\n\u00a0\n4.4.1.4.\u00a0Alteraciones\u00a0en\u00a0poblaci ones\u00a0de\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inm une\u00a0en\u00a0el\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0\nIgA\u00a0\nL a \u00a0i n f o r m a c i \u00f3 n \u00a0e x i s t e n t e \u00a0h a s t a \u00a0e l \u00a0m o m e n t o \u00a0d e \u00a0i n i c i a r \u00a0e s t e \u00a0t r a b a j o \u00a0a c e r c a \u00a0d e \u00a0l a s \u00a0\nalteraciones\u00a0recurrentes\u00a0en\u00a0las\u00a0distintas\u00a0poblaciones\u00a0de\u00a0linfoc itos\u00a0B\u00a0de\u00a0SP\u00a0de\u00a0pacientes\u00a0con\u00a0\nd\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA,\u00a0era\u00a0muy\u00a0limitada\u00a0y\u00a0con\u00a0frecuencia\u00a0con trovertida.\u00a0As\u00ed,\u00a0en\u00a0ninguno\u00a0de\u00a0los\u00a0\nestudios\u00a0realizados\u00a0(sobre\u00a0un\u00a0to tal\u00a0de\u00a0286\u00a0pacientes)\u00a0se\u00a0han\u00a0ob servado\u00a0alteraciones\u00a0en\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0inmaduros/transicionales\u00a0o\u00a0na\u00efve375\u2013380,\u00a0ni\u00a0en\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0IgM++D+375\u2013\n380.\u00a0Por\u00a0el\u00a0contrario,\u00a0varios\u00a0estudios\u00a0han\u00a0referido\u00a0la\u00a0existencia\u00a0 de\u00a0una\u00a0reducci\u00f3n\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo,\u00a0en\u00a0una\u00a0proporci\u00f3 n\u00a0variable,\u00a0pero\u00a0minoritaria\u00a0\n(6%\u201025%)378,379\u00a0de\u00a0los\u00a0casos,\u00a0y\u00a0claramente\u00a0inferior\u00a0a\u00a0la\u00a0observada\u00a0entre\u00a0pacie ntes\u00a0con\u00a0IDVC\u00a0(56\u2010\n81%)286\u2013290.\u00a0Esta\u00a0alteraci\u00f3n\u00a0se\u00a0ha\u00a0relacionado\u00a0en\u00a0una\u00a0serie\u00a0limitada\u00a0de\u00a0pa cientes\u00a0(n=28)\u00a0con\u00a0un\u00a0\ncomportamiento\u00a0cl\u00ednico\u00a0m\u00e1s\u00a0grave,\u00a0incluyendo\u00a0una\u00a0mayor\u00a0frecuenc ia\u00a0de\u00a0neumon\u00eda\u00a0(3,3%\u00a0 vs.\u00a0\n0,5%),\u00a0bronquiectasias\u00a0(57%\u00a0 vs.\u00a05%),\u00a0esplenomegalia\u00a0(43%\u00a0 vs.\u00a00%),\u00a0adenopat\u00edas\u00a0(71%\u00a0 vs.\u00a09%),\u00a0\nautoinmunidad\u00a0(57%\u00a0 vs.\u00a014%),\u00a0y\u00a0evoluci\u00f3n\u00a0a\u00a0IDVC379;\u00a0sin\u00a0embargo,\u00a03\u00a0de\u00a0los\u00a07\u00a0casos\u00a0con\u00a0n\u00fameros\u00a0\nr e d u c i d o s \u00a0d e \u00a0l i n f o c i t o s \u00a0B \u00a0d e \u00a0m e m o r i a \u00a0c o n \u00a0c a m b i o \u00a0d e \u00a0i s o t i p o \u00a0e s t u diados\u00a0 en\u00a0 este\u00a0 trabajo\u00a0\npresentaban\u00a0tambi\u00e9n\u00a0cifras\u00a0s\u00e9ricas\u00a0reducidas\u00a0de\u00a0algunas\u00a0subclas es\u00a0de\u00a0IgG379,\u00a0y\u00a0no\u00a0todos\u00a0los\u00a0\nautores\u00a0han\u00a0podido\u00a0confirmar\u00a0estas\u00a0asociaciones378.\u00a0En\u00a0un\u00a0estudio\u00a0m\u00e1s\u00a0reciente,\u00a0se\u00a0ha\u00a0mostrado\u00a0\nadem\u00e1s\u00a0que\u00a0este\u00a0descenso\u00a0podr\u00eda\u00a0deberse\u00a0a\u00a0una\u00a0reducci\u00f3n\u00a0prefere ncial\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0IgA+,\u00a0que\u00a0seg\u00fan\u00a0estos\u00a0autores\u00a0solo\u00a0estar\u00edan\u00a0presentes\u00a0en\u00a0<10%\u00a0de\u00a0lo s\u00a0pacientes380.\u00a0\nA d e m \u00e1 s , \u00a0e n \u00a0l o s \u00a0p a c i e n t e s \u00a0c o n \u00a0d \u00e9 f icit\u00a0 selectivo\u00a0 de\u00a0 IgA\u00a0 tambi\u00e9n\u00a0 s e\u00a0 han\u00a0 observado\u00a0 otras\u00a0\nalteraciones\u00a0celulares\u00a0descritas\u00a0en\u00a0la\u00a0IDVC,\u00a0como\u00a0la\u00a0reducci\u00f3n\u00a0 en\u00a0SP\u00a0del\u00a0n\u00famero\u00a0de\u00a0CPs\u00a0con\u00a0Introducci\u00f3n \n\u2010\u00a057\u00a0\u2010\u00a0\n\u00a0cambio\u00a0de\u00a0isotipo\u00a0(\u22480,3%\u00a0 vs.\u00a0\u22480,5%\u00a0del\u00a0total\u00a0de\u00a0linfocitos\u00a0B\u00a0en\u00a0donantes\u00a0sanos)\u00a0o\u00a0el\u00a0aument o\u00a0del\u00a0\nn\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0CD21\u2010\u00a0circulantes\u00a0(\u22489%\u00a0 vs.\u22486%\u00a0del\u00a0total\u00a0de\u00a0linfocitos\u00a0B\u00a0en\u00a0donantes\u00a0\nsanos)378.\u00a0 No\u00a0 obstante,\u00a0 dichas\u00a0 alteraciones\u00a0 siempre\u00a0 ser\u00edan\u00a0 menos\u00a0 signifi cativas\u00a0 que\u00a0 las\u00a0\nobservadas\u00a0en\u00a0pacientes\u00a0con\u00a0IDVC,\u00a0que\u00a0de\u00a0forma\u00a0sistem\u00e1tica\u00a0(94% \u00a0de\u00a0los\u00a0casos)\u00a0carecer\u00edan\u00a0de\u00a0\nCPs\u00a0circulantes\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u00a0y\u00a0que\u00a0mostrar\u00edan\u00a0un\u00a0incre mento\u00a0relativo\u00a0mayor\u00a0de\u00a0\nlinfocitos\u00a0B\u00a0CD21\u2010\u00a0(\u224818%\u00a0del\u00a0total\u00a0de\u00a0linfocitos\u00a0B)378.\u00a0\nAl\u00a0igual\u00a0que\u00a0ocurre\u00a0con\u00a0las\u00a0alteraciones\u00a0en\u00a0los\u00a0linfocitos\u00a0B,\u00a0l a\u00a0informaci\u00f3n\u00a0disponible\u00a0acerca\u00a0\ndel\u00a0estado\u00a0y\u00a0de\u00a0las\u00a0alteraciones\u00a0de\u00a0otras\u00a0poblaciones\u00a0leucocita rias\u00a0en\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0\nselectivo\u00a0de\u00a0IgA,\u00a0es\u00a0de\u00a0momento\u00a0muy\u00a0limitada.\u00a0Aunque\u00a0algunos\u00a0au tores\u00a0no\u00a0han\u00a0identificado\u00a0\nalteraciones\u00a0en\u00a0los\u00a0linfocitos\u00a0T\u00a0de\u00a0SP\u00a0de\u00a0pacientes\u00a0con\u00a0d\u00e9ficit \u00a0selectivo\u00a0de\u00a0IgA381,\u00a0otros\u00a0han\u00a0\ndescrito\u00a0un\u00a0descenso\u00a0del\u00a0n\u00famero\u00a0de\u00a0c\u00e9lulas\u00a0T\u00a0CD4+\u00a0y\u00a0T\u00a0CD4+\u00a0na\u00efve300,375\u00a0y/o\u00a0un\u00a0aumento\u00a0de\u00a0las\u00a0\nc\u00e9lulas\u00a0T\u00a0CD4+\u00a0y\u00a0T\u00a0CD8+\u00a0de\u00a0memoria\u00a0terminalmente\u00a0diferenciadas300.\u00a0De\u00a0forma\u00a0similar\u00a0a\u00a0lo\u00a0\ndescrito\u00a0en\u00a0la\u00a0IDVC,\u00a0tambi\u00e9n\u00a0se\u00a0ha\u00a0observado\u00a0que\u00a0los\u00a0pacientes\u00a0 con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0\npueden\u00a0presentar\u00a0un\u00a0descenso\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0c\u00e9lulas\u00a0T\u00a0regulado ras,\u00a0especialmente\u00a0en\u00a0\naquellos\u00a0casos\u00a0en\u00a0los\u00a0que\u00a0existen\u00a0manifestaciones\u00a0cl\u00ednicas\u00a0de\u00a0a utoinmunidad382;\u00a0sin\u00a0embargo,\u00a0\nestos\u00a0hallazgos\u00a0no\u00a0han\u00a0podido\u00a0ser\u00a0confirmados\u00a0por\u00a0otros\u00a0autores ,\u00a0que\u00a0incluso\u00a0refieren\u00a0un\u00a0\naumento\u00a0de\u00a0estas\u00a0c\u00e9lulas300,381.\u00a0\n\u00a0\n4.4.1.5.\u00a0Alteraciones\u00a0funcionale s\u00a0asociadas\u00a0a\u00a0d\u00e9ficit\u00a0selectivo \u00a0de\u00a0IgA\u00a0\nDesde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0funcional ,\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0paciente s\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0\nmuestran\u00a0una\u00a0menor\u00a0respuesta\u00a0tras\u00a0estimulaci\u00f3n\u00a0 in\u00a0vitro\u00a0con\u00a0CpG\u00a0y/o\u00a0CD40L,\u00a0consistente\u00a0en:\u00a0i)\u00a0\nmenor\u00a0 capacidad\u00a0 de\u00a0 diferenciaci\u00f3n\u00a0 a\u00a0 CP;\u00a0 ii)\u00a0 menor\u00a0 respuesta\u00a0 pro liferativa;\u00a0 y\u00a0 iii)\u00a0 menor\u00a0\nproducci\u00f3n\u00a0 in\u00a0vitro\u00a0de\u00a0Acs\u00a0de\u00a0isotipo\u00a0IgA380,383.\u00a0Sin\u00a0embargo,\u00a0se\u00a0ha\u00a0demostrado\u00a0tambi\u00e9n\u00a0que\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0individuos\u00a0asinto m\u00e1ticos\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0 de\u00a0IgA\u00a0ser\u00edan\u00a0capaces\u00a0de\u00a0producir\u00a0\nniveles\u00a0de\u00a0IgA\u00a0similares\u00a0a\u00a0los\u00a0de \u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0donantes\u00a0 sanos,\u00a0tras\u00a0estimulaci\u00f3n\u00a0 in\u00a0vitro383.\u00a0\n\u00a0\u00a0Introducci\u00f3n \n\u2010\u00a058\u00a0\u2010\u00a0\n\u00a04.4.2.\u00a0D\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0I gG\u00a0asociado\u00a0o\u00a0no\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0I gA\u00a0\n\u00a0El\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0se\u00a0describi\u00f3\u00a0por\u00a0primera\u00a0vez\u00a0en\u00a0 1970,\u00a0en\u00a0un\u00a0grupo\u00a0de\u00a0\npacientes\u00a0con\u00a0infecciones\u00a0recurrentes\u00a0y\u00a0niveles\u00a0normales\u00a0de\u00a0IgG384.\u00a0Seg\u00fan\u00a0la\u00a0ESID,\u00a0para\u00a0el\u00a0\ndiagn\u00f3stico\u00a0de\u00a0este\u00a0subtipo\u00a0de\u00a0I DP\u2010Ac\u00a0deben\u00a0cumplirse\u00a0los\u00a0sigui entes\u00a0criterios11:\u00a0i)\u00a0presencia\u00a0de\u00a0\ninfecciones\u00a0recurrentes;\u00a0ii)\u00a0nive les\u00a0s\u00e9ricos\u00a0bajos\u00a0de\u00a0una\u00a0o\u00a0m\u00e1s \u00a0subclases\u00a0de\u00a0IgG;\u00a0iii)\u00a0niveles\u00a0s\u00e9ricos\u00a0\nde\u00a0IgG\u00a0total\u00a0e\u00a0IgM\u00a0normales;\u00a0y\u00a0iv)\u00a0respuesta\u00a0IgG\u00a0normal\u00a0a\u00a0(algu nas)\u00a0vacunas;\u00a0v)\u00a0una\u00a0vez\u00a0se\u00a0hayan\u00a0\nexcluido\u00a0defectos\u00a0en\u00a0c\u00e9lulas\u00a0T.\u00a0Sin\u00a0embargo,\u00a0al\u00a0igual\u00a0que\u00a0ocurr e\u00a0con\u00a0el\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA,\u00a0\nalgunos\u00a0sujetos\u00a0que\u00a0presentan\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0son\u00a0t otalmente\u00a0asintom\u00e1ticos214,385.\u00a0\nEn\u00a0este\u00a0sentido,\u00a0cabe\u00a0se\u00f1alar\u00a0que\u00a0dado\u00a0que\u00a0existen\u00a0cambios\u00a0en\u00a0l os\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0las\u00a0distintas\u00a0\nsubclases\u00a0de\u00a0IgG\u00a0con\u00a0la\u00a0edad\u00a0(tal\u00a0como\u00a0hemos\u00a0revisado\u00a0anteriorm ente\u00a0en\u00a0esta\u00a0introducci\u00f3n),\u00a0la\u00a0\nutilizaci\u00f3n\u00a0de\u00a0valores\u00a0de\u00a0referencia\u00a0seg\u00fan\u00a0la\u00a0edad\u00a0resulta\u00a0espe cialmente\u00a0relevante\u00a0y\u00a0necesaria\u00a0\nen\u00a0este\u00a0grupo\u00a0de\u00a0pacientes214,386.\u00a0\nEn\u00a0t\u00e9rminos\u00a0generales,\u00a0el\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0puede\u00a0est ar\u00a0asociado\u00a0o\u00a0no\u00a0a\u00a0un\u00a0\nd\u00e9ficit\u00a0de\u00a0IgA387,\u00a0consider\u00e1ndose\u00a0actualmente\u00a0ambas\u00a0entidades,\u00a0tanto\u00a0por\u00a0parte\u00a0d e\u00a0la\u00a0ESID11\u00a0\ncomo\u00a0de\u00a0la\u00a0IUIS209,\u00a0como\u00a0dos\u00a0entidades\u00a0distintas,\u00a0a\u00a0pesar\u00a0de\u00a0ser\u00a0cl\u00ednicamente\u00a0sim ilares:\u00a0a)\u00a0d\u00e9ficit\u00a0\naislado\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0y\u00a0b) \u00a0d\u00e9ficit\u00a0de\u00a0IgA\u00a0asociado\u00a0a\u00a0d\u00e9fi cit\u00a0de\u00a0subclases\u00a0de\u00a0IgG.\u00a0Aunque\u00a0no\u00a0\nse\u00a0conoce\u00a0la\u00a0prevalencia\u00a0exacta\u00a0del\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG ,\u00a0se\u00a0estima\u00a0que\u00a0el\u00a015\u201020%\u00a0de\u00a0los\u00a0\nd\u00e9ficits\u00a0de\u00a0IgA\u00a0tienen\u00a0asociado\u00a0un\u00a0d\u00e9ficit\u00a0en\u00a0una\u00a0o\u00a0m\u00e1s\u00a0subclas es\u00a0de\u00a0IgG387,388.\u00a0En\u00a0este\u00a0sentido\u00a0\nmerece\u00a0destacar\u00a0que\u00a0el\u00a0d\u00e9ficit\u00a0en\u00a0subclases\u00a0de\u00a0IgG,\u00a0adem\u00e1s\u00a0de\u00a0e star\u00a0frecuentemente\u00a0asociado\u00a0\nal\u00a0d\u00e9ficit\u00a0de\u00a0IgA,\u00a0puede\u00a0afectar\u00a0a\u00a0m\u00e1s\u00a0de\u00a0una\u00a0subclase\u00a0de\u00a0IgG388.\u00a0De\u00a0todas\u00a0las\u00a0subclases\u00a0de\u00a0IgG\u00a0la\u00a0\nque\u00a0se\u00a0ve\u00a0afectada\u00a0con\u00a0mayor\u00a0frecuencia\u00a0es\u00a0la\u00a0IgG4\u00a0(\u224841%),\u00a0segu ida\u00a0de\u00a0la\u00a0IgG2\u00a0(\u224828%)\u00a0y\u00a0la\u00a0IgG3\u00a0\n(\u224817%)214,\u00a0siendo\u00a0el\u00a0d\u00e9ficit\u00a0aislado\u00a0de\u00a0IgG1,\u00a0por\u00a0definici\u00f3n,\u00a0menos\u00a0prev alente,\u00a0debido\u00a0a\u00a0que\u00a0un\u00a0\nd\u00e9ficit\u00a0de\u00a0esta\u00a0subclase\u00a0suele\u00a0provocar\u00a0un\u00a0d\u00e9ficit\u00a0global\u00a0de\u00a0lo s\u00a0niveles\u00a0de\u00a0IgG\u00a0total214.\u00a0En\u00a0la\u00a0\nmayor\u00eda\u00a0de\u00a0individuos\u00a0sintom\u00e1tic os\u00a0que\u00a0presentan\u00a0d\u00e9ficit\u00a0de\u00a0sub clases\u00a0de\u00a0IgG\u00a0existe\u00a0un\u00a0defecto\u00a0\nde\u00a0IgG2\u00a0(combinado\u00a0o\u00a0no\u00a0con\u00a0d\u00e9ficit\u00a0de\u00a0IgA),\u00a0que\u00a0se\u00a0asocia\u00a0con\u00a0 infecciones\u00a0respiratorias\u00a0(87\u2010\n100%),\u00a0causadas\u00a0principalmente\u00a0por\u00a0 H.influenza\u00a0 y/o\u00a0S.pneumoniae389\u2013391,\u00a0debido\u00a0al\u00a0importante\u00a0Introducci\u00f3n \n\u2010\u00a059\u00a0\u2010\u00a0\n\u00a0papel\u00a0de\u00a0la\u00a0IgG2\u00a0en\u00a0la\u00a0defensa\u00a0frente\u00a0a\u00a0polisac\u00e1ridos;\u00a0adem\u00e1s,\u00a0 estos\u00a0pacientes \u00a0tambi\u00e9n\u00a0padecen\u00a0\ncon\u00a0 relativa\u00a0 frecuencia\u00a0 infecciones\u00a0 cut\u00e1neas\u00a0 (6\u20109%)392,393\u00a0y \u00a0g a s t r o i n t e s t i n a l e s \u00a0( 5 \u2010 9 % )392,393,\u00a0\nadem\u00e1s\u00a0de\u00a0enfermedades\u00a0autoinmunes\u00a0(12\u201037%)285,394,395.\u00a0\n\u00a0 Aunque\u00a0en\u00a0casos\u00a0aislados\u00a0de\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0se\u00a0han \u00a0encontrado\u00a0deleciones\u00a0\nen\u00a0las\u00a0regiones\u00a0correspondientes\u00a0del\u00a0gen\u00a0 IGHC396,397,\u00a0en\u00a0la\u00a0actualidad\u00a0seguimos\u00a0sin\u00a0conocer\u00a0el\u00a0\norigen\u00a0de\u00a0esta\u00a0inmunodeficiencia,\u00a0debido\u00a0en\u00a0parte,\u00a0al\u00a0escaso\u00a0n\u00fa mero\u00a0de\u00a0estudios\u00a0inmunol\u00f3gicos\u00a0\nrealizados\u00a0 y\u00a0 su\u00a0 prevalencia\u00a0 relativamente\u00a0 baja.\u00a0 Aun\u00a0 as\u00ed,\u00a0 recien t e m e n t e \u00a0s e \u00a0h a n \u00a0d e s c r i t o \u00a0\nalteraciones\u00a0en\u00a0las\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0similares\u00a0a\u00a0las \u00a0observados\u00a0en\u00a0la\u00a0IDVC\u00a0(descenso\u00a0\nde\u00a0c\u00e9lulas\u00a0pre\u2010CG\u00a0y\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0y\u00a0sin\u00a0cambio \u00a0de\u00a0isotipo)\u00a0en\u00a07/21\u00a0casos\u00a0\nanalizados\u00a0(30%\u00a0 vs.\u00a080%\u00a0de\u00a0los\u00a0pacientes\u00a0con\u00a0IDVC)285.\u00a0Otras\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inmune,\u00a0como\u00a0\nlas\u00a0c\u00e9lulas\u00a0NK\u00a0y\u00a0las\u00a0c\u00e9lulas\u00a0dendr\u00edticas\u00a0tambi\u00e9n\u00a0parece\u00a0que\u00a0pod r\u00edan\u00a0estar\u00a0afectadas,\u00a0al\u00a0menos\u00a0en\u00a0\nparte\u00a0de\u00a0los\u00a0pacientes\u00a0que\u00a0prese ntan\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0Ig G285.\u00a0\n\u00a0 En\u00a0aquellos\u00a0casos\u00a0que\u00a0tienen\u00a0infecciones\u00a0recurrentes\u00a0se\u00a0recomi enda\u00a0el\u00a0uso\u00a0profil\u00e1ctico\u00a0\nde\u00a0antibi\u00f3ticos385,\u00a0mientras\u00a0que\u00a0la\u00a0terapia\u00a0con\u00a0Igs\u00a0de\u00a0sustituci\u00f3n\u00a0solo\u00a0est\u00e1\u00a0indi cada\u00a0cuando\u00a0las\u00a0\nmanifestaciones\u00a0cl\u00ednicas\u00a0son\u00a0muy\u00a0severas/graves.\u00a0Adem\u00e1s,\u00a0debe\u00a0r ealizarse\u00a0un\u00a0seguimiento\u00a0\nestrecho\u00a0de\u00a0todos\u00a0esto s\u00a0pacientes,\u00a0debido\u00a0a\u00a0la\u00a0posibilidad\u00a0de\u00a0q ue\u00a0evolucionen\u00a0a\u00a0IDVC385.\u00a0\n\u00a0\n4.4.3.\u00a0Otros\u00a0d\u00e9ficits\u00a0funcionales\u00a0B,\u00a0de\u00a0 isotipo\u00a0IgM\u00a0y\u00a0de\u00a0cadena\u00a0ligera\u00a0 kappa\u00a0\n\u00a0Dentro\u00a0de\u00a0las\u00a0IDP\u2010Ac,\u00a0adem\u00e1s\u00a0de\u00a0 los\u00a0subtipos\u00a0principales\u00a0de\u00a0enf ermedades\u00a0descritas\u00a0en\u00a0\napartados\u00a0anteriores\u00a0de\u00a0esta\u00a0introducci\u00f3n,\u00a0se\u00a0incluyen\u00a0otras\u00a0en tidades\u00a0menos\u00a0prevalentes\u00a0y/o\u00a0\nde\u00a0significado\u00a0cl\u00ednico\u00a0menos\u00a0relevante,\u00a0entre\u00a0las\u00a0que\u00a0merece\u00a0de stacar\u00a0el\u00a0d\u00e9ficit\u00a0de\u00a0cadena\u00a0ligera\u00a0\nkappa,\u00a0el\u00a0d\u00e9ficit\u00a0de\u00a0Acs\u00a0espec\u00edficos,\u00a0la\u00a0hipogammaglobulinemia\u00a0 transitoria\u00a0de\u00a0la\u00a0infancia\u00a0y\u00a0el\u00a0\nd\u00e9ficit\u00a0selectivo\u00a0de\u00a0Ig,\u00a0que\u00a0revisaremos\u00a0de\u00a0forma\u00a0breve\u00a0a\u00a0conti nuaci\u00f3n.\u00a0\nD\u00e9ficit\u00a0de\u00a0cadena\u00a0ligera\u00a0kappa .\u00a0Se\u00a0trata\u00a0de\u00a0una\u00a0inmunodeficiencia\u00a0en\u00a0la\u00a0que\u00a0se\u00a0observa\u00a0\nun\u00a0uso\u00a0restringido\u00a0de\u00a0la\u00a0cadena\u00a0ligera\u00a0lambda,\u00a0debido\u00a0a\u00a0una\u00a0alt eraci\u00f3n\u00a0gen\u00e9tica\u00a0de\u00a0tipo\u00a0Introducci\u00f3n \n\u2010\u00a060\u00a0\u2010\u00a0\n\u00a0autos\u00f3mica\u00a0recesiva\u00a0en\u00a0la\u00a0regi\u00f3n\u00a0constante\u00a0de\u00a0la\u00a0cadena\u00a0ligera\u00a0 kappa\u00a0de\u00a0las\u00a0Igs398,399.\u00a0En\u00a0general,\u00a0\nlos\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0de\u00a0cadena\u00a0ligera\u00a0kappa\u00a0son\u00a0pacientes\u00a0 asintom\u00e1ticos,\u00a0aunque\u00a0en\u00a0\nocasiones\u00a0esta\u00a0alteraci\u00f3n\u00a0se\u00a0aso cia\u00a0con\u00a0otros\u00a0defectos\u00a0inmunol\u00f3 gicos,\u00a0como\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0\nIgA\u00a0y/o\u00a0autoinmunidad399,400.\u00a0\nD\u00e9ficit\u00a0de\u00a0anticuerpos\u00a0espec\u00edficos.\u00a0 Los\u00a0pacientes \u00a0que\u00a0presentan\u00a0deficiencias\u00a0de\u00a0Acs\u00a0\nespec\u00edficos\u00a0muestran\u00a0habitualmente\u00a0cifras\u00a0normales\u00a0de\u00a0todas\u00a0las \u00a0Igs\u00a0s\u00e9ricas,\u00a0asociadas\u00a0a\u00a0un\u00a0\ndefecto\u00a0en\u00a0la\u00a0respuesta\u00a0Ag\u2010espec\u00edfica,\u00a0generalmente\u00a0frente\u00a0a\u00a0po lisac\u00e1ridos388,401,\u00a0lo\u00a0cual\u00a0provoca\u00a0\nque\u00a0padezcan\u00a0infecciones\u00a0recurrentes,\u00a0habitualmente\u00a0en\u00a0forma\u00a0de \u00a0infecciones\u00a0respiratorias\u00a0de\u00a0\ntipo\u00a0bacterianas.\u00a0En\u00a0ocasiones\u00a0esta\u00a0inmunodeficiencia\u00a0se\u00a0resuel ve\u00a0con\u00a0el\u00a0tiempo,\u00a0especialmente\u00a0\ncuando\u00a0se\u00a0diagnostica\u00a0en\u00a0ni\u00f1os401.\u00a0\nHipogammaglobulinemia\u00a0 transitoria\u00a0 de\u00a0 la\u00a0 infancia . \u00a0E s t a \u00a0e n t i d a d \u00a0s e \u00a0d e f i n e \u00a0p o r \u00a0l a \u00a0\nexistencia\u00a0de\u00a0cifras\u00a0bajas\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0s\u00e9ricas\u00a0en\u00a0ni\u00f1os\u00a0a\u00a0part ir\u00a0de\u00a0los\u00a06\u00a0meses\u00a0de\u00a0edad\u00a0y\u00a0que\u00a0\nsuelen\u00a0recuperarse\u00a0hasta\u00a0alcanzar\u00a0valores\u00a0normales,\u00a0alrededor\u00a0d e\u00a0los\u00a02\u00a0a\u00f1os\u00a0de\u00a0vida402.\u00a0La\u00a0\nmayor\u00eda\u00a0de\u00a0estos\u00a0ni\u00f1os\u00a0presentan\u00a0una\u00a0respuesta\u00a0a\u00a0vacunaci\u00f3n\u00a0nor mal\u00a0y\u00a0son\u00a0asintom\u00e1ticos,\u00a0\naunque\u00a0en\u00a0ocasiones\u00a0se\u00a0han\u00a0descrito\u00a0infecciones\u00a0recurrentes,\u00a0es pecialmente\u00a0infecciones\u00a0de\u00a0tipo\u00a0\nrespiratorio403.\u00a0A\u00a0pesar\u00a0de\u00a0que\u00a0son\u00a0muy\u00a0limitad os\u00a0los\u00a0estudios\u00a0fenot\u00edpicos\u00a0rea lizados\u00a0en\u00a0estos\u00a0\nni\u00f1os,\u00a0en\u00a0ellos\u00a0no\u00a0se\u00a0han\u00a0descrito\u00a0alteraciones\u00a0claras\u00a0en\u00a0los\u00a0d istintos\u00a0compartimentos\u00a0celulares\u00a0\nanalizados,\u00a0 compatibles\u00a0 con\u00a0 IDVC377.\u00a0 Por\u00a0 ello,\u00a0 ante\u00a0 la\u00a0 sospecha\u00a0 (o\u00a0 el\u00a0 diagn\u00f3stico)\u00a0 de\u00a0\nhipogammaglobulinemia\u00a0transitoria\u00a0de\u00a0la\u00a0infancia,\u00a0debe\u00a0hacerse\u00a0 un\u00a0seguimiento\u00a0estrecho\u00a0del\u00a0\nni\u00f1o,\u00a0con\u00a0el\u00a0fin\u00a0de\u00a0descartar\u00a0pueda\u00a0evolucionar\u00a0a\u00a0otras\u00a0inmunod eficiencias\u00a0como\u00a0un\u00a0d\u00e9ficit\u00a0\nselectivo\u00a0de\u00a0IgA\u00a0o\u00a0una\u00a0IDVC214,388,402.\u00a0\u00a0\nD\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgM.\u00a0 Los\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgM \u00a0se\u00a0caracterizan\u00a0por\u00a0\nmostrar\u00a0cifras\u00a0s\u00e9ricas\u00a0bajas\u00a0o\u00a0ausentes\u00a0de\u00a0IgM,\u00a0con\u00a0niveles\u00a0nor males\u00a0de\u00a0IgA\u00a0e\u00a0IgG.\u00a0Aunque\u00a0\nalgunos\u00a0pacientes\u00a0son\u00a0asintom\u00e1tico s,\u00a0en\u00a0general\u00a0presentan\u00a0mayor \u00a0incidencia\u00a0de\u00a0infecciones\u00a0\nbacterianas,\u00a0 especialmente\u00a0 de\u00a0 infecciones\u00a0 respiratorias404,405,\u00a0asociadas\u00a0 a\u00a0 una\u00a0 reducci\u00f3n\u00a0Introducci\u00f3n \n\u2010\u00a061\u00a0\u2010\u00a0\n\u00a0s i g n i f i c a t i v a \u00a0d e l \u00a0n \u00fa m e r o \u00a0d e \u00a0l o s \u00a0l i n f o c i t o s \u00a0B \u00a0d e \u00a0m e m o r i a \u00a0C D 2 7+\u00a0I g M++D+,\u00a0 sin\u00a0 que\u00a0 existan\u00a0\nalteraciones\u00a0importantes\u00a0en\u00a0el\u00a0c ompartimento\u00a0de\u00a0linfocitos\u00a0B\u00a0de \u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0\nisotipo377,404.\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\nHip\u00f3tesis de trabajo y \nobjetivos \n\u00a0\n\u00a0 \n \n \n  \n \n \n \n  \n \n\u00a0Hip\u00f3tesis de trabajo y objetivos \n\u2010\u00a065\u00a0\u2010\u00a0\n\u00a0Las\u00a0IDP\u2010Ac\u00a0son\u00a0un\u00a0grupo\u00a0heterog\u00e9neo\u00a0y\u00a0relativamente\u00a0numeroso\u00a0de \u00a0enfermedades\u00a0\ncaracterizadas\u00a0por\u00a0la\u00a0existencia\u00a0de\u00a0distintas\u00a0alteraciones\u00a0en\u00a0l a\u00a0respuesta\u00a0de\u00a0los\u00a0linfocitos\u00a0B.\u00a0En\u00a0\nconjunto,\u00a0constituyen\u00a0>50%\u00a0de\u00a0las\u00a0IDP,\u00a0siendo\u00a0la\u00a0IDVC\u00a0el\u00a0subtip o\u00a0de\u00a0IDP\u2010Ac\u00a0m\u00e1s\u00a0importante\u00a0\ndesde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0cl\u00ednico,\u00a0y\u00a0el\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0 la\u00a0entidad\u00a0m\u00e1s\u00a0prevalente.\u00a0En\u00a0pa\u00edses\u00a0\noccidentales,\u00a0la\u00a0IDVC\u00a0afecta\u00a0a \u00a01:25.000\u201050.000\u00a0individuos\u00a0y\u00a0se\u00a0 caracteriza\u00a0por\u00a0un\u00a0descenso\u00a0en\u00a0\nlos\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0IgG\u00a0e\u00a0IgA,\u00a0acompa\u00f1ados\u00a0o\u00a0no\u00a0de\u00a0descenso\u00a0 de\u00a0IgM11,231,236,246.\u00a0Este\u00a0d\u00e9ficit\u00a0de\u00a0\nIgs\u00a0s\u00e9ricas\u00a0se\u00a0asocia\u00a0a\u00a0infeccion es\u00a0recurrentes,\u00a0adem\u00e1s\u00a0de\u00a0otra s\u00a0complicaciones\u00a0debidas\u00a0entre\u00a0\notros\u00a0trastornos\u00a0a\u00a0autoinmunidad,\u00a0organomegalias,\u00a0granulomas\u00a0y\u00a0 enteropat\u00eda,\u00a0que\u00a0terminan\u00a0por\u00a0\ncondicionar\u00a0 una\u00a0 menor\u00a0 calidad\u00a0 de\u00a0 vida\u00a0 y\u00a0 una\u00a0 supervivencia\u00a0 signi ficativamente\u00a0\nacortada231,236,247,256.\u00a0A\u00a0su\u00a0vez,\u00a0el\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA,\u00a0se\u00a0estima\u00a0afecta\u00a0a\u00a01:6 00\u00a0individuos\u00a0en\u00a0\npa\u00edses\u00a0occidentales\u00a0y\u00a0se\u00a0define\u00a0por\u00a0la\u00a0existencia\u00a0de\u00a0un\u00a0descens o\u00a0en\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0IgA,\u00a0en\u00a0\nausencia\u00a0 de\u00a0 alteraciones\u00a0 en\u00a0 los\u00a0 dem\u00e1s\u00a0 isotipos\u00a0 o\u00a0 subclases\u00a0 de\u00a0 I g11,13.\u00a0 Aunque\u00a0 una\u00a0 parte\u00a0\nimportante\u00a0de\u00a0los\u00a0individuos\u00a0que \u00a0presentan\u00a0d\u00e9ficit\u00a0selectivo\u00a0de \u00a0IgA\u00a0permanecen\u00a0asintom\u00e1ticos,\u00a0\notros\u00a0sufren\u00a0infecciones\u00a0recurrentes\u00a0y\u00a0autoinmunidad,\u00a0pudiendo\u00a0 en\u00a0ocasiones\u00a0evolucionar\u00a0a\u00a0\nIDVC13,329,332,343\u2013345,354,355.\u00a0Con\u00a0menor\u00a0frecuencia,\u00a0se\u00a0observan\u00a0pacientes\u00a0con\u00a0IDP\u2010Ac\u00a0en\u00a0los \u00a0que\u00a0\nexiste\u00a0un\u00a0descenso\u00a0selectivo\u00a0de\u00a0una\u00a0o\u00a0m\u00e1s\u00a0subclases\u00a0de\u00a0IgG1\u20104,\u00a0 con\u00a0niveles\u00a0normales\u00a0de\u00a0IgG\u00a0total\u00a0\n(d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG)11,213,388;\u00a0este\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0puede\u00a0ocurrir\u00a0de\u00a0forma\u00a0\naislada\u00a0o\u00a0asociado\u00a0a\u00a0un\u00a0d\u00e9ficit\u00a0de\u00a0IgA,\u00a0estim\u00e1ndose\u00a0que\u00a0el\u00a015\u20102 0%\u00a0de\u00a0todos\u00a0los\u00a0d\u00e9ficits\u00a0de\u00a0IgA\u00a0\ntienen\u00a0asociado\u00a0un\u00a0d\u00e9ficit\u00a0de\u00a0una\u00a0o\u00a0m\u00e1s\u00a0subclases\u00a0de\u00a0IgG12.\u00a0Aunque\u00a0en\u00a0algunos\u00a0pacientes\u00a0el\u00a0\nd\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0cursa\u00a0de\u00a0forma\u00a0asintom\u00e1tica,\u00a0de\u00a0for ma\u00a0similar\u00a0a\u00a0lo\u00a0que\u00a0ocurre\u00a0en\u00a0el\u00a0\nd\u00e9ficit\u00a0 selectivo\u00a0 de\u00a0 IgA,\u00a0 otros\u00a0 presentan\u00a0 infecciones\u00a0 (especial mente\u00a0 respiratorias)\u00a0 y\u00a0\nautoinmunidad385,389,391,394,395.\u00a0\u00a0\nDe\u00a0lo\u00a0anteriormente\u00a0expuesto\u00a0se\u00a0 deduce\u00a0que,\u00a0en\u00a0la\u00a0actualidad,\u00a0l a\u00a0determinaci\u00f3n\u00a0de\u00a0los\u00a0\nniveles\u00a0s\u00e9ricos\u00a0de\u00a0Acs\u00a0constituye\u00a0un\u00a0marcador\u00a0de\u00a0referencia\u00a0par a\u00a0el\u00a0diagn\u00f3stico\u00a0y\u00a0clasificaci\u00f3n\u00a0\nde\u00a0los\u00a0tres\u00a0subtipos\u00a0m\u00e1s\u00a0prevalentes\u00a0y/o\u00a0cl\u00ednicamente\u00a0relevante s\u00a0de\u00a0IDP\u2010Ac\u00a0antes\u00a0referidos,\u00a0\nadem\u00e1s\u00a0 de\u00a0 proporcionar\u00a0 informaci \u00f3n\u00a0 cl\u00ednicamente\u00a0 relevante\u00a0 para\u00a0 el\u00a0 manejo\u00a0 de\u00a0 otras\u00a0Hip\u00f3tesis de trabajo y objetivos \n \n\u2010\u00a066\u00a0\u2010\u00a0\n\u00a0enfermedades\u00a0relacionadas\u00a0con\u00a0la\u00a0respuesta\u00a0inmune\u00a0como\u00a0infeccio nes,\u00a0autoinmunidad,\u00a0alergia,\u00a0\nneoplasias\u00a0de\u00a0CPs\u00a0e\u00a0inmunodeficiencias\u00a0secundarias406,407,16.\u00a0No\u00a0obstante,\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0\nAcs\u00a0pueden\u00a0no\u00a0reflejar\u00a0de\u00a0forma\u00a0adecuada\u00a0el\u00a0estado\u00a0actual\u00a0de\u00a0la \u00a0respuesta\u00a0B\u00a0y\u00a0la\u00a0capacidad\u00a0\nfuncional\u00a0de\u00a0los\u00a0linfocitos\u00a0B.\u00a0Por\u00a0un\u00a0lado,\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0A cs\u00a0s\u00e9ricos\u00a0son\u00a0producto\u00a0de\u00a0las\u00a0CPs\u00a0\nde\u00a0vida\u00a0larga\u00a0acumuladas,\u00a0en\u00a0ocasiones\u00a0durante\u00a0d\u00e9cadas,\u00a0en\u00a0los\u00a0 nichos\u00a0de\u00a0supervivencia\u00a0de\u00a0la\u00a0\nMO\u00a0y\u00a0el\u00a0MALT53,19,408,409.\u00a0Adem\u00e1s,\u00a0tradicionalmente\u00a0estas \u00a0CPs\u00a0son\u00a0meras\u00a0f\u00e1bricas\u00a0de\u00a0Acs\u00a0 y\u00a0no\u00a0\nresponden\u00a0frente\u00a0a\u00a0un\u00a0nuevo\u00a0contacto\u00a0con\u00a0el\u00a0Ag,\u00a0por\u00a0lo\u00a0que\u00a0no\u00a0r eflejan\u00a0la\u00a0capacidad\u00a0del\u00a0\ncompartimento\u00a0B\u00a0del\u00a0sistema\u00a0inmune\u00a0de\u00a0responder\u00a0frente\u00a0a\u00a0nuevos \u00a0Ags\u00a0o\u00a0frente\u00a0a\u00a0Ags\u00a0con\u00a0los\u00a0\nque\u00a0ya\u00a0ha\u00a0contactado\u00a0previamente,\u00a0funciones\u00a0que\u00a0recaen\u00a0sobre\u00a0lo s\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0y\u00a0linfocitos\u00a0\nB\u00a0de\u00a0memoria,\u00a0respectivamente53,106.\u00a0De\u00a0hecho,\u00a0estas\u00a0limitaciones\u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0Acs\u00a0s\u00e9ricos\u00a0\nse\u00a0extienden\u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0cl\u00ednico\u00a0a\u00a0las\u00a0IDP\u2010Ac,\u00a0ya\u00a0q ue\u00a0no\u00a0permiten\u00a0predecir\u00a0con\u00a0\nprecisi\u00f3n\u00a0el\u00a0comportamiento\u00a0cl\u00ednico\u00a0de\u00a0los\u00a0pacientes\u00a0que,\u00a0aun\u00a0p resentando\u00a0los\u00a0mismos\u00a0defectos\u00a0\ns\u00e9ricos,\u00a0muestran\u00a0manifestaciones\u00a0cl\u00ednicas\u00a0muy\u00a0distintas328,13,236,249,231.\u00a0Precisamente\u00a0por\u00a0este\u00a0\nmotivo,\u00a0se\u00a0ha\u00a0investigado\u00a0la\u00a0posible\u00a0utilidad\u00a0de\u00a0otros\u00a0par\u00e1metr os\u00a0para\u00a0mejorar\u00a0el\u00a0diagn\u00f3stico\u00a0y\u00a0\nsobre\u00a0todo\u00a0la\u00a0clasificaci\u00f3n\u00a0de\u00a0p acientes\u00a0con\u00a0IDP\u2010Ac,\u00a0como\u00a0la\u00a0pr esencia\u00a0de\u00a0mutaciones\u00a0gen\u00e9ticas\u00a0\ny/o\u00a0de\u00a0alteraciones\u00a0funcionales\u00a0detectadas\u00a0 in\u00a0vitro.\u00a0No\u00a0obstante,\u00a0estas\u00a0solo\u00a0son\u00a0aplicables\u00a0a\u00a0un\u00a0\nn\u00famero\u00a0 reducido\u00a0 de\u00a0 casos\u00a0 (<10%)\u00a0 y/o\u00a0 requieren\u00a0 de\u00a0 t\u00e9cnicas\u00a0 de\u00a0 la boratorio\u00a0 laboriosas\u00a0 y\u00a0\ncomplejas,\u00a0cuyos\u00a0resultados\u00a0no\u00a0h an\u00a0podido\u00a0ser\u00a0validados\u00a0cl\u00ednica mente231,305,213,265,250.\u00a0\nEn\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os,\u00a0diferentes\u00a0trabajos\u00a0han\u00a0demostrado\u00a0la\u00a0exis tencia\u00a0de\u00a0alteraciones\u00a0\nque\u00a0afectan\u00a0a\u00a0las\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0circulantes\u00a0de\u00a0pa cientes\u00a0con\u00a0IDVC,\u00a0y\u00a0en\u00a0menor\u00a0\nmedida\u00a0 con\u00a0 d\u00e9ficit\u00a0 selectivo\u00a0 de\u00a0 IgA,\u00a0 detectables\u00a0 mediante\u00a0 citom etr\u00eda\u00a0 de\u00a0 flujo\u00a0\nconvencional137,196,250,281,284\u2013288,290,292,378,379,410.\u00a0Dichas\u00a0anomal\u00edas\u00a0incluy en\u00a0sobre\u00a0todo\u00a0defectos\u00a0\nnum\u00e9ricos\u00a0en\u00a0las\u00a0poblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0en\u00a0distintos\u00a0estadios \u00a0madurativos,\u00a0especialmente\u00a0en\u00a0\nlos\u00a0linfocitos\u00a0B\u00a0de\u00a0 memoria\u00a0que\u00a0presentan\u00a0 cambio\u00a0de\u00a0isotipo137,250,284\u2013288,378,379.\u00a0As\u00ed,\u00a0se\u00a0 ha\u00a0\ndemostrado\u00a0que\u00a0aquellos\u00a0pacientes\u00a0con\u00a0IDP\u2010Ac\u00a0que\u00a0muestran\u00a0alg\u00fan \u00a0defecto\u00a0en\u00a0las\u00a0distintas\u00a0\npoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0SP\u00a0presentan\u00a0con\u00a0mayor\u00a0frecuenci a\u00a0manifestaciones\u00a0cl\u00ednicas,\u00a0Hip\u00f3tesis de trabajo y objetivos \n\u2010\u00a067\u00a0\u2010\u00a0\n\u00a0entre\u00a0 las\u00a0 que\u00a0 se\u00a0 incluyen\u00a0 autoinm unidad,\u00a0 adenopat\u00edas,\u00a0 organomeg alias\u00a0 y\u00a0\ngranulomas250,286,287,379.\u00a0Sin\u00a0embargo,\u00a0los\u00a0an\u00e1lisis\u00a0realiz ados\u00a0en\u00a0estos\u00a0estudios\u00a0se\u00a0han \u00a0restringido\u00a0\na\u00a0 unos\u00a0 pocos\u00a0 compartimentos\u00a0 de\u00a0 linfocitos\u00a0 B,\u00a0 que\u00a0 incluyen\u00a0 los\u00a0 l infocitos\u00a0\ninmaduros/transicionales\u00a0y\u00a0na\u00efve,\u00a0y\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria \u00a0con\u00a0y\u00a0sin\u00a0cambio\u00a0de\u00a0isotipo,\u00a0\nadem\u00e1s\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0CD21\u2010,\u00a0siendo\u00a0la\u00a0sensibilidad\u00a0de\u00a0las\u00a0t\u00e9cnicas\u00a0empleadas\u00a0limitada\u00a0(10\u20103\u2010\n10\u20104)250,285\u2013287,378\u2013380.\u00a0As\u00ed\u00a0mismo,\u00a0en\u00a0la\u00a0gran\u00a0mayor\u00eda\u00a0de\u00a0trabajos\u00a0referidos\u00a0hasta\u00a0la\u00a0 fecha\u00a0en\u00a0la\u00a0\nliteratura\u00a0no\u00a0se\u00a0han\u00a0utilizado\u00a0valores\u00a0de\u00a0referencia\u00a0por\u00a0(grupo \u00a0de)\u00a0edad250,286,287,378,379,\u00a0a\u00a0pesar\u00a0de\u00a0\nque\u00a0hay\u00a0evidencias\u00a0inequ\u00edvocas\u00a0sobre\u00a0la\u00a0existencia\u00a0de\u00a0important es\u00a0oscilaciones\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0\nc\u00e9lulas\u00a0 B\u00a0 totales\u00a0 y\u00a0 sus\u00a0 distintas\u00a0 poblaciones\u00a0 madurativas\u00a0 a\u00a0 lo\u00a0 largo\u00a0 de\u00a0 la\u00a0\nvida53,117,137,144,188,190,191,280.\u00a0\nDe\u00a0acuerdo\u00a0con\u00a0estos\u00a0antecedentes,\u00a0nos\u00a0planteamos\u00a0como\u00a0 hip\u00f3tesis\u00a0 de\u00a0trabajo\u00a0de\u00a0esta\u00a0\ntesis\u00a0 doctoral\u00a0 que\u00a0 la\u00a0 determinaci\u00f3n\u00a0 espec\u00edfica\u00a0 y\u00a0 sensible\u00a0 de\u00a0 un \u00a0 elevado\u00a0 n\u00famero\u00a0 de\u00a0\nsubpoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0identificadas\u00a0por\u00a0citometr\u00eda\u00a0de\u00a0 flujo,\u00a0no\u00a0solo\u00a0seg\u00fan\u00a0su\u00a0estadio\u00a0\nmadurativo,\u00a0sino\u00a0tambi\u00e9n\u00a0por\u00a0el\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Ig\u00a0expres ada,\u00a0adem\u00e1s\u00a0de\u00a0por\u00a0otros\u00a0\nmarcadores\u00a0 funcionales,\u00a0 podr\u00eda\u00a0 proporcionar\u00a0 informaci\u00f3n\u00a0 novedos a\u00a0 y\u00a0 \u00fatil\u00a0 acerca\u00a0 de\u00a0 las\u00a0\nalteraciones\u00a0de\u00a0la\u00a0respuesta\u00a0B\u00a0presentes\u00a0en\u00a0pacientes\u00a0con\u00a0IDP\u2010A c,\u00a0complementaria\u00a0a\u00a0la\u00a0derivada\u00a0\ndel\u00a0estudio\u00a0de\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0Acs,\u00a0y\u00a0potencialmente\u00a0\u00fati l\u00a0para\u00a0un\u00a0diagn\u00f3stico\u00a0y\u00a0clasificaci\u00f3n\u00a0\nm\u00e1s\u00a0precisos\u00a0de\u00a0las\u00a0IDP\u2010Ac.\u00a0\u00a0\nDe\u00a0acuerdo\u00a0con\u00a0esta\u00a0hip\u00f3tesis,\u00a0nos\u00a0planteamos\u00a0como\u00a0 objetivo\u00a0general\u00a0 del\u00a0presente\u00a0\ntrabajo\u00a0desarrollar\u00a0una\u00a0metodolog\u00eda\u00a0que\u00a0permitiera\u00a0analizar\u00a0en\u00a0profundi dad\u00a0el\u00a0compartimento\u00a0\nde\u00a0linfocitos\u00a0B\u00a0de\u00a0SP\u00a0de\u00a0individuos\u00a0sanos\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida ,\u00a0incluyendo\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0las\u00a0\nsubpoblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0que\u00a0expresan\u00a0diferente\u00a0isotipo\u00a0y\u00a0su bclase\u00a0de\u00a0Ig,\u00a0de\u00a0cara\u00a0a\u00a0establecer\u00a0\ncon\u00a0mayor\u00a0precisi\u00f3n\u00a0las\u00a0posibles\u00a0alteraciones\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0 y\u00a0su\u00a0utilidad\u00a0en\u00a0el\u00a0diagn\u00f3stico\u00a0y\u00a0\nclasificaci\u00f3n\u00a0de\u00a0este\u00a0grupo\u00a0de\u00a0ID P.\u00a0Para\u00a0ello,\u00a0planteamos\u00a0tres\u00a0 objetivos\u00a0concretos:\u00a0\n\u00a0Hip\u00f3tesis de trabajo y objetivos \n \n\u2010\u00a068\u00a0\u2010\u00a0\n\u00a01.\u2212\u00a0Seleccionar\u00a0y\u00a0validar\u00a0un\u00a0amplio\u00a0panel\u00a0de\u00a0Acs\u00a0monoclonales\u00a0p ara\u00a0la\u00a0detecci\u00f3n\u00a0\nespec\u00edfica\u00a0y\u00a0sensible\u00a0mediante\u00a0citometr\u00eda\u00a0de\u00a0flujo,\u00a0de\u00a0las\u00a0dist intas\u00a0subpoblaciones\u00a0de\u00a0linfocitos\u00a0\nB\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0CPs\u00a0de\u00a0SP\u00a0y\u00a0otros\u00a0tejidos\u00a0humanos,\u00a0que\u00a0expres an\u00a0diferentes\u00a0subclases\u00a0de\u00a0IgG\u00a0\ne\u00a0IgA.\u00a0\n2.\u2212\u00a0Analizar\u00a0la\u00a0distribuci\u00f3n\u00a0en\u00a0sangre\u00a0de\u00a0las\u00a0dis\u019fntas\u00a0subpobla ciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0 y\u00a0 de\u00a0 CPs\u00a0 que\u00a0 expresan\u00a0 diferentes\u00a0 isotipos\u00a0 y\u00a0 subclases\u00a0 d e\u00a0 Igs,\u00a0 adem\u00e1s\u00a0 de\u00a0 los\u00a0\ncompartimentos\u00a0de\u00a0linfocitos\u00a0B\u00a0in maduros/transicionales\u00a0y\u00a0na\u00efve ,\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida,\u00a0desde\u00a0el\u00a0\nmomento\u00a0del\u00a0nacimiento\u00a0hasta\u00a0la\u00a0vejez.\u00a0\n3.\u2212\u00a0De\ufb01nir\u00a0las\u00a0posibles\u00a0alteraciones\u00a0que\u00a0afectan\u00a0a\u00a0las\u00a0dis\u019fntas \u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0\nB\u00a0y\u00a0CPs\u00a0de\u00a0SP,\u00a0incluyendo\u00a0las\u00a0definidas\u00a0en\u00a0base\u00a0al\u00a0isotipo\u00a0y\u00a0su bclase\u00a0de\u00a0Ig\u00a0expresada,\u00a0en\u00a0pacientes\u00a0\ncon\u00a0IDVC,\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0asociado\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0IgA \u00a0y\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA,\u00a0y\u00a0evaluar\u00a0\nsu\u00a0posible\u00a0utilidad\u00a0en\u00a0el\u00a0diagn\u00f3st ico\u00a0y\u00a0clasificaci\u00f3n\u00a0de\u00a0estos\u00a0 subtipos\u00a0de\u00a0IDP\u2010Ac.\u00a0\u00a0\n\u00a0 \n  \u00a0\n\u00a0\n\u00a0 \n  \u00a0\n\u00a0 \n \n \n  \n \nMateriales,  \nm\u00e9todos \n y resultados \u00a0\n\u00a0\n\u00a0Materiales, m\u00e9todos y resultados \n\u2010\u00a073\u00a0\u2010\u00a0\n\u00a0En\u00a0esta\u00a0secci\u00f3n\u00a0de\u00a0la\u00a0memoria\u00a0se\u00a0 describen\u00a0las\u00a0muestras\u00a0(pacien tes\u00a0y\u00a0donantes\u00a0sanos),\u00a0\nmateriales\u00a0y\u00a0m\u00e9todos\u00a0empleados,\u00a0as\u00ed\u00a0como\u00a0los\u00a0resultados\u00a0obtenid os\u00a0en\u00a0el\u00a0presente\u00a0trabajo\u00a0\ndoctoral,\u00a0mediante\u00a0la\u00a0inclusi\u00f3n\u00a0de\u00a0los\u00a0art\u00edculos\u00a0originales\u00a0pub licados\u00a0y\u00a0en\u00a0revisi\u00f3n,\u00a0en\u00a0relaci\u00f3n\u00a0\ncon\u00a0 los\u00a0 objetivos\u00a0 planteados.\u00a0 Cada\u00a0 uno\u00a0 de\u00a0 los\u00a0 art\u00edculos\u00a0 viene\u00a0 p recedido\u00a0 de\u00a0 un\u00a0 resumen\u00a0\nredactado\u00a0en\u00a0castellano\u00a0para\u00a0fac ilitar\u00a0una\u00a0revisi\u00f3n\u00a0r\u00e1pida\u00a0de\u00a0l a\u00a0informaci\u00f3n\u00a0contenida\u00a0en\u00a0los\u00a0\nmismos.\u00a0Los\u00a0art\u00edculos\u00a0incluidos\u00a0 en\u00a0el\u00a0presente\u00a0apartado\u00a0son:\u00a0\n\u00a0\n1.\u2212\u00a0En\u00a0relaci\u00f3n\u00a0con\u00a0la\u00a0selecci\u00f3n\u00a0y\u00a0validaci\u00f3n\u00a0de\u00a0un\u00a0amplio\u00a0pane l\u00a0de\u00a0Acs\u00a0monoclonales\u00a0para\u00a0la\u00a0\ndetecci\u00f3n\u00a0espec\u00edfica\u00a0y\u00a0sensible\u00a0mediante\u00a0citometr\u00eda\u00a0de\u00a0flujo,\u00a0d e\u00a0las\u00a0distintas\u00a0subpoblaciones\u00a0de\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0CPs\u00a0de\u00a0SP\u00a0y\u00a0otros\u00a0tejidos\u00a0humanos, \u00a0que\u00a0expresan\u00a0diferentes\u00a0\nsubclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0( Objetivo\u00a01 ):\u00a0\nSelection\u00a0and\u00a0validation\u00a0of\u00a0antib ody\u00a0clones\u00a0against\u00a0IgG\u00a0and\u00a0IgA \u00a0subclasses\u00a0in\u00a0switched\u00a0\nmemory\u00a0B\u2010cells\u00a0and\u00a0plasma\u00a0cells. \u00a0\nElena\u00a0Blanco,\u00a0Martin\u00a0Perez\u2010Andres,\u00a0Luzalba\u00a0Sanoja\u2010Flores,\u00a0Marjo lein\u00a0Wentink,\u00a0Ondrej\u00a0Pelak,\u00a0\nMarta\u00a0 Mart\u00edn\u2010Ayuso,\u00a0 Georgiana\u00a0 Gr igore,\u00a0 Juan\u00a0 Torres\u2010Canizales,\u00a0 E duardo\u00a0 L\u00f3pez\u2010Granados,\u00a0\nTomas\u00a0Kalina,\u00a0Mirjam\u00a0van\u00a0der\u00a0Burg,\u00a0Sonia\u00a0Arriba\u2010M\u00e9ndez,\u00a0Santiag o\u00a0Santa\u00a0Cruz,\u00a0Noem\u00ed\u00a0Puig,\u00a0\nJacques\u00a0J.M.\u00a0van\u00a0Dongen,\u00a0Alberto\u00a0Orfao,\u00a0on\u00a0behalf\u00a0of\u00a0the\u00a0EuroFl ow\u00a0PID\u00a0group.\u00a0 Journal\u00a0of\u00a0\nImmunological\u00a0Methods. \u00a02017\u00a0Sep\u00a028.\u00a0doi:\u00a010.1016/j.jim.2017.09.008.\u00a0\n\u00a02.\u2212\u00a0En\u00a0relaci\u00f3n\u00a0con\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0la\u00a0distribuci\u00f3n\u00a0en\u00a0sangre\u00a0a\u00a0 lo\u00a0largo\u00a0de\u00a0la\u00a0vida,\u00a0de\u00a0las\u00a0distintas\u00a0\nsubpoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0CPs\u00a0que\u00a0expresan \u00a0diferentes\u00a0isotipos\u00a0y\u00a0subclases\u00a0\nde\u00a0 Igs,\u00a0 adem\u00e1s\u00a0 de\u00a0 los\u00a0 compartimentos\u00a0 de\u00a0 linfocitos\u00a0 B\u00a0 inmaduros/ transicionales\u00a0 y\u00a0 na\u00efve\u00a0\n(Objetivo\u00a02 ):\u00a0\nAge\u2010associated\u00a0distribution\u00a0of\u00a0normal\u00a0B\u2010cell\u00a0and\u00a0plasma\u00a0cell\u00a0su bsets\u00a0in\u00a0peripheral\u00a0\nblood.\u00a0\nElena\u00a0Blanco,\u00a0Mart\u00edn\u00a0P\u00e9rez\u2010Andr\u00e9s,\u00a0Sonia\u00a0Arriba\u2010M\u00e9ndez,\u00a0Teresa\u00a0 Contreras\u2010Sanfeliciano,\u00a0Ignacio\u00a0\nCriado,\u00a0Ondrej\u00a0Pelak,\u00a0Ana\u00a0Serra\u2010Caetano,\u00a0Alfonso\u00a0Romero,\u00a0Noem\u00ed\u00a0 Puig,\u00a0Ana\u00a0Remesal,\u00a0Juan\u00a0\nTorres\u00a0Canizales,\u00a0Eduardo\u00a0L\u00f3pez\u2010Granados,\u00a0Tomas\u00a0Kalina,\u00a0Ana\u00a0E.\u00a0 Sousa,\u00a0Menno\u00a0Van\u00a0Zelm,\u00a0Materiales, m\u00e9todos y resultados \n\u00a0\n\u2010\u00a074\u00a0\u2010\u00a0\n\u00a0Mirjam\u00a0Van\u00a0der\u00a0Burg,\u00a0Jacques\u00a0J.M.\u00a0van\u00a0Dongen,\u00a0Alberto\u00a0Orfao,\u00a0on \u00a0behalf\u00a0of\u00a0the\u00a0EuroFlow\u00a0PID\u00a0\ngroup.\u00a0Journal\u00a0of\u00a0Allergy\u00a0and\u00a0Clinical\u00a0Immunology ;\u00a02018\u00a0Mar\u00a02.\u00a0doi:\u00a010.1016/ j.jaci.2018.02.017.\u00a0\n\u00a0\n3.\u2212\u00a0En\u00a0relaci\u00f3n\u00a0con\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0las\u00a0posibles\u00a0alteracio nes\u00a0que\u00a0afectan\u00a0a\u00a0las\u00a0distintas\u00a0\npoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0y\u00a0CPs\u00a0de\u00a0SP,\u00a0incluyendo\u00a0las\u00a0definid as\u00a0en\u00a0base\u00a0al\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0\nIg\u00a0expresada,\u00a0en\u00a0pacientes\u00a0con\u00a0IDVC,\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0Ig G\u00a0asociado\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0IgA\u00a0y\u00a0d\u00e9ficit\u00a0\nselectivo\u00a0de\u00a0IgA,\u00a0y\u00a0su\u00a0posible\u00a0utilidad\u00a0en\u00a0el\u00a0diagn\u00f3stico\u00a0y\u00a0cla sificaci\u00f3n\u00a0de\u00a0estos\u00a0subtipos\u00a0de\u00a0IDP\u2010\nAc\u00a0(Objetivo\u00a03 ):\u00a0\u00a0\nDissection\u00a0of\u00a0defects\u00a0in\u00a0memory\u00a0B\u2010cell\u00a0and\u00a0plasma\u00a0cell\u00a0subsets\u00a0 expressing\u00a0different\u00a0\nimmunoglobulin\u00a0subclasses\u00a0provides\u00a0basis\u00a0for\u00a0(new)\u00a0re\u2010classific ation\u00a0of\u00a0CVID\u00a0and\u00a0Ig\u2010\nsubclass\u00a0deficiencies.\u00a0\nElena\u00a0Blanco,\u00a0Mart\u00edn\u00a0P\u00e9rez\u2010A ndr\u00e9s,\u00a0Sonia\u00a0Arriba\u2010M\u00e9ndez,\u00a0Cristina\u00a0Serrano,\u00a0Luc\u00eda\u00a0del\u00a0Pino\u2010\nMolina,\u00a0\u00a0Susana\u00a0Silva,\u00a0\u00a0Ignacio\u00a0C riado,\u00a0Ignacio\u00a0Madruga,\u00a0Ana\u00a0Se rra\u00a0Caetano,\u00a0Teresa\u00a0Contreras\u2010\nSanfeliciano,\u00a0Francisco\u00a0Sala,\u00a0Alejandro\u00a0Mart\u00edn,\u00a0Jos\u00e9\u00a0Mar\u00eda\u00a0Bast ida,\u00a0F\u00e9lix\u00a0Lorente,\u00a0Carlos\u00a0Prieto,\u00a0\nIgnacio\u00a0D\u00e1vila,\u00a0Miguel\u00a0Marcos,\u00a0Tomas\u00a0Kalina,\u00a0Marcela\u00a0Vlkova,\u00a0Ca rolien\u00a0Bonroy,\u00a0Jan\u00a0Philipp\u00e9,\u00a0\nEduardo\u00a0L\u00f3pez\u2010Granados,\u00a0Ana\u00a0E.\u00a0de\u00a0Sousa,\u00a0Mirjam\u00a0van\u00a0der\u00a0Burg,\u00a0J acques\u00a0J.M.\u00a0van\u00a0Dongen,\u00a0\nAlberto\u00a0Orfao,\u00a0on\u00a0behalf\u00a0of\u00a0the\u00a0EuroFlow\u00a0PID\u00a0group.\u00a0 Journal\u00a0of\u00a0Allergy\u00a0and\u00a0Clinical\u00a0Immunology \u00a0\n(sometido\u00a0para\u00a0publicaci\u00f3n\u00a0y\u00a0en\u00a0revisi\u00f3n).\u00a0\n\u00a0Materiales, m\u00e9todos y resultados \n\u00a0\n\u00a0\n\u2010\u00a075\u00a0\u2010\u00a0\n\u00a0Art\u00edculo 1 \nSelecci\u00f3n\u00a0y\u00a0validaci\u00f3n\u00a0de\u00a0clones\u00a0 de\u00a0anticuerpos\u00a0dirigidos\u00a0frent e\u00a0a\u00a0\nsubclases\u00a0de\u00a0IgA\u00a0e\u00a0IgG\u00a0expresadas \u00a0en\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0 c\u00e9lulas\u00a0\nplasm\u00e1ticas\u00a0que\u00a0presentan\u00a0cambio\u00a0de\u00a0isoti po\u00a0\n\u00a0\nElena\u00a0Blanco1,\u00a0Martin\u00a0Perez\u2010Andres1,\u00a0Luzalba\u00a0Sanoja\u2010Flores1,\u00a0Marjolein\u00a0Wentink2,\u00a0Ondrej\u00a0\nPelak3,\u00a0Marta\u00a0Mart\u00edn\u2010Ayuso4,\u00a0Georgiana\u00a0Grigore4,\u00a0Juan\u00a0Torres\u2010Canizales5,\u00a0Eduardo\u00a0L\u00f3pez\u2010\nGranados5,\u00a0Tomas\u00a0Kalina3,\u00a0Mirjam\u00a0van\u00a0der\u00a0Burg2,\u00a0Sonia\u00a0Arriba\u2010M\u00e9ndez6,\u00a0Santiago\u00a0Santa\u00a0Cruz7,\u00a0\nNoem\u00ed\u00a0Puig8,\u00a0Jacques\u00a0J.M.\u00a0van\u00a0Dongen9,\u00a0Alberto\u00a0Orfao1,\u00a0por\u00a0el\u00a0grupo\u00a0de\u00a0inmunodeficiencias\u00a0\nprimarias\u00a0de\u00a0EuroFlo w\u00a0(EuroFlow\u00a0PID).\u00a0\n\u00a0\n1Centro\u00a0de\u00a0Investigaci\u00f3n\u00a0del\u00a0C\u00e1nc er\u00a0(IBMCC,\u00a0USAL\u2010CSIC),\u00a0Departam ento\u00a0de\u00a0Medicina\u00a0y\u00a0Servicio\u00a0de\u00a0Citometr\u00eda\u00a0\n(NUCLEUS),\u00a0Universidad\u00a0de\u00a0Salama nca,\u00a0IBSAL\u00a0y\u00a0CIBERONC,\u00a0Salamanc a,\u00a0Espa\u00f1a.\u00a0\n2Departamento\u00a0de\u00a0Inmunolog\u00eda,\u00a0Centro\u00a0M\u00e9dico\u00a0de\u00a0la\u00a0Universidad\u00a0Er asmus,\u00a0Rotterdam,\u00a0Pa\u00edses\u00a0Bajos.\u00a0\n3Departamento\u00a0de\u00a0Hematolog\u00eda/Onco log\u00eda,\u00a02\u00ba\u00a0Facultad\u00a0de\u00a0Medicina, \u00a0Universidad\u00a0Charles,\u00a0Pr aga,\u00a0Rep\u00fablica\u00a0Checa.\u00a0\n4Cytognos\u00a0S.L.,\u00a0Salamanca,\u00a0Espa\u00f1a.\u00a0\n5Departamento\u00a0de\u00a0Inmunolog\u00eda\u00a0Cl\u00ednica,\u00a0Hospital\u00a0Universitario\u00a0La\u00a0 Paz,\u00a0Grupo\u00a0de\u00a0Fisiopatolog\u00eda\u00a0de\u00a0\nInmunodeficiencias,\u00a0Instituto\u00a0pa ra\u00a0la\u00a0investigaci\u00f3n\u00a0de\u00a0la\u00a0Salud \u00a0IdiPAZ,\u00a0Madrid,\u00a0Espa\u00f1a.\u00a0\n6Servicio\u00a0de\u00a0Pediatr\u00eda,\u00a0Hospital\u00a0 Universitario,\u00a0Salamanca,\u00a0Espa\u00f1 a.\u00a0\n7Servicio\u00a0de\u00a0otorrinolaringolog\u00eda,\u00a0Hospital\u00a0Universitario,\u00a0Salam anca,\u00a0Espa\u00f1a.\u00a0\n8Servicio\u00a0de\u00a0Hematolog\u00eda,\u00a0Hospita l\u00a0Universitario,\u00a0Salamanca,\u00a0Esp a\u00f1a.\u00a0\n9Departamento\u00a0de\u00a0Inmuno\u2010Hematolog\u00eda\u00a0y\u00a0Transfusi\u00f3n\u00a0de\u00a0Sangre,\u00a0Cen tro\u00a0M\u00e9dico\u00a0de\u00a0la\u00a0Universidad\u00a0de\u00a0Leiden,\u00a0\nUniversidad\u00a0de\u00a0Leiden,\u00a0L eiden,\u00a0Pa\u00edses\u00a0bajos.\u00a0\n\u00a0\n\u00a0\nJournal\u00a0of\u00a0Immunological\u00a0Methods\u00a0\nSeptiembre\u00a0de\u00a02017\u00a0\nDOI:\u00a010.1016/j.jim.2017.09.008\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nLa\u00a0informaci\u00f3n\u00a0suplementaria\u00a0correspondiente\u00a0a\u00a0este\u00a0art\u00edculo\u00a0es t\u00e1\u00a0disponible\u00a0en\u00a0form ato\u00a0electr\u00f3nico\u00a0en\u00a0\nla\u00a0p\u00e1gina\u00a0web\u00a0de\u00a0la\u00a0revista,\u00a0as\u00ed\u00a0como\u00a0en\u00a0el\u00a0anexo\u00a0II\u00a0y\u00a0el\u00a0CD\u2010RO M\u00a0adjuntos\u00a0al\u00a0final\u00a0de\u00a0la\u00a0presente\u00a0memoria.\u00a0\u00a0\n\u00a0Materiales, m\u00e9todos y resultados \n\u00a0\n\u2010\u00a076\u00a0\u2010\u00a0\n\u00a0Introducci\u00f3n.\u00a0 Hace\u00a0m\u00e1s\u00a0de\u00a020\u00a0a\u00f1os,\u00a0la\u00a0IUIS\u00a0junto\u00a0con\u00a0la\u00a0OMS\u00a0realizaron\u00a0estudi os\u00a0cooperativos\u00a0\nmultic\u00e9ntricos,\u00a0con\u00a0el\u00a0fin\u00a0de\u00a0validar\u00a0un\u00a0gran\u00a0n\u00famero\u00a0de\u00a0clones\u00a0 de\u00a0Acs\u00a0para\u00a0la\u00a0detecci\u00f3n\u00a0espec\u00edfica\u00a0\ny\u00a0sensible\u00a0de\u00a0los\u00a0distintos\u00a0isotipos\u00a0de\u00a0Igs\u00a0y\u00a0de\u00a0las\u00a0subclases\u00a0 de\u00a0IgG\u00a0e\u00a0IgA,\u00a0mediante\u00a0un\u00a0amplio\u00a0\nabanico\u00a0de\u00a0t\u00e9cnicas.\u00a0Esta\u00a0labor\u00a0de\u00a0estandarizaci\u00f3n\u00a0permiti\u00f3\u00a0est ablecer\u00a0la\u00a0utilidad\u00a0cl\u00ednica\u00a0de\u00a0los\u00a0\nniveles\u00a0de\u00a0las\u00a0subclases\u00a0IgG1\u20104\u00a0e\u00a0IgA1\u20102,\u00a0adem\u00e1s\u00a0de\u00a0los\u00a0isotipo s\u00a0de\u00a0Igs,\u00a0en\u00a0suero\u00a0y\u00a0otros\u00a0fluidos\u00a0\ncorporales.\u00a0Sin\u00a0embargo,\u00a0estos\u00a0trabajos\u00a0no\u00a0testaron\u00a0la\u00a0capacida d\u00a0de\u00a0estos\u00a0reactivos\u00a0para\u00a0\nidentificar\u00a0 las\u00a0 subclases\u00a0 IgG1\u20104\u00a0 e\u00a0 IgA1\u20102\u00a0 en\u00a0 la\u00a0 superficie\u00a0 de\u00a0 l o s \u00a0l i n f o c i t o s \u00a0B . \u00a0A u n q u e \u00a0\nposteriormente\u00a0 algunos\u00a0 ensayos\u00a0 locales\u00a0 han\u00a0 demostrado\u00a0 que\u00a0 ser\u00eda \u00a0 posible\u00a0 reconocer\u00a0 las\u00a0\nsubclases\u00a0de\u00a0Igs\u00a0expresadas\u00a0por\u00a0 los\u00a0linfocitos\u00a0B,\u00a0el\u00a0n\u00famero\u00a0de\u00a0 reactivos\u00a0testado\u00a0hasta\u00a0el\u00a0\nmomento\u00a0de\u00a0realizar\u00a0este\u00a0trabajo\u00a0 era\u00a0muy\u00a0limitado,\u00a0sin\u00a0que\u00a0exis tieran\u00a0m\u00e9todos\u00a0validados\u00a0\ncl\u00ednicamente\u00a0que\u00a0permitieran\u00a0ana lizar\u00a0de\u00a0forma\u00a0rutinaria\u00a0la\u00a0exp resi\u00f3n\u00a0de\u00a0estas\u00a0subclases\u00a0de\u00a0Igs\u00a0\nen\u00a0distintas\u00a0localizaciones\u00a0celulares\u00a0(citoplasma\u00a0 vs.\u00a0membrana),\u00a0en\u00a0linfocitos\u00a0B\u00a0en\u00a0diferentes\u00a0\nestadios\u00a0madurativos,\u00a0en\u00a0S P\u00a0y\u00a0otros\u00a0tejidos\u00a0humanos.\u00a0\nObjetivo. \u00a0Seleccionar\u00a0y\u00a0validar\u00a0un\u00a0amplio\u00a0panel\u00a0de\u00a0clones\u00a0de\u00a0Acs\u00a0comerci almente\u00a0disponibles\u00a0\npara\u00a0la\u00a0detecci\u00f3n\u00a0mediante\u00a0citometr\u00eda\u00a0de\u00a0flujo\u00a0de\u00a0las\u00a0distintas \u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0en\u00a0linfocitos\u00a0\nB\u00a0de\u00a0memoria\u00a0y\u00a0CPs\u00a0de\u00a0SP\u00a0y\u00a0otros\u00a0tejidos\u00a0humanos.\u00a0\nMuestras,\u00a0materiales\u00a0y\u00a0m\u00e9todos.\u00a0 En\u00a0una\u00a0primera\u00a0fase,\u00a0evaluamos\u00a0la\u00a0capacidad\u00a0de\u00a0identificar\u00a0las\u00a0\nIgs\u00a0expresadas\u00a0en\u00a0la\u00a0superficie\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0y\u00a0CPs\u00a0en\u00a0la \u00a0SP\u00a0de\u00a039\u00a0donantes\u00a0sanos\u00a0de\u00a0un\u00a0total\u00a0\n28\u00a0 clones\u00a0 de\u00a0 Acs\u00a0 distintos\u00a0 que\u00a0 hab\u00edan\u00a0 sido\u00a0 previamente\u00a0 validado s\u00a0 para\u00a0 la\u00a0 detecci\u00f3n\u00a0 y\u00a0\ncuantificaci\u00f3n\u00a0de\u00a0Acs\u00a0s\u00e9ricos\u00a0de\u00a0distintas\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0I gA.\u00a0Los\u00a0distintos\u00a0clones\u00a0de\u00a0Acs\u00a0\nseleccionados\u00a0en\u00a0la\u00a0fase\u00a0anterior\u00a0fueron\u00a0validados\u00a0posteriormen te\u00a0en\u00a019\u00a0muestras\u00a0de\u00a0SP,\u00a012\u00a0\nm u e s t r a s \u00a0d e \u00a0M O \u00a0y \u00a03 \u00a0m u e s t r a s \u00a0d e \u00a0a m \u00ed g d a l a \u00a0p r o c e d e n t e s \u00a0d e \u00a0v o l u n t a r ios\u00a0 sanos.\u00a0 Para\u00a0 el\u00a0\nprocesamiento\u00a0de\u00a0las\u00a0muestras\u00a0em pleamos\u00a0los\u00a0protocolos\u00a0estandar izados\u00a0por\u00a0el\u00a0consorcio\u00a0\neuropeo\u00a0EuroFlow\u00a0(www.euroflow.org).\u00a0En\u00a0todos\u00a0los\u00a0casos,\u00a0para\u00a0l a\u00a0evaluaci\u00f3n\u00a0de\u00a0los\u00a0Acs\u00a0\nespec\u00edficos\u00a0de\u00a0las\u00a0distintas\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA,\u00a0se\u00a0emplear on\u00a0combinaciones\u00a0de\u00a0estos\u00a0Acs\u00a0con\u00a0\notros\u00a0 reactivos\u00a0 que\u00a0 permit\u00edan\u00a0 la\u00a0 identificaci\u00f3n\u00a0 simult\u00e1nea\u00a0 de\u00a0 l infocitos\u00a0 B\u00a0Materiales, m\u00e9todos y resultados \n\u2010\u00a077\u00a0\u2010\u00a0\n\u00a0inmaduros/transicionales,\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0y\u00a0de\u00a0memoria,\u00a0y\u00a0de \u00a0CPs\u00a0circulantes,\u00a0separando\u00a0\ndentro\u00a0de\u00a0las\u00a0dos\u00a0\u00faltimas\u00a0poblaciones\u00a0celulares,\u00a0las\u00a0c\u00e9lulas\u00a0qu e\u00a0presentaban\u00a0cambio\u00a0de\u00a0isotipo\u00a0\nde\u00a0las\u00a0que\u00a0segu\u00edan\u00a0expresando\u00a0IgM\u00a0y/o\u00a0IgD.\u00a0El\u00a0an\u00e1lisis\u00a0de\u00a0las\u00a0m uestras\u00a0marcadas\u00a0se\u00a0realiz\u00f3\u00a0en\u00a0\ncit\u00f3metros\u00a0de\u00a0flujo\u00a0Fortes sa\u00a0X\u201020\u00a0y\u00a0FACSCanto\u00a0II.\u00a0\nResultados.\u00a0 Solamente\u00a017\u00a0de\u00a0los\u00a028\u00a0clones\u00a0de\u00a0 Acs\u00a0evaluados\u00a0mostraron\u00a0reacti vidad\u00a0frente\u00a0a\u00a0las\u00a0\ndistintas\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA \u00a0expresadas\u00a0en\u00a0la\u00a0membrana\u00a0de\u00a0l infocitos\u00a0B\u00a0y\u00a0CPs,\u00a0incluyendo\u00a04\u00a0\nclones\u00a0dirigidos\u00a0frente\u00a0a\u00a0IgG1\u00a0(SAG1,\u00a0HP6188,\u00a0HP6001\u00a0y\u00a0HP6186), \u00a03\u00a0frente\u00a0a\u00a0IgG2\u00a0(SAG2,\u00a0HP6014\u00a0\ny\u00a0HP6002),\u00a03\u00a0frente\u00a0a\u00a0IgG3\u00a0(SAG 3,\u00a0HP6095\u00a0y\u00a0HP6050),\u00a01\u00a0frente\u00a0a\u00a0 IgG4\u00a0(SAG4),\u00a03\u00a0frente\u00a0a\u00a0IgA1\u00a0\n(SAA1,\u00a0H69\u201011.4\u00a0y\u00a0B3506B4)\u00a0y\u00a03\u00a0frente\u00a0a\u00a0IgA2\u00a0(SAA2,\u00a02E2\u00a0y\u00a0A9604 D2).\u00a0En\u00a0un\u00a0segundo\u00a0paso,\u00a0\nseleccionamos\u00a0un\u00a0\u00fanico\u00a0clon\u00a0para\u00a0c ada\u00a0una\u00a0de\u00a0las\u00a0subclases\u00a0de\u00a0I g,\u00a0de\u00a0acuerdo\u00a0a\u00a0la\u00a0especificidad\u00a0\ne\u00a0 intensidad\u00a0 de\u00a0 fluorescencia\u00a0 observadas\u00a0 y\u00a0 la\u00a0 disponibilidad\u00a0 de \u00a0 reactivos\u00a0 conjugados\u00a0\ndirectamente\u00a0 con\u00a0 fluorocromos\u00a0 t\u00e9cnicamente\u00a0 compatibles.\u00a0 Los\u00a0 6\u00a0 c lones\u00a0 seleccionados,\u00a0\nespec\u00edficos\u00a0de\u00a0las\u00a0distintas\u00a0subclases\u00a0de\u00a0IgG 1\u20104\u00a0(SAG1,\u00a0SAG2,\u00a0SAG3\u00a0y\u00a0SAG4)\u00a0e\u00a0IgA1\u20102\u00a0(SAA1\u00a0y\u00a0\nSAA2),\u00a0fueron\u00a0validados\u00a0en\u00a04\u00a0laboratorios\u00a0diferentes\u00a0evaluando: \u00a01)\u00a0la\u00a0posible\u00a0reactividad\u00a0cruzada\u00a0\nentre\u00a0ellos,\u00a0es\u00a0decir,\u00a0comprobando\u00a0que\u00a0era\u00a0mutuamente\u00a0excluyent es;\u00a02)\u00a0el\u00a0marcaje\u00a0en\u00a0tejidos\u00a0\nhumanos\u00a0distintos\u00a0de\u00a0la\u00a0SP,\u00a0incluyendo\u00a0MO\u00a0y\u00a0am\u00edgdala;\u00a0y\u00a03)\u00a0su\u00a0c apacidad\u00a0para\u00a0identificar\u00a0las\u00a0\ns u b c l a s e s \u00a0d e \u00a0I g G \u00a0e \u00a0I g A \u00a0e x p r e s a d a s , \u00a0t a n t o \u00a0a \u00a0n i v e l \u00a0d e \u00a0l a \u00a0s u p e r f i c ie\u00a0 celular,\u00a0 como\u00a0 a\u00a0 nivel\u00a0\ncitoplasm\u00e1tico.\u00a0En\u00a0todos\u00a0los\u00a0tejidos\u00a0evaluados,\u00a0los\u00a06\u00a0clones\u00a0se leccionados\u00a0mostraron\u00a0un\u00a0marcaje\u00a0\nintenso\u00a0 en\u00a0 la\u00a0 membrana\u00a0 citoplasm \u00e1tica,\u00a0 en\u00a0 ausencia\u00a0 de\u00a0 reactivid a d \u00a0c r u z a d a \u00a0e n t r e \u00a0e l l o s , \u00a0\nindependientemente\u00a0del\u00a0tejido\u00a0analizado.\u00a0El\u00a0marcaje\u00a0citoplasm\u00e1t ico\u00a0para\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0\nmemoria\u00a0IgG1,\u00a0IgG2\u00a0e\u00a0IgG3\u00a0fue\u00a0m\u00e1s\u00a0d\u00e9bil\u00a0que\u00a0el\u00a0observado\u00a0en\u00a0la\u00a0 superficie\u00a0externa\u00a0de\u00a0la\u00a0\nmembrana\u00a0citoplasm\u00e1tica,\u00a0mientras\u00a0que\u00a0para\u00a0IgA1,\u00a0IgA2\u00a0e\u00a0IgG4,\u00a0l a\u00a0intensidad\u00a0de\u00a0fluorescencia\u00a0\nobtenida\u00a0con\u00a0ambos\u00a0protocolos\u00a0fue\u00a0similar.\u00a0A\u00a0su\u00a0vez,\u00a0las\u00a0CPs\u00a0mo straron,\u00a0de\u00a0forma\u00a0sistem\u00e1tica,\u00a0\nmayor\u00a0intensidad\u00a0de\u00a0ma rcaje\u00a0citoplasm\u00e1tico\u00a0 vs.\u00a0membrana\u00a0para\u00a0todas\u00a0las\u00a0subclases\u00a0de\u00a0Ig.\u00a0\nConclusiones.\u00a0 Tras\u00a0evaluar\u00a0un\u00a0amplio\u00a0panel\u00a0de\u00a0Acs\u00a0dirigidos\u00a0frente\u00a0a\u00a0las\u00a0dist intas\u00a0subclases\u00a0de\u00a0\nIgG\u00a0e\u00a0IgA,\u00a0pudimos\u00a0seleccionar\u00a06\u00a0clones\u00a0que\u00a0mostraban\u00a0una\u00a0eleva da\u00a0positividad\u00a0y\u00a0especificidad\u00a0Materiales, m\u00e9todos y resultados \n\u00a0\n\u2010\u00a078\u00a0\u2010\u00a0\n\u00a0a\u00a0la\u00a0hora\u00a0de\u00a0identificar\u00a0las\u00a0dif erentes\u00a0poblaciones\u00a0de\u00a0c\u00e9lulas\u00a0 B\u00a0que\u00a0expresan\u00a0cada\u00a0una\u00a0de\u00a0las\u00a0\ndistintas\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA .\u00a0Adem\u00e1s,\u00a0nuestros\u00a0resultados\u00a0m ostraron\u00a0que,\u00a0el\u00a0uso\u00a0de\u00a0los\u00a0clones\u00a0\nde\u00a0Acs\u00a0seleccionados,\u00a0en\u00a0combinaci\u00f3n\u00a0con\u00a0otros\u00a0marcadores\u00a0de\u00a0li nfocitos\u00a0B\u00a0y\u00a0protocolos\u00a0de\u00a0\nprocesamiento\u00a0de\u00a0muestras\u00a0previa mente\u00a0validados,\u00a0proporcionan\u00a0u na\u00a0herramienta\u00a0robusta\u00a0que\u00a0\npermite\u00a0la\u00a0identificaci\u00f3n\u00a0y\u00a0cuan tificaci\u00f3n\u00a0r\u00e1pida\u00a0(<3\u00a0horas),\u00a0y \u00a0sensible\u00a0(<10\u20105)\u00a0de\u00a0las\u00a0distintas\u00a0\nsubpoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0CPs\u00a0definidas\u00a0po r\u00a0la\u00a0expresi\u00f3n\u00a0de\u00a0diferentes\u00a0\nisotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs\u00a0(IgM,\u00a0IgD,\u00a0IgG1\u20104,\u00a0IgA1\u20102)\u00a0en\u00a0difer entes\u00a0tejidos\u00a0humanos,\u00a0con\u00a0una\u00a0\nmanipulaci\u00f3n\u00a0m\u00ednima\u00a0de\u00a0las\u00a0muestras.Material eliminado para la versi\u00f3n almacenada en el repos itorio del Ministerio de Educaci\u00f3n \npor estar sujeto a copyright.  \n   Materiales, m\u00e9todos y resultados \n\u2010\u00a091\u00a0\u2010\u00a0\n\u00a0Art\u00edculo 2 \nDistribuci\u00f3n\u00a0en\u00a0sangre\u00a0de\u00a0las\u00a0d istintas\u00a0subpoblaciones\u00a0de\u00a0linfo citos\u00a0B\u00a0y\u00a0\nde\u00a0c\u00e9lulas\u00a0plasm\u00e1ticas\u00a0normales\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida\u00a0\n\u00a0\nElena\u00a0Blanco1,\u00a0Mart\u00edn\u00a0Perez\u2010Andr\u00e9s1,\u00a0Sonia\u00a0Arriba\u2010Mendez2,\u00a0Teresa\u00a0Contreras\u2010Sanfeliciano3,\u00a0\nIgnacio\u00a0Criado1,\u00a0Ondrej\u00a0Pelak4,\u00a0Ana\u00a0Serra\u2010Caetano5,\u00a0Alfonso\u00a0Romero6,\u00a0Noem\u00ed\u00a0Puig7,\u00a0Ana\u00a0\nRemesal2,\u00a0Juan\u00a0Torres\u00a0Canizales8,\u00a0Eduardo\u00a0Lopez\u2010Granados8,\u00a0Tomas\u00a0Kalina4,\u00a0Ana\u00a0E.\u00a0Sousa5,\u00a0\nMenno\u00a0van\u00a0Zelm9,\u00a0Mirjam\u00a0van\u00a0der\u00a0Burg10,\u00a0Jacques\u00a0J.\u00a0M.\u00a0van\u00a0Dongen11,\u00a0Alberto\u00a0Orfao1,\u00a0por\u00a0el\u00a0\ngrupo\u00a0de\u00a0inmunodeficiencias\u00a0prima rias\u00a0de\u00a0EuroFlow\u00a0(Euroflow\u00a0PID ).\u00a0\n\u00a0\n1Centro\u00a0de\u00a0Investigaci\u00f3n\u00a0del\u00a0C\u00e1nc er\u00a0(IBMCC,\u00a0USAL\u2010CSIC),\u00a0Departam ento\u00a0de\u00a0Medicina\u00a0y\u00a0Servicio\u00a0de\u00a0Citometr\u00eda\u00a0\n(NUCLEUS),\u00a0Universidad\u00a0de\u00a0Salama nca,\u00a0IBSAL\u00a0y\u00a0CIBERONC,\u00a0Salamanc a,\u00a0Espa\u00f1a.\u00a0\n2Servicio\u00a0de\u00a0Pediatr\u00eda,\u00a0Hospital\u00a0 Universitario\u00a0de\u00a0Salamanca,\u00a0Sal amanca,\u00a0Espa\u00f1a.\u00a0\n3Servicio\u00a0de\u00a0Bioqu\u00edmica\u00a0Cl\u00ednica,\u00a0H ospital\u00a0Universitario\u00a0de\u00a0Salam anca,\u00a0Salamanca,\u00a0Espa\u00f1a.\u00a0\n4Departamento\u00a0de\u00a0Hematolog\u00eda/Onco log\u00eda,\u00a02\u00ba\u00a0Facultad\u00a0de\u00a0Medicina, \u00a0Universidad\u00a0Charles,\u00a0Pr aga,\u00a0Rep\u00fablica\u00a0Checa.\u00a0\n5Instituto\u00a0de\u00a0Medicina\u00a0Molecular, \u00a0Faculdad\u00a0de\u00a0Medicina,\u00a0Universi dad\u00a0de\u00a0Lisboa,\u00a0Lisboa,\u00a0Potugal.\u00a0\n6Centro\u00a0de\u00a0Salud\u00a0Miguel\u00a0Armijo,\u00a0S anidad\u00a0de\u00a0Castilla\u00a0y\u00a0Le\u00f3n\u00a0(SACY L),\u00a0Castilla\u00a0y\u00a0Le\u00f3n,\u00a0Salamanca,\u00a0Espa\u00f1a.\u00a0\n7Servicio\u00a0de\u00a0Hematolog\u00eda,\u00a0Hospita l\u00a0Universitario\u00a0de\u00a0Salamanca,\u00a0S alamanca,\u00a0Espa\u00f1a.\u00a0\n8Departamento\u00a0de\u00a0Inmunolog\u00eda\u00a0Cl\u00ednica,\u00a0Hospital\u00a0Universitario\u00a0La\u00a0 Paz,\u00a0Grupo\u00a0de\u00a0Fisiopatolog\u00eda\u00a0de\u00a0\nInmunodeficiencias,\u00a0Instituto\u00a0pa ra\u00a0la\u00a0investigaci\u00f3n\u00a0de\u00a0la\u00a0Salud \u00a0IdiPAZ,\u00a0Madrid,\u00a0Espa\u00f1a.\u00a0\n9Departamento\u00a0de\u00a0Inmunolog\u00eda\u00a0y\u00a0Patolog\u00eda,\u00a0Universidad\u00a0Monash\u00a0y\u00a0H ospital\u00a0Alfred,\u00a0Melbourne,\u00a0Victoria,\u00a0Australia.\u00a0\n10Departamento\u00a0de\u00a0Inmunolog\u00eda,\u00a0Cen tro\u00a0M\u00e9dico\u00a0de\u00a0la\u00a0Universidad\u00a0Er asmus,\u00a0Rotterdam,\u00a0Pa\u00edses\u00a0Bajos.\u00a0\n11Departamento\u00a0de\u00a0Inmuno\u2010Hematolog \u00eda\u00a0y\u00a0Transfusi\u00f3n\u00a0de\u00a0Sangre,\u00a0Cen tro\u00a0M\u00e9dico\u00a0de\u00a0la\u00a0Universidad\u00a0de\u00a0Leiden,\u00a0\nUniversidad\u00a0de\u00a0Leiden,\u00a0L eiden,\u00a0Pa\u00edses\u00a0bajos.\u00a0\n\u00a0\n\u00a0\n\u00a0\nJournal\u00a0of\u00a0Allergy\u00a0and\u00a0Clinical\u00a0Immunology\u00a0\nMarzo\u00a0de\u00a02018\u00a0\nDOI:\u00a010.1016/j.jaci.2018.02.017\u00a0\n\u00a0\n\u00a0\n\u00a0\nLa\u00a0informaci\u00f3n\u00a0suplementaria\u00a0correspondiente\u00a0a\u00a0este\u00a0art\u00edculo\u00a0es t\u00e1\u00a0disponible\u00a0en\u00a0form ato\u00a0electr\u00f3nico\u00a0en\u00a0\nla\u00a0p\u00e1gina\u00a0web\u00a0de\u00a0la\u00a0revista,\u00a0as\u00ed\u00a0como\u00a0en\u00a0el\u00a0anexo\u00a0II\u00a0y\u00a0el\u00a0CD\u2010RO M\u00a0adjuntos\u00a0al\u00a0final\u00a0de\u00a0la\u00a0presente\u00a0memoria.\u00a0\n\u00a0Materiales, m\u00e9todos y resultados \n\u00a0\n\u2010\u00a092\u00a0\u2010\u00a0\n\u00a0Introducci\u00f3n. \u00a0Los\u00a0niveles\u00a0solubles\u00a0de\u00a0Igs\u00a0presentes\u00a0en\u00a0suero\u00a0cambian\u00a0a\u00a0lo\u00a0la rgo\u00a0de\u00a0la\u00a0vida\u00a0y\u00a0\ncontribuyen\u00a0a\u00a0la\u00a0diferente\u00a0susceptibilidad\u00a0que\u00a0presenta\u00a0cada\u00a0in dividuo\u00a0a\u00a0padecer\u00a0infecciones,\u00a0\ninmunodeficiencia,\u00a0autoinmunidad\u00a0y/o\u00a0c\u00e1ncer.\u00a0Por\u00a0todo\u00a0ello,\u00a0los \u00a0niveles\u00a0de\u00a0Acs\u00a0se\u00a0han\u00a0empleado\u00a0\na\u00a0lo\u00a0largo\u00a0de\u00a0los\u00a0a\u00f1os\u00a0para\u00a0evaluar\u00a0la\u00a0respuesta\u00a0humoral\u00a0por\u00a0pa rte\u00a0de\u00a0los\u00a0linfocitos\u00a0B,\u00a0tanto\u00a0en\u00a0\nsituaciones\u00a0fisiol\u00f3gicas\u00a0como\u00a0pa tol\u00f3gicas.\u00a0No\u00a0obstante,\u00a0la\u00a0mayo r\u00eda\u00a0de\u00a0estas\u00a0Igs\u00a0tiene\u00a0su\u00a0origen\u00a0\nen\u00a0CPs\u00a0de\u00a0vida\u00a0larga\u00a0que\u00a0se\u00a0encuentran\u00a0en\u00a0la\u00a0MO\u00a0donde\u00a0se\u00a0acumul an\u00a0durante\u00a0a\u00f1os,\u00a0lo\u00a0que\u00a0hace\u00a0\nque\u00a0los\u00a0niveles\u00a0de\u00a0Acs\u00a0presentes\u00a0en\u00a0suero\u00a0no\u00a0reflejen\u00a0el\u00a0estado \u00a0real\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0en\u00a0ese\u00a0\nmomento.\u00a0Por\u00a0otro\u00a0lado,\u00a0se\u00a0ha\u00a0ob servado\u00a0que\u00a0las\u00a0poblaciones\u00a0may oritarias\u00a0de\u00a0linfocitos\u00a0B\u00a0\ninmaduros/transicionales,\u00a0 na\u00efve\u00a0 y\u00a0 de\u00a0 memoria\u00a0 presentes\u00a0 en\u00a0 SP\u00a0 su fren\u00a0 cambios\u00a0 en\u00a0 su\u00a0\ndistribuci\u00f3n\u00a0y\u00a0concentraci\u00f3n\u00a0con\u00a0la\u00a0edad,\u00a0especialmente\u00a0durante \u00a0los\u00a0dos\u00a0primeros\u00a0a\u00f1os\u00a0de\u00a0vida.\u00a0\nPese\u00a0a\u00a0todo\u00a0lo\u00a0anterior,\u00a0en\u00a0la\u00a0a ctualidad\u00a0no\u00a0existe\u00a0ning\u00fan\u00a0estu dio\u00a0en\u00a0el\u00a0que\u00a0se\u00a0analicen\u00a0los\u00a0\ncambios\u00a0en\u00a0las\u00a0distintas\u00a0 poblaciones\u00a0 de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria \u00a0y\u00a0d e\u00a0CPs\u00a0q u e\u00a0ex p resan\u00a0\ndiferentes\u00a0isotipos\u00a0y\u00a0subclases\u00a0 de\u00a0Igs,\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida.\u00a0\nObjetivo. \u00a0En\u00a0este\u00a0trabajo\u00a0nos\u00a0propusimos\u00a0evaluar\u00a0la\u00a0distribuci\u00f3n\u00a0en\u00a0sang re\u00a0de\u00a0los\u00a0distintos\u00a0\ncompartimentos\u00a0madurativos\u00a0de\u00a0c\u00e9lulas\u00a0B,\u00a0incluidas\u00a0las\u00a0diferent es\u00a0subpoblaciones\u00a0de\u00a0linfocitos\u00a0\nB\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0CPs\u00a0que\u00a0expresan\u00a0los\u00a0distintos\u00a0isotipos\u00a0y\u00a0sub clases\u00a0de\u00a0Igs,\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida.\u00a0\nMuestras,\u00a0materiales\u00a0y\u00a0m\u00e9todos. \u00a0En\u00a0conjunto\u00a0analizamos\u00a0un\u00a0total\u00a0de\u00a019\u00a0muestras\u00a0de\u00a0sangre\u00a0de\u00a0\ncord\u00f3n\u00a0umbilical\u00a0y\u00a0215\u00a0muestras\u00a0d e\u00a0SP\u00a0de\u00a0voluntarios\u00a0sanos,\u00a0sin \u00a0antecedentes\u00a0de\u00a0enfermedades\u00a0\nhematol\u00f3gicas\u00a0y/o\u00a0inmunol\u00f3gicas.\u00a0Seg\u00fan\u00a0su\u00a0edad,\u00a0los\u00a0voluntarios \u00a0sanos\u00a0se\u00a0agruparon\u00a0en:\u00a012\u00a0\nreci\u00e9n\u00a0nacidos\u00a0(menores\u00a0de\u00a012\u00a0d\u00edas),\u00a011\u00a0ni\u00f1os\u00a0de\u00a0entre\u00a01\u00a0y\u00a05\u00a0me ses,\u00a07\u00a0de\u00a0entre\u00a06\u00a0y\u00a011\u00a0meses,\u00a012\u00a0\nde\u00a0entre\u00a012\u00a0y\u00a017\u00a0meses,\u00a012\u00a0de\u00a0ent re\u00a018\u00a0y\u00a023\u00a0meses,\u00a025\u00a0de\u00a0entre\u00a0 2\u00a0y\u00a04\u00a0a\u00f1os\u00a0y\u00a022\u00a0ni\u00f1os\u00a0de\u00a0entre\u00a05\u00a0\ny\u00a09\u00a0a\u00f1os,\u00a014\u00a0sujetos\u00a0de\u00a0entre\u00a010\u00a0y\u00a017\u00a0a\u00f1os,\u00a032\u00a0adultos\u00a0de\u00a0entre \u00a018\u00a0y\u00a039\u00a0a\u00f1os,\u00a027\u00a0de\u00a0entre\u00a040\u00a0y\u00a059\u00a0\na\u00f1os,\u00a027\u00a0de\u00a0entre\u00a060\u00a0y\u00a079\u00a0a\u00f1os,\u00a0y\u00a012\u00a0adultos\u00a0con\u00a0m\u00e1s\u00a0de\u00a080\u00a0a\u00f1os .\u00a0Para\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0las\u00a0\nsubpoblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B,\u00a0se\u00a0marcaron\u00a0las\u00a0muestran\u00a0con\u00a0un\u00a0pa nel\u00a0de\u00a0Acs\u00a0conjugados\u00a0con\u00a012\u00a0\nfluorocromos\u00a0diferentes,\u00a0dirigidos\u00a0frente\u00a0a\u00a0las\u00a0distintas\u00a0subpo blaciones\u00a0B\u00a0y\u00a0los\u00a0diferentes\u00a0\nisotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs\u00a0empleando\u00a0protocolos\u00a0validados\u00a0prev iamente.\u00a0Para\u00a0ello\u00a0se\u00a0midieron\u00a0Materiales, m\u00e9todos y resultados \n\u2010\u00a093\u00a0\u2010\u00a0\n\u00a0un\u00a0m\u00ednimo\u00a0de\u00a05\u00a0millones\u00a0de\u00a0leucocitos\u00a0(incluyendo\u00a0\u2265100.000\u00a0linf ocitos\u00a0B)\u00a0en\u00a0un\u00a0cit\u00f3metro\u00a0de\u00a0\nflujo\u00a0Fortessa\u00a0X\u201020.\u00a0Adem\u00e1s,\u00a0en\u00a018\u00a0muestras\u00a0de\u00a0sangre\u00a0de\u00a0cord\u00f3n \u00a0y\u00a0en\u00a0201\u00a0muestras\u00a0de\u00a0SP\u00a0\n(incluyendo\u00a0donantes\u00a0de\u00a0todos\u00a0los\u00a0grupos\u00a0de\u00a0edad),\u00a0se\u00a0midieron\u00a0 los\u00a0niveles\u00a0solubles\u00a0en\u00a0plasma\u00a0\nde\u00a0Acs\u00a0de\u00a0distinto\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Ig,\u00a0mediante\u00a0t\u00e9cnicas\u00a0 de\u00a0nefelometr\u00eda/turbidimetr\u00eda.\u00a0\u00a0\nResultados.\u00a0 El\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0totales\u00a0en\u00a0sangre\u00a0aument\u00f3\u00a0de\u00a0forma\u00a0si gnificativa\u00a0desde\u00a0\nedades\u00a0muy\u00a0tempranas,\u00a0alcanzando \u00a0su\u00a0nivel\u00a0m\u00e1ximo\u00a0a\u00a0los\u00a01\u20105\u00a0mese s;\u00a0posteriormente,\u00a0el\u00a0n\u00famero\u00a0\nde\u00a0linfocitos\u00a0B\u00a0descendi\u00f3\u00a0de\u00a0forma\u00a0gradual\u00a0hasta\u00a0la\u00a0edad\u00a0adulta ,\u00a0manteni\u00e9ndose\u00a0estable\u00a0a\u00a0partir\u00a0\nde\u00a0ah\u00ed\u00a0hasta\u00a0edades\u00a0ya\u00a0avanzadas\u00a0(>\u00a080\u00a0a\u00f1os).\u00a0Los\u00a0n\u00fameros\u00a0de\u00a0li nfocitos\u00a0B\u00a0inmaduros\u00a0y\u00a0na\u00efve\u00a0en\u00a0\nsangre,\u00a0mostraron\u00a0un\u00a0perfil\u00a0muy\u00a0similar\u00a0al\u00a0descrito\u00a0anteriormen te,\u00a0alcanzando\u00a0su\u00a0nivel\u00a0m\u00e1s\u00a0\nelevado\u00a0entre\u00a0los\u00a01\u00a0y\u00a011\u00a0meses\u00a0de\u00a0edad,\u00a0y\u00a0sin\u00a0que\u00a0se\u00a0observasen \u00a0diferencias\u00a0significativas\u00a0entre\u00a0\nadultos\u00a0j\u00f3venes\u00a0y\u00a0mayores.\u00a0 \u00a0\n\u00a0 A\u00a0su\u00a0vez,\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0aumentaron\u00a0progresivamen te\u00a0desde\u00a0el\u00a0reci\u00e9n\u00a0\nnacido\u00a0hasta\u00a0los\u00a02\u20104\u00a0a\u00f1os\u00a0de\u00a0edad,\u00a0momento\u00a0en\u00a0el\u00a0que\u00a0empezaron\u00a0 a\u00a0descender\u00a0ha sta\u00a0los\u00a010\u201017\u00a0\na\u00f1os;\u00a0en\u00a0adultos,\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0se\u00a0mantu vo\u00a0estable\u00a0hasta\u00a0los\u00a060\u00a0a\u00f1os,\u00a0\ndescendiendo\u00a0posteriormente\u00a0de\u00a0forma\u00a0paulatina.\u00a0Pese\u00a0a\u00a0este\u00a0per fil\u00a0global,\u00a0cuando\u00a0analizamos\u00a0\nde\u00a0forma\u00a0individual\u00a0cada\u00a0poblaci\u00f3n\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria,\u00a0 observamos\u00a0patrones\u00a0muy\u00a0\ndiferentes\u00a0en\u00a0funci\u00f3n\u00a0del\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Ig\u00a0expresada.\u00a0A s\u00ed,\u00a0a\u00a0diferencia\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0\nde\u00a0memoria\u00a0CD27\u2010\u00a0con\u00a0cambio\u00a0de\u00a0isotipo,\u00a0presentes\u00a0ya\u00a0en\u00a0sangre\u00a0de\u00a0cord\u00f3n\u00a0umbili cal\u00a0y\u00a0en\u00a0reci\u00e9n\u00a0\nnacidos,\u00a0las\u00a0c\u00e9lulas\u00a0de\u00a0memoria\u00a0IgM++D+\u00a0solo\u00a0se\u00a0hac\u00edan\u00a0detectables\u00a0a\u00a0 partir\u00a0de\u00a0los\u00a01\u20105\u00a0meses\u00a0de\u00a0\nedad,\u00a0permaneciendo\u00a0su\u00a0n\u00famero\u00a0relativamente\u00a0estable\u00a0hasta\u00a0los\u00a02 \u20104\u00a0a\u00f1os;\u00a0por\u00a0el\u00a0contrario,\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0IgD+\u00a0alcanzaron\u00a0su\u00a0nivel\u00a0m\u00e1s\u00a0elevado\u00a0en\u00a0ni\u00f1os\u00a0de\u00a02\u20104\u00a0a\u00f1os.\u00a0A\u00a0su\u00a0vez ,\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0que\u00a0expresaban\u00a0IgG3,\u00a0IgG1\u00a0e\u00a0IgA1\u00a0(subcl ases\u00a0de\u00a0Igs\u00a0codificadas\u00a0en\u00a0el\u00a0\nsegundo\u00a0bloque\u00a0del\u00a0gen\u00a0 IGHC)\u00a0alcanzaban\u00a0sus\u00a0valores\u00a0m\u00e1ximos \u00a0en\u00a0sangre\u00a0entre\u00a0los\u00a02\u00a0y\u00a04\u00a0a\u00f1os \u00a0\nde\u00a0vida,\u00a0mientras\u00a0que\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0que\u00a0expresaba n\u00a0IgG2,\u00a0IgG4\u00a0e\u00a0IgA2\u00a0(subclases\u00a0\nde\u00a0Igs\u00a0codificadas\u00a0en\u00a0el\u00a0tercer\u00a0bloque\u00a0del\u00a0gen\u00a0 IGHC)\u00a0segu\u00edan\u00a0aumentando\u00a0en\u00a0SP\u00a0hasta\u00a0la\u00a0edad\u00a0\nadulta.\u00a0Materiales, m\u00e9todos y resultados \n\u00a0\n\u2010\u00a094\u00a0\u2010\u00a0\n\u00a0\u00a0 Respecto\u00a0a\u00a0las\u00a0CPs,\u00a0aunque\u00a0se\u00a0encontraban\u00a0ausentes\u00a0en\u00a0sangre\u00a0d e\u00a0cord\u00f3n\u00a0umbilical,\u00a0eran\u00a0\ndetectables\u00a0ya\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0(79%)\u00a0de\u00a0reci\u00e9n\u00a0nacidos,\u00a0en\u00a0los\u00a0qu e\u00a0estaban\u00a0mayoritariamente\u00a0\ni n t e g r a d a s \u00a0p o r \u00a0C P s \u00a0I g M+.\u00a0 Las\u00a0 CPs\u00a0 IgM+,\u00a0 IgG1+,\u00a0 IgG2+,\u00a0 IgG3+,\u00a0 IgA1+\u00a0e \u00a0I g A 2+\u00a0a u m e n t a r o n \u00a0\nexponencialmente\u00a0despu\u00e9s\u00a0del\u00a0nacimiento\u00a0hasta\u00a0los\u00a06\u201011\u00a0meses,\u00a0e dad\u00a0en\u00a0la\u00a0que\u00a0se\u00a0alcanzaron\u00a0\ncifras\u00a0\u224810\u00a0veces\u00a0superiores\u00a0a\u00a0las\u00a0del\u00a0adulto,\u00a0debido\u00a0a\u00a0que\u00a0dism inu\u00edan\u00a0progresivamente\u00a0a\u00a0partir\u00a0\ndel\u00a0a\u00f1o\u00a0de\u00a0vida.\u00a0Las\u00a0CPs\u00a0IgD+\u00a0e\u00a0IgG4+\u00a0mostraron\u00a0niveles\u00a0m\u00e1ximos\u00a0en\u00a0ni\u00f1os\u00a0de\u00a0entre\u00a02\u00a0y\u00a05\u00a0a\u00f1os\u00a0y\u00a0\nde\u00a0entre\u00a05\u00a0y\u00a09\u00a0a\u00f1os,\u00a0respectivamente.\u00a0Estos\u00a0n\u00fameros\u00a0reflejan\u00a0un a\u00a0producci\u00f3n\u00a0masiva\u00a0de\u00a0CPs\u00a0en\u00a0\nedades\u00a0tempranas\u00a0de\u00a0la\u00a0vida,\u00a0con\u00a0un\u00a0descenso\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0inf ancia,\u00a0lo\u00a0que\u00a0les\u00a0confiere\u00a0una\u00a0\ncin\u00e9tica\u00a0claramente\u00a0distinta\u00a0de\u00a0la\u00a0observada\u00a0para\u00a0las\u00a0correspon dientes\u00a0Igs\u00a0solubles,\u00a0excepto\u00a0en\u00a0\nel\u00a0caso\u00a0de\u00a0la\u00a0IgD,\u00a0cuyo\u00a0valor\u00a0m\u00e1ximo\u00a0en\u00a0plasma\u00a0se\u00a0alcanz\u00f3\u00a0tambi \u00e9n\u00a0a\u00a0los\u00a02\u20104\u00a0a\u00f1os\u00a0de\u00a0vida,\u00a0al\u00a0igual\u00a0\nque\u00a0ocurr\u00eda\u00a0con\u00a0el\u00a0pico\u00a0de\u00a0las\u00a0CPs\u00a0y\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0mem oria\u00a0IgD+.\u00a0Los\u00a0niveles\u00a0plasm\u00e1ticos\u00a0\nde\u00a0IgM\u00a0aumentaron\u00a0ya\u00a0en\u00a0ni\u00f1os\u00a0de\u00a01\u20105\u00a0meses,\u00a0manteni\u00e9ndose\u00a0relat ivamente\u00a0estables\u00a0a\u00a0partir\u00a0\nde\u00a0esa\u00a0edad.\u00a0Respecto\u00a0a\u00a0las\u00a0subc lases\u00a0de\u00a0IgG,\u00a0sus\u00a0niveles\u00a0eran\u00a0 ya\u00a0elevados\u00a0en\u00a0el\u00a0plasma\u00a0de\u00a0reci\u00e9n\u00a0\nnacidos\u00a0debido\u00a0a\u00a0la\u00a0IgG\u00a0de\u00a0origen\u00a0materno,\u00a0sufriendo\u00a0durante\u00a0el \u00a0primer\u00a0a\u00f1o\u00a0un\u00a0descenso\u00a0\ntransitorio.\u00a0A\u00a0partir\u00a0de\u00a0aqu\u00ed,\u00a0los\u00a0niveles\u00a0de\u00a0IgG\u00a0aumentaron\u00a0si gnificativamente\u00a0alcanzando\u00a0la\u00a0IgG3\u00a0\ne\u00a0IgG1\u00a0sus\u00a0valores\u00a0m\u00e1ximos\u00a0a\u00a0los\u00a05\u20109\u00a0a\u00f1os,\u00a0mientras\u00a0que\u00a0la\u00a0IgG2 \u00a0y\u00a0la\u00a0IgG4\u00a0solo\u00a0alcanzaron\u00a0sus\u00a0\nniveles\u00a0m\u00e1s\u00a0elevados\u00a0en\u00a0plasma\u00a0en\u00a0adultos\u00a0de\u00a018\u201039\u00a0a\u00f1os.\u00a0De\u00a0for ma\u00a0similar,\u00a0los\u00a0niveles\u00a0solubles\u00a0\nde\u00a0IgA1\u00a0en\u00a0plasma\u00a0alcanzaron\u00a0val ores\u00a0m\u00e1ximos\u00a0de\u00a0forma\u00a0m\u00e1s\u00a0r\u00e1pid a\u00a0(pico\u00a0m\u00e1ximo\u00a0a\u00a0los\u00a010\u201017\u00a0\na\u00f1os)\u00a0que\u00a0los\u00a0de\u00a0IgA2\u00a0(valores\u00a0m\u00e1ximos\u00a0a\u00a0los\u00a040\u201039\u00a0a\u00f1os).\u00a0Una\u00a0v ez\u00a0alcanzados\u00a0los\u00a0valores\u00a0\nm\u00e1ximos\u00a0de\u00a0las\u00a0distintas\u00a0Igs,\u00a0estos\u00a0se\u00a0mantuvieron\u00a0relativament e\u00a0estables\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida\u00a0\nhasta\u00a0edades\u00a0superiores\u00a0a\u00a0los\u00a080\u00a0a\u00f1os.\u00a0\nConclusiones. \u00a0El\u00a0pico\u00a0de\u00a0producci\u00f3n\u00a0de\u00a0las\u00a0CPs\u00a0precede\u00a0en\u00a0a\u00f1os,\u00a0o\u00a0incluso\u00a0d\u00e9 cadas,\u00a0al\u00a0de\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0al\u00a0de\u00a0los\u00a0niveles\u00a0solubles\u00a0de\u00a0Igs,\u00a0co nstituyendo\u00a0un\u00a0marcador\u00a0(en\u00a0tiempo\u00a0\nreal)\u00a0del\u00a0estado\u00a0exacto\u00a0de\u00a0la\u00a0respuesta\u00a0B.\u00a0Adem\u00e1s,\u00a0las\u00a0subpobla ciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0\ny\u00a0CPs\u00a0que\u00a0expresan\u00a0diferentes\u00a0is otipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs\u00a0muest ran\u00a0una\u00a0cin\u00e9tica\u00a0muy\u00a0diferente\u00a0\nen\u00a0sangre\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida,\u00a0seg\u00fan\u00a0el\u00a0bloque\u00a0del\u00a0gen\u00a0 IGHC\u00a0en\u00a0el\u00a0que\u00a0est\u00e1n\u00a0codificadas;\u00a0esto\u00a0Materiales, m\u00e9todos y resultados \n\u2010\u00a095\u00a0\u2010\u00a0\n\u00a0probablemente\u00a0refleja\u00a0la\u00a0ocurrencia\u00a0de\u00a0ciclos\u00a0consecutivos\u00a0de\u00a0c ambio\u00a0de\u00a0isotipo\u00a0tras\u00a0sucesivos\u00a0\nreencuentros\u00a0con\u00a0Ags,\u00a0generando\u00a0un\u00a0ac\u00famulo\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0m emoria\u00a0de\u00a0isotipos\u00a0m\u00e1s\u00a0\ntolerog\u00e9nicos\u00a0(i.e.\u00a0IgG2\u00a0e\u00a0IgG4) \u00a0a\u00a0medida\u00a0que\u00a0avanza\u00a0la\u00a0edad.\u00a0P or\u00a0otra\u00a0parte,\u00a0estos\u00a0resultados\u00a0\nproporcionan\u00a0un\u00a0marco\u00a0de\u00a0referencia\u00a0para\u00a0el\u00a0estudio\u00a0de\u00a0las\u00a0pobl aciones\u00a0de\u00a0linfocitos\u00a0B\u00a0durante\u00a0\nel\u00a0 envejecimiento\u00a0 y\u00a0 en\u00a0 enfermedades\u00a0 del\u00a0 sistema\u00a0 inmune,\u00a0 especia lmente\u00a0 en\u00a0\ninmunodeficiencias,\u00a0inflamaci\u00f3n, \u00a0alergia,\u00a0autoinmunidad\u00a0e\u00a0infec ciones.\u00a0\n\u00a0\u00a0\n\u00a0\u00a0Age-associated distribution of normal B-cell and\nplasma cell subsets in peripheral blood\nElena Blanco, MSc,aMart /C19\u0131n P/C19erez-Andr /C19es, PhD,aSonia Arriba-M /C19endez, MD, PhD,bTeresa Contreras-Sanfeliciano, MD,c\nIgnacio Criado, MSc,aOndrej Pelak, PhD,dAna Serra-Caetano, MSc,eAlfonso Romero, MD,fNoem /C19\u0131 Puig, MD, PhD,g\nAna Remesal, MD,bJuan Torres Canizales, MD,hEduardo L /C19opez-Granados, MD, PhD,hTomas Kalina, MD, PhD,d\nAna E. Sousa, MD, PhD,fMenno van Zelm, PhD,i,jMirjam van der Burg, PhD,j\nJacques J. M. van Dongen, MD, PhD,kand Alberto Orfao, MD, PhD,aon behalf of the EuroFlow PID group Salamanca\nand Madrid, Spain, Prague, Czech Republic, Lisbon, Portugal, Melbourne, Australia, and Rotterdam and Leiden, The Netherlands\nGRAPHICAL ABSTRACT\nSoluble Ig levels\nAgePlasma cells\nMemory B- cellsAge-related patterns for plasma cells, memory B-cells, and Ig levels\ny: years\nm: months\nIg: immunoglobulin\nIGHC : immunoglobulin heavy chain constant region\nCells/\u03bcl Cells/\u03bcl mg/dl\nA\ng\ne\nCe\nll\ns\n/\n\u03bc\nl\n Ce\nll\ns\n/\n\u03bc\nl\n mg\n/\nd\nl\np\n p\n ,\n y\n ,\n g\nFromathe Department of Medicine, Cancer Research Centre (IBMCC, USAL-CSIC),\nCytometry Service (NUCLEUS), University of Salamanca (USAL), the Institute of\nBiomedical Research of Salamanca (IBSAL), Salamanca, and the BiomedicalResearch Networking Centre Consortium of Oncology (CIBERONC) Instituto deSalud Carlos III, Madrid;\nbServicio de Pediatr /C19\u0131a,cServicio de Bioqu /C19\u0131mica Cl /C19\u0131nica,\nandgServicio de Hematolog /C19\u0131a, Hospital Universitario de Salamanca, Salamanca;\ndCLIP, Department of Haematology/Oncology, 2nd Faculty of Medicine, Charles Uni-\nversity, Prague;eInstituto de Medicina Molecular, Faculdade de Medicina, Universi-\ndade de Lisboa, Lisbon;fCentro de Salud Miguel Armijo, Sanidad de Castilla y\nLe/C19on (SACYL), Castilla y Le /C19on, Salamanca;hDepartamento de Inmunolog /C19\u0131a, Hospital\nUniversitario La Paz, Madrid;ithe Department of Immunology and Pathology, Monash\nUniversity and Alfred Hospital, Melbourne;jthe Department of Immunology, Erasmus\nUniversity Medical Center (Erasmus MC), Rotterdam; andkthe Department of Immu-\nnohematology and Blood Transfusion, Leiden University Medical Center.\nE.B. was supported by a grant from Junta de Castilla y Le /C19on (Fondo Social Europeo,\nORDEN EDU/346/2013, Valladolid, Spain). This work was supported by the CB16/\n12/00400 grant (CIBERONC, Instituto de Salud Carlos III, Ministerio de Econom /C19\u0131a y\nCompetitividad, Madrid, Spain, and FONDOS FEDER) and the FIS PI12/00905-\nFEDER grant from the Fondo de Investigaciones Sanitarias of Instituto de SaludCarlos III (Madrid, Spain). O.P. and T.K. were supported by the Ministry of Education,Youth and Sports (NPU I no. LO1604 and 15-28541A). The coordination and\ninnovation processes of this study were supported by the EuroFlow Consortium.\nDisclosure of potential con\ufb02ict of interest: E. Blanco, M. P /C19erez-Andr /C19es, E. L /C19opez-\nGranados, T. Kalina, M. van Zelm, M. van der Burg, J. J. M. van Dongen, and A. Orfao\neach report being one of the inventors on the EuroFlow-owned patent PCT/NL 2015/050762 (Diagnosis of primary immunode\ufb01ciencies), which is licensed to Cytognos, acompany that pays royalties to the EuroFlow Consortium. M. van Zelm reports grantsfrom the NHMRC and has a patent issued (EP 2780711 B1). J. J. M. van Dongen and A.\nOrfao report an Educational Services Agreement from BD Biosciences The rest of the\nauthors declare that they have no relevant con\ufb02icts of interest.\nReceived for publication July 27, 2017; revised December 15, 2017; accepted for publi-\ncation February 5, 2018.\nCorresponding author: Alberto Orfao, MD, PhD, Department of Medicine, Cancer\nResearch Center, University of Salamanca, Paseo de la Universidad de Coimbra s/n,\n37007 Salamanca, Spain. E-mail: orfao@usal.es .\n0091-6749\n/C2112018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of\nAllergy, Asthma & Immunology. This is an open access article under the CC BY-NC-\nND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).\nhttps://doi.org/10.1016/j.jaci.2018.02.017\n1Background: Humoral immunocompetence develops stepwise\nthroughout life and contributes to individual susceptibility to\ninfection, immunode\ufb01ciency, autoimmunity, and neoplasia.Immunoglobulin heavy chain (IgH) isotype serum levels can\npartly explain such age-related differences, but their\nrelationship with the IgH isotype distribution within memory B-cell (MBC) and plasma cell (PCs) compartments remains to beinvestigated.\nObjective: We studied the age-related distribution of MBCs and\nPCs expressing different IgH isotypes in addition to theimmature/transitional and naive B-cell compartments.\nMethods: B-cell and PC subsets and plasma IgH isotype levels\nwere studied in cord blood (n 519) and peripheral blood\n(n5215) from healthy donors aged 0 to 90 years by using \ufb02ow\ncytometry and nephelometry, respectively.Results: IgH-switched MBCs expressing IgG\n1, IgG 2, IgG 3, IgA 1,\nand IgA 2were already detected in cord blood and newborns at\nvery low counts, whereas CD271IgM11IgD1MBCs only\nbecame detectable at 1 to 5 months and remained stable until 2to 4 years, and IgD MBCs peaked at 2 to 4 years, with bothpopulations decreasing thereafter. MBCs expressing IgH\nisotypes of the second immunoglobulin heavy chain constant\nregion (IGHC) gene block (IgG\n1, IgG 3, and IgA 1) peaked later\nduring childhood (2-4 years), whereas MBCs expressing third\nIGHC gene block immunoglobulin isotypes (IgG 2, IgG 4, and\nIgA 2) reached maximum values during adulthood. PCs were\nalready detected in newborns, increasing in number until 6 to11 months for IgM, IgG\n1, IgG 2, IgG 3, IgA 1, and IgA 2; until 2 to\n4 years for IgD; and until 5 to 9 years for IgG 4and decreasing\nthereafter. For most IgH isotypes (except IgD and IgG 4),\nmaximum plasma levels were reached after PC and MBC\ncounts peaked.Conclusions: PC counts reach maximum values early in life,followed by MBC counts and plasma IgH isotypes. Importantly,\nIgH isotypes from different IGHC gene blocks show different\npatterns, probably re\ufb02ecting consecutive cycles of IgH isotype\nswitch recombination through life. (J Allergy Clin Immunol\n2018;nnn :nnn-nnn.)\nKey words: Immunoglobulins, IgH isotype, subclass, memory B\ncells, plasma cells, \ufb02ow cytometry, reference ranges, normal B cells,age-related values\nSerum immunoglobulin levels are widely accepted as the most\nreliable surrogate marker for B-cell functionality in healthy\ndonors and patients with different immune-related diseases.1-6\nThus, reference serum immunoglobulin values per age grouphave been generally adopted as the measure of changes inB-cell immunocompetence through life.\n7-17\nOverall, increasing serum immunoglobulin levels are observed\nwith age, although patterns vary for the distinct immunoglobulinheavy chain (IgH) isotypes and subclasses. At birth, serum\ncontains low IgM and IgA levels, whereas maternal immuno-\nglobulin molecules provide near-adult levels of serum IgG.\n13-15,18\nOnce maternal antibodies are cleared, the infant\u2019s antibody re-\nsponses are initially dominated by IgM, and serum IgM, IgG,\nand IgA values reach approximately 100%, 60%, and 30% ofadult levels by the \ufb01rst year of life, respectively.\n14,15Total serum\nIgG levels gradually increase at early ages; however, different\nproduction patterns are observed for the 4 IgG subclasses.16,17Although IgG 3and IgG 1levels increase faster and reach adult-\nlike concentrations at 5 to 10 years of age, IgG 2production is\ndelayed, with maximum levels at adulthood.16,17Similarly, pro-\nduction of IgG 4appears to be delayed, but reference values per\nage group vary signi\ufb01cantly among healthy subjects.16,17Further-\nmore, both IgA 1and IgA 2levels increase gradually during child-\nhood,8,19,20reaching maximum IgA 1production around the\nsecond decade of life, whereas IgA 2serum levels keep increasing\nthroughout adulthood.12Finally, IgE serum levels peak around\n10 years and decrease thereafter to adult levels.21A common\nfeature for all serum IgH isotype subclasses (except for IgD,\nIgG 4, and IgE) is that their levels accumulate with\nage.7,8,11,12,16Once maximum levels are reached, serum IgH iso-\ntype subclass levels remain remarkably stable, without signi\ufb01cantchanges in older subjects.\n18\nIn contrast to serum immunoglobulin levels, more dynamic\nchanges have been observed for total B-cell numbers and thecomposition of the B-cell compartment in peripheral blood (PB).Early studies reported that total B-cell counts increase 2-fold\nimmediately after birth, remain high until 2 years, and gradually\ndecrease approximately 6.5-fold until adulthood.\n22Detailed im-\nmunophenotypic analyses demonstrated that the initial increase\nis mostly due to an increased B-cell production in bone marrow\n(BM) and release of high numbers of immature/transitional andnaive B cells into PB, with maximum values at 0 to 12 months\nof age.\n23,24This early wave of recently produced B cells is fol-\nlowed by increased numbers of memory B cells (MBCs) that\nrapidly increase from 2 months of life, remain high until age5 years, and gradually decrease thereafter to adult-like\nvalues.\n23-26During adulthood, the number of immature/transi-\ntional and naive B cells remains stable, whereas MBC and newly\ngenerated plasma cell (PC) counts gradually decrease in subjects\nolder than 60 years.27,28\nThus far, accurate and robust detection of low PC counts in PB\n(eg, in infants) appeared to be a challenge,23,25,26and information\non IgH isotypes and subclasses within MBC and PC subsets re-\nmains limited,27with absence of age-related reference values.\nLikewise, recent studies on antigen-experienced B cells express-\ning different IgH isotypes did not discriminate between MBCs\nand PCs25and/or did not provide data about the IgG 1to IgG 4\nand IgA 1and IgA 2subclasses.24,26,27\nHere we dissected the PB compartments of MBCs and PCs\ninto 38 distinct subsets expressing different IgH isotypes andtheir subclasses and investigated their distribution in a largeseries of normal cord blood (CB) and PB from healthy\nEuropean donors aged 0 to 90 years. Our ultimate goal was\nto de\ufb01ne the kinetics of the different B-cell and PC subsetsAbbreviations used\nBM: Bone marrow\nCB: Cord blood\nIgH: Immunoglobulin heavy chain\nIGHC : Immunoglobulin heavy chain constant region\nMBC: Memory B cell\nPB: Peripheral blood\nPC: Plasma cell\nRT: Room temperature\nsm: Surface membrane\nSSC: Side scatterJ ALLERGY CLIN IMMUNOL\nnnn20182BLANCO ET ALthrough life and their correlation with plasma IgH isotype\nsubclass levels.\nMETHODS\nSamples\nEDTA-anticoagulated CB (n 519) and PB samples from 215 healthy\nEuropean Caucasian donors (aged 0-90 years) with no past history of\nimmunologic or hematologic diseases (including allergy) were studied:\nnewborns (<12 days; 14 cases); children aged 1 to 5 months (11 cases), 6 to11 months (7 cases), 12 to 17 months (12 cases), 18 to 23 months (12 cases), 2to 4 years (25 cases), 5 to 9 years (22 cases), and 10 to 17 years (14 cases); and\nadults aged 18 to 39 years (32 cases), 40 to 59 years (27 cases), 60 to 79 years\n(27 cases), and greater than 80 years (12 cases). All samples were collectedafter informed consent was provided by the subjects, their legal representa-tives, or both, according to the Declaration of Helsinki. The study was\napproved by the local ethics committees of the participating centers\n(University of Salamanca, Salamanca, Spain; Charles University, Prague,Czech Republic; University of Lisbon, Lisbon, Portugal; and La Paz Hospital,\nMadrid, Spain).\nAll subjects were vaccinated following similar national vaccination\nschedules (European Centre for Disease Prevention and Control; http://\nvaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx ). CB was from Spain,\nPortugal, and the Czech Republic, newborns and children aged 1 to 23 months\nwere from Spain and the Czech Republic, and all cases older than 2 years werefrom Spain. Donors with any sign or suspicion of immunologic or hematologicdiseases (including an abnormal infection rate or a known history of allergies)\nwere excluded from the study. In addition, a questionnaire with environmental\nfactors that could potentially affect development of the immune system,\n25,29,30\nwas conducted in children less than 4 years of age (n 536), with no differ-\nences observed in the frequency of these factors among the age groups evalu-\nated (see Table E1 in this article\u2019s Online Repository at www.jacionline.org ).\nAlso, the exact dates of different vaccinations received were collected in a sub-\nset of 72 children. Elderly donors (>80 years) were representative of a broader\ngroup of elderly persons in the Salamanca region (median life expectancy, 82\nand 87 years for men and women, respectively).\nMultiparameter \ufb02ow cytometric identi\ufb01cation of B\ncells and their maturation-associated andimmunoglobulin isotype subclass subsets\nSamples were processed within less than 24 hours after collection; 107cells\nper sample were stained with the EuroFlow 12-color IgH-isotype B-cell tube\n(seeTable E2 in this article\u2019s Online Repository at www.jacionline.org ). IgH\nisotypes and subclasses were assessed in every sample by using surface mem-\nbrane staining; in addition, in a subset of 6 children (age, 3 65 years) and 6\nadults (age, 33 68 years) surface membrane plus cytoplasmic staining was\ndone in parallel.\nBoth protocols were performed strictly according to the EuroFlow\nBulkLysis standard operating procedure, as previously described (a detailed\nprotocol is provided in the Methods section in this article\u2019s Online Repository\natwww.jacionline.org andwww.EuroFlow.org ).31,32A minimum of 5 3106\nleukocytes (including > _105B cells) was acquired per tube with Fortessa\nX-20 or LSR II Flow Cytometers (BD Biosciences, San Jose, Calif), and\nFACSDiva software (BD Biosciences) was used. Instrument setup was stan-\ndardized across laboratories according to the EuroFlow standard operatingprocedure\n33adapted for 12-color measurements. For data analysis, In\ufb01nicyt\nsoftware (Cytognos, Salamanca, Spain) was used. Absolute counts were\ncalculated by using a dual-platform assay.34\nAnalysis of plasma IgH isotype subclass levels\nPlasma from 18 CB and 201 PB samples from all age groups was obtained\nby means of sequential centrifugation of PB (800 gfor 10 minutes) and\nplatelet-rich plasma (2000 gfor 5 minutes) and immediately stored at\n2808C until analysis. Soluble IgM, IgE, and IgG 1to IgG 4subclass levelswere measured by using conventional nephelometry (Dimension Vista;Siemens Healthcare, Erlanger, Germany), whereas IgA\n1,I g A 2,a n dI g D\nlevels were measured by using the SPA PLUS turbidimetric system (Binding\nSite, Birmingham, United Kingdom). For samples with IgH isotype subclass\nconcentrations of greater than the measurable range, appropriate dilutions\nwere made.\nStatistical analyses\nTo assess statistical signi\ufb01cance (set at P<.05) of differences observed be-\ntween distinct age groups, Mann-Whitney Uand Wilcoxon tests for unpaired\nand paired (continuous) variables were used, respectively. For categorical var-iables, the Fisher exact test was applied (SPSS software, version 23; IBM,\nArmonk, NY).\nRESULTS\nIdenti\ufb01cation of maturation and isotypicsubpopulations of PB B cells\nBased on their staining pattern for CD19, CD27, CD38, CD5,\nCD24, CD21, surface membrane (sm) IgM, smIgD, and side scatter\n(SSC), B cells (CD191SSClo/intforward scatterlo/intlymphocytes)\nwere classi\ufb01ed into maturation-associated subsets ( Fig 1 ,Aand\nB,a n ds e e Fig E1 in this article\u2019s Online Repository at www.\njacionline.org ).27,35First, PCs were de\ufb01ned by a\nCD3811CD271CD242CD212CD52CD19loSSCintphenotype.\nThen pre\u2013germinal center B cells were identi\ufb01ed by their unique\nCD272smIgM1smIgD1CD5hetfeatures; this subset was subdi-\nvided subsequently into immature/transitional CD38hi\nCD24hismIgM11IgD1B cells and CD382CD24hetsmIgM1\nIgD11naive B lymphocytes. Afterward, unswitched MBCs were\nidenti\ufb01ed by their unique CD38loCD52CD271\nsmIgM11IgD1phenotype, and switched MBCs were de\ufb01ned as\nCD38loCD52smIgM2IgD2B cells (see Fig E1 ). Despite CD10\nbeing reported to identify immature/transitional B cells, the combi-nation of markers used here has proved suf\ufb01cient to discriminatereproducibly between mature and immature B cells.\n27,36\nMBCs and PCs were further subclassi\ufb01ed according to their\nsmIgH phenotype into (1) smIgM11IgD1, smIgD1, smIgA 11,\nsmIgA 21, smIgG 11, smIgG 21, smIgG 31, and smIgG 41MBCs\nand (2) smIgM1, smIgD1, smIgA 11, smIgA 21, smIgG 11,\nsmIgG 21, smIgG 31, and smIgG 41PCs, respectively ( Fig 2 ,A\nandB, and Fig 2 ,DandE). All subsets of naive cells and\nMBCs were further subclassi\ufb01ed according to CD21 expression,\nand the subset of switched MBCs was also further subdivided\nbased on CD27 expression. Although a minor fraction of PCsdid not show smIgH, no statistically signi\ufb01cant differences\nwere observed in the IgH isotype and subclass distribution of\nPCs when staining for smIgH was compared with cytoplasmicIgH, either in children (n 56) or adults (n 56), except for the\npercentage of IgH\n2PCs, which was lower when cytoplamsic\nversus Sm staining was used (see Fig E2 in this article\u2019s Online\nRepository at www.jacionline.org ), which is in line with previous\n\ufb01ndings.32\nKinetics of total B cells and maturation-associated\nB-cell subsets through life\nTotal lymphocyte and B-cell counts reached maximum levels at\napproximately 1 to 5 months of age. The total lymphocyte count\nincreased progressively from CB to newborns and 1- to 5-month-old children, whereas B cells showed a slightly delayedJ ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 3signi\ufb01cant increase during this period ( P>.05 for CB vs for new-\nborns; P5.001 for newborns vs 1- to 5-month-old children).\nThereafter, absolute B-cell counts progressively decreased until\nadulthood (18 years), remaining relatively stable afterward(Fig 1 ,C,D, and I, and see Table E3 in this article\u2019s Online\nRepository at www.jacionline.org ).\nMost CB B cells corresponded to immature/transitional and\nnaive B cells ( Fig 1 ,E,F, and I, and see Table E3). Still, a minor3000\n2000\n100400\n<0.011000\nA\nB1400\n1000\n30200\n<0.01600\n400\n200\n100\n30\n<0.01150\n100\n50\n10\n<0.01**\n*Number of cells/\u03bcl\nAge (months or years)#\n\u00a7\u00a7\n\u00a7\u00a710000\n8000\n20004000\n<0.0160002500\n2000\n5001000\n<0.011500*Total \nlymphocytesTotal B-cells\nImmature B-cells Na\u00efve B-cells\nMemory B-cells Plasma cells\nC\nHE F\nGDC S S\nCD19B-cells\nMemory\nB-cells\nNa\u00efve\nB-cells\nImmature/transitional\nB-cellsPlasma \ncellsTotal \nlymphocytes\nI*\nTotal lymphocytes\nTotal B-cells\nImmature B-cellsNa\u00efve B-cells\nMemory B-cells\nPlasma cells7000\n3000\n1000\n100\n10\n<0.01Number of cells/\u03bcl\nAge (months or years)\u00a7*\u00a7\n\u00a7\n##\n\u00a7#\n***#\n##*\n*\nFIG 1. Age distribution of PB lymphocytes, total B cells, and maturation-associated B-cell subsets. A,Dot\nplot representation of total lymphocytes (blue) and B cells (light orange). B,Three-dimensional Automated\nPopulation Separator (APS) view: principal component 1 versus principal component 2 versus principal\ncomponent 3. Graphic representation of the B-cell maturation\u2013associated subsets is shown as follows:\nimmature/transitional (green), naive (pink), and MBCs (orange), and PCs (violet). The APS representation,which generates automatic separation of clusters of cells based on their immunophenotype, was used asa visualization tool. The gating strategy is described in Fig E1 .C-H, Absolute counts (cells per microliter)\nof lymphocytes (Fig 1, C), total B cells (Fig 1, D), and maturation-associated B-cell subsets (Fig 1, E-H) pre-\nsent in CB and PB distributed by age. Notched boxes represent 25th and 75th percentile values; middle line\ncorresponds to median values, and vertical lines represent the highest and lowest values that are neither\noutliers nor extreme values. I,Lines link median values of total lymphocytes; total B cells, immature/transi-\ntional naive MBCs, and PCs. *P < .05, # P< .01, and \u00a7 P< .001 versus the previous age group, respectively. NB,\nNewborn.J ALLERGY CLIN IMMUNOL\nnnn20184BLANCO ET ALfraction of IgH-switched MBCs was detected in most CB (95% of\nsubjects) in the absence of PCs ( < _0.01 PCs/ mL;Fig 1 ,G-I, and see\nTable E3). Interestingly, although no signi\ufb01cant differences wereobserved in immature/transitional, naive, and MBC numbers be-tween CB and newborn samples, PCs became detectable at low\nnumbers in most newborns ( P< .001). Through life, the number\nof PB immature/transitional and naive B cells showed a similar\npro\ufb01le to that of total B cells, with a peak at 1 to 11 months(P< _.001 vs CB) and a progressively signi\ufb01cant decrease until\nadulthood ( P<.001 vs 18- to 39-year-old subjects). Subjects older\nthan 18 years showed relatively stable numbers of both immature/transitional and naive B cells ( Fig 1 ,E,F, and I, and see Table E3).\nMBC and PC counts increased from CB and newborn samples\nto 1- to 5-month-old children ( P< _.001). PC counts already started\nto decrease in children older than 23 months ( P5.03), with agradually continued decrease through adulthood. In contrast,MBC counts increased gradually until age 2 to 4 years\n(P< .001 vs 1- to 5-month-old children) followed by a decrease\nuntil a plateau was reached that lasted through adolescence (10-\n17 years) until adulthood (40-59 years); afterward, MBC counts\nprogressively decreased ( P5.02 vs >80 years; Fig 1 ,GandH,\nand see Table E3).\nAge distribution of MBCs expressing distinct IgH\nisotypes and subclasses\nRelative and absolute counts of MBCs expressing different\nIgH isotypes and subclasses varied signi\ufb01cantly through life\n(Figs 2 and3). smIgM11IgD1MBCs represented the largest\nfraction of MBCs (approximately 80%) in 1- to 5-month-old\nsmIgG1+smIgG2\nsmIgG2+smIgG3 smIgG2+smIgG3smIgG1+smIgG2smIgD\nsmIgMA\nC\nBDPlasma cells Memory B-cells\nsmIgA1+smIgG4smIgA1+smIgA2\nsmIgD\nsmIgM\nsmIgM+ + D+\nsmIgA1+smIgA2+Only smIgD+\nsmIgG1+smIgG2+smIgG3+\nsmIgG4+smIgM+\nsmIgA1+smIgA2+Only smIgD+\nsmIgG1+smIgG2+smIgG3+\nsmIgG4+smIgA1+smIgG4smIgA1+smIgA2\nF\nAge (months or years) f o %y r om eM B-cellssmIgG1+smIgG2+smIgG3+smIgG4+\nsmIgA1+smIgA2+smIgH-\nonly smIgD+\nsmIgM++ D+E\nAge (months or years)% of P lasma cells\nsmIgG1+smIgG2+smIgG3+smIgG4+\nsmIgA1+smIgA2+\nonly smIgD+\nsmIgM+smIgH-\n\u00a7100\n80\n60\n40\n20\n0100\n80\n60\n40\n20\n0\u00a7\u00a7\n\u00a7\n\u00a7\u00a7\u00a7\u00a7\n# #**\n##\u00a7*\n#*\n##\n**\n*\n*\n*#*\n\u00a7#\n**\n#\n****\n#*\nAPS 2\nFIG 2. Distribution of different IgH isotype and subclass subsets of PB MBCs and PCs by age. AandD,Dot\nplot graphic representation of MBC (Fig 2, A) and PC (Fig 2, D) subsets expressing distinct smIgH isotypes\nand isotype subclasses: IgM(D 1) (violet), IgG 1(light blue), IgG 2(light green), IgG 3(dark blue), IgG 4(dark\ngreen), IgA 1(orange), IgA 2(yellow), and IgD (brown); smIgH2B cells are highlighted in gray. Band E,\nThree-dimensional Automated Population Separator (APS) view: principal component 1 versus principal\ncomponent 2 vs principal component 3 of the IgH isotype and subclass subsets of MBCs (Fig 2, B) and\nPCs (Fig 2, E) identi\ufb01ed by the same color code as described above. The APS graphic representation, which\ngenerates automatic separation of clusters of cells based on their immunophenotype, was used as a visu-\nalization tool. CandF,Relative distribution of the distinct IgH isotype and subclass subsets of MBCs and PCs\nin the different age groups analyzed. *P < .05, # P< .01, and \u00a7 P< .001 versus the previous age group, respec-\ntively. NB, Newborn.J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 5children, being signi\ufb01cantly expanded versus those in CB and\nnewborns ( P< .001), with a subsequent decrease to 40% to\n50% of MBCs. Conversely, smIgG 11, smIgG 31, and smIgA 11\nswitched MBCs showed a transient relative decrease among 1-to 5-month-old children versus newborns ( P< _.01), with their rela-\ntive numbers increasing signi\ufb01cantly at 6 to 11 months until 2 to\n4 years for smIgG\n11(P5.001 for 6-11 months vs 1-5 and 2-\n4 years vs 18-23 months) and at 5 to 9 years for smIgG 31\n(P5.02), when they started to decrease, particularly in the tran-\nsition to adulthood. In turn, the percentage of smIgA 11MBCs\nincreased progressively from 2 to 4 years until 10 to 17 years\n(P5.003 for 2-4 years vs 5-9 years and P< .001 for 2-4 years\nvs 10-17 years), remaining rather stable from then onward. In\ncontrast, both smIgG 21and smIgA 21MBCs reached their high-\nest representation in young (18-39 years) adults ( P< _.001). During\nadulthood, no signi\ufb01cant changes were observed in the relativedistribution of most IgH subsets of MBCs, with a few exceptions(Fig 2 ,C).Regarding absolute counts, very low numbers of MBCs were\nobserved in CB and newborns, with similar frequencies ofsubjects with detectable IgH subsets of MBCs (see Table E4 in\nthis article\u2019s Online Repository at www.jacionline.org ). Subse-\nquently, nonswitched smIgM\n11IgD1MBCs became detectable\nat signi\ufb01cantly increased counts among 1- to 5-month-old chil-dren ( P5.001), with numbers remaining fairly stable until 4 years\nand subsequently decreasing signi\ufb01cantly to adult levels at 10 to\n17 years ( P< .002, Fig 3 ). After 60 years, progressively lower\nnumbers of smIgM\n11IgD1MBCs were observed ( P5.002 for\n40-59 years vs >80 years). The smIgD1IgM2MBCs showed a\nvery similar pro\ufb01le: increased counts until 2 to 4 years of\nage, which progressively decreased thereafter ( Fig 3 and see\nTable E4).\nIn contrast, MBCs expressing smIgG 3, smIgG 1, and smIgA 1\n(IgH isotype subclasses of the second immunoglobulin heavychain constant region [IGHC] gene block) showed progressively\nhigher counts until 2 to 4 years ( P< _.03) and remained relatively3\n2\n1\n<0.010.4smIgG4+r e b m u N of y r o m e m B- cells/\u03bcl\n30\n20\n10\n4\n<0.011smIgA1+6\n4\n2\n<0.011\n0.415\n10\n5\n<0.011smIgG2+\n150\n100\n50\n10\n<0.01smIgG1+20\n10\n5\n<0.011smIgG3+ 200\n150\n100\n50\n<0.01smIgM++D+\n10\n6\n0.3\n<0.012smIgA2+A\nB\n#\n#S\u03bc S\u03b33 S\u03b32 S\u03b31 S\u03b34 S\u03b11 S\u03b12 S\u03b5V    D J C\u03bc C\u03b4 C\u03b33 C\u03b31 C\u03b11 C\u03b32 C\u03b34 C\u03b5 C\u03b12 \u03c8\u03b5 \u03c8\u03b3\nAge (months or years)MEMORY B-CELLS\nsmIgD+\u00a7\n\u00a7\n\u00a7\u00a7\u00a7\u00a7\n***#\n##\n*\u00a7*\n#\n#*\n#*\n*2ndIGHC gene block 3rd IGHC gene block 1stIGHC gene block\nFIG 3. Absolute count of CB and PB IgH isotype and subclass subsets of MBCs in healthy subjects grouped\nby age. A,Schematic illustration of the human IGH gene constant region. B,Absolute number of different\nsubsets of MBCs expressing distinct isotypes and subclasses in CB and PB according to age. Notched boxes\nrepresent 25th and 75th percentile values; middle line corresponds to median values, and vertical lines\nrepresent the highest and lowest values that are neither outliers nor extreme values. Colored lines link me-\ndian MBC absolute count values. *P < .05, # P< .01, and \u00a7 P< .001 versus the previous age group, respec-\ntively. NB, Newborn.J ALLERGY CLIN IMMUNOL\nnnn20186BLANCO ET ALstable until 10 to 17 years of age. Interestingly, although MBC\ncounts with smIgG 21and smIgA 21expression (IgH isotype sub-\nclasses of the third IGHC gene block) also increased in childhood,\nthese counts continued increasing until adulthood, with signi\ufb01-cantly higher counts among 18- to 39-year-old adults versus\nyounger subjects ( P5.03 and P5.005, respectively). Despite\nrepresenting a minor subset (<1% and <1 cell/m L for most do-\nnors), particularly among children, smIgG\n41MBCs peaked at\n40 to 59 years ( Fig 3 and see Table E4).\nInterestingly, the immunophenotype of switched MBCs\ndiffered signi\ufb01cantly between CB/newborns versus older\nchildren and adults. Thus although switched MBCs in CB\nand newborns lacked CD27, most MBCs from children older\nthan 1 month and adults (80% to 90%) were CD271. The per-\ncentage of CD271smIgG 31MBCs also increased after the \ufb01rst\nmonth (40% to 60%), but the fraction of CD272cells re-\nmained signi\ufb01cantly greater ( > _40%) in smIgG 31MBCs than\nin MBCs with other IgH isotype subclasses (see Fig E3 in\nthis article\u2019s Online Repository at www.jacionline.org ). More-\nover, although CB and newborn MBCs were mostly CD211,a\nsigni\ufb01cantly higher proportion of CD212switched MBCs was\nobserved among 1- to 11-month-old children versus all other\nage groups. In contrast, the percentage of CD212naive B lym-\nphocytes and CD212smIgM11IgD1MBCs remained low and\nrelatively stable among all age groups. Similar to CD27, thepercentage of CD212cells within smIgG 31MBCs was also\ngreater than among MBCs expressing other smIgH isotypesubclasses (see Fig E4 in this article\u2019s Online Repository at\nwww.jacionline.org ).\nAge distribution of PC subsets expressing different\nIgH isotypes and subclasses\nDespite their absence in normal CB, PCs were detected in most\nnewborn samples (79%) and in all childhood and adult PB\nsamples analyzed. In contrast to MBCs, PCs from newborns weremostly IgM\n1(68% to 96% of PCs), with only 7% to 25% of NBs\nshowing smIgG11(range, 0% to 13%), smIgA 11(range, 0% to\n6.8%), smIgG 21(range, 0% to 2.3%) and/or smIgA 21PCs\n(range, 0% to 2.3%; Fig 2 ,F, and see Table E4).\nChildren at 1 to 5 months had greater percentages of\nsmIgG 31, smIgG 11, smIgA 11, smIgG 21, and smIgA 21PCs\nthan newborns ( P< _.003), whereas the proportion of smIgM1\nPCs decreased at this age ( P< _.001). Thereafter, the relative dis-\ntribution of circulating PCs expressing different IgH isotypesand subclasses remained relatively stable, except for a transientincrease in IgA\n11PC counts at 10 to 17 years, a decrease in\nIgG 31PC counts in adults, and a progressive increment of\nsmIgG 21and smIgA 21cell counts until 10 to 17 and 18 to\n39 years, respectively ( Fig 2 ,F). Finally, the relative number#\n#0.2\n0.1\n<0.010.4smIgG4+20\n1\n<0.011040smIgM+\n<0.0110\n5\n2\n0.30smIgA2+smIgG1+ 25\n5\n1\n<0.01154\n2\n1\n<0.010.3smIgG3+\n50\n30\n10\n<0.013smIgA1+#r e b m u N a m s a l p  f o cells/\u03bcl\nAge (months or years)PLASMA CELLS\n4\n2\n1\n<0.010.3smIgG2+\n2\n1\n<0.010.3smIgD+\u00a7\n\u00a7\u00a7\u00a7\n\u00a7\u00a7*\n**\n*\n*#\n*\n**#\n*#\n*#\n*\n#*#\n**\nFIG 4. Absolute CB and PB counts of IgH isotype and subclass subsets of PCs in healthy subjects grouped by\nage. Absolute number of different subsets of PCs expressing distinct IgH isotypes and subclasses in CB and\nPB according to age. Notched boxes represent 25th and 75th percentile values; middle line corresponds to\nmedian values, and vertical lines represent the highest and lowest values that are neither outliers nor\nextreme values. Colored lines link median PC absolute count values. ** P< .05, # P< .01, and \u00a7 P< .001 versus\nthe previous age group, respectively. NB, Newborn.J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 7of smIgD1and smIgG 41PCs was greater among 2- to 4-year-\nold ( P5.001) and 5- to 9-year-old children ( P5.01), respec-\ntively ( Fig 2 ,F).\nRegarding absolute counts, the number of PB smIgM1PCs\nincreased signi\ufb01cantly during the \ufb01rst year of life ( P< .001).\nThereafter, smIgM1PCs decreased gradually from 1 to 2 years\nonward, reaching the lowest levels among adults older than\n60 years. In contrast, IgD1PC numbers peaked at 2 to 4 years,\nprogressively decreasing thereafter ( Fig 4 ). Increased smIgG 31\nand smIgG 11PC counts were already detected among 1- to 5-\nmonth-old children ( P< _.001). In turn, PCs expressing smIgA 1,\nsmIgA 2, and smIgG 2showed signi\ufb01cantly increased counts\nfrom newborns to 6- to 11-month-old children ( P< _.02). All\nthese IgH-switched PC subsets decreased gradually in the tran-sition from late childhood to adulthood. Finally, smIgG\n41PC\nnumbers peaked at 5 to 9 years, decreasing thereafter ( Fig 4\nand see Table E4).Plasma levels of distinct IgH isotypes and\nsubclasses through life\nAll IgG subclasses (IgG 1-IgG 4) were systematically detected\nalready in CB and newborn plasma. In contrast, IgM and IgA 2\nwere detected in only a fraction of the CB (61% and 65% cases,\nrespectively) and newborn (60% and 10% cases, respectively)plasma samples investigated; no IgA\n1or IgD plasma levels of\ngreater than the limit of detection (>3.58 and >0.66 mg/dL,\nrespectively) were found in newborn samples, and IgA 1was\nfound in only 1 CB sample. Later, soluble IgM, IgA 1, and IgA 2\nplasma levels became detectable systematically (except IgM in1 donor) at higher levels among 1- to 5-month-old children\n(P< _.004); IgA\n1and IgA 2plasma levels gradually increased there-\nafter, whereas IgM plasma levels started to (slightly) decrease\namong 40- to 59-year-old adults. IgD plasma levels remained\nrelatively stable through life until the age of 80 years. Regarding10\n6\n2\nLOD0.6IgD100\n80\n60\n40\nLOD20IgG3\n500\n300\n100\n30\nLODIgA1300\n200\n100\nLOD10IgG41200\n800\n400\nLODIgG1200\n100\n50\n10\nLODIgM 600\n400\n200\nLODIgG2 e l b u l o SI g  a m s a l p levels (mg/dl)\nAge (months or years)SOLUBLE Ig PLASMA LEVELS\n2000\n1000\n500\nLOD1500Total Ig*\n*\n\u00a7\u00a7\n\u00a7\u00a7\n#\n#*\n*\n#*\u00a7*\n#\n#\n*200\n100\n40\n10\nLODIgE (IU/ml) ***\n100\n60\n20\nLOD3IgA2\n*\u00a7#**## \u00a7\nFIG 5. Plasma levels of distinct soluble IgH isotypes and subclasses through life. Plasma levels of the\ndistinct soluble IgH isotypes and subclasses are shown per age group. Total immunoglobulin (Ig), IgM, IgD,\nIgG, and IgA subclass concentrations are expressed in milligrams per deciliter, and IgE levels are expressed\nin international units per milliliter. Notched boxes represent 25th and 75th percentile values; middle line cor-\nresponds to median values, and vertical lines represent the highest and lowest values that are neither out-\nliers nor extreme values. Colored lines link median values of sequential age groups. *P < .05, # P< .01, and\n\u00a7P< .001 versus the previous age group, respectively. NB, Newborn.J ALLERGY CLIN IMMUNOL\nnnn20188BLANCO ET ALthe different IgG subclasses, a transient decrease in IgG 1, IgG 2,\nand IgG 4(but not IgG 3) levels, as well as total immunoglobulin\nplasma levels, was observed during the \ufb01rst year of life, with\nthe levels of all IgG subclasses and total immunoglobulin levelsincreasing thereafter until elderly age. Finally, IgE plasma levels\npeaked at 10 to 17 years, remaining relatively stable thereafter\n(Fig 5 and see Table E5 in this article\u2019s Online Repository at\nwww.jacionline.org ).\nDISCUSSION\nSerum/plasma immunoglobulin levels have been used classi-\ncally to de\ufb01ne the ability (eg, protection against infection) orinability (eg, immunode\ufb01ciency) of B cells to mount effective andsustained immune responses. However, in recent years,\nincreasing evidence indicates that a subgroup of long-lived PCs\naccumulate in the BM over years (or even decades) and are themajor contributor to immunoglobulin plasma levels.\n18,27,37More-\nover, comparison of B-cell numbers and serum antibody levels ininfection models has shown that speci\ufb01c MBCs are more affectedby age than serum antibody levels.\n38Therefore immunoglobulin\nlevels in plasma might not re\ufb02ect the actual status of the B-cell\ncompartment in real time. Nevertheless, this hypothesis has not\nbeen fully con\ufb01rmed, and direct detailed evaluation of theB-cell compartment through life has been only partially achieved.\nHere we analyzed the distribution of 38 subsets of MBCs and\nPCs, including those expressing different IgH isotype subclasses,through life and their relationships with the corresponding IgH\nplasma levels. Only IgE MBCs and PCs, identi\ufb01cation of which in\nPB of healthy (nonallergic) donors remains controversial,\n39-41\ncould not be studied because of the absence of reliable and sensi-\ntive antibody reagents to detect them on the cell surface mem-\nbrane in healthy subjects at very low levels,32despite several\nanti-IgE clones being tested here for analyses that includedmore than 100,000 B cells (data not shown).\nIn line with previous observations,\n42increased production of\nimmature/transitional and naive B cells was observed duringthe \ufb01rst year of life. Afterward, BM production decreased pro-\ngressively until adulthood, when immature/transitional and naive\nB-cell counts in PB stabilized. No further age-related differenceswere observed when young versus elderly adults were compared,\nas also reported by others.\n27\nAlthough serologic studies in steady-state7-10,14-16,18and\nimmunized43subjects suggest that children have a lower ability\nto produce PCs,44direct quanti\ufb01cation of circulating PCs\nshowed that PCs become detectable in newborns and are pro-\nduced at massive levels in infants, when their PC counts are10-fold greater than in young adults. Of note, no correlation\nwas observed between the number of PCs and the vaccination\nschedule (data not shown), despite all infant but newborn sam-ples were analyzed more than 8 days apart from the last\nvaccine. These results suggest that previously used methods to\nevaluate B-cell effector functions are probably biased by long-lived BM PC immunoglobulin production, and \ufb02ow cytometry\nprovides direct evaluation of the actual PC counts.\n28In this re-\ngard, circulating PCs are a very dynamic cell population with a\nhigh turnover rate27,28that might offer a closer view into\nongoing B-cell responses. In fact, our results indicate that PC\nproduction precedes (the peak of) production of both MBCs\nand serum immunoglobulin levels by years or even decades, de-pending on the IgH isotype subclass evaluated (see Fig E5).In line with this, new preliminary observations from our group\nindicate that the number of circulating normal PCs correlates with\nhypogammaglobulinemia, risk of infection, and BM PC produc-\ntion in both B-cell and PC neoplasms (Criado et al, unpublisheddata; Sanoja-Flores et al\n45). Therefore evaluation of PC counts in\nPB emerges as a surrogate marker for (future) PC production inBM and potentially also an early predictor of primary antibodyde\ufb01ciencies, particularly because the diagnosis of many primaryantibody de\ufb01ciencies is currently delayed to children 4 years old\nor older because of the slower constitution of antibody levels in\nserum.\n46,47\nOf note, massive PC production associated with early (\ufb01rst)\nantigen stimulation of naive B cells does not translate into aparallel increase in corresponding antibody serum levels. Thusaccumulation of long-lived PCs in BM, which are required to\nproduce signi\ufb01cant antibody serum levels, might still be limited in\ninfants because of the intrinsic (pro)-apoptotic susceptibility ofnewly generated PCs,\n27,28the immaturity of the BM environment\nafter birth,48and/or over\ufb01lling of BM by highly proliferating\nB-cell precursors during childhood,42which might occupy the\nBM survival niches for PCs. In turn, when signi\ufb01cant levels ofserum immunoglobulins are generated, decreased PC counts of\nthe corresponding IgH isotype were observed, probably because\nof antibody-dependent modulation of B-cell responses.\n49,50Inter-\nestingly, immature/transitional and naive B-cell counts and IgH\nplasma levels remained stable through adulthood, whereas the\nnumber of PCs and MBCs decreased in the elderly versus youngeradults, which is in line with previous \ufb01ndings.\n27,28The reduced\nability to produce antigen-experienced B cells might explainwhy elderly subjects more frequently have severe infections anda lower capacity to produce antigen-speci\ufb01c antibodies aftervaccination, despite having similar (even slightly higher) serum\nantibody levels versus younger adults\n44,51-54\nOverall, the observed kinetics of the sequential waves of PCs,\nMBCs, and plasma IgH levels throughout life were in\ufb02uenced bythe relative position of the IgH isotype/subclass gene segments\nwithin the IGHC locus. Thus IgG\n3and IgG 1production peaks\nappear to precede those of IgG 2and IgG 4for PCs (1-5 months\nvs 6-11 months and 5-9 years), MBCs (2-4 years vs 18-39 years),and serum antibody levels (5-9 years vs 18-39 years; see Fig E6 in\nthis article\u2019s Online Repository at www.jacionline.org ). Among\nIgA subclasses, no age-related differences were observed forthe PC peaks (both detected in 6- to 11-month-old children),which could be due to the fast rate of IgA responses induced bymassive gut bacterial colonization after birth.\n55Nevertheless,\nwhen IgA MBCs and IgA plasma levels were analyzed, wecon\ufb01rmed that IgA\n1MBC and serum IgA 1levels increased faster\nthan levels of their IgA 2counterparts (2-4 years vs 18-39 years\nand 10-17 years vs 40-59 years, respectively). In line with these\ufb01ndings, previous reports indicate that IgG\n2, IgG 4, and IgA 2\nshow a greater number of mutated sequences and greater levels\nof antigen selection than IgG 3, IgG 1, and IgA 1,56,57supporting\nthe notion that IgH isotypes encoded by the third block of the\nIGHC locus might, at least in part, be generated by secondary\nclass-switch recombination events. Sequential production of\ndifferent IgH isotypes might also in\ufb02uence the pattern of B-cell\nresponses during life. Thus although IgH molecules from the \ufb01rstand second IGHC gene blocks (IgM and IgG\n3, IgG 1, and IgA 1)\nshow a higher ability for complement binding, opsonization,and triggering of natural killer cell\u2013mediated cytotoxicity, thosefrom the third block of the IGHC locus (IgG\n2, IgG 4, and IgA 2)J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 9have increased neutralization activity.58-60If such differences\nhold functional relevance, sequential production of distinct IgG\nand IgA subclasses through life might lead to a more tolerogenic\nresponse in adults versus children, with a potential for lower ex-pansions of terminally switched MBCs with increasing age.\nIn addition to massive PC production during the \ufb01rst year of\nlife, vaccination does not mount a sustained immune response ininfants, particularly against encapsulated bacteria.\n44This sug-\ngests that the immaturity of the secondary B-cell response in in-\nfants might be related not only to a lower number of circulating\nMBCs but also to the ability of these MBCs to respond againstdifferent stimulatory conditions. In fact, MBCs from CB, new-\nborns, and infants less than 2 years of age showed signi\ufb01cant\nphenotypic differences to those of children older than 2 yearsand adults; such differences involved functional markers poten-\ntially associated with maturation of other cellular and soluble\ncomponents of the immune system. Thus in line with the absenceof organized germinal centers during fetal life and in new-borns,\n61-63the very few switched MBCs detected in CB and new-\nborns lacked CD27, a molecule that has been previouslyassociated with T-dependent germinal center B-cell re-sponses.\n35,64Further expansion of CD271MBCs during the \ufb01rst\nyear of life occurred in parallel with an increased proportion ofCD21\n2(C3d receptor) MBCs with a limited ability to respond\nto polysaccharide-complement complexes.65,66The fact that\nwithin naive B cells the percentage of CD212cells remains stable\nwith age and shows a comparable in vitro response to polysaccha-\nride antigens in children and adults67suggests that external fac-\ntors affecting antigen recognition might increase the productionof C3d receptor\u2013de\ufb01cient MBCs in children of around 1 year ofage when serum C3 levels reach adult-like values.\n68Thus the\nlimited availability of C3d and C3d-antigen complexes in infants\nless than 1 year old because low serum C3 levels69might\ncontribute to reduced signaling for expression of this receptor dur-\ning antigen recognition. In line with this, other age-related pheno-\ntypic subsets of MBCs have been previously reported, such as the\n\u2018\u2018atypical\u2019\u2019 MBCs and the minor population of CD11c1(iC3b re-\nceptor) B cells,70-72which overlapped here with CD212cells both\nin children and adults (see Fig E7 in this article\u2019s Online Repos-\nitory at www.jacionline.org ), as well as in other studies.27\nAlthough we did not con\ufb01rm here in human subjects previous ob-\nservations about the potential expansion of atypical\nCD272CD212MBCs or other CD212subsets of B cells in\nelderly subjects (see Fig E8 in this article\u2019s Online Repository\natwww.jacionline.org ), there might be additional phenotypic\nmarkers that might contribute to better understand B-cell immu-nity at advanced ages.\nAltogether, these results suggest that maturation of other\ncomponents of the immune response (eg, complement levelsand germinal centers in lymphoid tissues) potentially contributeto determine the number of MBCs generated and their phenotype\nand consequently also their functional abilities. However, the\neffect of these environmental costimulatory signals might also bein\ufb02uenced by the position of the IgH isotype in the IGHC gene\nbecause, independent of age, a higher proportion of CD27\n2and\nCD212MBCs was observed among those B-cell compartments\nexpressing upstream IgH isotypes (eg, IgG 3) versus those display-\ning IgH subclasses located at the end of the IGHC gene (eg, IgG 2).\nOverall, our results support the notion that despite serum IgH\nlevels possibly provide important information about the long-lived steady-state PCs that accumulate in BM, they are not enoughto fully understand the humoral immunocompetence status of asubject. PCs in PB emerge as a robust earlier sensor of actual\nongoing immune responses, whereas progressive accumulation of\nMBCs expressing IgH isotypes and subclasses encoded by thedownstream part of the IGHC locus re\ufb02ect potential terminal\nsequential class-switching and accumulation of MBCs expressingmore tolerogenic isotypes at more advanced ages, as alsocon\ufb01rmed by very preliminary data on longitudinal changes inchildren (see Fig E9 in this article\u2019s Online Repository at www.\njacionline.org ). Additionally, we provide normal reference values\nfor PCs and MBCs expressing different IgH isotypes and sub-classes that, once con\ufb01rmed in larger longitudinal series of sub-\njects from different genetic and geographic backgrounds, might\nbe of value in future studies in patients with multiple disease con-ditions, particularly immunode\ufb01ciency, in\ufb02ammation, allergy,\nautoimmunity, and infection.\nKey messages\ndDistinct age-related production patterns are observed for\nPCs, MBCs, and immunoglobulin plasma levels.\ndPCs, MBCs, and antibodies of different IgH isotypes cor-\nresponding to the different IGHC gene blocks peak at\ndistinct ages, likely re\ufb02ecting consecutive cycles of IgHclass-switch recombination through life.\nREFERENCES\n1.Al-Herz W, Bous\ufb01ha A, Casanova J-L, Chatila T, Conley ME, Cunningham-Run-\ndles C, et al. Primary immunode\ufb01ciency diseases: an update on the classi\ufb01cationfrom the international union of immunological societies expert committee for pri-mary immunode\ufb01ciency. Front Immunol 2014;5:162 .\n2.Ochs HD, Wedgwood RJ. IgG subclass de\ufb01ciencies. Annu Rev Med 1987;38:325-40 .\n3.Siegrist C-A. General aspects of vaccination. Vaccine Immunol 2008;2:17-36 .\n4.Freeman JA, Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, Han P, et al.\nImmunoglobulin G subclass de\ufb01ciency and infection risk in 150 patients withchronic lymphocytic leukemia. Leuk Lymphoma 2013;54:99-104 .\n5.van den Wall Bake AW, Daha MR, van der Ark A, Hiemstra PS, Radl J, van EsLA. Serum levels and in vitro production of IgA subclasses in patients with pri-mary IgA nephropathy. Clin Exp Immunol 1988;74:115-20 .\n6.Zhang H, Li P, Wu D, Xu D, Hou Y, Wang Q, et al. Serum IgG subclasses in auto-\nimmune diseases. Medicine (Baltimore) 2015;94:e387 .\n7.Schauer U, Stemberg F, Rieger CHL, Borte M, Schubert S, Riedel F, et al. IgG\nsubclass concentrations in certi\ufb01ed reference material 470 and reference valuesfor children and adults determined with the binding site reagents. Clin Chem2003;49:1924-9.\n8.Schauer U, Stemberg F, Rieger CHL, Borte M, Schubert S, Riedel F, et al. Estab-\nlishment of age-dependent reference values for IgA subclasses. Clin Chim Acta2003;328:129-33 .\n9.van der Giessen M, Rossouw E, van Veen T, van Loghem E, Zegers BJ, SanderPC. Quanti\ufb01cation of IgG subclasses in sera of normal adults and healthy childrenbetween 4 and 12 years of age. Clin Exp Immunol 1975;21:501-9 .\n10.Bird D, Duffy S, Isaacs D, Webster ADB. Reference children for IgG subclasses\nin preschool. Arch Dis Child 1985;60:204-7 .\n11.Haraldsson A, Weemaes CMR, Jonasdottir S, Olafsson O, Van De Wiel G, Goertz\nJ, et al. Serum immunoglobulinD in infants and children. Scand J Immunol 2000;51:415-8.\n12.Berth M, Delanghe J, Langlois M, De Buyzere M. Reference values of serum IgAsubclasses in caucasian adults by immunonephelometry. Clin Chem 1999;45:\n309-10 .\n13.Stiehm ER, Fudenberg HH. Serum levels of immune globulins in health and dis-\nease: a survey. Pediatrics 1966;37:715-27 .\n14.Buckley RH, Dees SC, O\u2019Fallon WM. Serum immunoglobulins. I. Levels innormal children and in uncomplicated childhood allergy. Pediatrics 1968;41:600-11 .J ALLERGY CLIN IMMUNOL\nnnn201810BLANCO ET AL15.Allansmith M, McClellan BH, Butterworth M, Maloney JR. The development of\nimmunoglobulin levels in man. J Pediatr 1968;72:276-90 .\n16.Plebani A, Ugazio AG, Avanzini MA, Massimi P, Zonta L, Monafo V, et al.\nSerum IgG subclass concentrations in healthy subjects at different age: agenormal percentile charts. Eur J Pediatr 1989;149:164-7 .\n17.Vlug A, Nieuwenhuys EJ, van Eijk RV, Geertzen HG, van Houte AJ. Nephelo-metric measurements of human IgG subclasses and their reference ranges. Ann\nBiol Clin (Paris) 1994;52:561-7 .\n18.Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody\nlevels. Annu Rev Immunol 2005;23:367-86 .\n19.Conley ME, Arbeter A, Douglas SD. Serum levels of IgA1 and IgA2 in children\nand in patients with IgA de\ufb01ciency. Mol Immunol 1983;20:977-81 .\n20.Ozawa N, Shimizu M, Imai M, Miyakawa Y, Mayumi M. Selective absence ofimmunoglobulin A1 or A2 among blood donors and hospital patients. Transfusion\n1986;26:73-6 .\n21.Martins TB, Bandhauer ME, Bunker AM, Roberts WL, Hill HR. New childhood\nand adult reference intervals for total IgE. J Allergy Clin Immunol 2014;133:589-91 .\n22.Comans-Bitter WM, De Groot R, Van den Beemd R, Neijens HJ, Hop WCJ,Groeneveld K, et al. Immunophenotyping of blood lymphocytes in childhood:\nReference values for lymphocyte subpopulations. J Pediatr 1997;130:388-93 .\n23.Piatosa B, Wolska-Kusnierz B, Pac M, Siewiera K, Galkowska E, Bernatowska E.\nB cell subsets in healthy children: Reference values for evaluation of B cell matu-ration process in peripheral blood. Cytometry B Clin Cytom 2010;78:372-81 .\n24.van Gent R, van Tilburg CM, Nibbelke EE, Otto SA, Gaiser JF, Janssens-Korpela\nPL, et al. Re\ufb01ned characterization and reference values of the pediatric T- and B-cell compartments. Clin Immunol 2009;133:95-107 .\n25.van den Heuvel D, Jansen MA, Nasserinejad K, Dik WA, van Lochem EG, Bak-\nker-Jonges LE, et al. Effects of nongenetic factors on immune cell dynamics inearly childhood: the Generation R Study. J Allergy Clin Immunol 2017;139:1923-34.e17 .\n26.Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell\nsubpopulations from infancy to adulthood. Clin Exp Immunol 2010;162:271-9.\n27.Perez-Andres M, Paiva B, Nieto WG, Caraux A, Schmitz A, Almeida J, et al. Hu-\nman peripheral blood B-Cell compartments: a crossroad in B-cell traf\ufb01c. Cytom-etry B Clin Cytom 2010;78:47-60 .\n28.Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, et al. Circulating\nhuman B and plasma cells. Age-associated changes in counts and detailed char-acterization of circulating normal CD138- and CD138 1plasma cells. Haemato-\nlogica 2010;95:1016-20 .\n29.Jansen MAE, van den Heuvel D, van Zelm MC, Jaddoe VWV, Hofman A, de\nJongste JC, et al. Decreased memory B cells and increased CD8 memory T cellsin blood of breastfed children: the generation R study. PLoS One 2015;10:e0126019 .\n30.Carr EJ, Dooley J, Garcia-Perez JE, Lagou V, Lee JC, Wouters C, et al. The\ncellular composition of the human immune system is shaped by age and cohab-\nitation. Nat Immunol 2016;17:461-8 .\n31.Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garc /C19\u0131a-S/C19anchez O,\nB\u20acottcher S, et al. Next Generation Flow for highly sensitive and standardized\ndetection of minimal residual disease in multiple myeloma. Leukemia 2017;\n31:2094-103 .\n32.Blanco E, Perez-Andres M, Sanoja-Flores L, Wentink M, Pelak O, Mart /C19\u0131n-Ayuso\nM, et al. Selection and validation of antibody clones against IgG and IgA sub-\nclasses in switched memory B-cells and plasma cells. J Immunol Methods2017 [Epub ahead of print] .\n33.Kalina T, Flores-Montero J, van der Velden VHJ, Martin-Ayuso M, B \u20acottcher S,\nRitgen M, et al. EuroFlow standardization of \ufb02ow cytometer instrument settings\nand immunophenotyping protocols. Leukemia 2012;26:1986-2010 .\n34.Rudolf-Oliveira RCM, Goncalves KT, Martignago ML, Mengatto V, Gaspar PC,\nde Moraes ACR, et al. Determination of lymphocyte subset reference ranges in\nperipheral blood of healthy adults by a dual-platform \ufb02ow cytometry method. Im-munol Lett 2015;163:96-101 .\n35.Berkowska M, Driessen GJ, Bikos V, Grosserichter-Wagener C, StamatopoulosK,\nCerutti A, et al. Human memory B cells originate from three distinct germinal\ncenter-dependent and -independent maturation pathways. Blood 2011;118:\n2150-8 .\n36.Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE, et al. Identi\ufb01-\ncation and characterization of circulating human transitional B cells. Blood 2011;105:4390-8 .\n37.Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow.\nNature 1997;388:133-4 .\n38.van Twillert I, van Gaans-van den Brink JAM, Poelen MCM, Helm K, Kuipers B,\nSchipper M, et al. Age related differences in dynamics of speci\ufb01c memory B cell\npopulations after clinical pertussis infection. PLoS One 2014;9:e85227 .39.Wong KJ, Timbrell V, Xi Y, Upham JW, Collins AM, Davies JM. IgE 1B cells\nare scarce, but allergen-speci\ufb01c B cells with a memory phenotype circulate in pa-\ntients with allergic rhinitis. Allergy 2015;70:420-8 .\n40.Berkowska MA, Heeringa JJ, Hajdarbegovic E, Van Der Burg M, Thio HB, Van\nHagen PM, et al. Human IgE1 B cells are derived from T cell-dependent and T\ncell-independent pathways. J Allergy Clin Immunol 2014;134:688-97.e6 .\n41.Czarnowicki T, Gonzalez J, Bonifacio KM, Shemer A, Xiangyu P, Kunjravia N,\net al. Diverse activation and differentiation of multiple B-cell subsets in patients\nwith atopic dermatitis but not in patients with psoriasis. J Allergy Clin Immunol2016;137:118-29.e5 .\n42.Jensen K, Schaffer L, Olstad OK, Bechensteen AG, Hellebostad M, TjonnfjordGE, et al. Striking decrease in the total precursor B-cell compartment during earlychildhood as evidenced by \ufb02ow cytometry and gene expression changes. PediatrHematol Oncol 2010;27:31-45 .\n43.Blanchard Rohner G, Snape MD, Kelly DF, John T, Morant A, Yu L-M, et al. Themagnitude of the antibody and memory B cell responses during priming with aprotein-polysaccharide conjugate vaccine in human infants is associated withthe persistence of antibody and the intensity of booster response. J Immunol2008;180:2165-73.\n44.Siegrist C-A, Aspinall R. B-cell responses to vaccination at the extremes of age.\nNat Rev Immunol 2009;9:185-94 .\n45.Sanoja-Flores L, Paiva B, Flores-Montero JA, Puig N, Burgos L, Garc /C19\u0131a O, et al.\nNext Generation Flow (NGF): a hgh sensitive technique to detect circulating pe-\nripheral blood (PB) clonal plasma cells (cPC) in patients with newly diagnosedplasma cell neoplasms (PCN). Blood 2015;126(23) .\n46.Grimbacher B. The European Society for Immunode\ufb01ciencies (ESID) registry2014. Clin Exp Immunol 2014;178(suppl):18-20 .\n47.Notarangelo LD, Fischer A, Geha RS, Casanova J-L, Chapel H, Conley ME, et al.Primary immunode\ufb01ciencies: 2009 update. J Allergy Clin Immunol 2009;124:1161-78 .\n48.Pihlgren M, Friedli M, Tougne C, Rochat A-F, Lambert P-H, Siegrist C-A.Reduced ability of neonatal and early-life bone marrow stromal cells to supportplasmablast survival. J Immunol 2006;176:165-72 .\n49.Moller G, Wigzell H. Antibody synthesis at the cellular level. Antibody-inducedsuppression of 19S and 7S antibody response. J Exp Med 1965;121:969-89 .\n50.Cerottini JC, McConahey PJ, Dixon FJ. The immunosuppressive effect ofpassively administered antibody IgG fragments. J Immunol 1969;102:1008-15 .\n51.Hannoun C, Megas F, Piercy J. Immunogenicity and protective ef\ufb01cacy of in\ufb02u-\nenza vaccination. Virus Res 2004;103:133-8 .\n52.Goodwin K, Viboud C, Simonsen L. Antibody response to in\ufb02uenza vaccinationin the elderly: a quantitative review. Vaccine 2006;24:1159-69 .\n53.Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine.Part II. A cost-effectiveness analysis for invasive disease in the elderly in Englandand Wales. Eur J Epidemiol 2004;19:365-75 .\n54.Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin\nInfect Dis 2008;46:1078-84 .\n55.Gr\u20aconlund MM, Arvilommi H, Kero P, Lehtonen OP, Isolauri E. Importance of in-\ntestinal colonisation in the maturation of humoral immunity in early infancy: a\nprospective follow up study of healthy infants aged 0-6 months. Arch Dis ChildFetal Neonatal Ed 2000;83:F186-92.\n56.Collins AM, Jackson KJL. A temporal model of human IgE and IgG antibody\nfunction. Front Immunol 2013;4:1-6 .\n57.Jackson KJL, Wang Y, Collins AM. Human immunoglobulin classes and sub-\nclasses\nshow variability in VDJ gene mutation levels. Immunol Cell Biol 2014;\n92:1-5 .\n58.Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure\nto effector functions. Front Immunol 2014;5:1-17 .\n59.Schroeder HWJ, Cavacini L. Structure and Function of Immunoglobulins.\nJ Allergy Clin Immunol 2010;125(suppl):S41-52 .\n60.Woof JM, Russell MW. Structure and function relationships in IgA. Mucosal Im-\nmunol 2011;4:590-7.\n61.Barzanji AJ, Emery JL. Germinal centers in the spleens of neonates and still-\nbirths. Early Hum Dev 1978;1:363-9 .\n62.Luscieti P, Hubschmid T, Cottier H, Hess MW, Sobin LH. Human lymph node\nmorphology as a function of age and site. J Clin Pathol 1980;33:454-61 .\n63.Westerga J, Timens W. Immunohistological analysis of human fetal lymph nodes.\nScand J Immunol 1989;29:103-12.\n64.Fecteau JF, C ^ot/C19eG ,N /C19eron S. A new memory CD27-IgG 1B cell population in\nperipheral blood expressing VH genes with low frequency of somatic mutation.\nJ Immunol 2006;177:3728-36.\n65.Grif\ufb01oen AW, Rijkers GT, Janssens-Korpela P, Zegers BJM. Pneumococcal poly-\nsaccharides complexed with C3d bind to human B lymphocytes via complement\nreceptor type 2. Infect Immun 1991;59:1839-45 .J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 1166.Thiel J, Kimmig L, Salzer U, Grudzien M, Lebrecht D, Hagena T, et al. Genetic\nCD21 de\ufb01ciency is associated with hypogammaglobulinemia. J Allergy Clin Im-\nmunol 2012;129:801-10.e6 .\n67.Halista SM, Johnson-Robbins LA, El-Mohandes AE, Lees A, Mond JJ, Katona\nIM. Characterization of early activation events in cord blood B cells after stimu-lation with T cell-independent activators. Pediatr Res 1998;43:496-503 .\n68.Pedraz C, Lorente F, Pedraz MJ, Salazar Villalobos V. [Development of the serum\nlevels of complement during the \ufb01rst year of life]. An Esp Pediatr 1980;13:571-6 .\n69.Johnston RBJ, Altenburger KM, Atkinson AWJ, Curry RH. Complement in the\nnewborn infant. Pediatrics 1979;64:781-6 .70.Pupovac A, Good-Jacobson KL. An antigen to remember: regulation of B cell\nmemory in health and disease. Curr Opin Immunol 2017;45:89-96 .\n71.Naradikian MS, Hao Y, Cancro MP. Age-associated B cells: key mediators of\nboth protective and autoreactive humoral responses. Immunol Rev 2016;269:118-29 .\n72.S/C19anchez ML, Almeida J, Vidriales B, L /C19opez-Berges MC, Garc /C19\u0131a-Marcos MA,\nMoro MJ, et al. Incidence of phenotypic aberrations in a series of 467 patients\nwith B chronic lymphoproliferative disorders: basis for the design of speci\ufb01c\nfour-color stainings to be used for minimal residual disease investigation. Leuke-mia 2002;16:1460-9.J ALLERGY CLIN IMMUNOL\nnnn201812BLANCO ET ALMateriales, m\u00e9todos y resultados \n\u00a0\n\u2010\u00a0109\u00a0\u2010\u00a0\n\u00a0Art\u00edculo 3  \nLa\u00a0disecci\u00f3n\u00a0de\u00a0los\u00a0defectos\u00a0de\u00a0las\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B \u00a0de\u00a0\nmemoria\u00a0y\u00a0c\u00e9lulas\u00a0plasm\u00e1ticas\u00a0que\u00a0expresan\u00a0diferentes\u00a0subclases \u00a0de\u00a0\ninmunoglobulinas\u00a0proporciona\u00a0 una\u00a0base\u00a0s\u00f3lida\u00a0para\u00a0una\u00a0(nueva)\u00a0r e\u2010\nclasificaci\u00f3n\u00a0de\u00a0la\u00a0IDVC\u00a0y\u00a0de\u00a0 los\u00a0d\u00e9ficits\u00a0de\u00a0subclases\u00a0de\u00a0\ninmunoglobulinas\u00a0\nElena\u00a0Blanco1,\u00a0Mart\u00edn\u00a0P\u00e9rez\u2010Andr\u00e9s1,\u00a0Sonia\u00a0Arriba\u2010M\u00e9ndez2,\u00a0Cristina\u00a0Serrano3,\u00a0Luc\u00eda\u00a0del\u00a0Pino\u2010\nMolina4,\u00a0Susana\u00a0Silva5,\u00a0Ignacio\u00a0Criado1,\u00a0Ignacio\u00a0Madruga6,\u00a0Ana\u00a0Serra\u00a0Caetano5,\u00a0Teresa\u00a0\nContreras\u2010Sanfeliciano7,\u00a0Francisco\u00a0Sala8,\u00a0Alejandro\u00a0Mart\u00edn9,\u00a0Jos\u00e9\u00a0Mar\u00eda\u00a0Bastida9,\u00a0F\u00e9lix\u00a0Lorente2,\u00a0\nCarlos\u00a0Prieto10,\u00a0Ignacio\u00a0D\u00e1vila11,\u00a0Miguel\u00a0Marcos6,\u00a0Tomas\u00a0Kalina12,\u00a0Marcela\u00a0Vlkova13,\u00a0Carolien\u00a0\nBonroy14,\u00a0Jan\u00a0Philipp\u00e914,\u00a0Eduardo\u00a0L\u00f3pez\u2010Granados4,\u00a0Ana\u00a0E.\u00a0da\u00a0Sousa5,\u00a0Mirjam\u00a0van\u00a0der\u00a0Burg15,\u00a0\nJacques\u00a0J.M.\u00a0van\u00a0Dongen16,\u00a0Alberto\u00a0Orfao1,\u00a0por\u00a0el\u00a0grupo\u00a0de\u00a0inmunodeficiencias\u00a0primarias\u00a0de\u00a0\nEuroFlow\u00a0(EuroFlow\u00a0PID).\u00a0\n1Centro\u00a0de\u00a0Investigaci\u00f3n\u00a0del\u00a0C\u00e1nc er\u00a0(IBMCC,\u00a0USAL\u2010CSIC),\u00a0Departam ento\u00a0de\u00a0Medicina\u00a0y\u00a0Servicio\u00a0de\u00a0Citometr\u00eda\u00a0\n(NUCLEUS),\u00a0Universidad\u00a0de\u00a0Salama nca,\u00a0IBSAL\u00a0y\u00a0CIBERONC,\u00a0Salamanc a,\u00a0Espa\u00f1a.\u00a0\n2Servicio\u00a0de\u00a0Pediatr\u00eda,\u00a0Hospital\u00a0 Universitario\u00a0de\u00a0Salamanca,\u00a0Sal amanca,\u00a0Espa\u00f1a.\u00a0\n3Servicio\u00a0de\u00a0Inmunolog\u00eda,\u00a0Fundaci\u00f3 n\u00a0Jim\u00e9nez\u00a0D\u00edaz,\u00a0Madrid,\u00a0Espa\u00f1a .\u00a0\n4Departamento\u00a0de\u00a0Inmunolog\u00eda\u00a0Cl\u00ednica,\u00a0Hospital\u00a0Universitario\u00a0La\u00a0 Paz,\u00a0Grupo\u00a0de\u00a0Fisiopatolog\u00eda\u00a0de\u00a0\nInmunodeficiencias,\u00a0Instituto\u00a0pa ra\u00a0la\u00a0investigaci\u00f3n\u00a0de\u00a0la\u00a0Salud \u00a0IdiPAZ,\u00a0Madrid,\u00a0Espa\u00f1a.\u00a0\n5Instituto\u00a0de\u00a0Medicina\u00a0Molecular, \u00a0Faculdad\u00a0de\u00a0Medicina,\u00a0Universi dad\u00a0de\u00a0Lisboa,\u00a0Portugal.\u00a0\n6Servicio\u00a0de\u00a0Medicina\u00a0Interna,\u00a0Hos pital\u00a0Universitario\u00a0de\u00a0Salaman ca,\u00a0IBSAL;\u00a0Departamento\u00a0de\u00a0Medicina,\u00a0Universidad\u00a0\nde\u00a0Salamanca,\u00a0Salamanca,\u00a0Espa\u00f1a.\u00a0\n7Servicio\u00a0de\u00a0Bioqu\u00edmica\u00a0Cl\u00ednica,\u00a0H ospital\u00a0Universitario\u00a0de\u00a0Salam anca,\u00a0Salamanca,\u00a0Espa\u00f1a.\u00a0\n8Servicio\u00a0de\u00a0Hematolog\u00eda,\u00a0Hospita l\u00a0de\u00a0Navarra,\u00a0Pamplona,\u00a0Espa\u00f1a. \u00a0\n9Servicio\u00a0de\u00a0Hematolog\u00eda,\u00a0Hospita l\u00a0Universitario\u00a0de\u00a0Salamanca,\u00a0I BSAL,\u00a0Salamanca,\u00a0Espa\u00f1a.\u00a0\n10Servicio\u00a0de\u00a0Bioinform\u00e1tica\u00a0(NUCL EUS),\u00a0Universidad\u00a0de\u00a0Salamanca, \u00a0Salamanca,\u00a0Espa\u00f1a.\u00a0\n11Servicio\u00a0de\u00a0Alergia,\u00a0Hospital\u00a0Un iversitario\u00a0de\u00a0Salamanca,\u00a0IBSAL ,\u00a0Departamento\u00a0de\u00a0Ciencias\u00a0Biom\u00e9dicas\u00a0y\u00a0del\u00a0\nDiagn\u00f3stico,\u00a0Universidad\u00a0de\u00a0Sa lamanca,\u00a0Salamanca,\u00a0Espa\u00f1a.\u00a0\n12Departamento\u00a0de\u00a0Hematolog\u00eda/Onco log\u00eda,\u00a02\u00ba\u00a0Facultad\u00a0de\u00a0Medicina, \u00a0Universidad\u00a0Charles,\u00a0Praga,\u00a0Rep\u00fablica\u00a0Checa\u00a0\n13Departamento\u00a0de\u00a0Inmunolog\u00eda\u00a0Cl\u00edn ica\u00a0y\u00a0Alergolog\u00eda,\u00a0Hospital\u00a0Uni versitario\u00a0St\u00a0Anne,\u00a0Facultad\u00a0de\u00a0Medicina,\u00a0\nUniversidad\u00a0Masaryk,\u00a0Brno,\u00a0Rep\u00fablica\u00a0Checa.\u00a0\n14Departamento\u00a0de\u00a0Medicina\u00a0de\u00a0Labo ratorio,\u00a0Hospital\u00a0Universitario \u00a0de\u00a0Gante,\u00a0Gante,\u00a0B\u00e9lgica.\u00a0\n15Departamento\u00a0de\u00a0Inmunolog\u00eda,\u00a0Cen tro\u00a0M\u00e9dico\u00a0de\u00a0la\u00a0Universidad\u00a0Er asmus,\u00a0Rotterdam,\u00a0Pa\u00edses\u00a0Bajos.\u00a0\n16Departamento\u00a0de\u00a0Inmuno\u2010Hematolog \u00eda\u00a0y\u00a0Transfusi\u00f3n\u00a0de\u00a0Sangre,\u00a0Cen tro\u00a0M\u00e9dico\u00a0de\u00a0la\u00a0Universidad\u00a0de\u00a0Leiden,\u00a0\nUniversidad\u00a0de\u00a0Leiden,\u00a0L eiden,\u00a0Pa\u00edses\u00a0bajos.\u00a0\n\u00a0\nJournal\u00a0of\u00a0Allergy\u00a0and\u00a0Clinical\u00a0Immunology\u00a0\n(sometido\u00a0para\u00a0publicaci\u00f3n\u00a0y\u00a0en\u00a0revisi\u00f3n)\u00a0\n\u00a0\nLa\u00a0informaci\u00f3n\u00a0suplementaria\u00a0correspondiente\u00a0a\u00a0este\u00a0art\u00edculo\u00a0es t\u00e1\u00a0disponible\u00a0en\u00a0el\u00a0anexo\u00a0II\u00a0y\u00a0el\u00a0CD\u2010ROM\u00a0\nadjuntos\u00a0al\u00a0final\u00a0de\u00a0la\u00a0presen te\u00a0memoria\u00a0de\u00a0Tesis\u00a0doctoral.Materiales, m\u00e9todos y resultados \n\u00a0\n\u2010\u00a0110\u00a0\u2010\u00a0\n\u00a0Introducci\u00f3n.\u00a0 Las\u00a0 IDP\u2010Ac\u00a0 son\u00a0 un\u00a0 grupo\u00a0 heterog\u00e9n eo\u00a0 de\u00a0 enfermedades\u00a0 caracteriza das\u00a0\nfundamentalmente\u00a0por\u00a0una\u00a0producci \u00f3n\u00a0deficitaria\u00a0de\u00a0\u22651\u00a0isotipo(s )\u00a0o\u00a0subclase(s)\u00a0de\u00a0Ig(s),\u00a0cuya\u00a0\nclasificaci\u00f3n\u00a0se\u00a0basa\u00a0(principal mente)\u00a0en\u00a0el\u00a0isotipo\u00a0o\u00a0subclase \u00a0afectado.\u00a0En\u00a0conjunto,\u00a0las\u00a0IDP\u2010Ac\u00a0\nsuponen\u00a0la\u00a0mayor\u00eda\u00a0(50\u201070%)\u00a0de\u00a0las\u00a0IDP.\u00a0Desde\u00a0el\u00a0punto\u00a0de\u00a0vista \u00a0cl\u00ednico,\u00a0estos\u00a0pacientes\u00a0\nmuestran\u00a0un\u00a0comportamiento\u00a0variable,\u00a0desde\u00a0casos\u00a0en\u00a0los\u00a0que\u00a0la\u00a0 enfermedad\u00a0permanece\u00a0\nasintom\u00e1tica\u00a0durante\u00a0toda\u00a0la\u00a0vid a,\u00a0hasta\u00a0otros\u00a0en\u00a0los\u00a0que\u00a0se\u00a0ma nifiesta\u00a0bajo\u00a0la\u00a0forma\u00a0de\u00a0\ninfecciones\u00a0bacterianas\u00a0graves,\u00a0autoinmunidad\u00a0y/o\u00a0organomegalia s.\u00a0En\u00a0estos\u00a0pacientes,\u00a0el\u00a0\nposible\u00a0defecto\u00a0gen\u00e9tico\u00a0subyacente\u00a0solo\u00a0se\u00a0conoce\u00a0en\u00a0<10%\u00a0de\u00a0l os\u00a0pacientes,\u00a0lo\u00a0que\u00a0ha\u00a0\nreforzado\u00a0el\u00a0papel\u00a0del\u00a0estudio\u00a0de\u00a0las\u00a0subpoblaciones\u00a0linfocitar ias\u00a0de\u00a0SP\u00a0mediante\u00a0citometr\u00eda\u00a0de\u00a0\nflujo,\u00a0en\u00a0el\u00a0diagn\u00f3stico\u00a0y\u00a0clasificaci\u00f3n\u00a0de\u00a0este\u00a0grupo\u00a0de\u00a0IDP,\u00a0 habi\u00e9ndose\u00a0asociado\u00a0la\u00a0existencia\u00a0\nde\u00a0alteraciones\u00a0en\u00a0las\u00a0distintas \u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de \u00a0SP,\u00a0especialmente\u00a0el\u00a0descenso\u00a0de\u00a0\nl o s \u00a0l i n f o c i t o s \u00a0B \u00a0d e \u00a0m e m o r i a \u00a0c o n \u00a0c a m b i o \u00a0d e \u00a0i s o t i p o , \u00a0c o n \u00a0u n a \u00a0m a y o r\u00a0 frecuencia\u00a0 de\u00a0 casos\u00a0\nsintom\u00e1ticos.\u00a0\nObjetivo.\u00a0 El\u00a0objetivo\u00a0de\u00a0este\u00a0trabajo\u00a0se\u00a0centr\u00f3\u00a0en\u00a0identificar\u00a0las\u00a0posibl es\u00a0alteraciones\u00a0num\u00e9ricas\u00a0\nde\u00a0las\u00a0distintas\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0y\u00a0CPs\u00a0de\u00a0SP,\u00a0inclu yendo\u00a0aquellas\u00a0que\u00a0expresan\u00a0\ndiferentes\u00a0isotipos\u00a0y\u00a0subclases\u00a0 de\u00a0Igs,\u00a0en\u00a0pacientes\u00a0con\u00a0IDVC,\u00a0 d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0asociado\u00a0\na\u00a0d\u00e9ficit\u00a0de\u00a0IgA\u00a0y\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA,\u00a0y\u00a0su\u00a0relaci\u00f3n\u00a0con\u00a0 el\u00a0comportamiento\u00a0cl\u00ednico\u00a0de\u00a0la\u00a0\nenfermedad.\u00a0\nMuestras,\u00a0materiales\u00a0y\u00a0m\u00e9todos.\u00a0 En\u00a0conjunto,\u00a0se\u00a0incluyeron\u00a0e n\u00a0el\u00a0estudio\u00a0un\u00a0total\u00a0de\u00a0111\u00a0\npacientes\u00a0con\u00a0IDP\u2010Ac\u00a0(47\u00a0con\u00a0IDVC,\u00a059\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0 IgA\u00a0y\u00a05\u00a0con\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0\nIgG\u00a0asociado\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0IgA),\u00a0 y\u00a0140\u00a0donantes\u00a0sanos\u00a0pareados\u00a0p or\u00a0grupo\u00a0de\u00a0edad\u00a0(4\u20105\u00a0a\u00f1os,\u00a06\u20109\u00a0\na\u00f1os,\u00a010\u201017\u00a0a\u00f1os,\u00a018\u201039\u00a0a\u00f1os,\u00a040\u201059\u00a0a\u00f1os,\u00a060\u201079\u00a0a\u00f1os\u00a0y\u00a0>80\u00a0a\u00f1os ).\u00a0En\u00a0todos\u00a0los\u00a0pacientes\u00a0y\u00a0\ncontroles\u00a0se\u00a0obtuvieron\u00a0muestras\u00a0de\u00a0SP\u00a0que\u00a0fueron\u00a0analizadas\u00a0me diante\u00a0citometr\u00eda\u00a0de\u00a0flujo,\u00a0\nutilizando\u00a0el\u00a0panel\u00a0de\u00a0Acs\u00a0dirigid os\u00a0frente\u00a0a\u00a0los\u00a0distintos\u00a0iso tipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs\u00a0y\u00a0protocolos\u00a0\nvalidados\u00a0previamente.\u00a0En\u00a0cada\u00a0mu estra\u00a0se\u00a0analizaron\u00a0un\u00a0m\u00ednimo\u00a0 de\u00a05\u00a0millones\u00a0de\u00a0leucocitos,\u00a0Materiales, m\u00e9todos y resultados \n\u00a0\n\u2010\u00a0111\u00a0\u2010\u00a0\n\u00a0empleando\u00a0un\u00a0cit\u00f3metro\u00a0de\u00a0flujo\u00a0Fortessa\u00a0X\u201020.\u00a0Los\u00a0pacientes\u00a0fu eron\u00a0clasificados\u00a0de\u00a0acuerdo\u00a0a\u00a0\nlos\u00a0defectos\u00a0observados\u00a0en\u00a0las\u00a0subpoblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0corr espondientes\u00a0a\u00a0distintos\u00a0estadios\u00a0\nmadurativos\u00a0y\u00a0definidos\u00a0por\u00a0el\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Ig\u00a0(IgM,\u00a0I gD,\u00a0IgG1\u20104,\u00a0IgA1\u20102)\u00a0expresada,\u00a0\ncorrelacionando\u00a0dichos\u00a0patrones\u00a0de\u00a0alteraci\u00f3n\u00a0con\u00a0el\u00a0subtipo\u00a0di agn\u00f3stico\u00a0y\u00a0las\u00a0manifestaciones\u00a0\ncl\u00ednicas\u00a0de\u00a0la\u00a0enfermedad.\u00a0\u00a0\nResultados.\u00a0 En\u00a0todos\u00a0los\u00a0pacientes\u00a0diagnosticados\u00a0de\u00a0IDP\u2010Ac \u00a0se\u00a0detectaron\u00a0alteraciones\u00a0en\u00a0al\u00a0\nmenos\u00a0una\u00a0poblaci\u00f3n\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y/o\u00a0CPs\u00a0de\u00a0SP,\u00a0r especto\u00a0a\u00a0los\u00a0valores\u00a0normales\u00a0\nde\u00a0referencia\u00a0para\u00a0su\u00a0grupo\u00a0de\u00a0edad.\u00a0Entre\u00a0los\u00a0pacientes\u00a0con\u00a0d\u00e9 ficit\u00a0selectivo\u00a0de\u00a0IgA,\u00a0las\u00a0\nalteraciones\u00a0encontradas\u00a0estaban\u00a0restringidas\u00a0a\u00a0los\u00a0compartimen tos\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0\ny\u00a0de\u00a0CPs\u00a0IgA+.\u00a0Aunque\u00a0la\u00a0pr\u00e1ctica\u00a0totalidad\u00a0de\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0selecti vo\u00a0de\u00a0IgA\u00a0presentaban\u00a0\nun\u00a0defecto\u00a0severo\u00a0de\u00a0CPs\u00a0IgA+,\u00a0se\u00a0identificaron\u00a0dos\u00a0grupos\u00a0bien\u00a0definidos\u00a0de\u00a0pacientes\u00a0con\u00a0\ndistinto\u00a0comportamiento\u00a0cl\u00ednico,\u00a0dependiendo\u00a0del\u00a0grado\u00a0de\u00a0afect aci\u00f3n\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0IgA+.\u00a0As\u00ed,\u00a0aquellos\u00a0pacientes\u00a0con\u00a0un\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0que\u00a0p resentaban\u00a0mayor\u00a0\ngrado\u00a0de\u00a0afectaci\u00f3n\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0IgA+,\u00a0presentaron\u00a0mayor\u00a0frecuencia\u00a0de\u00a0\ninfecciones\u00a0 no\u00a0 respiratorias\u00a0 y\u00a0 de\u00a0 autoinmunidad\u00a0 espec\u00edfica\u00a0 de\u00a0 \u00f3 rgano,\u00a0 adem\u00e1s\u00a0 de\u00a0 una\u00a0\nprevalencia\u00a0de\u00a0antecedentes\u00a0fam iliares\u00a0de\u00a0IDP\u2010Ac\u00a0m\u00e1s\u00a0elevada.\u00a0\nA\u00a0su\u00a0vez,\u00a0los\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0asociad o\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0IgA\u00a0y\u00a0con\u00a0\nIDVC\u00a0mostraron,\u00a0adem\u00e1s\u00a0de\u00a0las\u00a0alteraciones\u00a0t\u00edpicas\u00a0del\u00a0d\u00e9ficit\u00a0 selectivo\u00a0de\u00a0IgA,\u00a0distintos\u00a0perfiles\u00a0\nde\u00a0afectaci\u00f3n\u00a0de\u00a0diferentes\u00a0subpoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0y\u00a0CP s\u00a0IgG+,\u00a0y,\u00a0con\u00a0menor\u00a0frecuencia\u00a0\ntambi\u00e9n\u00a0de\u00a0memoria\u00a0IgM++D+,\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0y\u00a0linfocito s\u00a0B\u00a0inmaduros/transicionales.\u00a0A s\u00ed,\u00a0de\u00a0\nacuerdo\u00a0con\u00a0el\u00a0patr\u00f3n\u00a0de\u00a0alteraci\u00f3n\u00a0de\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0A cs,\u00a0todos\u00a0los\u00a0pacientes\u00a0que\u00a0\npresentaban\u00a0d\u00e9ficit\u00a0de\u00a0subclases \u00a0de\u00a0IgG\u00a0asociado\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0I gA\u00a0presentaban\u00a0un\u00a0descenso\u00a0\nsignificativo\u00a0del\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0IgA+\u00a0e\u00a0IgG2+,\u00a0asociado\u00a0en\u00a02\u00a0de\u00a0los\u00a05\u00a0casos\u00a0\nanalizados,\u00a0a\u00a0CPs\u00a0detectables\u00a0en \u00a0SP.\u00a0Por\u00a0el\u00a0contrario,\u00a0todos\u00a0lo s\u00a0pacientes\u00a0diagnosticados\u00a0de\u00a0IDVC\u00a0\ncarec\u00edan\u00a0de\u00a0CPs\u00a0de\u00a0isotipo\u00a0IgG\u00a0e \u00a0IgA\u00a0en\u00a0frecuencia\u00a0superiores\u00a0a \u00a00,01\u00a0c\u00e9lulas/\u00b5l.\u00a0Sin\u00a0embargo,\u00a0en\u00a0Materiales, m\u00e9todos y resultados \n\u00a0\n\u2010\u00a0112\u00a0\u2010\u00a0\n\u00a0funci\u00f3n\u00a0de\u00a0las\u00a0alteraciones\u00a0observadas\u00a0en\u00a0las\u00a0subpoblaciones\u00a0li nfocitos\u00a0B\u00a0de\u00a0memoria,\u00a0pudimos\u00a0\nsubclasificar\u00a0los\u00a0pacientes\u00a0en\u00a06\u00a0grupos,\u00a0seg\u00fan\u00a0los\u00a0isotipos\u00a0y\u00a0s ubclases\u00a0de\u00a0inmunoglobulina\u00a0\nafectados:\u00a0i)\u00a0Grupo\u00a06,\u00a0casos\u00a0con\u00a0un\u00a0descenso\u00a0marcado\u00a0de\u00a0todas\u00a0l as\u00a0subpoblaciones\u00a0de\u00a0linfocitos\u00a0\nB\u00a0de\u00a0memoria;\u00a0ii)\u00a0Grupo\u00a05,\u00a0pacientes\u00a0que\u00a0presentaban\u00a0un\u00a0d\u00e9ficit \u00a0num\u00e9rico\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0CD27+\u00a0con\u00a0valores\u00a0casi\u00a0normales\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0CD27\u2010\u00a0IgG3+;\u00a0iii)\u00a0Grupo\u00a04,\u00a0\npacientes\u00a0que\u00a0carecen\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0 isotipo;\u00a0y\u00a0iv)\u00a0casos\u00a0que\u00a0\npresentaban\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0IgG3+\u00a0e\u00a0IgG1+\u00a0y\u00a0sin\u00a0cambio\u00a0de\u00a0isotipo\u00a0(IgM++D+)\u00a0en\u00a0\nausencia\u00a0(Grupo\u00a03)\u00a0y;\u00a0v)\u00a0en\u00a0prese ncia\u00a0(Grupo\u00a02)\u00a0de\u00a0linfocitos\u00a0B \u00a0de\u00a0memoria\u00a0IgG2+;\u00a0y\u00a0vi)\u00a0Grupo\u00a01,\u00a0\ncasos\u00a0que\u00a0presentaban\u00a0adem\u00e1s\u00a0linfocitos\u00a0de\u00a0memoria\u00a0IgA1+.\u00a0Estos\u00a0diferentes\u00a0patrones\u00a0de\u00a0\nalteraci\u00f3n\u00a0 celular\u00a0 se\u00a0 asociaban\u00a0 con\u00a0 distintos\u00a0 perfiles\u00a0 de\u00a0 manif estaciones\u00a0 cl\u00ednicas.\u00a0 As\u00ed,\u00a0 los\u00a0\npacientes\u00a0 que\u00a0 manten\u00edan\u00a0 linfocitos\u00a0 B\u00a0 de\u00a0 memoria\u00a0 IgM++D+,\u00a0 IgG3+\u00a0e \u00a0I g G 1+\u00a0 circulantes,\u00a0\npresentaban\u00a0una\u00a0cl\u00ednica\u00a0m\u00e1s\u00a0leve, \u00a0respecto\u00a0a\u00a0los\u00a0que\u00a0mostraban\u00a0 un\u00a0d\u00e9ficit\u00a0de\u00a0estas\u00a0poblaciones\u00a0\nB.\u00a0En\u00a0concreto,\u00a0los\u00a0pacientes\u00a0que\u00a0no\u00a0ten\u00edan\u00a0linfocitos\u00a0B\u00a0de\u00a0mem oria\u00a0circulantes\u00a0con\u00a0cambio\u00a0de\u00a0\nisotipo,\u00a0se\u00a0caracterizaron\u00a0por\u00a0 una\u00a0mayor\u00a0frecuencia\u00a0de\u00a0enteropa t\u00eda\u00a0y\u00a0citopenias\u00a0autoinmunes,\u00a0\nmientras\u00a0que\u00a0los\u00a0casos\u00a0que\u00a0presentaban\u00a0un\u00a0d\u00e9ficit\u00a0num\u00e9rico\u00a0de\u00a0t odos\u00a0los\u00a0tipos\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0CD27+,\u00a0asociado\u00a0a\u00a0valores\u00a0(casi)\u00a0normales\u00a0de\u00a0IgG3+,\u00a0presentaban\u00a0con\u00a0mayor\u00a0frecuencia\u00a0\nhepatomegalia\u00a0y\u00a0autoinmunidad\u00a0es pec\u00edfica\u00a0de\u00a0\u00f3rgano.\u00a0As\u00ed\u00a0mismo,\u00a0 los\u00a0pacientes\u00a0con\u00a0un\u00a0marcado\u00a0\ndescenso\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfoci tos\u00a0B\u00a0de\u00a0memoria\u00a0de\u00a0todos\u00a0los\u00a0i sotipos,\u00a0presentaban\u00a0un\u00a0\nfenotipo\u00a0cl\u00ednico\u00a0mixto\u00a0entre\u00a0los\u00a0dos\u00a0grupos\u00a0anteriores,\u00a0con\u00a0ele vada\u00a0frecuencia\u00a0de\u00a0enteropat\u00eda,\u00a0\ncitopenias\u00a0autoinmunes\u00a0y\u00a0hepatom egalia,\u00a0asociadas\u00a0a\u00a0mayor\u00a0preva lencia\u00a0de\u00a0bronquiectasias\u00a0y\u00a0\ngranulomas. \u00a0\u00a0\nConclusiones .\u00a0El\u00a0an\u00e1lisis\u00a0detallado\u00a0de\u00a0los\u00a0di stintos\u00a0compartimentos\u00a0de\u00a0linf ocitos\u00a0B\u00a0y\u00a0CPs\u00a0de\u00a0SP\u00a0\nde\u00a0acuerdo\u00a0al\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0IgG1\u20104\u00a0e\u00a0IgA1\u20102\u00a0que\u00a0expresa n,\u00a0junto\u00a0a\u00a0su\u00a0estadio\u00a0madurativo,\u00a0\nmediante\u00a0 citometr\u00eda\u00a0 de\u00a0 flujo\u00a0 de\u00a0 alta\u00a0 sensibilidad\u00a0 (<10\u20105),\u00a0 permite\u00a0 identificar\u00a0 perfiles\u00a0\ncaracter\u00edsticos\u00a0de\u00a0alteraciones\u00a0de\u00a0dichas\u00a0poblaciones\u00a0de\u00a0linfoc itos\u00a0B\u00a0y\u00a0CPs,\u00a0asociadas\u00a0a\u00a0distinto\u00a0\ncomportamiento\u00a0cl\u00ednico.\u00a0Globalmen te,\u00a0las\u00a0CPs\u00a0de\u00a0SP\u00a0ser\u00edan\u00a0el\u00a0co mpartimento\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0m\u00e1s\u00a0Materiales, m\u00e9todos y resultados \n\u00a0\n\u2010\u00a0113\u00a0\u2010\u00a0\n\u00a0sensible\u00a0para\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0IDP\u2010Ac,\u00a0mientras\u00a0que\u00a0el\u00a0an\u00e1lisi s\u00a0de\u00a0las\u00a0distintas\u00a0subpoblaciones\u00a0\nde\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria,\u00a0definidas\u00a0de\u00a0acuerdo\u00a0al\u00a0isotipo\u00a0y\u00a0s ubclase\u00a0de\u00a0Ig\u00a0que\u00a0expresan,\u00a0\npermitir\u00eda\u00a0 discriminar\u00a0 entre\u00a0 grupos\u00a0 de\u00a0 pacientes\u00a0 con\u00a0 IDP\u2010Ac\u00a0 que \u00a0p r e s e n t a n \u00a0d i s t i n t o \u00a0\ncomportamiento\u00a0cl\u00ednico,\u00a0proporci onando\u00a0la\u00a0evaluaci\u00f3n\u00a0de\u00a0estas\u00a0p oblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B,\u00a0\ninformaci\u00f3n\u00a0 complementaria\u00a0 a\u00a0 la\u00a0 obtenida\u00a0 con\u00a0 el\u00a0 estudio\u00a0 de\u00a0 los\u00a0 niveles\u00a0 s\u00e9ricos\u00a0 de\u00a0 Acs,\u00a0\ncontribuyendo\u00a0a\u00a0entender\u00a0mejor\u00a0la\u00a0patog\u00e9nesis\u00a0de\u00a0las\u00a0IDP\u2010Ac\u00a0y\u00a0a \u00a0mejorar\u00a0su\u00a0diagn\u00f3stico,\u00a0\nclasificaci\u00f3n\u00a0y\u00a0monitorizaci\u00f3n,\u00a0especialmente\u00a0en\u00a0aquellos\u00a0casos \u00a0que\u00a0han\u00a0sido\u00a0tratados\u00a0con\u00a0Igs\u00a0de\u00a0\nsustituci\u00f3n.\u00a0\n\u00a0\u2010\u00a0115\u00a0\u2010\u00a0\n\u00a0Dissection\u00a0of\u00a0defects\u00a0in\u00a0memory\u00a0 B\u2010cell\u00a0and\u00a0plasma\u00a0cell\u00a0subsets\u00a0\nexpressing\u00a0different\u00a0immunoglob ulin\u00a0subclasses\u00a0provides\u00a0basis\u00a0\nfor\u00a0(new)\u00a0re\u2010classification\u00a0of\u00a0CV ID\u00a0and\u00a0Ig\u2010subclass\u00a0deficiencie s.\u00a0\nElena\u00a0Blanco,\u00a0MSc1\u00a7;\u00a0Mart\u00edn\u00a0P\u00e9rez\u2010Andr\u00e9s,\u00a0PhD1\u00a7;\u00a0Sonia\u00a0Arriba\u2010M\u00e9ndez,\u00a0MD,\u00a0PhD2;\u00a0Cristina\u00a0\nSerrano,\u00a0MD3;\u00a0Luc\u00eda\u00a0del\u00a0Pino\u2010Molina ,\u00a0PhD4;\u00a0Susana\u00a0Silva,\u00a0MD;\u00a0PhD5;\u00a0Ignacio\u00a0Criado\u00a0MSc1;\u00a0Ignacio\u00a0\nMadruga\u00a0MD6;\u00a0Ana\u00a0Serra\u00a0Caetano\u00a0MSc5;\u00a0Teresa\u00a0Contreras\u2010Sanfeliciano\u00a0MD7;\u00a0Francisco\u00a0Sala,\u00a0\nMD8;\u00a0Alejandro\u00a0Mart\u00edn,\u00a0MD,\u00a0PhD9;\u00a0Jos\u00e9\u00a0Mar\u00eda\u00a0Bastida,\u00a0MD,\u00a0PhD9;\u00a0F\u00e9lix\u00a0Lorente,\u00a0MD,\u00a0PhD2;\u00a0Carlos\u00a0\nPrieto,\u00a0PhD\u00a010;\u00a0Ignacio\u00a0D\u00e1vila,\u00a0MD,\u00a0PhD11;\u00a0Miguel\u00a0Marcos,\u00a0MD,\u00a0PhD6;\u00a0Tomas\u00a0Kalina,\u00a0MD,\u00a0PhD12;\u00a0\nMarcela\u00a0 Vlkova,\u00a0 PhD13;\u00a0 Carolien\u00a0 Bonroy,\u00a0 PhD14;\u00a0 Jan\u00a0 Philipp\u00e9,\u00a0 MD,\u00a0 PhD14;\u00a0 Eduardo\u00a0 L\u00f3pez\u2010\nGranados,\u00a0MD,\u00a0PhD4;\u00a0Ana\u00a0E.\u00a0da\u00a0Sousa\u00a0PhD5;\u00a0Mirjam\u00a0van\u00a0der\u00a0Burg,\u00a0PhD15;Jacques\u00a0J.M.\u00a0van\u00a0\nDongen,\u00a0MD,\u00a0PhD16*;\u00a0Alberto\u00a0Orfao,\u00a0MD,\u00a0PhD1*,\u00a0on\u00a0behalf\u00a0of\u00a0the\u00a0 EuroFlow\u00a0PID\u00a0group.\u00a0\u00a0\n\u00a7Both\u00a0authors\u00a0contributed\u00a0equally\u00a0t o\u00a0this\u00a0work\u00a0and\u00a0should\u00a0both\u00a0b e\u00a0considered\u00a0as\u00a0first\u00a0author.\u00a0\n*Both\u00a0authors\u00a0contributed\u00a0equally\u00a0to\u00a0this\u00a0work\u00a0and\u00a0should\u00a0both\u00a0 be\u00a0considered\u00a0as\u00a0last\u00a0author.\u00a0\nAffiliations:\u00a0\n1Department\u00a0of\u00a0Medicine,\u00a0Cancer\u00a0Research\u00a0Centre\u00a0(IBMCC,\u00a0USAL\u2010CSI C),\u00a0Cytometry\u00a0Service\u00a0(NUCLEUS),\u00a0University\u00a0\nof\u00a0Salamanca\u00a0(USAL),\u00a0Institute\u00a0of\u00a0Biomedical\u00a0Research\u00a0of\u00a0Salama nca\u00a0(IBSAL),\u00a0Salamanca,\u00a0Spain\u00a0and\u00a0Biomedical\u00a0\nResearch\u00a0Networking\u00a0Centre\u00a0Consortium\u00a0of\u00a0Oncology\u00a0(CIBERONC)\u00a0In stituto\u00a0de\u00a0salud\u00a0Carlo s\u00a0III,\u00a0Madrid,\u00a0Spain;\u00a0\n2Servicio\u00a0de\u00a0Pediatr\u00eda,\u00a0Hospital\u00a0Universitario\u00a0de\u00a0 Salamanca,\u00a0Sal amanca,\u00a0 Spain;\u00a03Servicio\u00a0 de\u00a0 inmunolog\u00eda,\u00a0\nFundaci\u00f3n\u00a0 Jim\u00e9nez\u00a0 D\u00edaz,\u00a0 Madrid,\u00a0 Spain;\u00a04Clinical\u00a0 Immunology\u00a0 Department,\u00a0 University\u00a0 Hospital\u00a0 La\u00a0\nPaz\u00a0and\u00a0Physiopathology\u00a0 of\u00a0 Lymphocytes\u00a0 in\u00a0 Immunodeficiencies\u00a0 Gr oup,\u00a0 IdiPAZ\u00a0 Institute\u00a0 for\u00a0 Health\u00a0\nResearch,\u00a0Madrid,\u00a0Spain;\u00a05Instituto\u00a0de\u00a0Medicina\u00a0Molecular,\u00a0Faculdade\u00a0de\u00a0Medicina,\u00a0Univers idade\u00a0de\u00a0Lisboa,\u00a0\nPortugal;\u00a06Servicio\u00a0de\u00a0Medicina\u00a0Interna,\u00a0Hospital\u00a0Universitario\u00a0de\u00a0Salaman ca,\u00a0Institute\u00a0for\u00a0Biomedical\u00a0Research\u00a0\nof\u00a0Salamanca\u00a0(IBSAL),\u00a0Department\u00a0of\u00a0Medicine,\u00a0University\u00a0of\u00a0Sal amanca\u00a0(USAL),\u00a0Salamanca,\u00a0Spain;\u00a07Servicio\u00a0de\u00a0\nBioqu\u00edmica\u00a0cl\u00ednica,\u00a0Hospital\u00a0Universitario\u00a0de\u00a0Salamanca,\u00a0Salama nca,\u00a0Spain;\u00a08Servicio\u00a0de\u00a0Hematolog\u00eda,\u00a0Hospital\u00a0\nde\u00a0 Navarra,\u00a0 Pamplona,\u00a0 Spain;\u00a09Servicio\u00a0 de\u00a0 Hematolog\u00eda,\u00a0 Hospital\u00a0 Universitario\u00a0 de\u00a0 Salamanca,\u00a0 I BSAL,\u00a0\nSalamanca,\u00a0Spain;\u00a010Bioinformatics\u00a0service\u00a0(NUCLEUS),\u00a0University\u00a0of\u00a0Salamanca,\u00a0Sala manca,\u00a0Spain;\u00a011Servicio\u00a0de\u00a0\nAlergia,\u00a0 Hospital\u00a0 Universitario\u00a0 de\u00a0 Salamanca,\u00a0 Institute\u00a0 for\u00a0 Bio medical\u00a0 Research\u00a0 of\u00a0 Salamanca\u00a0 (IBSAL),\u00a0\nBiomedical\u00a0and\u00a0Diagnosis\u00a0Science\u00a0 Department,\u00a0University\u00a0of\u00a0Sala manca\u00a0(USAL),\u00a0Salamanca,\u00a0Spain;\u00a012CLIP,\u00a0Dept\u00a0\nof\u00a0Haematology/Oncology,\u00a02nd\u00a0Faculty\u00a0of\u00a0Medicine,\u00a0Charles\u00a0Unive rsity,\u00a0Prague,\u00a0Czech\u00a0Republic;\u00a013Department\u00a0\nof\u00a0Clinical\u00a0Immunology\u00a0and\u00a0Allergology,\u00a0St\u00a0Anne's\u00a0University\u00a0Ho spital,\u00a0and\u00a0Faculty\u00a0of\u00a0Medicine,\u00a0Masaryk\u00a0\nUniversity,\u00a0Brno,\u00a0Czech\u00a0Republic;\u00a014Department\u00a0of\u00a0Laboratory\u00a0Medicine,\u00a0University\u00a0Hospital\u00a0Ghent,\u00a0G hent,\u00a0\nBelgium;\u00a015Department\u00a0of\u00a0Immunology,\u00a0Erasmus\u00a0University\u00a0Medical\u00a0Center\u00a0(Er asmus\u00a0MC),\u00a0Rotterdam,\u00a0The\u00a0\nNetherlands;\u00a016Department\u00a0of\u00a0Immunohematology\u00a0and\u00a0Blood\u00a0Transfusion,\u00a0Leiden\u00a0Un iversity\u00a0Medical\u00a0Center\u00a0\n(LUMC),\u00a0Leiden,\u00a0The\u00a0Netherlands.\u00a0\n\u00a0\nCorresponding\u00a0author:\u00a0\u00a0\u00a0\nProf.\u00a0Alberto\u00a0Orfao,\u00a0MD,\u00a0PhD.\u00a0\u00a0\nDepartment\u00a0of\u00a0Medicine,\u00a0Cancer\u00a0Research\u00a0Center\u00a0\nUniversity\u00a0of\u00a0Salamanca.\u00a0\nPaseo\u00a0de\u00a0la\u00a0Universidad\u00a0de\u00a0Coimbra\u00a0s/n\u00a0\n37007\u00a0Salamanca,\u00a0Spain.\u00a0\nTel:\u00a0+34\u00a0923\u00a0294\u00a0811\u00a0\nEmail:\u00a0orfao@usal.es \u00a0\n\u00a0\u2010\u00a0116\u00a0\u2010\u00a0\n\u00a0Funding\u00a0sources: \u00a0Elena\u00a0Blanco\u00a0was\u00a0supported\u00a0by\u00a0a\u00a0grant\u00a0from\u00a0the\u00a0 Junta\u00a0de\u00a0Castilla\u00a0y\u00a0Le\u00f3n \u00a0(Fondo\u00a0\nSocial\u00a0Europeo ,\u00a0ORDEN\u00a0EDU/346/2013,\u00a0Valladolid,\u00a0Spain).\u00a0This\u00a0work\u00a0was\u00a0support ed\u00a0by:\u00a0the\u00a0\nCB16/12/00400\u00a0 grant\u00a0 (CIBERONC,\u00a0 Instituto\u00a0 de\u00a0 Salud\u00a0 Carlos\u00a0 III,\u00a0 Ministerio\u00a0 de\u00a0 Econom\u00eda\u00a0 y\u00a0\nCompetitividad ,\u00a0\u2010Madrid,\u00a0Spain\u2010\u00a0and\u00a0 FONDOS\u00a0FEDER ),\u00a0the\u00a0FIS\u00a0PI12/00905\u2010FEDER\u00a0grant\u00a0( Fondo\u00a0\nde\u00a0Investigaci\u00f3n\u00a0Sanitaria\u00a0of\u00a0Instituto\u00a0de\u00a0Salud\u00a0Carlos\u00a0III ,\u00a0Madrid,\u00a0Spain)\u00a0and\u00a0AP119882013\u00a0grant\u00a0\n(Fundaci\u00f3n\u00a0Mutua\u00a0Madrile\u00f1a,\u00a0Madrid,\u00a0Spain).\u00a0The\u00a0coordination\u00a0an d\u00a0innovation\u00a0processes\u00a0of\u00a0this\u00a0\nstudy\u00a0were\u00a0supported\u00a0by\u00a0the\u00a0EuroFlow\u00a0Consortium.\u00a0\n\u00a0Conflict\u00a0of\u00a0interest\u00a0disclosure: \u00a0E.\u00a0Blanco,\u00a0M.\u00a0P\u00e9rez\u2010Andr\u00e9s,\u00a0E.\u00a0L\u00f3pez\u2010Granados,\u00a0T.\u00a0Kalina,\u00a0M.\u00a0\nVlkova,\u00a0M.\u00a0van\u00a0der\u00a0Burg,\u00a0J.\u00a0J.\u00a0M.\u00a0van\u00a0Dongen,\u00a0and\u00a0A.\u00a0Orfao\u00a0each \u00a0report\u00a0being\u00a0one\u00a0of\u00a0the\u00a0inventors\u00a0\non\u00a0 the\u00a0 EuroFlow\u2010owned\u00a0 patent\u00a0 PCT/NL\u00a0 2015/\u00a0 050762\u00a0 (Diagnosis\u00a0 of\u00a0 primary\u00a0\nimmunodeficiencies),\u00a0which\u00a0is\u00a0licensed\u00a0to\u00a0Cytognos,\u00a0a\u00a0company\u00a0t hat\u00a0pays\u00a0royalties\u00a0to\u00a0the\u00a0\nE u r o F l o w \u00a0C o n s o r t i u m . \u00a0J . \u00a0J . \u00a0M . \u00a0v a n \u00a0D o n g e n \u00a0a n d \u00a0A . \u00a0O r f a o \u00a0r e p o r t \u00a0a n \u00a0 Educational\u00a0 Services\u00a0\nAgreement\u00a0from\u00a0BD\u00a0Biosciences.\u00a0The\u00a0rest\u00a0of\u00a0the\u00a0authors\u00a0declare\u00a0 that\u00a0they\u00a0have\u00a0no\u00a0relevant\u00a0\nconflicts\u00a0of\u00a0interest.\u00a0\n\u00a0\u2010\u00a0117\u00a0\u2010\u00a0\n\u00a0ABSTRACT\u00a0\u00a0\nBackground.\u00a0 Predominantly\u00a0 antibody\u00a0 deficiencies\u00a0 (PAD)\u00a0 are\u00a0 the\u00a0 most\u00a0 prevalen t\u00a0 primary\u00a0\nimmune\u00a0deficiencies,\u00a0but\u00a0the\u00a0B\u2010cell\u00a0defects\u00a0and\u00a0underlying\u00a0gene tic\u00a0alterations\u00a0remain\u00a0largely\u00a0\nunknown.\u00a0Objective.\u00a0 We\u00a0investigated\u00a0PAD\u00a0patients\u00a0for\u00a0the\u00a0distribution\u00a0of\u00a041\u00a0blood\u00a0B \u2010cell\u00a0and\u00a0plasma\u00a0cell\u00a0\n(PC)\u00a0subsets,\u00a0including\u00a0subsets\u00a0defined\u00a0by\u00a0expression\u00a0of\u00a0distin ct\u00a0immunoglobulin\u00a0heavy\u00a0chain\u00a0\n(IgH)\u00a0subclasses.\u00a0\nMethods. \u00a0Blood\u00a0samples\u00a0from\u00a0111\u00a0PAD\u00a0patients\u00a0\u201347\u00a0common\u00a0variable\u00a0immuno deficiency\u00a0\n(CVID),\u00a059\u00a0selective\u00a0IgA\u2010deficien cy\u00a0(IgADef)\u00a0and\u00a05\u00a0IgG\u00a0subclass \u00a0deficiency\u00a0with\u00a0IgA\u00a0deficiency\u00a0\n(IgG/Adef)\u2013\u00a0and\u00a0140\u00a0age\u2010matched\u00a0controls\u00a0were\u00a0studied\u00a0by\u00a0flowcy tometry\u00a0using\u00a0EuroFlow\u00a0IgH\u2010\nisotype\u00a0stainings.\u00a0Patients\u00a0were\u00a0classified\u00a0according\u00a0to\u00a0their\u00a0 B\u2010cell\u00a0and\u00a0PC\u00a0immune\u00a0profile\u00a0and\u00a0\nthe\u00a0obtained\u00a0patient\u00a0clusters\u00a0we re\u00a0correlated\u00a0with\u00a0clinical\u00a0man ifestations\u00a0of\u00a0PAD.\u00a0\nResults.\u00a0Decreased\u00a0counts\u00a0of\u00a0blood\u00a0PCs\u00a0a nd/or\u00a0memory\u00a0B\u2010cells\u00a0(MBCs)\u00a0expr essing\u00a0distinct\u00a0IgA\u2010\u00a0\nand\u00a0IgG\u2010subclasses\u00a0were\u00a0identified\u00a0in\u00a0all\u00a0PAD\u00a0patients.\u00a0In\u00a0IgAD ef\u00a0patients,\u00a0B\u2010cell\u00a0defects\u00a0were\u00a0\nmainly\u00a0 restricted\u00a0 to\u00a0 surface\u2010membrane(sm)IgA\n+\u00a0 PCs\u00a0 and\u00a0 MBCs\u00a0 with\u00a0 two\u00a0 clear\u00a0 subgroups\u00a0\nshowing\u00a0strongly\u00a0decreased\u00a0smIgA+PCs\u00a0with\u00a0mild\u00a0 vs.\u00a0severe\u00a0smIgA+MBCs\u00a0defects\u00a0and\u00a0higher\u00a0\nfrequencies\u00a0 of\u00a0 non\u2010respiratory\u00a0 infections,\u00a0 autoimmunity,\u00a0 and\u00a0 af f e c t e d \u00a0f a m i l y \u00a0m e m b e r s . \u00a0\nIgG/Adef\u00a0and\u00a0CVID\u00a0patients\u00a0showed\u00a0defects\u00a0in\u00a0both\u00a0smIgA+\u00a0and\u00a0smIgG+\u00a0MBCs\u00a0and\u00a0PCs.\u00a0Absence\u00a0\nof\u00a0switched\u2010PCs\u00a0was\u00a0systematica lly\u00a0found\u00a0in\u00a0CVID\u00a0with\u00a0six\u00a0diffe rent\u00a0defective\u00a0MBC\u00a0(and\u00a0clinical)\u00a0\nprofiles:\u00a0i)\u00a0profound\u00a0decrease\u00a0of\u00a0MBCs;\u00a0ii)\u00a0defective\u00a0CD27+MBCs\u00a0with\u00a0almost\u00a0normal\u00a0IgG3+\u00a0MBCs;\u00a0\niii)\u00a0absence\u00a0of\u00a0switched\u2010MBCs;\u00a0and\u00a0iv)\u00a0presence\u00a0of\u00a0both\u00a0unswitc hed\u00a0and\u00a0switched\u2010MBCs\u00a0without\u00a0\nand;\u00a0v)\u00a0with\u00a0IgG2+MBCs;\u00a0and\u00a0vi)\u00a0with\u00a0IgA1+MBCs.\u00a0\nConclusion .\u00a0Distinct\u00a0PAD\u00a0defective\u00a0B\u2010cell\u00a0patterns\u00a0were\u00a0identified\u00a0which\u00a0 are\u00a0associated\u00a0with\u00a0\nunique\u00a0clinical\u00a0profiles.\u00a0\u00a0\n\u00a0\n\u00a0\u2010\u00a0118\u00a0\u2010\u00a0\n\u00a0Key\u00a0messages.\u00a0\n\uf0b7 Evaluation\u00a0 of\u00a0 blood\u00a0 B\u2010cells\u00a0 and\u00a0 plasma\u00a0 cells\u00a0 expressing\u00a0 distinc t\u00a0 immunoglobulin\u00a0\nsubclasses\u00a0provides\u00a0a\u00a0new\u00a0highly\u2010sensitive\u00a0approach\u00a0for\u00a0identif ication\u00a0of\u00a0specific\u00a0B\u2010cell\u00a0\ndefects\u00a0of\u00a0diagnostic\u00a0relevance\u00a0in\u00a0patients\u00a0with\u00a0predominantly\u00a0 antibody\u00a0deficiencies.\u00a0\n\uf0b7 Detailed\u00a0dissection\u00a0of\u00a0blood\u00a0memory\u00a0B\u2010cell\u00a0and\u00a0plasma\u00a0cell\u00a0subs ets\u00a0expressing\u00a0different\u00a0\nimmunoglobulin\u00a0subclasses,\u00a0identifies\u00a0distinct\u00a0deficient\u00a0immune \u00a0profiles\u00a0in\u00a0patients\u00a0with\u00a0\nprimary\u00a0antibody\u00a0deficiencies,\u00a0which\u00a0correlate\u00a0with\u00a0both\u00a0the\u00a0di agnostic\u00a0subtype\u00a0and\u00a0\nclinical\u00a0manifestations\u00a0of\u00a0the\u00a0disease.\u00a0\n\u00a0Capsule\u00a0summary. \u00a0Dissection\u00a0of\u00a0the\u00a0blood\u00a0plasma\u00a0cell\u00a0and\u00a0memory\u00a0B\u2010cell\u00a0compartm ents\u00a0and\u00a0\ntheir\u00a0 immunoglobulin\u2010subclass\u00a0 expression\u00a0 patterns\u00a0 in\u00a0 predominan tly\u00a0 antibody\u00a0 deficiencies\u00a0\nshows\u00a0unique\u00a0B\u2010cell\u00a0defective\u00a0profiles\u00a0associated\u00a0with\u00a0the\u00a0diag nostic\u00a0subtype\u00a0and\u00a0clinical\u00a0\nmanifestations\u00a0of\u00a0the\u00a0disease.\u00a0\u00a0\n \nKey\u00a0words.\u00a0 Immunodeficiency,\u00a0primary\u00a0antibody\u00a0deficiency,\u00a0selective\u00a0IgA\u00a0de ficiency,\u00a0CVID,\u00a0\nimmunophenotyping,\u00a0 immunoglobulins,\u00a0 Ig\u2010subclasses,\u00a0 memory\u00a0 B\u2010cel ls,\u00a0 plasma\u00a0 cells,\u00a0 flow\u00a0\ncytometry,\u00a0diagnosis,\u00a0classification.\u00a0\n\u00a0\nAbbreviations.\u00a0 Ab:\u00a0antibody ;\u00a0CVID:\u00a0common\u00a0variable\u00a0immunodeficiency;\u00a0HD:\u00a0healthy\u00a0donor;\u00a0Ig:\u00a0\nimmunoglobulin;\u00a0IgH:\u00a0immunoglobulin\u00a0heavy\u00a0chain ;\u00a0IgG/Adef:\u00a0IgG\u00a0subclass\u00a0deficiency\u00a0with\u00a0IgA\u00a0\ndeficiency;\u00a0GC:\u00a0germinal\u00a0center; \u00a0MBC:\u00a0memory\u00a0B\u2010cell;\u00a0PAD:\u00a0predo minantly\u00a0antibody\u00a0deficiency;\u00a0\nPC:\u00a0plasma\u00a0cell;\u00a0PID:\u00a0primary\u00a0immune\u00a0deficiency; \u00a0IgAdef:\u00a0selective\u00a0IgA\u00a0deficiency;\u00a0SOP:\u00a0standard\u00a0\noperating\u00a0procedure.\u00a0\u2010\u00a0119\u00a0\u2010\u00a0\n\u00a0INTRODUCTION \u00a0\nPredominantly\u00a0 antibody\u00a0 deficiencies\u00a0 (PADs)\u00a0 are\u00a0 the\u00a0 most\u00a0 prevale nt\u00a0 primary\u00a0\nimmunodeficiencies\u00a0(PIDs;\u00a050\u201070%\u00a0of\u00a0all\u00a0PIDs),1,2\u00a0and\u00a0comprise\u00a0a\u00a0heterogeneous\u00a0spectrum\u00a0of\u00a0\ndisorders\u00a0with\u00a0defective\u00a0production\u00a0of\u00a0\u22651\u00a0immunoglobulin\u00a0(Ig)\u2010i sotype\u00a0and/or\u00a0Ig\u2010subclass;\u00a0the\u00a0\nunderlying\u00a0pathogenic\u00a0mechanisms\u00a0remain\u00a0largely\u00a0unknown.1,2\u00a0Current\u00a0classification\u00a0of\u00a0PAD\u00a0\nstrongly\u00a0relies\u00a0on\u00a0the\u00a0affected\u00a0serum\u00a0Ig\u2010heavy\u00a0chain\u00a0(IgH)\u00a0isot ype(s)\u00a0and\u00a0subclass(es)\u00a0levels\u00a0and\u00a0\nincludes:\u00a01)\u00a0selective\u00a0IgA\u2010deficiency\u00a0(IgAdef)\u00a0characterized\u00a0by \u00a0an\u00a0isolated\u00a0defect\u00a0of\u00a0serum\u00a0IgA\u00a0\n(prevalence:\u00a0 \u22481:100\u20101,000\u00a0 individuals);\u00a03\u20135\u00a0 2)\u00a0 IgG\u2010subclass\u00a0 deficiency\u00a0 with\u00a0 IgA\u2010deficiency\u00a0\n(IgG/Adef)\u00a0with\u00a0reduced\u00a0IgA\u00a0and\u00a0\u22651\u00a0IgG\u2010subclass\u00a0serum\u00a0levels\u00a0(\u2248 15\u201020%\u00a0of\u00a0IgA\u2010deficiencies);6\u00a0\nand,\u00a03)\u00a0common\u00a0variable\u00a0immunodeficiency\u00a0(CVID),\u00a0characterized\u00a0 by\u00a0low\u00a0(total)\u00a0IgG\u00a0serum\u00a0\nlevels,\u00a0 decreased\u00a0 IgA\u00a0 and/or\u00a0 IgM,\u00a0 and\u00a0 a\u00a0 more\u00a0 severe\u00a0 clinical\u00a0 pr esentation,\u00a0 but\u00a0 a\u00a0 lower\u00a0\nprevalence\u00a0(\u22481:25,000\u201050,000\u00a0individuals).4,5\u00a0Although\u00a0recurrent\u00a0bacterial\u00a0infections\u00a0of\u00a0the\u00a0\nrespiratory\u00a0tract\u00a0are\u00a0the\u00a0clinical\u00a0hallmark\u00a0of\u00a0PADs,\u00a0clinical\u00a0m anifestations\u00a0vary\u00a0substantially\u00a0\namong\u00a0individual\u00a0patients,\u00a0from\u00a0( almost)\u00a0asymptomatic\u00a0cases,\u00a0to \u00a0patients\u00a0presenting\u00a0with\u00a0\nrecurrent\u00a0severe\u00a0infections\u00a0associated\u00a0with\u00a0other\u00a0non\u2010infectiou s\u00a0disorders,\u00a0e.g.\u00a0autoimmunity,\u00a0\nallergy,\u00a0lymphoproliferation,\u00a0lymphadenopathy,\u00a0splenomegaly,\u00a0he patomegaly,\u00a0enteropathy\u00a0and\u00a0\ngranulomatous\u00a0disease.1,3,7\u201310\u00a0Of\u00a0note,\u00a0asymptomatic\u00a0individuals\u00a0who\u00a0present\u00a0with\u00a0low/absent\u00a0\nserum\u00a0IgA,\u00a0while\u00a0diagnosed\u00a0as\u00a0IgAdef\u00a0by\u00a0the\u00a0International\u00a0Union \u00a0of\u00a0Immunological\u00a0Societies\u00a0\n(IUIS),\u00a0do\u00a0not\u00a0fulfill\u00a0the\u00a0Europe an\u00a0Society\u00a0for\u00a0Immunodeficienc ies\u00a0(ESID)\u00a0diagnostic\u00a0criteria\u00a0for\u00a0\nIgAdef.5\u00a0\nDespite\u00a0extensive\u00a0efforts,\u00a0genetic\u00a0(i.e.\u00a0monogenic)\u00a0alterations \u00a0responsible\u00a0for\u00a0PADs\u00a0are\u00a0\ndetected\u00a0in\u00a0<10%\u00a0cases.1,2,11\u00a0In\u00a0such\u00a0setting,\u00a0altered\u00a0distrib utions\u00a0of\u00a0distinct\u00a0blood\u00a0B\u2010\u00a0an d\u00a0T\u2010cell\u00a0\nsubpopulations\u00a0by\u00a0flowcytometry\u00a0might\u00a0provide\u00a0key\u00a0(complementar y)\u00a0diagnostic\u00a0information,\u00a0\nparticularly\u00a0for\u00a0patients\u00a0with\u00a0low\u00a0serum\u00a0antibody\u00a0(Ab)\u2010isotype\u00a0 levels\u00a0and\u00a0non\u2010specific\u00a0clinical\u00a0\nfeatures.5,12,13\u00a0In\u00a0addition,\u00a0several\u00a0controversial\u00a0results\u00a0have\u00a0been\u00a0reported\u00a0 in\u00a0CVID\u00a0concerning\u00a0\nthe\u00a0potential\u00a0association\u00a0between \u00a0specific\u00a0B\u2010cell\u00a0alterations\u00a0\u2212 e.g.\u00a0decreased\u00a0(rela\u019fve)\u00a0numbers\u00a0\u2010\u00a0120\u00a0\u2010\u00a0\n\u00a0of\u00a0CD27+\u00a0(antigen\u2010experienced)\u00a0switched\u2010B\u2010cells\u00a0in\u00a0blood\u2212\u00a0and\u00a0relevant\u00a0 clinical\u00a0manifesta\u019fons,\u00a0\nsuch\u00a0as\u00a0\u00a0splenomegaly,\u00a0granulomat ous\u00a0disease\u00a0and\u00a0autoimmunity,14\u201318\u00a0while\u00a0preservation\u00a0of\u00a0\nCD27+\u00a0class\u2010switched\u00a0memory\u00a0B\u2010cells\u00a0(MBCs)\u00a0has\u00a0been\u00a0considered\u00a0as\u00a0a\u00a0 surrogate\u00a0marker\u00a0for\u00a0the\u00a0\nability\u00a0to\u00a0respond\u00a0to\u00a0vaccination.5\u00a0Similarly,\u00a0decreased\u00a0CD27+\u00a0(antigen\u2010experienced)\u00a0switched\u2010B\u2010\ncell\u00a0counts\u00a0in\u00a0blood\u00a0have\u00a0been\u00a0a ssociated\u00a0with\u00a0a\u00a0worse\u00a0clinical \u00a0outcome\u00a0in\u00a0IgAdef,19\u00a0while\u00a0\ndecreased\u00a0percentages\u00a0of\u00a0CD21+\u00a0B\u2010cells\u00a0and\u00a0an\u00a0increased\u00a0proportion\u00a0of\u00a0immature/transitional\u00a0\nB\u2010cells,\u00a0have\u00a0both\u00a0been\u00a0correlated\u00a0to\u00a0distinct\u00a0CVID\u00a0clinical\u00a0pr ofiles.15,18,20\u00a0\u00a0\nDespite\u00a0the\u00a0above\u00a0B\u2010cell\u00a0subset\u00a0correlates,\u00a0the\u00a0actual\u00a0clinical \u00a0relevance\u00a0of\u00a0such\u00a0B\u2010cell\u00a0\ndefects\u00a0in\u00a0PAD\u00a0still\u00a0remains\u00a0elusive.\u00a0This\u00a0is\u00a0probably\u00a0due\u00a0to\u00a0t he\u00a0limited\u00a0number\u00a0of\u00a0B\u2010cell\u00a0\npopulations\u00a0investigated\u00a0in\u00a0most\u00a0 studies.\u00a0For\u00a0example,\u00a0in\u00a0many\u00a0 studies\u00a0focused\u00a0on\u00a0antigen\u2010\nexperienced\u00a0B\u2010cells,\u00a0no\u00a0distinction\u00a0is\u00a0made\u00a0between\u00a0(relative\u00a0l ong\u2010living)\u00a0MBCs\u00a0and\u00a0(newly\u2010\ngenerated)\u00a0circulating\u00a0plasma\u00a0cells\u00a0(PCs)14,15,19\u00a0and\u00a0very\u00a0few\u00a0reports\u00a0have\u00a0investigated\u00a0the\u00a0\nprecise\u00a0relationship\u00a0between\u00a0defects\u00a0in\u00a0specific\u00a0IgH\u2010isotypes\u00a0a nd\u00a0the\u00a0number\u00a0of\u00a0blood\u00a0B\u2010cells\u00a0\nand\u00a0PCs\u00a0that\u00a0express\u00a0them.21,22\u00a0Moreover,\u00a0no\u00a0study\u00a0ha s\u00a0investigated\u00a0so\u00a0far\u00a0the\u00a0IgG1\u20104\u00a0and\u00a0IgA1 \u2010\n2\u2010subclass\u00a0distribution\u00a0within\u00a0the\u00a0PC\u00a0and\u00a0MBC\u00a0compartments\u00a0of\u00a0P AD\u00a0patients.\u00a0Finally,\u00a0most\u00a0\nreports\u00a0on\u00a0B\u2010cell\u00a0compartments\u00a0in\u00a0PAD,\u00a0do\u00a0not\u00a0consider\u00a0(normal) \u00a0age\u2010associated\u00a0variations,\u00a0and\u00a0\nonly\u00a0a\u00a0few\u00a0studies\u00a0subdivided\u00a0healthy\u00a0donors\u00a0(HD)\u00a0and\u00a0PAD\u00a0patie nts\u00a0into\u00a0a\u00a0few\u00a0(n=3\u20104)\u00a0age\u2010\ngroups.17,20,22\u00a0However,\u00a0age\u2010matched\u00a0reference\u00a0 values\u00a0are\u00a0of\u00a0utmost\u00a0importance \u00a0because\u00a0PAD\u00a0\ncan\u00a0present\u00a0at\u00a0any\u00a0age1,7,9,13\u00a0and\u00a0major\u00a0age\u2010related\u00a0differences\u00a0exist\u00a0in\u00a0the\u00a0distribution\u00a0of \u00a0blood\u00a0\nB\u2010cell\u00a0subsets\u00a0throughout\u00a0life23.\u00a0\nHere\u00a0we\u00a0investigated\u00a0for\u00a0the\u00a0first\u00a0time,\u00a0the\u00a0distribution\u00a0of\u00a041 \u00a0distinct\u00a0blood\u00a0B\u2010cell\u00a0and\u00a0PC\u00a0\nsubsets\u00a0in\u00a0111\u00a0PAD\u00a0patients\u00a0 vs.\u00a0140\u00a0age\u2010matched\u00a0controls.\u00a0Based \u00a0on\u00a0the\u00a0B\u2010cell\u00a0and\u00a0PC\u00a0defects\u00a0\nencountered,\u00a0eight\u00a0distinct\u00a0defective\u00a0immune\u00a0profiles\u00a0were\u00a0iden tified,\u00a0which\u00a0are\u00a0associated\u00a0with\u00a0\nboth\u00a0the\u00a0diagnostic\u00a0subtype\u00a0and\u00a0clinical\u00a0manifestations\u00a0of\u00a0PAD. \u00a0\u00a0\n\u00a0\u2010\u00a0121\u00a0\u2010\u00a0\n\u00a0METHODS \u00a0\nPatients\u00a0and\u00a0controls.\u00a0 Overall,\u00a0111\u00a0PAD\u00a0patients4\u00a0(mean\u00a0age:\u00a032\u00b119y;\u00a0range\u00a04\u201087y)\u00a0and\u00a0140\u00a0HD\u00a0\n(mean\u00a0age:\u00a039\u00b126y;\u00a0range:\u00a04\u201090y),\u00a0were\u00a0studied.\u00a0PAD\u00a0patients\u00a0we re\u00a0subclassified\u00a0by\u00a0the\u00a0IUIS4\u00a0\nand\u00a0ESID\u00a0criteria5\u00a0into:\u00a059\u00a0and\u00a034\u00a0IgAdef\u00a0(mean\u00a0age,\u00a026\u00b120y),\u00a0respectively,\u00a05\u00a0IgG /Adef\u00a0(mean\u00a0\nage,\u00a0 33\u00b111y)\u00a0 and\u00a0 47\u00a0 CVID\u00a0 (mean\u00a0 age,\u00a0 41\u00b117y)\u00a0 cases.\u00a0 Twenty\u2010five\u00a0 asymptomatic\u00a0 IgAdef\u00a0\nindividuals\u00a0(mean\u00a0age,\u00a024\u00b115y)\u00a0with\u00a0serum\u00a0IgA\u00a0<7\u00a0mg/dL,\u00a0did\u00a0not \u00a0fulfill\u00a0the\u00a0ESID\u00a0criteria5\u00a0for\u00a0\nIgAdef\u00a0(e.g.\u00a0no\u00a0increased\u00a0suscep tibility\u00a0to\u00a0infections,\u00a0autoimm unity\u00a0or\u00a0affected\u00a0family\u00a0members).\u00a0\nFrom\u00a0each\u00a0subject,\u00a0EDTA\u2010anticoa gulated\u00a0blood\u00a0samples\u00a0were\u00a0colle cted\u00a0after\u00a0informed\u00a0consent\u00a0\nwas\u00a0given\u00a0by\u00a0each\u00a0individual\u00a0and/or\u00a0their\u00a0legal\u00a0representatives .\u00a0The\u00a0study\u00a0was\u00a0approved\u00a0by\u00a0the\u00a0\nlocal\u00a0ethics\u00a0committees.\u00a0\nFlowcytometric\u00a0identification\u00a0of \u00a0blood\u00a0B\u2010cells\u00a0and\u00a0their\u00a0subset s.\u00a0Total\u00a0B\u2010cell\u00a0counts\u00a0and\u00a0the\u00a0\ndistribution\u00a0of\u00a041\u00a0distinct\u00a0B\u2010cell\u00a0subsets\u00a0were\u00a0analyzed\u00a0by\u00a0flo wcytometry,\u00a0after\u00a0staining\u00a0107\u00a0\nnucleated\u00a0cells \u00a0with\u00a0the\u00a0EuroFlow\u00a012\u2010color\u00a0IgH\u2010iso type\u00a0B\u2010cell\u00a0tube\u00a0(Supplementa ry\u00a0Table\u00a01)\u00a0and\u00a0\nbulk\u2010lyse\u00a0standard\u00a0operating\u00a0procedure\u00a0(SOP)\u00a0( www.EuroFlow.org ),\u00a0as\u00a0described\u00a0elsewhere.24,25\u00a0\nPer\u00a0 sample,\u00a0 \u22655x106\u00a0l e u k o c y t e s \u00a0w e r e \u00a0m e a s u r e d \u00a0i n \u00a0a n \u00a0L S R \u2010 F o r t e s s a \u00a0X \u2010 2 0 \u00a0f l o w c y t o m e t e r \u00a0\n\u2212Becton/Dickinson\u00a0Biosciences\u00a0(B D),\u00a0San\u00a0Jos\u00e9,\u00a0CA\u2212.\u00a0Instrument\u00a0s et\u2010up\u00a0and\u00a0calibration\u00a0was\u00a0\nperformed\u00a0according\u00a0to\u00a0the\u00a0EuroFlow\u00a0SOP\u00a0( www.EuroFlow.org )26.\u00a0For\u00a0data\u00a0analysis,\u00a0the\u00a0Infinicyt\u00a0\nsoftware\u00a0(Cytognos\u00a0S.L.,\u00a0Sa lamanca,\u00a0Spain)\u00a0was\u00a0used.\u00a0\nCD19+\u00a0B\u2010cells\u00a0and\u00a0PCs\u00a0were\u00a0both\u00a0identified\u00a0by\u00a0their\u00a0low\u2010to\u2010intermedi ate\u00a0forward\u00a0(FSC)\u00a0\nand\u00a0sideward\u00a0(SSC)\u00a0light\u00a0scatter\u00a0properties,\u00a0and\u00a0subsequently\u00a0s ubclassified\u00a0into\u00a041\u00a0different\u00a0\nsubpopulations\u00a0based\u00a0on\u00a0their\u00a0maturation\u00a0stage\u00a0and\u00a0the\u00a0expressi on\u00a0of\u00a0distinct\u00a0IgH\u2010isotypes\u00a0and\u00a0\nIgH\u2010subclasses,\u00a0as\u00a0previously\u00a0described23\u00a0(Supplementary\u00a0Figure\u00a01).\u00a0First ,\u00a0the\u00a0following\u00a0B\u2010cell\u00a0\nsubpopulations\u00a0were\u00a0defined\u00a0based\u00a0on\u00a0their\u00a0staining\u00a0profile\u00a0for \u00a0CD19,\u00a0CD38,\u00a0CD24,\u00a0CD21,\u00a0CD27,\u00a0\nCD5,\u00a0 surface\u00a0 membrane\u00a0 (sm)IgM\u00a0 and\u00a0 smIgD:\u00a0 i)\u00a0 CD27\u2010CD38hiCD24hiCD5+smIgM++D+\u00a0\nimmature/transitional\u00a0 B\u2010cells;\u00a0 and\u00a0 ii)\u00a0 CD27\u2010CD38\u2010CD24hetCD5hetsmIgM+IgD++\u00a0naive\u00a0 B\u2010\u2010\u00a0122\u00a0\u2010\u00a0\n\u00a0lymphocytes;\u00a0iii)\u00a0CD27+CD38loCD5\u2010CD24hetsmIgM++D+\u00a0unswitched\u2010MBCs;\u00a0iv)\u00a0CD27+/\u2010CD38loCD5\u2010\nCD24hetsmIgM\u2010D\u2010\u00a0switched\u2010MBCs;\u00a0and,\u00a0v)\u00a0CD27++CD38hiCD5\u2010CD21\u2010CD24\u2010\u00a0PCs.\u00a0MBCs\u00a0and\u00a0PCs\u00a0were\u00a0\nfurther\u00a0subclassified\u00a0according\u00a0to\u00a0their\u00a0IgH\u2010isotypes\u00a0and\u00a0IgH\u2010s ubclasses\u00a0into:\u00a0i)\u00a0smIgM++D+,\u00a0\nsmIgD+\u2010only,\u00a0smIgA1+,\u00a0smIgA2+,\u00a0smIgG1+,\u00a0smIgG2+,\u00a0smIgG3+\u00a0and\u00a0smIgG4+\u00a0MBCs,\u00a0and\u00a0ii)\u00a0smIgM+\u2010\nonly,\u00a0smIgD+\u2010only,\u00a0smIgA1+,\u00a0smIgA2+,\u00a0smIgG1+,\u00a0smIgG2+,\u00a0smIgG3+\u00a0and\u00a0smIgG4+\u00a0PCs,\u00a0respectively.\u00a0\nThe\u00a0above\u00a0subpopulations\u00a0of\u00a0naive\u00a0B\u2010lymphocytes\u00a0and\u00a0MBCs\u00a0were\u00a0f urther\u00a0subsetted\u00a0based\u00a0on\u00a0\nCD21\u00a0(CD21+\u00a0vs.\u00a0CD21\u2010\u00a0naive\u00a0and\u00a0MBCs\u00a0subsets),\u00a0and\u00a0CD27\u00a0expression\u00a0(CD27+\u00a0and\u00a0CD27\u2010\u00a0MBCs)\u00a0\n(Supplementary\u00a0Figure\u00a01).\u00a0\nStatistical\u00a0analyses.\u00a0 Statistical\u00a0analyses\u00a0were\u00a0perfor med\u00a0with\u00a0either\u00a0R\u00a0(v3.2.3;\u00a0http s://www.r\u2010\nproject.org/)27\u00a0or\u00a0the\u00a0SPSS\u00a0(SPSS\u00a0v23.0,\u00a0IBM,\u00a0Armonk,\u00a0NY)\u00a0software\u00a0packages.\u00a0T o\u00a0investigate\u00a0the\u00a0\nstatistical\u00a0significance\u00a0(set\u00a0at\u00a0 P\u2010values\u00a0<0.05)\u00a0of\u00a0differences\u00a0observed\u00a0between\u00a0groups,\u00a0the\u00a0\nMcNemar\u2019s\u00a0and\u00a0Fisher\u2212exact\u00a0tests\u00a0for\u00a0categorical\u00a0variables\u00a0and\u00a0 the\u00a0Mann\u2010Whitney\u2212U\u00a0test\u00a0for\u00a0\ncontinuous\u00a0variables,\u00a0were\u00a0used.\u00a0Unsupervised\u00a0clustering\u00a0analys is\u00a0of\u00a0patient\u00a0data\u00a0based\u00a0on\u00a0the\u00a0\nK\u2010means\u00a0learning\u00a0algorithm28\u00a0and\u00a0Euclidean\u00a0distances\u00a0was\u00a0performed\u00a0using\u00a0blood\u00a0B\u2010cell\u00a0subse t\u00a0\ncounts\u00a0normalized\u00a0by\u00a0age\u2010group\u00a0(Supplementary\u00a0Table\u00a02),\u00a0based\u00a0o n\u00a0(previously\u00a0reported)\u00a0\nreference\u00a0values23\u2013log10\u00a0(patient\u00a0value/minimum\u00a0normal\u00a0val ue)\u2013;\u00a0age\u2010normalized\u00a0values\u00a0pe r\u00a0\npatient\u00a0 and\u00a0 B\u2010cell/PC\u00a0 subset\u00a0 were\u00a0 represented\u00a0 in\u00a0 heatmaps\u00a0 using \u00a0 gplots\u00a0 (R\u2212package).29\u00a0\nWhenever,\u00a0B\u2010cell\u2212and\u00a0PC\u2212subset\u00a0counts\u00a0were\u00a0below\u00a0the\u00a0method\u2019s\u00a0l imit\u00a0of\u00a0detec\u019fon\u00a0(LOD)\u00a0\n(<0.01\u00a0cells/\u00b5L)\u00a0for\u00a0more\u00a0than\u00a0one\u00a0HD\u00a0age\u2010group\u00a0\u2013lower\u00a0limit\u00a0in \u00a0normal\u00a0(LLN)<LOD\u2013\u00a0they\u00a0were\u00a0\nexcluded\u00a0from\u00a0analysis.\u00a0\n\u00a0\u00a0 \u00a0\u2010\u00a0123\u00a0\u2010\u00a0\n\u00a0RESULTS\u00a0\nBlood\u00a0distribution\u00a0of\u00a0the\u00a0major\u00a0(maturation\u2010associated)\u00a0subpopu lations\u00a0of\u00a0B\u2010cells\u00a0and\u00a0PCs .\u00a0\nTotal\u00a0B\u2010cell\u00a0and\u00a0PC\u00a0counts\u00a0were\u00a0significantly\u00a0decreased\u00a0in\u00a0most \u00a0CVID\u00a0patients\u00a0(51%\u00a0and\u00a098%,\u00a0\nrespectively)\u00a0 vs.\u00a0age\u2010matched\u00a0HD.\u00a0In\u00a0contrast,\u00a0decreased\u00a0PC\u00a0numbers\u00a0with\u00a0normal \u00a0B\u2010cell\u00a0counts\u00a0\nwere\u00a0found\u00a0in\u00a080%\u00a0IgG/Adef\u00a0and\u00a046%\u00a0IgAdef\u00a0cases\u00a0( P<0.001\u00a0vs.\u00a0CVID)\u00a0(Figure\u00a01;\u00a0Supplementary\u00a0\nTable\u00a03).\u00a0In\u00a0fact,\u00a0the\u00a0majority\u00a0of\u00a0CVID\u00a0(92%)\u00a0and\u00a0IgG/Adef\u00a0(60% )\u00a0patients\u00a0showed\u00a0no\u00a0PCs\u00a0in\u00a0blood,\u00a0\nwhile\u00a0PCs\u00a0were\u00a0detected\u00a0(\u22650.07\u00a0P Cs/\u00b5L)\u00a0in\u00a0every\u00a0IgAdef\u00a0case.\u00a0\u00a0\nAbnormally\u00a0 low\u00a0 MBC\u00a0 counts\u00a0 were\u00a0 observed\u00a0 in\u00a0 most\u00a0 CVID\u00a0 patients\u00a0 ( 70%),\u00a0 with\u00a0\nundetectable\u00a0MBCs\u00a0(<0.01\u00a0MBCs/\u00b5L)\u00a0in\u00a017%\u00a0of\u00a0cases,\u00a0while\u00a0all\u00a0Ig G/Adef\u00a0(P=0.004\u00a0vs.\u00a0CVID)\u00a0and\u00a0\nvirtually\u00a0all\u00a0IgAdef\u00a0(91%;\u00a0 P<0.001)\u00a0individuals\u00a0had\u00a0normal\u00a0MBC\u00a0counts.\u00a0Immature/transitiona l\u00a0\nand\u00a0naive\u00a0B\u2010lymphocytes\u00a0were\u00a0decreased\u00a0in\u00a0a\u00a0smaller\u00a0fraction\u00a0of \u00a0PAD\u00a0cases\u00a0\u221234%\u00a0and\u00a034%\u00a0in\u00a0\nCVID,\u00a020%\u00a0and\u00a00%\u00a0in\u00a0IgG/Adef,\u00a0and\u00a012%\u00a0and\u00a02%\u00a0in\u00a0IgAdef\u00a0patients ,\u00a0respectively\u2212\u00a0mostly\u00a0at\u00a0the\u00a0\nexpense\u00a0 of\u00a0 CD21+B\u2010cells\u00a0 (Figures\u00a0 1\u22122;\u00a0 Supplementary\u00a0 results;\u00a0 Supplementary\u00a0 Figu re\u00a0 2;\u00a0\nSupplementary\u00a0 Table\u00a0 3),\u00a0 with\u00a0 only\u00a0 11%\u00a0 and\u00a0 4%\u00a0 of\u00a0 CVID\u00a0 patients\u00a0 s howing\u00a0 undetectable\u00a0\nimmature/transitional\u00a0and\u00a0naive\u00a0 B\u2010cells,\u00a0respectively\u00a0(Figure\u00a01 ;\u00a0Supplementary\u00a0Table\u00a03).\u00a0\nBlood\u00a0distribution\u00a0of\u00a0MBCs\u00a0and\u00a0PCs\u00a0expressing\u00a0distinct\u00a0IgA\u2010subc lasses.\u00a0Reduced\u00a0smIgA1+\u00a0\nand/or\u00a0smIgA2+\u00a0PC\u00a0counts\u00a0were\u00a0found\u00a0in\u00a0virtually\u00a0all\u00a0PAD\u00a0patients\u00a0(Figure\u00a01;\u00a0 Supplementary\u00a0\nTable\u00a03):\u00a0100%\u00a0of\u00a0CVID\u00a0and\u00a0IgG/Adef\u00a0cases,\u00a0and\u00a097%\u00a0of\u00a0IgAdef\u00a0pa tients.\u00a0Interestingly,\u00a0while\u00a0\nsmIgA1+\u00a0and\u00a0smIgA2+\u00a0PCs\u00a0were\u00a0both\u00a0undetectable\u00a0in\u00a0all\u00a0CVID\u00a0and\u00a0IgG/Adef\u00a0patients,\u00a0 residual\u00a0\nsmIgA+\u00a0PCs\u00a0were\u00a0found\u00a0in\u00a039%\u00a0of\u00a0IgAdef\u00a0cases,\u00a0such\u00a0cells\u00a0correspondin g\u00a0to\u00a0both\u00a0IgA\u2010subclasses\u00a0\nin\u00a027%\u00a0cases,\u00a0to\u00a0smIgA1+\u2010only\u00a0in\u00a010%\u00a0and\u00a0to\u00a0smIgA2+\u2010only\u00a0in\u00a02%\u00a0IgAdef\u00a0patients.\u00a0In\u00a0line\u00a0with\u00a0\nthese\u00a0findings,\u00a0reduced\u00a0smIgA1+\u00a0and/or\u00a0smIgA2+\u00a0MBC\u00a0counts\u00a0were\u00a0also\u00a0ob served\u00a0in\u00a0virtually\u00a0all\u00a0\nCVID\u00a0(98%),\u00a0IgG/Adef\u00a0(100%)\u00a0and\u00a0IgAdef\u00a0(98%)\u00a0patients,\u00a0being\u00a0ab sent\u00a0in\u00a0most\u00a0CVID\u00a0(92%)\u00a0and\u00a0\nIgG/Adef\u00a0(100%)\u00a0cases,\u00a0while\u00a0pre sent\u00a0in\u00a049%\u00a0of\u00a0IgAdef\u00a0cases,\u00a0co rresponding\u00a0to\u00a0both\u00a0smIgA1+\u00a0and\u00a0\nsmIgA2+\u00a0 MBCs\u00a0 in\u00a0 37%\u00a0 cases,\u00a0 and\u00a0 to\u00a0 smIgA1+\u2010only\u00a0 in\u00a0 12%\u00a0 IgAdef\u00a0 patients\u00a0 (Figure\u00a0 1;\u00a0\u2010\u00a0124\u00a0\u2010\u00a0\n\u00a0Supplementary\u00a0Table\u00a03).\u00a0\nBlood\u00a0distribution\u00a0of\u00a0MBCs\u00a0and\u00a0PCs\u00a0expressing\u00a0different\u00a0IgG\u2010sub classes.\u00a0None\u00a0of\u00a0the\u00a0CVID\u00a0\npatients\u00a0showed\u00a0circulating\u00a0smIgG+PCs\u00a0(<0.01\u00a0cells/\u00b5l\u00a0\u2212Supplementary\u00a0Figure\u00a03;\u00a0Supplementary\u00a0\nTable\u00a03\u2212).\u00a0In\u00a0contrast,\u00a0smIgG+PCs\u00a0were\u00a0present\u00a0in\u00a040%\u00a0of\u00a0IgG/Adef\u00a0and\u00a090%\u00a0of\u00a0IgAdef\u00a0patients\u00a0\n(P=0.01),\u00a0with\u00a0normal\u00a0total\u00a0smIgG+PC\u00a0counts\u00a0in\u00a040%\u00a0and\u00a071%\u00a0cases,\u00a0 respectively.\u00a0Moreover,\u00a0in\u00a0\nmost\u00a0CVID\u00a0patients\u00a0smIgG+MBCs\u00a0were\u00a0decreased\u00a0(87%)\u00a0or\u00a0absent\u00a0(30%),\u00a0whereas\u00a0such\u00a0decreas e\u00a0\nwas\u00a0seen\u00a0in\u00a0only\u00a010%\u00a0of\u00a0IgAdef\u00a0and\u00a00%\u00a0of\u00a0IgG/Adef\u00a0cases.\u00a0When\u00a0d issected\u00a0by\u00a0IgG\u2010subclasses,\u00a0\nC V I D \u00a0p a t i e n t s \u00a0m o r e \u00a0f r e q u e n t l y \u00a0s h o w e d \u00a0d e c r e a s e d \u00a0o r \u00a0a b s e n t \u00a0s m I g G 2+\u00a0 (94%\u00a0 and\u00a0 70%,\u00a0\nrespectively)\u00a0than\u00a0smIgG1+\u00a0(89%\u00a0and\u00a040%,\u00a0 P>0.05\u00a0and\u00a0 P<0.001,\u00a0respectively)\u00a0and\u00a0smIgG3+\u00a0MBCs\u00a0\n(53%\u00a0and\u00a030%,\u00a0respectively;\u00a0 P<0.001).\u00a0Conversely,\u00a0all\u00a0Ig Adef\u00a0patients\u00a0had\u00a0smIgG1\u20103+MBCs,\u00a0each\u00a0\nsubset\u00a0being\u00a0decreased\u00a0in\u00a0\u22649%\u00a0patients.\u00a0In\u00a0turn,\u00a0IgG/Adef\u00a0patie nts\u00a0systematically\u00a0showed\u00a0\ndecreased\u00a0 smIgG2+MBC\u00a0 counts\u00a0 with\u00a0 normal\u00a0 smIgG1+\u00a0a n d \u00a0s m I g G 3+\u00a0M B C \u00a0n u m b e r s \u00a0\n(Supplementary\u00a0Figure\u00a03;\u00a0Supplementary\u00a0Table\u00a03).\u00a0\nAltered\u00a0blood\u00a0distribution\u00a0profiles\u00a0of\u00a0B\u2010cell\u00a0and\u00a0PC\u00a0subsets.\u00a0 Unsupervised\u00a0clustering\u00a0analysis\u00a0\nidentified\u00a0five\u00a0major\u00a0immune\u00a0profiles\u00a0of\u00a0alteration\u00a0of\u00a0B\u2010cell\u00a0a nd\u00a0PC\u00a0subset\u00a0counts\u00a0in\u00a0PAD\u00a0patients,\u00a0\nwhich\u00a0closely\u00a0related\u00a0to\u00a0the\u00a0IUIS\u00a0diagnostic\u00a0categories\u00a0of\u00a0PAD\u00a0 (Figure\u00a02A).4\u00a0Thus,\u00a0IgAdef\u00a0cases\u00a0\nsplit\u00a0between\u00a0the\u00a0PAD\u20101\u00a0and\u00a0PAD\u20102\u00a0clusters\u00a0and\u00a0IgG/Adef\u00a0between \u00a0the\u00a0PAD\u20102\u00a0and\u00a0PAD\u20103\u00a0groups,\u00a0\nwhile\u00a0CVID\u00a0cases\u00a0fell\u00a0into\u00a0the\u00a0PAD \u20103,\u00a0PAD\u20104\u00a0and\u00a0PAD\u20105\u00a0clusters\u00a0 with\u00a0four\u00a0outliers\u00a0in\u00a0PAD\u20101\u00a0and\u00a0\nPAD\u20102\u00a0(Figure\u00a02A).\u00a0In\u00a0detail,\u00a0PAD\u20101\u00a0included\u00a030\u00a0patients\u00a0with\u00a0r educed\u00a0but\u00a0detectable\u00a0smIgA+PCs\u00a0\nor\u00a0smIgA+MBCs\u00a0(smIgA+MBCs\u00a0range:\u00a0from\u00a010\u2010fold\u00a0below\u00a0the\u00a0LLN\u00a0to\u00a0virtually\u00a0normal\u00a0coun ts):\u00a0\n27/30\u00a0PAD\u20101\u00a0cases\u00a0previously\u00a0diagnosed\u00a0as\u00a0IgAdef,\u00a0and\u00a0three\u00a0CVI D\u00a0patients\u00a0with\u00a0no\u00a0PCs\u00a0but\u00a0\ndetectable\u00a0 IgA1+\u00a0 and\u00a0 IgA2+\u00a0 MBCs\u00a0 and\u00a0 virtually\u00a0 normal\u00a0 IgG1\u20103+\u00a0 MBCs\u00a0 counts.\u00a0 PAD\u22122\u00a0 was\u00a0\ncharacterized\u00a0by\u00a0severely\u00a0decreased\u00a0smIgA+MBCs\u00a0(\u226530\u00a0times\u00a0below\u00a0the\u00a0LLN;\u00a0absent\u00a0in\u00a033/35\u00a0\npatients)\u00a0and\u00a0absence\u00a0of\u00a0smIgA+PCs,\u00a0but\u00a0(similarly\u00a0to\u00a0PAD\u20101)\u00a0virtually\u00a0normal\u00a0smIgG1\u20103+MBC\u00a0\ncounts;\u00a0this\u00a0PAD\u20102\u00a0cluster\u00a0included\u00a032\u00a0IgAdef\u00a0patients,\u00a02\u00a0IgG/A def\u00a0cases\u00a0and\u00a0one\u00a0CVID\u00a0patient\u00a0\u2010\u00a0125\u00a0\u2010\u00a0\n\u00a0who\u00a0lacked\u00a0PCs\u00a0and\u00a0smIgA+MBCs,\u00a0but\u00a0had\u00a0normal\u00a0smIgG+MBC\u00a0numbers.\u00a0PAD\u20103\u00a0cases\u00a0consisted\u00a0\nof\u00a022\u00a0CVID\u00a0(88%)\u00a0and\u00a03\u00a0IgG/Adef\u00a0(12%)\u00a0patients\u00a0with\u00a0either\u00a0unde tectable\u00a0switched\u2212PCs\u00a0(both\u00a0\nIgG+\u00a0and\u00a0IgA+\u00a0PCs)\u00a0and\u00a0severely\u00a0decreased\u00a0smIgA1+/A2+MBCs\u00a0(absent\u00a0in\u00a021/25\u00a0cases),\u00a0but\u00a0\npresenting\u00a0 with\u00a0 a\u00a0 heterogeneous\u00a0 defect\u00a0 on\u00a0 IgG+MBCs,\u00a0 consisting\u00a0 of\u00a0 severely\u00a0 reduced\u00a0\nsmIgG2+MBCs\u00a0(absent\u00a0in\u00a014/25),\u00a0with\u00a0a\u00a0milder\u00a0decrease\u00a0of\u00a0smIgG1+\u00a0(80%\u00a0of\u00a0cases)\u00a0and\u00a0smIgG3+\u00a0\n(20%)\u00a0MBC\u00a0counts.\u00a0Finally,\u00a0all\u00a0PAD\u20104\u00a0and\u00a0PAD\u20105\u00a0patients\u00a0were\u00a0CV ID\u00a0who\u00a0had\u00a0undetectable\u00a0(8/11\u00a0\ncases)\u00a0or\u00a0severely\u00a0reduced\u00a0IgG 1+\u00a0and\u00a0IgG 2+\u00a0MBCs\u00a0(PAD\u20104),\u00a0or\u00a0no\u00a0MBCs\u00a0(PAD\u20105),\u00a0except\u00a0for\u00a0two\u00a0of\u00a0\nthese\u00a0later\u00a0cases\u00a0that\u00a0showed\u00a0detectable\u00a0IgG3+MBCs\u00a0at\u00a0levels\u00a0\u226412\u2010fold\u00a0below\u00a0the\u00a0LLN.\u00a0\u00a0\nIgAdef\u00a0blood\u00a0B\u2010cell\u00a0and\u00a0PC\u00a0immune\u00a0profiles.\u00a0 IgAdef\u00a0patients\u00a0split\u00a0in\u00a0two\u00a0subgroups\u00a0with\u00a0\ndifferent\u00a0patterns\u00a0of\u00a0alteration\u00a0of\u00a0smIgA+MBCs\u00a0(Figure\u00a02B):\u00a0present\u00a0in\u00a0IgAdef\u20101,\u00a0while\u00a0virtually\u00a0\nabsent\u00a0in\u00a0IgAdef\u20102\u00a0cases\u00a0(Figure\u00a03B).\u00a0Interestingly,\u00a0these\u00a0two\u00a0 subgroups\u00a0did\u00a0not\u00a0show\u00a0a\u00a0strong\u00a0\nassociation\u00a0with\u00a0the\u00a0ESID\u00a0diagnostic\u00a0criteria5\u00a0for\u00a0clinical\u00a0IgAdef,\u00a0met\u00a0in\u00a035%\u00a0of\u00a0IgAdef\u20101\u00a0cases\u00a0 vs.\u00a0\n65%\u00a0of\u00a0IgAdef\u20102\u00a0cases\u00a0( P>0.05)\u00a0(Supplementary\u00a0Table\u00a04A).\u00a0Of\u00a0note,\u00a0IgAdef\u20101\u00a0cases\u00a0were\u00a0o lder\u00a0\nthan\u00a0IgAdef\u20102\u00a0patients\u00a0both\u00a0at\u00a0the\u00a0time\u00a0of\u00a0analysis\u00a0(31\u00b120y \u00a0vs.\u00a018\u00b113y,\u00a0respectively;\u00a0 P=0.01)\u00a0and\u00a0\nat\u00a0diagnosis\u00a0(28\u00b120y \u00a0vs.\u00a016\u00b114y,\u00a0respectively; \u00a0P=0.04),\u00a0with\u00a0a\u00a0similar\u00a0male/female\u00a0distribution.\u00a0\nDespite\u00a0no\u00a0differences\u00a0were\u00a0observed\u00a0in\u00a0IgM\u00a0serum\u00a0levels\u00a0at\u00a0dia gnosis,\u00a0serum\u00a0IgG\u00a0was\u00a0slightly\u00a0\nlower\u00a0in\u00a0sIgADef\u20101\u00a0(1,285\u00b1324\u00a0 vs.\u00a01,477\u00b1248\u00a0mg/dl).\u00a0In\u00a0turn,\u00a0while\u00a0around\u00a0one\u00a0third\u00a0of\u00a0both\u00a0\nIgAdef\u20102\u00a0and\u00a0IgAdef\u20101\u00a0had\u00a0past\u00a0history\u00a0of\u00a0recurrent\u00a0respiratory \u00a0infections\u00a0at\u00a0presentation,\u00a0the\u00a0\nIgAdef\u20102\u00a0showed\u00a0a\u00a0higher\u00a0frequency\u00a0of\u00a0other\u00a0(recurrent)\u00a0infecti ons\u00a0(19%\u00a0 vs.\u00a00%,\u00a0respectively;\u00a0\nP=0.02),\u00a0tissue\u2010specific\u00a0autoimmunity\u00a0(28%\u00a0 vs.\u00a07%,\u00a0resp ec tively;\u00a0 P=0.04)\u00a0 and\u00a0other\u00a0family\u00a0\nmembers\u00a0affected\u00a0(22%\u00a0 vs.\u00a00%,\u00a0respectively;\u00a0 P=0.02)\u00a0(Figure\u00a04A;\u00a0Supplementary\u00a0Table\u00a05).\u00a0\nCVID\u00a0blood\u00a0B\u2010cell\u00a0and\u00a0PC\u00a0immune\u00a0profiles.\u00a0 Overall,\u00a06\u00a0subgroups\u00a0of\u00a0CVID\u00a0(CVID\u20101\u00a0to\u00a0CVID\u20106)\u00a0with\u00a0\ndifferent\u00a0 patterns\u00a0 of\u00a0 altered\u00a0 B\u2010cell\u00a0 subsets\u00a0 and\u00a0 complete\u00a0 absen ce\u00a0 of\u00a0 switched\u2010PCs,\u00a0 were\u00a0\nidentified\u00a0(Figure\u00a02C;\u00a0Figure\u00a03C).\u00a0CVID\u20101\u00a0and\u00a0CVID\u20102\u00a0included\u00a0p atients\u00a0with\u00a0both\u00a0detectable\u00a0\nsmIgMD+\u00a0MBCs\u00a0and\u00a0switched\u2010MBCs\u00a0of\u00a0all\u00a0 smIgG1\u20103\u00a0subclasses,\u00a0CVID\u20101\u00a0pati ents\u00a0also\u00a0presenting\u00a0\u2010\u00a0126\u00a0\u2010\u00a0\n\u00a0either\u00a0normal\u00a0or\u00a0slightly\u00a0reduced\u00a0IgA1+\u00a0MBCs.\u00a0In\u00a0contrast,\u00a0CVID\u20103\u00a0showed\u00a0a\u00a0more\u00a0severe\u00a0smIgG2+\u00a0\nM B C \u00a0d e f e c t \u00a0( a t \u00a0l e a s t \u00a03 \u2010 f o l d \u00a0b e l o w \u00a0t h e \u00a0L L N ) \u00a0f r e q u e n t l y \u00a0( 1 2 / 1 5 \u00a0c a ses)\u00a0 with\u00a0 undetectable\u00a0\nsmIgG2+MBCs\u00a0(<0.01\u00a0cells/\u00b5l).\u00a0CVID\u20104\u00a0patients\u00a0had\u00a0no\u00a0switched\u2010MBCs.\u00a0CV ID\u20105\u00a0patients\u00a0showed\u00a0\nmore\u00a0severe\u00a0defects\u00a0involving\u00a0all\u00a0CD27+MBC\u00a0subsets\u00a0(\u226510\u2010fold\u00a0below\u00a0the\u00a0LLN),\u00a0but\u00a0almost\u00a0\nnormal\u00a0CD27\u2010\u00a0smIgG3+MBC\u00a0counts.\u00a0Finally,\u00a0CVID\u20106\u00a0cases\u00a0had\u00a0severely\u00a0decreased\u00a0switch ed\u2010\u00a0and\u00a0\nunswitched\u2010MBCs\u00a0including\u00a0\u22640.06\u00a0IgG3+MBCs/\u00b5l\u00a0(\u226512\u2010fold\u00a0below\u00a0the\u00a0LLN)\u00a0(Figures\u00a02C\u00a0and\u00a03C).\u00a0\u00a0\nO v e r a l l , \u00a0a \u00a0c l o s e \u00a0a s s o c i a t i o n \u00a0b e t w e e n \u00a0t h e \u00a0C V I D \u2010 1 \u2010 6 \u00a0c l u s t e r s \u00a0a n d \u00a0 the\u00a0 EUROclass\u00a0\nclassification\u00a0of\u00a0CVID18\u00a0was\u00a0observed.\u00a0EUROclass\u00a0smB+\u00a0patients\u00a0were\u00a0subclassified\u00a0here\u00a0into\u00a0the\u00a0\nCVID\u20101\u00a0(50%),\u00a0CVID\u20102\u00a0(25%)\u00a0and\u00a0CVID\u20103\u00a0(25%)\u00a0clusters,\u00a0depending \u00a0on\u00a0their\u00a0normal\u00a0 vs.\u00a0low\u00a0smIgA+\u00a0\nand\u00a0smIgG2+\u00a0MBC\u00a0counts. \u00a0EUROclass\u00a0B\u2010\u00a0patients\u00a0were\u00a0included\u00a0in\u00a0our\u00a0CVID\u20106\u00a0cluster,\u00a0except\u00a0for\u00a0\ntwo\u00a0cases\u00a0with\u00a0<1%\u00a0PB\u00a0B\u2010cells\u00a0but\u00a0preserved\u00a0MBC\u00a0counts,\u00a0thereby \u00a0classified\u00a0here\u00a0as\u00a0CVID\u20104\u00a0and\u00a0\nCVID\u20105,\u00a0respectively.\u00a0However,\u00a0EUROclass\u00a0smB\u2010\u00a0patients\u00a0split\u00a0across\u00a0the\u00a0different\u00a0CVID\u20102\u20106\u00a0\nclusters:\u00a0CVID\u20102,\u00a010%;\u00a0CVID\u20103,\u00a045%;\u00a0CVID\u20104,\u00a016%;\u00a0CVID\u20105,\u00a019%;\u00a0a nd\u00a0CVID\u20106,\u00a010%\u00a0of\u00a0smB\u2010\u00a0cases\u00a0\n(Figure\u00a02C;\u00a0Supplementary\u00a0Table\u00a04B).\u00a0Inclusion\u00a0of\u00a0other\u00a0EUROcla ss\u00a0parameters,\u00a0like\u00a0CD21\u00a0\nexpression\u00a0(Supplementary\u00a0Table\u00a04B)\u00a0or\u00a0immature/transitional\u00a0B\u2010 cell\u00a0counts\u00a0did\u00a0not\u00a0result\u00a0in\u00a0\nsignificantly\u00a0different\u00a0distributions\u00a0of\u00a0smB\u2010\u00a0patients\u00a0across\u00a0our\u00a0CVID\u20101\u20106\u00a0clusters\u00a0(data\u00a0not\u00a0\nshown).\u00a0\nA\u00a0similar\u00a0age,\u00a0gender\u00a0distribution\u00a0and\u00a0frequency\u00a0of\u00a0recurrent\u00a0i nfections\u00a0(75%\u00a0to\u00a0100%)\u00a0\nwas\u00a0observed\u00a0among\u00a0the\u00a0CVID\u00a0clusters,\u00a0except\u00a0for\u00a0CVID\u20106\u00a0patient s,\u00a0who\u00a0were\u00a0significantly\u00a0older\u00a0\nthan\u00a0CVID\u20102\u00a0and\u00a0CVID\u20103\u00a0cases\u00a0( P\u22640.04).\u00a0In\u00a0addition,\u00a0no\u00a0differences\u00a0were\u00a0observed\u00a0regarding\u00a0\nserum\u00a0Ig\u00a0at\u00a0diagnosis,\u00a0except\u00a0for\u00a0lower\u00a0IgM\u00a0levels\u00a0in\u00a0CVID\u20101\u00a0 vs.\u00a0CVID\u20102\u00a0cases\u00a0( P=0.03)\u00a0and\u00a0similar\u00a0\nclinical\u00a0manifestations\u00a0were\u00a0observed\u00a0among\u00a0patients\u00a0with\u00a0prese rved\u00a0smIgG1+MBCs\u00a0(CVID\u20101,\u00a0\nCVID\u20102\u00a0and\u00a0CVID\u20103\u00a0cases).\u00a0Interestingly,\u00a067%\u00a0of\u00a0CVID\u20104\u00a0patients \u00a0showed\u00a0autoimmune\u00a0cytopenias\u00a0\n\u2212absent\u00a0in\u00a0both\u00a0CVID\u20101\u00a0and\u00a0CVID\u20102\u00a0cases\u00a0and\u00a0infrequent\u00a0(8%)\u00a0in\u00a0 CVID\u20103;\u00a0P=0.02\u2212\u00a0and\u00a0they\u00a0more\u00a0\nfrequently\u00a0had\u00a0enteropathy\u00a0(67%\u00a0 vs.\u00a00%\u00a0in\u00a0CVID\u20102,\u00a0 P=0.04).\u00a0In\u00a0contrast,\u00a0CVID\u20105\u00a0patients\u00a0very\u00a0\u2010\u00a0127\u00a0\u2010\u00a0\n\u00a0frequently\u00a0had\u00a0hepatomegaly\u00a0(57%\u00a0 vs.\u00a00%\u00a0in\u00a0CVID\u20103;\u00a0 P=0.009)\u00a0and\u00a0tissue\u2010sp ecific\u00a0autoimmunity\u00a0\n\u221267%\u00a0vs.\u00a00%\u00a0in\u00a0CVID\u20104\u00a0( P=0.03)\u00a0and\u00a010%\u00a0in\u00a0CVID\u20106\u00a0( P=0.04)\u2212.\u00a0Finally,\u00a0CVID\u20106\u00a0cases\u00a0displayed\u00a0a\u00a0\nmixed\u00a0clinical\u00a0profile\u00a0between\u00a0CVID\u20104\u00a0\u2013enteropathy:\u00a078%\u00a0 vs.\u00a00%\u00a0in\u00a0CVID\u20102\u00a0( P=0.01)\u00a0and\u00a017%\u00a0in\u00a0\nCVID\u20103\u00a0(P=0.008);\u00a0and\u00a0autoimmune\u00a0cytopenias\u00a0(50%\u00a0 vs.\u00a08%\u00a0in\u00a0CVID\u20103;\u00a0 P=0.04)\u2212\u00a0and\u00a0CVID\u20105\u00a0cases\u00a0\n\u2212high\u00a0frequency\u00a0of\u00a0hepatomegaly\u00a0(56%\u00a0 vs.\u00a0in\u00a00%\u00a0in\u00a0CVID\u20103;\u00a0 P=0.006)\u2212together\u00a0with\u00a0a\u00a0high\u00a0\nfrequency\u00a0of\u00a0bronchiectasis\u00a0(80% \u00a0vs.\u00a025%\u00a0in\u00a0CVID\u20103\u00a0( P=0.02)\u00a0and\u00a014%\u00a0in\u00a0CVID\u20105\u00a0( P=0.01).\u00a0All\u00a0\ncases\u00a0with\u00a0granuloma\u00a0clustered\u00a0in\u00a0this\u00a0CVID\u20106\u00a0group\u00a0(30%)\u00a0(Figu re\u00a04B;\u00a0Supplementary\u00a0Table\u00a06). \u00a0\nDISCUSSION \u00a0\n\u00a0Current\u00a0IUIS\u00a0and\u00a0ESID\u00a0guidelines\u00a0for\u00a0diagnosis\u00a0and\u00a0classificati on\u00a0of\u00a0PADs\u00a0relies\u00a0on\u00a0Ab\u00a0\nserum\u00a0levels,\u00a0response\u00a0to\u00a0vaccination\u00a0and\u00a0clinical\u00a0manifestatio ns\u00a0of\u00a0PAD,4,5,7\u00a0in\u00a0the\u00a0absence\u00a0of\u00a0\nwell\u2010defined\u00a0genetic\u00a0markers.30,31\u00a0Although\u00a0the\u00a0number\u00a0of\u00a0affected\u00a0serum\u00a0Ab\u2010isotypes\u00a0provides\u00a0\na\u00a0rough\u00a0estimation\u00a0of\u00a0PAD\u00a0patients\u2019\u00a0susceptibility\u00a0to\u00a0suffer\u00a0fr om\u00a0less\u00a0(e.g.\u00a0IgAdef)\u00a0 vs.\u00a0more\u00a0severe\u00a0\n(CVID)\u00a0disease\u00a0complications\u00a0in\u00a0the\u00a0short\u2010term,4,5\u00a0it\u00a0cannot\u00a0accurately\u00a0predict\u00a0for\u00a0longer\u2010term\u00a0\noutcome\u00a0of\u00a0individual\u00a0patients\u00a0wit hin\u00a0each\u00a0PAD\u00a0subgroup.\u00a0B\u2010cell \u00a0maturation\u2010associated\u00a0defects\u00a0\nidentified\u00a0by\u00a0flowcytometry\u00a0have\u00a0proven\u00a0useful\u00a0for\u00a0the\u00a0diagnosi s\u00a0and\u00a0classification\u00a0of\u00a0CVID\u00a0\npatients,5,18,20\u00a0because\u00a0they\u00a0more\u00a0precisely\u00a0reflect\u00a0the\u00a0medium\u2010term\u00a0B\u2010cell\u2010ass ociated\u00a0protective\u00a0\npotential,\u00a0than\u00a0their\u00a0corresponding\u00a0serum\u00a0Ab\u2010isotype\u00a0levels.\u00a0Ho wever,\u00a0such\u00a0B\u2010cell\u00a0defects\u00a0have\u00a0\nbeen\u00a0poorly\u00a0explored\u00a0in\u00a0IgG/Adef\u00a0and\u00a0IgAdef\u00a0patients,19,32\u00a0while\u00a0the\u00a0blood\u00a0distribution\u00a0of\u00a0B\u2010cells\u00a0\nand\u00a0PCs\u00a0expressing\u00a0distinct\u00a0Ig\u2010subclasses\u00a0has\u00a0never\u00a0been\u00a0invest igated\u00a0so\u00a0far,\u00a0neither\u00a0in\u00a0CVID\u00a0nor\u00a0\nin\u00a0IgAdef.\u00a0Here\u00a0we\u00a0investigated\u00a0for\u00a0the\u00a0first\u00a0time,\u00a0the\u00a0Ig\u2010isot ype\u00a0and\u00a0Ig\u2010subclass\u00a0distribution\u00a0of\u00a0\nMBCs\u00a0and\u00a0PCs\u00a0in\u00a0blood\u00a0of\u00a0PAD\u00a0patients,\u00a0and\u00a0correlated\u00a0the\u00a0alter ed\u00a0immune\u00a0profiles\u00a0identified,\u00a0\nwith\u00a0the\u00a0diagnostic\u00a0subgroups\u00a0and\u00a0clinical\u00a0manifestations\u00a0of\u00a0th e\u00a0disease.\u00a0Since\u00a0the\u00a0blood\u00a0B\u2010cell\u00a0\ncompartment\u00a0is\u00a0highly\u00a0dynamic\u00a0 along\u00a0an\u00a0individual\u2019s\u00a0lifetime,23,33\u201336\u00a0B\u2010cell\u00a0defects\u00a0were\u00a0defined\u00a0\nper\u00a0age\u2010group.\u00a0\u00a0\nEvery\u00a0CVID,\u00a0IgG/Adef\u00a0and\u00a0IgAdef\u00a0patient\u00a0showed\u00a0decreased\u00a0counts \u00a0for\u00a0\u22651\u00a0B\u2010cell\u00a0subsets.\u00a0\nThis\u00a0contrasts\u00a0with\u00a0previous\u00a0flo wcytometry\u00a0studies\u00a0that\u00a0detecte d\u00a0B\u2010cell\u00a0defects\u00a0in\u00a0only\u00a06\u201086%\u00a0of\u00a0\u2010\u00a0128\u00a0\u2010\u00a0\n\u00a0PAD\u00a0patients,\u00a0namely\u00a077%\u201086%\u00a0in\u00a0CVID,14,15,18,20,22,37,38\u00a06%\u201025%\u00a0in\u00a0IgAdef19,32\u00a0and\u00a030%\u00a0in\u00a0selective\u00a0\nIgG\u2010subclass\u00a0deficiency\u00a0(with\u00a0or\u00a0without\u00a0IgAdef).38\u00a0This\u00a0high\u00a0frequency\u00a0of\u00a0B\u2010cell\u00a0defects\u00a0most\u00a0\nlikely\u00a0reflects\u00a0the\u00a0more\u00a0detailed\u00a0dissection\u00a0of\u00a0the\u00a0blood\u00a0B\u2010cel l\u00a0and\u00a0PC\u00a0compartments,\u00a0together\u00a0\nwith\u00a0the\u00a0higher\u00a0sensitivity\u00a0of\u00a0our\u00a0 vs.\u00a0previous\u00a0methods,\u00a0and/or\u00a0the\u00a0use\u00a0of\u00a0age\u2010matched\u00a0reference\u00a0\nranges.\u00a0\u00a0\nRecently\u2010produced,\u00a0short\u2010lived\u00a0blood\u00a0PCs,39\u00a0particularly\u00a0IgA+PCs,\u00a0emerged\u00a0as\u00a0the\u00a0most\u00a0\nsensitive\u00a0population\u00a0for\u00a0diagnosis\u00a0of\u00a0PAD,\u00a0followed\u00a0by\u00a0switched \u00a0and\u00a0non\u2010switched\u00a0MBCs,\u00a0with\u00a0\nprogressively\u00a0more\u00a0severe\u00a0immunological\u00a0defects\u00a0in\u00a0the\u00a0spectrum \u00a0of\u00a0IgAdef\u00a0to\u00a0IgG/Adef\u00a0and\u00a0\nCVID.\u00a0Thus,\u00a0decreased\u00a0smIgA1+\u00a0and/or\u00a0smIgA2+\u00a0PC\u00a0counts\u00a0were\u00a0found\u00a0in\u00a0all\u00a0PAD\u00a0patients,\u00a0except\u00a0\nin\u00a0two\u00a0IgAdef\u00a0cases\u00a0who\u00a0showed\u00a0reduced\u00a0smIgA1+\u00a0and\u00a0smIgA2+\u00a0MBCs.\u00a0In\u00a0addition,\u00a0decreased\u00a0\ntotal\u00a0and/or\u00a0switched\u2010PCs\u00a0emerged\u00a0as\u00a0a\u00a0hallmark\u00a0of\u00a0CVID,\u00a0in\u00a0lin e\u00a0with\u00a0previous\u00a0BM\u00a0and\u00a0lymph\u00a0\nnode\u00a0findings.40,41Of\u00a0note,\u00a0IgAdef\u00a0patients\u00a0showed\u00a0cellular\u00a0defects\u00a0typically\u00a0rest ricted\u00a0to\u00a0smIgA+\u00a0\nPCs\u00a0and\u00a0MBCs,\u00a0without\u00a0significa nt\u00a0alterations\u00a0of\u00a0total\u00a0smIgG+\u00a0MBC\u00a0and\u00a0PC\u00a0counts,\u00a0which\u00a0were\u00a0\nrestricted\u00a0to\u00a0the\u00a0more\u00a0severe\u00a0IgG/Adef,\u00a0and\u00a0particularly,\u00a0CVID\u00a0 cases.\u00a0Nevertheless,\u00a0compared\u00a0to\u00a0\na\u00a0previous\u00a0study21\u00a0where\u00a0<10%\u00a0IgAdef\u00a0patients\u00a0had\u00a0smIgA+MBCs,\u00a0a\u00a0greater\u00a0percentage\u00a0of\u00a0our\u00a0\nIgAdef\u00a0cases\u00a0showed\u00a0circulating\u00a0smIgA+MBCs\u00a0(\u224850%)\u00a0and/or\u00a0PCs\u00a0(\u224840%).\u00a0This\u00a0discrepancy\u00a0is\u00a0\nprobably\u00a0due\u00a0to\u00a0the\u00a0greater\u00a0sensitivity\u00a0of\u00a0our\u00a0EuroFlow\u00a0strateg ies\u00a0and\u00a0methods\u00a0with\u00a0\u22655x106\u00a0(vs.\u00a0\n5x104)\u00a0cells\u00a0analyzed21.\u00a0Our\u00a0findings\u00a0are\u00a0in\u00a0line\u00a0with\u00a0previous\u00a0studies\u00a0demonstrating\u00a0 S\u03b1\u2010switch\u00a0\nrecombination\u00a0in\u00a0blood\u00a0B\u2010cells\u00a0from\u00a02/4\u00a0IgAdef\u00a0patients.42\u00a0Interestingly,\u00a0IgAdef\u00a0cases\u00a0that\u00a0\nshowed\u00a0a\u00a0preserved\u00a0IgA\u2010switching\u00a0capacity,\u00a0displayed\u00a0a\u00a0milder\u00a0c linical\u00a0phenotype,\u00a0with\u00a0less\u00a0risk\u2010\nfactors\u00a0 for\u00a0 CVID\u00a0 progression\u00a0 (e.g.\u00a0 autoimmunity),43\u00a0b u t \u00a0a \u00a0s i m i l a r \u00a0p r e v a l e n c e \u00a0o f \u00a0r e c u r r e n t \u00a0\nrespiratory\u00a0infections.\u00a0Altogether,\u00a0these\u00a0findings\u00a0suggest\u00a0that \u00a0detailed\u00a0evaluation\u00a0of\u00a0blood\u00a0B\u2010cell\u00a0\nand\u00a0PC\u00a0defects,\u00a0might\u00a0contribute\u00a0to\u00a0an\u00a0improved\u00a0classification\u00a0 and\u00a0clinical\u00a0management\u00a0of\u00a0\nIgAdef\u00a0patients.\u00a0\nComplete\u00a0lack\u00a0of\u00a0blood\u00a0switched\u00a0PCs\u00a0was\u00a0the\u00a0hallmark\u00a0of\u00a0CVID.\u00a0W hereas\u00a0reduced\u00a0\nnumbers\u00a0of\u00a0switched\u2010MBCs\u00a0have\u00a0been\u00a0extensively\u00a0reported\u00a0in\u00a0CVID ,14\u201316,18,20\u00a0this\u00a0is\u00a0the\u00a0first\u00a0time\u00a0\u2010\u00a0129\u00a0\u2010\u00a0\n\u00a0that\u00a0these\u00a0cells\u00a0were\u00a0dissected\u00a0at\u00a0the\u00a0Ig\u2010subclass\u00a0level,\u00a0simil arly\u00a0to\u00a0what\u00a0is\u00a0routinely\u00a0done\u00a0for\u00a0\nserum\u00a0IgG 1\u20104\u00a0levels.\u00a0Progressive\u00a0deterioration\u00a0in\u00a0IgG\u2010switching\u00a0capacity\u00a0was \u00a0observed\u00a0in\u00a0MBCs\u00a0of\u00a0\nCVID\u00a0patients,\u00a0which\u00a0directly\u00a0correlated\u00a0with\u00a0their\u00a0consecutive \u00a0location\u00a0in\u00a0the\u00a0 IGHC\u00a0gene\u00a0locus:\u00a0\nIgM<IgG3<IgG1<IgG2.\u00a0In\u00a0line\u00a0with\u00a0these\u00a0results,\u00a0 Piqueras\u00a0et\u00a0al.14\u00a0showed\u00a0a\u00a0similar\u00a0pattern\u00a0of\u00a0\nreduced\u00a0 mRNA\u00a0 expression\u00a0 for\u00a0 the\u00a0 different\u00a0 Ig\u2010isotypes/Ig\u2010subcla sses:\u00a0\nIgM>IgG3\u2265IgG1>IgG2>IgA1>IgA2>IgG4.\u00a0At\u00a0present,\u00a0it\u00a0is\u00a0well\u2010estab lished\u00a0that\u00a0downstream\u00a0IgG\u2010\nsubclasses\u00a0are\u00a0produced,\u00a0at\u00a0least \u00a0in\u00a0part,\u00a0by\u00a0consecutive\u00a0switc hing\u00a0of\u00a0B\u2010cells\u00a0during\u00a0repeated\u00a0\nrounds\u00a0of\u00a0(MBC)\u00a0response,44\u201347\u00a0leading\u00a0to\u00a0a\u00a0greater\u00a0frequency\u00a0of\u00a0somatic\u00a0hypermutation44,46,47\u00a0\nand\u00a0switch\u00a0regions\u00a0bearing\u00a0remnants\u00a0of\u00a0indirect\u00a0class\u2010switching46\u00a0in\u00a0cells\u00a0expressing\u00a0downstream\u00a0\nIg\u2010isotype/Ig\u2010subclasses.\u00a0Interestingly,\u00a0we\u00a0recently\u00a0identified \u00a0a\u00a0similar\u00a0pattern\u00a0of\u00a0sequential\u00a0\nproduction\u00a0of\u00a0MBC\u00a0expressing\u00a0distinct\u00a0Ig\u2010subclasses\u00a0during\u00a0life time\u00a023.\u00a0These\u00a0findings,\u00a0together\u00a0\nwith\u00a0recent\u00a0observations\u00a0using\u00a0genome\u2010wide\u00a0sequencing\u00a0approache s,\u00a0suggest\u00a0that\u00a0consecutive\u00a0\nswitching\u00a0 along\u00a0 the \u00a0I G H C\u00a0l o c u s \u00a0m i g h t \u00a0\u00a0d e t e r i o r a t e \u00a0i n \u00a0P A D , \u00a0p o s s i b l y \u00a0d u e \u00a0t o \u00a0c o m b i n e d \u00a0\nhypomorphic/deleterious\u00a0 variants,48\u201350\u00a0 haploinsufficient\u00a0 genes51\u201354\u00a0 and\u00a0 epigenetic\u00a0\nmodifications55\u00a0 involving\u00a0 B\u2010cell\u00a0 response\u00a0 pathways,\u00a0 rather\u00a0 than\u00a0 a\u00a0 single\u00a0 genet ic\u00a0 defect.\u00a0\nProgressive\u00a0deterioration\u00a0of\u00a0sequential\u00a0class\u2010switching\u00a0along\u00a0t he\u00a0IGHC\u00a0locus,\u00a0along\u00a0with\u00a0reduced\u00a0\nMBC\u00a0and\u00a0lack\u00a0of\u00a0PC,\u00a0lead\u00a0to\u00a0a\u00a0pr ogressively\u00a0more\u00a0restricted\u00a0rep ertoire\u00a0and\u00a0decreased\u00a0functional\u00a0\ncapacity\u00a0of\u00a0MBCs\u00a0expressing\u00a0do wnstream\u00a0IgG\u2010subclasses.\u00a0\nPrevious\u00a0flowcytometry\u00a0approaches\u00a0typically\u00a0excluded\u00a0CVID\u00a0patie nts\u00a0with\u00a0<1%\u00a0B\u2010cells\u00a0\nfrom\u00a0analysis,\u00a0due\u00a0to\u00a0insufficient\u00a0B\u2010cell\u00a0numbers\u00a0for\u00a0robust\u00a0di ssection\u00a0of\u00a0its\u00a0major\u00a0subsets.15,18\u00a0\nOur\u00a0high\u2010sensitive\u00a0approach\u00a0allows\u00a0detection\u00a0of\u00a0low\u00a0numbers\u00a0of\u00a0 blood\u00a0MBCs\u00a0and\u00a0PCs\u00a0expressing\u00a0\nIgG1\u20104\u00a0and\u00a0IgA1\u20102\u00a0\u00a0subclasses,\u00a0showing\u00a0that\u00a0most\u00a0CVID\u00a0patients\u00a0 retain\u00a0the\u00a0ability\u00a0for\u00a0class\u2010\nswitching,\u00a0including\u00a0the\u00a0great\u00a0majority\u00a0(>70%)\u00a0of\u00a0smB\u2010\u00a0cases\u00a0presenting\u00a0with\u00a0dramatically\u00a0\nreduced\u00a0 switched\u2010MBCs.18\u00a0 This\u00a0 is\u00a0 consistent\u00a0 with\u00a0 more\u00a0 la borious\u00a0 functional\u00a0 studies\u00a0 that \u00a0\ndemonstrated\u00a0(residual)\u00a0capacity\u00a0of\u00a0B\u2010cells\u00a0to\u00a0produce\u00a0IgG,\u00a0als o\u00a0among\u00a0smB\u2010\u00a0patients.56\u00a0Our\u00a0\nEuroFlow\u00a0strategy\u00a0for\u00a0highly\u2010sen sitive\u00a0Ig\u2010subclass\u00a0analysis\u00a0of\u00a0 blood\u00a0B\u2010cells\u00a0and\u00a0PCs,\u00a0identified\u00a0six\u00a0\u2010\u00a0130\u00a0\u2010\u00a0\n\u00a0CVID\u00a0subgroups\u00a0with\u00a0different\u00a0IgG\u2010switching\u00a0patterns\u00a0and\u00a0clinic al\u00a0profiles,\u00a0even\u00a0within\u00a0smB\u2010\nnegative\u00a0CVID\u00a0patients.\u00a0The\u00a0three\u00a0clinically\u00a0milder\u00a0subgroups\u00a0i ncluded\u00a0patients\u00a0capable\u00a0of\u00a0\nproducing\u00a0MBCs\u00a0of\u00a0the\u00a0(first\u00a03)\u00a0IgM/D,\u00a0IgG3\u00a0and\u00a0IgG1\u00a0Ig\u2010isotype s/subclasses\u00a0located\u00a0upstream\u00a0\nin\u00a0the\u00a0IGHC\u00a0locus\u00a0(independently\u00a0of\u00a0smIgG2+\u00a0and\u00a0IgA+\u00a0MBC\u00a0counts),\u00a0who\u00a0might\u00a0potentially\u00a0\nrequire\u00a0less\u00a0IgG\u2010substitution\u00a0therapy.56\u00a0In\u00a0fact,\u00a0despite\u00a0patients\u00a0of\u00a0all\u00a0groups\u00a0have\u00a0higher\u00a0\nfrequency\u00a0of\u00a0infections,\u00a0those\u00a0within\u00a0the\u00a0CVID\u20101\u20103\u00a0groups\u00a0requi red\u00a0less\u00a0hospital\u00a0care\u00a0(data\u00a0not\u00a0\nshown).\u00a0CVID\u20104\u00a0cases\u00a0were\u00a0still\u00a0capable\u00a0of\u00a0CD27+\u00a0unswitched\u2010MBC\u00a0production,\u00a0and\u00a0typically\u00a0\npresented\u00a0with\u00a0enteropathy\u00a0and\u00a0cytopenias,\u00a0like\u00a0in\u00a0hyper\u2010IgM\u00a0sy ndromes.57\u201359\u00a0However\u00a0they\u00a0\nhad\u00a0no\u00a0PCs\u00a0(including\u00a0no\u00a0IgM+\u00a0PCs\u00a0in\u00a0all\u00a0but\u00a0one\u00a0case)\u00a0and\u00a0they\u00a0showed\u00a0a\u00a0typical\u00a0CVID\u2010relate d\u00a0\nserum\u00a0Ab\u2010profile,\u00a0in\u00a0the\u00a0absence\u00a0of\u00a0 in\u00a0vitro\u00a0functional\u00a0defects\u00a0associated\u00a0with\u00a0hyper\u2010IgM\u00a0\nsyndromes60\u00a0(data\u00a0not\u00a0shown).\u00a0\nThe\u00a0two\u00a0clinically\u00a0more\u00a0severe\u00a0CVID\u20105,\u00a0and\u00a0particularly\u00a0CVID\u20106, \u00a0patient\u00a0subgroups\u00a0had\u00a0\ndramatically\u00a0 decreased\u00a0 CD27+\u00a0 unswitched\u2010and\u00a0 switched\u2010MBCs,\u00a0 except\u00a0 for\u00a0 CD27\u2010CD21\u2010\nIgG3+MBCs\u00a0that\u00a0were\u00a0found\u00a0to\u00a0be\u00a0almost\u00a0normal\u00a0in\u00a0CVID\u20105\u00a0(but\u00a0not\u00a0in\u00a0 CVID\u20106)\u00a0cases.\u00a0From\u00a0the\u00a0\nc l i n i c a l \u00a0p o i n t \u00a0o f \u00a0v i e w , \u00a0C V I D \u2010 5 \u00a0a n d \u00a0C V I D \u2010 6 \u00a0p a t i e n t s \u00a0s h o w e d \u00a0d i s e a se\u00a0 symptoms\u00a0 (e.g.\u00a0\norganomegalies)\u00a0reflecting\u00a0an\u00a0im paired\u00a0ability\u00a0to\u00a0mount\u00a0GC\u00a0resp onses.23,46,61\u00a0Altogether,\u00a0these\u00a0\nfindings\u00a0suggest\u00a0that\u00a0even\u00a0if\u00a0the\u00a0residual\u00a0CD27\u2010CD21\u2010smIgG3+\u00a0MBCs\u00a0could\u00a0offer\u00a0some\u00a0immune\u00a0\nprotection\u00a0in\u00a0CVID\u20105,\u00a0in\u00a0CVID\u20105\u00a0and\u00a0CVID\u20106\u00a0cases\u00a0the\u00a0underlying \u00a0immune\u00a0dysregulation\u00a0leads\u00a0to\u00a0\na\u00a0polyclonal\u00a0lymphocytic\u00a0infiltration\u00a0of\u00a0secondary\u00a0lymphoid\u00a0tis sues,\u00a0previously\u00a0associated\u00a0with\u00a0\nincreased\u00a0risk\u00a0for\u00a0lymphoid\u00a0malignancy\u00a0in\u00a0CVID.62\u00a0In\u00a0fact,\u00a0all\u00a0patients\u00a0with\u00a0hematologic\u00a0tumors\u00a0\nwere\u00a0clustered\u00a0in\u00a0CVID\u20105\u00a0and\u00a0CVID\u20106\u00a0(Supplementary\u00a0Table\u00a06).\u00a0Al though\u00a0it\u00a0is\u00a0tempting\u00a0to\u00a0\nhypothesize\u00a0that\u00a0such\u00a0stepwise\u00a0d eterioration\u00a0of\u00a0IgG\u2010switching\u00a0c apacity\u00a0might\u00a0reflect\u00a0disease\u00a0\nprogression,\u00a0no\u00a0significant\u00a0differences\u00a0in\u00a0age\u00a0(or\u00a0time\u00a0from\u00a0di agnosis)\u00a0were\u00a0observed\u00a0among\u00a0the\u00a0\nabove\u00a0CVID\u00a0patient\u00a0subgroups\u00a0(ex cept\u00a0for\u00a0CVID\u20106\u00a0patients,\u00a0which \u00a0were\u00a0older\u00a0at\u00a0time\u00a0of\u00a0analysis\u00a0\nthan\u00a0CVID\u20102\u00a0and\u00a0CVID\u20103\u00a0cases).\u00a0\u2010\u00a0131\u00a0\u2010\u00a0\n\u00a0The\u00a0most\u00a0severe\u00a0CVID\u00a0immunological\u00a0phenotype\u00a0\u2212(CVID\u20106)\u2212\u00a0also\u00a0sh owed\u00a0signi\ufb01cantly\u00a0\nreduced\u00a0pre\u2010GC\u00a0B\u2010cells,\u00a0reflecting\u00a0a\u00a0markedly\u00a0defective\u00a0BM\u00a0B\u2010ce ll\u00a0production.\u00a018,20,41\u00a0Most\u00a0blood\u00a0\nB\u2010cells\u00a0 in\u00a0 these\u00a0 patients\u00a0 showe d\u00a0 an\u00a0 immature/transitional\u00a0 pheno type,\u00a0 reflecting\u00a0 their\u00a0\npremature\u00a0egress\u00a0from\u00a0BM,39\u00a0while\u00a0residual\u00a0naive\u00a0B\u2010cells\u00a0were\u00a0enriched\u00a0in\u00a0the\u00a0minor\u00a0CD21lo\u00a0\nnaive\u00a0B\u2010cell\u00a0subset.\u00a0The\u00a0reduced\u00a0pre\u2010GC\u00a0B\u2010cells,\u00a0together\u00a0with\u00a0 the\u00a0low\u00a0in\u00a0vitro\u00a0response\u00a0of\u00a0both\u00a0\nimmature\u00a0and\u00a0CD21lo\u00a0naive\u00a0B\u2010cells,39,63\u00a0might\u00a0explain\u00a0the\u00a0marked\u00a0Ag\u2010experienced\u00a0B\u2010cell\u00a0defect\u00a0\ninvolving\u00a0all\u00a0Ig\u2010isotypes\u00a0found\u00a0in\u00a0CVID\u20106\u00a0cases.\u00a0In\u00a0line\u00a0with\u00a0p revious\u00a0observations20,\u00a0these\u00a0\npatients\u00a0also\u00a0had\u00a0decreased\u00a0naive\u00a0T\u2010CD4+\u00a0and\u00a0T\u2010CD8+\u00a0counts\u00a0vs.\u00a0age\u2010matched\u00a0HD\u00a0and\u00a0other\u00a0CVID\u00a0\npatients\u00a0(data\u00a0not\u00a0shown),\u00a0but\u00a0t hey\u00a0did\u00a0not\u00a0fulfill\u00a0the\u00a0diagnos tic\u00a0criteria\u00a0for\u00a0late\u2010onset\u00a0combined\u00a0\nimmunodeficiency;5\u00a0the\u00a0potential\u00a0existence\u00a0of\u00a0underlying\u00a0hypomorfic\u00a0defects\u00a0and\u00a0v ariants\u00a0of\u00a0\ngenes\u00a0related\u00a0to\u00a0the\u00a0production\u00a0of\u00a0lymphocytes\u00a0( RAG,\u00a0DCLRE1C,\u00a0NHEJ1 )\u00a0previously\u00a0related\u00a0to\u00a0\nCVID\u2010like\u00a0clinical\u00a0phenotypes,\u00a0remains\u00a0to\u00a0be\u00a0more\u00a0deeply\u00a0invest igated\u00a0in\u00a0those\u00a0CVID\u20106\u00a0cases.48\u2013\n50\u00a0\nIn\u00a0summary,\u00a0detailed\u00a0dissection\u00a0of\u00a0circulating\u00a0MBCs\u00a0and\u00a0PCs\u00a0int o\u00a0subsets\u00a0expressing\u00a0\ndistinct\u00a0Ig\u2010subclasses\u00a0in\u00a0PAD,\u00a0provides\u00a0complementary\u00a0informati on\u00a0to\u00a0serum\u00a0Ab\u00a0isotype\u2010levels,\u00a0\nand\u00a0 might\u00a0 contribute\u00a0 to\u00a0 a\u00a0 better\u00a0 pathogenic\u00a0 understanding\u00a0 of\u00a0 PA D,\u00a0 with\u00a0 improved\u00a0 PAD\u00a0\ndiagnosis,\u00a0subclassification,\u00a0and\u00a0monitoring\u00a0(particularly\u00a0in\u00a0c ase\u00a0of\u00a0Ig\u2010replacement\u00a0therapy).\u00a0\nBlood\u00a0PCs\u00a0emerged\u00a0here\u00a0as\u00a0the\u00a0mo st\u00a0sensitive\u00a0diagnostic\u00a0blood\u00a0c ellular\u00a0compartment,\u00a0while\u00a0\nanalysis\u00a0of\u00a0blood\u00a0MBC\u00a0subsets\u00a0appeared\u00a0informative\u00a0to\u00a0discrimin ate\u00a0patients\u00a0with\u00a0different\u00a0\nclinical\u00a0profiles.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u2010\u00a0132\u00a0\u2010\u00a0\n\u00a0REFERENCES\u00a0\n1.\u00a0\u00a0 Durandy\u00a0A,\u00a0Kracker\u00a0S,\u00a0Fischer\u00a0A.\u00a0Primary\u00a0antibody\u00a0deficienc ies.\u00a0Nat\u00a0Rev\u00a0Immunol\u00a02013;13:519\u2013\n33.\u00a0\u00a0\n2.\u00a0\u00a0 Wood\u00a0PM.\u00a0Primary\u00a0antibody\u00a0de ficiency\u00a0syndromes.\u00a0Curr\u00a0Opin\u00a0H ematol\u00a02010;17:356\u201361.\u00a0\u00a0\n3.\u00a0\u00a0 Wang\u00a0 N,\u00a0 Hammarstrom\u00a0 L.\u00a0 IgA\u00a0 deficiency:\u00a0 what\u00a0 is\u00a0 new?\u00a0 Curr\u00a0 Op in\u00a0 Allergy\u00a0 Clin\u00a0 Immunol\u00a0\n2012;12:602\u20138.\u00a0\u00a0\n4.\u00a0\u00a0 Picard\u00a0C,\u00a0Bobby\u00a0Gaspar\u00a0H,\u00a0Al\u2010Herz\u00a0W,\u00a0Bousfiha\u00a0A,\u00a0Casanova\u00a0J \u2010L,\u00a0Chatila\u00a0T,\u00a0et\u00a0al.\u00a0International\u00a0Union\u00a0\nof\u00a0Immunological\u00a0Societies:\u00a02017\u00a0Primary\u00a0Immunodeficiency\u00a0Disea ses\u00a0Committee\u00a0Report\u00a0on\u00a0\nInborn\u00a0Errors\u00a0of\u00a0Immunity.\u00a0J\u00a0Clin\u00a0Immunol\u00a02018;38:96\u2013128.\u00a0\u00a0\n5.\u00a0\u00a0 Abinun\u00a0M,\u00a0Albert\u00a0M,\u00a0Buckland\u00a0SBCM,\u00a0Bustamante\u00a0J,\u00a0Cant\u00a0A,\u00a0Ca sanova\u00a0J\u2010L,\u00a0et\u00a0al.\u00a0ESID\u00a0Registry\u00a0\u2013\u00a0\nWorking\u00a0Definitions\u00a0for\u00a0Clin ical\u00a0Diagnosis\u00a0of\u00a0PID.\u00a02017.\u00a0\u00a0\n6.\u00a0\u00a0 Ballow\u00a0M.\u00a0Primary\u00a0immunodeficiency\u00a0disorders:\u00a0antibody\u00a0defi ciency.\u00a0J\u00a0Allergy\u00a0Clin\u00a0Immunol\u00a0\n2002;109:581\u201391.\u00a0\u00a0\n7.\u00a0\u00a0 Jolles\u00a0S.\u00a0The\u00a0variable\u00a0in\u00a0common\u00a0variable\u00a0immunodeficiency: \u00a0a\u00a0disease\u00a0of\u00a0complex\u00a0phenotypes.\u00a0J\u00a0\nallergy\u00a0Clin\u00a0Immunol\u00a0Pr act\u00a02013;1:545\u201356.\u00a0\u00a0\n8.\u00a0\u00a0 Yazdani\u00a0R,\u00a0Azizi\u00a0G,\u00a0Abolhassani\u00a0H,\u00a0Aghamohammadi\u00a0A.\u00a0Selecti ve\u00a0IgA\u00a0Deficiency:\u00a0Epidemiology,\u00a0\nPathogenesis,\u00a0 Clinical\u00a0 Phenotype ,\u00a0 Diagnosis,\u00a0 Prognosis\u00a0 and\u00a0 Mana gement.\u00a0 Scand\u00a0 J\u00a0 Immunol\u00a0\n2017;85:3\u201312.\u00a0\u00a0\n9.\u00a0\u00a0 Cunningham\u2010Rundles\u00a0C.\u00a0The\u00a0many\u00a0faces\u00a0of\u00a0common\u00a0variable\u00a0imm unodeficiency.\u00a0Hematol\u00a0Am\u00a0Soc\u00a0\nHematol\u00a0Educ\u00a0Progr\u00a02012;2012:301\u20135.\u00a0\u00a0\n10.\u00a0\u00a0 Chapel\u00a0H,\u00a0Lucas\u00a0M,\u00a0Patel\u00a0S,\u00a0Lee\u00a0M,\u00a0Cunningham\u2010Rundles\u00a0C,\u00a0R esnick\u00a0E,\u00a0et\u00a0al.\u00a0Confirmation\u00a0and\u00a0\nimprovement\u00a0of\u00a0criteria\u00a0for\u00a0clinical\u00a0phenotyping\u00a0in\u00a0common\u00a0vari able\u00a0immunodeficiency\u00a0disorders\u00a0\nin\u00a0replicate\u00a0cohorts.\u00a0J\u00a0Allergy\u00a0 Clin\u00a0Immunol\u00a02012;130:1197\u20138.\u00a0\u00a0\n11.\u00a0\u00a0 Chapel\u00a0 H.\u00a0 Common\u00a0 Variable\u00a0 Immunodeficiency\u00a0 Disorders\u00a0 (CVID )\u00a0 \u2010\u00a0 Diagnoses\u00a0 of\u00a0 Exclusion,\u00a0\nEspecially\u00a0Combined\u00a0Immune\u00a0Defe cts.\u00a0J\u00a0allergy\u00a0Clin\u00a0Immunol\u00a0Prac t\u00a02016;4:1158\u20139.\u00a0\u00a0\n12.\u00a0\u00a0 Bertinchamp\u00a0R,\u00a0Gerard\u00a0L,\u00a0Boutboul\u00a0D,\u00a0Malphettes\u00a0M,\u00a0Fieschi \u00a0C,\u00a0Oksenhendler\u00a0E.\u00a0Exclusion\u00a0of\u00a0\nPatients\u00a0 with\u00a0 a\u00a0 Severe\u00a0 T\u2010Cell\u00a0 Defect\u00a0 Improves\u00a0 the\u00a0 Definition\u00a0 of \u00a0 Common\u00a0 Variable\u00a0\nImmunodeficiency.\u00a0J\u00a0allergy\u00a0Clin\u00a0Immunol\u00a0Pract\u00a02016;4:1147\u201357.\u00a0 \u00a0\n13.\u00a0\u00a0 Bonilla\u00a0FA,\u00a0Barlan\u00a0I,\u00a0Chapel\u00a0 H,\u00a0Costa\u2010Carvalho\u00a0BT,\u00a0Cunning ham\u2010Rundles\u00a0C,\u00a0de\u00a0la\u00a0Morena\u00a0MT,\u00a0et\u00a0al.\u00a0\nInternational\u00a0Consensus\u00a0Document \u00a0(ICON):\u00a0Common\u00a0Variable\u00a0Immuno deficiency\u00a0Disorders.\u00a0J\u00a0\nallergy\u00a0Clin\u00a0Immunol\u00a0Pract\u00a02016;4:38\u201359.\u00a0\u00a0\n14.\u00a0\u00a0 Piqueras\u00a0B,\u00a0Lavenu\u2010Bombled\u00a0C,\u00a0Galicier\u00a0L,\u00a0Bergeron\u2010van\u00a0der \u00a0Cruyssen\u00a0F,\u00a0Mouthon\u00a0L,\u00a0Chevret\u00a0S,\u00a0et\u00a0\nal.\u00a0Common\u00a0variable\u00a0immunodeficiency\u00a0patient\u00a0classification\u00a0bas ed\u00a0on\u00a0impaired\u00a0B\u00a0cell\u00a0\u00a0memory\u00a0\ndifferentiation\u00a0correlates\u00a0with \u00a0clinical\u00a0aspects.\u00a0J\u00a0Clin\u00a0Immuno l\u00a02003;23:385\u2013400.\u00a0\u00a0\n15.\u00a0\u00a0 Warnatz\u00a0K,\u00a0Denz\u00a0A,\u00a0Drager\u00a0R,\u00a0Braun\u00a0M,\u00a0Groth\u00a0C,\u00a0Wolff\u2010Vorbe ck\u00a0G,\u00a0et\u00a0al.\u00a0Severe\u00a0deficiency\u00a0of\u00a0\nswitched\u00a0memory\u00a0B\u00a0cells\u00a0(CD27(+)Ig M(\u2010)IgD(\u2010))\u00a0in\u00a0s ubgroups\u00a0of\u00a0p atients\u00a0with\u00a0common\u00a0variable\u00a0\nimmunodeficiency:\u00a0a\u00a0new\u00a0approach \u00a0to\u00a0classify\u00a0a\u00a0he terogeneous\u00a0di sease.\u00a0Blood\u00a02002;99:1544\u201351.\u00a0\u00a0\u2010\u00a0133\u00a0\u2010\u00a0\n\u00a016.\u00a0\u00a0 Al\u00a0Kindi\u00a0M,\u00a0Mundy\u00a0J,\u00a0Sullivan \u00a0T,\u00a0Smith\u00a0W,\u00a0Kette\u00a0F,\u00a0Smith\u00a0A ,\u00a0et\u00a0al.\u00a0Utility\u00a0of\u00a0peripheral\u00a0blood\u00a0B\u00a0cell\u00a0\nsubsets\u00a0analysis\u00a0in\u00a0common\u00a0variable\u00a0immunodeficiency.\u00a0Clin\u00a0Exp\u00a0 Immunol\u00a02012;167:275\u201381.\u00a0\u00a0\n17.\u00a0\u00a0 Pia \u0327tosa\u00a0B,\u00a0Pac\u00a0M,\u00a0Siewiera\u00a0K,\u00a0Pietr ucha\u00a0B,\u00a0Klaudel\u2010Dreszler\u00a0M,\u00a0Her opolita\u0144ska\u2010Pliszka\u00a0E,\u00a0et\u00a0al.\u00a0\nCommon\u00a0variable\u00a0immune\u00a0deficiency\u00a0in\u00a0children\u00a0\u2010\u00a0Clinical\u00a0charac teristics\u00a0varies\u00a0depending\u00a0on\u00a0\ndefect\u00a0in\u00a0peripheral\u00a0B\u00a0cell\u00a0maturation.\u00a0J\u00a0Clin\u00a0Immunol\u00a02013;33: 731\u201341.\u00a0\u00a0\n18.\u00a0\u00a0 Wehr\u00a0C,\u00a0Kivioja\u00a0T,\u00a0Schmitt\u00a0C,\u00a0Ferry\u00a0B,\u00a0Witte\u00a0T,\u00a0Eren\u00a0E,\u00a0et \u00a0al.\u00a0The\u00a0EUROclass\u00a0trial:\u00a0defining\u00a0subgroups\u00a0\nin\u00a0common\u00a0variable\u00a0immunodeficiency.\u00a0Blood\u00a02008;111:77\u201385.\u00a0\u00a0\n19.\u00a0\u00a0 Aghamohammadi\u00a0A,\u00a0Abolhassani\u00a0H,\u00a0Biglari\u00a0M,\u00a0Abolmaali\u00a0S,\u00a0Mo azzami\u00a0K,\u00a0Tabatabaeiyan\u00a0M,\u00a0et\u00a0al.\u00a0\nAnalysis\u00a0of\u00a0switched\u00a0memory\u00a0B\u00a0ce lls\u00a0in\u00a0patients\u00a0with\u00a0IgA\u00a0defici ency.\u00a0Int\u00a0Arch\u00a0Allergy\u00a0Immunol\u00a0\n2011;156:462\u20138.\u00a0\u00a0\n20.\u00a0\u00a0 Driessen\u00a0GJ,\u00a0van\u00a0Zelm\u00a0MC,\u00a0van\u00a0Hagen\u00a0PM,\u00a0Hartwig\u00a0NG,\u00a0Trip\u00a0M ,\u00a0Warris\u00a0A,\u00a0et\u00a0al.\u00a0B\u2010cell\u00a0replication\u00a0\nhistory\u00a0and\u00a0somatic\u00a0hypermutation\u00a0status\u00a0identify\u00a0distinct\u00a0path ophysiologic\u00a0backgrounds\u00a0in\u00a0\ncommon\u00a0variable\u00a0immunodeficiency.\u00a0Blood\u00a02011;118:6814\u201323.\u00a0\u00a0\n21.\u00a0\u00a0 Marasco\u00a0E,\u00a0Farroni\u00a0C,\u00a0Cascioli\u00a0S,\u00a0Marcellini\u00a0V,\u00a0Scarsella\u00a0 M,\u00a0Giorda\u00a0E,\u00a0et\u00a0al.\u00a0B\u2010cell\u00a0activation\u00a0with\u00a0\nCD40L\u00a0 or\u00a0 CpG\u00a0 measures\u00a0 the\u00a0 function\u00a0 of\u00a0 B\u2010cell\u00a0 subsets\u00a0 and\u00a0 identi fies\u00a0 specific\u00a0 defects\u00a0 in\u00a0\nimmunodeficient\u00a0patients.\u00a0Eur\u00a0J\u00a0Immunol\u00a02017;47:131\u201343.\u00a0\u00a0\n22.\u00a0\u00a0 Driessen\u00a0GJ,\u00a0Dalm\u00a0VASH,\u00a0van\u00a0Hagen\u00a0PM,\u00a0Grashoff\u00a0HA,\u00a0Hartwig \u00a0NG,\u00a0van\u00a0Rossum\u00a0AMC,\u00a0et\u00a0al.\u00a0\nCommon\u00a0 variable\u00a0 immunodeficiency\u00a0 a nd\u00a0 idiopathic\u00a0 primary\u00a0 hypogam maglobulinemia:\u00a0 two\u00a0\ndifferent\u00a0conditions\u00a0within\u00a0the\u00a0same\u00a0disease\u00a0spectrum.\u00a0Haematol ogica\u00a02013;98:1617\u201323.\u00a0\u00a0\n23.\u00a0\u00a0 Blanco\u00a0E,\u00a0P\u00e9rez\u2010Andr\u00e9s\u00a0M,\u00a0Arriba\u2010M\u00e9ndez\u00a0S,\u00a0Contreras\u2010Sanfe liciano\u00a0T,\u00a0Criado\u00a0I,\u00a0Pelak\u00a0O,\u00a0et\u00a0al.\u00a0Age\u2010\nassociated\u00a0distribution\u00a0of\u00a0normal\u00a0B\u2010cell\u00a0and\u00a0plasma\u00a0cell\u00a0subset s\u00a0in\u00a0peripheral\u00a0blood.\u00a0J\u00a0Allergy\u00a0Clin\u00a0\nImmunol\u00a02018;in\u00a0press.\u00a0\u00a0\n24.\u00a0\u00a0 Flores\u2010Montero\u00a0J,\u00a0Sanoja\u2010Flores\u00a0L,\u00a0Paiva\u00a0B,\u00a0Puig\u00a0N,\u00a0Garc\u00eda \u2010S\u00e1nchez\u00a0O,\u00a0B\u00f6ttcher\u00a0S,\u00a0et\u00a0al.\u00a0Next\u00a0\nGeneration\u00a0Flow\u00a0for\u00a0highly\u00a0sensit ive\u00a0and\u00a0standardized\u00a0detection \u00a0of\u00a0minimal\u00a0residual\u00a0disease\u00a0in\u00a0\nmultiple\u00a0myeloma.\u00a0Leukem ia\u00a02017;31:2094\u20132103.\u00a0\u00a0\n25.\u00a0\u00a0 Blanco\u00a0E,\u00a0Perez\u2010Andres\u00a0M,\u00a0Sanoja\u2010Flores\u00a0L,\u00a0Wentink\u00a0M,\u00a0Pela k\u00a0O,\u00a0Mart\u00edn\u2010Ayuso\u00a0M,\u00a0et\u00a0al.\u00a0Selection\u00a0\nand\u00a0validation\u00a0of\u00a0antibody\u00a0clon es\u00a0against\u00a0IgG\u00a0and\u00a0IgA\u00a0subclasse s\u00a0in\u00a0switched\u00a0memory\u00a0B\u2010cells\u00a0and\u00a0\nplasma\u00a0cells.\u00a0J\u00a0Immunol\u00a0Methods\u00a02017;in\u00a0press.\u00a0\u00a0\n26.\u00a0\u00a0 Kalina\u00a0T,\u00a0Flores\u2010Montero\u00a0J,\u00a0van\u00a0der\u00a0Velden\u00a0VHJ,\u00a0Martin\u2010Ayu so\u00a0M,\u00a0B\u00f6ttcher\u00a0S,\u00a0Ritgen\u00a0M,\u00a0et\u00a0al.\u00a0\nEuroFlow\u00a0 standardization\u00a0 of\u00a0 flow\u00a0 cytometer\u00a0 instrument\u00a0 settings\u00a0 and\u00a0 immunophenotyping\u00a0\nprotocols.\u00a0Leukemia\u00a02012;26:1986\u20132010.\u00a0\u00a0\n27.\u00a0\u00a0 R\u00a0Core\u00a0Team.\u00a0R:\u00a0A\u00a0Language\u00a0and\u00a0Environment\u00a0for\u00a0Statistical \u00a0Computing.\u00a02015;\u00a0\n28.\u00a0\u00a0 MacQueen\u00a0J.\u00a0Some\u00a0methods\u00a0for\u00a0classification\u00a0and\u00a0analysis\u00a0o f\u00a0multivariate\u00a0observations.\u00a0In:\u00a0\nProceedings\u00a0of\u00a0the\u00a0Fifth\u00a0Berkeley\u00a0Symposium\u00a0on\u00a0Mathematical\u00a0Sta tistics\u00a0and\u00a0Probability,\u00a0Volume\u00a0\n1:\u00a0Statistics.\u00a0Berkeley,\u00a0Calif.: \u00a0University\u00a0of\u00a0California\u00a0Press ;\u00a01967.\u00a0page\u00a0281\u201397.\u00a0\n29.\u00a0\u00a0 Warnes\u00a0GR,\u00a0Bolker\u00a0B,\u00a0Bonebakker\u00a0L,\u00a0Gentleman\u00a0R,\u00a0Liaw\u00a0WHA,\u00a0 Lumley\u00a0T,\u00a0et\u00a0al.\u00a0gplots:\u00a0Various\u00a0R\u00a0\nProgramming\u00a0Tools\u00a0for\u00a0Plotting\u00a0Data.\u00a0R\u00a0Packag.\u00a0version\u00a02.17.0.2 015;2015.\u00a0\u00a0\n30.\u00a0\u00a0 Bogaert\u00a0DJA,\u00a0Dullaers\u00a0M,\u00a0Lambrecht\u00a0BN,\u00a0Vermaelen\u00a0KY,\u00a0De\u00a0Ba ere\u00a0E,\u00a0Haerynck\u00a0F.\u00a0Genes\u00a0associated\u00a0\nwith\u00a0 common\u00a0 variable\u00a0 immunodefi ciency:\u00a0 one\u00a0 diagnosis\u00a0 to\u00a0 rule\u00a0 th e m \u00a0a l l ? \u00a0J \u00a0M e d \u00a0G e n e t \u00a0\n2016;53:575\u201390.\u00a0\u00a0\u2010\u00a0134\u00a0\u2010\u00a0\n\u00a031.\u00a0\u00a0 Kienzler\u00a0A\u2010K,\u00a0Hargreaves\u00a0CE,\u00a0Patel\u00a0SY.\u00a0The\u00a0role\u00a0of\u00a0genomic s\u00a0in\u00a0common\u00a0variable\u00a0immunodeficiency\u00a0\ndisorders.\u00a0Clin\u00a0Exp\u00a0Immu nol\u00a02017;188:326\u201332.\u00a0\u00a0\n32.\u00a0\u00a0 Nechvatalova\u00a0 J,\u00a0 Pikulova\u00a0 Z,\u00a0 Stikarovska\u00a0 D,\u00a0 Pesak\u00a0 S,\u00a0 Vlkova \u00a0 M,\u00a0 Litzman\u00a0 J.\u00a0 B\u2010lymphocyte\u00a0\nsubpopulations\u00a0in\u00a0patients\u00a0with\u00a0se lective\u00a0IgA\u00a0deficiency.\u00a0J\u00a0Cli n\u00a0Immunol\u00a02012;32:441\u20138.\u00a0\u00a0\n33.\u00a0\u00a0 Piatosa\u00a0B,\u00a0Wolska\u2010Kusnierz\u00a0B,\u00a0Pac\u00a0M,\u00a0Siewiera\u00a0K,\u00a0Galkowska \u00a0E,\u00a0Bernatowska\u00a0E.\u00a0B\u00a0cell\u00a0subsets\u00a0in\u00a0\nhealthy\u00a0children:\u00a0Reference\u00a0values\u00a0for\u00a0evaluation\u00a0of\u00a0B\u00a0cell\u00a0mat uration\u00a0process\u00a0in\u00a0peripheral\u00a0blood.\u00a0\nCytom\u00a0Part\u00a0B\u00a0\u2010\u00a0Clin\u00a0Cytom\u00a02010;78:372\u201381.\u00a0\u00a0\n34.\u00a0\u00a0 van\u00a0Gent\u00a0R,\u00a0van\u00a0Tilburg\u00a0CM,\u00a0Nibbelke\u00a0EE,\u00a0Otto\u00a0SA,\u00a0Gaiser\u00a0J F,\u00a0Janssens\u2010Korpela\u00a0PL,\u00a0et\u00a0al.\u00a0Refined\u00a0\ncharacterization\u00a0and\u00a0reference\u00a0values\u00a0of\u00a0the\u00a0pediatric\u00a0T\u2010\u00a0and\u00a0B \u2010cell\u00a0compartments.\u00a0Clin\u00a0Immunol\u00a0\n2009;133:95\u2013107.\u00a0\u00a0\n35.\u00a0\u00a0 Morbach\u00a0H,\u00a0Eichhorn\u00a0EM,\u00a0Liese\u00a0JG,\u00a0Girschick\u00a0HJ.\u00a0Reference\u00a0 values\u00a0for\u00a0B\u00a0cell\u00a0subpopulations\u00a0from\u00a0\ninfancy\u00a0to\u00a0adulthood.\u00a0Clin\u00a0Exp\u00a0Immunol\u00a02010;162:271\u20139.\u00a0\u00a0\n36.\u00a0\u00a0 van\u00a0den\u00a0Heuvel\u00a0D,\u00a0Jansen\u00a0MAE,\u00a0Nasserinejad\u00a0K,\u00a0Dik\u00a0WA,\u00a0van\u00a0 Lochem\u00a0EG,\u00a0Bakker\u2010Jonges\u00a0LE,\u00a0et\u00a0al.\u00a0\nEffects\u00a0of\u00a0nongenetic\u00a0factors\u00a0on\u00a0immune\u00a0cell\u00a0dynamics\u00a0in\u00a0early\u00a0 childhood:\u00a0The\u00a0Generation\u00a0R\u00a0Study.\u00a0\nJ\u00a0Allergy\u00a0Clin \u00a0Immunol\u00a02017;\u00a0\n37.\u00a0\u00a0 Huck\u00a0K,\u00a0Feyen\u00a0O,\u00a0Ghosh\u00a0S,\u00a0Beltz\u00a0K,\u00a0Bellert\u00a0S,\u00a0Niehues\u00a0T.\u00a0M emory\u00a0B\u2010cells\u00a0in\u00a0healthy\u00a0and\u00a0antibody\u2010\ndeficient\u00a0children.\u00a0Clin\u00a0I mmunol\u00a02009;131:50\u20139.\u00a0\u00a0\n38.\u00a0\u00a0 Bogaert\u00a0 DJA,\u00a0 De\u00a0 Bruyne\u00a0 M,\u00a0 Debacker\u00a0 V,\u00a0 Depuydt\u00a0 P,\u00a0 De\u00a0 Preter \u00a0K , \u00a0B o n r o y \u00a0C , \u00a0e t \u00a0a l . \u00a0T h e \u00a0\nimmunophenotypic\u00a0fingerprint\u00a0of\u00a0patients\u00a0with\u00a0primary\u00a0antibody\u00a0 deficiencies\u00a0is\u00a0partially\u00a0present\u00a0\nin\u00a0their\u00a0asymptomatic\u00a0first\u2010degree\u00a0relatives.\u00a0Haematologica\u00a0201 7;102:192\u2013202.\u00a0\u00a0\n39.\u00a0\u00a0 Perez\u2010Andres\u00a0M,\u00a0Paiva\u00a0B,\u00a0Nieto\u00a0WG,\u00a0Caraux\u00a0A,\u00a0Schmitz\u00a0A,\u00a0Al meida\u00a0J,\u00a0et\u00a0al.\u00a0Human\u00a0peripheral\u00a0blood\u00a0\nB\u2010Cell\u00a0compartments:\u00a0A\u00a0crossroad\u00a0 in\u00a0B\u2010cell\u00a0traffic.\u00a0Cytom\u00a0Part\u00a0 B\u00a0\u2010\u00a0Clin\u00a0Cytom\u00a02010;78:47\u201360.\u00a0\u00a0\n40.\u00a0\u00a0 Unger\u00a0S,\u00a0Seidl\u00a0M,\u00a0Schmitt\u2010Graeff\u00a0A,\u00a0Bohm\u00a0J,\u00a0Schrenk\u00a0K,\u00a0Weh r\u00a0C,\u00a0et\u00a0al.\u00a0Ill\u2010defined\u00a0germinal\u00a0centers\u00a0\nand\u00a0severely\u00a0reduced\u00a0plasma\u00a0cells\u00a0are\u00a0histological\u00a0hallmarks\u00a0of \u00a0lymphadenopathy\u00a0in\u00a0patients\u00a0with\u00a0\ncommon\u00a0variable\u00a0immunodeficiency.\u00a0J\u00a0Clin\u00a0Immunol\u00a02014;34:615\u201326 .\u00a0\u00a0\n41.\u00a0\u00a0 Ochtrop\u00a0MLG,\u00a0Goldacker\u00a0S,\u00a0May\u00a0AM,\u00a0Rizzi\u00a0M,\u00a0Draeger\u00a0R,\u00a0Haus chke\u00a0D,\u00a0et\u00a0al.\u00a0T\u00a0and\u00a0B\u00a0lymphocyte\u00a0\nabnormalities\u00a0 in\u00a0 bone\u00a0 marrow\u00a0 biopsies\u00a0 of\u00a0 common\u00a0 variable\u00a0 immuno deficiency.\u00a0 Blood\u00a0\n2011;118:309\u201318.\u00a0\u00a0\n42.\u00a0\u00a0 Wang\u00a0Z,\u00a0Yunis\u00a0D,\u00a0Irigoyen\u00a0M,\u00a0Kitchens\u00a0B,\u00a0Bottaro\u00a0A,\u00a0Alt\u00a0F. \u00a0Discordance\u00a0between\u00a0IgA\u00a0switching\u00a0at\u00a0\nthe\u00a0DNA\u00a0level\u00a0and\u00a0IgA\u00a0expression\u00a0at\u00a0the\u00a0mRNA\u00a0level\u00a0in\u00a0IgA\u2010defic ient\u00a0patients.\u00a0Clin\u00a0Immunol\u00a0\n1999;91:263\u201370.\u00a0\u00a0\n43.\u00a0\u00a0 Aghamohammadi\u00a0A,\u00a0Mohammadi\u00a0J,\u00a0Parvaneh\u00a0N,\u00a0Rezaei\u00a0N,\u00a0Moin\u00a0M ,\u00a0Espanol\u00a0T,\u00a0et\u00a0al.\u00a0Progression\u00a0\nof\u00a0selective\u00a0IgA\u00a0deficiency\u00a0to\u00a0common\u00a0variable\u00a0immunodeficiency .\u00a0Int\u00a0Arch\u00a0Allergy\u00a0Immunol\u00a0\n2008;147:87\u201392.\u00a0\u00a0\n44.\u00a0\u00a0 Jackson\u00a0KJL,\u00a0Wang\u00a0Y,\u00a0Collins\u00a0AM.\u00a0Human\u00a0immunoglobulin\u00a0clas ses\u00a0and\u00a0subclasses\u00a0show\u00a0variability\u00a0\nin\u00a0VDJ\u00a0gene\u00a0mutation\u00a0levels.\u00a0Immunol\u00a0Cell\u00a0Biol\u00a02014;92:1\u20135.\u00a0\u00a0\n45.\u00a0\u00a0 Collins\u00a0AM,\u00a0Jackson\u00a0KJL.\u00a0A\u00a0Temporal\u00a0Model\u00a0of\u00a0Human\u00a0IgE\u00a0and \u00a0IgG\u00a0Antibody\u00a0Function.\u00a0Front\u00a0\nImmunol\u00a02013;4:235.\u00a0\u00a0\n46.\u00a0\u00a0 Berkowska\u00a0M,\u00a0Driessen\u00a0G,\u00a0Bik os\u00a0V,\u00a0Grosserichter\u2010Wagener\u00a0C, \u00a0Stamatopoulos\u00a0K,\u00a0Cerutti\u00a0A,\u00a0et\u00a0al.\u00a0\u2010\u00a0135\u00a0\u2010\u00a0\n\u00a0Human\u00a0 memory\u00a0 B\u00a0 cells\u00a0 originate\u00a0 from\u00a0 three\u00a0 distinct\u00a0 germinal\u00a0 cen ter\u2010dependent\u00a0 and\u00a0 \u2010\nindependent\u00a0maturation\u00a0pathways.\u00a0Blood\u00a02011;118:2150\u20138.\u00a0\u00a0\n47.\u00a0\u00a0 de\u00a0Jong\u00a0BG,\u00a0IJspeert\u00a0H,\u00a0Marques\u00a0L,\u00a0van\u00a0der\u00a0Burg\u00a0M,\u00a0van\u00a0Don gen\u00a0JJ,\u00a0Loos\u00a0BG,\u00a0et\u00a0al.\u00a0Human\u00a0IgG2\u2010\u00a0\nand\u00a0IgG4\u2010expressing\u00a0memory\u00a0B\u00a0ce lls\u00a0display\u00a0enhanced\u00a0molecular\u00a0a nd\u00a0phenotypic\u00a0signs\u00a0of\u00a0maturity\u00a0\nand\u00a0accumulate\u00a0with\u00a0age.\u00a0Immuno l\u00a0Cell\u00a0Biol\u00a02017;95:744\u201352.\u00a0\u00a0\n48.\u00a0\u00a0 Volk\u00a0T,\u00a0Pannicke\u00a0U,\u00a0Reisli\u00a0I,\u00a0Bulashevska\u00a0A,\u00a0Ritter\u00a0J,\u00a0Bjo rkman\u00a0A,\u00a0et\u00a0al.\u00a0DCLRE1C\u00a0(ARTEMIS)\u00a0\nmutations\u00a0causing\u00a0phenotypes\u00a0ranging\u00a0from\u00a0atypical\u00a0severe\u00a0combi ned\u00a0immunodeficiency\u00a0to\u00a0mere\u00a0\nantibody\u00a0deficiency.\u00a0Hum\u00a0Mol\u00a0Genet\u00a02015;24:7361\u201372.\u00a0\u00a0\n49.\u00a0\u00a0 Abolhassani\u00a0H,\u00a0Cheraghi\u00a0T,\u00a0Rezaei\u00a0N,\u00a0Aghamohammadi\u00a0A,\u00a0Hamm arstrom\u00a0L.\u00a0Common\u00a0Variable\u00a0\nImmunodeficiency\u00a0or\u00a0Late\u2010Onset\u00a0C ombined\u00a0Immunodeficiency:\u00a0A\u00a0New \u00a0Hypomorphic\u00a0JAK3\u00a0Patient\u00a0\nand\u00a0Review\u00a0of\u00a0the\u00a0Literature.\u00a0 J\u00a0Investig\u00a0Allerg ol\u00a0Clin\u00a0Immunol\u00a0 2015;25:218\u201320.\u00a0\u00a0\n50.\u00a0\u00a0 Abolhassani\u00a0H,\u00a0Wang\u00a0N,\u00a0Aghamohammadi\u00a0A,\u00a0Rezaei\u00a0N,\u00a0Lee\u00a0YN,\u00a0 Frugoni\u00a0F,\u00a0et\u00a0al.\u00a0A\u00a0hypomorphic\u00a0\nrecombination\u2010activating\u00a0gene\u00a01\u00a0 (RAG1)\u00a0mutation\u00a0resulting\u00a0in\u00a0a\u00a0 phenotype\u00a0resembling\u00a0common\u00a0\nvariable\u00a0immunodeficiency.\u00a0J\u00a0A llergy\u00a0Clin\u00a0Immunol\u00a02014;134:1375 \u201380.\u00a0\u00a0\n51.\u00a0\u00a0 Kuehn\u00a0HS,\u00a0Boisson\u00a0B,\u00a0Cunningham\u2010Rundles\u00a0C,\u00a0Reichenbach\u00a0J,\u00a0 Stray\u2010Pedersen\u00a0A,\u00a0Gelfand\u00a0EW,\u00a0et\u00a0al.\u00a0\nLoss\u00a0of\u00a0B\u00a0Cells\u00a0in\u00a0Patients\u00a0with\u00a0H eterozygous\u00a0Mutations\u00a0in\u00a0IKAR OS.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02016;374:1032\u2013\n43.\u00a0\u00a0\n52.\u00a0\u00a0 Schubert\u00a0D,\u00a0Bode\u00a0C,\u00a0Kenefeck\u00a0R,\u00a0Hou\u00a0TZ,\u00a0Wing\u00a0JB,\u00a0Kennedy\u00a0A ,\u00a0et\u00a0al.\u00a0Autosomal\u00a0dominant\u00a0immune\u00a0\ndysregulation\u00a0syndrome\u00a0in\u00a0humans\u00a0with\u00a0CTLA4\u00a0mutations.\u00a0Nat\u00a0Med\u00a0 2014;20:1410\u20136.\u00a0\u00a0\n53.\u00a0\u00a0 Fliegauf\u00a0M,\u00a0Bryant\u00a0VL,\u00a0Frede\u00a0N,\u00a0Slade\u00a0C,\u00a0Woon\u00a0S\u2010T,\u00a0Lehnert \u00a0K,\u00a0et\u00a0al.\u00a0Haploinsufficiency\u00a0of\u00a0the\u00a0NF\u2010\nkappaB1\u00a0Subunit\u00a0p50\u00a0in\u00a0Common\u00a0Variable\u00a0Immunodeficiency.\u00a0Am\u00a0J\u00a0H um\u00a0Genet\u00a02015;97:389\u2013403.\u00a0\u00a0\n54.\u00a0\u00a0 Tuijnenburg\u00a0P,\u00a0Lango\u00a0Allen\u00a0H,\u00a0Burns\u00a0SO,\u00a0Greene\u00a0D,\u00a0Jansen\u00a0M H,\u00a0Staples\u00a0E,\u00a0et\u00a0al.\u00a0Loss\u2010of\u2010function\u00a0\nnuclear\u00a0factor\u00a0\u03baB\u00a0subunit\u00a01\u00a0(NFKB1)\u00a0variants\u00a0are\u00a0the\u00a0most\u00a0commo n\u00a0monogenic\u00a0cause\u00a0of\u00a0common\u00a0\nvariable\u00a0immunodeficiency\u00a0in\u00a0Europeans.\u00a0J\u00a0Allergy\u00a0Clin\u00a0Immunol\u00a0 2018;in\u00a0press.\u00a0\u00a0\n5 5 . \u00a0 \u00a0 R o d r \u00ed g u e z \u2010 C o r t e z \u00a0V C , \u00a0d e l \u00a0P i n o \u2010 M o l i n a \u00a0L , \u00a0R o d r \u00ed g u e z \u2010 U b r e v a \u00a0J ,\u00a0 Ciudad\u00a0 L,\u00a0 G\u00f3mez\u2010Cabrero\u00a0 D,\u00a0\nCompany\u00a0C,\u00a0et\u00a0al.\u00a0Monozygotic\u00a0twins\u00a0discordant\u00a0for\u00a0common\u00a0varia ble\u00a0immunodeficiency\u00a0reveal\u00a0\nimpaired\u00a0 DNA\u00a0 demethylation\u00a0 durin g\u00a0 na\u00efve\u2010to\u2010memory\u00a0 B\u2010cell\u00a0 transi tion.\u00a0 Nat\u00a0 Commun\u00a0\n2015;6:7335.\u00a0\u00a0\n56.\u00a0\u00a0 R\u00f6sel\u00a0 AL,\u00a0 Scheibenbogen\u00a0 C,\u00a0 Schliesser\u00a0 U,\u00a0 Sollwedel\u00a0 A,\u00a0 Hoff meister\u00a0 B,\u00a0 Hanitsch\u00a0 L,\u00a0 et\u00a0 al.\u00a0\nClassification\u00a0of\u00a0common\u00a0variab le\u00a0immunodeficiencies\u00a0using\u00a0flow \u00a0cytometry\u00a0and\u00a0a\u00a0memory\u00a0B\u2010cell\u00a0\nfunctionality\u00a0assay.\u00a0J\u00a0Allergy\u00a0 Clin\u00a0Immunol\u00a02015;135:198\u2013208.\u00a0\u00a0\n57.\u00a0\u00a0 Leven\u00a0EA,\u00a0Maffucci\u00a0P,\u00a0Ochs\u00a0HD,\u00a0Scholl\u00a0PR,\u00a0Buckley\u00a0RH,\u00a0Fule ihan\u00a0RL,\u00a0et\u00a0al.\u00a0Hyper\u00a0IgM\u00a0Syndrome:\u00a0a\u00a0\nReport\u00a0from\u00a0the\u00a0USIDNET\u00a0Registry.\u00a0J\u00a0Clin\u00a0Immunol\u00a02016;36:490\u201350 1.\u00a0\u00a0\n58.\u00a0\u00a0 Qamar\u00a0N,\u00a0Fuleihan\u00a0RL.\u00a0The\u00a0hyper\u00a0IgM\u00a0syndromes.\u00a0Clin\u00a0Rev\u00a0Al lergy\u00a0Immunol\u00a02014;46:120\u201330.\u00a0\u00a0\n59.\u00a0\u00a0 de\u00a0la\u00a0Morena\u00a0MT.\u00a0Clinical\u00a0Phenotypes\u00a0of\u00a0Hyper\u2010IgM\u00a0Syndrome s.\u00a0J\u00a0allergy\u00a0Clin\u00a0Immunol\u00a0Pract\u00a0\n2016;4:1023\u201336.\u00a0\u00a0\n60.\u00a0\u00a0 O\u2019Gorman\u00a0MR,\u00a0Zaas\u00a0D,\u00a0Paniagua\u00a0M,\u00a0Corrochano\u00a0V,\u00a0Scholl\u00a0PR,\u00a0 Pachman\u00a0LM.\u00a0Development\u00a0of\u00a0a\u00a0\nrapid\u00a0whole\u00a0blood\u00a0flow\u00a0cytometry\u00a0procedure\u00a0for\u00a0the\u00a0diagnosis\u00a0of \u00a0\u00a0X\u2010linked\u00a0hyper\u2010IgM\u00a0syndrome\u00a0\npatients\u00a0and\u00a0carriers.\u00a0Clin\u00a0Immunol\u00a0Immunopathol\u00a01997;85:172\u201381 .\u00a0\u00a0\u2010\u00a0136\u00a0\u2010\u00a0\n\u00a061.\u00a0\u00a0 Fecteau\u00a0JF,\u00a0C\u00f4t\u00e9\u00a0G,\u00a0N\u00e9ron\u00a0S.\u00a0A\u00a0new\u00a0memory\u00a0CD27\u2010IgG+\u00a0B\u00a0cell \u00a0population\u00a0in\u00a0peripheral\u00a0blood\u00a0\nexpressing\u00a0VH\u00a0genes\u00a0with\u00a0low\u00a0fre quency\u00a0of\u00a0somatic \u00a0mutation.\u00a0J\u00a0I mmunol\u00a02006;177:3728\u201336.\u00a0\u00a0\n62.\u00a0\u00a0 Chapel\u00a0H,\u00a0Lucas\u00a0M,\u00a0Lee\u00a0M,\u00a0Bjorkander\u00a0J,\u00a0Webster\u00a0D,\u00a0Grimbac her\u00a0B,\u00a0et\u00a0al.\u00a0Common\u00a0variable\u00a0\nimmunodeficiency\u00a0disorders:\u00a0div ision\u00a0into\u00a0distinct\u00a0clinical\u00a0phe notypes.\u00a0Blood\u00a02008;112:277\u201386.\u00a0\u00a0\n63.\u00a0\u00a0 Isnardi\u00a0I,\u00a0Ng\u00a0Y,\u00a0Menard\u00a0L,\u00a0Meyers\u00a0G,\u00a0Saadoun\u00a0D,\u00a0Srdanovic\u00a0 I,\u00a0et\u00a0al.\u00a0Complement \u00a0receptor\u00a02/CD21\u2010\u00a0\nhuman\u00a0naive\u00a0B\u00a0cells\u00a0contain\u00a0most ly\u00a0autoreactive\u00a0unresponsive\u00a0cl ones.\u00a0Blood\u00a02010;115:5026\u201336.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\u2010\u00a0137\u00a0\u2010\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nFigure\u00a01.\u00a0Absolute\u00a0counts\u00a0of\u00a0distinct\u00a0maturation\u2010associated\u00a0sub populations\u00a0of\u00a0blood\u00a0B\u2010cells\u00a0and \u00a0plasma\u00a0cells\u00a0(Panel\u00a0A),\u00a0and\u00a0th e\u00a0\ntotal\u00a0switched,\u00a0total\u00a0IgA\u00a0and\u00a0Ig A\u00a0subclass\u00a0subsets\u00a0of\u00a0memory\u00a0B\u2010 cells\u00a0(Panel\u00a0B)\u00a0and\u00a0plasma\u00a0cells\u00a0(Panel\u00a0C)\u00a0in\u00a0CVID\u00a0(n=47),\u00a0IgG\u2010 subclass\u00a0\ndeficiency\u00a0with\u00a0IgA\u00a0deficiency\u00a0(n=5)\u00a0and\u00a0selective\u00a0IgA\u00a0deficien cy\u00a0patients\u00a0(n=59)\u00a0 vs.\u00a0healthy\u00a0donors\u00a0(n=140)\u00a0distributed\u00a0by\u00a0age.\u00a0\u00a0\nIndividual\u00a0cases\u00a0are\u00a0represented\u00a0by\u00a0green\u00a0(selective\u00a0IgA\u00a0defici ency),\u00a0blue\u00a0(IgG\u2010subclass\u00a0deficiency\u00a0with\u00a0IgA\u00a0deficiency),\u00a0red\u00a0 (CVID),\u00a0and\u00a0\ngrey\u00a0dots\u00a0(healthy\u00a0donors).\u00a0Dotted\u00a0grey\u00a0lines\u00a0represent\u00a0maximum \u00a0and\u00a0minimum\u00a0age\u2010associated\u00a0reference\u00a0(range)\u00a0values.\u00a0The\u00a0\npercentage\u00a0of\u00a0patients\u00a0with\u00a0reduced\u00a0numbers\u00a0compared\u00a0to\u00a0age\u00a0ref erence\u00a0values\u00a0per\u00a0age\u00a0group\u00a0is\u00a0d epicted\u00a0above\u00a0each\u00a0plot\u00a0using\u00a0t he\u00a0\nsame\u00a0color\u00a0code.\u00a0CVID,\u00a0co mmon\u00a0variable\u00a0immunodeficiency. \u00a0\n\u2010\u00a0138\u00a0\u2010\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0Figure\u00a02.\u00a0Heatmap\u2010based\u00a0cluster\u00a0analysis\u00a0of\u00a0all\u00a0patients\u00a0with\u00a0p redominantly\u00a0antibody\u00a0deficiency\u00a0(Panel\u00a0A),\u00a0and\u00a0those\u00a0with\u00a0sele ctive\u00a0\nIgA\u00a0deficiency\u00a0(panel\u00a0B)\u00a0and\u00a0CVID\u00a0(Panel\u00a0C).\u00a0 Each\u00a0heatmap\u00a0represents\u00a0counts\u00a0of\u00a0the\u00a0different\u00a0B\u2010cell\u00a0subsets\u00a0 normalized\u00a0by\u00a0the\u00a0lower\u00a0\nlimit\u00a0value\u00a0in\u00a0normal\u00a0controls\u00a0(LLN)\u00a0for\u00a0the\u00a0corresponding\u00a0age\u2010 group\u00a0(columns)\u00a0 vs.\u00a0individual\u00a0cases\u00a0(rows).\u00a0Hi gher\u00a0red\u00a0color\u00a0intensities\u00a0\nrepresent\u00a0a\u00a0deeper\u00a0degree\u00a0of\u00a0deficiency\u00a0in\u00a0a\u00a0log\n10\u00a0scale,\u00a0compare\u00a0to\u00a0the\u00a0corresponding\u00a0age\u2010matched\u00a0LLN.\u00a0Individua l\u00a0patients\u00a0(rows)\u00a0\nare\u00a0identified\u00a0by\u00a0i)\u00a0their\u00a0IUIS\u00a0(clinical)\u00a0diagnosis\u00a0(panel\u00a0A;\u00a0 light\u00a0green\u00a0for\u00a0selective\u00a0IgA\u00a0deficiency,\u00a0intermediate\u00a0green\u00a0fo r\u00a0IgG\u00a0subclass\u00a0\ndeficiency\u00a0with\u00a0IgA\u00a0deficiency\u00a0and\u00a0dark\u00a0green\u00a0for\u00a0CVID);\u00a0and\u00a0ii )\u00a0their\u00a0corresponding\u00a0ESID\u00a0SIgAD\u00a0 diagnosis\u00a0(panel\u00a0B),\u00a0including \u00a0SIgAD\u00a0\ncases\u00a0which\u00a0fulfilled\u00a0(black)\u00a0or\u00a0n ot\u00a0(grey)\u00a0the\u00a0ESID\u00a0criteria\u00a0f or\u00a0selective\u00a0IgA\u00a0deficiency;\u00a0a nd\u00a0iii)\u00a0CVID\u00a0EUROclass\u00a0classifica tion\u00a0subgroup\u00a0\n(panel\u00a0C),\u00a0smB+\u00a0CD21normal,\u00a0smB+\u00a0CD21lo,\u00a0smB\u2010\u00a0CD21normal,\u00a0smB\u2010\u00a0CD21lo\u00a0and\u00a0B\u2010\u00a0from\u00a0lighter\u00a0to\u00a0darker\u00a0violet.\u00a0The\u00a0identified\u00a0PAD\u00a01\u20105\u00a0\n(panel\u00a0A),\u00a0IgAdef\u00a01\u20102\u00a0(panel\u00a0B)\u00a0and\u00a0CVID\u00a01\u20106\u00a0(panel\u00a0C)\u00a0clusters \u00a0are\u00a0depicted\u00a0at\u00a0the\u00a0right\u00a0side\u00a0of\u00a0each\u00a0heatmap.\u00a0CVID,\u00a0common\u00a0v ariable\u00a0\nimmunodeficiency;\u00a0ESID,\u00a0Europea n\u00a0Society\u00a0for\u00a0Immunodeficiencies ;\u00a0LLN,\u00a0lower\u00a0limit\u00a0of\u00a0normality;\u00a0PAD,\u00a0predominantly\u00a0antibody\u00a0\ndeficiency;\u00a0IgG/ADef,\u00a0IgG\u00a0subcla ss\u00a0deficiency\u00a0with\u00a0IgA\u00a0deficien cy;\u00a0sIgADef,\u00a0selective\u00a0IgA\u00a0deficiency. \u00a0\n\u00a0\n\u2010\u00a0139\u00a0\u2010\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nFigure\u00a03.\u00a0Illustrating\u00a0dot\u00a0plot\u00a0examples\u00a0of\u00a0the\u00a0numerical\u00a0distr ibution\u00a0of\u00a0blood\u00a0unswitched\u2010\u00a0and\u00a0switched\u2010memory\u00a0B\u2010cell\u00a0\nand\u00a0plasma\u00a0cell\u00a0subsets\u00a0expressing\u00a0different\u00a0Ig\u2010isotypes\u00a0and\u00a0Ig \u2010subclasses\u00a0in\u00a0a\u00a0representativ e\u00a0healthy\u00a0donor\u00a0 (panel\u00a0A)\u00a0and\u00a0\nin\u00a0representative\u00a0patients\u00a0with\u00a0selective\u00a0IgA\u00a0deficiency\u00a0(Panel \u00a0B)\u00a0and\u00a0CVID\u00a0(Panel\u00a0C).\u00a0 Each\u00a0plot\u00a0corresponds\u00a0to\u00a03\u2010D\u00a0\nAutomated\u00a0Population\u00a0Separator\u00a0(A PS)\u00a0views\u00a0of\u00a0Principal\u00a0Compone nt\u00a01\u00a0(PC1)\u00a0 vs.\u00a0PC2\u00a0vs.\u00a0PC3,\u00a0of\u00a0the\u00a0distinct\u00a0subsets\u00a0of\u00a0\nmemory\u00a0B\u2010cells\u00a0and\u00a0plasma\u00a0cells\u00a0d efined\u00a0by\u00a0the\u00a0Ig\u2010isotype\u00a0and\u00a0I g\u2010subclass\u00a0expressed:\u00a0IgM(D+)\u00a0(gr een),\u00a0IgG1\u00a0(light\u00a0blue),\u00a0IgG2\u00a0\n(intermediate\u00a0blue),\u00a0IgG3\u00a0(dark\u00a0 blue),\u00a0IgG4\u00a0(black),\u00a0IgA1\u00a0(oran ge),\u00a0IgA2\u00a0(yellow)\u00a0and\u00a0IgD\u00a0(violet).\u00a0CVID,\u00a0common\u00a0variable\u00a0\nimmunodeficiency;\u00a0sIgADef,\u00a0 selective\u00a0IgA\u00a0deficiency. \u00a0\n\u2010\u00a0140\u00a0\u2010\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\nFigure\u00a04.\u00a0Frequency\u00a0of\u00a0distinct\u00a0clinical\u00a0manifestations\u00a0of\u00a0PAD\u00a0 and\u00a0the\u00a0existence\u00a0( vs.\u00a0absence)\u00a0of\u00a0affected\u00a0family\u00a0members\u00a0among\u00a0\nthe\u00a0distinct\u00a0clusters\u00a0(i.e.\u00a0groups)\u00a0of\u00a0selective\u00a0IgA\u00a0deficiency \u00a0and\u00a0CVID\u00a0patients\u00a0defined\u00a0by\u00a0their\u00a0distinct\u00a0patterns\u00a0of\u00a0altere d\u00a0blood\u00a0B\u2010\ncell\u00a0and\u00a0PC\u00a0subset\u00a0counts.\u00a0 Radar\u00a0charts\u00a0represent\u00a0the\u00a0percentage\u00a0of\u00a0selective\u00a0IgA\u00a0deficien cy\u00a0(panel\u00a0A)\u00a0and\u00a0CVID\u00a0(panel\u00a0B)\u00a0patients\u00a0\npresenting\u00a0with\u00a0each\u00a0type\u00a0of\u00a0cli nical\u00a0manifestation\u00a0of\u00a0the\u00a0dise ase\u00a0and\u00a0the\u00a0presence\u00a0of\u00a0family\u00a0members\u00a0affected\u00a0by\u00a0PAD.\u00a0Colored \u00a0lines\u00a0\nindicate\u00a0the\u00a0distinct\u00a0patient\u00a0gr oups\u00a0as\u00a0defined\u00a0by\u00a0clustering\u00a0a nalysis\u00a0based\u00a0on\u00a0the\u00a0B\u2010cell\u00a0and\u00a0PC\u00a0subset\u00a0defects\u00a0identified\u00a0(s ee\u00a0also\u00a0\nFigure\u00a02).\u00a0\n#P<0.05\u00a0for\u00a0IgAdef\u20101 \u00a0vs.\u00a0IgAdef\u20102;\u00a0a\u00a0P<0.05\u00a0for\u00a0CVID\u20102\u00a0vs.\u00a0CVID\u20104;\u00a0b\u00a0P<0.05\u00a0for\u00a0CVID\u20102\u00a0vs.\u00a0CVID\u20106;\u00a0c\u00a0P<0.05\u00a0for\u00a0CVID\u20103\u00a0vs.\u00a0\nCVID\u20104;\u00a0d\u00a0P<0.05\u00a0for\u00a0CVID\u20103\u00a0vs.\u00a0CVID\u20105;\u00a0e\u00a0P<0.05\u00a0for\u00a0CVID\u20103\u00a0vs.\u00a0CVID\u20106;\u00a0f\u00a0P<0.05\u00a0for\u00a0CVID\u20104\u00a0vs.\u00a0CVID\u20105;\u00a0g\u00a0P<0.05\u00a0for\u00a0CVID\u20105\u00a0vs.\u00a0CVID\u20106 \u00a0\n\u00a0\n  \u00a0\n\u00a0\n\u00a0 \n \n \n \n \n \nDiscusi\u00f3n \n   \n\u00a0\n\u00a0\n\u00a0 Discusi\u00f3n \n\u2010\u00a0145\u00a0\u2010\u00a0\n\u00a0Las\u00a0IDP\u2010Ac\u00a0son\u00a0un\u00a0grupo\u00a0de\u00a0trastornos\u00a0del\u00a0sistema\u00a0inmune\u00a0asocia dos\u00a0a\u00a0una\u00a0alteraci\u00f3n\u00a0de\u00a0\nla\u00a0respuesta\u00a0de\u00a0los\u00a0linfocitos\u00a0B,\u00a0en\u00a0cuyo\u00a0diagn\u00f3stico\u00a0y\u00a0clasifi caci\u00f3n\u00a0juegan\u00a0un\u00a0papel\u00a0clave\u00a0los\u00a0\nniveles\u00a0s\u00e9ricos\u00a0de\u00a0los\u00a0isotipos\u00a0y/o\u00a0subclases\u00a0de\u00a0Acs11,209,213.\u00a0Sin\u00a0embargo,\u00a0la\u00a0utilidad\u00a0cl\u00ednica\u00a0de\u00a0los\u00a0\nniveles\u00a0s\u00e9ricos\u00a0de\u00a0Acs\u00a0presenta\u00a0algunas\u00a0limitaciones,\u00a0a\u00a0la\u00a0hora \u00a0de\u00a0reflejar\u00a0de\u00a0forma\u00a0fidedigna\u00a0las\u00a0\ncapacidades\u00a0y\u00a0el\u00a0estado\u00a0de\u00a0la\u00a0respuesta\u00a0B19,53,100,409,\u00a0siendo\u00a0por\u00a0otra\u00a0parte\u00a0el\u00a0comportamiento\u00a0\ncl\u00ednico\u00a0 de\u00a0 pacientes\u00a0 con\u00a0 un\u00a0 mismo\u00a0 subtipo\u00a0 diagn\u00f3stico\u00a0 de\u00a0 IDP\u2010Ac ,\u00a0 muy\u00a0\nheterog\u00e9neo13,231,236,249,328.\u00a0Globalmente,\u00a0los\u00a0pacientes\u00a0con\u00a0IDP\u2010Ac\u00a0se\u00a0caracterizan\u00a0por\u00a0mos trar\u00a0\nuna\u00a0gran\u00a0variabilidad\u00a0en\u00a0cuanto\u00a0a\u00a0manifestaciones\u00a0cl\u00ednicas\u00a0y\u00a0su \u00a0grado\u00a0de\u00a0severidad,\u00a0incluyendo\u00a0\ndesde\u00a0casos\u00a0asintom\u00e1ticos\u00a0hasta\u00a0pacientes\u00a0que\u00a0presentan\u00a0infecci ones\u00a0graves\u00a0y\u00a0recurrentes,\u00a0\nasociadas\u00a0 a\u00a0 otras\u00a0 complicaciones\u00a0 no\u00a0 infecciosas244,246,247,249\u2013252,256,257,\u00a0 que\u00a0 terminan\u00a0 por\u00a0\ncondicionar\u00a0en\u00a0muchos\u00a0casos,\u00a0una\u00a0menor\u00a0calidad\u00a0de\u00a0vida\u00a0y\u00a0una\u00a0su pervivencia\u00a0significativamente\u00a0\nacortada247,249,256.\u00a0\u00a0Por\u00a0otra\u00a0parte,\u00a0en\u00a0la\u00a0gran\u00a0mayor\u00eda\u00a0de\u00a0pacientes,\u00a0como\u00a0por\u00a0ej emplo\u00a0en\u00a0aquellos\u00a0\ndiagnosticados\u00a0de\u00a0IDVC,\u00a0no\u00a0logra\u00a0realizarse\u00a0un\u00a0diagn\u00f3stico\u00a0defi nitivo\u00a0basado\u00a0en\u00a0la\u00a0demostraci\u00f3n\u00a0\nde\u00a0una\u00a0(o\u00a0varias)\u00a0alteraciones\u00a0g en\u00e9ticas\u00a0patog\u00e9nicas,\u00a0al\u00a0carece r\u00a0de\u00a0un\u00a0defecto\u00a0monog\u00e9nico\u00a0\nconocido\u00a0(>90%\u00a0de\u00a0los\u00a0casos)231,265,266.\u00a0Por\u00a0todo\u00a0ello,\u00a0se\u00a0estima\u00a0que\u00a0el\u00a0diagn\u00f3stico\u00a0y\u00a0clasificaci\u00f3n\u00a0\nde\u00a0las\u00a0IDP\u2010Ac,\u00a0se\u00a0retrasa\u00a0de\u00a0media\u00a0entre\u00a04\u00a0y\u00a09\u00a0a\u00f1os236,244,245,\u00a0desde\u00a0las\u00a0primeras\u00a0manifestaciones\u00a0\ncl\u00ednicas\u00a0y/o\u00a0hallazgos\u00a0de\u00a0laboratorio,\u00a0lo\u00a0que\u00a0puede\u00a0llevar\u00a0a\u00a0la \u00a0instauraci\u00f3n\u00a0de\u00a0da\u00f1o\u00a0tisular\u00a0\nirreversible\u00a0en\u00a0los\u00a0\u00f3rganos\u00a0afectados.\u00a0\u00a0\nDesde\u00a0hace\u00a0tiempo,\u00a0se\u00a0ha\u00a0identificado\u00a0la\u00a0existencia\u00a0de\u00a0alteraci ones\u00a0en\u00a0la\u00a0distribuci\u00f3n\u00a0y\u00a0\nn\u00famero\u00a0de\u00a0distintas\u00a0poblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0SP\u00a0de\u00a0pacientes \u00a0con\u00a0IDVC\u00a0por\u00a0citometr\u00eda\u00a0de\u00a0\nflujo,\u00a0asoci\u00e1ndose\u00a0el\u00a0perfil\u00a0de\u00a0alteraciones\u00a0descritas,\u00a0con\u00a0el\u00a0 comportamiento\u00a0cl\u00ednico\u00a0de\u00a0la\u00a0\nenfermedad,\u00a0\u00a0especialmente\u00a0el\u00a0descenso\u00a0del\u00a0n\u00famero\u00a0de\u00a0linfocitos \u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0\nisotipo250,253,284,286,287,379.\u00a0Sin\u00a0embargo,\u00a0en\u00a0los\u00a0estudios\u00a0publicados\u00a0con\u00a0anterioridad\u00a0a\u00a0la \u00a0realizaci\u00f3n\u00a0\nde\u00a0esta\u00a0tesis\u00a0doctoral,\u00a0\u00fanicamente\u00a0se\u00a0evaluaba\u00a0un\u00a0n\u00famero\u00a0limita do\u00a0de\u00a0poblaciones\u00a0celulares\u00a0y,\u00a0\nal\u00a0contrario\u00a0de\u00a0lo\u00a0que\u00a0ocurre\u00a0co n\u00a0la\u00a0determinaci\u00f3n\u00a0de\u00a0Acs\u00a0s\u00e9ric os,\u00a0no\u00a0se\u00a0discriminaba\u00a0dentro\u00a0de\u00a0\nlos\u00a0linfocitos\u00a0B,\u00a0aquellos\u00a0que\u00a0expresan\u00a0diferentes\u00a0isotipos\u00a0y\u00a0s ubclases\u00a0de\u00a0Igs250,253,284,286,287,379.\u00a0\u00a0Discusi\u00f3n \n\u00a0\n\u2010\u00a0146\u00a0\u2010\u00a0\n\u00a0Adem\u00e1s,\u00a0debido\u00a0a\u00a0su\u00a0baja\u00a0sensibilidad,\u00a0en\u00a0muchos\u00a0de\u00a0estos\u00a0estud ios\u00a0no\u00a0fue\u00a0posible\u00a0identificar\u00a0\nde\u00a0forma\u00a0sensible\u00a0y\u00a0reproducible\u00a0las\u00a0CPs\u00a0circulantes250,286,287,379,\u00a0ni\u00a0las\u00a0dem\u00e1s\u00a0subpoblaciones\u00a0B\u00a0\ncuando\u00a0los\u00a0pacientes\u00a0presentaban\u00a0n\u00fameros\u00a0reducidos\u00a0de\u00a0linfocito s\u00a0B\u00a0en\u00a0SP\u00a0(<1%\u00a0de\u00a0los\u00a0linfocitos\u00a0\ntotales)250,286.\u00a0Por\u00a0otro\u00a0lado,\u00a0los\u00a0valores\u00a0de\u00a0referencia\u00a0establecidos\u00a0para\u00a0de finir\u00a0los\u00a0defectos\u00a0en\u00a0\nlos\u00a0distintos\u00a0compartimentos\u00a0de\u00a0linfocitos\u00a0B\u00a0no\u00a0han\u00a0tenido\u00a0en\u00a0c uenta\u00a0de\u00a0forma\u00a0casi\u00a0sistem\u00e1tica\u00a0\nlos\u00a0cambios\u00a0descritos\u00a0en\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de \u00a0sangre\u00a0con\u00a0la\u00a0edad136,137,189,191,\u00a0a\u00a0\npesar\u00a0de\u00a0que\u00a0las\u00a0IDP\u2010Ac\u00a0pueden\u00a0ser\u00a0diagnosticadas\u00a0a\u00a0cualquier\u00a0e dad.\u00a0\n\u00a0Dado\u00a0que\u00a0entend\u00edamos\u00a0que\u00a0la\u00a0evaluaci\u00f3n\u00a0directa\u00a0de\u00a0las\u00a0alteraci ones\u00a0presentes\u00a0en\u00a0los\u00a0\ndistintos\u00a0compartimentos\u00a0madurativos\u00a0de\u00a0los\u00a0linfocitos\u00a0B,\u00a0inclu idas\u00a0las\u00a0subpoblaciones\u00a0de\u00a0c\u00e9lulas\u00a0\nB\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0CPs\u00a0que\u00a0expresan\u00a0distintos\u00a0isotipos\u00a0y\u00a0subclas es\u00a0de\u00a0Igs,\u00a0podr\u00eda\u00a0contribuir\u00a0a\u00a0un\u00a0\nmayor\u00a0conocimiento\u00a0de\u00a0los\u00a0mecani smos\u00a0fisiopatol\u00f3gicos\u00a0subyacent es\u00a0a\u00a0las\u00a0IDP\u2010Ac,\u00a0e\u00a0incluso\u00a0a\u00a0su\u00a0\nclasificaci\u00f3n\u00a0y\u00a0estratificaci\u00f3n\u00a0 pron\u00f3stica,\u00a0nos\u00a0planteamos\u00a0como \u00a0primer\u00a0objetivo\u00a0de\u00a0nuestro\u00a0\nestudio,\u00a0 desarrollar\u00a0 una\u00a0 metodolog\u00eda\u00a0 que\u00a0 permitiera\u00a0 diseccionar \u00a0l o s \u00a0c o m p a r t i m e n t o s \u00a0d e \u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0CPs\u00a0de\u00a0SP\u00a0y\u00a0\u00f3rganos\u00a0linfoides,\u00a0en\u00a0 funci\u00f3n\u00a0del\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0\nIg\u00a0expresado.\u00a0Empleando\u00a0esta\u00a0metodolog\u00eda,\u00a0nos\u00a0propusimos\u00a0como\u00a0s egundo\u00a0objetivo,\u00a0conocer\u00a0\nen\u00a0profundidad\u00a0los\u00a0cambios\u00a0que\u00a0se\u00a0producen,\u00a0tanto\u00a0en\u00a0las\u00a0poblac iones\u00a0B\u00a0de\u00a0SP\u00a0clasificadas\u00a0de\u00a0\nacuerdo\u00a0a\u00a0su\u00a0estadio\u00a0madurativo\u00a0 como\u00a0por\u00a0la\u00a0expresi\u00f3n\u00a0de\u00a0distin tos\u00a0isotipos\u00a0de\u00a0Igs\u00a0y\u00a0subclases\u00a0\nde\u00a0IgG\u00a0e\u00a0IgA,\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida.\u00a0\u00a0Una\u00a0vez\u00a0establecida\u00a0la\u00a0me todolog\u00eda\u00a0y\u00a0los\u00a0valores\u00a0de\u00a0referencia\u00a0\npor\u00a0edad,\u00a0establecimos\u00a0como\u00a0tercer\u00a0objetivo\u00a0de\u00a0este\u00a0trabajo\u00a0doc toral,\u00a0identificar\u00a0las\u00a0posibles\u00a0\nalteraciones\u00a0de\u00a0las\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0SP,\u00a0que\u00a0fuer an\u00a0caracter\u00edsticas\u00a0de\u00a0pacientes\u00a0con\u00a0\nIDP\u2010Ac\u00a0y\u00a0de\u00a0sus\u00a0principales\u00a0subt ipos\u00a0diagn\u00f3sticos,\u00a0tratando\u00a0ade m\u00e1s\u00a0de\u00a0correlacionar\u00a0dichas\u00a0\nalteraciones\u00a0con\u00a0las\u00a0manifestaciones\u00a0cl\u00ednicas\u00a0de\u00a0la\u00a0enfermedad. \u00a0En\u00a0este\u00a0apartado\u00a0de\u00a0la\u00a0memoria\u00a0\ndel\u00a0trabajo\u00a0doctoral\u00a0realizado,\u00a0abordaremos\u00a0la\u00a0discusi\u00f3n\u00a0gen\u00e9ri ca\u00a0de\u00a0los\u00a0resultados\u00a0obtenidos\u00a0\nde\u00a0forma\u00a0separada\u00a0para\u00a0cada\u00a0 uno\u00a0de\u00a0estos\u00a0tres\u00a0objetivos.\u00a0\n\u00a0\u00a0Discusi\u00f3n \n\u2010\u00a0147\u00a0\u2010\u00a0\n\u00a01.\u00a0Selecci\u00f3n\u00a0y\u00a0validaci\u00f3n\u00a0de\u00a0clones\u00a0de\u00a0Acs\u00a0para\u00a0la\u00a0identificaci \u00f3n\u00a0de\u00a0distintas\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0\nIgA\u00a0en\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0CPs\u00a0de\u00a0sangre. \u00a0\n\u00a0 La\u00a0relevancia\u00a0cl\u00ednica\u00a0de\u00a0la\u00a0cuantificaci\u00f3n\u00a0de\u00a0los\u00a0niveles\u00a0s\u00e9ri cos\u00a0de\u00a0Igs\u00a0agrupadas\u00a0por\u00a0\nisotipo\u00a0y\u00a0subclase,\u00a0deriva\u00a0de\u00a0la\u00a0posibilidad\u00a0de\u00a0disponer\u00a0y\u00a0empl ear\u00a0Acs\u00a0espec\u00edficos,\u00a0sensibles\u00a0y\u00a0\nrobustos,\u00a0 que\u00a0 permiten\u00a0 su\u00a0 determinaci\u00f3n\u00a0 en\u00a0 diferentes\u00a0 fluidos\u00a0 c orporales,\u00a0 de\u00a0 forma\u00a0\nreproducible\u00a0entre\u00a0distintos\u00a0laboratorios\u00a0y\u00a0mediante\u00a0distintas\u00a0 t\u00e9cnicas.\u00a0Para\u00a0que\u00a0esto\u00a0fuera\u00a0una\u00a0\nrealidad,\u00a0a\u00a0finales\u00a0de\u00a0los\u00a0a\u00f1os\u00a0 80\u00a0y\u00a0principios\u00a0de\u00a0los\u00a090\u00a0la\u00a0IU IS\u00a0organiz\u00f3\u00a0junto\u00a0a\u00a0la\u00a0OMS\u00a0una\u00a0serie\u00a0\nde\u00a0estudios\u00a0multic\u00e9ntricos\u00a0cuyo\u00a0objetivo\u00a0fue:\u00a0evaluar\u00a0el\u00a0desemp e\u00f1o\u00a0de\u00a0distintos\u00a0clones\u00a0de\u00a0Acs\u00a0\npara\u00a0todos\u00a0y\u00a0cada\u00a0uno\u00a0de\u00a0los\u00a0isotipos\u00a0y\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA411\u2013413.\u00a0Mediante\u00a0este\u00a0esfuerzo,\u00a0se\u00a0\nvalidaron\u00a0distintos\u00a0clones\u00a0de\u00a0Acs\u00a0espec\u00edficos\u00a0de\u00a0cada\u00a0isotipo\u00a0y \u00a0subclase\u00a0de\u00a0Ig,\u00a0tanto\u00a0desde\u00a0el\u00a0\npunto\u00a0de\u00a0vista\u00a0de\u00a0su\u00a0idoneidad\u00a0para\u00a0llevar\u00a0a\u00a0cabo\u00a0estas\u00a0determi naciones\u00a0mediante\u00a0un\u00a0amplio\u00a0\nabanico\u00a0 de\u00a0 t\u00e9cnicas\u00a0 \u2013por\u00a0 ejemplo ,\u00a0 mediante\u00a0 hemaglutinaci\u00f3n\u00a0 e\u00a0 in hibici\u00f3n\u00a0 de\u00a0 la\u00a0\nhemaglutinaci\u00f3n,\u00a0 ELISA\u00a0 (del\u00a0 ingl\u00e9s,\u00a0 enzyme\u2010linked\u00a0 immunoabsorbent\u00a0 assay ),\u00a0\ninmunocitoqu\u00edmica,\u00a0 inmunohistoqu\u00edmica,\u00a0 electrotransferencia,\u00a0 in munoprecipitaci\u00f3n\u00a0 y\u00a0\naglutinaci\u00f3n\u00a0en\u00a0l\u00e1tex,\u00a0entre\u00a0otros\u2212,\u00a0como\u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0vis ta\u00a0cl\u00ednico411\u2013413.\u00a0Sin\u00a0embargo,\u00a0no\u00a0\nse\u00a0valid\u00f3\u00a0la\u00a0utilizaci\u00f3n\u00a0de\u00a0estos\u00a0reactivos\u00a0para\u00a0el\u00a0estudio\u00a0de\u00a0 c\u00e9lulas\u00a0B\u00a0mediante\u00a0citometr\u00eda\u00a0de\u00a0\nflujo411\u2013413.\u00a0Ante\u00a0esta\u00a0situaci\u00f3n,\u00a0y\u00a0a\u00a0pesar\u00a0del\u00a0tiempo\u00a0transcurrido\u00a0desde\u00a0 entonces,\u00a0y\u00a0de\u00a0disponer\u00a0\nde\u00a0herramientas\u00a0validadas\u00a0para\u00a0la\u00a0cuantificaci\u00f3n\u00a0de\u00a0Igs\u00a0soluble s\u00a0por\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Ig,\u00a0el\u00a0\nn\u00famero\u00a0de\u00a0estudios\u00a0que\u00a0han\u00a0tratado\u00a0de\u00a0cuantificar\u00a0los\u00a0linfocito s\u00a0B\u00a0que\u00a0expresan\u00a0distintas\u00a0\nsubclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0ha\u00a0sido\u00a0muy\u00a0limitado131,414\u2013416.\u00a0Aun\u00a0as\u00ed,\u00a0en\u00a0algunos\u00a0trabajos\u00a0se\u00a0ha\u00a0\ndemostrado\u00a0que\u00a0es\u00a0factible\u00a0ident ificar\u00a0las\u00a0subclases\u00a0de\u00a0Igs\u00a0exp resadas\u00a0en\u00a0c\u00e9lulas\u00a0B\u00a0procedentes\u00a0\nde\u00a0cultivo\u00a0o\u00a0de\u00a0la\u00a0fracci\u00f3n\u00a0de\u00a0c\u00e9lulas\u00a0mononucleadas\u00a0aisladas\u00a0d e\u00a0SP.\u00a0Por\u00a0el\u00a0contrario,\u00a0ninguno\u00a0de\u00a0\nestos\u00a0estudios\u00a0ha\u00a0demostrado\u00a0la\u00a0 posibilidad\u00a0de\u00a0realizar\u00a0dicho\u00a0a n\u00e1lisis\u00a0directamente\u00a0en\u00a0SP\u00a0total,\u00a0\nni\u00a0tampoco\u00a0se\u00a0realizaron\u00a0comparaciones\u00a0entre\u00a0los\u00a0distintos\u00a0clon es\u00a0frente\u00a0a\u00a0un\u00a0mismo\u00a0isotipo\u00a0y\u00a0\nsubclase\u00a0de\u00a0Ig,\u00a0validados\u00a0para\u00a0otros\u00a0m\u00e9todos,\u00a0o\u00a0se\u00a0analiz\u00f3\u00a0su\u00a0p erfil\u00a0de\u00a0expresi\u00f3n\u00a0en\u00a0distintos\u00a0\ncompartimentos\u00a0madurativos\u00a0de\u00a0linfocitos\u00a0B,\u00a0en\u00a0diferentes\u00a0tejid os\u00a0y\u00a0para\u00a0distintas\u00a0localizaciones\u00a0Discusi\u00f3n \n\u00a0\n\u2010\u00a0148\u00a0\u2010\u00a0\n\u00a0celulares\u00a0(e.g.\u00a0membrana\u00a0 vs.\u00a0intracitoplasm\u00e1ticas)131,414\u2013416.\u00a0Por\u00a0todo\u00a0ello,\u00a0nos\u00a0planteamos\u00a0como\u00a0\nprimer\u00a0objetivo\u00a0de\u00a0este\u00a0trabajo\u00a0evaluar\u00a0la\u00a0idoneidad\u00a0de\u00a0los\u00a0clo nes\u00a0comercialmente\u00a0disponibles\u00a0\npara\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0las\u00a0distintas\u00a0subclases\u00a0de\u00a0IgG1\u20104\u00a0e\u00a0I gA1\u20102,\u00a0para\u00a0su\u00a0utilizaci\u00f3n\u00a0por\u00a0\ncitometr\u00eda\u00a0de\u00a0flujo,\u00a0con\u00a0el\u00a0fin\u00a0de\u00a0seleccionar\u00a0y\u00a0validar\u00a0un\u00a0gru po\u00a0de\u00a0reactivos\u00a0id\u00f3neos\u00a0para\u00a0ser\u00a0\nempleados\u00a0en\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0dichas\u00a0subclases\u00a0de\u00a0Igs\u00a0en\u00a0la \u00a0superficie\u00a0y/o\u00a0citoplasma\u00a0de\u00a0\nlinfocitos\u00a0B\u00a0y\u00a0CPs\u00a0de\u00a0SP,\u00a0de\u00a0forma\u00a0sensible,\u00a0espec\u00edfica\u00a0y\u00a0repro ducible,\u00a0en\u00a0diferentes\u00a0condiciones\u00a0\ny\u00a0sobre\u00a0distintos\u00a0tipo s\u00a0de\u00a0muestras\u00a0humanas.\u00a0\nTal\u00a0como\u00a0hemos\u00a0referido\u00a0ya\u00a0en\u00a0la\u00a0introducci\u00f3n\u00a0de\u00a0esta\u00a0memoria,\u00a0 las\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0\nIgA\u00a0presentan\u00a0un\u00a0elevado\u00a0grado\u00a0de\u00a0homolog\u00eda\u00a0entre\u00a0ellas,\u00a0lo\u00a0cua l\u00a0dificulta\u00a0la\u00a0generaci\u00f3n\u00a0de\u00a0\nclones\u00a0de\u00a0Acs\u00a0capaces\u00a0de\u00a0diferenciar\u00a0de\u00a0forma\u00a0espec\u00edfica\u00a0cada\u00a0u na\u00a0de\u00a0las\u00a0subclases\u00a0de\u00a0ambas\u00a0\nIgs.\u00a0Aun\u00a0as\u00ed,\u00a0hoy\u00a0se\u00a0sabe\u00a0que\u00a0existen\u00a0ep\u00edtopos\u00a0espec\u00edficos\u00a0de\u00a0c ada\u00a0subclase\u00a0de\u00a0IgG\u00a0e\u00a0IgA,\u00a0que\u00a0\nadem\u00e1s\u00a0de\u00a0estar\u00a0\u00edntimamente\u00a0relacionados\u00a0con\u00a0sus\u00a0funciones\u00a0y\u00a0ca racter\u00edsticas\u00a0biol\u00f3gicas,\u00a0\npermiten\u00a0generar\u00a0Acs\u00a0espec\u00edficos\u00a0frente\u00a0a\u00a0cada\u00a0una\u00a0de\u00a0ellas5,8,411\u2013413,417,418.\u00a0En\u00a0el\u00a0caso\u00a0de\u00a0las\u00a0\nsubclases\u00a0de\u00a0IgG,\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0las\u00a0diferencias\u00a0estructurales\u00a0q ue\u00a0existen\u00a0entre\u00a0ellas,\u00a0se\u00a0localizan\u00a0\nen\u00a0la\u00a0regi\u00f3n\u00a0bisagra\u00a0y\u00a0en\u00a0los\u00a0residuos\u00a0del\u00a0dominio\u00a0CH2\u00a0m\u00e1s\u00a0cerc anos\u00a0a\u00a0esta\u00a0regi\u00f3n,\u00a0zona\u00a0a\u00a0trav\u00e9s\u00a0\nde\u00a0la\u00a0cual\u00a0se\u00a0produce\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0la\u00a0Ig\u00a0a\u00a0la\u00a0prote\u00edna\u00a0C1q\u00a0del\u00a0s istema\u00a0del\u00a0complemento\u00a0y\u00a0a\u00a0los\u00a0\nreceptores\u00a0celulares\u00a0Fc\u03b3R5,7,8.\u00a0De\u00a0forma\u00a0similar,\u00a0las\u00a0principales\u00a0diferencias\u00a0entre\u00a0las\u00a0subcl ases\u00a0de\u00a0\nIgA\u00a0est\u00e1n\u00a0relacionadas\u00a0con\u00a0el\u00a0mayor\u00a0tama\u00f1o\u00a0de\u00a0la\u00a0regi\u00f3n\u00a0bisagra \u00a0de\u00a0la\u00a0subclase\u00a0IgA1\u00a0respecto\u00a0a\u00a0\nla\u00a0IgA2,\u00a0lo\u00a0cual\u00a0le\u00a0hace\u00a0tambi\u00e9n\u00a0m\u00e1s\u00a0susceptible\u00a0a\u00a0la\u00a0ruptura\u00a0p roteol\u00edtica,\u00a0a\u00a0la\u00a0vez\u00a0que\u00a0favorece\u00a0\nsu\u00a0acceso\u00a0al\u00a0Ag\u00a0reconocido30.\u00a0Probablemente\u00a0por\u00a0esto,\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0clones\u00a0de\u00a0Acs\u00a0evalu ados\u00a0\nen\u00a0 nuestro\u00a0 estudio\u00a0 que\u00a0 mostraron\u00a0 una\u00a0 adecuada\u00a0 reactividad\u00a0 frent e\u00a0 a\u00a0 subclases\u00a0 de\u00a0 Igs\u00a0\nexpresadas\u00a0en\u00a0los\u00a0linfocitos\u00a0B\u00a0y\u00a0CPs\u00a0humanas,\u00a0estaban\u00a0dirigidos \u00a0frente\u00a0a\u00a0ep\u00edtopos\u00a0localizados\u00a0en\u00a0\nestas\u00a0regiones411\u2013413,416\u2013420.\u00a0Los\u00a0motivos\u00a0por\u00a0los\u00a0que\u00a0los\u00a0dem\u00e1s\u00a0clones\u00a0no\u00a0presentaban\u00a0react ividad,\u00a0\nni\u00a0en\u00a0linfocitos\u00a0B\u00a0ni\u00a0en\u00a0CPs,\u00a0siguen\u00a0siendo\u00a0desconocidos.\u00a0No\u00a0ob stante,\u00a0dado\u00a0que\u00a0muchos\u00a0de\u00a0estos\u00a0\nclones\u00a0de\u00a0Acs\u00a0ten\u00edan\u00a0su\u00a0ep\u00edtopo\u00a0en\u00a0la\u00a0regi\u00f3n\u00a0CH3,\u00a0la\u00a0ausencia\u00a0d e\u00a0reactividad\u00a0observada,\u00a0podr\u00eda\u00a0\nser\u00a0debida\u00a0a\u00a0la\u00a0existencia\u00a0de\u00a0un\u00a0impedimento\u00a0est\u00e9rico,\u00a0dado\u00a0que \u00a0dicho\u00a0dominio\u00a0CH3\u00a0podr\u00eda\u00a0estar\u00a0Discusi\u00f3n \n\u2010\u00a0149\u00a0\u2010\u00a0\n\u00a0menos\u00a0 accesible\u00a0 cuando\u00a0 la\u00a0 Ig\u00a0 se\u00a0 encuentra\u00a0 anclada\u00a0 en\u00a0 la\u00a0 membran a\u00a0 citoplasm\u00e1tica.\u00a0\nAlternativamente,\u00a0 podr\u00eda\u00a0 deberse\u00a0 a\u00a0 que\u00a0 los\u00a0 ep\u00edtopos\u00a0 identificad os\u00a0 por\u00a0 estos\u00a0 clones\u00a0 sean\u00a0\ndependientes\u00a0de\u00a0las\u00a0condiciones\u00a0de\u00a0ensayo,\u00a0e.g.\u00a0estar\u00a0en\u00a0format o\u00a0soluble\u00a0o\u00a0inmovilizado\u00a0en\u00a0un\u00a0\nsustrato\u00a0de\u00a0fase\u00a0s\u00f3lida.\u00a0Finalmente,\u00a0en\u00a06\u00a0clones\u00a0que\u00a0mostraron\u00a0 un\u00a0marcaje\u00a0adecuado\u00a0de\u00a0los\u00a0\nlinfocitos\u00a0 B\u00a0 de\u00a0 memoria\u00a0 y\u00a0 de\u00a0 las\u00a0 CPs,\u00a0 no\u00a0 conoc\u00edamos\u00a0 la\u00a0 localiza ci\u00f3n\u00a0 exacta\u00a0 del\u00a0 ep\u00edtopo\u00a0\nidentificado,\u00a0excepto\u00a0que\u00a0este\u00a0se\u00a0encontraba\u00a0en\u00a0el\u00a0Fc\u00a0de\u00a0la\u00a0Ig; \u00a0la\u00a0alta\u00a0homolog\u00eda\u00a0que\u00a0existe\u00a0entre\u00a0\nlos\u00a0dominios\u00a0CH3\u00a0de\u00a0las\u00a0distintas\u00a0subclases\u00a0del\u00a0mismo\u00a0isotipo\u00a0d e\u00a0Ig8\u00a0sugiere\u00a0que\u00a0probablemente,\u00a0\nno\u00a0vayan\u00a0dirigidos\u00a0frente\u00a0a\u00a0esta\u00a0regi\u00f3n,\u00a0quedando\u00a0por\u00a0mapear\u00a0co n\u00a0precisi\u00f3n\u00a0la\u00a0zona\u00a0reconocida.\u00a0\nEn\u00a0definitiva,\u00a0nuestros\u00a0resultados \u00a0parecen\u00a0indicar\u00a0que\u00a0la\u00a0regi\u00f3 n\u00a0CH2,\u00a0junto\u00a0con\u00a0la\u00a0regi\u00f3n\u00a0bisagra,\u00a0\nconstituyen\u00a0los\u00a0dominios\u00a0de\u00a0las\u00a0mol\u00e9culas\u00a0de\u00a0Igs\u00a0m\u00e1s\u00a0eficientes \u00a0para\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0Acs\u00a0espec\u00edficos\u00a0\nde\u00a0las\u00a0distintas\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA,\u00a0cuando\u00a0estas\u00a0Igs\u00a0se\u00a0en cuentran\u00a0en\u00a0la\u00a0membrana\u00a0de\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0y\u00a0de\u00a0las\u00a0CPs.\u00a0\nAdem\u00e1s\u00a0de\u00a0las\u00a0caracter\u00edsticas\u00a0de l\u00a0ep\u00edtopo,\u00a0existen\u00a0otros\u00a0factor es\u00a0que\u00a0pueden\u00a0influir\u00a0y\u00a0\nmodular\u00a0la\u00a0reactividad\u00a0de\u00a0un\u00a0clon\u00a0de\u00a0Ac\u00a0dirigido\u00a0frente\u00a0a\u00a0una\u00a0p rote\u00edna\u00a0concreta,\u00a0como\u00a0la\u00a0t\u00e9cnica\u00a0\ny\u00a0el\u00a0protocolo\u00a0empleados\u00a0para\u00a0el \u00a0marcaje,\u00a0y\u00a0el\u00a0tipo\u00a0celular\u00a0y/o \u00a0tejido\u00a0empleado411\u2013413,421,422.\u00a0Esto\u00a0\nes\u00a0debido\u00a0a\u00a0que\u00a0los\u00a0ep\u00edtopos\u00a0de\u00a0una\u00a0prote\u00edna\u00a0dada\u00a0var\u00edan\u00a0(y\u00a0por \u00a0tanto\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0los\u00a0clones\u00a0de\u00a0\nAcs\u00a0tambi\u00e9n),\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0l\u00ednea\u00a0celular\u00a0o\u00a0del\u00a0estadio\u00a0madu rativo\u00a0de\u00a0la\u00a0misma,\u00a0como\u00a0\nconsecuencia\u00a0de:\u00a0i)\u00a0modificacion es\u00a0post\u2010transcripcionales\u00a0concr etas423,\u00a0ii)\u00a0splicing\u00a0alternativo422,\u00a0\niii)\u00a0la\u00a0existencia\u00a0de\u00a0polimorfismos424,\u00a0y/o\u00a0iv)\u00a0el\u00a0estado\u00a0de\u00a0polimerizaci\u00f3n\u00a0de\u00a0la\u00a0prote\u00edna\u00a0diana425.\u00a0\nAdem\u00e1s,\u00a0la\u00a0disponibilidad\u00a0de\u00a0los\u00a0ep\u00edtopos\u00a0para\u00a0la\u00a0uni\u00f3n\u00a0de\u00a0Acs, \u00a0as\u00ed\u00a0como\u00a0la\u00a0propia\u00a0uni\u00f3n\u00a0de\u00a0los\u00a0\nAcs\u00a0a\u00a0los\u00a0mismos,\u00a0puede\u00a0modificarse\u00a0seg\u00fan\u00a0las\u00a0caracter\u00edsticas\u00a0d e\u00a0la\u00a0t\u00e9cnica\u00a0empleada\u00a0para\u00a0el\u00a0\nrevelado\u00a0de\u00a0la\u00a0uni\u00f3n,\u00a0incluyendo\u00a0el\u00a0tipo\u00a0de\u00a0anticoagulante\u00a0y\u00a0la \u00a0t\u00e9cnica\u00a0de\u00a0marcaje\u00a0empleados\u00a0\n(membrana\u00a0 vs.\u00a0citoplasm\u00e1tico)\u00a0y\u00a0la\u00a0cantidad\u00a0 y\u00a0concentraci\u00f3n\u00a0de\u00a0la\u00a0prote\u00edna\u00a0 disponible\u00a0en\u00a0forma\u00a0\nsoluble,\u00a0unida\u00a0a\u00a0una\u00a0c\u00e9lula,\u00a0o\u00a0inmovilizada\u00a0sobre\u00a0un\u00a0sustrato\u00a0s \u00f3lido416,421,426,427.\u00a0Adem\u00e1s,\u00a0en\u00a0el\u00a0\ncaso\u00a0concreto\u00a0de\u00a0los\u00a0clones\u00a0de\u00a0Acs\u00a0dirigidos\u00a0frente\u00a0a\u00a0las\u00a0disti ntas\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA,\u00a0y\u00a0de\u00a0\nacuerdo\u00a0con\u00a0nuestros\u00a0resultados,\u00a0estudios\u00a0previos\u00a0en\u00a0los\u00a0que\u00a0se \u00a0emplearon\u00a0otros\u00a0tipos\u00a0de\u00a0Discusi\u00f3n \n\u00a0\n\u2010\u00a0150\u00a0\u2010\u00a0\n\u00a0ensayos,\u00a0mostraron\u00a0que\u00a0su\u00a0eficacia\u00a0depend\u00eda\u00a0de\u00a0la\u00a0t\u00e9cnica\u00a0emple ada,\u00a0probablemente\u00a0debido\u00a0a\u00a0\nvariaciones\u00a0en\u00a0los\u00a0ep\u00edtopos\u00a0diana\u00a0de\u00a0cada\u00a0clon,\u00a0asociadas\u00a0a\u00a0las \u00a0diferentes\u00a0condiciones\u00a0de\u00a0cada\u00a0\nensayo411\u2013413,421;\u00a0precisamente\u00a0esto,\u00a0llev\u00f3\u00a0a\u00a0que\u00a0no\u00a0se\u00a0pudieran\u00a0seleccionar\u00a0clo nes\u00a0de\u00a0referencia\u00a0\npara\u00a0todas\u00a0las\u00a0t\u00e9cnicas\u00a0y\u00a0protocolos\u00a0evaluados,\u00a0si\u00a0no\u00a0que\u00a0se\u00a0pr opusieron\u00a0candidatos\u00a0para\u00a0las\u00a0\ndistintas\u00a0aplicaciones411\u2013413.\u00a0De\u00a0acuerdo\u00a0con\u00a0ello,\u00a0de\u00a0los\u00a028\u00a0clones\u00a0evaluados\u00a0en\u00a0nuestro\u00a0es tudio,\u00a0\ny\u00a0que\u00a0previamente\u00a0hab\u00edan\u00a0mostrado \u00a0reactividad\u00a0espec\u00edfica\u00a0de\u00a0sub clase\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0frente\u00a0a\u00a0Igs\u00a0\nsolubles411\u2013413,\u00a0 solo\u00a0 17\u00a0 mostraron\u00a0 reactividad\u00a0 frente\u00a0 a\u00a0 las\u00a0 correspondientes\u00a0 s ubclases,\u00a0\nexpresadas\u00a0en\u00a0la\u00a0membrana\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0CPs.\u00a0 Otros\u00a0dos\u00a0clones\u00a0espec\u00edficos\u00a0\nde\u00a0IgG2\u00a0e\u00a0IgA1\u00a0(HP6207\u00a0y\u00a0512\u2010H5.1,\u00a0 respectivamente),\u00a0mostraron\u00a0 reactividad\u00a0d\u00e9bil\u00a0en\u00a0linfocitos\u00a0\nB\u00a0de\u00a0memoria,\u00a0mientras\u00a0que\u00a0esta\u00a0estaba\u00a0ausente\u00a0en\u00a0CPs.\u00a0Los\u00a09\u00a0cl ones\u00a0restantes\u00a0no\u00a0mostraron\u00a0\nreactividad\u00a0frente\u00a0a\u00a0ninguna\u00a0subclase\u00a0de\u00a0IgG\u00a0e\u00a0IgA,\u00a0ni\u00a0entre\u00a0lo s\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0ni\u00a0en\u00a0las\u00a0\nCPs.\u00a0\u00a0\n\u00a0 De\u00a0los\u00a017\u00a0clones\u00a0que\u00a0mostraron\u00a0reactividad\u00a0inequ\u00edvoca\u00a0en\u00a0la\u00a0me mbrana\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0B,\u00a0\nseleccionamos\u00a06\u00a0(uno\u00a0para\u00a0cada\u00a0subclase\u00a0de\u00a0IgG\u00a0e\u00a0IgA)\u00a0de\u00a0acuerd o\u00a0a\u00a0su\u00a0especificidad,\u00a0intensidad\u00a0\nde\u00a0marcaje\u00a0y\u00a0la\u00a0disponibilidad\u00a0comercial\u00a0de\u00a0reactivos\u00a0conjugado s\u00a0con\u00a0fluorocromos\u00a0compatibles,\u00a0\npara\u00a0su\u00a0posterior\u00a0validaci\u00f3n:\u00a0SAG1,\u00a0SAG2,\u00a0SAG3,\u00a0SAG4,\u00a0SAA1\u00a0y\u00a0SA A2,\u00a0dirigidos\u00a0frente\u00a0a\u00a0IgG1,\u00a0\nIgG2,\u00a0IgG3,\u00a0IgG4,\u00a0IgA1\u00a0e\u00a0IgA2,\u00a0respectivamente.\u00a0En\u00a0el\u00a0caso\u00a0de\u00a0I gG4,\u00a0solo\u00a01\u00a0de\u00a0los\u00a06\u00a0clones\u00a0\nevaluados\u00a0(SAG4)\u00a0mostr\u00f3\u00a0positividad\u00a0en\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0 y\u00a0CPs,\u00a0a\u00a0pesar\u00a0de\u00a0que\u00a0en\u00a0un\u00a0\nestudio\u00a0previo\u00a0se\u00a0hab\u00eda\u00a0mostra do\u00a0marcaje\u00a0con\u00a0otro\u00a0clon\u00a0(HP6098) \u00a0en\u00a0linfocitos\u00a0B\u00a0purificados415.\u00a0\nPara\u00a0las\u00a0dem\u00e1s\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA,\u00a0exist\u00edan\u00a0otros\u00a0clones,\u00a0a lternativos\u00a0a\u00a0los\u00a0seleccionados,\u00a0\nque\u00a0hab\u00edan\u00a0mostrado\u00a0en\u00a0la\u00a0primera\u00a0evaluaci\u00f3n\u00a0global,\u00a0una\u00a0intens idad\u00a0de\u00a0marcaje\u00a0y\u00a0especificidad\u00a0\nsimilares\u00a0a\u00a0la\u00a0de\u00a0lo s\u00a0clones\u00a0elegidos.\u00a0\u00a0\n\u00a0 En\u00a0esta\u00a0segunda\u00a0etapa\u00a0de\u00a0validac i\u00f3n\u00a0de\u00a0los\u00a06\u00a0clones\u00a0selecciona dos,\u00a0determinamos\u00a0en\u00a0\nprimer\u00a0lugar,\u00a0la\u00a0posible\u00a0existencia\u00a0de\u00a0reactividad\u00a0cruzada\u00a0de\u00a0c ada\u00a0clon\u00a0con\u00a0m\u00e1s\u00a0de\u00a0una\u00a0subclase\u00a0\nde\u00a0Ig,\u00a0comprobando\u00a0que\u00a0los\u00a06\u00a0reactivos\u00a0seleccionados\u00a0se\u00a0un\u00edan\u00a0d e\u00a0forma\u00a0espec\u00edfica\u00a0tanto\u00a0a\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0como\u00a0a\u00a0las\u00a0CPs,\u00a0y\u00a0que\u00a0las\u00a0c\u00e9lulas\u00a0ident ificadas\u00a0con\u00a0cada\u00a0clon\u00a0eran\u00a0Discusi\u00f3n \n\u2010\u00a0151\u00a0\u2010\u00a0\n\u00a0negativas\u00a0para\u00a0los\u00a05\u00a0clones\u00a0restantes.\u00a0En\u00a0vista\u00a0de\u00a0estos\u00a0result ados,\u00a0decidimos\u00a0juntar\u00a0todos\u00a0los\u00a0\nclones\u00a0en\u00a0una\u00a0sola\u00a0combinaci\u00f3n\u00a0de\u00a0Acs,\u00a0utilizando\u00a0dos\u00a0Acs\u00a0del\u00a0m ismo\u00a0clon\u00a0conjugados\u00a0con\u00a0dos\u00a0\nfluorocromos\u00a0diferentes\u00a0(i.e.\u00a0IgG2\u2010PE\u00a0e\u00a0IgG2\u2010FITC;\u00a0IgA1\u2010APC\u00a0e\u00a0I gA1\u00a0PerCP\u2010Cy5.5);\u00a0as\u00ed,\u00a0era\u00a0posible\u00a0\nrealizar\u00a0la\u00a0visualizaci\u00f3n\u00a0del\u00a0ma rcaje\u00a0completo\u00a0frente\u00a0a\u00a0las\u00a06\u00a0s ubclases\u00a0de\u00a0IgG1\u20104\u00a0e\u00a0IgA1\u20102,\u00a0en\u00a0un\u00a0\nn\u00famero\u00a0relativamente\u00a0reducido\u00a0de\u00a0fluorescencias\u00a0(n=4).\u00a0Esta\u00a0apr oximaci\u00f3n\u00a0hab\u00eda\u00a0sido\u00a0validada\u00a0\npreviamente\u00a0para\u00a0otros\u00a0Acs,\u00a0tanto\u00a0por\u00a0nuestro\u00a0grupo\u00a0como\u00a0por\u00a0ot ros\u00a0autores428\u2013430,\u00a0y\u00a0permiti\u00f3\u00a0\ncomprobar\u00a0 que\u00a0 as\u00ed,\u00a0 podr\u00edamos\u00a0 evaluar\u00a0 de\u00a0 forma\u00a0 espec\u00edfica,\u00a0 sensi ble\u00a0 y\u00a0 reproducible,\u00a0 tres\u00a0\nsubclases\u00a0diferentes\u00a0de\u00a0Igs\u00a0utilizando\u00a0\u00fanicamente\u00a0un\u00a0par\u00a0de\u00a0flu orocromos.\u00a0\u00a0\nDado\u00a0que\u00a0no\u00a0todos\u00a0los\u00a0clones\u00a0de\u00a0Acs\u00a0que\u00a0reconocen\u00a0prote\u00ednas\u00a0en\u00a0 la\u00a0cara\u00a0externa\u00a0de\u00a0la\u00a0\nmembrana\u00a0citoplasm\u00e1tica\u00a0de\u00a0c\u00e9lulas\u00a0vivas,\u00a0reaccionan\u00a0con\u00a0la\u00a0mis ma\u00a0prote\u00edna\u00a0cuando\u00a0esta\u00a0est\u00e1\u00a0\npresente\u00a0a\u00a0nivel\u00a0intracelular\u00a0en\u00a0el\u00a0ret\u00edculo\u00a0endoplasm\u00e1tico427,\u00a0decidimos\u00a0comprobar\u00a0si\u00a0los\u00a0clones\u00a0\nde\u00a0Acs\u00a0seleccionados\u00a0pod\u00edan\u00a0detectar\u00a0las\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA ,\u00a0tambi\u00e9n\u00a0en\u00a0el\u00a0citoplasma\u00a0de\u00a0las\u00a0\nc\u00e9lulas\u00a0B\u00a0de\u00a0memoria,\u00a0y\u00a0sobre\u00a0todo,\u00a0de\u00a0las\u00a0CPs.\u00a0En\u00a0este\u00a0sentido ,\u00a0nuestros\u00a0resultados\u00a0mostraron\u00a0\ntambi\u00e9n\u00a0que\u00a0los\u00a06\u00a0clones\u00a0selecci onados\u00a0eran\u00a0capaces\u00a0de\u00a0reconoce r\u00a0la\u00a0subclase\u00a0correspondiente\u00a0\nde\u00a0Ig,\u00a0tanto\u00a0en\u00a0la\u00a0membrana\u00a0externa,\u00a0como\u00a0en\u00a0el\u00a0citoplasma\u00a0de\u00a0l as\u00a0CPs,\u00a0con\u00a0una\u00a0distribuci\u00f3n\u00a0\nrelativa\u00a0de\u00a0CPs\u00a0IgG1\u20104\u00a0e\u00a0IgA1\u20102\u00a0similar\u00a0a\u00a0la\u00a0observada\u00a0cuando\u00a0s e\u00a0realizaba\u00a0\u00fanicamente\u00a0el\u00a0marcaje\u00a0\nde\u00a0membrana;\u00a0sin\u00a0embargo,\u00a0observamos\u00a0un\u00a0menor\u00a0porcentaje\u00a0de\u00a0CPs \u00a0que\u00a0no\u00a0expresaban\u00a0Igs.\u00a0\nEstos\u00a0resultados\u00a0est\u00e1n\u00a0de\u00a0acuerdo\u00a0con\u00a0el\u00a0menor\u00a0nivel\u00a0de\u00a0expresi \u00f3n\u00a0de\u00a0Igs\u00a0(y\u00a0otras\u00a0mol\u00e9culas\u00a0\nasociadas\u00a0al\u00a0BCR)\u00a0descrito\u00a0en\u00a0la\u00a0membrana\u00a0 vs.\u00a0citoplasma\u00a0de\u00a0las\u00a0CPs53.\u00a0A\u00a0su\u00a0vez,\u00a0a\u00a0pesar\u00a0del\u00a0\nintenso\u00a0marcaje\u00a0observado\u00a0para\u00a0las\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0en\u00a0la \u00a0membrana\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria,\u00a0el\u00a0marcaje\u00a0intracelular\u00a0para\u00a0IgG1,\u00a0IgG2\u00a0e\u00a0IgG3\u00a0en\u00a0esta s\u00a0c\u00e9lulas\u00a0fue\u00a0muy\u00a0bajo\u00a0(o\u00a0\nindetectable),\u00a0mientras\u00a0que\u00a0para\u00a0IgG4,\u00a0IgA1\u00a0e\u00a0IgA2,\u00a0era\u00a0similar \u00a0al\u00a0observado\u00a0en \u00a0la\u00a0membrana\u00a0\ncitoplasm\u00e1tica.\u00a0Estos\u00a0resultados \u00a0indican\u00a0que\u00a0el\u00a0marcaje\u00a0intrace lular\u00a0podr\u00eda\u00a0ser\u00a0m\u00e1s\u00a0adecuado\u00a0\npara\u00a0una\u00a0identificaci\u00f3n\u00a0m\u00e1s\u00a0sensible\u00a0y\u00a0precisa\u00a0de\u00a0las\u00a0Igs\u00a0en\u00a0CP s,\u00a0mientras\u00a0que\u00a0la\u00a0tinci\u00f3n\u00a0de\u00a0\nmembrana\u00a0ser\u00eda\u00a0la\u00a0id\u00f3nea\u00a0para\u00a0el\u00a0estudio\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de \u00a0memoria.\u00a0\u00a0Discusi\u00f3n \n\u00a0\n\u2010\u00a0152\u00a0\u2010\u00a0\n\u00a0Una\u00a0vez\u00a0que\u00a0los\u00a0reactivos\u00a0selecci onados\u00a0hab\u00edan\u00a0demostrado\u00a0un\u00a0ad ecuado\u00a0marcaje\u00a0en\u00a0\nSP,\u00a0y\u00a0debido\u00a0a\u00a0la\u00a0variabilidad\u00a0de\u00a0marcaje\u00a0que\u00a0se\u00a0ha\u00a0descrito\u00a0pa ra\u00a0algunos\u00a0clones\u00a0de\u00a0Acs\u00a0en\u00a0funci\u00f3n\u00a0\ndel\u00a0tejido\u00a0del\u00a0que\u00a0se\u00a0trate422,\u00a0decidimos\u00a0testar\u00a0los\u00a0Acs\u00a0seleccionados\u00a0en\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0otros\u00a0 tejidos\u00a0\nhumanos.\u00a0As\u00ed,\u00a0pudimos\u00a0demostrar\u00a0 que,\u00a0tanto\u00a0en\u00a0muestras\u00a0de\u00a0MO\u00a0co mo\u00a0en\u00a0las\u00a0am\u00edgdalas\u00a0\nanalizadas,\u00a0todos\u00a0los\u00a0clones\u00a0sel eccionados\u00a0eran\u00a0capaces\u00a0de\u00a0dete ctar\u00a0sus\u00a0correspondientes\u00a0\nsubclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0en\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0las\u00a0CPs ,\u00a0demostrando\u00a0su\u00a0utilidad\u00a0tambi\u00e9n\u00a0\npara\u00a0el\u00a0estudio\u00a0de\u00a0estas\u00a0poblaci ones\u00a0B\u00a0en\u00a0tejidos\u00a0humanos\u00a0disti ntos\u00a0de\u00a0SP.\u00a0 \u00a0\u00a0\n\u00a0 Finalmente,\u00a0 cabe\u00a0 se\u00f1alar\u00a0 que\u00a0 un\u00a0 subgrupo\u00a0 de\u00a0 los\u00a0 clones\u00a0 de\u00a0 Acs\u00a0 evaluados,\u00a0\nespecialmente\u00a0los\u00a0dirigidos\u00a0frente\u00a0a\u00a0IgG1\u00a0e\u00a0IgG3,\u00a0mostraron\u00a0rea ctividad\u00a0cruzada\u00a0frente\u00a0a\u00a0\nneutr\u00f3filos\u00a0y\u00a0monocitos.\u00a0En\u00a0este\u00a0sentido,\u00a0se\u00a0sabe\u00a0que\u00a0tanto\u00a0la\u00a0 IgG1\u00a0como\u00a0la\u00a0IgG3\u00a0poseen\u00a0especial\u00a0\navidez\u00a0 por\u00a0 los\u00a0 receptores\u00a0 Fc\u03b3RI\u00a0 y\u00a0 Fc\u03b3RIII,\u00a0 expresados\u00a0 de\u00a0 forma\u00a0 intensa\u00a0 y\u00a0 homog\u00e9nea\u00a0 en\u00a0\nmonocitos\u00a0maduros\u00a0y\u00a0granulocito s\u00a0neutr\u00f3filos,\u00a0respectivamente5,8,\u00a0asoci\u00e1ndose\u00a0as\u00ed\u00a0este\u00a0marcaje\u00a0\naparentemente\u00a0inespec\u00edfico\u00a0con\u00a0la\u00a0expresi\u00f3n\u00a0de\u00a0los\u00a0Fc\u03b3R\u00a0antes\u00a0m encionados.\u00a0En\u00a0su\u00a0conjunto,\u00a0\nestos\u00a0resultados\u00a0sugieren\u00a0que\u00a0los \u00a0clones\u00a0de\u00a0Acs\u00a0anti\u2010IgG1\u00a0y\u00a0ant i\u2010IgG3\u00a0podr\u00edan\u00a0estar\u00a0uni\u00e9ndose\u00a0a\u00a0\nlos\u00a0complejos\u00a0FcR\u03b3\u2010IgG\u00a0presentes\u00a0en\u00a0la\u00a0superficie\u00a0de\u00a0los\u00a0neutr\u00f3 filos\u00a0y\u00a0de\u00a0los\u00a0monocitos.\u00a0En\u00a0este\u00a0\ncontexto\u00a0merece\u00a0destacar,\u00a0que\u00a0de\u00a0acuerdo\u00a0con\u00a0la\u00a0baja\u00a0capacidad\u00a0 de\u00a0los\u00a0Acs\u00a0de\u00a0tipo\u00a0IgG2,\u00a0IgG4,\u00a0\nIgA1\u00a0e\u00a0IgA2\u00a0para\u00a0unirse\u00a0a\u00a0los\u00a0receptores\u00a0FcR5,8,\u00a0no\u00a0se\u00a0observ\u00f3\u00a0marcaje\u00a0inespec\u00edfico\u00a0en\u00a0neutr\u00f3filos\u00a0\ny\u00a0monocitos\u00a0de\u00a0ning\u00fan\u00a0tipo\u00a0(IgG2),\u00a0o\u00a0este\u00a0solo\u00a0fue\u00a0detectado\u00a0de \u00a0forma\u00a0d\u00e9bil\u00a0en\u00a0algunas\u00a0muestras\u00a0\n(IgA1,\u00a0IgA2\u00a0e\u00a0IgG4).\u00a0Por\u00a0otra\u00a0parte\u00a0cabe\u00a0se\u00f1alar\u00a0que,\u00a0algunos\u00a0d e\u00a0los\u00a0clones\u00a0que\u00a0no\u00a0mostraban\u00a0\nreactividad\u00a0frente\u00a0a\u00a0su\u00a0subclase\u00a0de\u00a0IgG\u00a0o\u00a0IgA\u00a0presente\u00a0en\u00a0la\u00a0me mbrana\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0y\u00a0de\u00a0CPs,\u00a0pero\u00a0que\u00a0se\u00a0ha b\u00eda\u00a0demostrado\u00a0s\u00ed\u00a0detectaban\u00a0la s\u00a0correspondientes\u00a0subclases\u00a0\nde\u00a0Igs\u00a0cuando\u00a0se\u00a0empleaban\u00a0otras\u00a0t\u00e9cnicas412,413,431,\u00a0mostraban\u00a0positividad\u00a0en\u00a0granulocitos\u00a0\nneutr\u00f3filos\u00a0y\u00a0monocitos\u00a0maduros \u00a0de\u00a0SP.\u00a0Estos\u00a0hallazgos\u00a0sugieren \u00a0que\u00a0los\u00a0ep\u00edtopos\u00a0de\u00a0estos\u00a0Acs\u00a0\npodr\u00edan\u00a0estar\u00a0disponibles\u00a0\u00fanicamente\u00a0en\u00a0la\u00a0forma\u00a0secretada\u00a0de\u00a0l a\u00a0Ig,\u00a0o\u00a0cuando\u00a0esta\u00a0se\u00a0encuentra\u00a0\nunida\u00a0a\u00a0Ags\u00a0formando\u00a0inmunocomple jos.\u00a0Aunque\u00a0los\u00a0linfocitos\u00a0B\u00a0e xpresan\u00a0Fc\u03b3RIIb\u00a0(CD32b),\u00a0el\u00a0\nmarcaje\u00a0de\u00a0nuestros\u00a0clones\u00a0de\u00a0Acs\u00a0no\u00a0pudo\u00a0ser\u00a0debido\u00a0a\u00a0uniones\u00a0 inespec\u00edficas\u00a0a\u00a0este\u00a0receptor,\u00a0Discusi\u00f3n \n\u2010\u00a0153\u00a0\u2010\u00a0\n\u00a0ya\u00a0que\u00a0CD32b\u00a0se\u00a0expresa\u00a0de\u00a0forma\u00a0uniforme\u00a0en\u00a0pr\u00e1cticamente\u00a0todo s\u00a0los\u00a0linfocitos\u00a0B432,\u00a0mientras\u00a0\nque\u00a0nuestros\u00a0clones\u00a0reaccionaron\u00a0d e\u00a0forma\u00a0espec\u00edfica\u00a0frente\u00a0a\u00a0l os\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0las\u00a0\nCPs\u00a0IgG+\u00a0o\u00a0IgA+.\u00a0\n\u00a0 En\u00a0resumen,\u00a0tras\u00a0la\u00a0evaluaci\u00f3n\u00a0de\u00a0un\u00a0amplio\u00a0panel\u00a0de\u00a0Acs\u00a0espec \u00edficos\u00a0de\u00a0las\u00a0distintas\u00a0\nsubclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA,\u00a0y\u00a0que\u00a0ha b\u00edan\u00a0sido\u00a0validados\u00a0previamente \u00a0para\u00a0otros\u00a0m\u00e9todos,\u00a0nuestros\u00a0\nresultados\u00a0muestran\u00a0que\u00a0existen\u00a0clones\u00a0y\u00a0conjugados\u00a0fluorescent es\u00a0de\u00a0clones\u00a0de\u00a0Acs\u00a0espec\u00edficos\u00a0\nde\u00a0las\u00a0distintas\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA,\u00a0que\u00a0con\u00a0los\u00a0protocolos \u00a0propuestos,\u00a0proporcionan\u00a0una\u00a0\nherramienta\u00a0r\u00e1pida\u00a0(<3\u00a0horas),\u00a0espec\u00edfica,\u00a0sensible\u00a0(<10\u20105)\u00a0y\u00a0reproducible\u00a0para\u00a0la\u00a0identificaci\u00f3n\u00a0y\u00a0\ncuantificaci\u00f3n\u00a0de\u00a0las\u00a0distintas\u00a0subpoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0 de\u00a0memoria\u00a0y\u00a0CPs\u00a0que\u00a0expresan\u00a0\ndiferentes\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0tanto\u00a0en\u00a0SP\u00a0como\u00a0en\u00a0otros\u00a0tej idos\u00a0humanos,\u00a0siendo\u00a0la\u00a0\nexpresi\u00f3n\u00a0de\u00a0dichas\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0m\u00e1s\u00a0elevada\u00a0en\u00a0la\u00a0me mbrana\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0que\u00a0en\u00a0su\u00a0citoplasma,\u00a0al \u00a0contrario\u00a0de\u00a0lo\u00a0observado\u00a0en\u00a0l as\u00a0CPs.\u00a0\n2.\u00a0 Distribuci\u00f3n\u00a0 en\u00a0 SP\u00a0 a\u00a0 lo\u00a0 largo \u00a0 de\u00a0 la\u00a0 vida\u00a0 de\u00a0 distintas\u00a0 subpob laciones\u00a0 de\u00a0 linfocitos\u00a0 B\u00a0\ninmaduros/transicionales,\u00a0na\u00efve\u00a0y\u00a0de\u00a0memoria,\u00a0y\u00a0de\u00a0CPs\u00a0que\u00a0expr esan\u00a0diferente\u00a0isotipo\u00a0y\u00a0\nsubclase\u00a0de\u00a0Ig.\u00a0\nUna\u00a0vez\u00a0dispon\u00edamos\u00a0de\u00a0un\u00a0panel\u00a0validado\u00a0de\u00a0Acs\u00a0espec\u00edficos\u00a0de\u00a0 las\u00a0distintas\u00a0subclases\u00a0\nde\u00a0IgG\u00a0e\u00a0IgA,\u00a0nuestro\u00a0inter\u00e9s\u00a0se\u00a0centr\u00f3\u00a0en\u00a0conocer\u00a0las\u00a0variacio nes\u00a0que\u00a0ocurren\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0\nvida\u00a0en\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0las\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0m emoria\u00a0y\u00a0CPs\u00a0presentes\u00a0en\u00a0sangre,\u00a0\ny\u00a0que\u00a0pudieran\u00a0servir\u00a0a\u00a0su\u00a0vez,\u00a0como\u00a0referencia\u00a0para\u00a0identifica r\u00a0alteraciones\u00a0en\u00a0las\u00a0mismas\u00a0\nasociadas\u00a0a\u00a0IDP\u2010Ac.\u00a0\nActualmente,\u00a0 existen\u00a0 m\u00faltiples\u00a0 evidencias\u00a0 que\u00a0 indican\u00a0 que\u00a0 la\u00a0 di stribuci\u00f3n\u00a0 de\u00a0 los\u00a0\nlinfocitos\u00a0B\u00a0en\u00a0distintos\u00a0estadios\u00a0madurativos\u00a0sufre\u00a0modificaci ones\u00a0en\u00a0SP,\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0\nvida53,117,136,189\u2013191.\u00a0As\u00ed\u00a0mismo,\u00a0se\u00a0sabe\u00a0tambi\u00e9n\u00a0que\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0los\u00a0dis tintos\u00a0isotipos\u00a0y\u00a0\nsubclases\u00a0de\u00a0Igs,\u00a0var\u00edan\u00a0con\u00a0la\u00a0edad19,170,171,183,187,433.\u00a0Sin\u00a0embargo,\u00a0al\u00a0iniciar\u00a0este\u00a0trabajo\u00a0no\u00a0se\u00a0\nconoc\u00eda\u00a0si\u00a0exist\u00edan\u00a0cambios\u00a0que\u00a0afectaran\u00a0a\u00a0las\u00a0poblaciones\u00a0cel ulares\u00a0B\u00a0que\u00a0expresan\u00a0distintos\u00a0\ni s o t i p o s \u00a0y \u00a0s u b c l a s e s \u00a0d e \u00a0I g s . \u00a0L a \u00a0d e f i n i c i \u00f3 n \u00a0d e \u00a0v a l o r e s \u00a0d e \u00a0r e f e r e ncia\u00a0 normales\u00a0 para\u00a0 dichas\u00a0Discusi\u00f3n \n\u00a0\n\u2010\u00a0154\u00a0\u2010\u00a0\n\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0identificadas\u00a0de\u00a0forma\u00a0espec\u00edfica\u00a0p or\u00a0el\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Ig\u00a0que\u00a0\nexpresan\u00a0y\u00a0clasificadas\u00a0seg\u00fan\u00a0su\u00a0estadio\u00a0madurativo,\u00a0constituye \u00a0un\u00a0paso\u00a0previo\u00a0e\u00a0imprescindible,\u00a0\nal\u00a0estudio\u00a0de\u00a0sus\u00a0alteraciones\u00a0en\u00a0pacientes\u00a0con\u00a0IDP\u2010Ac.\u00a0Por\u00a0tod o\u00a0ello,\u00a0en\u00a0esta\u00a0fase\u00a0del\u00a0trabajo\u00a0\ndoctoral\u00a0empleamos\u00a0los\u00a0reactivos\u00a0y\u00a0los\u00a0protocolos\u00a0validados\u00a0en\u00a0 el\u00a0objetivo\u00a0anterior,\u00a0para\u00a0\nestudiar\u00a0en\u00a0profundidad\u00a0los\u00a0cambios\u00a0que\u00a0se\u00a0producen\u00a0en\u00a0las\u00a0subp oblaciones\u00a0B\u00a0de\u00a0sangre,\u00a0desde\u00a0\nel\u00a0nacimiento\u00a0hasta\u00a0la\u00a0vejez,\u00a0investigando\u00a0tambi\u00e9n\u00a0su\u00a0posible\u00a0r elaci\u00f3n\u00a0con\u00a0los\u00a0niveles\u00a0solubles\u00a0\nde\u00a0Igs\u00a0en\u00a0plasma.\u00a0\nTanto\u00a0los\u00a0linfocitos\u00a0B\u00a0totales,\u00a0como\u00a0los\u00a0linfocitos\u00a0B\u00a0inmaduros /transicionales\u00a0y\u00a0na\u00efve\u00a0\naumentaron\u00a0 dr\u00e1sticamente\u00a0 durante \u00a0 el\u00a0 primer\u00a0 a\u00f1o\u00a0 de\u00a0 vida,\u00a0 hallazg os\u00a0 que\u00a0 corroboran\u00a0 los\u00a0\nresultados\u00a0encontrados\u00a0pre viamente\u00a0por\u00a0otros\u00a0autores189,190.\u00a0A\u00a0partir\u00a0de\u00a0esa\u00a0edad,\u00a0el\u00a0n\u00famero\u00a0\nabsoluto\u00a0de\u00a0estas\u00a0poblaciones\u00a0B\u00a0en\u00a0SP\u00a0fue\u00a0disminuyendo\u00a0progresi vamente\u00a0hasta\u00a0la\u00a0edad\u00a0adulta,\u00a0\nmomento\u00a0a\u00a0partir\u00a0del\u00a0cual\u00a0se\u00a0estabilizaron.\u00a0Este\u00a0patr\u00f3n\u00a0de\u00a0vari aci\u00f3n\u00a0num\u00e9rica\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0\npre\u2010CG\u00a0en\u00a0SP\u00a0probablemente\u00a0refleja\u00a0una\u00a0producci\u00f3n\u00a0aumentada\u00a0de\u00a0 linfocitos\u00a0B\u00a0por\u00a0parte\u00a0de\u00a0la\u00a0\nMO,\u00a0que\u00a0alcanza\u00a0su\u00a0m\u00e1ximo\u00a0entre\u00a0los\u00a06\u00a0y\u00a0los\u00a020\u00a0meses\u00a0de\u00a0vida,\u00a0p ara\u00a0disminuir\u00a0posteriormente\u00a0\nhasta\u00a0la\u00a0edad\u00a0adulta154.\u00a0En\u00a0este\u00a0sentido\u00a0y\u00a0de\u00a0acuerdo\u00a0con\u00a0estudios\u00a0previos53,\u00a0no\u00a0se\u00a0observaron\u00a0\ndiferencias\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0inmaduros/transicional es\u00a0o\u00a0linfocitos\u00a0B\u00a0na\u00efve,\u00a0entre\u00a0\nadultos\u00a0j\u00f3venes\u00a0y\u00a0ancianos,\u00a0lo\u00a0cual\u00a0sugiere\u00a0que\u00a0el\u00a0envejecimien to\u00a0del\u00a0sistema\u00a0inmune\u00a0no\u00a0se\u00a0\nasocia,\u00a0en\u00a0t\u00e9rminos\u00a0globales,\u00a0a\u00a0 una\u00a0disminuci\u00f3n\u00a0de\u00a0la\u00a0producci\u00f3 n\u00a0de\u00a0linfocitos\u00a0B\u00a0en\u00a0la\u00a0MO,\u00a0pese\u00a0\na\u00a0la\u00a0reducci\u00f3n\u00a0significativa\u00a0del\u00a0componente\u00a0hematopoy\u00e9tico\u00a0de\u00a0l a\u00a0misma\u00a0en\u00a0edades\u00a0avanzadas\u00a0\nde\u00a0la\u00a0vida152,153.\u00a0\u00a0\n\u00a0 En\u00a0contraposici\u00f3n\u00a0con\u00a0la\u00a0producci\u00f3n\u00a0masiva\u00a0de\u00a0linfocitos\u00a0B\u00a0pre \u2010CG\u00a0durante\u00a0la\u00a0infancia\u00a0\ntemprana,\u00a0los\u00a0estudios\u00a0serol\u00f3gic os\u00a0llevados\u00a0a\u00a0cabo\u00a0en\u00a0donantes\u00a0 sanos19,170,182,187,433,434\u00a0y\u00a0en\u00a0\nsujetos\u00a0vacunados435\u00a0sugieren\u00a0que\u00a0los\u00a0ni\u00f1os\u00a0tienen\u00a0una\u00a0baja\u00a0capacidad\u00a0para\u00a0producir \u00a0Acs,\u00a0y\u00a0por\u00a0\nende,\u00a0CPs.\u00a0Sin\u00a0embargo,\u00a0nuestros\u00a0resultados\u00a0demuestran\u00a0la\u00a0prese ncia\u00a0de\u00a0CPs\u00a0circulantes\u00a0en\u00a0la\u00a0\nsangre\u00a0de\u00a0reci\u00e9n\u00a0nacidos\u00a0(aunque\u00a0n o\u00a0en\u00a0sangre\u00a0de\u00a0cord\u00f3n),\u00a0siend o\u00a0estas\u00a0fundamentalmente\u00a0de\u00a0\nisotipo\u00a0IgM,\u00a0lo\u00a0que\u00a0podr\u00eda\u00a0reflej ar\u00a0una\u00a0exposici\u00f3n\u00a0repentina\u00a0a\u00a0 nuevos\u00a0Ags\u00a0ambientales,\u00a0tras\u00a0el\u00a0Discusi\u00f3n \n\u2010\u00a0155\u00a0\u2010\u00a0\n\u00a0nacimiento71.\u00a0De\u00a0acuerdo\u00a0con\u00a0esta\u00a0hip\u00f3tesis,\u00a0los\u00a0ni\u00f1os\u00a0de\u00a0entre\u00a06\u00a0meses\u00a0y\u00a02 \u00a0a\u00f1os\u00a0mostraron\u00a0una\u00a0\nproducci\u00f3n\u00a0masiva\u00a0de\u00a0CPs,\u00a0alcanz ando\u00a0estas\u00a0c\u00e9lulas\u00a0a\u00a0esta\u00a0edad\u00a0 valores\u00a0diez\u00a0veces\u00a0superiores\u00a0a\u00a0\nlos\u00a0observados\u00a0posteriormente\u00a0en \u00a0adultos\u00a0j\u00f3venes.\u00a0No\u00a0obstante,\u00a0 esta\u00a0producci\u00f3n\u00a0masiva\u00a0de\u00a0CPs,\u00a0\nno\u00a0se\u00a0acompa\u00f1\u00f3\u00a0de\u00a0un\u00a0aumento\u00a0paralelo\u00a0de\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de \u00a0Acs.\u00a0En\u00a0este\u00a0sentido,\u00a0dado\u00a0que\u00a0\nlas\u00a0CPs\u00a0de\u00a0vida\u00a0larga\u00a0constituyen\u00a0la\u00a0mayor\u00a0fuente\u00a0de\u00a0producci\u00f3n \u00a0de\u00a0Acs\u00a0s\u00e9ricos19,53,100,\u00a0para\u00a0que\u00a0\nexista\u00a0 una\u00a0 producci\u00f3n\u00a0 significativa\u00a0 de\u00a0 estos,\u00a0 debe\u00a0 producirse\u00a0 p reviamente\u00a0 un\u00a0 ac\u00famulo\u00a0 y\u00a0\naumento\u00a0de\u00a0CPs\u00a0de\u00a0vida\u00a0larga\u00a0en\u00a0MO.\u00a0Por\u00a0tanto,\u00a0la\u00a0aparente\u00a0disc repancia\u00a0entre\u00a0la\u00a0producci\u00f3n\u00a0\nrelativamente\u00a0baja\u00a0de\u00a0Acs\u00a0observada\u00a0en\u00a0 ni\u00f1os\u00a0y\u00a0el\u00a0aumento\u00a0masiv o\u00a0del\u00a0 n\u00famero\u00a0 de\u00a0 CPs\u00a0\ncirculantes,\u00a0podr\u00eda\u00a0tener\u00a0su\u00a0origen\u00a0en\u00a0la\u00a0capacidad\u00a0reducida\u00a0de \u00a0estas\u00a0c\u00e9lulas\u00a0para\u00a0emigrar\u00a0a\u00a0la\u00a0\nM O \u00a0y / o \u00a0a c u m u l a r s e \u00a0e n \u00a0l o s \u00a0n i c h o s \u00a0d e \u00a0s u p e r v i v e n c i a \u00a0d e \u00a0l a \u00a0m i s m a , \u00a0a sociada\u00a0 a\u00a0 la\u00a0 mayor\u00a0\nsusceptibilidad\u00a0 que\u00a0 presentan\u00a0 las\u00a0 CPs\u00a0 reci\u00e9n\u00a0 producidas\u00a0 de\u00a0 mori r\u00a0 por\u00a0 apoptosis53,117,\u00a0 la\u00a0\ninmadurez\u00a0del\u00a0ambiente\u00a0medular\u00a0tras\u00a0el\u00a0nacimiento155\u00a0y/o\u00a0la\u00a0menor\u00a0disponibilidad\u00a0de\u00a0nichos\u00a0\npara\u00a0 su\u00a0 supervivencia\u00a0 por\u00a0 la\u00a0 elevada\u00a0 producci\u00f3n\u00a0 y\u00a0 proliferaci\u00f3n \u00a0 de\u00a0 precursores\u00a0 B154.\u00a0\nPosteriormente,\u00a0al\u00a0incrementarse\u00a0los\u00a0niveles\u00a0de\u00a0Igs\u00a0solubles,\u00a0o bservamos\u00a0un\u00a0descenso\u00a0paralelo\u00a0\nde\u00a0las\u00a0CPs\u00a0que\u00a0expresaban\u00a0los\u00a0correspondientes\u00a0isotipos\u00a0de\u00a0Igs; \u00a0esto\u00a0podr\u00eda\u00a0ser\u00a0debido\u00a0al\u00a0efecto\u00a0\ninmunomodulador\u00a0de\u00a0la\u00a0respuesta\u00a0de\u00a0los\u00a0linfocitos\u00a0ejercido\u00a0por\u00a0 parte\u00a0de\u00a0los\u00a0Acs436\u2013438.\u00a0\n\u00a0 En\u00a0conjunto,\u00a0estos\u00a0hallazgos\u00a0sugieren\u00a0que\u00a0los\u00a0m\u00e9todos\u00a0utilizad os\u00a0cl\u00e1sicamente\u00a0para\u00a0\nevaluar\u00a0la\u00a0funci\u00f3n\u00a0efectora\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0(i.e.\u00a0niveles\u00a0s \u00e9ricos\u00a0de\u00a0Acs),\u00a0probablemente\u00a0est\u00e9n\u00a0\nsesgados\u00a0por\u00a0la\u00a0producci\u00f3n\u00a0de\u00a0Ig s\u00a0por\u00a0parte\u00a0de\u00a0las\u00a0CPs\u00a0de\u00a0vida\u00a0 larga\u00a0de\u00a0MO19,53,100.\u00a0Dado\u00a0que\u00a0las\u00a0\nCPs\u00a0medulares\u00a0pueden\u00a0acumularse\u00a0durante\u00a0a\u00f1os19,\u00a0los\u00a0niveles\u00a0de\u00a0Acs\u00a0s\u00e9ricos\u00a0no\u00a0reflejar\u00edan\u00a0de\u00a0\nforma\u00a0fidedigna\u00a0el\u00a0estado\u00a0real\u00a0de\u00a0la\u00a0respuesta\u00a0B\u00a0en\u00a0un\u00a0momento\u00a0 concreto.\u00a0Por\u00a0el\u00a0contrario,\u00a0la\u00a0\nevaluaci\u00f3n\u00a0del\u00a0n\u00famero\u00a0de\u00a0CPs\u00a0producidas\u00a0en\u00a0sangre,\u00a0cuyos\u00a0m\u00e1ximo s\u00a0preceden\u00a0en\u00a0a\u00f1os\u00a0o\u00a0incluso\u00a0\nd\u00e9cadas\u00a0a\u00a0los\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0los\u00a0niveles\u00a0s olubles\u00a0en\u00a0plasma\u00a0de\u00a0Igs\u00a0del\u00a0isotipo\u00a0\ncorrespondiente,\u00a0permitir\u00edan\u00a0estimar\u00a0de\u00a0forma\u00a0m\u00e1s\u00a0directa\u00a0el\u00a0es tado\u00a0de\u00a0la\u00a0respuesta\u00a0B.\u00a0Esta\u00a0\nhip\u00f3tesis\u00a0se\u00a0ve\u00a0reforzada\u00a0por\u00a0el\u00a0hecho\u00a0de\u00a0que,\u00a0al\u00a0constituir\u00a0la s\u00a0CPs\u00a0de\u00a0SP\u00a0una\u00a0poblaci\u00f3n\u00a0celular\u00a0\ncon\u00a0un\u00a0alta\u00a0tasa\u00a0de\u00a0recambio53,117,\u00a0su\u00a0evaluaci\u00f3n\u00a0podr\u00eda\u00a0proporcionar\u00a0una\u00a0informaci\u00f3n\u00a0mucho\u00a0Discusi\u00f3n \n\u00a0\n\u2010\u00a0156\u00a0\u2010\u00a0\n\u00a0m\u00e1s\u00a0aproximada\u00a0del\u00a0estado\u00a0de\u00a0la\u00a0 respuesta\u00a0B\u00a0en\u00a0tiempo\u00a0real.\u00a0Est o\u00a0explicar\u00eda\u00a0la\u00a0estrecha\u00a0relaci\u00f3n\u00a0\nsecuencial\u00a0existente\u00a0entre\u00a0el\u00a0descenso\u00a0del\u00a0n\u00famero\u00a0de\u00a0CPs\u00a0normal es\u00a0circulantes,\u00a0previa\u00a0a\u00a0la\u00a0\nhipogammaglobulinemia,\u00a0asociada\u00a0a\u00a0mayor\u00a0riesgo\u00a0de\u00a0infecci\u00f3n\u00a0y\u00a0a \u00a0una\u00a0menor\u00a0producci\u00f3n\u00a0de\u00a0\nCPs\u00a0de\u00a0MO,\u00a0observada\u00a0en\u00a0pacientes\u00a0con\u00a0neoplasias\u00a0de\u00a0linfocitos\u00a0 B439\u00a0y\u00a0de\u00a0CPs440.\u00a0Por\u00a0todo\u00a0lo\u00a0\nanteriormente\u00a0expuesto,\u00a0la\u00a0evaluaci\u00f3n\u00a0del\u00a0n\u00famero\u00a0de\u00a0CPs\u00a0circula ntes\u00a0en\u00a0sangre\u00a0emerge\u00a0como\u00a0\nun\u00a0marcador\u00a0subrogado\u00a0de\u00a0la\u00a0producci\u00f3n\u00a0(futura)\u00a0de\u00a0CPs\u00a0en\u00a0MO\u00a0y\u00a0 de\u00a0los\u00a0niveles\u00a0de\u00a0Igs\u00a0solubles,\u00a0\nplanteando\u00a0la\u00a0posibilidad\u00a0de\u00a0que\u00a0su\u00a0evaluaci\u00f3n\u00a0sea\u00a0de\u00a0gran\u00a0util idad\u00a0cl\u00ednica,\u00a0especialmente\u00a0en\u00a0\nIDP\u2010Ac\u00a0 que\u00a0 no\u00a0 pueden\u00a0 diagnosticarse\u00a0 antes\u00a0 de\u00a0 los\u00a0 4\u00a0 a\u00f1os,\u00a0 debido \u00a0a \u00a0l a \u00a0r e c o n s t i t u c i \u00f3 n \u00a0\nrelativamente\u00a0lenta\u00a0de\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0Acs\u00a0durante\u00a0la\u00a0in fancia11,210;\u00a0en\u00a0estos\u00a0casos,\u00a0la\u00a0\nevaluaci\u00f3n\u00a0cuantitativa\u00a0de\u00a0las\u00a0CPs\u00a0circulantes\u00a0podr\u00eda\u00a0constitui r\u00a0un\u00a0marcador\u00a0temprano\u00a0de\u00a0IDP\u2010\nAc.\u00a0\nEn\u00a0la\u00a0edad\u00a0adulta,\u00a0al\u00a0contrario\u00a0de\u00a0lo\u00a0descrito\u00a0anteriormente\u00a0pa ra\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0\nAcs,\u00a0los\u00a0linfocitos\u00a0B\u00a0inmaduros/t ransicionales\u00a0y\u00a0los\u00a0linfocitos \u00a0B\u00a0na\u00efve,\u00a0que\u00a0permanecieron\u00a0\nrelativamente\u00a0estables\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0los\u00a0a\u00f1os,\u00a0tanto\u00a0las\u00a0CPs\u00a0co mo\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria,\u00a0\nmostraron\u00a0un\u00a0descenso\u00a0significativo\u00a0en\u00a0individuos\u00a0de\u00a0edad\u00a0m\u00e1s\u00a0a vanzada,\u00a0lo\u00a0que\u00a0estar\u00eda\u00a0de\u00a0\nacuerdo\u00a0con\u00a0lo\u00a0observado\u00a0en\u00a0estudios\u00a0previos\u00a0por\u00a0otros\u00a0autores53,117.\u00a0Esta\u00a0menor\u00a0capacidad\u00a0de\u00a0\ngenerar\u00a0linfocitos\u00a0B\u00a0efectores\u00a0en\u00a0respuesta\u00a0a\u00a0estimulaci\u00f3n\u00a0anti g\u00e9nica\u00a0podr\u00eda\u00a0constituir\u00a0una\u00a0de\u00a0\nlas\u00a0causas\u00a0de\u00a0la\u00a0mayor\u00a0tasa\u00a0de\u00a0i nfecciones\u00a0(y\u00a0mortalidad\u00a0debido \u00a0a\u00a0las\u00a0mismas),\u00a0y\u00a0de\u00a0la\u00a0menor\u00a0\nrespuesta\u00a0a\u00a0vacunaci\u00f3n,\u00a0observada\u00a0en\u00a0ancianos152,\u00a0a\u00a0pesar\u00a0de\u00a0que\u00a0estos\u00a0mostraron\u00a0niveles\u00a0de\u00a0\nAcs\u00a0similares\u00a0(o\u00a0incluso\u00a0ligeram ente\u00a0aumentados),\u00a0respecto\u00a0a\u00a0ad ultos\u00a0j\u00f3venes145,152,441\u2013444.\u00a0\n\u00a0 En\u00a0l\u00edneas\u00a0generales,\u00a0la\u00a0cin\u00e9tica \u00a0observada\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vi da,\u00a0tanto\u00a0para\u00a0las\u00a0CPs,\u00a0como\u00a0\npara\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0circulantes\u00a0y\u00a0los\u00a0niveles\u00a0s\u00e9ri cos\u00a0de\u00a0Acs,\u00a0fue\u00a0diferente\u00a0en\u00a0funci\u00f3n\u00a0\ndel\u00a0isotipo\u00a0y/o\u00a0subclase\u00a0de\u00a0Ig\u00a0y,\u00a0especialmente,\u00a0de\u00a0la\u00a0posici\u00f3n \u00a0relativa\u00a0que\u00a0el\u00a0isotipo/subclase\u00a0de\u00a0\ncada\u00a0Ig\u00a0ocupa\u00a0en\u00a0el\u00a0gen\u00a0 IGHC.\u00a0As\u00ed,\u00a0los\u00a0picos\u00a0de\u00a0producci\u00f3n\u00a0de\u00a0IgG3\u00a0e\u00a0IgG1\u00a0precedieron\u00a0a\u00a0los \u00a0de\u00a0\nla\u00a0IgG2\u00a0e\u00a0IgG4\u00a0para\u00a0las\u00a0CPs\u00a0(1\u20105\u00a0meses\u00a0 vs.\u00a06\u201011\u00a0meses\u00a0y\u00a05\u20109\u00a0a\u00f1os,\u00a0resp ectivamente),\u00a0linfocitos\u00a0B\u00a0\nde\u00a0memoria\u00a0(2\u20104\u00a0a\u00f1os\u00a0 vs.\u00a018\u201039\u00a0a\u00f1os)\u00a0y\u00a0niveles\u00a0solubles\u00a0de\u00a0Acs\u00a0(5\u20109\u00a0a\u00f1os\u00a0 vs.\u00a018\u201039\u00a0a\u00f1os).\u00a0Por\u00a0el\u00a0Discusi\u00f3n \n\u2010\u00a0157\u00a0\u2010\u00a0\n\u00a0contrario,\u00a0las\u00a0CPs\u00a0IgA+\u00a0no\u00a0mostraron\u00a0diferencias\u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0edad\u00a0a\u00a0la\u00a0que\u00a0alcanzaba n\u00a0los\u00a0\nvalores\u00a0m\u00e1ximos\u00a0seg\u00fan\u00a0la\u00a0subclase\u00a0de\u00a0Ig\u00a0expresada\u00a0(ambas\u00a0tuvier on\u00a0su\u00a0pico\u00a0de\u00a0producci\u00f3n\u00a0a\u00a0los\u00a0\n6\u201011\u00a0meses);\u00a0esto\u00a0posiblemente\u00a0sea\u00a0debido\u00a0a\u00a0la\u00a0especialmente\u00a0r\u00e1 pida\u00a0respuesta\u00a0de\u00a0tipo\u00a0IgA\u00a0\ninducida\u00a0por\u00a0la\u00a0colonizaci\u00f3n\u00a0bacteriana\u00a0masiva\u00a0del\u00a0intestino\u00a0tr as\u00a0el\u00a0nacimiento163.\u00a0Sin\u00a0embargo,\u00a0\nen\u00a0el\u00a0caso\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0los\u00a0niveles\u00a0solu bles\u00a0en\u00a0plasma\u00a0de\u00a0Acs,\u00a0observamos\u00a0\nque\u00a0la\u00a0IgA1\u00a0se\u00a0incrementaba\u00a0de\u00a0forma\u00a0significativamente\u00a0m\u00e1s\u00a0r\u00e1p ida\u00a0que\u00a0la\u00a0IgA2\u00a0(2\u20104\u00a0a\u00f1os\u00a0 vs.\u00a0\n18\u201039\u00a0a\u00f1os\u00a0para\u00a0los\u00a0linfocitos\u00a0 B\u00a0de\u00a0memoria\u00a0y\u00a010\u201017\u00a0a\u00f1os\u00a0 vs.\u00a040\u201059\u00a0a\u00f1os\u00a0para\u00a0los\u00a0niveles\u00a0de\u00a0Acs\u00a0\ns\u00e9ricos).\u00a0Estudios\u00a0previos\u00a0sugieren\u00a0que\u00a0los\u00a0isotipos\u00a0y\u00a0subclase s\u00a0de\u00a0Igs\u00a0codificados\u00a0distalmente\u00a0en\u00a0\nel\u00a0tercer\u00a0bloque\u00a0del\u00a0gen\u00a0 IGHC\u00a0(IgG2,\u00a0IgG4\u00a0e\u00a0IgA2)\u00a0pueden,\u00a0al\u00a0menos\u00a0parcialmente,\u00a0ser\u00a0generado s\u00a0\nmediante\u00a0 cambios\u00a0 secuenciales\u00a0 (i.e.\u00a0 secundarios)\u00a0 de\u00a0 isotipo\u00a0 de\u00a0 Ig,\u00a0 al\u00a0 producirse\u00a0 nuevos\u00a0\ncontactos\u00a0por\u00a0parte\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0generados\u00a0en \u00a0un\u00a0contacto\u00a0anterior\u00a0con\u00a0Ag94\u2013\n98.\u00a0\u00a0\nEsta\u00a0hip\u00f3tesis\u00a0se\u00a0fundamenta\u00a0en\u00a0el\u00a0mayor\u00a0n\u00famero\u00a0de\u00a0mutaciones\u00a0s om\u00e1ticas\u00a0y\u00a0los\u00a0niveles\u00a0\nm\u00e1s\u00a0elevados\u00a0de\u00a0selecci\u00f3n\u00a0antig\u00e9nica\u00a0que\u00a0muestran\u00a0estas\u00a0subclas es\u00a0de\u00a0IgG\u00a0(IgG2\u00a0e\u00a0IgG4)\u00a0e\u00a0IgA\u00a0\n(IgA2)\u00a0respecto\u00a0a\u00a0IgG1,\u00a0IgG3\u00a0e\u00a0IgA195\u201397,\u00a0as\u00ed\u00a0como\u00a0en\u00a0la\u00a0presencia\u00a0en\u00a0estas\u00a0c\u00e9lulas,\u00a0de\u00a0remanentes\u00a0\nde\u00a0secuencias\u00a0procedentes\u00a0de\u00a0cambios\u00a0de\u00a0isotipo\u00a0de\u00a0Ig\u00a0previos95,96.\u00a0Aunque\u00a0en\u00a0un\u00a0primer\u00a0\nmomento\u00a0se\u00a0sugiri\u00f3\u00a0que\u00a0estos\u00a0cambi os\u00a0de\u00a0isotipo\u00a0consecutivos\u00a0so lo\u00a0se\u00a0producir\u00edan\u00a0durante\u00a0el\u00a0\ncurso\u00a0de\u00a0una\u00a0infecci\u00f3n95,96,\u00a0nuestros\u00a0resultados,\u00a0junto\u00a0con\u00a0los\u00a0de\u00a0otros\u00a0autores97,\u00a0sugieren\u00a0que\u00a0\nestos\u00a0podr\u00edan\u00a0producirse\u00a0tambi\u00e9n \u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida,\u00a0tras\u00a0el \u00a0reencuentro\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0generados\u00a0en\u00a0una\u00a0primera\u00a0respuesta\u00a0frente\u00a0a\u00a0un\u00a0determin ado\u00a0Ag,\u00a0con\u00a0dicho\u00a0Ag.\u00a0En\u00a0\nl\u00edneas\u00a0generales,\u00a0las\u00a0subclases\u00a0de\u00a0Igs\u00a0codificadas\u00a0en\u00a0el\u00a0tercer \u00a0bloque\u00a0del\u00a0gen\u00a0 IGHC\u00a0(IgG2,\u00a0IgG4\u00a0e\u00a0\nIgA2)\u00a0presentan\u00a0una\u00a0menor\u00a0capacidad\u00a0para\u00a0activar\u00a0complemento,\u00a0p ara\u00a0opsonizar,\u00a0y\u00a0para\u00a0activar\u00a0\na\u00a0las\u00a0c\u00e9lulas\u00a0NK,\u00a0granulocitos\u00a0n eutr\u00f3filos\u00a0y\u00a0monocitos/macr\u00f3fag os,\u00a0cuando\u00a0se\u00a0comparan\u00a0con\u00a0los\u00a0\nisotipos/subclases\u00a0de\u00a0Igs\u00a0codificadas\u00a0en\u00a0el\u00a0primer\u00a0y\u00a0segundo\u00a0bl oque\u00a0del\u00a0gen\u00a0 IGHC\u00a0(IgM,\u00a0IgG3,\u00a0\nIgG1\u00a0e\u00a0IgA1)5,8,30.\u00a0Por\u00a0lo\u00a0tanto,\u00a0la\u00a0producci\u00f3n\u00a0secuencial\u00a0de\u00a0los\u00a0distintos\u00a0isoti pos\u00a0y\u00a0subclases\u00a0de\u00a0\nIgs\u00a0de\u00a0acuerdo\u00a0a\u00a0su\u00a0posici\u00f3n\u00a0en\u00a0el\u00a0gen\u00a0 IGHC,\u00a0observada\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida,\u00a0podr\u00eda\u00a0estar\u00a0asociada\u00a0Discusi\u00f3n \n\u00a0\n\u2010\u00a0158\u00a0\u2010\u00a0\n\u00a0tambi\u00e9n\u00a0con\u00a0respuestas\u00a0m\u00e1s\u00a0tolerog\u00e9nicas\u00a0en\u00a0adultos\u00a0 versus\u00a0ni\u00f1os,\u00a0con\u00a0menor\u00a0potencial\u00a0para\u00a0\ngenerar\u00a0expansiones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0is otipo\u00a0en\u00a0individuos\u00a0de\u00a0edad\u00a0\nm\u00e1s\u00a0avanzada.\u00a0\u00a0 Adem\u00e1s\u00a0de\u00a0presentar\u00a0niveles\u00a0m\u00e1s\u00a0bajos\u00a0de\u00a0Acs\u00a0s\u00e9ricos,\u00a0los\u00a0ni\u00f1o s\u00a0de\u00a0corta\u00a0edad\u00a0muestran\u00a0\ntambi\u00e9n\u00a0una\u00a0respuesta\u00a0a\u00a0vacunaci\u00f3n\u00a0distinta,\u00a0al\u00a0no\u00a0lograr\u00a0gener ar\u00a0una\u00a0respuesta\u00a0sostenida,\u00a0\nparticularmente\u00a0 frente\u00a0 a\u00a0 bacterias\u00a0 encapsuladas\n152.\u00a0 Esto\u00a0 sugiere\u00a0 que\u00a0 la\u00a0 inmadurez\u00a0 de\u00a0 las\u00a0\nrespuestas\u00a0secundarias\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0en\u00a0estos\u00a0ni\u00f1os\u00a0podr\u00ed a\u00a0estar\u00a0relacionada,\u00a0no\u00a0solo\u00a0con\u00a0\nel\u00a0menor\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria,\u00a0sino\u00a0tambi\u00e9n\u00a0con\u00a0la \u00a0capacidad\u00a0de\u00a0estas\u00a0c\u00e9lulas\u00a0\npara\u00a0responder\u00a0frente\u00a0a\u00a0est\u00edmulos\u00a0antig\u00e9nicos.\u00a0De\u00a0hecho,\u00a0nuestr os\u00a0resultados\u00a0demuestran\u00a0que\u00a0\nlos\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0de\u00a0sangre\u00a0de\u00a0cord\u00f3n,\u00a0neonatos\u00a0y\u00a0ni\u00f1 os\u00a0menores\u00a0de\u00a02\u00a0a\u00f1os,\u00a0presentan\u00a0\nimportantes\u00a0diferencias\u00a0fenot\u00edpicas,\u00a0respecto\u00a0a\u00a0los\u00a0linfocitos\u00a0 B\u00a0de\u00a0memoria\u00a0de\u00a0ni\u00f1os\u00a0mayores\u00a0de\u00a0\ndos\u00a0a\u00f1os\u00a0y\u00a0de\u00a0adultos,\u00a0con\u00a0patrones\u00a0fenot\u00edpicos\u00a0que\u00a0implican\u00a0di stinto\u00a0perfil\u00a0de\u00a0expresi\u00f3n\u00a0de\u00a0\nmarcadores\u00a0funcionales\u00a0potencialmente\u00a0relacionados\u00a0con\u00a0la\u00a0madur aci\u00f3n\u00a0de\u00a0otros\u00a0componentes\u00a0\ndel\u00a0sistema\u00a0inmune,\u00a0como\u00a0el\u00a0CG\u00a0de\u00a0los\u00a0OLS\u00a0(i.e.\u00a0CD21\u00a0y\u00a0CD27).\u00a0A s\u00ed,\u00a0los\u00a0pocos\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0detectados\u00a0en\u00a0sangre\u00a0de\u00a0cord\u00f3n\u00a0y\u00a0de\u00a0reci\u00e9n\u00a0nacidos,\u00a0se\u00a0 caracterizaron\u00a0por\u00a0carecer\u00a0de\u00a0\nexpresi\u00f3n\u00a0de\u00a0CD27,\u00a0una\u00a0mol\u00e9cula\u00a0co\u2010estimuladora\u00a0cuya\u00a0expresi\u00f3n\u00a0 est\u00e1\u00a0relacionada\u00a0con\u00a0la\u00a0\nrespuesta\u00a0B\u00a0del\u00a0CG\u00a0depen diente\u00a0de\u00a0linfocitos\u00a0T111,123.\u00a0De\u00a0acuerdo\u00a0con\u00a0estos\u00a0 resultados,\u00a0estudios\u00a0\nrealizados\u00a0en\u00a0tejidos\u00a0procedentes\u00a0de\u00a0OLS\u00a0han\u00a0demostrado\u00a0la\u00a0ause ncia\u00a0de\u00a0CGs\u00a0durante\u00a0la\u00a0vida\u00a0\nfetal\u00a0y\u00a0en\u00a0reci\u00e9n\u00a0nacidos157,158,445.\u00a0Esto\u00a0est\u00e1\u00a0de\u00a0acuerdo\u00a0con\u00a0la\u00a0expansi\u00f3n\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0CD27+\u00a0observada\u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0primer\u00a0a\u00f1o\u00a0de\u00a0vida.\u00a0\nEn\u00a0paralelo\u00a0con\u00a0el\u00a0aumento\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0CD27+\u00a0observado\u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0\nprimer\u00a0a\u00f1o\u00a0de\u00a0vida,\u00a0se\u00a0produce\u00a0tambi\u00e9n\u00a0un\u00a0aumento\u00a0de\u00a0los\u00a0linfoc itos\u00a0B\u00a0de\u00a0memoria\u00a0CD21\u2010\u00a0\n( r e c e p t o r \u00a0d e \u00a0C 3 b ) , \u00a0a s o c i a d o s \u00a0a \u00a0u n a \u00a0m e n o r \u00a0c a p a c i d a d \u00a0d e \u00a0r e s p o n d e r \u00a0f r e n t e \u00a0a \u00a0c o m p l e j o s \u00a0\ncomplemento\u2010polisac\u00e1rido446,447.\u00a0Pese\u00a0a\u00a0este\u00a0aumento\u00a0de\u00a0los\u00a0 linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0CD21\u2010,\u00a0el\u00a0\nporcentaje\u00a0de\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0CD21\u2010\u00a0permanec\u00eda\u00a0estable\u00a0durante\u00a0este\u00a0periodo,\u00a0siendo\u00a0la\u00a0\nrespuesta\u00a0 in\u00a0vitro\u00a0a\u00a0polisac\u00e1ridos\u00a0por\u00a0parte\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0de\u00a0estos\u00a0n i\u00f1os,\u00a0comparable\u00a0Discusi\u00f3n \n\u2010\u00a0159\u00a0\u2010\u00a0\n\u00a0a\u00a0la\u00a0observada\u00a0en\u00a0adultos448.\u00a0En\u00a0conjunto,\u00a0estos\u00a0hallazgos\u00a0sugirieren\u00a0que\u00a0podr\u00edan\u00a0existir\u00a0f actores\u00a0\nexternos\u00a0que\u00a0afectan\u00a0al\u00a0reconocimiento\u00a0del\u00a0Ag\u00a0y\u00a0que\u00a0contribuyen \u00a0a\u00a0aumentar\u00a0la\u00a0producci\u00f3n\u00a0de\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0expresi\u00f3n\u00a0deficitaria\u00a0del\u00a0receptor\u00a0 de\u00a0C3d\u00a0en\u00a0ni\u00f1os\u00a0de\u00a0hasta\u00a0\u22481\u00a0a\u00f1o\u00a0\nde\u00a0vida,\u00a0momento\u00a0en\u00a0el\u00a0que\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0C3\u00a0alcanzan\u00a0l os\u00a0valores\u00a0observados\u00a0en\u00a0\nadultos449.\u00a0De\u00a0acuerdo\u00a0con\u00a0estos\u00a0datos,\u00a0cabr\u00eda\u00a0plantearse\u00a0la\u00a0posibilidad\u00a0 de\u00a0que\u00a0durante\u00a0el\u00a0primer\u00a0\na\u00f1o\u00a0de\u00a0vida\u00a0la\u00a0disponibilidad\u00a0relativamente\u00a0limitada\u00a0de\u00a0C3d\u00a0y\u00a0d e\u00a0complejos\u00a0C3d\u2010Ag,\u00a0contribuyese\u00a0\na\u00a0 reducir\u00a0 la\u00a0 se\u00f1alizaci\u00f3n\u00a0 necesaria\u00a0 para\u00a0 la\u00a0 expresi\u00f3n\u00a0 de\u00a0 este\u00a0 r eceptor\u00a0 B\u00a0 durante\u00a0 el\u00a0\nreconocimiento\u00a0 antig\u00e9nico,\u00a0 lo\u00a0 cual\u00a0 ocasionar\u00eda\u00a0 el\u00a0 incremento\u00a0 ob servado\u00a0 de\u00a0 c\u00e9lulas\u00a0 B\u00a0 de\u00a0\nmemoria\u00a0CD21+\u00a0a\u00a0partir\u00a0de\u00a0entonces.\u00a0\n\u00a0A\u00a0diferencia\u00a0de\u00a0lo\u00a0comentado\u00a0en \u00a0ni\u00f1os,\u00a0en\u00a0adultos\u00a0no\u00a0observamo s\u00a0cambios\u00a0en\u00a0las\u00a0\npoblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0CD27\u00a0y/o\u00a0CD21,\u00a0a\u00a0pesar\u00a0de\u00a0q ue\u00a0estudios\u00a0previos\u00a0han\u00a0\ndescrito\u00a0que\u00a0ciertas\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B,\u00a0como\u00a0las\u00a0llam adas\u00a0\u201cc\u00e9lulas\u00a0de\u00a0memoria\u00a0at\u00edpicas\u201d\u00a0\n(CD27\u2010CD21\u2010)\u00a0 o\u00a0 los\u00a0 linfocitos\u00a0 B\u00a0 CD11c+\u00a0 (que\u00a0 en\u00a0 nuestro\u00a0 estudio\u00a0 y\u00a0 en\u00a0 otros\u00a0 estudios\u00a0 se\u00a0\ncorresponden\u00a0con\u00a0los\u00a0linfocitos\u00a0B\u00a0CD21\u201053)\u00a0aumentar\u00edan\u00a0durante\u00a0el\u00a0envejecimiento129,450.\u00a0No\u00a0\nobstante,\u00a0no\u00a0podemos\u00a0descartar\u00a0l a\u00a0existencia\u00a0de\u00a0otros\u00a0marcadore s\u00a0fenot\u00edpicos\u00a0o\u00a0de\u00a0otras\u00a0\npoblaciones\u00a0celulares\u00a0B,\u00a0que\u00a0puedan\u00a0contribuir\u00a0a\u00a0entender\u00a0mejor \u00a0los\u00a0cambios\u00a0en\u00a0la\u00a0inmunidad\u00a0\nde\u00a0los\u00a0linfocitos\u00a0B\u00a0que\u00a0ocurren\u00a0en\u00a0edades\u00a0avanzadas\u00a0y/o\u00a0durante \u00a0el\u00a0envejecimiento.\u00a0En\u00a0este\u00a0\nsentido,\u00a0estudios\u00a0recientes\u00a0de\u00a0nuestro\u00a0grupo\u00a0sugieren\u00a0que\u00a0el\u00a0\u201cf enotipo\u00a0envejeci do\u201d\u00a0del\u00a0sistema\u00a0\ninmune,\u00a0podr\u00eda\u00a0estar\u00a0relacionado\u00a0con\u00a0cambios\u00a0derivados\u00a0de\u00a0la\u00a0ex pansi\u00f3n\u00a0de\u00a0peque\u00f1os\u00a0clones\u00a0\nde\u00a0c\u00e9lulas\u00a0B\u00a0con\u00a0fenotipo\u00a0predominantemente\u00a0similar\u00a0al\u00a0de\u00a0la\u00a0le ucemia\u00a0linf\u00e1tica\u00a0cr\u00f3nica\u00a0(LLC)\u00a0y\u00a0\nque\u00a0afectan\u00a0a\u00a0>20%\u00a0de\u00a0los\u00a0sujetos\u00a0mayores\u00a0de\u00a070\u00a0a\u00f1os439.\u00a0\nEn\u00a0conjunto,\u00a0estos\u00a0resultados\u00a0s ugieren\u00a0que\u00a0las\u00a0caracter\u00edsticas\u00a0 fenot\u00edpicas\u00a0y\u00a0la\u00a0capacidad\u00a0\nfuncional\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0podr\u00edan\u00a0verse\u00a0afectado s\u00a0por\u00a0la\u00a0maduraci\u00f3n\u00a0de\u00a0otros\u00a0\ncomponentes\u00a0de\u00a0la\u00a0respuesta\u00a0inmu ne,\u00a0como\u00a0los\u00a0niveles\u00a0de\u00a0prote\u00edn as\u00a0del\u00a0complemento\u00a0o\u00a0el\u00a0\nestado\u00a0de\u00a0los\u00a0CGs\u00a0en\u00a0los\u00a0tejidos\u00a0linfoides.\u00a0Adem\u00e1s,\u00a0la\u00a0posici\u00f3n \u00a0del\u00a0isotipo\u00a0y\u00a0de\u00a0la\u00a0subclase\u00a0de\u00a0Ig\u00a0\nen\u00a0el\u00a0gen\u00a0 IGHC\u00a0parece\u00a0tener\u00a0un\u00a0importante\u00a0papel\u00a0en\u00a0las\u00a0caracter\u00edsticas\u00a0fenot\u00edp icas\u00a0y\u00a0funcionales\u00a0Discusi\u00f3n \n\u00a0\n\u2010\u00a0160\u00a0\u2010\u00a0\n\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria,\u00a0ya\u00a0que\u00a0aquellos\u00a0que\u00a0expresan\u00a0lo s\u00a0isotipos\u00a0m\u00e1s\u00a0cercanos\u00a0a\u00a0la\u00a0\nregi\u00f3n\u00a0V(D)J\u00a0(e.g.\u00a0IgG3)\u00a0contienen\u00a0mayor\u00a0porcentaje\u00a0de\u00a0c\u00e9lulas\u00a0CD27\u2010CD21\u2010,\u00a0frente\u00a0a\u00a0aquellos\u00a0\nisotipos\u00a0y\u00a0subclases\u00a0localizadas\u00a0al\u00a0final\u00a0del\u00a0gen\u00a0 IGHC\u00a0(e.g.\u00a0IgG2),\u00a0independientemente\u00a0de\u00a0la\u00a0edad\u00a0\ndel\u00a0individuo.\u00a0\u00a0\nEn\u00a0definitiva,\u00a0con\u00a0el\u00a0trabajo\u00a0re alizado\u00a0y\u00a0en\u00a0base\u00a0a\u00a0los\u00a0resulta dos\u00a0obtenidos\u00a0podemos\u00a0\nafirmar\u00a0que,\u00a0a\u00a0pesar\u00a0de\u00a0que\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0Acs\u00a0proporci onan\u00a0una\u00a0informaci\u00f3n\u00a0valiosa\u00a0\nacerca\u00a0del\u00a0estado\u00a0de\u00a0las\u00a0CPs\u00a0de\u00a0vida\u00a0larga\u00a0de\u00a0MO,\u00a0y\u00a0presumiblem ente\u00a0tambi\u00e9n\u00a0del\u00a0MALT,\u00a0estos\u00a0\nprobablemente\u00a0no\u00a0reflejan\u00a0de\u00a0forma\u00a0adecuada\u00a0el\u00a0estado\u00a0de\u00a0la\u00a0res puesta\u00a0B\u00a0de\u00a0un\u00a0individuo\u00a0en\u00a0\nt i e m p o \u00a0r e a l . \u00a0P o r \u00a0e l \u00a0c o n t r a r i o , \u00a0e l \u00a0p i c o \u00a0d e \u00a0p r o d u c c i \u00f3 n \u00a0d e \u00a0C P s \u00a0c i r culantes\u00a0 que\u00a0 preced\u00eda\u00a0 en\u00a0\na\u00f1os/d\u00e9cadas\u00a0a\u00a0la\u00a0producci\u00f3n\u00a0de\u00a0 linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0nivel es\u00a0s\u00e9ricos\u00a0m\u00e1ximos\u00a0de\u00a0Acs,\u00a0\nsugiere\u00a0 que\u00a0 la\u00a0 evaluaci\u00f3n\u00a0 cuantitativa\u00a0 de\u00a0 esta\u00a0 poblaci\u00f3n\u00a0 B\u00a0 en\u00a0 S P\u00a0 podr\u00eda\u00a0 proporcionar\u00a0\ninformaci\u00f3n\u00a0 m\u00e1s\u00a0 fiable\u00a0 del\u00a0 estad o\u00a0 de\u00a0 la\u00a0 respuesta\u00a0 B\u00a0 de\u00a0 un\u00a0 indiv iduo\u00a0 en\u00a0 un\u00a0 momento\u00a0\ndeterminado,\u00a0especialmente\u00a0si\u00a0tenemos\u00a0en\u00a0cuenta\u00a0su\u00a0elevada\u00a0tasa \u00a0de\u00a0recambio.\u00a0Adem\u00e1s,\u00a0la\u00a0\nacumulaci\u00f3n\u00a0 progresiva\u00a0 a\u00a0 lo\u00a0 largo\u00a0 de\u00a0 la\u00a0 vida\u00a0 de\u00a0 linfocitos\u00a0 B\u00a0 de \u00a0m e m o r i a \u00a0q u e \u00a0e x p r e s a n \u00a0\nisotipos/subclases\u00a0de\u00a0Igs\u00a0codificadas\u00a0por\u00a0los\u00a0segmentos\u00a0del\u00a0gen \u00a0IGHC\u00a0m\u00e1s\u00a0alejados\u00a0de\u00a0V(D)J,\u00a0\ns u g i e r e n \u00a0l a \u00a0e x i s t e n c i a \u00a0d e \u00a0c i c l o s \u00a0d e \u00a0c a m b i o s \u00a0d e \u00a0i s o t i p o \u00a0c o n s e c u t ivos,\u00a0 que\u00a0 ocasionan\u00a0 la\u00a0\nacumulaci\u00f3n\u00a0 de\u00a0 linfocitos\u00a0 B\u00a0 de\u00a0 memoria\u00a0 que\u00a0 expresan\u00a0 isotipos\u00a0 y\u00a0 subclases\u00a0 de\u00a0 Igs\u00a0 m\u00e1s\u00a0\ntolerog\u00e9nicas\u00a0 en\u00a0 individuos\u00a0 de\u00a0 e dad\u00a0 m\u00e1s\u00a0 avanzada.\u00a0 Finalmente,\u00a0 c on\u00a0 este\u00a0 trabajo\u00a0\nproporcionamos\u00a0por\u00a0primera\u00a0vez,\u00a0 valores\u00a0de\u00a0normalidad\u00a0por\u00a0grupo \u00a0de\u00a0edad\u00a0para\u00a0las\u00a0m\u00faltiples\u00a0\nsubpoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0CPs\u00a0de\u00a0SP\u00a0que\u00a0expre san\u00a0diferentes\u00a0isotipos\u00a0y\u00a0\nsubclases\u00a0de\u00a0Igs;\u00a0esto\u00a0proporciona\u00a0un\u00a0marco\u00a0de\u00a0referencia\u00a0para\u00a0 el\u00a0estudio\u00a0de\u00a0pacientes\u00a0con\u00a0IDP\u2010\nAc\u00a0 y\u00a0 otras\u00a0 enfermedades\u00a0 en\u00a0 las\u00a0 que\u00a0 est\u00e1\u00a0 implicada\u00a0 la\u00a0 respuesta\u00a0 B,\u00a0 como\u00a0 la\u00a0 alergia,\u00a0\nautoinmunidad,\u00a0infecciones\u00a0y\u00a0c\u00e1ncer439.\u00a0\n\u00a0\u00a0Discusi\u00f3n \n\u2010\u00a0161\u00a0\u2010\u00a0\n\u00a03.\u00a0Distribuci\u00f3n\u00a0de\u00a0las\u00a0distintas\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de \u00a0memoria\u00a0y\u00a0CPs\u00a0de\u00a0sangre\u00a0en\u00a0\npacientes\u00a0con\u00a0IDP\u2010Ac.\u00a0\n\u00a0Una\u00a0vez\u00a0validada\u00a0la\u00a0metodolog\u00eda\u00a0desarrollada\u00a0para\u00a0una\u00a0disecci\u00f3n \u00a0detallada\u00a0de\u00a0las\u00a0\ndistintas\u00a0subpoblaciones\u00a0B\u00a0de\u00a0SP,\u00a0y\u00a0establecidos\u00a0los\u00a0valores\u00a0de \u00a0referencia\u00a0de\u00a0normalidad\u00a0por\u00a0\ngrupo\u00a0de\u00a0edad,\u00a0nuestro\u00a0inter\u00e9s\u00a0se\u00a0centr\u00f3\u00a0en\u00a0determinar\u00a0las\u00a0posi bles\u00a0alteraciones\u00a0de\u00a0dichas\u00a0\npoblaciones\u00a0 de\u00a0 linfocitos\u00a0 B\u00a0 y\u00a0 de\u00a0 CPs\u00a0 circulantes\u00a0 en\u00a0 pacientes\u00a0 c on\u00a0 diferentes\u00a0 subtipos\u00a0\ndiagn\u00f3sticos\u00a0de\u00a0IDP\u2010Ac,\u00a0incluyendo\u00a0como\u00a0entidades\u00a0m\u00e1s\u00a0prevalent es\u00a0el\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA,\u00a0\nel\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0asociado\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0IgA,\u00a0y\u00a0la\u00a0 IDVC.\u00a0\u00a0\nEn\u00a0t\u00e9rminos\u00a0globales,\u00a0la\u00a0edad\u00a0de\u00a0los\u00a0pacientes\u00a0estudiados\u00a0oscil \u00f3\u00a0entre\u00a0los\u00a04\u00a0a\u00f1os\u00a0y\u00a0los\u00a090\u00a0\na\u00f1os.\u00a0De\u00a0acuerdo\u00a0con\u00a0los\u00a0resultados\u00a0obtenidos\u00a0en\u00a0el\u00a0apartado\u00a0an terior,\u00a0y\u00a0las\u00a0variaciones\u00a0\nobservadas\u00a0en\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0las\u00a0distintas\u00a0poblaciones\u00a0de\u00a0c \u00e9lulas\u00a0B\u00a0en\u00a0SP\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida,\u00a0\npara\u00a0 la\u00a0 identificaci\u00f3n\u00a0 adecuada\u00a0 de\u00a0 una\u00a0 distribuci\u00f3n\u00a0 alterada\u00a0 de \u00a0 dichas\u00a0 poblaciones\u00a0 B\u00a0 en\u00a0\nindividuos\u00a0con\u00a0IDP\u2010Ac\u00a0se\u00a0requer\u00eda\u00a0de\u00a0forma\u00a0sistem\u00e1tica,\u00a0de\u00a0la\u00a0c omparaci\u00f3n\u00a0con\u00a0los\u00a0valores\u00a0de\u00a0\nreferencia\u00a0de\u00a0normalidad\u00a0establecidos,\u00a0pareados\u00a0por\u00a0grupo\u00a0de\u00a0ed ad.\u00a0Con\u00a0esta\u00a0aproximaci\u00f3n,\u00a0\ntodos\u00a0los\u00a0pacientes\u00a0analizados\u00a0 que\u00a0presentaban\u00a0IDP\u2010Ac,\u00a0mostraro n\u00a0n\u00fameros\u00a0reducidos\u00a0respecto\u00a0\na\u00a0donantes\u00a0sanos\u00a0del\u00a0mismo\u00a0grupo\u00a0etario\u00a0de\u00a0al\u00a0menos\u00a0una\u00a0poblaci \u00f3n\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0\ny/o\u00a0CPs\u00a0definidas\u00a0en\u00a0base\u00a0a\u00a0la\u00a0expresi\u00f3n\u00a0de\u00a0distintas\u00a0subclases \u00a0de\u00a0IgG\u00a0e\u00a0IgA.\u00a0Esta\u00a0elevada\u00a0\nprevalencia\u00a0de\u00a0alteraciones\u00a0B\u00a0co ntrasta\u00a0con\u00a0los\u00a0resultados\u00a0de\u00a0e studios\u00a0previos,\u00a0en\u00a0los\u00a0que\u00a0se\u00a0\nhab\u00eda\u00a0analizado\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0las\u00a0subpoblaciones\u00a0de\u00a0linfoc itos\u00a0B\u00a0de\u00a0pacientes\u00a0con\u00a0IDP\u2010Ac\u00a0\nutilizando\u00a0citometr\u00eda\u00a0de\u00a0flujo,\u00a0y\u00a0 en\u00a0los\u00a0que\u00a0solamente\u00a0se\u00a0logra ron\u00a0identificar\u00a0defectos\u00a0en\u00a0las\u00a0\nc\u00e9lulas\u00a0B\u00a0del\u00a06\u201086%\u00a0de\u00a0los\u00a0casos,\u00a0incluyendo\u00a077\u201086%\u00a0de\u00a0los\u00a0paci entes\u00a0con\u00a0IDVC137,196,250,284\u2013287,\u00a0\n\u224830%\u00a0de\u00a0los\u00a0sujetos\u00a0con\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0(con\u00a0o\u00a0sin\u00a0 d\u00e9ficit\u00a0de\u00a0IgA\u00a0asociado)285\u00a0y\u00a06\u201025%\u00a0\nde\u00a0los\u00a0casos\u00a0que\u00a0presentaban\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA378,379.\u00a0La\u00a0mayor\u00a0sensibilidad\u00a0observada\u00a0en\u00a0\nnuestro\u00a0estudio,\u00a0probablemente\u00a0sea\u00a0debida\u00a0a\u00a0que\u00a0el\u00a0n\u00famero\u00a0de\u00a0po blaciones\u00a0evaluadas\u00a0en\u00a0\nestudios\u00a0previos\u00a0era\u00a0mucho\u00a0m\u00e1s\u00a0limitado,\u00a0restringi\u00e9ndose\u00a0mayori tariamente\u00a0al\u00a0an\u00e1lisis\u00a0de\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0inmaduros/transiciona les\u00a0y\u00a0na\u00efve,\u00a0adem\u00e1s\u00a0del\u00a0conju nto\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0Discusi\u00f3n \n\u00a0\n\u2010\u00a0162\u00a0\u2010\u00a0\n\u00a0con\u00a0 y\u00a0 sin\u00a0 cambio\u00a0 de\u00a0 isotipo,\u00a0 y\u00a0 de\u00a0 los\u00a0 linfocitos\u00a0 B\u00a0 CD21\u2010250,286,287,378,379.\u00a0 Por\u00a0 otra\u00a0 parte,\u00a0 la\u00a0\nsensibilidad\u00a0alcanzada\u00a0con\u00a0nuestra\u00a0metodolog\u00eda\u00a0fue\u00a0tambi\u00e9n\u00a0clar amente\u00a0superior\u00a0a\u00a0la\u00a0de\u00a0dichos\u00a0\nestudios\u00a0previos250,285,286,379,380,\u00a0ya\u00a0que\u00a0analizamos\u00a0un\u00a0m\u00ednimo\u00a0de\u00a05\u00a0millones\u00a0de\u00a0c\u00e9lulas\u00a0nucleada s\u00a0\nde\u00a0SP\u00a0(vs.\u00a0\u2264500.000)\u00a0por\u00a0paciente.\u00a0Finalmente,\u00a0cabe\u00a0se\u00f1alar\u00a0que\u00a0en\u00a0la\u00a0may or\u00eda\u00a0de\u00a0los\u00a0estudios\u00a0\nprevios,\u00a0no\u00a0se\u00a0tuvieron\u00a0en\u00a0cuent a\u00a0los\u00a0cambios\u00a0que\u00a0se\u00a0producen\u00a0e n\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0las\u00a0\ndiferentes\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida250,286,287,378,379,\u00a0lo\u00a0cual\u00a0podr\u00eda\u00a0influir\u00a0\ntambi\u00e9n\u00a0en\u00a0la\u00a0diferente\u00a0sensibilid ad\u00a0obtenida\u00a0en\u00a0estos\u00a0trabajos \u00a0respecto\u00a0a\u00a0la\u00a0descrita\u00a0aqu\u00ed.\u00a0\u00a0\nDe\u00a0acuerdo\u00a0con\u00a0la\u00a0hip\u00f3tesis\u00a0planteada\u00a0acerca\u00a0de\u00a0la\u00a0posibilidad\u00a0 de\u00a0que\u00a0las\u00a0CPs\u00a0circulantes\u00a0\npudieran\u00a0constituir\u00a0el\u00a0marcador\u00a0m\u00e1s\u00a0sensible\u00a0para\u00a0la\u00a0evaluaci\u00f3n \u00a0de\u00a0la\u00a0respuesta\u00a0B\u00a0en\u00a0tiempo\u00a0\nreal,\u00a0las\u00a0CPs\u00a0de\u00a0SP,\u00a0y\u00a0de\u00a0forma\u00a0especial\u00a0las\u00a0CPs\u00a0IgA+,\u00a0representaron\u00a0la\u00a0poblaci\u00f3n\u00a0celular\u00a0m\u00e1s\u00a0\nsensible\u00a0para\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0I DP\u2010Ac,\u00a0ya\u00a0que\u00a0se\u00a0encontraban\u00a0d isminuidas\u00a0num\u00e9ricamente\u00a0en\u00a0\nla\u00a0pr\u00e1ctica\u00a0totalidad\u00a0(98%)\u00a0de\u00a0los\u00a0pacientes\u00a0analizados.\u00a0La\u00a0\u00fani ca\u00a0excepci\u00f3n\u00a0la\u00a0constituyeron\u00a0dos\u00a0\ncasos\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0que\u00a0presentaban\u00a0valores\u00a0norm ales\u00a0de\u00a0CPs\u00a0circulantes,\u00a0tanto\u00a0\nIgA1+\u00a0como\u00a0IgA2+,\u00a0asociados\u00a0a\u00a0un\u00a0descenso\u00a0del\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria \u00a0IgA1+\u00a0e\u00a0IgA2+.\u00a0\nAdem\u00e1s,\u00a0exist\u00edan\u00a0importantes\u00a0diferencias\u00a0en\u00a0el\u00a0patr\u00f3n\u00a0de\u00a0altera ciones\u00a0detectado\u00a0en\u00a0los\u00a0distintos\u00a0\nsubtipos\u00a0diagn\u00f3sticos\u00a0de\u00a0IDP\u2010Ac.\u00a0\u00a0\nEn\u00a0l\u00edneas\u00a0generales,\u00a0las\u00a0alteraciones\u00a0observadas\u00a0en\u00a0los\u00a0pacient es\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0\nIgA\u00a0estaban\u00a0restringidas\u00a0a\u00a0los\u00a0linfocitos\u00a0B\u00a0IgA+\u00a0y\u00a0las\u00a0CPs\u00a0IgA+,\u00a0sin\u00a0que\u00a0en\u00a0estos\u00a0pacientes\u00a0se\u00a0\nobservaran\u00a0d\u00e9ficits\u00a0significativo s\u00a0en\u00a0los\u00a0compartimentos\u00a0de\u00a0c\u00e9l ulas\u00a0IgG+\u00a0o\u00a0en\u00a0las\u00a0poblaciones\u00a0pre\u2010\nCG.\u00a0Sin\u00a0embargo,\u00a0a\u00a0pesar\u00a0de\u00a0los\u00a0defectos\u00a0observados\u00a0en\u00a0los\u00a0linf ocitos\u00a0B\u00a0de\u00a0memoria\u00a0IgA+\u00a0y\u00a0las\u00a0\nCPs\u00a0IgA+,\u00a0cerca\u00a0de\u00a0la\u00a0mitad\u00a0de\u00a0los\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0I gA\u00a0mostraron\u00a0niveles\u00a0\ndetectables\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0IgA+\u00a0y\u00a0de\u00a0CPs\u00a0IgA+.\u00a0De\u00a0acuerdo\u00a0con\u00a0estos\u00a0resultados,\u00a0en\u00a0\nun\u00a0estudio\u00a0previo\u00a0se\u00a0hab\u00eda\u00a0mostrado\u00a0tambi\u00e9n\u00a0que\u00a0en\u00a02\u00a0de\u00a04\u00a0pacie ntes\u00a0estudiados\u00a0con\u00a0d\u00e9ficit\u00a0\nselectivo\u00a0de\u00a0IgA,\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0SP\u00a0presentaban\u00a0expresi\u00f3n\u00a0 de\u00a0las\u00a0regiones\u00a0S\u00b5\u2010S\u03b1,\u00a0lo\u00a0cual\u00a0\napoyar\u00eda\u00a0la\u00a0existencia\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0IgA+\u00a0en\u00a0estos\u00a0sujetos451.\u00a0Adem\u00e1s,\u00a0recientemente\u00a0se\u00a0ha\u00a0\nidentificado\u00a0mediante\u00a0citometr\u00eda\u00a0de\u00a0flujo\u00a0la\u00a0presencia\u00a0de\u00a0linfo citos\u00a0B\u00a0de\u00a0memoria\u00a0IgA+\u00a0en\u00a0SP\u00a0de\u00a0Discusi\u00f3n \n\u2010\u00a0163\u00a0\u2010\u00a0\n\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0de\u00a0IgA,\u00a0aunque\u00a0en\u00a0este\u00a0estudio\u00a0dichas\u00a0c\u00e9l ulas\u00a0solo\u00a0estaban\u00a0presentes\u00a0en\u00a0\n<10%\u00a0de\u00a0los\u00a0pacientes\u00a0evaluados380,\u00a0probablemente\u00a0debido\u00a0a\u00a0que\u00a0solo\u00a0se\u00a0analizaron\u00a0en\u00a0cada\u00a0\ncaso\u00a0\u22485x104\u00a0leucocitos380,\u00a0frente\u00a0a\u00a0los\u00a0\u22655x106\u00a0evaluados\u00a0en\u00a0nuestro\u00a0trabajo.\u00a0Desde\u00a0el\u00a0punto\u00a0de\u00a0\nvista\u00a0cl\u00ednico,\u00a0los\u00a0pacientes\u00a0que \u00a0mostraron\u00a0una\u00a0capacidad\u00a0de\u00a0cam bio\u00a0de\u00a0isotipo\u00a0a\u00a0IgA\u00a0preservada,\u00a0\npresentaban\u00a0 un\u00a0 fenotipo\u00a0 (cl\u00ednico)\u00a0 menos\u00a0 severo,\u00a0 asociado\u00a0 a\u00a0 una\u00a0 menor\u00a0 frecuencia\u00a0 de\u00a0\nautoinmunidad\u00a0(caracter\u00edstica\u00a0que\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0puede\u00a0esta r\u00a0relacionada\u00a0con\u00a0un\u00a0mayor\u00a0\nriesgo\u00a0de\u00a0progresi\u00f3n\u00a0a\u00a0IDVC354,355),\u00a0de\u00a0infecciones\u00a0no\u2010respiratorias\u00a0y\u00a0de\u00a0antecedentes\u00a0familiares \u00a0\nde\u00a0IDP\u2010Ac.\u00a0Por\u00a0lo\u00a0tanto,\u00a0podr\u00edamos\u00a0concluir\u00a0que\u00a0la\u00a0evaluaci\u00f3n\u00a0d etallada\u00a0de\u00a0los\u00a0defectos\u00a0de\u00a0\nlinfocitos\u00a0B\u00a0y\u00a0CPs\u00a0de\u00a0SP\u00a0de\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0 IgA,\u00a0podr\u00eda\u00a0contribuir\u00a0a\u00a0una\u00a0mejor\u00a0\nsubclasificaci\u00f3n\u00a0y\u00a0manejo\u00a0c l\u00ednico\u00a0de\u00a0estos\u00a0pacientes.\u00a0\nAl\u00a0contrario\u00a0de\u00a0lo\u00a0que\u00a0ocurr\u00eda\u00a0en\u00a0sujetos\u00a0con\u00a0d\u00e9ficit\u00a0selectivo \u00a0de\u00a0IgA,\u00a0los\u00a0pacientes\u00a0con\u00a0\nIDVC\u00a0mostraron\u00a0alteraciones\u00a0que\u00a0 afectaban\u00a0tanto\u00a0a\u00a0los\u00a0compartim entos\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0IgA+\u00a0como\u00a0\nIgG+.\u00a0De\u00a0hecho,\u00a0la\u00a0ausencia\u00a0de\u00a0CPs\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u00a0(tanto\u00a0IgA+\u00a0como\u00a0IgG+)\u00a0fue\u00a0una\u00a0\ncaracter\u00edstica\u00a0com\u00fan\u00a0a\u00a0todos\u00a0los\u00a0pacientes\u00a0con\u00a0IDVC,\u00a0hallazgo\u00a0q ue\u00a0est\u00e1\u00a0de\u00a0acuerdo\u00a0con\u00a0estudios\u00a0\nprevios\u00a0que\u00a0han\u00a0demostrado\u00a0la\u00a0existencia\u00a0de\u00a0defectos\u00a0en\u00a0las\u00a0CPs \u00a0de\u00a0MO283,\u00a0ganglio\u00a0linf\u00e1tico298\u00a0y\u00a0\nSP284\u00a0de\u00a0estos\u00a0sujetos.\u00a0Por\u00a0otro\u00a0lado,\u00a0varios\u00a0autores\u00a0han\u00a0descrito\u00a0t ambi\u00e9n\u00a0defectos\u00a0en\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u00a0en\u00a0pacientes\u00a0con\u00a0 IDVC,\u00a0habiendo\u00a0relacionado\u00a0\nadem\u00e1s\u00a0 estas\u00a0 alteraciones,\u00a0 con\u00a0 un\u00a0 comportamiento\u00a0 cl\u00ednico\u00a0 m\u00e1s\u00a0 se vero\u00a0 de\u00a0 la\u00a0\nenfermedad250,281,284,286,287.\u00a0 Nuestro\u00a0 trabajo\u00a0 constituye\u00a0 el\u00a0 primer\u00a0 estudio\u00a0 en\u00a0 el\u00a0 que\u00a0 se\u00a0 ha\u00a0\ndiseccionado\u00a0el\u00a0compartimento\u00a0de\u00a0 los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0co n\u00a0cambio\u00a0de\u00a0isotipo\u00a0en\u00a0funci\u00f3n\u00a0\nde\u00a0la\u00a0subclase\u00a0concreta\u00a0de\u00a0Ig\u00a0expresada,\u00a0de\u00a0forma\u00a0similar\u00a0a\u00a0lo\u00a0 realizado\u00a0de\u00a0manera\u00a0rutinaria\u00a0para\u00a0\nel\u00a0an\u00e1lisis\u00a0de\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0IgG1\u20104.\u00a0De\u00a0este\u00a0modo,\u00a0ide ntificamos\u00a0un\u00a0deterioro\u00a0progresivo\u00a0\nde\u00a0la\u00a0capacidad\u00a0de\u00a0cambio\u00a0de\u00a0isotipo\u00a0de\u00a0IgG\u00a0de\u00a0los\u00a0linfocitos\u00a0B \u00a0de\u00a0memoria\u00a0de\u00a0estos\u00a0pacientes,\u00a0\nque\u00a0afectaba\u00a0de\u00a0forma\u00a0secuencial\u00a0a\u00a0IgG2>IgG1>IgG3>IgM,\u00a0siguiend o\u00a0una\u00a0trayectoria\u00a0inversa\u00a0a\u00a0la\u00a0\nde\u00a0la\u00a0localizaci\u00f3n\u00a0de\u00a0estos\u00a0isotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs\u00a0en\u00a0el\u00a0g en\u00a0IGHC.\u00a0De\u00a0acuerdo\u00a0con\u00a0estos\u00a0\nhallazgos,\u00a0previamente\u00a0se\u00a0hab\u00eda\u00a0descrito\u00a0ya\u00a0un\u00a0patr\u00f3n\u00a0similar\u00a0d e\u00a0frecuencia\u00a0de\u00a0expresi\u00f3n\u00a0de\u00a0Discusi\u00f3n \n\u00a0\n\u2010\u00a0164\u00a0\u2010\u00a0\n\u00a0ARNm\u00a0para\u00a0los\u00a0diferentes\u00a0isotipos/subclases\u00a0de\u00a0Igs\u00a0en\u00a0c\u00e9lulas\u00a0B \u00a0de\u00a0SP\u00a0de\u00a0pacientes\u00a0con\u00a0IDVC:\u00a0\nIgG4<IgA2<IgA1<IgG2<IgG1\u2264IgG3<IgM287.\u00a0\u00a0\nCom o\u00a0h em os\u00a0c om ent ad o\u00a0p reviam en te ,\u00a0varios\u00a0estudios,\u00a0incluido\u00a0el\u00a0 nuestro452,\u00a0han\u00a0\nsugerido\u00a0que,\u00a0en\u00a0el\u00a0gen\u00a0 IGHC,\u00a0las\u00a0subclases\u00a0de\u00a0Igs\u00a0m\u00e1s\u00a0alejadas\u00a0de\u00a0V(D)J\u00a0se\u00a0producir\u00edan,\u00a0al \u00a0menos\u00a0\nen\u00a0parte,\u00a0por\u00a0cambios\u00a0de\u00a0isotipo\u00a0y\u00a0subclase\u00a0consecutivos,\u00a0duran te\u00a0ciclos\u00a0repetidos\u00a0de\u00a0re\u2010\nencuentro\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0su\u00a0correspondiente \u00a0Ag95\u201397,111.\u00a0Estos\u00a0hallazgos,\u00a0\njunto\u00a0con\u00a0conocimientos\u00a0recientes\u00a0derivados\u00a0de\u00a0la\u00a0secuenciaci\u00f3n \u00a0del\u00a0genoma\u00a0completo\u00a0de\u00a0\npacientes\u00a0con\u00a0IDVC,\u00a0sugieren\u00a0que\u00a0el\u00a0deterioro\u00a0observado\u00a0en\u00a0el\u00a0c ambio\u00a0de\u00a0isotipo\u00a0consecutivo\u00a0a\u00a0\nl o \u00a0l a r g o \u00a0d e l \u00a0g e n \u00a0 IGHC\u00a0e n \u00a0l a \u00a0I D V C , \u00a0p o d r \u00ed a \u00a0s e r \u00a0d e b i d o \u00a0a \u00a0u n a \u00a0c o m b i n a c i \u00f3 n \u00a0d e \u00a0v a r i a n t e s \u00a0\nhipom\u00f3rficas/perjudiciales268,271,\u00a0 genes\u00a0 haploinsuficientes272,453\u2013455\u00a0 y/o\u00a0 modificaciones\u00a0\nepigen\u00e9ticas278\u00a0que\u00a0afecten\u00a0a\u00a0las\u00a0rutas\u00a0de\u00a0se\u00f1alizaci\u00f3n\u00a0implicadas\u00a0en\u00a0la\u00a0respu esta\u00a0de\u00a0los\u00a0linfocitos\u00a0\nB\u00a0a\u00a0Ag,\u00a0m\u00e1s\u00a0que\u00a0a\u00a0un\u00a0defecto\u00a0gen\u00e9tico\u00a0\u00fanico.\u00a0Estas\u00a0alteraciones \u00a0inducir\u00edan,\u00a0adem\u00e1s\u00a0de\u00a0un\u00a0defecto\u00a0\nen\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0CPs,\u00a0un\u00a0deterioro\u00a0 que\u00a0afectar\u00eda\u00a0de\u00a0forma\u00a0\nprogresiva\u00a0(y\u00a0secuencial)\u00a0a\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0memoria\u00a0que\u00a0expresan\u00a0i sotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs\u00a0\nlocalizadas\u00a0en\u00a0el\u00a0gen \u00a0IGHC\u00a0de\u00a0forma\u00a0cada\u00a0vez\u00a0m\u00e1s\u00a0cercana\u00a0a\u00a0la\u00a0regi\u00f3n\u00a0V(D)J;\u00a0esto\u00a0conlleva r\u00eda\u00a0a\u00a0la\u00a0\ndisponibilidad\u00a0de\u00a0un\u00a0repertorio\u00a0B\u00a0cada\u00a0vez\u00a0m\u00e1s\u00a0restringido\u00a0y\u00a0co n\u00a0menor\u00a0capacidad\u00a0funcional,\u00a0\ndentro\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria.\u00a0\nDe\u00a0forma\u00a0habitual,\u00a0en\u00a0los\u00a0estudios\u00a0previos\u00a0en\u00a0los\u00a0que\u00a0se\u00a0emple\u00f3 \u00a0la\u00a0citometr\u00eda\u00a0de\u00a0flujo\u00a0\npara\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0las\u00a0poblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0SP\u00a0de\u00a0pacie ntes\u00a0con\u00a0IDVC,\u00a0se\u00a0han\u00a0excluido\u00a0de\u00a0\ncualquier\u00a0an\u00e1lisis\u00a0aquellos\u00a0pacien tes\u00a0con\u00a0IDVC\u00a0que\u00a0presentaban\u00a0 <1%\u00a0de\u00a0linfocitos\u00a0B,\u00a0respecto\u00a0al\u00a0\ntotal\u00a0de\u00a0linfocitos;\u00a0esto\u00a0ha\u00a0sido\u00a0motivado\u00a0por\u00a0el\u00a0hecho\u00a0de\u00a0que\u00a0 la\u00a0metodolog\u00eda\u00a0empleada\u00a0en\u00a0estos\u00a0\ntrabajos,\u00a0no\u00a0alcanzaba\u00a0una\u00a0sensi bilidad\u00a0suficiente\u00a0para\u00a0poder\u00a0i dentificar\u00a0dentro\u00a0de\u00a0las\u00a0c\u00e9lulas\u00a0B,\u00a0\nsus\u00a0subpoblaciones\u00a0mayoritarias250,286.\u00a0Sin\u00a0embargo,\u00a0al\u00a0aumentar\u00a0la\u00a0sensibilidad\u00a0mediante\u00a0el\u00a0\nan\u00e1lisis\u00a0 de\u00a0 un\u00a0 m\u00ednimo\u00a0 de\u00a0 5\u00a0 millones\u00a0 de\u00a0 leucocitos,\u00a0 nuestros\u00a0 res ultados\u00a0 demuestran\u00a0 la\u00a0\nposibilidad,\u00a0 no\u00a0 solo\u00a0 de\u00a0 identificar,\u00a0 sino\u00a0 tambi\u00e9n\u00a0 de\u00a0 cuantifica r \u00a0d e \u00a0f o r m a \u00a0p r e c i s a , \u00a0l a s \u00a0\nsubpoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0pre\u2010CG,\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0 y\u00a0CPs\u00a0que\u00a0expresan\u00a0distintas\u00a0Discusi\u00f3n \n\u2010\u00a0165\u00a0\u2010\u00a0\n\u00a0subclases\u00a0de\u00a0IgG1\u20104\u00a0e\u00a0IgA1\u20102.\u00a0Gracias\u00a0a\u00a0ello,\u00a0pudimos\u00a0comprobar \u00a0que,\u00a0a\u00a0pesar\u00a0del\u00a0descenso\u00a0del\u00a0\nn\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u00a0caracte r\u00edstico\u00a0de\u00a0los\u00a0pacientes\u00a0con\u00a0\nIDVC,\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0casos\u00a0analizados\u00a0conservaba\u00a0la\u00a0capacida d\u00a0de\u00a0cambio\u00a0de\u00a0isotipo\u00a0de\u00a0Ig.\u00a0De\u00a0\nhecho,\u00a0incluso\u00a0en\u00a0aquellos\u00a0pacientes\u00a0clasificados\u00a0dentro\u00a0del\u00a0su btipo\u00a0de\u00a0IDVC\u00a0smB\u2010\u00a0de\u00a0acuerdo\u00a0\ncon\u00a0el\u00a0sistema\u00a0propuesto\u00a0por\u00a0EUROclass250,\u00a0y\u00a0que\u00a0se\u00a0caracterizan\u00a0por\u00a0mostrar\u00a0un\u00a0n\u00famero\u00a0muy\u00a0\nreducido\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u00a0(\u22642%\u00a0 de\u00a0todos\u00a0los\u00a0linfocitos\u00a0B),\u00a0m\u00e1s\u00a0\nde\u00a0dos\u00a0tercios\u00a0de\u00a0ellos\u00a0presentaban\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con \u00a0cambio\u00a0de\u00a0isotipo\u00a0de\u00a0Ig\u00a0en\u00a0\nniveles\u00a0detectables\u00a0en\u00a0SP;\u00a0estos \u00a0hallazgos\u00a0apoyan\u00a0los\u00a0resultado s\u00a0de\u00a0estudios\u00a0previos\u00a0en\u00a0los\u00a0que\u00a0\nse\u00a0utiliz\u00f3\u00a0la\u00a0t\u00e9cnica\u00a0de\u00a0ELISpot\u00a0para\u00a0demostrar\u00a0que\u00a0los\u00a0linfoci tos\u00a0B\u00a0de\u00a0SP\u00a0de\u00a0pacientes\u00a0con\u00a0IDVC\u00a0\nposeen\u00a0 capacidad\u00a0funcional\u00a0residual\u00a0 de\u00a0 producir\u00a0 Acs\u00a0IgG\u00a0demostr ada\u00a0in\u00a0vitro,\u00a0incluso\u00a0 en\u00a0\n(algunos)\u00a0casos\u00a0clasificados\u00a0como\u00a0smB\u2010305;\u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0terap\u00e9utico,\u00a0se\u00a0ha\u00a0sugerido\u00a0\nque\u00a0dichos\u00a0pacientes\u00a0(potencialmente)\u00a0podr\u00edan\u00a0necesitar\u00a0dosis\u00a0m enores\u00a0de\u00a0Igs\u00a0de\u00a0sustituci\u00f3n305.\u00a0\nGlobalmente,\u00a0seg\u00fan\u00a0el\u00a0patr\u00f3n\u00a0de\u00a0alteraciones\u00a0B\u00a0observado\u00a0en\u00a0la\u00a0 SP\u00a0de\u00a0pacientes\u00a0con\u00a0\nIDVC,\u00a0identificamos\u00a06\u00a0subgrupos\u00a0diferentes\u00a0asociados\u00a0con\u00a0distin tos\u00a0perfiles\u00a0cl\u00ednicos.\u00a0As\u00ed,\u00a0aquellos\u00a0\npacientes\u00a0que\u00a0manten\u00edan\u00a0la\u00a0capacidad\u00a0de\u00a0producir\u00a0linfocitos\u00a0de\u00a0 memoria\u00a0IgM/D,\u00a0IgG3\u00a0e\u00a0IgG1,\u00a0es\u00a0\ndecir,\u00a0de\u00a0producir\u00a0isotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs\u00a0codificadas\u00a0en\u00a0l as\u00a0localizaciones\u00a0m\u00e1s\u00a0cercanas\u00a0a\u00a0la\u00a0\nregi\u00f3n\u00a0V(D)J\u00a0del\u00a0gen \u00a0IGHC\u00a0(independientemente\u00a0de\u00a0los\u00a0n\u00fameros\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0\nIgG2+\u00a0e\u00a0IgA+)\u00a0(grupos\u00a01,\u00a02\u00a0y\u00a03),\u00a0presentaban\u00a0manifestaciones\u00a0cl\u00ednicas\u00a0menos \u00a0graves\u00a0y\u00a0requer\u00edan\u00a0\nde\u00a0menor\u00a0atenci\u00f3n\u00a0hospitalaria\u00a0respecto\u00a0a\u00a0los\u00a0dem\u00e1s\u00a0pacientes\u00a0c on\u00a0IDVC\u00a0(grupos\u00a04,\u00a05\u00a0y\u00a06).\u00a0Por\u00a0\nel\u00a0contrario,\u00a0los\u00a0pacientes\u00a0en\u00a0los\u00a0que\u00a0se\u00a0observaba\u00a0ausencia\u00a0to tal\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0\ncambio\u00a0de\u00a0isotipo\u00a0en\u00a0SP,\u00a0aunque\u00a0ten\u00edan\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0 CD27+\u00a0IgM++D+\u00a0(grupo\u00a04),\u00a0\nmostraron\u00a0mayor\u00a0frecuencia\u00a0de\u00a0citopenias\u00a0autoinmunes\u00a0y\u00a0enteropa t\u00eda.\u00a0Ambas\u00a0caracter\u00edsticas\u00a0\ncl\u00ednicas\u00a0son\u00a0t\u00edpicas\u00a0tambi\u00e9n\u00a0de\u00a0los\u00a0s\u00edndromes\u00a0h\u00edper\u2010IgM306,307,456,\u00a0pero\u00a0a\u00a0diferencia\u00a0de\u00a0estos\u00a0\n\u00faltimos,\u00a0en\u00a0este\u00a0subgrupo\u00a0de\u00a0pacientes\u00a0con\u00a0IDVC\u00a0no\u00a0se\u00a0detectaba n\u00a0CPs\u00a0(incluidas\u00a0CPs\u00a0IgM+)\u00a0\nexcepto\u00a0en\u00a0un\u00a0caso,\u00a0asociado\u00a0a\u00a0un\u00a0perfil\u00a0de\u00a0Acs\u00a0s\u00e9ricos\u00a0t\u00edpico\u00a0 de\u00a0IDVC,\u00a0en\u00a0ausencia\u00a0de\u00a0los\u00a0\ndefectos\u00a0funcionales\u00a0( in\u00a0vitro)\u00a0asociados\u00a0a\u00a0s\u00edndromes\u00a0h\u00edper\u2010IgM457.\u00a0Discusi\u00f3n \n\u00a0\n\u2010\u00a0166\u00a0\u2010\u00a0\n\u00a0As\u00ed\u00a0mismo,\u00a0los\u00a0pacientes\u00a0con\u00a0IDVC\u00a0que\u00a0presentaban\u00a0un\u00a0d\u00e9ficit\u00a0se vero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0CD27+\u00a0con\u00a0y\u00a0sin\u00a0cambio\u00a0de\u00a0isotipo\u00a0de\u00a0Ig,\u00a0pero\u00a0manten\u00edan\u00a0una\u00a0producci\u00f3 n\u00a0residual\u00a0de\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0CD27\u2010CD21\u2010IgG3+\u00a0(grupo\u00a05)\u00a0y\u00a0los\u00a0pacientes\u00a0que\u00a0mostraban\u00a0ausencia\u00a0\npr\u00e1cticamente\u00a0total\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0(grupo\u00a06),\u00a0prese ntaban\u00a0manifestaciones\u00a0cl\u00ednicas\u00a0\nm\u00e1s\u00a0 graves\u00a0 (e.g.\u00a0 organomegalias\u00a0 y\u00a0 mayor\u00a0 frecuencia\u00a0 de\u00a0 tumores\u00a0 h ematol\u00f3gicos),\u00a0\nprobablemente\u00a0debidas\u00a0a\u00a0su\u00a0incapacidad\u00a0de\u00a0montar\u00a0respuestas\u00a0inm unes\u00a0en\u00a0los\u00a0CGs\u00a0de\u00a0los\u00a0\nOLS111,123,452.\u00a0Adem\u00e1s\u00a0de\u00a0las\u00a0alteraciones\u00a0ya\u00a0descritas,\u00a0los\u00a0pacientes\u00a0del\u00a0gr upo\u00a06\u00a0se\u00a0caracterizaron\u00a0\npor\u00a0presentar\u00a0tambi\u00e9n,\u00a0una\u00a0reducci\u00f3n\u00a0significativa\u00a0del\u00a0n\u00famero\u00a0d e\u00a0linfocitos\u00a0B\u00a0pre\u2010CG\u00a0en\u00a0SP,\u00a0lo\u00a0\ncual\u00a0podr\u00eda\u00a0reflejar\u00a0un\u00a0defecto\u00a0en\u00a0la\u00a0producci\u00f3n\u00a0de\u00a0estas\u00a0c\u00e9lul as\u00a0en\u00a0la\u00a0MO250,283,284.\u00a0Adem\u00e1s,\u00a0la\u00a0\nm a y o r \u00ed a \u00a0d e \u00a0l i n f o c i t o s \u00a0B \u00a0d e \u00a0e s t o s \u00a0p a c i e n t e s \u00a0m o s t r a r o n \u00a0u n \u00a0f e n o t i p o\u00a0 inmaduro/transicional,\u00a0\nreflejando\u00a0su\u00a0salida\u00a0prematura\u00a0de\u00a0la\u00a0MO53;\u00a0a\u00a0la\u00a0vez,\u00a0dentro\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0detectados\u00a0\nen\u00a0estos\u00a0sujetos,\u00a0exist\u00eda\u00a0un\u00a0aum ento\u00a0relativo\u00a0del\u00a0compartimento \u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0CD21\u2010\u00a0frente\u00a0a\u00a0las\u00a0\nc\u00e9lulas\u00a0 B\u00a0 na\u00efve\u00a0 CD21+.\u00a0 Tanto\u00a0 las\u00a0 c\u00e9lulas\u00a0 inmaduras\u00a0 como\u00a0 los\u00a0 linfocitos\u00a0 B\u00a0 na\u00efve\u00a0 CD21\u2010\u00a0s e \u00a0\ncaracterizan\u00a0por\u00a0presentar\u00a0una\u00a0menor\u00a0capacidad\u00a0de\u00a0respuesta\u00a0 in\u00a0vitro53,119,\u00a0lo\u00a0que\u00a0unido\u00a0al\u00a0\ndefecto\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0pre\u2010CG,\u00a0podr\u00eda\u00a0contribuir\u00a0a\u00a0 explicar\u00a0la\u00a0disminuci\u00f3n\u00a0global,\u00a0e\u00a0\nincluso\u00a0la\u00a0ausencia\u00a0total,\u00a0de\u00a0linfocitos\u00a0B\u00a0dependientes\u00a0de\u00a0Ag\u00a0c aracter\u00edstica\u00a0de\u00a0estos\u00a0pacientes.\u00a0\nAdem\u00e1s,\u00a0 aunque\u00a0 este\u00a0 subgrupo\u00a0 de\u00a0 IDVC\u00a0 no\u00a0 llega\u00a0 a\u00a0 cumplir\u00a0 los\u00a0 cri terios\u00a0 diagn\u00f3sticos\u00a0 de\u00a0\ninmunodeficiencia\u00a0 combinada11,\u00a0 inclu\u00eda\u00a0 pacientes\u00a0 que\u00a0 mostraban\u00a0 tambi\u00e9n\u00a0 n\u00fameros\u00a0\nsignificativamente\u00a0reducidos\u00a0de\u00a0linfocitos\u00a0na\u00efve\u00a0T\u00a0CD4+\u00a0y\u00a0T\u00a0CD8+,\u00a0respecto\u00a0tanto\u00a0a\u00a0donantes\u00a0\nsanos\u00a0de\u00a0la\u00a0misma\u00a0franja\u00a0etaria,\u00a0como\u00a0a\u00a0otros\u00a0pacientes\u00a0con\u00a0IDV C,\u00a0de\u00a0forma\u00a0similar\u00a0a\u00a0lo\u00a0\nobservado\u00a0por\u00a0otros\u00a0autores\u00a0en\u00a0p acientes\u00a0con\u00a0estas\u00a0caracter\u00edsti cas284.\u00a0En\u00a0conjunto,\u00a0estos\u00a0\ndefectos\u00a0B\u00a0sugieren\u00a0la\u00a0posible\u00a0existencia\u00a0de\u00a0mutaciones\u00a0hipom\u00f3r ficas\u00a0y\u00a0variantes\u00a0en\u00a0genes\u00a0\nrelacionados\u00a0 con\u00a0 la\u00a0 producci\u00f3n\u00a0 de\u00a0 linfocitos\u00a0 ( RAG,\u00a0 DLREC,\u00a0 NHEJ1 ),\u00a0 identificadas\u00a0 en\u00a0 otros\u00a0\npacientes\u00a0con\u00a0fenotipos\u00a0cl\u00ednicos\u00a0similares\u00a0a\u00a0IDVC268,269,271.\u00a0Ante\u00a0estos\u00a0hallazgos,\u00a0ser\u00eda\u00a0l\u00f3gico\u00a0\npensar\u00a0que\u00a0el\u00a0deterioro\u00a0variable\u00a0de\u00a0la\u00a0capacidad\u00a0de\u00a0cambio\u00a0de\u00a0i sotipo\u00a0de\u00a0Ig\u00a0observado\u00a0en\u00a0los\u00a0\npacientes\u00a0 diagnosticados\u00a0 de\u00a0 IDVC\u00a0 podr\u00eda\u00a0 reflejar\u00a0 distintos\u00a0 mome ntos\u00a0 evolutivos\u00a0 de\u00a0 la\u00a0Discusi\u00f3n \n\u2010\u00a0167\u00a0\u2010\u00a0\n\u00a0enfermedad;\u00a0sin\u00a0embargo,\u00a0no\u00a0observamos\u00a0diferencias\u00a0significativ as\u00a0en\u00a0la\u00a0edad\u00a0de\u00a0los\u00a0pacientes\u00a0\nincluidos\u00a0 en\u00a0 los\u00a0 distintos\u00a0 grupos\u00a0 identificados,\u00a0 a\u00a0 excepci\u00f3n\u00a0 de l\u00a0 grupo\u00a0 6,\u00a0 cuyos\u00a0 pacientes\u00a0\npresentaban\u00a0en\u00a0el\u00a0momento\u00a0de\u00a0realizar\u00a0el\u00a0estudio\u00a0edades\u00a0m\u00e1s\u00a0ava nzadas\u00a0que\u00a0los\u00a0de\u00a0los\u00a0grupos\u00a0\n2\u00a0y\u00a03.\u00a0\nFinalmente,\u00a0tal\u00a0como\u00a0ser\u00eda\u00a0de\u00a0esperar,\u00a0los\u00a0pacientes\u00a0con\u00a0d\u00e9fici t\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0\nasociado\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0IgA,\u00a0mostraron\u00a0un\u00a0perfil\u00a0de\u00a0alteraciones\u00a0 en\u00a0las\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0\nde\u00a0SP\u00a0intermedio\u00a0entre\u00a0el\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0y\u00a0la\u00a0IDVC,\u00a0c areciendo\u00a0algunos\u00a0de\u00a0ellos\u00a0de\u00a0CPs\u00a0\ncirculantes.\u00a0Adem\u00e1s,\u00a0de\u00a0acuerdo\u00a0con\u00a0el\u00a0defecto\u00a0secuencial\u00a0en\u00a0el \u00a0cambio\u00a0de\u00a0isotipo\u00a0y\u00a0subclases\u00a0\nde\u00a0IgG\u00a0e\u00a0IgA\u00a0observado\u00a0en\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0de\u00a0pacientes\u00a0 con\u00a0IDVC,\u00a0los\u00a0pacientes\u00a0con\u00a0\nd\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0asociado\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0IgA\u00a0mostraron \u00a0\u00fanicamente\u00a0alteraciones\u00a0en\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0IgA+\u00a0e\u00a0IgG2+,\u00a0de\u00a0acuerdo\u00a0con\u00a0el\u00a0defecto\u00a0en\u00a0los\u00a0niveles\u00a0s\u00e9ricos\u00a0de\u00a0Acs\u00a0que\u00a0\npresentaban.\u00a0\nEn\u00a0resumen,\u00a0nuestros\u00a0resultados\u00a0muestran\u00a0que,\u00a0mientras\u00a0que\u00a0las\u00a0 CPs\u00a0son\u00a0la\u00a0poblaci\u00f3n\u00a0\nde\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0SP\u00a0m\u00e1s\u00a0sensible\u00a0para\u00a0el\u00a0diagn\u00f3stico\u00a0de\u00a0IDP\u2010Ac,\u00a0 los\u00a0defectos\u00a0en\u00a0las\u00a0subpoblaciones\u00a0\nde\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria,\u00a0y\u00a0en\u00a0especial\u00a0de\u00a0las\u00a0definidas\u00a0por\u00a0 el\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Ig\u00a0\nexpresada,\u00a0permiten\u00a0subclasificar \u00a0con\u00a0elevada\u00a0precisi\u00f3n\u00a0pacient es\u00a0con\u00a0perfiles\u00a0cl\u00ednicos\u00a0distintos.\u00a0\nDe\u00a0este\u00a0modo,\u00a0podemos\u00a0concluir\u00a0que\u00a0el\u00a0estudio\u00a0detallado\u00a0de\u00a0los\u00a0 linfocitos\u00a0B\u00a0y\u00a0CPs\u00a0circulantes\u00a0de\u00a0\nacuerdo\u00a0a\u00a0la\u00a0subclase\u00a0de\u00a0Ig\u00a0expresada\u00a0y\u00a0a\u00a0otros\u00a0marcadores\u00a0func ionales\u00a0(i.e.\u00a0CD27\u00a0y\u00a0CD21),\u00a0y\u00a0su\u00a0\ncomparaci\u00f3n\u00a0con\u00a0valores\u00a0de\u00a0referencia\u00a0definidos\u00a0por\u00a0grupo\u00a0de\u00a0ed ad,\u00a0contribuye\u00a0a\u00a0entender\u00a0\nmejor\u00a0la\u00a0patogenia\u00a0de\u00a0las\u00a0IDP\u2010Ac,\u00a0a\u00a0facilitar\u00a0un\u00a0diagn\u00f3stico\u00a0y\u00a0 clasificaci\u00f3n\u00a0m\u00e1s\u00a0precisos\u00a0de\u00a0este\u00a0\ngrupo\u00a0de\u00a0enfermedades,\u00a0y\u00a0potencialmente\u00a0tambi\u00e9n,\u00a0a\u00a0poder\u00a0realiz ar\u00a0una\u00a0monitorizaci\u00f3n\u00a0m\u00e1s\u00a0\neficiente\u00a0de\u00a0estos\u00a0pacientes.\u00a0\u00a0\n\u00a0 \n \n \n \n \n  \n \n \n \n  \u00a0\n\u00a0\n\u00a0 \n \n \n \n \n \nConclusiones \n  \u00a0\n\u00a0 \n  Conclusiones \n\u00a0\n\u2010\u00a0171\u00a0\u2010\u00a0\n\u00a0E n \u00a0r e l a c i \u00f3 n \u00a0c o n \u00a0e l \u00a0p r i m e r \u00a0o b j e t i v o , \u00a0c e n t r a d o \u00a0e n \u00a0s e l e c c i o n a r \u00a0y \u00a0v alidar\u00a0 un\u00a0 panel\u00a0 de\u00a0 Acs\u00a0\nmonoclonales\u00a0para\u00a0la\u00a0detecci\u00f3n\u00a0espec\u00edfica\u00a0y\u00a0sensible\u00a0de\u00a0las\u00a0dis tintas\u00a0subclases\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0\nexpresadas\u00a0en\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0CPs\u00a0de\u00a0SP\u00a0y\u00a0otros\u00a0tejid os\u00a0humanos,\u00a0mediante\u00a0\ncitometr\u00eda\u00a0de\u00a0flujo:\u00a0\n\u00a0 1.\u2212\u00a0De\u00a0todos\u00a0los\u00a0clones\u00a0de\u00a0Acs\u00a0comercialmente\u00a0disponibles\u00a0y\u00a0pr eviamente\u00a0validados\u00a0para\u00a0\nla\u00a0identificaci\u00f3n\u00a0de\u00a0subclases\u00a0de\u00a0IgA\u00a0e\u00a0IgG\u00a0mediante\u00a0distintas\u00a0 t\u00e9cnicas,\u00a0solo\u00a0una\u00a0parte\u00a0de\u00a0ellos\u00a0\nfueron\u00a0capaces\u00a0de\u00a0identificar\u00a0estas\u00a0subclases\u00a0de\u00a0Igs\u00a0cuando\u00a0est aban\u00a0expresadas\u00a0en \u00a0la\u00a0superficie\u00a0\nde\u00a0 linfocitos\u00a0 B\u00a0 de\u00a0 memoria\u00a0 y\u00a0 CPs,\u00a0 lo\u00a0 que\u00a0 pone\u00a0 de\u00a0 manifiesto\u00a0 la\u00a0 necesidad\u00a0 de\u00a0 evaluar\u00a0\nminuciosamente\u00a0cualquier\u00a0clon\u00a0de\u00a0Ac\u00a0antes\u00a0de\u00a0poder\u00a0incluirlo\u00a0en \u00a0un\u00a0panel\u00a0diagn\u00f3stico\u00a0de\u00a0\ncitometr\u00eda\u00a0de\u00a0flujo.\u00a0\n\u00a0 2.\u2212\u00a0Los\u00a0clones\u00a0de\u00a0Acs\u00a0seleccionados\u00a0y\u00a0validados,\u00a0as\u00ed\u00a0como\u00a0los\u00a0 protocolos\u00a0propuestos,\u00a0\npermiten\u00a0la\u00a0identificaci\u00f3n\u00a0y\u00a0cuantificaci\u00f3n\u00a0r\u00e1pida,\u00a0espec\u00edfica, \u00a0sensible\u00a0y\u00a0reproducible\u00a0de\u00a0las\u00a0\ndistintas\u00a0poblaciones\u00a0de\u00a0linfoci tos\u00a0B\u00a0y\u00a0CPs\u00a0presentes\u00a0en\u00a0SP\u00a0y\u00a0o tros\u00a0tejidos,\u00a0en\u00a0funci\u00f3n\u00a0del\u00a0isotipo\u00a0\ny\u00a0subclase\u00a0de\u00a0Ig\u00a0expresada,\u00a0y\u00a0de\u00a0la\u00a0localizaci\u00f3n\u00a0predominante\u00a0( de\u00a0membrana\u00a0 vs.\u00a0citoplasm\u00e1tica)\u00a0\nde\u00a0la\u00a0misma.\u00a0\nEn\u00a0relaci\u00f3n\u00a0con\u00a0el\u00a0segundo\u00a0objetivo,\u00a0encaminado\u00a0a\u00a0definir\u00a0la\u00a0di stribuci\u00f3n\u00a0normal\u00a0a\u00a0lo\u00a0\nlargo\u00a0de\u00a0la\u00a0vida\u00a0de\u00a0las\u00a0distintas\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0d e\u00a0memoria\u00a0y\u00a0CPs\u00a0circulantes,\u00a0\ndefinidas\u00a0en\u00a0funci\u00f3n\u00a0del\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Ig\u00a0que\u00a0expresan: \u00a0\u00a0\n3.\u2212\u00a0Los\u00a0linfocitos\u00a0B\u00a0inmaduros,\u00a0na\u00efve\u00a0y\u00a0de\u00a0memoria,\u00a0as\u00ed\u00a0como\u00a0la s\u00a0CPs,\u00a0alcanzan\u00a0sus\u00a0niveles\u00a0\nm\u00e1ximos\u00a0en\u00a0sangre\u00a0antes\u00a0de\u00a0los\u00a04\u00a0a\u00f1os\u00a0de\u00a0vida,\u00a0disminuyendo\u00a0pos teriormente\u00a0hasta\u00a0la\u00a0edad\u00a0\nadulta.\u00a0A\u00a0partir\u00a0de\u00a0ah\u00ed,\u00a0los\u00a0lin focitos\u00a0B\u00a0inmaduros/transiciona les\u00a0y\u00a0na\u00efve\u00a0se\u00a0mantienen\u00a0estables,\u00a0\nmientras\u00a0que\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0CPs\u00a0vuel ven\u00a0a\u00a0disminuir\u00a0a\u00a0partir\u00a0de\u00a0los\u00a0\n60\u00a0a\u00f1os,\u00a0pudiendo\u00a0este\u00a0descenso\u00a0estar\u00a0relacionado\u00a0con\u00a0la\u00a0menor\u00a0 respuesta\u00a0a\u00a0vacunaci\u00f3n\u00a0y\u00a0la\u00a0\nmayor\u00a0tasa\u00a0de\u00a0infecciones\u00a0descrit a\u00a0entre\u00a0estos\u00a0sujetos,\u00a0a\u00a0pesar \u00a0de\u00a0que\u00a0poseen\u00a0niveles\u00a0de\u00a0Acs\u00a0\nsimilares\u00a0a\u00a0los\u00a0de\u00a0adultos\u00a0j\u00f3venes.\u00a0Conclusiones \n\u00a0\n\u2010\u00a0172\u00a0\u2010\u00a0\n\u00a04.\u2212\u00a0El\u00a0an\u00e1lisis\u00a0comparativo\u00a0de\u00a0los\u00a0patrones\u00a0de\u00a0distribuci\u00f3n\u00a0de\u00a0 las\u00a0CPs\u00a0y\u00a0de\u00a0los\u00a0linfocitos\u00a0\nB\u00a0de\u00a0memoria\u00a0en\u00a0sangre,\u00a0as\u00ed\u00a0como\u00a0de\u00a0los\u00a0Acs\u00a0solubles\u00a0en\u00a0plasma, \u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida,\u00a0muestra\u00a0\nque\u00a0existe\u00a0una\u00a0cin\u00e9tica\u00a0diferente\u00a0para\u00a0cada\u00a0uno\u00a0de\u00a0ellos,\u00a0alcan z\u00e1ndose\u00a0el\u00a0pico\u00a0de\u00a0producci\u00f3n\u00a0de\u00a0\nCPs\u00a0varios\u00a0a\u00f1os\u00a0antes\u00a0que\u00a0el\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria,\u00a0y\u00a0que\u00a0 los\u00a0niveles\u00a0(m\u00e1ximos)\u00a0de\u00a0Acs\u00a0de\u00a0\nlos\u00a0correspondientes\u00a0isotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs.\u00a0Esto\u00a0sugiere\u00a0 que\u00a0el\u00a0n\u00famero\u00a0de\u00a0CPs\u00a0en\u00a0SP\u00a0podr\u00eda\u00a0\nconstituir\u00a0el\u00a0marcador\u00a0m\u00e1s\u00a0sensible\u00a0a\u00a0la\u00a0hora\u00a0de\u00a0evaluar\u00a0el\u00a0est ado\u00a0de\u00a0la\u00a0respuesta\u00a0B\u00a0de\u00a0un\u00a0\nindividuo\u00a0en\u00a0tiempo\u00a0real.\u00a0\n5.\u2212\u00a0Las\u00a0CPs\u00a0y\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0de\u00a0sangre,\u00a0as\u00ed\u00a0como\u00a0l os\u00a0Acs\u00a0de\u00a0distintas\u00a0\nsubclases\u00a0e\u00a0isotipos\u00a0de\u00a0Igs\u00a0que\u00a0corresponden\u00a0a\u00a0diferentes\u00a0bloqu es\u00a0del\u00a0gen \u00a0IGHC,\u00a0alcanzan\u00a0sus\u00a0\nniveles\u00a0m\u00e1s\u00a0elevados\u00a0a\u00a0diferentes\u00a0edades,\u00a0lo\u00a0que\u00a0probablemente\u00a0 refleja\u00a0los\u00a0ciclos\u00a0consecutivos\u00a0\nde\u00a0cambio\u00a0de\u00a0isotipo\u00a0de\u00a0Ig\u00a0que\u00a0ocurren\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida.\u00a0L a\u00a0acumulaci\u00f3n\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0que\u00a0expresan\u00a0isotipos\u00a0de\u00a0Igs\u00a0del\u00a0tercer\u00a0(y\u00a0\u00faltimo)\u00a0bloq ue\u00a0del\u00a0gen\u00a0 IGHC,\u00a0podr\u00eda\u00a0estar\u00a0\nasociada\u00a0con\u00a0una\u00a0respuesta\u00a0B\u00a0con\u00a0caracter\u00edsticas\u00a0m\u00e1s\u00a0tolerog\u00e9ni cas,\u00a0t\u00edpica\u00a0de\u00a0edades\u00a0m\u00e1s\u00a0\navanzadas\u00a0de\u00a0la\u00a0vida.\u00a0\nEn\u00a0relaci\u00f3n\u00a0con\u00a0el\u00a0tercer\u00a0objetivo,\u00a0centrado\u00a0en\u00a0definir\u00a0con\u00a0pre cisi\u00f3n\u00a0las\u00a0posibles\u00a0\nalteraciones\u00a0en\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0las\u00a0distintas\u00a0poblaciones\u00a0de \u00a0linfocitos\u00a0B\u00a0y\u00a0de\u00a0CPs\u00a0de\u00a0SP\u00a0en\u00a0\npacientes\u00a0con\u00a0IDP\u2010Ac,\u00a0y\u00a0su\u00a0posible\u00a0relaci\u00f3n\u00a0con\u00a0el\u00a0subtipo\u00a0diag n\u00f3stico\u00a0y\u00a0el\u00a0comportamiento\u00a0\ncl\u00ednico\u00a0de\u00a0la\u00a0enfermedad:\u00a0\n6.\u2212\u00a0Un\u00a0an\u00e1lisis\u00a0detallado\u00a0de\u00a0los\u00a0 compartimentos\u00a0de\u00a0linfocitos\u00a0B \u00a0de\u00a0memoria\u00a0y\u00a0de\u00a0CPs\u00a0de\u00a0\nSP,\u00a0clasificados\u00a0en\u00a0funci\u00f3n\u00a0del\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Ig\u00a0que\u00a0ex presan\u00a0y\u00a0de\u00a0los\u00a0marcadores\u00a0\nfuncionales\u00a0CD27\u00a0y\u00a0CD21,\u00a0demostr\u00f3\u00a0la\u00a0existencia\u00a0de\u00a0alteraciones \u00a0B\u00a0en\u00a0todos\u00a0los\u00a0pacientes\u00a0con\u00a0\nIDP\u2010Ac,\u00a0observ\u00e1ndose\u00a0distintos\u00a0patrones\u00a0de\u00a0alteraci\u00f3n\u00a0para\u00a0los\u00a0 diferentes\u00a0subtipos\u00a0diagn\u00f3sticos\u00a0\nde\u00a0 este\u00a0 grupo\u00a0 de\u00a0 enfermedades;\u00a0 estos\u00a0 hallazgos,\u00a0 sugieren\u00a0 que\u00a0 el \u00a0 an\u00e1lisis\u00a0 de\u00a0 estas\u00a0\nsubpoblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0SP\u00a0podr\u00eda\u00a0constituir\u00a0una\u00a0herrami enta\u00a0\u00fatil\u00a0en\u00a0el\u00a0diagn\u00f3stico,\u00a0\nclasificaci\u00f3n\u00a0e\u00a0incluso,\u00a0la\u00a0moni torizaci\u00f3n\u00a0de\u00a0estos\u00a0pacientes.\u00a0Conclusiones \n\u00a0\n\u2010\u00a0173\u00a0\u2010\u00a0\n\u00a07.\u2212\u00a0Los\u00a0pacientes\u00a0con\u00a0d\u00e9\ufb01cit\u00a0selectivo\u00a0de\u00a0IgA\u00a0se\u00a0caracterizan\u00a0p or\u00a0presentar\u00a0un\u00a0defecto\u00a0\nsevero\u00a0de\u00a0producci\u00f3n\u00a0de\u00a0CPs\u00a0IgA1+\u00a0y/o\u00a0IgA2+,\u00a0aunque\u00a0pueden\u00a0definirse\u00a0dos\u00a0grupos\u00a0de\u00a0pacientes\u00a0\ncon\u00a0distinto\u00a0comportamiento\u00a0cl\u00ednico,\u00a0seg\u00fan\u00a0el\u00a0grado\u00a0de\u00a0afectaci \u00f3n\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0\nIgA+\u00a0circulantes.\u00a0Estos\u00a0hallazgos\u00a0sugieren\u00a0que\u00a0el\u00a0estudio\u00a0de\u00a0dichas \u00a0subpoblaciones\u00a0celulares\u00a0\npodr\u00eda\u00a0contribuir\u00a0al\u00a0diagn\u00f3stico\u00a0y\u00a0subclasificaci\u00f3n\u00a0de\u00a0paciente s\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA.\u00a0\n8.\u2212\u00a0De\u00a0forma\u00a0sistem\u00e1tica,\u00a0los\u00a0pa cientes\u00a0con\u00a0IDVC\u00a0carecen\u00a0de\u00a0CPs \u00a0circulantes\u00a0IgG+\u00a0e\u00a0IgA+.\u00a0\nAdem\u00e1s,\u00a0estos\u00a0pacientes\u00a0presentan\u00a0tambi\u00e9n,\u00a0un\u00a0deterioro\u00a0progres ivo\u00a0de\u00a0la\u00a0capacidad\u00a0de\u00a0cambio\u00a0\n(secuencial)\u00a0de\u00a0isotipo\u00a0de\u00a0Ig\u00a0en \u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0de \u00a0SP,\u00a0que\u00a0progresivamente\u00a0afectan\u00a0\na\u00a0cada\u00a0vez\u00a0m\u00e1s\u00a0isotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs\u00a0seg\u00fan\u00a0su\u00a0localizaci\u00f3 n\u00a0en\u00a0el\u00a0gen\u00a0 IGHC:\u00a0de\u00a0los\u00a0m\u00e1s\u00a0\ndistales\u00a0a\u00a0los\u00a0m\u00e1s\u00a0cercanos\u00a0a\u00a0la\u00a0regi\u00f3n\u00a0V(D)J\u00a0del\u00a0gen\u00a0 IGHC.\u00a0As\u00ed,\u00a0seg\u00fan\u00a0el\u00a0patr\u00f3n\u00a0de\u00a0alteraciones\u00a0\nobservado\u00a0podemos\u00a0definir\u00a0hasta\u00a06\u00a0subgrupos\u00a0de\u00a0pacientes\u00a0con\u00a0ID VC\u00a0distintos,\u00a0que\u00a0muestran\u00a0\ndiferente\u00a0comportamiento\u00a0cl\u00ednico. \u00a0Estos\u00a0hallazgos\u00a0apoyan\u00a0la\u00a0uti lidad\u00a0del\u00a0an\u00e1lisis\u00a0de\u00a0las\u00a0distintas\u00a0\nsubpoblaciones\u00a0de\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0SP\u00a0mediante\u00a0citometr\u00eda\u00a0de\u00a0flujo, \u00a0en\u00a0el\u00a0diagn\u00f3stico\u00a0y\u00a0clasificaci\u00f3n\u00a0\nde\u00a0la\u00a0IDVC.\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n \n \n  \u00a0\n\u00a0\n\u00a0 \n \n \n \n \nAnexo I\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0Tabla\u00a0suplementaria\u00a01.\u2212\u00a0Genes\u00a0relacionados\u00a0con\u00a0mutaciones\u00a0monog \u00e9nicas\u00a0en\u00a0IDVC.\u00a0\n\u00a0Gen,\u00a0\nOMIM\u00a0\n\u00a0Localizaci\u00f3n/\u00a0\nFunci\u00f3n\u00a0en\u00a0\nlinfocito\u00a0B\u00a0N\u00ba\u00a0pacientes\u00a0\nanalizados/\u00a0\nInicio\u00a0de\u00a0s\u00edntomas\u00a0Efecto\u00a0sobre\u00a0la\u00a0\nprote\u00edna/\u00a0\nHerencia\u00a0Alteraciones\u00a0en\u00a0c\u00e9lulas\u00a0\ndel\u00a0sistema\u00a0inmune\u00a0Otras\u00a0alteraciones\u00a0\ninmunol\u00f3gicas\u00a0Manifestaciones\u00a0\ncl\u00ednicas\u00a0\u00a0Familiares\u00a0\ncon\u00a0IDP\u2010Ac\u00a0Familiares\u00a0\nasintom\u00e1ticos\u00a0Poblaci\u00f3n\u00a0\ngeneral\u00a0Fenotipo\u00a0\nIDVC/otra\u00a0IDP\u00a0\n(IUIS)\u00a0Referencias\u00a0\nbibliogr\u00e1ficas\u00a0\nTACI\u00a0\n\u00a0\n604907\u00a017p11.2\u00a0\n\u00a0\nCambio\u00a0de\u00a0\nisotipo,\u00a0\ndiferenciaci\u00f3n\u00a0y\u00a0\nsupervivencia\u00a0de\u00a0\nCP\u00a0y\u00a0respuesta\u00a0T\u2010\nindependiente\u00a0\u22652150\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0\ny\u00a0adulta\u00a0\n\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\nnormal)\u00a0\n\u00a0\nAD/AR\u00a0\n\u00a0Linfocitos\u00a0B\u00a0totales\u2191,\u00a0\u2193\u00a0o\u00a0\nnormales\u00a0y\u00a0de\u00a0memoria\u2193\u00a0o\u00a0\nnormales.\u00a0\nLinfocitos\u00a0T\u00a0(totales\u00a0y\u00a0\nsubpoblaciones)\u2193\u00a0o\u00a0normales.\u00a0IgG\u2193,\u00a0IgA\u00a0e\u00a0IgM\u00a0\u2193o\u00a0\nnormal,\u00a0respuesta\u00a0a\u00a0\nvacunas\u00a0de\u00a0\npolisac\u00e1ridos\u00a0\u2193o\u00a0\nnormal.\u00a0\n\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n,\u00a0hiperplasia\u00a0\nlinfoide,\u00a0\norganomegalias\u00a0y\u00a0\ngranuloma.\u00a0\n\u00a0Si\u00a0\n(D\u00e9ficit\u00a0de\u00a0\nIgA\u00a0y\u00a0de\u00a0\nsubclases\u00a0de\u00a0\nIgG)\u00a0Si\u00a0 Si\u00a0IDVC\u00a0\n(predisposici\u00f3n)\u00a0273,370,372,458\n\u2013467\u00a0\nBAFF\u2010R\u00a0\n\u00a0\n606269\u00a022q13.2\u00a0\u00a0Supervivencia\u00a082\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0\ny\u00a0adulta\u00a0PF/GF\u00a0\n(expresi\u00f3n\u00a0normal)\u00a0\n\u00a0\nAR\u00a0\u00a0Linfocitos\u00a0B\u00a0totales,\u00a0na\u00efve\u00a0y\u00a0de\u00a0\nmemoria\u00a0\u2193\u00a0o\u00a0normales,\u00a0\u00a0\nlinfocitos\u00a0(T\u00a0totales\u00a0y\u00a0\nsubpoblaciones)\u00a0normales.\u00a0IgG\u2193,\u00a0\nIgA\u00a0e\u00a0IgM\u00a0\u2193\u00a0o\u00a0\nnormales,\u00a0respuesta\u00a0a\u00a0vacunas\u00a0de\u00a0polisac\u00e1ridos\u2193.\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n,\u00a0AI\u00a0y\u00a0enteropat\u00eda\u00a0Si\u00a0\n(D\u00e9ficit\u00a0de\u00a0IgA\u00a0y\u00a0de\u00a0IgM)\u00a0Si\u00a0 Si\u00a0IDVC\u00a0\n(predisposici\u00f3n)\u00a0\n274,283,465,468\n\u2013471\u00a0\nTNFSF12\u00a0\n(TWEAK)\u00a0\n\u00a0\n602695\u00a017p13.1\u00a0\n\u00a0\nUni\u00f3n\u00a0a\u00a0BAFF\u00a0\n\u00a0\u00a0\n3\u00a0(1\u00a0familia)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0\ny\u00a0adulta\u00a0\n\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\nnormal)\u00a0\n\u00a0\nAD\u00a0Linfocitos\u00a0B\u00a0totales\u2193\u00a0o\u00a0\nnormales,\u00a0de\u00a0memoria\u2193,\u00a0\u00a0\nlinfocitos\u00a0T\u00a0CD8+\u00a0y\u00a0T\u00a0CD8\u2010CD4\u2010\u2191\u00a0IgG\u2193,\nIgA\u00a0e\u00a0IgM\u2193\u00a0o\u00a0normal,\u00a0\n\u2193respuesta\u00a0a\u00a0\nvacunas\u00a0de\u00a0\npolisac\u00e1ridos\u00a0y\u00a0\nproteicas.\u00a0\n\u00a0Infecciones\u00a0\nrespiratorias,\u00a0\nmeningitis,\u00a0\nosteomielitis,\u00a0citopenias\u00a0\nautoinmunes.\u00a0Si\u00a0(D\u00e9ficit\u00a0de\u00a0\nIgG2)\u00a0No\u00a0 No\u00a0 IDVC\u00a0472\u00a0\nNFKB1\u00a0\n\u00a0\n164011\u00a04q24\u00a0\n\u00a0\nDiferenciaci\u00f3n,\u00a0\nsupervivencia,\u00a0\ncambio\u00a0de\u00a0isotipo\u00a0\ny\u00a0tolerancia\u00a042\u00a0(27\u00a0familias)\u00a0\n\u00a0\nNi\u00f1os\u00a0y\u00a0adultos\u00a0\n\u00a0\n\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\u2193)\u00a0\n\u00a0\nAD\u00a0Linfocitos\u00a0B\u00a0totales\u00a0normales,\u00a0de\u00a0\nmemoria\u00a0IgM++D+\u00a0normales,\u00a0de\u00a0\nmemoria\u00a0IgG+\u00a0e\u00a0IgA+\u00a0CD27+\u00a0\n\u2193linfocitos\u00a0B\u00a0CD21\u2010\u2191\u00a0y\u00a0\nlinfocitos\u00a0T\u00a0normales.\u00a0\n\u00a0IgG\u2193,\nIgA\u00a0e\u00a0IgM\u2193\u00a0o\u00a0\nnormales,\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0\nde\u00a0polisac\u00e1ridos\u00a0y\u00a0\u00a0\nproteicas\u2193\u00a0o\u00a0normal.\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n,\u00a0AI,\u00a0\nadenopat\u00edas\u00a0y\u00a0\norganomegalias.\u00a0Si\u00a0\n(D\u00e9ficit\u00a0de\u00a0\nIgA\u00a0y\u00a0de\u00a0\nsubclases\u00a0de\u00a0\nIgG)\u00a0Si\u00a0 No\u00a0 IDVC\u00a0272,473\u2013477\u00a0\nNFKB2\u00a0\n\u00a0\n164012\u00a010q24.32\u00a0\nDiferenciaci\u00f3n,\u00a0\nsupervivencia,\u00a0\ncambio\u00a0de\u00a0isotipo\u00a0\ny\u00a0tolerancia\u00a023\u00a0(14\u00a0familias)\u00a0\n\u00a0\nNi\u00f1os\u00a0y\u00a0adultos\u00a0\n\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\u2193\u00a0o\u00a0\nnormal)\u00a0\n\u00a0\nAD\u00a0Linfocitos\u00a0B\u00a0totales\u00a0y\u00a0de\u00a0\nmemoria\u00a0IgM++D+\u00a0\u2193\u00a0o\u00a0normales,\u00a0\nde\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0\nisotipo\u2193,\u00a0linfocitos\u00a0T\u00a0CD4+\u00a0y\u00a0\nCD8+\u00a0normales,\u00a0de\u00a0memoria\u00a0y\u00a0\nfoliculares\u00a0\u2193\u00a0o\u00a0normales.\u00a0\n\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193,\u00a0\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0\nde\u00a0polisac\u00e1ridos\u00a0y\u00a0\nproteicas\u2193\u00a0o\u00a0normal.\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n,\u00a0infecciones\u00a0\nlocalizadas\u00a0por\u00a0herpes\u00a0\nsimple,\u00a0d\u00e9ficit\u00a0de\u00a0\nhormonas\u00a0pituitarias\u00a0y\u00a0\nAI\u00a0(alopecia).\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0478\u2013486\u00a0\u00a0\n\u00a0Tabla\u00a0suplementaria\u00a01\u00a0(continuaci\u00f3n)\u00a0\nGen,\u00a0\nOMIM\u00a0\n\u00a0Localizaci\u00f3n/\u00a0\nFunci\u00f3n\u00a0en\u00a0\nlinfocito\u00a0B\u00a0N\u00ba\u00a0pacientes\u00a0analizados/\u00a0\nInicio\u00a0de\u00a0s\u00edntomasEfecto\u00a0sobre\u00a0la\u00a0\nprote\u00edna/\u00a0\nHerencia\n\u00a0Alteraciones\u00a0en\u00a0c\u00e9lulas\u00a0\ndel\u00a0sistema\u00a0inmune \u00a0Otras\u00a0alteraciones\u00a0inmunol\u00f3gicas\n\u00a0Manifestaciones\u00a0cl\u00ednicas\u00a0 \u00a0Familiares\u00a0con\u00a0IDP\u2010Ac\n\u00a0Familiares\u00a0asintom\u00e1ticos\n\u00a0Poblaci\u00f3n\u00a0general\n\u00a0Fenotipo\u00a0IDVC/otra\u00a0\nIDP\u00a0(IUIS)\n\u00a0Referencias\u00a0\nbibliogr\u00e1ficas \u00a0\nIKZF1\u00a0\n(IKAROS)\u00a0\n\u00a0\n603029\u00a07p12.2\u00a0\n\u00a0\nDiferenciaci\u00f3n\u00a0\nlinfoide\u00a024\u00a0(9\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0\ny\u00a0adulta\u00a0PF\u00a0\n(expresi\u00f3n\u2193\u00a0o\u00a0\nnormal)\u00a0\n\u00a0\nAD\u00a0LinfocitosB\u00a0totales\u2193,\u00a0\nde\u00a0memoria\u2193\u00a0o\u00a0normales,\u00a0\npresencia\u00a0de\u00a0CP\u00a0en\u00a0MO,\u00a0\nlinfocitos\u00a0T\u00a0tota les\u00a0y\u00a0CD8+\u00a0\u2191\u00a0o\u00a0\nnormales,\u00a0CD4+\u2193\u00a0o\u00a0normales.\u00a0IgG\u2193,\nIgA\u00a0e\u00a0IgM\u00a0\u2193\u00a0o\u00a0normal,\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0de\u00a0\npolisac\u00e1ridos\u00a0y\u00a0\nproteicas\u00a0\u2193\u00a0o\u00a0normal.\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n,\u00a0\ncitopenias\u00a0autoinmunes\u00a0y\u00a0\ntumores\u00a0hematol\u00f3gicos.\u00a0No\u00a0Si\u00a0(en\u00a0ni\u00f1os,\u00a0\nposible\u00a0evoluci\u00f3n)\u00a0No\u00a0 IDVC\u00a0265,453,473\u00a0\nPIK3CD\u00a0\n\u00a0\n602839\u00a01p36.22\u00a0\n\u00a0\nCascada\u00a0de\u00a0\nse\u00f1alizaci\u00f3n\u00a0a\u00a0\ntrav\u00e9s\u00a0del\u00a0Co\u2010\nBCR,\u00a0IL21,\u00a0CD27\u00a0\ny\u00a0BAFF.\u00a0>150\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0GF\u00a0\n(expresi\u00f3n\u00a0\nnormal)\u00a0\n\u00a0\nAD\u00a0Linfocitos\u00a0B\u00a0tot ales\u00a0y\u00a0na\u00efve\u2193\u00a0o\u00a0\nnormales,\u00a0inmaduros\u2191\u00a0o\u00a0\nnormales,\u00a0de\u00a0memoria\u00a0con\u00a0y\u00a0\nsin\u00a0cambio\u00a0de\u00a0isotipo\u00a0normales\u00a0\no\u00a0\u2193,\u00a0linfocitos\u00a0T\u00a0totales,\u00a0CD4+\u00a0\n(totales\u00a0y\u00a0na\u00efve)\u00a0y\u00a0CD8+\u00a0na\u00efve\u2193\u00a0\no\u00a0normales,\u00a0T\u00a0CD4+\u00a0de\u00a0\nmemoria\u00a0y\u00a0CD8+\u00a0totales\u00a0y\u00a0de\u00a0\nmemoria\u2191.\u00a0IgG\u00a0e\u00a0IgA\u2193o\u00a0normal\u00a0(en\u00a0\nla\u00a0mayor\u00eda),\u00a0\u00a0\nIgM\u2191\u00a0o\u00a0normal,\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0\nproteicas\u00a0y\u00a0de\u00a0\npolisac\u00e1ridos\u2193\u00a0o\u00a0\nnormal.\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n,\u00a0\n(t\u00edpicamente\u00a0EBV\u00a0y\u00a0CMV),\u00a0\nLP,\u00a0AI,\u00a0organomegalias,\u00a0\nlinfoma,\u00a0retraso\u00a0\nneurol\u00f3gico\u00a0y\u00a0retraso\u00a0en\u00a0\nel\u00a0crecimiento.\u00a0No\u00a0 Si\u00a0(un\u00a0caso)\u00a0 No\u00a0 IDVC\u00a0487\u2013489\u00a0\nPIK3R1\u00a0\n\u00a0\n171833\u00a05q13.1\u00a0\n\u00a0\nCascada\u00a0de\u00a0\nse\u00f1alizaci\u00f3n\u00a0a\u00a0\ntrav\u00e9s\u00a0del\u00a0Co\u2010\nBCR,\u00a0IL21,\u00a0CD27\u00a0\ny\u00a0BAFF.\u00a052\u00a0\n(47\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0\nY\u00a0adulta\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\nnormal)\u00a0\n\u00a0\nAD\u00a0Linfocitos\u00a0B\u00a0total es\u00a0y\u00a0na\u00efve\u00a0\u2193\u00a0o\u00a0\nnormales,\u00a0inmaduros\u2191\u00a0o\u00a0\nnormales,\u00a0de\u00a0memoria\u00a0con\u00a0y\u00a0\nsin\u00a0cambio\u00a0de\u00a0isotipo\u00a0normales\u00a0\no\u00a0\u2193,\u00a0linfocitos\u00a0T\u00a0totales,\u00a0CD4+\u00a0\n(totales\u00a0y\u00a0na\u00efve)\u00a0y\u00a0CD8+\u00a0na\u00efve\u2193\u00a0\no\u00a0normales,\u00a0T\u00a0CD8+\u00a0totales\u00a0y\u00a0de\u00a0\nmemoria\u2191.\u00a0IgG\u00a0e\u00a0IgA\u00a0normal\u00a0o\u00a0\u2193\u00a0\n(en\u00a0la\u00a0mayor\u00eda)\u00a0,\u00a0IgM\u2191\u00a0\no\u00a0normal,\u00a0respuesta\u00a0a\u00a0\nvacunas\u00a0de\u00a0\npolisac\u00e1ridos\u00a0\u2193\u00a0o\u00a0\nnormal.\u00a0Similar\u00a0al\u00a0d\u00e9ficit\u00a0de\u00a0\nPIK3CD\u00a0pero\u00a0con\u00a0mayor\u00a0\nprevalencia\u00a0de\u00a0linfoma,\u00a0\nretraso\u00a0neurol\u00f3gico\u00a0y\u00a0de\u00a0\ncrecimiento\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0487,488,490\u00a0\nCD19\u00a0\n\u00a0\n107265\u00a016p11.2\u00a0\n\u00a0\nCo\u2010receptor\u00a0de\u00a0\nc\u00e9lula\u00a0B\u00a011\u00a0\u00a0\n(8\u00a0familias)\u00a0\n\u00a0Edad\u00a0pedi\u00e1trica\u00a0y\u00a0adulta\u00a0PF\u00a0\n(expresi\u00f3n\u2193\u00a0o\u00a0\nausente)\u00a0\u00a0AR\u00a0Linfocitos\u00a0B\u00a0totales\u00a0normales,\u00a0\nde\u00a0memoria\u00a0IgM\n++D+,\u00a0IgG+\u00a0e\u00a0\nIgA+\u00a0CD27+\u2193\u00a0con\u00a0IgA+\u00a0CD27\u2010\u00a0\nnormales,\u00a0linfocitos\u00a0T\u00a0(totales\u00a0y\u00a0\nsubpoblaciones)\u00a0normales,\u00a0expresi\u00f3n\u2193\u00a0de\u00a0CD21.\u00a0IgG\u00a0e\u00a0IgA\u2193,\u00a0IgM\u2193\u00a0o\u00a0\nnormal,\u00a0respuesta\u00a0a\u00a0\nvacunas\u00a0de\u00a0\npolisac\u00e1ridos\u00a0y\u00a0proteicas\u2193.\u00a0\u00a0\n\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n\u00a0\n(incluyendo\u00a0\nglomerulonefritis),\u00a0hematuria\u00a0microsc\u00f3pica\u00a0y\u00a0nefropat\u00eda.\u00a0\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0\n272,491\u2013495\u00a0\nCD21\u00a0\n\u00a0\n120650\u00a01q32.2\u00a0\n\u00a0\nCo\u2010receptor\u00a0de\u00a0\nc\u00e9lula\u00a0B\u00a02\u00a0(2\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\nausente)\u00a0\n\u00a0\nAR\u00a0\n\u00a0Linfocitos\u00a0B\u00a0totales\u00a0normales,\u00a0\nde\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0\nisotipo\u2193,\u00a0linfocitos\u00a0T\u00a0(totales\u00a0y\u00a0\nsubpoblaciones)\u00a0normales.\u00a0IgG\u00a0e\u00a0IgA\u2193,\u00a0IgM\u2193\u00a0o\u00a0\nnormal,\u00a0respuesta\u00a0a\u00a0\nvacunas\u00a0de\u00a0\npolisac\u00e1ridos\u2193.\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n,\u00a0\nenteropat\u00eda,\u00a0\nesplenomegalia\u00a0y\u00a0\nmialgias.\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0447,496\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0Tabla\u00a0suplementaria\u00a01\u00a0(continuaci\u00f3n)\u00a0\n\u00a0Gen,\u00a0\nOMIM\u00a0\n\u00a0Localizaci\u00f3n/\u00a0\nFunci\u00f3n\u00a0en\u00a0\nlinfocito\u00a0B\u00a0N\u00ba\u00a0pacientes\u00a0analizados/\u00a0\nInicio\u00a0de\u00a0s\u00edntomasEfecto\u00a0sobre\u00a0\nla\u00a0prote\u00edna/\u00a0\nHerencia\n\u00a0Alteraciones\u00a0en\u00a0c\u00e9lulas\u00a0\ndel\u00a0sistema\u00a0inmune \u00a0Otras\u00a0alteraciones\u00a0inmunol\u00f3gicas\n\u00a0Manifestaciones\u00a0cl\u00ednicas\u00a0\n\u00a0Familiares\u00a0con\u00a0IDP\u2010Ac\n\u00a0Familiares\u00a0asintom\u00e1ticos\n\u00a0Poblaci\u00f3n\u00a0general\n\u00a0Fenotipo\u00a0IDVC/otra\u00a0\nIDP\u00a0(IUIS)\n\u00a0Referencias\u00a0\nbibliogr\u00e1ficas \u00a0\nCD81\u00a0\n\u00a0\n186845\u00a011p15.5\u00a0\n\u00a0\nCo\u2010receptor\u00a0de\u00a0\nc\u00e9lula\u00a0B\u00a01\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\nausente)\u00a0\n\u00a0\nAR\u00a0\n\u00a0Linfocitos\u00a0B\u00a0totales\u00a0normales,\nde\u00a0memoria\u2193,\u00a0linfocitos\u00a0T\u00a0\n(totales\u00a0y\u00a0subpoblaciones)\u00a0\nnormales,\u00a0\nexpresi\u00f3n\u2193\u00a0de\u00a0CD21,\u00a0\nexpresi\u00f3n\u00a0ausente\u00a0de\u00a0CD19.\u00a0IgG\u2193,\u00a0IgA\u00a0e\u00a0IgM\u2193\u00a0o\u00a0\nnormal,\u00a0respuesta\u00a0a\u00a0\nvacunas\u00a0de\u00a0\npolisac\u00e1ridos\u00a0y\u00a0\nproteicas\u2193.\u00a0\n\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n\u00a0(incluyendo\u00a0\nglomerulonefritis)\u00a0y\u00a0\ns\u00edndrome\u00a0inflamatorio.\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0497\u00a0\nCD20\u00a0\n\u00a0\n112210\u00a011q12.2\u00a0\n\u00a0\nActivaci\u00f3n\u00a0y\u00a0\ndiferenciaci\u00f3n\u00a0\nde\u00a0c\u00e9lulas\u00a0B\u00a01\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0\n\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\nausente)\u00a0\n\u00a0\nAR\u00a0Linfocitos\u00a0B\u00a0totales\u00a0normales,\nde\u00a0memoria\u00a0con\u00a0cambio\u00a0de\u00a0\nisotipo\u2193,\u00a0linfocitos\u00a0T\u00a0(totales\u00a0y\u00a0\nsubpoblaciones)\u00a0normales.\u00a0\n\u00a0IgG\u2193,\u00a0IgM\u00a0e\u00a0IgA\u00a0\nnormal,\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0de\u00a0\npolisac\u00e1ridos\u2193.\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n.\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0498\u00a0\n\u00a0\nVAV1\u00a0\n\u00a0\n164875\u00a019p13.3\u00a0\n\u00a0\nCascada\u00a0de\u00a0\nse\u00f1alizaci\u00f3n\u00a0a\u00a0\ntrav\u00e9s\u00a0del\u00a0BCR\u00a01\u00a0\n\u00a0\nEdad\u00a0adulta\u00a0PF\u00a0\n(expresi\u00f3n\u2193)\u00a0\n\u00a0\nAD\u00a0Linfocitos\u00a0B\u00a0normales,\u00a0linfocitos\u00a0\nT\u00a0totales\u00a0y\u00a0CD8+\u00a0normales,\u00a0CD4+\u00a0\n\u2193.\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193.\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n.\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0499\u00a0\nRAC2\u00a0\n\u00a0\n602049\u00a022q13.1\u00a0\n\u00a0\nCascada\u00a0de\u00a0\nse\u00f1alizaci\u00f3n\u00a0a\u00a0\ntrav\u00e9s\u00a0del\u00a0BCR\u00a02\u00a0(1\u00a0familia)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0\ny\u00a0adulta\u00a0PF\u00a0(expresi\u00f3n\u00a0\nausente)\u00a0\n\u00a0\nAR\u00a0Linfocitos\u00a0B\u2193,\u00a0linfocitos\u00a0T\u00a0\ntotales,\u00a0CD4+\u00a0y\u00a0CD8+\u00a0normales,\u00a0\nCD4+\u00a0y\u00a0CD8+\u00a0na\u00efve\u00a0bajos\u00a0\n(incluyendo\u00a0emigrantes\u00a0\nrecientes),\u00a0Treg\u2193.\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193,\u00a0\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0de\u00a0\npolisac\u00e1ridos\u2193.\u00a0\n\u00a0\n\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n\u00a0(incluyendo\u00a0\nglomerulonefritis),\u00a0\nretraso\u00a0en\u00a0el\u00a0\ncrecimiento,\u00a0urticaria,\u00a0\u00a0\nalergia\u00a0y\u00a0defectos\u00a0de\u00a0\ncoagulaci\u00f3n.\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0500\u00a0\nBLK\u00a0\n\u00a0\n191305\u00a08p23.1\u00a0\n\u00a0\nCascada\u00a0de\u00a0\nse\u00f1alizaci\u00f3n\u00a0a\u00a0\ntrav\u00e9s\u00a0del\u00a0BCR\u00a02\u00a0(1\u00a0familia)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0\u00a0PF\u00a0(expresi\u00f3n\u00a0\nnormal)\u00a0\n\u00a0\nAD\u00a0Linfocitos\u00a0B\u2193o\u00a0normales,\nde\u00a0memoria\u00a0IgA+\u2193,\u00a0de\u00a0\nmemoria\u00a0IgG+\u00a0normales,\u00a0\nlinfocitos\u00a0T\u00a0totales,\u00a0CD4+\u00a0y\u00a0CD8+\u00a0\nnormales.\u00a0IgG\u2193,\u00a0IgA\u00a0e\u00a0IgM\u2193o\u00a0\nnormal,\u00a0respuesta\u00a0a\u00a0\nvacunas\u00a0de\u00a0\npolisac\u00e1ridos\u2193.\u00a0\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0501\u00a0\nIRF2BP2\u00a0\n\u00a0\n615332\u00a01q42.3\u00a0\n\u00a0\nDiferenciaci\u00f3n\u00a0\ny\u00a0proliferaci\u00f3n\u00a0\nde\u00a0c\u00e9lulas\u00a0B\u00a0de\u00a0\nmemoria\u00a0y\u00a0CP\u00a03\u00a0(1\u00a0familia)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0GF\u00a0\n(expresi\u00f3n\u2191)\u00a0\n\u00a0\nAD\u00a0Linfocitos\u00a0B\u00a0normales,\u00a0\nde\u00a0memoria\u2193\u00a0o\u00a0ausentes,\u00a0\nlinfocitos\u00a0T\u00a0normales.\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193,\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0de\u00a0\npolisac\u00e1ridos\u00a0y/o\u00a0\nproteicas\u2193.\u00a0Infecciones\u00a0\nrespiratorias\u00a0y\u00a0AI.\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0502\u00a0\u00a0\n\u00a0Tabla\u00a0suplementaria\u00a01\u00a0(continuaci\u00f3n)\u00a0\nGen,\u00a0\nOMIM\u00a0\n\u00a0Localizaci\u00f3n/\u00a0\nFunci\u00f3n\u00a0en\u00a0\nlinfocito\u00a0B\u00a0N\u00ba\u00a0pacientes\u00a0analizados/\u00a0\nInicio\u00a0de\u00a0s\u00edntomasEfecto\u00a0sobre\u00a0\nla\u00a0prote\u00edna/\u00a0\nHerencia\n\u00a0Alteraciones\u00a0en\u00a0c\u00e9lulas\u00a0\ndel\u00a0sistema\u00a0inmune \u00a0Otras\u00a0alteraciones\u00a0inmunol\u00f3gicas\n\u00a0Manifestaciones\u00a0cl\u00ednicas\u00a0 \u00a0Familiares\u00a0con\u00a0IDP\u2010Ac\n\u00a0Familiares\u00a0asintom\u00e1ticos\n\u00a0Poblaci\u00f3n\u00a0general\n\u00a0Fenotipo\u00a0IDVC/otra\u00a0\n\u00a0IDP\u00a0(IUIS)\n\u00a0Referencias\u00a0\nbibliogr\u00e1ficas \u00a0\nATP6AP1\u00a0\n\u00a0\n300197\u00a0\n\u00a0\n\u00a0Xq28\u00a0\n\u00a0\nDiferenciaci\u00f3n,\u00a0\nprocesamiento\u00a0\nde\u00a0Ag\u00a0y\u00a0\nproducci\u00f3n\u00a0de\u00a0Ig\u00a0\n(no\u00a0confirmado)\u00a011\u00a0(6\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0PF\u00a0\n(expresi\u00f3n\u2193)\u00a0\n\u00a0\nLigada\u00a0a\u00a0\ncromosoma\u00a0X\u00a0Linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0con\u00a0\ncambio\u00a0de\u00a0isotipo\u2193.\u00a0\n(no\u00a0existe\u00a0informaci\u00f3n\u00a0sobre\u00a0\notras\u00a0poblaciones)\u00a0IgG\u2193,\u00a0IgA\u00a0e\u00a0IgM\u2193o\u00a0\nnormal,\u00a0respuesta\u00a0a\u00a0\nvacunas\u00a0infantiles\u2193\u00a0(no\u00a0\nespecificado\u00a0tipo)\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n,\u00a0\norganomegalias\u00a0y\u00a0\ns\u00edntomas\u00a0neurol\u00f3gicos.\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0503\u00a0\nTRNT1\u00a0\n\u00a0\n612907\u00a03p26.2\u00a0\u00a0\u00a0\n\u00a0\nS\u00edntesis\u00a0de\u00a0\nprote\u00ednas\u00a027\u00a0(20\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0\n\u00a0PF\u00a0\n(expresi\u00f3n\u2193\u00a0\no\u00a0normal)\u00a0\n\u00a0\nAR\u00a0\n\u00a0Linfocitos\u00a0B\u2193,\u00a0inmaduros\u2191,\u00a0\nna\u00efve\u00a0y\u00a0memoria\u00a0con\u00a0cambio\u00a0\nde\u00a0isotipo\u2193\u00a0y\u00a0linfocitos\u00a0T\u00a0CD4+\u00a0\n\u2193\u00a0(solo\u00a0descrito\u00a0en\u00a0algunos\u00a0\ncasos)\u00a0\n\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193\u00a0Episodios\u00a0de\u00a0fiebre,\u00a0\nanemia\u00a0siderobl\u00e1stica,\u00a0\nretraso\u00a0en\u00a0el\u00a0crecimiento\u00a0\ny\u00a0problemas\u00a0\nneurol\u00f3gicos.\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0504\u2013508\u00a0\nTTC37\u00a0\n\u00a0\n614649\u00a0\n\u00a08p11.21\u00a0\u00a0\n\u00a0\nDesconocida\u00a0\n\u00a0\n\u00a096\u00a0(85\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0PF\u00a0(expresi\u00f3n\u00a0\nnormal)\u00a0\n\u00a0\nAR\u00a0No\u00a0existe\u00a0informaci\u00f3n.\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193.\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0de\u00a0\npolisac\u00e1ridos\u2193.\u00a0\n\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n,\u00a0alteraciones\u00a0\nen\u00a0el\u00a0pelo\u00a0(pelo\u00a0lanoso,\u00a0\ntricorrexis\u00a0nudosa),\u00a0\nmalformaciones\u00a0faciales,\u00a0\nenfermedad\u00a0hep\u00e1tica\u00a0y\u00a0\ndiarrea.\u00a0No\u00a0 No\u00a0 No\u00a0 IDVC\u00a0509\u00a0\nSEC61A1\u00a0\n609213\u00a03q21.3\u00a0\u00a0\n\u00a0\nTransporte\u00a0de\u00a0\nprote\u00ednas\u00a0en\u00a0el\u00a0\nRE\u00a011\u00a0(2\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0PF\u00a0\n(expresi\u00f3n\u2193)\u00a0\n\u00a0\nAD\u00a0Linfocitos\u00a0B\u00a0y\u00a0T\u00a0normales.\u00a0CPs\u00a0\nen\u00a0SP\u00a0y\u00a0su\u00a0generaci\u00f3n\u00a0tras\u00a0\nestimulaci\u00f3n\u00a0 in\u00a0vitro\u2193.\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193\u00a0(en\u00a0un\u00a0\npaciente\u00a0eran\u00a0\nnormales),\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0de\u00a0\npolisac\u00e1ridos\u2193\u00a0o\u00a0\nnormal\u00a0y\u00a0a\u00a0proteicas\u2193\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n.\u00a0No\u00a0 No\u00a0 No\u00a0IDVC\u00a0(todav\u00eda\u00a0\nno\u00a0recogido\u00a0en\u00a0\nla\u00a0clasificaci\u00f3n\u00a0\nde\u00a0la\u00a0IUIS)\u00a0510\u00a0\nPRKCD\u00a0\n\u00a0\n176977\u00a03p21.1\u00a0\n\u00a0\nCascada\u00a0de\u00a0\nse\u00f1alizaci\u00f3n\u00a0a\u00a0\ntrav\u00e9s\u00a0del\u00a0BCR\u00a06\u00a0(4\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0PF\u00a0\n(expresi\u00f3n\u2193\u00a0\no\u00a0ausente)\u00a0\n\u00a0\nAR\u00a0Linfocitos\u00a0B\u00a0totales\u2193\u00a0o\u00a0\nnormales\u00a0o\u2191,\u00a0inmaduros\u00a0y\u00a0\nna\u00efve\u00a0normales\u00a0o\u2191,\u00a0\u00a0\nlinfocitos\u00a0de\u00a0memoria\u00a0con\u00a0\ncambio\u00a0de\u00a0isotipo\u2193,\u00a0linfocitos\u00a0\nB\u00a0CD21\u2010\u2191,\u00a0\nlinfocitos\u00a0T\u00a0totales,\u00a0CD4+\u00a0y\u00a0\nCD8+\u2193\u00a0o\u00a0normales,\u00a0CD4\u2010CD8\u2010\u00a0\n\u2191\u00a0o\u00a0normales,\u00a0\nc\u00e9lulas\u00a0NK\u2193\u00a0o\u00a0normales.\u00a0IgG\u2193\u00a0o\u00a0normal,\u00a0\u00a0\nIgA\u00a0e\u00a0IgM\u2191\u00a0o\u00a0normal,\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0\nproteicas\u00a0y\u00a0de\u00a0\npolisac\u00e1ridos\u2193o\u00a0\nnormal.\u00a0Infecciones\u00a0de\u00a0\nrepetici\u00f3n,\u00a0infecciones\u00a0\npor\u00a0virus\u00a0herpes\u00a0(EBV\u00a0y\u00a0\nCMV),\u00a0AI\u00a0sist\u00e9mica\u00a0grave\u00a0\n(similar\u00a0a\u00a0lupus\u00a0\neritematoso\u00a0sist\u00e9mico),\u00a0\norganomegalias,\u00a0LP\u00a0y\u00a0\nretraso\u00a0en\u00a0el\u00a0\ncrecimiento.\u00a0\u00a0No\u00a0 No\u00a0 No\u00a0D\u00e9ficit\u00a0de\u00a0\nPRKCD\u00a0\n\u00a0\n(inmuno\u2010\ndesregulaci\u00f3n)\u00a0511\u2013514\u00a0\u00a0\u00a0\n\u00a0\n\u00a0Tabla\u00a0suplementaria\u00a01\u00a0(continuaci\u00f3n)\u00a0\nGen,\u00a0\nOMIM\u00a0\n\u00a0Localizaci\u00f3n/\u00a0\nFunci\u00f3n\u00a0en\u00a0\nlinfocito\u00a0B\u00a0N\u00ba\u00a0pacientes\u00a0analizados/\u00a0\nInicio\u00a0de\u00a0s\u00edntomasEfecto\u00a0\nsobre\u00a0la\u00a0\nprote\u00edna/\u00a0Herencia\n\u00a0Alteraciones\u00a0en\u00a0c\u00e9lulas\u00a0del\u00a0sistema\u00a0inmune\n\u00a0Otras\u00a0alteraciones\u00a0inmunol\u00f3gicas\n\u00a0Manifestaciones\u00a0cl\u00ednicas\u00a0 \u00a0Familiares\u00a0con\u00a0IDP\u2010Ac\n\u00a0Familiares\u00a0asintom\u00e1ticos\n\u00a0Poblaci\u00f3n\u00a0general\n\u00a0Fenotipo\u00a0IDVC/otra\u00a0\n\u00a0IDP\u00a0(IUIS)\n\u00a0Referencias\u00a0\nbibliogr\u00e1ficas \u00a0\nPLCG2\u00a0\n\u00a0\n600220\u00a016q23.3\u00a0\n\u00a0\nCascada\u00a0de\u00a0\nse\u00f1alizaci\u00f3n\u00a0a\u00a0\ntrav\u00e9s\u00a0del\u00a0BCR\u00a030\u00a0(4\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0\npedi\u00e1trica\u00a0GF\u00a0\n(expresi\u00f3n\u00a0\nnormal)\u00a0\n\u00a0\nAD\u00a0Linfocitos\u00a0B\u00a0totales\u2193\u00a0o\u00a0\nnormales,\u00a0de\u00a0memoria\u00a0IgG+\u00a0e\u00a0\nIgA+\u2193,\u00a0linfocitos\u00a0T\u00a0(totales\u00a0y\u00a0\nsupoblaciones)\u00a0normales,\u00a0\nc\u00e9lulas\u00a0NK\u2193\u00a0o\u00a0normales.\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193\u00a0o\u00a0\nnorma,\u00a0respuesta\u00a0a\u00a0\nvacunas\u00a0de\u00a0\npolisac\u00e1ridos\u2193\u00a0o\u00a0\nnormal.\u00a0\u00a0Problemas\u00a0de\u00a0piel\u00a0(urticaria\u00a0fr\u00eda\u00a0\ny\u00a0atop\u00eda)\u00a0AI,\u00a0granulomas,\u00a0\ninfecciones\u00a0por\u00a0hongos,\u00a0\nbacterias\u00a0y\u00a0herpes\u00a0z\u00f3ster.\u00a0No\u00a0 No\u00a0 No\u00a0PLAID\u00a0\n(S\u00edndrome\u00a0\nautoinflamatorio)\u00a0515,516\u00a0\nCTLA\u20104\u00a0\n\u00a0\n123890\u00a02q33.2\u00a0\n\u00a0Se\u00f1alizaci\u00f3n\u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0\nCD80/CD86\u00a0>100\u00a0\n\u00a0Edad\u00a0\npedi\u00e1trica\u00a0y\u00a0\nadulta\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\u2193)\u00a0\n\u00a0\nAD\u00a0Linfocitos\u00a0B\u00a0totales\u2193\u00a0o\u00a0\nnormales,memoria\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u00a0,\u00a0CD21\n\u2010\u2191,\u00a0linfocitos\u00a0\nT\u00a0totales,\u00a0CD4+\u00a0y\u00a0CD8+\u00a0(na\u00efve\u00a0y\u00a0\ntotales)\u2193\u00a0o\u00a0normales,\u00a0de\u00a0memoria\u00a0CD4\n+\u00a0y\u00a0CD8+,\u00a0Treg\u00a0y\u00a0T\u00a0\nCD4\u2010\u00a0CD8\u2010\u2193\u00a0o\u00a0normales,\u00a0\u00a0\nc\u00e9lulas\u00a0NK\u2193\u00a0o\u00a0normales.\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193\u00a0o\u00a0\nnormal\u00a0(en\u00a0la\u00a0mayor\u00eda),\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0de\u00a0\npolisac\u00e1ridos\u2193\u00a0o\u00a0normal.\u00a0\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n\u00a0\n(incluyendo\u00a0g\u00e9rmenes\u00a0oportunistas),\u00a0AI\u00a0grave\u00a0\n(frecuentemente\u00a0citopenias),\u00a0\nLP\u00a0con\u00a0infiltraci\u00f3n\u00a0de\u00a0\u00f3rganos,\u00a0enteropat\u00eda,\u00a0organomegalias,\u00a0adenopat\u00edas,\u00a0c\u00e1ncer\u00a0y\u00a0retraso\u00a0\nde\u00a0crecimiento.\u00a0\u00a0Si\u00a0\u00a0\n(D\u00e9ficit\u00a0de\u00a0\nIgA)\u00a0Si\u00a0 No\u00a0D\u00e9ficit\u00a0de\u00a0 CTLA\u20104\u00a0\n\u00a0(Inmuno\u2010\ndesregulaci\u00f3n)\u00a0\n454,473,517\u2013\n523524\u00a0\nLRBA\u00a0\n\u00a0\n606453\u00a04q31.3\u00a0\n\u00a0\nRegulaci\u00f3n\u00a0de\u00a0\nCTLA\u20104\u00a077\u00a0\u00a0\n(57\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0\npedi\u00e1trica\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\n\u2193\u00a0o\u00a0\nausente\u00a0en\u00a0\nla\u00a0mayor\u00eda)\u00a0\n\u00a0\nAR\u00a0Linfocitos\u00a0B\u00a0totales,\u00a0de\u00a0\nmemoria\u00a0y\u00a0CPs\u2193\u00a0o\u00a0normales,\u00a0\ninmaduras\u00a0y\u00a0na\u00efve\u2193o\u00a0\nnormales\u00a0o\u2191,\u00a0\u00a0linfocitos\u00a0CD21\u2010\u00a0\nnormales\u00a0o\u2191,\u00a0linfocitos\u00a0T\u00a0\ntotales,\u00a0Treg,\u00a0CD4+\u00a0y\u00a0CD8+\u00a0\n(totales\u00a0y\u00a0na\u00efve)\u2193\u00a0o\u00a0normales,\u00a0\nde\u00a0memoria\u00a0CD4+\u00a0y\u00a0CD8+\u00a0y\u00a0T\u00a0\nfoliculares\u00a0normales\u00a0o\u2191.\u00a0IgG\u00a0e\u00a0IgA\u2191\u00a0o\u00a0normal\u00a0o\u00a0\n\u2193\u00a0(en\u00a0la\u00a0mayor\u00eda),\u00a0IgM\u00a0\n\u2193\u00a0o\u00a0normal,\u00a0respuesta\u00a0a\u00a0\nvacunas\u00a0proteicas\u00a0y\u00a0de\u00a0\npolisac\u00e1ridos\u2193\u00a0o\u00a0\nnormal.\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n\u00a0\n(incluyendo\u00a0g\u00e9rmenes\u00a0\noportunistas),\u00a0AI\u00a0grave\u00a0y\u00a0de\u00a0\ninicio\u00a0temprano,\u00a0\n(especialmente\u00a0citopenias\u00a0y\u00a0\nenfermedad\u00a0inflamatoria\u00a0\nintestinal),\u00a0LP\u00a0con\u00a0infiltraci\u00f3n\u00a0\nde\u00a0\u00f3rganos,\u00a0organomegalias,\u00a0\nadenopat\u00edas,\u00a0c\u00e1ncer\u00a0y\u00a0retraso\u00a0\nde\u00a0crecimiento.\u00a0No\u00a0Si\u00a0(dos\u00a0casos\u00a0<\u00a0\nde\u00a018\u00a0a\u00f1os\u00a0\nasintom\u00e1ticos;\u00a0\nposible\u00a0\nevoluci\u00f3n)\u00a0No\u00a0D\u00e9ficit\u00a0de\u00a0 LRBA\u00a0\n\u00a0(Inmuno\u2010\ndesregulaci\u00f3n)\u00a0272,473,525\u2013\n538\u00a0\nICOS\u00a0\n\u00a0\n604558\u00a02q33.2\u00a0\n\u00a0\nCambio\u00a0de\u00a0\nisotipo,\u00a0\nformaci\u00f3n\u00a0de\u00a0\nCG,\u00a0\ndiferenciaci\u00f3n\u00a016\u00a0\n(7\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0\npedi\u00e1trica\u00a0y\u00a0\nadulta\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\nausente)\u00a0\n\u00a0\nAR\u00a0Linfocitos\u00a0B\u00a0totales\u2193\u00a0o\u00a0\nnormales,\u00a0de\u00a0memoria\u00a0\nausentes\u00a0o\u2193,\u00a0CPs\u00a0en\u00a0MO\u00a0\nausentes,\u00a0linfocitos\u00a0TCD4+,\u00a0\nTCD8+\u00a0y\u00a0T\u00a0foliculares\u2193\u00a0o\u00a0\nnormales.\u00a0IgG\u2193,\u00a0IgA\u00a0e\u00a0IgM\u2193\u00a0o\u00a0\nnormal,\u00a0respuesta\u00a0a\u00a0\nvacunas\u00a0proteicas\u00a0y\u00a0de\u00a0\npolisac\u00e1ridos\u2193.\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n\u00a0\n(incluyendo\u00a0g\u00e9rmenes\u00a0\noportunistas),\u00a0AI,\u00a0\norganomegalias,\u00a0hiperplasia\u00a0\nlinfoide\u00a0y\u00a0granulomas.\u00a0No\u00a0 No\u00a0 No\u00a0D\u00e9ficit\u00a0de\u00a0 ICOS\u00a0\n(CID)\u00a0539\u2013543\u00a0\nCD27\u00a0\n\u00a0\n186711\u00a012p13.31\u00a0\n\u00a0\nDiferenciaci\u00f3n,\u00a0\nsupervivencia\u00a0y\u00a0\ncambio\u00a0de\u00a0\nisotipo\u00a017\n(9\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0\npedi\u00e1trica\u00a0y\u00a0\nadulta\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\n\u2193\u00a0o\u00a0\nausente)\u00a0\n\u00a0\nAR\u00a0Linfocitos\u00a0B\u00a0totales\u2193\u00a0o\u00a0\nnormales,\u00a0de\u00a0memoria\u00a0\nausentes,\u00a0\nlinfocitos\u00a0T\u00a0CD4+\u2193\u00a0o\u00a0normales,\u00a0\nT\u00a0CD8+\u00a0y\u00a0CD4\u2010CD8\u2010\u2191\u00a0o\u00a0\nnormales.\u00a0IgG\u2193,\u00a0normal\u00a0o\u2191,\u00a0\nIgA\u00a0e\u00a0IgM\u2193\u00a0o\u00a0normal,\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0\nproteicas\u00a0y\u00a0de\u00a0\npolisac\u00e1ridos\u2193\u00a0o\u00a0\nnormal.\u00a0Infecciones\u00a0cr\u00f3nicas,\u00a0graves\u00a0y\u00a0\nat\u00edpicas\u00a0por\u00a0EBV,\u00a0\nanemia\u00a0apl\u00e1sica\u00a0y\u00a0linfoma.\u00a0No\u00a0 No\u00a0 No\u00a0Deficiencia\u00a0de\u00a0\nCD27\u00a0\n(Inmuno\u2010\ndesregulaci\u00f3n)\u00a0544\u2013546\u00a0\u00a0\n\u00a0Tabla\u00a0suplementaria\u00a01\u00a0(continuaci\u00f3n)\u00a0\nGen,\u00a0\nOMIM\u00a0\n\u00a0Localizaci\u00f3n/\u00a0\nFunci\u00f3n\u00a0en\u00a0\nlinfocito\u00a0B\u00a0N\u00ba\u00a0pacientes\u00a0analizados/\u00a0\nInicio\u00a0de\u00a0s\u00edntomasEfecto\u00a0sobre\u00a0la\u00a0\nprote\u00edna/\u00a0\nHerencia\n\u00a0Alteraciones\u00a0en\u00a0c\u00e9lulas\u00a0\ndel\u00a0sistema\u00a0inmune \u00a0Otras\u00a0alteraciones\u00a0inmunol\u00f3gicas\n\u00a0Manifestaciones\u00a0cl\u00ednicas\u00a0 \u00a0Familiares\u00a0con\u00a0IDP\u2010Ac\n\u00a0Familiares\u00a0asintom\u00e1ticos\n\u00a0Poblaci\u00f3n\u00a0general\n\u00a0Fenotipo\u00a0IDVC/otra\u00a0\n\u00a0IDP\u00a0(IUIS)\n\u00a0Referencias\u00a0\nbibliogr\u00e1ficas \u00a0\nIL21R\u00a0\n\u00a0\n605383\u00a016p12.1\u00a0\n\u00a0\nCambio\u00a0de\u00a0\nisotipo,\u00a0\nformaci\u00f3n\u00a0\ndel\u00a0CG\u00a0y\u00a0\ndiferenciaci\u00f3n\u00a08\u00a0(6\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0PF\u00a0\n(expresi\u00f3n\u2193\u00a0o\u00a0\nausente)\u00a0\n\u00a0\nAR\u00a0Linfocitos\u00a0B\u00a0total es\u2193,\u00a0normales\u00a0o\u00a0\n\u2191,\u00a0\nde\u00a0memoria\u00a0IgM++D+\u00a0y\u00a0con\u00a0cambio\u00a0\nde\u00a0isotipo\u2193\u00a0o\u00a0normales,\u00a0\nlinfocitos\u00a0T\u00a0tota les\u00a0normales,\u00a0\nT\u00a0CD4+,\u00a0CD8+\u00a0y\u00a0T\u00a0foliculares\u2193\u00a0o\u00a0\nnormales,\u00a0c\u00e9lulas\u00a0NK\u2193\u00a0o\u00a0normales.\u00a0IgG\u00a0e\u00a0IgA\u2193\u00a0o\u00a0\nnormal,\u00a0\nIgM\u2191\u00a0o\u00a0normal,\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0\nproteicas\u00a0y\u00a0de\u00a0\npolisac\u00e1ridos\u2193.\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n,\u00a0\n(incluyendo\u00a0g\u00e9rmenes\u00a0\noportunistas) \u00a0\norganomegalias,\u00a0lupus\u00a0\ndiscoide\u00a0e\u00a0inflamaci\u00f3n\u00a0de\u00a0\nla\u00a0piel,\u00a0enfermedad\u00a0\nhep\u00e1tica\u00a0y\u00a0retraso\u00a0de\u00a0\ncrecimiento.\u00a0\n\u00a0No\u00a0 No \u00a0 No\u00a0D\u00e9ficit\u00a0de\u00a0\nIL21R\u00a0\n(CID)\u00a0\n\u00a0547\u2013550\u00a0\nIL21\u00a0\n\u00a0\n605384\u00a04q27\u00a0\n\u00a0\nCambio\u00a0de\u00a0\nisotipo,\u00a0\nformaci\u00f3n\u00a0del\u00a0\nCG\u00a0y\u00a0\ndiferenciaci\u00f3n\u00a01\u00a0\n\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0PF\u00a0\n(expresi\u00f3n\u00a0\nnormal)\u00a0\n\u00a0\nAR\u00a0Linfocitos\u00a0B\u00a0total es\u2193,\u00a0de\u00a0memoria\u00a0\nIgM++D+\u00a0y\u00a0con\u00a0cambio\u00a0de\u00a0isotipo\u2193\u00a0IgG\u2193,\u00a0IgA\u00a0e\u00a0IgM\u00a0\nnormal,\u00a0IgE\u2191,\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0\nproteicas\u00a0y\u00a0de\u00a0\npolisac\u00e1ridos\u2193.\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n,\u00a0\nenfermedad\u00a0inflamatoria\u00a0\nintestinal\u00a0y\u00a0retraso\u00a0de\u00a0\ncrecimiento.\u00a0No\u00a0 No\u00a0 No\u00a0D\u00e9ficit\u00a0de\u00a0\nIL21\u00a0\u00a0\n(CID)\u00a0\n\u00a0551\u00a0\nSTAT3\u00a0\n\u00a0\n102582\u00a0\n\u00a017q21.2\u00a0\u00a0\u00a0\n\u00a0\nReacci\u00f3n\u00a0de\u00a0\nCG,\u00a0\nDiferenciaci\u00f3n\u00a0\ny\u00a0cambio\u00a0de\u00a0\nisotipo.\u00a023\u00a0(20\u00a0familias)\u00a0\n\u00a0\nEdad\u00a0pedi\u00e1trica\u00a0\n\u00a0GF\u00a0(expresi\u00f3n\u00a0\nnormal)\u00a0\n\u00a0\nAD\u00a0Incompleto\u00a0(solo\u00a0algunos\u00a0casos).\nLinfocitos\u00a0B\u00a0normales,\u00a0na\u00efve\u2191,\u00a0de\u00a0\nmemoria\u00a0IgMD+\u2191\u00a0o\u00a0normales,\u00a0\ntransicionales\u00a0y\u00a0de\u00a0memoria\u00a0con\u00a0\ncambio\u00a0de\u00a0isotipo\u2193\u00a0o\u00a0normales,\u00a0\nlinfocitos\u00a0T\u00a0totales\u00a0y\u00a0CD4+(totales\u00a0y\u00a0\nna\u00efve)\u2193\u00a0o\u00a0normales,\u00a0T\u00a0CD8+\u00a0\nnormales,\u00a0TCD8+\u00a0y\u00a0TCD4+\u00a0de\u00a0\nmemoria\u00a0normales\u00a0o\u2191.\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193o\u00a0\nnormales.\u00a0\n\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n\u00a0\n(incluyendo\u00a0g\u00e9rmenes\u00a0\noportunistas),\u00a0AI,\u00a0LP,\u00a0\norganomegalias\u00a0y\u00a0retraso\u00a0\nde\u00a0crecimiento.\u00a0No\u00a0 Si\u00a0 No\u00a0Mutaci\u00f3n\u00a0\ncon\u00a0\nganancia\u00a0\nde\u00a0funci\u00f3n\u00a0\nen\u00a0STAT3\u00a0267,473,552\u2013\n554\u00a0\nIL2RG*\u00a0\n308380\u00a0Xq13.1\u00a0\n\u00a0\nDiferenciaci\u00f3n\u00a02\u00a0(1\u00a0familia)\u00a0\n\u00a0\nEdad\u00a0adulta\u00a0y\u00a0\npedi\u00e1trica\u00a0PF\u00a0(expresi\u00f3n\u2193)\u00a0\n\u00a0\nLigada\u00a0a\u00a0\ncromosoma\u00a0X\u00a0Linfocitos\u00a0B\u00a0y\u00a0T\u00a0normales,\u00a0ausencia\u00a0\nde\u00a0c\u00e9lulas\u00a0NK.\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193.\u00a0\nrespuesta\u00a0a\u00a0vacunas\u00a0\nde\u00a0polisac\u00e1ridos\u00a0y\u00a0\nnormal\u00a0y\u00a0\nproteicas\u2193.\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n,\u00a0\nAI\u00a0(espec\u00edfica\u00a0de\u00a0\u00f3rgano)\u00a0No\u00a0 No\u00a0 No\u00a0D\u00e9ficit\u00a0en\u00a0\nILR2G\u00a0(\u03b3c)\u00a0\u00a0\n\u00a0\n(SCID\u00a0T\u2010B+)\u00a0270\u00a0\nRAG1*\u00a0\n\u00a0\n179615\u00a0\n\u00a011p12\u00a0\u00a0\u00a0\n\u00a0\nRecombinaci\u00f3n\u00a0\nV(D)J\u00a03\u00a0(3\u00a0familias)\u00a0PF\u00a0\u00a0\n\u00a0\nAR\u00a0Linfocitos\u00a0B\u2193,\u00a0de\u00a0memoria\u00a0con\u00a0\ncambio\u00a0de\u00a0isotipo\u2193,\u00a0linfocitos\u00a0T\u00a0\ntotales\u2193\u00a0de\u00a0memoria\u2191,\u00a0c\u00e9lulas\u00a0\nNK\u2193\u00a0o\u00a0normales.\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193.\nrespuesta\u00a0a\u00a0vacunas\u00a0\nde\u00a0polisac\u00e1ridos\u2193\u00a0y\u00a0\na\u00a0proteicas\u00a0normal,\u00a0\nausencia\u00a0de\u00a0\nisohemaglutininas.\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n,\u00a0\nAI,\u00a0organomegalias\u00a0y\u00a0\nlinfoproliferaci\u00f3n.\u00a0No\u00a0 No\u00a0 No\u00a0D\u00e9ficit\u00a0en\u00a0\nRAG1\u00a0\n(SCID\u00a0T\u2010B\u2010)\u00a0268,555\u00a0\u00a0\u00a0\n\u00a0\n\u00a0Tabla\u00a0suplementaria\u00a01\u00a0(continuaci\u00f3n)\u00a0\nTabla\u00a0adaptada,\u00a0y\u00a0actualizada\u00a0a\u00a0partir\u00a0de\u00a0Bogaert\u00a0 et\u00a0al265.\u00a0y\u00a0Picard\u00a0et\u00a0al.209.\u00a0*Genes\u00a0t\u00edpicamente\u00a0asociados\u00a0a\u00a0inmunodeficiencias\u00a0combinadas\u00a0 severas,\u00a0en\u00a0los\u00a0que\u00a0se\u00a0han\u00a0observ ado\u00a0mutaciones\u00a0hipom\u00f3rficas\u00a0qu e\u00a0originan\u00a0\nfenotipos\u00a0de\u00a0IDVC,\u00a0incluy\u00e9ndose\u00a0en\u00a0la\u00a0tabla\u00a0solamente\u00a0el\u00a0n\u00famero \u00a0y\u00a0las\u00a0caracter\u00edsticas\u00a0de\u00a0esos\u00a0c asos.\u00a0\u2193,\u00a0descenso;\u00a0\u2191,\u00a0aumento;\u00a0 AD,\u00a0autos\u00f3mica\u00a0dominante;\u00a0AI,\u00a0autoinmunidad;\u00a0AR,\u00a0autos\u00f3mica\u00a0rec esiva;\u00a0CMV,\u00a0citomegalovirus;\u00a0\nCID,\u00a0inmunodeficiencia\u00a0combinada\u00a0(del\u00a0ingl\u00e9s,\u00a0 combined\u00a0immunodeficiency );\u00a0EBV,\u00a0virus\u00a0de\u00a0Epstein\u2010Barr;\u00a0IDVC,\u00a0inmunodeficiencia\u00a0variable \u00a0com\u00fan;\u00a0IDP\u2010Ac,\u00a0inmunodeficiencia\u00a0 predominantemente\u00a0de\u00a0anticuer pos;\u00a0LP,\u00a0\nlinfoproliferaci\u00f3n;\u00a0PF,\u00a0p\u00e9rdida\u00a0d e\u00a0funci\u00f3n;\u00a0GF,\u00a0ganancia\u00a0de\u00a0fun ci\u00f3n;\u00a0SCID,\u00a0inmunodeficiencia\u00a0c ombinada\u00a0severa\u00a0(del\u00a0ingl\u00e9s,\u00a0 severe\u00a0combined\u00a0immunodeficiency ).\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0Gen,\u00a0\nOMIM\u00a0\n\u00a0Localizaci\u00f3n/\u00a0\nFunci\u00f3n\u00a0en\u00a0\nlinfocito\u00a0B\u00a0N\u00ba\u00a0pacientes\u00a0analizados/\u00a0\nInicio\u00a0de\u00a0s\u00edntomasEfecto\u00a0sobre\u00a0la\u00a0\nprote\u00edna/\u00a0\nHerencia\n\u00a0Alteraciones\u00a0en\u00a0c\u00e9lulas\u00a0\ndel\u00a0sistema\u00a0inmune \u00a0Otras\u00a0alteraciones\u00a0inmunol\u00f3gicas\n\u00a0Manifestaciones\u00a0cl\u00ednicas\u00a0 \u00a0Familiares\u00a0con\u00a0IDP\u2010Ac\n\u00a0Familiares\u00a0asintom\u00e1ticos\n\u00a0Poblaci\u00f3n\u00a0general\n\u00a0Fenotipo\u00a0IDVC/otra\u00a0\n\u00a0IDP\u00a0(IUIS)\n\u00a0Referencias\u00a0\nbibliogr\u00e1ficas \u00a0\nJAK3*\u00a0\n\u00a0\n600173\u00a0\n\u00a0\u00a019p13.11 \u00a0\u00a0\u00a0\nDiferenciaci\u00f3n\u00a0\ny\u00a0supervivencia\u00a01\u00a0PF\u00a0\u00a0\n\u00a0\nAR\u00a0Linfocitos\u00a0B\u00a0totales\u00a0normales,\u00a0\nLinfocitos\u00a0T\u00a0y\u00a0NK\u00a0normales\u00a0(\u2193en\u00a0\nestudio\u00a0posterior).\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193,\u00a0\nausencia\u00a0de\u00a0\nisohemaglutininas.\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n\u00a0\n(incluyendo\u00a0g\u00e9rmenes\u00a0\noportunistas),\u00a0\nlinfoproliferaci\u00f3n,\u00a0\nenteropat\u00eda\u00a0y\u00a0retraso\u00a0de\u00a0\ncrecimiento.\u00a0No\u00a0 No\u00a0 No\u00a0D\u00e9ficit\u00a0en\u00a0\nJAK3\u00a0\n(SCID\u00a0T\u2010B+)\u00a0269\u00a0\nDCLRE1C*\u00a0\n605988\u00a010p13\u00a0\u00a0\u00a0\nRecombinaci\u00f3n\u00a0\nV(D)J\u00a03\u00a0(1\u00a0familia)\u00a0PF\u00a0\u00a0\n\u00a0\nAR\u00a0Linfocitos\u00a0B\u2193,\u00a0linfocitos\u00a0T\u00a0totales\u00a0\nnormales,\u00a0y\u00a0na\u00efve\u2193.\u00a0IgG,\u00a0IgA\u00a0e\u00a0IgM\u2193\u00a0Infecciones\u00a0de\u00a0repetici\u00f3n\u00a0\ny\u00a0AI.\u00a0No\u00a0 No\u00a0 No\u00a0D\u00e9ficit\u00a0de\u00a0\nArtemis\u00a0\n(SCID\u00a0T\u2010B\u2010)\u00a0271\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n \n  \u00a0\u00a0\n\u00a0\n\u00a0 \n \n \n \n \n \nAnexo II \n \n  \u00a0\n\u00a0\n\u00a0 \n  \u00a0\u00a0\n\u2010\u00a0187\u00a0\u2010\u00a0\n\u00a0MATERIAL SUPLEMENTARIO CORRESPONDIENTE AL \nART\u00cdCULO 1 \n \n \nSelecci\u00f3n\u00a0y\u00a0validaci\u00f3n\u00a0de\u00a0clones\u00a0 de\u00a0anticuerpos\u00a0dirigidos\u00a0frent e\u00a0a\u00a0\nsubclases\u00a0de\u00a0IgA\u00a0e\u00a0IgG\u00a0expresadas \u00a0en\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0 c\u00e9lulas\u00a0\nplasm\u00e1ticas\u00a0que\u00a0presentan\u00a0cambio\u00a0de\u00a0isoti po\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nE n \u00a0e s t a \u00a0s e c c i \u00f3 n \u00a0s e \u00a0r e c o g e n : \u00a01 ) \u00a0u n \u00a0e j e m p l o \u00a0i l u s t r a t i v o \u00a0d e l \u00a0m a r c a j e \u00a0d e \u00a0l o s \u00a0c l o n e s \u00a0d e \u00a0A c s \u00a0\nseleccionados\u00a0dirigidos\u00a0frente\u00a0a\u00a0 las\u00a0distintas\u00a0subclases\u00a0de\u00a0IgG \u00a0e\u00a0IgA\u00a0y\u00a0su\u00a0marcaje\u00a0cruzado\u00a0\n(Supplementary\u00a0Figure\u00a0S1 );\u00a02)\u00a0un\u00a0ejemplo\u00a0ilustrativo\u00a0del\u00a0marcaje\u00a0citoplasm\u00e1tico\u00a0en\u00a0CPs\u00a0 de\u00a0MO\u00a0\nde\u00a0los\u00a0clones\u00a0de\u00a0Acs\u00a0seleccionados\u00a0dirigidos\u00a0frente\u00a0a\u00a0las\u00a0subcl ases\u00a0de\u00a0IgG\u00a0e\u00a0IgA\u00a0( Supplementary\u00a0\nFigure\u00a0 S2 );\u00a0 3)\u00a0 un\u00a0 ejemplo\u00a0 ilustrativo\u00a0 del\u00a0 marcaje\u00a0 citoplasm\u00e1tico\u00a0 de\u00a0 los\u00a0 clones\u00a0 de\u00a0 Acs\u00a0\nseleccionados\u00a0dirigidos\u00a0frente\u00a0a\u00a0 las\u00a0distintas\u00a0subclases\u00a0de\u00a0IgG \u00a0e\u00a0IgA,\u00a0con\u00a0y\u00a0sin\u00a0bloqueo\u00a0previo\u00a0de\u00a0\nlas\u00a0mismas\u00a0en\u00a0la\u00a0membrana\u00a0( Supplementary\u00a0Figure\u00a0S3 );\u00a04)\u00a0un\u00a0ejemplo\u00a0ilustrativo\u00a0del\u00a0marcaje\u00a0de\u00a0\nlos\u00a0clones\u00a0SAG4\u00a0y\u00a0HP6098\u00a0dirigidos\u00a0frente\u00a0a\u00a0IgG4\u00a0en\u00a0un\u00a0donante\u00a0 sano\u00a0(Supplementary\u00a0Figure\u00a0S4 );\u00a0\n5)\u00a0el\u00a0\u00edndice\u00a0de\u00a0marcaje\u00a0y\u00a0el\u00a0porcentaje\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memo ria\u00a0y\u00a0CPs\u00a0positivas\u00a0para\u00a0los\u00a0clones\u00a0\nde\u00a0Acs\u00a0seleccionados\u00a0dirigidos\u00a0frente\u00a0a\u00a0las\u00a0distintas\u00a0subclases \u00a0de\u00a0IgG\u00a0e\u00a0IgA,\u00a0con\u00a0y\u00a0sin\u00a0bloqueo\u00a0\nprevio\u00a0de\u00a0dichas\u00a0subclases\u00a0en\u00a0la\u00a0membrana\u00a0( Supplementary\u00a0Table\u00a0S1) ;\u00a06)\u00a0un\u00a0resumen\u00a0de\u00a0los\u00a0\nresultados\u00a0de\u00a0marcaje\u00a0obtenidos\u00a0para\u00a0los\u00a0clones\u00a0de\u00a0Acs\u00a0seleccio nados\u00a0y\u00a0alternativos\u00a0en\u00a0linfocitos\u00a0\nB\u00a0de\u00a0memoria\u00a0y\u00a0CPs\u00a0( Supplementary\u00a0Table\u00a0S2) .\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nJournal\u00a0of\u00a0Immunological\u00a0Methods\u00a0\nSeptiembre\u00a0de\u00a02017\u00a0\nDOI:\u00a010.1016/j.jim.2017.09.008\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\n Material eliminado para la versi\u00f3n almacenada en el repos itorio del Ministerio de Educaci\u00f3n \npor estar sujeto a copyright.  \n   \u00a0\u00a0\n\u2010\u00a0195\u00a0\u2010\u00a0\n\u00a0MATERIAL SUPLEMENTARIO CORRESPONDIENTE AL \nART\u00cdCULO 2 \n \nDistribuci\u00f3n\u00a0en\u00a0sangre\u00a0de\u00a0las\u00a0d istintas\u00a0subpoblaciones\u00a0de\u00a0linfo citos\u00a0B\u00a0y\u00a0\nde\u00a0c\u00e9lulas\u00a0plasm\u00e1ticas\u00a0normales\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nEn\u00a0esta\u00a0secci\u00f3n\u00a0se\u00a0recogen:\u00a01)\u00a0breve\u00a0descripci\u00f3n\u00a0del\u00a0protocolo\u00a0 de\u00a0procesamiento\u00a0de\u00a0las\u00a0muestras\u00a0\ny\u00a0del\u00a0marcaje\u00a0para\u00a0CD11c\u00a0( Methods);\u00a02)\u00a0estrategia\u00a0empleada\u00a0para\u00a0la\u00a0identificaci\u00f3n\u00a0de\u00a0las\u00a0\npoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0por\u00a0estadio\u00a0madurativo\u00a0( Figure\u00a0E1);\u00a03)\u00a0distribuci\u00f3n\u00a0relativa\u00a0en\u00a05\u00a0ni\u00f1os\u00a0\ny\u00a05\u00a0adultos\u00a0de\u00a0los\u00a0isotipos\u00a0y\u00a0su bclases\u00a0de\u00a0Igs\u00a0en\u00a0CPs\u00a0cuando\u00a0se \u00a0realiza\u00a0un\u00a0marcaje\u00a0de\u00a0membrana\u00a0\nvs.\u00a0membrana+citoplasm\u00e1tico\u00a0( Figure\u00a0E2 );\u00a04)\u00a0porcentaje\u00a0de\u00a0c\u00e9lulas\u00a0CD27\u2010\u00a0en\u00a0los\u00a0linfocitos\u00a0B\u00a0de\u00a0\nmemoria\u00a0en\u00a0sangre\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida\u00a0( Figure\u00a0E3);\u00a05)\u00a0porcentaje\u00a0de\u00a0c\u00e9lulas\u00a0CD21\u2010\u00a0dentro\u00a0de\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0na\u00efve\u00a0y\u00a0de\u00a0memoria\u00a0en\u00a0sangre\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida \u00a0(Figure\u00a0E4 );\u00a06)\u00a0comparaci\u00f3n\u00a0de\u00a0las\u00a0\nmedianas\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria,\u00a0CPs\u00a0e\u00a0Igs\u00a0solubles\u00a0en\u00a0plas ma,\u00a0de\u00a0cada\u00a0uno\u00a0de\u00a0los\u00a0isotipos\u00a0\ny\u00a0subclases\u00a0de\u00a0Igs\u00a0en\u00a0sangre\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida\u00a0( Figure\u00a0E5);\u00a07)\u00a0comparaci\u00f3n\u00a0entre\u00a0la\u00a0distribuci\u00f3n\u00a0\nde\u00a0IgG\u00a0e\u00a0IgA\u00a0total\u00a0 vs.\u00a0sus\u00a0subclases\u00a0dentro\u00a0de\u00a0los\u00a0linfo citos\u00a0B\u00a0de\u00a0memoria,\u00a0CPs\u00a0y\u00a0los\u00a0 Acs\u00a0solubles\u00a0\nen\u00a0plasma,\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida\u00a0( Figure\u00a0E6);\u00a08)\u00a0ejemplo\u00a0ilustrativo\u00a0del\u00a0marcaje\u00a0obtenido\u00a0con\u00a0CD11c\u00a0\nen\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0de\u00a0un\u00a0ni\u00f1o\u00a0y\u00a0un\u00a0adulto\u00a0( Figure\u00a0E7 );\u00a09)\u00a0distribuci\u00f3n\u00a0relativa\u00a0de\u00a0los\u00a0\nlinfocitos\u00a0B\u00a0de\u00a0memoria\u00a0t\u00edpicos,\u00a0 at\u00edpicos\u00a0y\u00a0otros\u00a0linfocitos\u00a0CD 21\u2010\u00a0a\u00a0lo\u00a0largo\u00a0de\u00a0la\u00a0vida\u00a0( Figure\u00a0E8 );\u00a0\n10)\u00a0ejemplo\u00a0ilustrativo\u00a0de\u00a0la\u00a0distribuci\u00f3n\u00a0de\u00a0los\u00a0linfocitos\u00a0B\u00a0 de\u00a0memoria\u00a0y\u00a0CPs\u00a0que\u00a0expresan\u00a0\ndistinto\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Igs\u00a0en\u00a0un\u00a0ni\u00f1o\u00a0evaluado\u00a0a\u00a0dos\u00a0ed ades\u00a0distintas\u00a0( Figure\u00a0E8 );\u00a011)\u00a0\ncaracter\u00edsticas\u00a0demogr\u00e1ficas\u00a0de\u00a0 los\u00a0ni\u00f1os\u00a0menores\u00a0de\u00a04\u00a0a\u00f1os\u00a0inc luidos\u00a0en\u00a0el\u00a0estudio\u00a0\u00a0( Table\u00a0E1);\u00a0\n12)\u00a0combinaci\u00f3n\u00a0de\u00a0Acs\u00a0monoclonales\u00a0utilizados\u00a0en\u00a0el\u00a0estudio:\u00a0t ubo\u00a0EuroFlow\u00a0de\u00a012\u00a0colores\u00a0para\u00a0\nla\u00a0evaluaci\u00f3n\u00a0de\u00a0isotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs \u00a0(Table\u00a0E2);\u00a013)\u00a0n\u00famero\u00a0absoluto\u00a0de\u00a0linfocitos\u00a0totales,\u00a0\nlinfocitos\u00a0B\u00a0y\u00a0subpoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0de\u00a0distintos\u00a0esta dios\u00a0madurativos\u00a0en\u00a0donantes\u00a0\nsanos\u00a0de\u00a0diferentes\u00a0grupos\u00a0de\u00a0edad\u00a0( Table\u00a0E3);\u00a014)\u00a0porcentaje\u00a0de\u00a0casos\u00a0con\u00a0n\u00fameros\u00a0detectables\u00a0\nde\u00a0linfocitos\u00a0B\u00a0de\u00a0memoria\u00a0y\u00a0CPs,\u00a0con\u00a0expresi\u00f3n\u00a0de\u00a0los\u00a0distinto s\u00a0isotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs,\u00a0as\u00ed\u00a0\ncomo\u00a0sus\u00a0n\u00fameros\u00a0absolutos\u00a0en\u00a0donantes\u00a0sanos\u00a0de\u00a0diferentes\u00a0grup os\u00a0de\u00a0edad\u00a0( Table\u00a0E4);\u00a015)\u00a0\nniveles\u00a0solubles\u00a0en\u00a0plasma\u00a0de\u00a0los\u00a0distintos\u00a0isotipos\u00a0y\u00a0subclase s\u00a0de\u00a0Igs\u00a0en\u00a0donantes\u00a0sanos\u00a0de\u00a0\ndiferentes\u00a0grupos\u00a0de\u00a0edad\u00a0( Table\u00a0E5).\u00a0\n\u00a0\u00a0\n\u00a0\u00a0\nJournal\u00a0of\u00a0Allergy\u00a0and\u00a0Clinical\u00a0Immunology\u00a0\nMarzo\u00a0de\u00a02018\u00a0\nDOI:\u00a010.1016/j.jaci.2018.02.017\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\u00a0METHODS\nSample preparation\nForty-eight milliliters of an ammonium chloride solution was mixed\nwith 2 mL of PB in a 50-mL tube and incubated for 15 minutes at room\ntemperature (RT) while gently shaking in a roller to lyse nonnucleated red\ncells. Then the cell suspension was centrifuged for 10 minutes at 800 g,a n d\nthe supernatant was removed by using a Pasteur pipette or a vacuum sys-\ntem without disturbing the cell pellet. Thereafter, cells were washed with50 mL of PBS containing 0.5% BSA and 0.09% sodium azide (PBS-BSA;\npH 7.6) and centrifuged at 800 gfor 5 minutes, and the supernatant was\nremoved. Subsequently, 4 mL of PBS plus 0.09% of NaN\n3plus 0.5% of\nBSA was added, and the cell suspension was transferred to a 5-mL tube,\nwhich was centrifuged at 540 gfor 5 minutes. After removal of the super-\nnatant, sample cellularity was counted in a hematologic analyzer. Tenmillion nucleated cells were stained subsequently with the 12-color Euro-Flow antibody combination (30 minutes at RT). When only smIgH stain-\ning was performed, 2 mL of FACS lysing solution (BD Biosciences, San\nJose, Calif) diluted 1:10 (vol/vol) in distilled water was added, and cellswere sequentially incubated for another 10 minutes at RT, washed, and re-\ns u s p e n d e di n5 0 0 mL of PBS-BSA. In turn, when surface membrane plus\ncytoplasmic IgH staining was performed, after surface membrane staining,\nthe cell suspension was washed and incubated with solution A of the Fix &Perm Reagent Kit (An der Grub, Vienna, Austria) for 15 minutes at RT.\nAfterward, washed cells were incubated for another 15 minutes at RT\nwith solution B of the Fix & Perm Reagent Kit and antibodies againstIgM, IgD, IgG\n1to IgG 4,a n dI g A 1and IgA 2; then stained cells were\nwashed and resuspended in 500 mL of PBS-BSA. In both protocols cells\nwere acquired immediately after sample preparation was completed orstored at 4 8C for a maximum of 1 hour.\nCD11c staining\nIn 6 adults (35 68 years) and 6 children (3 65 years), in addition to the\nEuroFlow 12-color IgH isotype B-cell tube ( Table E2 ), a similar tube that con-\ntained an anti-CD11c PE-Cy7 (clone B-ly6; BD) reagent instead of CD5 PE-Cy7 was stained in parallel. The protocol used was the same as described\nabove, and 5 310\n6leukocytes were measured per sample.J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 12.e1SSC\nSmIgM\nCD21\nCD5\nD g I m S 7 2D C 42D CCD388 3 D CCD19IMMATURE NA\u00cfVEUNSWITCHED \nMBCSWITCHED\nMBCPLASMA \nCELLS\nSmIgM7 2 D C\nFIG E1. Gating strategy used for identi\ufb01cation of maturation-associated B-cell subsets. Bivariate dot plot\ngraphic representations of the gating strategy used to identify immature, naive, switched, and unswitched\nMBCs and PCs, according to their pattern of expression of CD19, CD27, CD38, CD5, CD24, CD21, smIgM, andsmIgD and their side-scatter (SSC) features are shown.J ALLERGY CLIN IMMUNOL\nnnn201812.e2 BLANCO ET AL100\n80\n60\n40\n20\n0\nProtocol% of Plasma cells\nSm Sm + CyCHILDREN (n=6)\nsmIgG1+smIgG2+smIgG3+smIgG4+\nsmIgA1+smIgA2+\nonly smIgD+\nsmIgM+smIgH-ADULTS (n=6)\nProtocol% of P lasma cells\nSm Sm + Cy100\n80\n60\n40\n20\n0* *\nFIG E2. Comparison of the relative distribution in PC of subsets expressing distinct IgH isotypes and\nsubclasses when surface membrane only versus surface membrane plus cytoplasmic staining of aliquots of\nthe same sample (n 512) was performed. Bars represent relative distribution of the distinct IgH isotype and\nsubclass subsets of PCs with the sm-only versus surface membrane plus cytoplasmic IgH staining in chil-dren (n 56) and adults (n 56). *P< .05, surface membrane only versus surface membrane plus cytoplasmic\nstaining.J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 12.e3100\n020406080\nNDND ND100\n020406080Memory IgA1+\n020406080100 Memory IgA2+020406080100\nNDNDMemory IgG4+\nMemory IgD+0204060801000406080100\n20Memory IgG3+\n020406080100Memory IgG2+%CD27\u2013 memory B-cellsMemory IgG1+\nAge (years or months)*\u00a7 #\u00a7#\n# \u00a7****#*\n# #\nFIG E3. Relative distribution of CD272B cells within each subset of CB and PB memory B lymphocytes ex-\npressing different IgH isotypes and isotype subclasses through life. Bars represent percentage values of\nCD272B cells within each MBC compartment. *P < .05, # P< .01, and \u00a7 P< .001 versus the previous age\ngroup, respectively. NB, Newborn.J ALLERGY CLIN IMMUNOL\nnnn201812.e4 BLANCO ET AL100020406080100\n0204060100\n80\n020406080100\n020406080100 Memory IgA2+20406080100\n0\n020406080Na\u00efveMemory IgG3+\nMemory IgG1+\nMemory IgA1+Memory IgG2+\nMemory IgG4+\nMemory IgD+\nAge (years or months)NDND1 2 D C %\u2013 e v \u00ef a N d nay r o m e mB - s l l e c\nND ND ND20406080100\n0\n20406080100Memory IgM++D+\nND ND20406080100\n0\n20406080100\n0\n20406080100\n0*#\n*\n\u00a7#\n* *#**\n*\n* *##\n*\nFIG E4. Relative distribution of CD212B cells within each subset of CB and PB naive B lymphocytes and\nMBCs expressing different IgH isotypes and isotype subclasses through life. Bars represent percentage\nvalues of CD212B cells within each B-cell compartment. *P < .05, # P< .01, and \u00a7 P< .001 versus the previous\nage group, respectively. NB, Newborn.J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 12.e5050100150\n020406080100\n13579 1 1 1 3LOD <0.01\n00,511,52\n00,511,52\n13579 1 1 1 3LOD <0.010.51.5\n0.51.5\n0204060\n012345\n13579 1 1 1 3<0.01 LODIgD+IgG4+IgM++(D)+\nIgA2+\n02004006008001000\n01020304050\n13579 1 1 1 3LOD <0.01r e b m u N fos l l ecl\u03bc/Soluble Ig plasma levels ( mg/dl)IgG2+\n050100150200250\n05101520\n13579 1 1 1 3LOD <0.01IgG3+\n01020304050\n02468\n13579 1 1 1 3LOD <0.01\nIgG1+\nAge (years or months)IgA1+\n0100200300400\n0246\n13579 1 1 1 3LOD <0.01\n020406080100\n00,10,20,30,4\n1 3 5 7 9 11 130.4\n0.3\n0.2\n0.1\nLOD <0.01\nFIG E5. Direct comparison among median numbers of CB and PB MBCs, PCs, and immunoglobulin (Ig)sol-\nuble levels of the same IgH isotype and isotype subclasses through life. Lines correspond to median abso-\nlute numbers of MBCs (gray), PCs (black), and soluble immunoglobulin plasma levels (in milligram per\ndeciliter; red) per age group. LOD, Limit of detection; NB, newborn.J ALLERGY CLIN IMMUNOL\nnnn201812.e6 BLANCO ET AL300\n100\n20200\nLOD20\n10\n5\n1\nLOD LOD\n1200\n800\n400\nLOD100\nLOD60\n40\n1020\n210\n16\nLODA B C\nD E FSoluble levels (mg/dl)\nAge (years or months)20\n510r e b m u N fos l l ecl \u03bc /PLASMA CELLS MEMORY B-CELLSSOLUBLE PLASMA \nLEVELS\nIgG1Total IgGIgA2Total IgA\nIgA1\nIgG2IgG3\nIgG4IgA1 IgA1\nIgA2\nIgG1\nIgG3IgG2\nIgG4IgG4IgG3IgG2IgG1Total IgA Total IgA\nTotal IgG Total IgG1\nIgA2\nFIG E6. Comparison of the distribution of CB/PB MBCs and PCs, as well as soluble immunoglobulin plasma\nlevels, through life: total IgA and IgG versus individual cellular and soluble compartments of IgA and IgG\nsubclasses. Lines link median values of total IgA (black), IgA 1(orange), and IgA 2(yellow) MBCs (A), PCs (B),\nand soluble immunoglobulin plasma levels (C)plus total IgG (gray), IgG 1(light blue), IgG 2(light green), IgG 3\n(dark blue), and IgG 4(dark green) MBCs (D), PCs (E), and soluble immunoglobulin plasma levels (F).LOD,\nLimit of detection; NB, newborn.J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 12.e7ADULT\n CHILD\nFIG E7. Pattern of expression of CD21 in CD11c1in MBCs. Dot plots illus-\ntrating CD11c expression with MBCs of a representative healthy child and\na healthy adult are shown. In both types of samples, CD11c1MBCs system-\natically corresponded to CD212MBCs in line with previous \ufb01ndings re-\nported in the literature.27,71J ALLERGY CLIN IMMUNOL\nnnn201812.e8 BLANCO ET ALMemory IgA1+Memory IgA2+Memory IgG4+Memory IgG3+ Memory IgG2+\nMemory IgG1+\nMe\nmo\nry\nIgD\n+Memory IgD+\nND ND NDNDND20406080100\n0\n20406080100\n020406080100\n020406080100\n020406080100\n020406080100\n020406080100\n0% y r o m e m B-cellsCD27+CD21+\nCD27+CD21-\nCD27-CD21+\nCD27-CD21-\nAge (years or months)\u00a7#\n*\n*#\n\u00a7\n\u00a7\n\u00a7\n#####\n\u00a7\n\u00a7\n\u00a7#\n#\n#\n**\n\u00a7*\n*\n* *##\n#\n**\n*\n*\n#\n*\n**\n*\n****\n*\n*#\n*#\n**\n*\n*\n##**\n##\n#*\n**\n*\n* *A)\nB)\nFIG E8. Relative distribution of typical, atypical, and other CD212B cells within each compartment of MBCs\nexpressing different IgH isotypes and subclasses through life. A,Representative dot plot of MBCs grouped\naccording to CD21 and CD27 expression. B,Bars represent percentage values of typical (CD271CD211),\natypical (CD272CD212), other CD212B cells (CD271CD212) and CD272CD211MBCs within each subset of\nMBCs expressing different IgH isotypes and subclasses. *P < .05, # P< .01, and \u00a7 P< .001 versus the previous\nage group, respectively. NB, Newborn.J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 12.e9Memory B-cells23 MONTHS\nPlasma cellsIgMD\nIgMD\nIgMIgMIgA1\nIgA1\nIgA1\nIgA1IgA2\nIgA2\nIgA2IgDIgG2IgG2\nIgG2IgG2\nIgG4IgG4IgG4IgG4\nIgG1\nIgG1IgG1\nIgG1IgG3IgG3\nIgG3IgG3\nIgA2IgDA)\nB)41 MONTHS\nFIG E9. t-Distributed stochastic neighbor embedding plots showing the relative size of different subsets of\nMBCs and PCs expressing distinct IgH isotypes and subclasses in a single child at 2 different ages (23 and\n41 months). Please note the relative decrease in, for example, IgG 3MBCs (A)and both IgM and IgG 3PCs at\nthe expense of a larger IgA 1and IgG 1PC area (B).J ALLERGY CLIN IMMUNOL\nnnn201812.e10 BLANCO ET ALTABLE E1. Demographics of children younger than 4 years included in the study\nEnvironmental factorsAge group\n0-5 mo 6-11 mo 12-17 mo 18-23 mo 2-4 y\nBreast-feeding ever 80% 100% 71% 86% 92%\nBreast-feeding until 6 mo \u2014 60% 30% 50% 50%\nDay care 20% 40% 71% 43% 83%\nPets 20% 20% 14% 0% 25%\nRural environment 0% 40% 43% 29% 17%\nSmoking parents 60% 20% 14% 29% 25%\nSmoking during pregnancy 20% 40% 14% 14% 17%\nDelivery\nVaginal 100% 60% 86% 71% 92%\nCaesarean 0% 20% 14% 29% 8%\nPercentage of subjects analyzed presenting each environmental factor per age group.J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 12.e11TABLE E2. EuroFlow 12- color IgH isotype B-cell tube\nFluorochrome\nconjugated toantibodyreagent BV421 BV510 BV711 BV650 BV786 FITC PerCP-Cy5.5 PE PE-CF594 PE-Cy7 APC APC-H7\nAntibody\nmarkerCD27 smIgM CD21 CD24 CD19 smIgG 31\nsmIgG 2smIgA 11\nsmIgA 2smIgG 11\nsmIgG 2smIgD CD5 smIgG 41\nsmIgA 1CD38\nAntibody\ncloneM-T271 MHM-88 B-ly4 ML5 SJ25C1 SAG3/SAG2 SAA1/SAA2 SAG1/SAG2 IA6-2 L17F12 SAG4/SAA1 HB7\nAntibody\nmanufacturerBD Biosciences,\nSan Jose, CalifBioLegend,\nSan Diego,\nCalifBD\nBiosciencesBD\nBiosciencesBD\nBiosciencesCytognos,\nSalamanca,SpainCytognos Cytognos BD\nBiosciencesBD\nBiosciencesCytognos BD\nBiosciences\nCombination of \ufb02uorochrome-conjugated antibodies used for the immunophenotypic analysis of PB samples by \ufb02ow cytometry.\nAPC, Allophycocyanin; FITC , \ufb02uorescein isothiocyanate; PE, phycoerythrin; PerCP , peridinin-chlorophyll-protein complex.J ALLERGY CLIN IMMUNOL\nnnn201812.e12 BLANCO ET ALTABLE E3. Absolute number of PB lymphocytes, total B cells, and maturation-associated B-cell subsets in healthy control subjects distributed per age group\nCB (n519) NB (n 514) 1-5 mo (n 511)6-11 mo\n(n57)12-17 mo\n(n512)18-23 mo\n(n512)2-4 y\n(n525)5-9 y\n(n522)10-17 y\n(n514)18-39 y\n(n532)40-59 y\n(n527)60-79 y\n(n527)>80 y\n(n512)\nLymphocytes 3,710\n(2,041-5,687)5,049\n(2,581-8,360)6,771\n(2,443-9,955)5,709\n(5,150-8,531)6,547(4,611-9,924)5,014\n(3,798-11,033)4,184(1,620-6,856)3,134(1,967-4,564)3,109(1,749-3,739)2,504(1,479-3,681)2,273(1,280-3,192)2,408(1,531-4,891)2,386(938-2,793)\nTotal B cells 502\n(313-1,280)357\n(108-1,322)1533 (470-4,327) 1,294\n(869-2,316)1,186(692-1,737)965\n(268-1,559)825\n(302-1,637)451 (157-725) 360 (174-630) 220 (41-470) 148 (91-413) 173 (36-384) 141 (42-283)\nImmature\nB cells116 (40-316) 65 (15-343) 449 (228-1,398) 268\n(111-384)157\n(105-389)120\n(39-300)108 (36-314) 41 (12-84) 37 (11-111) 5.6 (0.25-24) 6.0 (0.84-23) 6.1 (0.69-36) 5.7 (1.3-23)\nNaive B cells 426 (214-962) 298 (71-976) 981 (186-2,620) 812\n(508-1,686)677\n(232-1,293)678\n(181-1,254)473\n(204-1,064)265 (68-505) 189 (75-401) 111 (13-288) 83 (26-244) 109 (20-280) 80 (15-210)\nMemory\nB cells0.3 (<0.01-3.0) 0.4 (<0.01-2.3) 73 (20-283) 115\n(48-219)111\n(79-291)131\n(44-241)182 (48-343) 123 (64-282) 68 (31-160) 91 (23-221) 70 (25-173) 56 (13-128) 30 (8.1-119)\nPCs <0.01 0.3 (<0.01-4.2) 21.2 (1.6-48) 53\n(24-104)28 (8.1-82) 43\n(4.8-144)18 (4.1-52) 13 (3.5-45) 8.5 (1.3-27) 4.4 (1.1-25) 2.7 (0.6-9.7) 1.2 (0.3-7.1) 1.5 (0.14-18)\nResults are expressed as median number of cells per microliter (range).\nNB, Newborn.J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 12.e13TABLE E4. Percentage of cases with detectable numbers of PB MBCs and PCs expressing different IgH isotypes and isotype subclasses and their absolute numbers per age\ngroup\nCB\n(n519)NB\n(n514)1-5 mo\n(n511)6-11 mo\n(n57)12-17 mo\n(n512)18-23 mo\n(n512)2-4 y\n(n525)5-9 y\n(n522)10-17 y\n(n514)18-39 y\n(n532)40-59 y\n(n527)60-79 y\n(n527)>80 y\n(n512)\nMBC subsets\nIgMD1\nCases 0% 0% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%\nCells/mL <0.01 <0.01 61 (8.6-245) 84 (21-170) 76 (45-186) 81 (31-153) 92 (24-207) 54 (23-147) 29 (17-78) 38 (7.9-122) 36 (12-114) 27\n(7.4-72)11 (2-56)\nIgD1\nCases 0% 0% 9% 57% 50% 78% 96% 95% 79% 69% 57% 48% 25%\nCells/mL <0.01 <0.01 <0.01 0.1 (<0.01-1.4) 0.4\n(<0.01-2.1)0.4\n(<0.01-5.6)2.0 (<0.01-6.9) 1.1\n(<0.01-2.9)0.3\n(<0.01-1.7)0.2 (<0.01-2.4) 0.06\n(<0.01-0.9)0.01\n(<0.01-1.2)0.01\n(<0.01-0.4)\nIgG 11\nCases 63% 86% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%\nCells/mL 0.1\n(<0.01-0.6)0.2\n(<0.01-0.8)2.3 (0.1-13) 12.5 (6.9-28) 19 (11-65) 28 (6.9-69) 49 (11-130) 30 (12-86) 18 (7-42) 18 (3.2-40) 11 (2.8-30) 9.1 (1.3-22) 6.7 (2.0-31)\nIgG 21\nCases 37% 21% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%\nCells/mL0 (<0.01-0.2) 0.04\n(<0.01-0.2)0.3 (<0.01-1.2) 0.6 (0.4-3.5) 1.4 (0.5-3.4) 2.9 (0.6-6.1) 3.4 (0.8-11) 4.4 (0.7-15) 3.0 (0.7-10) 5.9 (1.6-30) 4.7 (0.6-14) 3.6 (1.0-11) 2.4 (0.4-12)\nIgG 31\nCases 74% 50% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%\nCells/mL 0.06\n(<0.01-0.7)0.03\n(<0.01-0.5)0.9 (0.4-4.7) 2.8 (1.4-6.2) 4.3 (1.6-14) 5.5 (1.5-12) 6.0 (1.8-17) 7.4 (2.4-16) 3.0 (1.1-8.3) 3.0 (0.5-8.4) 2.1 (0.7-6.6) 2.3 (0.4-8.1) 2.0 (0.7-6.5)\nIgG 41\nCases 0% 0% 18% 71% 83% 92% 76% 86% 86% 91% 89% 92% 92%\nCells/mL <0.01 <0.01 <0.01\n(<0.01-0.6)0.07 (<0.01-0.4) 0.3\n(<0.01-1.4)0.1\n(<0.01-0.5)0.1\n(<0.01-1.9)0.4\n(<0.01-2.0)0.2\n(<0.01-2.9)0.4 (<0.01-2.4) 0.4\n(<0.01-4.1)0.4\n(<0.01-2.1)0.3\n(<0.01-2.3)\nIgA 11\nCases 90% 79% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%\nCells/mL 0.1\n(<0.01-1.2)0.1\n(<0.01-1.1)2.3 (0.4-8.6) 6.7 (3.9-13) 7.5 (5.5-33) 11 (1.5-22) 14 (5.7-28) 12 (4.6-24) 9.0 (2.9-21) 11 (2.1-43) 8.1 (2.5-27) 6.2 (2.2-22) 4.7 (1.7-25)\nIgA 21\nCases 63% 36% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%\nCells/mL 0.04\n(0-0.3)<0.01\n(<0.01-0.3)0.7 (0.07-1.7) 1.3 (0.6-4.3) 1.5 (0.3-7.9) 2.5 (0.5-5.6) 2.5 (0.8-18) 3.2 (1.0-13) 2.7 (0.8-5.9) 4.1 (1.2-18) 3.6 (0.4-14) 3.4 (0.7-9.0) 2.5 (0.6-11)\nPC subsets\nIgM1\nCases 0% 79% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%\nCells/mL <0.01 0.3\n(<0.01-2.9)3.9 (0.3-12) 8.3 (4.8-52) 4.7 (1.1-8) 8.5 (0.6-40) 2.6 (0.6-7.2) 1.4 (0.6-14) 0.8 (0.2-5.7) 0.4 (0.05-4.7) 0.2 (0.04-1.0) 0.1\n(0.01-0.8)0.1\n(0.02-1.1)\nIgD1\nCases 0% 0% 0% 14% 50% 33% 84% 55% 36% 31% 19% 15% 17%\nCells/mL <0.01 <0.01 <0.01\n(<0.01-0.2)<0.01 (<0.01-0.7) <0.01\n(<0.01-0.8)<0.01\n(<0.01-2.4)0.3\n(<0.01-2.3)0.04(<0.01-0.8)<0.01(<0.01-2.0)<0.01 (<0.01-1.1) <0.01\n(<0.01-0.1)<0.01(<0.01-0.2)<0.01(<0.01-0.02)\nIgG 11\nCases 0% 14% 100% 100% 100% 100% 100% 100% 100% 100% 93% 100% 92%\nCells/mL <0.01 <0.01\n(<0.01-0.5)4.5 (0.5-16) 10 (4.7-19.3) 8.5 (0.4-14) 8.5 (1.7-26) 3.3 (0.3-13) 1.9 (0.1-7.7) 1.1 (0.1-4.8) 0.4 (0.05-4.4) 0.2\n(<0.01-1.7)0.1\n(0.01-0.6)0.1\n(<0.01-1.6)\n(Continued)J ALLERGY CLIN IMMUNOL\nnnn201812.e14 BLANCO ET ALTABLE E4 .(Continued)\nCB\n(n519)NB\n(n514)1-5 mo\n(n511)6-11 mo\n(n57)12-17 mo\n(n512)18-23 mo\n(n512)2-4 y\n(n525)5-9 y\n(n522)10-17 y\n(n514)18-39 y\n(n532)40-59 y\n(n527)60-79 y\n(n527)>80 y\n(n512)\nIgG 21\nCases 0% 25% 82% 100% 75% 100% 100% 100% 100% 97% 96% 96% 100\nCells/mL <0.01 <0.01\n(<0.01-0.1)0.3\n(<0.01-1.0)1.1 (0.4-2.4) 0.3\n(<0.01-2.4)1.3 (1.3-4.7) 0.5 (0.02-1.5) 0.7\n(0.07-2.3)0.5 (0.08-0.8) 0.2 (<0.01-2.6) 0.2\n(<0.01-0.7)0.09\n(<0.01-1.6)0.1\n(0.03-1.6)\nIgG 31\nCases 0% 0% 100% 100% 93% 92% 68% 76% 86% 59% 63% 27% 67%\nCells/mL <0.01 <0.01 0.2 (0.05-1.3) 0.7 (0.1-1.5) 0.6 (<0.01-3.4) 0.6\n(<0.01-2.5)0.1\n(<0.01-2.1)0.2\n(<0.01-1.3)0.08\n(<0.01-0.4)0.03 (<0.01-0.3) 0.02\n(<0.01-0.2)<0.01\n(<0.01-0.2)<0.01(<0.01-0.23)\nIgG 41\nCases 0% 0% 9% 14% 48% 50% 20% 50% 43% 44% 30% 27% 33%\nCells/mL <0.01 <0.01 <0.01\n(<0.01-0.15)<0.01 (<0.01-0.1) <0.01\n(<0.01-0.4)<0.01(<0.01-0.3)<0.01(<0.01-0.2)0.02(<0.01-0.2)<0.01(<0.01-0.2)<0.01 (<0.01-0.4) <0.01\n(<0.01-0.1)<0.01(<0.01-0.1)<0.01(<0.01-0.02)\nIgA 11\nCases 0% 14% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100\nCells/mL <0.01 <0.01\n(<0.01-0.3)6.1 (0.3-17) 17 (10-44) 9.6 (3.4-33) 10 (1.2-80) 7.3 (1.3-20) 4.4 (0.6-16) 3.1 (0.5-14) 1.7 (0.3-6.9) 0.9 (0.2-3.8) 0.4\n(0.04-3.3)0.6\n(0.03-7.1)\nIgA 21\nCases 0% 7% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 92%\nCells/mL <0.01 <0.01\n(<0.01-0.1)1.2 (0.04-4.0) 2.8 (1.6-9.0) 1.6 (0.3-15) 2.6 (0.4-4.5) 1.1 (0.3-4.4) 1.5 (0.3-3.5) 1.0 (0.3-3.6) 0.7 (0.2-4.2) 0.3\n(0.04-2.9)0.3\n(0.06-1.2)0.2\n(<0.01-1.2)\nResults are expressed as percentages of cases and median absolute numbers of cells per microliter (range).\nNB, Newborn.J ALLERGY CLIN IMMUNOL\nVOLUME nnn, NUMBER nnBLANCO ET AL 12.e15TABLE E5. Soluble plasma levels of different immunoglobulin isotypes and isotype subclasses through life\nIgH isotypes/\nsubclassesCB\n(n518)NB\n(n510)1-5 mo(n59)6-11 mo\n(n57)12-17 mo\n(n512)18-23 mo\n(n512)2-4 y\n(n525) 5-9 y (n 522)10-17 y\n(n514)18-39 y\n(n531)40-59 y\n(n527)60-79 y\n(n521)>80 y\n(n511)\nTotal\nimmunoglobulin748 (516-1484) 1108\n(818-1223)433 (267-634) 607 (377-915) 837\n(542-1317)866\n(469-1092)946\n(596-1559)1213\n(814-1654)1234(686-1716)1532(1082-2182)1430(1073-1852)1546(978-1922)1682(1087-1804)\nIgM 8.6 (<LOD-142) 15\n(<LOD-23)71\n(<LOD-158)52 (37-193) 59 (6-110) 82 (42-142) 89 (54-135) 89 (32-210) 75 (42-94) 107 (35-200) 104 (56-225) 84 (43-240) 79 (52-245)\nIgD <LOD <LOD 0.3\n(<LOD-0.7)LOD\n(<LOD-3.7)0.4\n(<LOD-3.1)0.9\n(<LOD-5.2)1.8\n(<LOD-22)1.3 (<LOD-96) 0.7 (<LOD-6) 1.4\n(<LOD-13)1.1\n(<LOD-5.9)1.0\n(<LOD-8.7)0.4\n(<LOD-1.4)\nIgG\n1 560 (368-893) 833 (514-915) 241 (142-434) 424 (142-563) 506 (394-718) 628 (321-958) 616\n(328-1200)691 (459-942) 642 (405-931) 652\n(390-1040)592\n(357-963)657 (477-986) 649\n(451-1100)\nIgG 2 187 (101-400) 200 (133-256) 75 (46-115) 50 (29-104) 62 (21-632) 108 (72-223) 102 (59-223) 186 (61-403) 240 (125-361) 370\n(172-771)377\n(204-587)377\n(173-543)336\n(226-518)\nIgG 3 25 (12-66) 26 (15-36) 16 (9.6-38) 29 (20-70) 28 (21-236) 25 (12-58) 34 (11-86) 40 (20-74) 34 (21-72) 38 (11-86) 40 (23-188) 41 (20-96) 45 (24-85)\nIgG 4 34 (8-222) 34 (13-114) 9.0 (1.8-20) 1.8 (1.3-19) 22 (0.6-74) 8 (1.8-46) 13 (0.9-138) 38 (2.2-138) 56 (1.1-198) 92 (0.7-335) 45 (3.4-127) 46 (6.2-174) 55 (13-104)\nIgA 1 <LOD (<LOD-48) <LOD 13 (3.7-20.4) 23 (6.5-73) 27 (14-81) 31 (7-101) 52 (7-308) 87 (29-233) 146 (37-299) 138 (70-327) 139 (66-286) 156 (77-377) 214 (60-493)\nIgA 2 0.5 (<LOD-9) <LOD\n(<LOD-0.6)2.3 (0.7-7.2) 6.6 (0.7-7.7) 2.5 (1.0-11) 6.0 (2.6-35) 7.1 (1.4-39) 13 (1.0-35) 19 (7.1-44) 30 (11-131) 48 (14-80) 47 (14-122) 41 (25-114)\nIgE <LOD <LOD <LOD\n(<LOD-11)<LOD\n(<LOD-10)14\n(<LOD-202)4.8\n(<LOD-45)16\n(<LOD-102)8.4\n(<LOD-139)33\n(<LOD-444)20\n(<LOD-269)22\n(<LOD-45)13\n(<LOD-196)28\n(<LOD-105)\nResults are expressed as medians (ranges). Total immunoglobulin and IgM, IgD, IgG, and IgA subclasses are expressed in milligrams per deciliter. IgE levels are expressed in international units per milliliter.\nLOD , Limit of detection; NB, newborn.J ALLERGY CLIN IMMUNOL\nnnn201812.e16 BLANCO ET AL\u00a0\n\u2010\u00a0213\u00a0\u2010\u00a0\n\u00a0MATERIAL SUPLEMENTARIO CORRESPONDIENTE AL \nART\u00cdCULO 3 \n \nLa\u00a0disecci\u00f3n\u00a0de\u00a0los\u00a0defectos\u00a0de\u00a0las\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B \u00a0de\u00a0\nmemoria\u00a0y\u00a0c\u00e9lulas\u00a0plasm\u00e1ticas\u00a0que\u00a0expresan\u00a0diferentes\u00a0subclases \u00a0de\u00a0\ninmunoglobulinas\u00a0proporciona\u00a0 una\u00a0base\u00a0s\u00f3lida\u00a0para\u00a0una\u00a0(nueva)\u00a0r e\u2010\nclasificaci\u00f3n\u00a0de\u00a0la\u00a0IDVC\u00a0y\u00a0de\u00a0 los\u00a0d\u00e9ficits\u00a0de\u00a0subclases\u00a0de\u00a0\ninmunoglobulinas\u00a0\n\u00a0\n\u00a0\nEn\u00a0esta\u00a0secci\u00f3n\u00a0se\u00a0recogen:\u00a01)\u00a0re sultados\u00a0correspondientes\u00a0a\u00a0la \u00a0distribuci\u00f3n\u00a0alterada\u00a0de\u00a0las\u00a0\npoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0CD21+\u00a0y\u00a0CD27+\u00a0en\u00a0pacientes\u00a0con\u00a0IDP\u2010Ac\u00a0( Supplementary\u00a0results );\u00a02)\u00a0\nla\u00a0estrategia\u00a0de\u00a0identificaci\u00f3n\u00a0de\u00a0las\u00a0poblaciones\u00a0de\u00a0linfocito s\u00a0B\u00a0por\u00a0estadio\u00a0madurativo\u00a0y\u00a0\nexpresi\u00f3n\u00a0de\u00a0distinto\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Ig\u00a0( Supplementary\u00a0Figure\u00a01 );\u00a03)\u00a0los\u00a0n\u00fameros\u00a0absolutos\u00a0\nde\u00a0las\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0na\u00efve\u00a0y\u00a0de\u00a0memoria\u00a0definidas \u00a0por\u00a0el\u00a0patr\u00f3n\u00a0de\u00a0expresi\u00f3n\u00a0de\u00a0\nCD21\u00a0y\u00a0CD27\u00a0en\u00a0SP\u00a0de\u00a0donantes\u00a0sanos,\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0sele ctivo\u00a0de\u00a0IgA,\u00a0d\u00e9ficit\u00a0de\u00a0subclases\u00a0\nde\u00a0IgG\u00a0asociado\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0IgA\u00a0e\u00a0IDVC\u00a0( Supplementary\u00a0Figure\u00a02 );\u00a04)\u00a0los\u00a0n\u00fameros\u00a0absolutos\u00a0de\u00a0\nlas\u00a0poblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0definidas\u00a0en\u00a0funci\u00f3n\u00a0del\u00a0estadi o\u00a0madurativo\u00a0y\u00a0de\u00a0la\u00a0expresi\u00f3n\u00a0de\u00a0\ndistinto\u00a0isotipo\u00a0y\u00a0subclase\u00a0de\u00a0Ig\u00a0en\u00a0SP\u00a0de\u00a0donantes\u00a0sanos,\u00a0paci entes\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA,\u00a0\nd\u00e9ficit\u00a0de\u00a0subclases\u00a0de\u00a0IgG\u00a0asociado\u00a0a\u00a0d\u00e9ficit\u00a0de\u00a0IgA\u00a0e\u00a0IDVC\u00a0( Supplementary\u00a0Figure\u00a03 );\u00a05)\u00a0la\u00a0\ncombinaci\u00f3n\u00a0de\u00a0Acs\u00a0monoclonale s\u00a0utilizados\u00a0en\u00a0el\u00a0estudio:\u00a0tubo\u00a0 EuroFlow\u00a0de\u00a012\u00a0colores\u00a0para\u00a0la\u00a0\nevaluaci\u00f3n\u00a0de\u00a0los\u00a0isotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs\u00a0( Supplementary\u00a0Table\u00a01 );\u00a06)\u00a0la\u00a0distribuci\u00f3n\u00a0por\u00a0grupo\u00a0\nde\u00a0edad\u00a0de\u00a0los\u00a0donantes\u00a0sanos\u00a0y\u00a0pacientes\u00a0con\u00a0diferente\u00a0diagn\u00f3s tico\u00a0incluidos\u00a0en\u00a0el\u00a0estudio\u00a0\n(Supplementary\u00a0 Table\u00a0 2 );\u00a0 7)\u00a0 la\u00a0 frecuencia\u00a0 de\u00a0 pacientes\u00a0 con\u00a0 inmunodeficiencia\u00a0\np r e d o m i n a n t e m e n t e \u00a0d e \u00a0A c s \u00a0q u e \u00a0p r e s e n t a b a n \u00a0n \u00fa m e r o s \u00a0r e d u c i d o s \u00a0o \u00a0i n detectables\u00a0 de\u00a0\nsubpoblaciones\u00a0de\u00a0linfocitos\u00a0B\u00a0definidas\u00a0por\u00a0estadio\u00a0madurativo \u00a0y\u00a0expresi\u00f3n\u00a0de\u00a0los\u00a0distintos\u00a0\nisotipos\u00a0y\u00a0subclases\u00a0de\u00a0Igs\u00a0( Supplementary\u00a0Table\u00a03 );\u00a08)\u00a0la\u00a0relaci\u00f3n\u00a0existe nte\u00a0entre\u00a0los\u00a0subgrupos\u00a0\nde\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0de\u00a0IgA\u00a0e\u00a0IDVC\u00a0de\u00a0nuestra\u00a0ser ie\u00a0clasificados\u00a0de\u00a0acuerdo\u00a0a\u00a0las\u00a0\nclasificaciones\u00a0ESID\u00a0y\u00a0EUR Oclass,\u00a0respectivamente\u00a0( Supplementary\u00a0Table\u00a04 );\u00a09)\u00a0Manifestaciones\u00a0\ncl\u00ednicas\u00a0y\u00a0antecedentes\u00a0familiares\u00a0de\u00a0IDP\u2010Ac\u00a0de\u00a0los\u00a0subgrupos\u00a0d e\u00a0pacientes\u00a0con\u00a0d\u00e9ficit\u00a0selectivo\u00a0\nde\u00a0IgA\u00a0identificados\u00a0en\u00a0nuestro\u00a0estudio\u00a0( Supplementary\u00a0Table\u00a05 );\u00a010)\u00a0Manifestaciones\u00a0cl\u00ednicas\u00a0y\u00a0\nantecedentes\u00a0familiares\u00a0de\u00a0IDP\u2010Ac\u00a0de\u00a0los\u00a0pacientes\u00a0incluidos\u00a0en \u00a0los\u00a0distintos\u00a0subgrupos\u00a0de\u00a0IDVC\u00a0\nidentificados\u00a0en\u00a0nuestro\u00a0estudio\u00a0( Supplementary\u00a0Table\u00a06 ).\u00a0\n\u00a0\n\u00a0\u00a0\nJournal\u00a0of\u00a0Allergy\u00a0and\u00a0Clinical\u00a0Immunology\u00a0\n(sometido\u00a0para\u00a0publicaci\u00f3n\u00a0y\u00a0en\u00a0revisi\u00f3n)\u00a0\n\u00a0\n\u00a0 \n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0SUPPLEMENTARY\u00a0RESULTS\u00a0\nAltered\u00a0distribution\u00a0of\u00a0PB\u00a0CD21+\u00a0and\u00a0CD27+\u00a0B\u2010cell\u00a0subsets. \u00a0In\u00a0CVID,\u00a0reduced\u00a0naive\u00a0B\u2010cell\u00a0(34%)\u00a0\nand\u00a0MBC\u00a0(70%)\u00a0counts\u00a0were\u00a0mostly\u00a0at\u00a0the\u00a0expense\u00a0of\u00a0CD21+\u00a0cells\u00a0(40%\u00a0 vs.\u00a011%\u00a0for\u00a0CD21\u2010\u00a0naive\u00a0\nB\u2010cells\u00a0and\u00a079%\u00a0 vs.\u00a055%\u00a0for\u00a0CD21\u2010\u00a0MBCs,\u00a0respectively)\u00a0(Supplementary\u00a0Figure\u00a03;\u00a0Supplementary\u00a0\nTable\u00a03).\u00a0In\u00a0contrast,\u00a0a\u00a0similar\u00a0frequency\u00a0of\u00a0reduced\u00a0CD27+\u00a0vs.\u00a0CD27\u2010\u00a0MBCs\u00a0was\u00a0found\u00a0in\u00a0CVID\u00a0\n(68%\u00a0vs.\u00a070%,\u00a0respectively)\u00a0and\u00a0IgADef\u00a0patients\u00a0(7%\u00a0 vs.\u00a010%,\u00a0respectively)\u00a0(Supplementary\u00a0\nFigure\u00a03;\u00a0Supplementary\u00a0Table\u00a03).\u00a0\u00a0\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n\u00a0\nSupplementary\u00a0Figure\u00a01.\u00a0Gating\u00a0strategy\u00a0used\u00a0for\u00a0the\u00a0identifica tion\u00a0of\u00a0the\u00a0distinct\u00a0major\u00a0(maturation\u2010associated)\u00a0\nB\u2010cell\u00a0and\u00a0plasma\u00a0cell\u00a0subpopula tions\u00a0in\u00a0peripheral\u00a0blood\u00a0(Pane l\u00a0A)\u00a0as\u00a0well\u00a0as\u00a0their\u00a0subsets\u00a0of\u00a0switched\u2010memory\u00a0B\u2010\ncells\u00a0and\u00a0plasma\u00a0cells\u00a0(Panel\u00a0B). \u00a0Illustrating\u00a0bivariate\u00a0dot\u2010plot\u00a0 graphical\u00a0representations\u00a0of\u00a0t he\u00a0gating\u00a0strategy\u00a0used\u00a0\nto\u00a0identify\u00a0immature,\u00a0naive,\u00a0unswitched\u2010\u00a0and\u00a0switched\u2010memory\u00a0B\u2010 cells\u00a0and\u00a0plasma\u00a0cells,\u00a0according\u00a0to\u00a0their\u00a0pattern\u00a0\nof\u00a0expression\u00a0of\u00a0CD27,\u00a0CD38,\u00a0CD5,\u00a0CD24,\u00a0CD21,\u00a0smIgM\u00a0and\u00a0smIgD\u00a0( panel\u00a0A).\u00a0Illustrating\u00a0bivariate\u00a0dot\u2010plot\u00a0graphical\u00a0\nrepresentation\u00a0of\u00a0the\u00a0gating\u00a0str ategy\u00a0used\u00a0to\u00a0classify\u00a0switched \u00a0memory\u00a0B\u2010cells\u00a0and\u00a0plasma\u00a0cells\u00a0according\u00a0to\u00a0their\u00a0\ndifferential\u00a0expression\u00a0of\u00a0distinct\u00a0IgG\n1\u20104\u00a0and\u00a0IgA 1\u20102\u00a0subclasses\u00a0(panel\u00a0B). \u00a0\nSupplementary\u00a0Figure\u00a01.  \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nSupplementary\u00a0Figure\u00a02.\u00a0Peripheral\u00a0blood\u00a0distribution\u00a0of\u00a0subset s\u00a0of\u00a0naive\u00a0(panel\u00a0A)\u00a0and\u00a0memory\u00a0B\u2010cells\u00a0(panel\u00a0B)\u00a0\nas\u00a0defined\u00a0by\u00a0the\u00a0pa ttern\u00a0of\u00a0expression\u00a0of\u00a0CD21\u00a0and\u00a0CD27,\u00a0in\u00a0pa tients\u00a0with\u00a0selective\u00a0IgA\u00a0deficiency\u00a0(n=59),\u00a0IgG\u00a0\nsubclass\u00a0deficiency\u00a0with\u00a0IgA\u00a0defi ciency\u00a0(n=5)\u00a0and\u00a0CVID\u00a0(n=47)\u00a0 vs.\u00a0healthy\u00a0donors\u00a0distributed\u00a0by\u00a0age.\u00a0\u00a0 Individual\u00a0\ncases\u00a0are\u00a0represented\u00a0by\u00a0green\u00a0(selective\u00a0IgA\u00a0deficiency),\u00a0blue \u00a0(IgG\u00a0subclass\u00a0deficiency\u00a0with\u00a0IgA\u00a0deficiency),\u00a0red\u00a0\n(CVID),\u00a0and\u00a0grey\u00a0dots\u00a0(healthy\u00a0donors).\u00a0Dotted\u00a0grey\u00a0lines\u00a0repre sent\u00a0age\u2010associated\u00a0maximum\u00a0and\u00a0minimum\u00a0normal\u00a0\nreference\u00a0(range)\u00a0values.\u00a0CVID :\u00a0common\u00a0variable\u00a0immunodeficienc y.\u00a0\n\u00a0\u00a0\nSupplementary\u00a0Figure\u00a02.  \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nSupplementary\u00a0Figure\u00a03.\u00a0Absolute\u00a0counts\u00a0of\u00a0distinct\u00a0maturation\u2010 associated\u00a0subpopulations\u00a0of\u00a0blood\u00a0B\u2010cells\u00a0and\u00a0\nplasma\u00a0cells\u00a0(Panel\u00a0A),\u00a0and\u00a0the\u00a0Ig\u2010isotype\u00a0and\u00a0Ig\u2010subclass\u00a0subs ets\u00a0of\u00a0memory\u00a0B\u2010cells\u00a0(Pan el\u00a0B)\u00a0and\u00a0plasma\u00a0cells\u00a0\n(Panel\u00a0C)\u00a0in\u00a0CVID\u00a0(n=47),\u00a0IgG\u2010subclass\u00a0deficiency\u00a0with\u00a0IgA\u00a0defi ciency\u00a0(n=5)\u00a0and\u00a0selective\u00a0IgA\u00a0deficiency\u00a0patients\u00a0\n(n=59)\u00a0vs.\u00a0healthy\u00a0donors\u00a0(n=140)\u00a0distributed\u00a0by\u00a0age.\u00a0\u00a0 Individual\u00a0cases\u00a0are\u00a0represent ed\u00a0by\u00a0green\u00a0(selective\u00a0IgA\u00a0\ndeficiency),\u00a0blue\u00a0(IgG\u2010subclass\u00a0deficiency\u00a0with\u00a0IgA\u00a0deficiency) ,\u00a0red\u00a0(CVID),\u00a0and\u00a0grey\u00a0dots\u00a0(healthy\u00a0donors).\u00a0Dotted\u00a0grey\u00a0\nlines\u00a0 represent\u00a0 maximum\u00a0 and\u00a0 minimum\u00a0 age\u2010associated\u00a0 reference\u00a0 (r ange)\u00a0 values.\u00a0 CVID:\u00a0 common\u00a0 variable\u00a0\nimmunodeficiency.\u00a0\nSupplementary\u00a0Figure\u00a03.  \u00a0\n\u00a0Supplementary\u00a0Table\u00a01 .\u00a0Euroflow\u00a0Ig\u2010isotype\u00a0B\u2010cell\u00a0tube.\u00a0 Combination\u00a0of\u00a0fluorochrome\u2010conjugated\u00a0\nantibodies\u00a0used\u00a0for\u00a0the\u00a0immunoph enotypic\u00a0analysis\u00a0of\u00a0PB\u00a0samples \u00a0by\u00a0flow\u00a0cytometry.\u00a0\nBD,\u00a0Becton/Dickinson\u00a0Biosciences\u00a0(San\u00a0Jos\u00e9,\u00a0CA);\u00a0Biolegend\u00a0(San \u00a0Diego,\u00a0CA);\u00a0Cytognos\u00a0SL\u00a0(Salamanca,\u00a0Spain).\u00a0\n\u00a0\n\u00a0\u00a0\u00a0 Fluorochrome\u00a0conjugated\u00a0to\u00a0the\u00a0Ab\u00a0reagent \u00a0\n\u00a0 BV421\u00a0 BV510\u00a0 BV711\u00a0 BV650\u00a0 BV786\u00a0 FITC\u00a0PerCP\u2010\nCy5.5\u00a0PE\u00a0PE\u2010\nCF594\u00a0PECy7\u00a0 APC\u00a0 APCH7\u00a0\nAntibody\u00a0\nmarker\u00a0CD27\u00a0 smIgM\u00a0 CD21\u00a0 CD24\u00a0 CD19\u00a0smIgG3\n+\u00a0\nsmIgG2\u00a0smIgA1\n+\u00a0\nsmIgA2\u00a0smIgG1\n+\u00a0\nsmIgG2\u00a0smIgD\u00a0 CD5\u00a0smIgG4\n+\u00a0\nsmIgA1\u00a0CD38\u00a0\nAntibody\u00a0\n\u00a0clone\u00a0M\u2010T271\u00a0 MHM\u201088\u00a0 B\u2010ly4\u00a0 ML5\u00a0 SJ25C1\u00a0SAG3/\u00a0\nSAG2\u00a0SAA1/\u00a0\nSAA2\u00a0SAG1/\u00a0\nSAG2\u00a0IA6\u20102\u00a0L17F1\n2\u00a0SAG4/\u00a0\nSAA1\u00a0HB7\u00a0\nAntibody\u00a0\nreagent\u00a0\nmanufacturer\u00a0BD\u00a0Biolegend \u00a0BD\u00a0BD\u00a0BD\u00a0 Cytognos\u00a0 Cytognos \u00a0Cytognos \u00a0BD\u00a0BD\u00a0Cytognos \u00a0BD\u00a0\u00a0\n\u00a0Supplementary\u00a0Table\u00a02.\u00a0Distribution\u00a0per\u00a0age\u00a0group\u00a0of\u00a0all\u00a0predom inantly\u00a0antibody\u00a0deficiency\u00a0patients\u00a0(grouped\u00a0per\u00a0\ndisease\u00a0category)\u00a0and\u00a0healthy\u00a0 donors\u00a0analyzed\u00a0in\u00a0this\u00a0study.\u00a0\nResults\u00a0expressed\u00a0as\u00a0number\u00a0of\u00a0individuals.\u00a0Y:\u00a0years;\u00a0IgADef:\u00a0s elective\u00a0IgA\u00a0deficiency;\u00a0IgG/Adef:\u00a0IgG\u00a0subclass\u00a0deficiency\u00a0\nwith\u00a0IgA\u00a0deficiency;\u00a0CVID:\u00a0co mmon\u00a0variable\u00a0immunodeficiency.\u00a0\n\u00a0\u00a0Age\u00a0group\u00a0 IgADef\u00a0 IgG/Adef CVID\u00a0 Healthy\u00a0donors\u00a0\n4\u20105y\u00a0 7\u00a0 0\u00a0 0\u00a0 13\u00a0\n6\u20109y\u00a0 8\u00a0 0\u00a0 2\u00a0 15\u00a0\n10\u201017y\u00a0 11\u00a0 0\u00a0 2\u00a0 14\u00a0\n18\u201039y\u00a0 21\u00a0 3\u00a0 17\u00a0 32\u00a0\n40\u201059y\u00a0 10\u00a0 2\u00a0 19\u00a0 27\u00a0\n60\u201079y\u00a0 1\u00a0 0\u00a0 6\u00a0 27\u00a0\n>80y\u00a0 1\u00a0 0\u00a0 1\u00a0 12\u00a0\nTOTAL\u00a0 59\u00a0 5\u00a0 47\u00a0 140\u00a0\u00a0\n\u00a0Supplementary\u00a0 Table\u00a0 3.\u00a0 Frequency\u00a0 of\u00a0 predominantly\u00a0 antibody\u00a0 defi ciency\u00a0 patients\u00a0 presenting\u00a0 with\u00a0 abnormally\u00a0\ndecreased\u00a0counts\u00a0of\u00a0PB\u00a0subsets\u00a0of\u00a0maturation\u2010associated\u00a0B\u2010cells \u00a0and\u00a0plasma\u00a0cells\u00a0expressing\u00a0distinct\u00a0Ig\u2010isotypes\u00a0and\u00a0Ig\u2010\nsubclasses.\u00a0\u00a0\nResults\u00a0expressed\u00a0as\u00a0percentage\u00a0of\u00a0cases\u00a0showing\u00a0absolute\u00a0count s\u00a0of\u00a0specific\u00a0B\u2010cell\u00a0subsets\u00a0below\u00a0the\u00a0lower\u00a0limit\u00a0of\u00a0\nnormal\u00a0values\u00a0(<LLN)\u00a0in\u00a0PB,\u00a0compared\u00a0to\u00a0previously\u00a0defined\u00a0refe rence\u00a0range\u00a0values\u00a0per\u00a0age\u00a0group\u00a0(Blanco\u00a0et\u00a0al.),\u00a0or\u00a0below\u00a0\nthe\u00a0limit\u00a0of\u00a0detection\u00a0(<LOD)\u00a0of\u00a0the\u00a0method\u00a0(<0.01\u00a0cels/ul).\u00a0aIgADef\u00a0vs.\u00a0CVID;\u00a0bIgG/Adef \u00a0vs.\u00a0CVID;\u00a0cIgADef\u00a0vs.\u00a0IgG/Adef \u00a0\nIgADef:\u00a0 selective\u00a0 IgA\u00a0 deficiency ;\u00a0 IgG/Adef:\u00a0 IgG\u00a0 subclass\u00a0 defici ency\u00a0 with\u00a0 IgA\u00a0 deficiency;\u00a0 CVID:\u00a0 common\u00a0 variable\u00a0\nimmunodeficiency.\u00a0\u00a0NS:\u00a0no\u00a0significant\u00a0differences.\u00a0\u00a0\n\u00a0\u00a0PB\u00a0B\u2010cell\u00a0subset\u00a0Decreased \u00a0\n(<LLN)Absent\u00a0\n(<LOD)\u00a0\nIgADef\u00a0\n(n=59)\u00a0IgG/Adef\u00a0\n(n=5)\u00a0CVID\n(n=47)\u00a0P\u2010\nvalues\u00a0IgADef\n(n=59)\u00a0IgG/Adef\u00a0\n(n=5)\u00a0CVID\n(n=47)\u00a0P\u2010\nvalues\u00a0\nTotal\u00a0B\u2010cells\u00a0 \u00a0 2%\u00a0 0%\u00a0 51%\u00a0<0.04a,b\u00a00%\u00a0 0%\u00a0 0%\u00a0 NS\u00a0\n\u00a0 Immature \u00a0 12%\u00a0 20%\u00a0 34%\u00a0 0.006a\u00a00%\u00a0 0%\u00a0 11%\u00a0 0.02a\u00a0\n\u00a0Naive\u00a0 2%\u00a0 0%\u00a0 34%\u00a0<0.001a\u00a00%\u00a0 0%\u00a0 4%\u00a0 NS\u00a0\n\u00a0\u00a0 C D 2 1+\u00a0 3%\u00a0 20%\u00a0 40%\u00a0<0.001a\u00a00%\u00a0 0%\u00a0 4%\u00a0 NS\u00a0\n\u00a0\u00a0 CD21\u2010\u00a0 2%\u00a0 0%\u00a0 11%\u00a0 NS\u00a0 0%\u00a0 0%\u00a0 4%\u00a0 NS\u00a0\n\u00a0 Memory\u00a0B\u2010cells \u00a0 9%\u00a0 0%\u00a0 70%\u00a0 <0.004a,b\u00a00%\u00a0 0%\u00a0 17%\u00a0 0.001a\u00a0\n\u00a0\u00a0 CD27+\u00a0 7%\u00a0 0%\u00a0 68%\u00a0 <0.006a,b\u00a00%\u00a0 0%\u00a0 26%\u00a0 <0.001a\u00a0\n\u00a0\u00a0 C D 2 7\u2010\u00a0 10%\u00a0 0%\u00a0 70%\u00a0 <0.004a,b\u00a00%\u00a0 0%\u00a0 30%\u00a0 <0.001a\u00a0\n\u00a0\u00a0 CD21+\u00a0 9%\u00a0 0%\u00a0 79%\u00a0 <0.001a,b\u00a00%\u00a0 0%\u00a0 17%\u00a0 0.001a\u00a0\n\u00a0\u00a0 C D 2 1\u2010\u00a0 14%\u00a0 0%\u00a0 55%\u00a0 <0.03a,b\u00a00%\u00a0 0%\u00a0 17%\u00a0 0.001a\u00a0\n\u00a0\u00a0Unswithed\u00a0 3%\u00a0 20%\u00a0 62%\u00a0 <0.001a\u00a00%\u00a0 0%\u00a0 26%\u00a0 <0.001a\u00a0\n\u00a0 \u00a0 Switched\u00a0 20%\u00a0 40%\u00a0 89%\u00a0 <0.03a,b\u00a00%\u00a0 0%\u00a0 30%\u00a0 <0.001a\u00a0\n\u00a0\u00a0 IgG+\u00a0 10%\u00a0 0%\u00a0 87%\u00a0 <0.001a,b\u00a00%\u00a0 0%\u00a0 30%\u00a0 <0.001a\u00a0\n\u00a0\u00a0 I g G 3+\u00a0 9%\u00a00 % \u00a0 53%\u00a0<0.03a,b\u00a00%\u00a0 0%\u00a0 30%\u00a0 <0.001a\u00a0\n\u00a0\u00a0 IgG1+\u00a0 9%\u00a0 0%\u00a0 89%\u00a0<0.001a,b\u00a00%\u00a0 0%\u00a0 40%\u00a0 <0.001a\u00a0\n\u00a0\u00a0 I g G 2+\u00a0 7%\u00a0 100%\u00a0 94%\u00a0 <0.001a,c\u00a00%\u00a0 40%\u00a0 70%\u00a0 <0.005a,c\u00a0\n\u00a0IgG3+or\u00a0IgG1+or\u00a0IgG2+15%\u00a0 100%\u00a0 96%\u00a0 <0.001a,c\u00a00%\u00a0 40%\u00a0 70%\u00a0<0.005a,c\u00a0\n\u00a0\u00a0 I g A+\u00a0 95%\u00a0100%\u00a096%\u00a0NS\u00a0 51%\u00a0 100%\u00a0 83%\u00a0 <0.04a,c\u00a0\n\u00a0\u00a0 IgA1+\u00a0 86%\u00a0100%\u00a096%\u00a0NS\u00a0 51%\u00a0 100%\u00a0 83%\u00a0 <0.04a,c\u00a0\n\u00a0\u00a0 I g A 2+\u00a0 92%\u00a0100%\u00a098%\u00a0NS\u00a0 63%\u00a0 100%\u00a0 92%\u00a0 <0.001a\u00a0\n\u00a0\u00a0IgA1+or\u00a0IgA2+\u00a098%\u00a0 100%\u00a0 98%\u00a0 NS\u00a0 63%\u00a0 100%\u00a0 92%\u00a0 <0.001a\u00a0\n\u00a0 Plasma\u00a0cells \u00a0 46%\u00a0 80%\u00a0 98%\u00a0 <0.001a\u00a00%\u00a0 60%\u00a0 92%\u00a0 <0.001a,c\u00a0\n\u00a0\u00a0Unswitched\u00a0 10%\u00a0 60%\u00a0 96%\u00a0 <0.04a,b,c\u00a02%\u00a0 60%\u00a0 92%\u00a0<0.001a,c\u00a0\n\u00a0 \u00a0 Switched\u00a0 66%\u00a0 80%\u00a0 100%\u00a0 <0.001a\u00a09%\u00a0 60%\u00a0 100%\u00a0 <0.02a,b,c\u00a0\n\u00a0\u00a0IgG+\u00a0 29%\u00a0 60%\u00a0 100%\u00a0 <0.008a,b\u00a010%\u00a0 60%\u00a0 100%\u00a0 <0.02a,b,c\u00a0\n\u00a0\u00a0 I g A+\u00a0 95%\u00a0100%\u00a0100%\u00a0NS\u00a0 61%\u00a0 100%\u00a0 100%\u00a0 <0.001a\u00a0\n\u00a0\u00a0IgA1+\u00a0 88%\u00a0 100%\u00a0100%\u00a0 0.01a\u00a063%\u00a0 100%\u00a0100%\u00a0 <0.001a\u00a0\n\u00a0\u00a0 I g A 2+\u00a0 93%\u00a0100%\u00a0100%\u00a0NS\u00a0 71%\u00a0 100%\u00a0 100%\u00a0 <0.001a\u00a0\n\u00a0\u00a0 I g A 1+or\u00a0IgA2+\u00a097%\u00a0 100%\u00a0 100%\u00a0 NS\u00a0 73%\u00a0 100%\u00a0 100%\u00a0 <0.001a\u00a0\n\u00a0\n\u00a0Supplementary\u00a0Table\u00a04.\u00a0Correspondence\u00a0between\u00a0the\u00a0subgroups\u00a0of\u00a0 selective\u00a0IgA\u00a0deficiency\u00a0(IgADef)\u00a0and\u00a0CVID\u00a0\npatients\u00a0here\u00a0identified\u00a0based\u00a0on\u00a0the\u00a0pattern\u00a0of\u00a0alteration\u00a0of\u00a0 distinct\u00a0PB\u00a0maturation\u2010ass ociated\u00a0B\u2010cell\u00a0and\u00a0plasma\u00a0\ncell\u00a0subsets\u00a0expressing\u00a0distinct\u00a0Ig\u2010isotypes\u00a0and\u00a0Ig\u2010subclasses\u00a0 and\u00a0both\u00a0the\u00a0ESID\u00a0classification\u00a0of\u00a0IgADef\u00a0patients\u00a0\ndiagnosed\u00a0by\u00a0the\u00a0IUIS\u00a0criteria\u00a0(panel\u00a0A)\u00a0and\u00a0the\u00a0Euroclass\u00a0clas sification\u00a0of\u00a0CVID\u00a0(panel\u00a0B).\u00a0\n\u00a0\nResults\u00a0expressed\u00a0as\u00a0percentage\u00a0of\u00a0cases.\u00a0 IgAdef:\u00a0selective\u00a0IgA\u00a0deficiency.\u00a0\n\u00a0\n\u00a0\nResults\u00a0expressed\u00a0as\u00a0percentage\u00a0of\u00a0cases.\u00a0 CVID:\u00a0common\u00a0variable\u00a0immunodeficiency. \u00a0\n\u00a0\n\u00a0A\u00a0\u00a0\u00a0IgADef\u00a0PATIENT\u00a0CLUSTERS\u00a0\nESID\u00a0criteria \u00a0IgAdef\u20101\u00a0\u00a0\n(n=27)\u00a0IgAdef\u20102\u00a0\n(n=32)\u00a0\nESID\u00a0(Symptomatic\u00a0or\u00a0affected\u00a0family\u00a0member)\u00a0(n=34)\u00a0 38%\u00a0 62%\u00a0\nNon\u00a0ESID\u00a0(asymptomatic\u00a0and/or\u00a0no\u00a0family\u00a0member\u00a0affected)\u00a0\n(n=25)\u00a056%\u00a0 44%\u00a0\nB\u00a0 \u00a0\nCVID\u00a0PATIENT\u00a0CLUSTERS\u00a0\nEuroclass\u00a0CVID\u00a0subgroup\u00a0 \u00a0CVID\u20101\u00a0\u00a0\n(n=4)\u00a0CVID\u20102\u00a0c\n(n=5)\u00a0CVID\u20103\u00a0\u00a0\n(n=15)\u00a0CVID\u20104\u00a0\u00a0\n(n=6)\u00a0CVID\u20105\u00a0\u00a0\n(n=7)\u00a0CVID\u20106\u00a0\n(n=10)\u00a0\nB+\u00a0(n=38)\u00a0 \u00a0 \u00a0 10%\u00a0 13%\u00a0 40%\u00a0 13%\u00a0 16%\u00a0 8%\u00a0\n\u00a0 SmB+\u00a0(n=8)\u00a0 \u00a0 50%\u00a0 25%\u00a0 25%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0\n\u00a0 \u00a0 SmB+\u00a0CD21norm\u00a0(n=5)\u00a0 40%\u00a0 40%\u00a0 20%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0\n\u00a0 \u00a0 SmB+\u00a0CD21lo\u00a0(n=3)\u00a0 67%\u00a0 0%\u00a0 33%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0\n\u00a0 SmB\u2010\u00a0(n=37)\u00a0 \u00a0 0%\u00a0 10%\u00a0 45%\u00a0 16%\u00a0 19%\u00a0 10%\u00a0\n\u00a0 \u00a0 SmB\u2010\u00a0CD21norm\u00a0(n=11)\u00a0 0%\u00a0 9%\u00a0 46%\u00a0 18%\u00a0 9%\u00a0 18%\u00a0\n\u00a0 \u00a0 SmB\u2010\u00a0CD21lo\u00a0(n=19)\u00a0 0%\u00a0 11%\u00a0 42%\u00a0 16%\u00a0 26%\u00a0 5%\u00a0\nB\u2010\u00a0(n=9)\u00a0 \u00a0 \u00a0 0%\u00a0 0%\u00a0 0%\u00a0 11%\u00a0 11%\u00a0 78%\u00a0\u00a0\n\u00a0Supplementary\u00a0Table\u00a05.\u00a0Frequency\u00a0of\u00a0selective\u00a0IgA\u00a0deficiency\u00a0pa tients\u00a0(IgAdef)\u00a0presenting\u00a0with\u00a0different\u00a0clinical\u00a0\nmanifestations\u00a0of\u00a0the\u00a0disease\u00a0and\u00a0their\u00a0corresponding\u00a0family\u00a0hi story\u00a0of\u00a0primary\u00a0antibody\u00a0 deficiency,\u00a0according\u00a0to\u00a0\nthe\u00a0subgroups\u00a0of\u00a0IgAdef\u00a0patients\u00a0defined\u00a0on\u00a0the\u00a0basis\u00a0of\u00a0the\u00a0pa ttern\u00a0of\u00a0alteration\u00a0of\u00a0their \u00a0PB\u00a0maturation\u2010associated\u00a0\nB\u2010cell\u00a0and\u00a0plasma\u00a0cell\u00a0subsets\u00a0ex pressing\u00a0distinct\u00a0Ig\u2010isotypes\u00a0 and\u00a0Ig\u2010subclasses. \u00a0\nResults\u00a0expressed\u00a0as\u00a0percentage\u00a0of\u00a0patients\u00a0presenting\u00a0with\u00a0cli nical\u00a0manifestation\u00a0of\u00a0the\u00a0disease.\u00a0None\u00a0of\u00a0the\u00a0cases\u00a0\npresented\u00a0cytopenias,\u00a0splenomega ly,\u00a0hepatomegaly,\u00a0lymphadenopat hy,\u00a0granuloma\u00a0or\u00a0hematologic\u00a0tumors.\u00a0#\u00a0P\u22640.05\u00a0\nvs.\u00a0IgAdef\u20101.\u00a0IgAdef:\u00a0selective\u00a0IgA\u00a0deficiency\u00a0NS:\u00a0no\u00a0statistical ly\u00a0significant\u00a0differences\u00a0were\u00a0found.\u00a0\u00a0Clinical\u00a0manifestations\u00a0of\u00a0the\u00a0disease \u00a0\u00a0 IgAdef\u00a0PATIENT\u00a0CLUSTERS\u00a0 \u00a0\nTotal\u00a0\n(n=59)\u00a0IgAdef\u20101\u00a0\u00a0\n(n=26)\u00a0IgAdef\u20102\u00a0\u00a0\n(n=33)\u00a0P\u2010values\u00a0\nIgG\u00a0at\u00a0diagnosis\u00a0\u00a0 \u00a0 1404\u00b1291\u00a0 1285\u00b1324\u00a0 1477\u00b1248#\u00a0 0.03\u00a0\nIgM\u00a0\u00a0at\u00a0diagnosis\u00a0 \u00a0 134\u00b182\u00a0 133\u00b198\u00a0 135\u00b167\u00a0 NS\u00a0\nIgA\u00a0at\u00a0diagnosis\u00a0 \u00a0 <7\u00a0 <7\u00a0 <7\u00a0 NS\u00a0\nAge\u00a0(years)\u00a0 \u00a0 23\u00b119\u00a0 18\u00b113\u00a0 31\u00b119#\u00a00.01\u00a0\nAge\u00a0at\u00a0diagnosis\u00a0(years)\u00a0 \u00a0 28\u00b145\u00a0 15\u00b114\u00a0 29\u00b120#\u00a00.04\u00a0\nGender\u00a0(male/female)\u00a0 \u00a0 29/30\u00a0 14/12 \u00a0 18/15\u00a0 NS\u00a0\nAffected\u00a0family\u00a0members\u00a0 \u00a0 13%\u00a0 0%\u00a0 22%#\u00a0 0.02\u00a0\nInfectious\u00a0disease\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n\u00a0 Respiratory\u00a0infections\u00a0 32%\u00a0 30%\u00a0 34%\u00a0 NS\u00a0\n\u00a0 Bronchiectasias\u00a0 2%\u00a0 0%\u00a0 3%\u00a0 NS\u00a0\n\u00a0 Other\u00a0infections\u00a0 10%\u00a0 0%\u00a0 19%#\u00a0 0.02\u00a0\n\u00a0 TOTAL\u00a0 34%\u00a0 30%\u00a0 38%\u00a0 NS\u00a0\nAutoimmune\u00a0diseases\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n\u00a0 Tissue\u2010specific\u00a0autoimmunity\u00a0 19%\u00a0 7%\u00a0 28%#\u00a0 0.04\u00a0\n\u00a0 Systemic\u00a0autoimmunity\u00a0 19%\u00a0 15%\u00a0 22%\u00a0 NS\u00a0\n\u00a0 TOTAL\u00a0 31%\u00a0 19%\u00a0 41%\u00a0 NS\u00a0\nEnteropathy\u00a0 \u00a0 2%\u00a0 0%\u00a0 3%\u00a0 NS\u00a0\nSolid\u00a0tumors\u00a0 \u00a0 2%\u00a0 0%\u00a0 3%\u00a0 NS\u00a0\nAllergy\u00a0 \u00a0 26%\u00a0 36%\u00a0 20%\u00a0 NS\u00a0\n\u00a0\n\u00a0Supplementary\u00a0Table\u00a06.\u00a0Frequency\u00a0of\u00a0CVID\u00a0patients\u00a0presenting\u00a0wi th\u00a0clinical\u00a0manifestations\u00a0and\u00a0family\u00a0records\u00a0of\u00a0\nprimary\u00a0antibody\u00a0deficiency\u00a0according\u00a0to\u00a0the\u00a0distinct\u00a0clusters\u00a0 here\u00a0defined\u00a0based\u00a0on\u00a0the\u00a0patterns\u00a0of\u00a0alteration\u00a0of\u00a0PB\u00a0\nmaturation\u2010associated\u00a0B\u2010cell\u00a0and\u00a0 plasma\u00a0cell\u00a0subsets\u00a0expressing \u00a0distinct\u00a0Ig\u2010isotypes\u00a0and\u00a0Ig\u2010subclasses.\u00a0\nResults\u00a0expressed\u00a0as\u00a0percentage\u00a0of\u00a0patients\u00a0presenting\u00a0with\u00a0eac h\u00a0type\u00a0of\u00a0clinical\u00a0manifestation\u00a0of\u00a0the\u00a0disease.\u00a0a\u00a0 P\u22640.05\u00a0\nvs.\u00a0CVID\u20101;\u00a0b\u00a0 P\u22640.05\u00a0vs.\u00a0CVID\u20102;\u00a0c\u00a0 P\u22640.05\u00a0vs.\u00a0CVID\u20103;\u00a0d\u00a0 P\u22640.05\u00a0vs.\u00a0CVID\u20104.\u00a0CVID:\u00a0common\u00a0variable\u00a0immunodeficiency;\u00a0NS:\u00a0\nno\u00a0statistically\u00a0significant\u00a0differences\u00a0detected\u00a0( P>0.05).\u00a0\u00a0 \u00a0 CVID\u00a0PATIENT\u00a0CLUSTERS \u00a0 \u00a0\nClinical\u00a0manifestations\u00a0of\u00a0the\u00a0\ndisease\u00a0TOTAL\u00a0\n(n=47)\u00a0CVID\u20101\u00a0\u00a0\n(n=4)\u00a0CVID\u20102\u00a0\u00a0\n(n=5)\u00a0CVID\u20103\u00a0\u00a0\n(n=15)\u00a0CVID\u20104\u00a0\n(n=6)\u00a0CVID\u20105\u00a0\u00a0\n(n=7)\u00a0CVID\u20106\n(n=10)\u00a0P\u2010values\u00a0\n\u00a0 231\u00b1171\u00a0 153\u00b1143\u00a0 287\u00b1176\u00a0 237\u00b1183\u00a0 284\u00b1245\u00a0 325\u00b1137\u00a0 147\u00b1122\u00a0 NS\u00a0\nIgM\u00a0\u00a0at\u00a0diagnosis\u00a0 35\u00b156\u00a0 7\u00b19b\u00a047\u00b128\u00a0 59\u00b197\u00a0 34\u00b129\u00a0 18\u00b119\u00a0 22\u00b129\u00a0 0.03\u00a0\nIgA\u00a0at\u00a0diagnosis\u00a0 7\u00b116\u00a0 22\u00b138\u00a0 4\u00b15\u00a0 6\u00b113\u00a0 11\u00b116\u00a0 2\u00b13\u00a0 5\u00b19\u00a0 NS\u00a0\nAge\u00a0(years)\u00a0 41\u00b117\u00a0 59\u00b122\u00a0 34\u00b112\u00a0 36\u00b112\u00a0 37\u00b125\u00a0 41\u00b117\u00a0 48\u00b111b,c\u00a0<0.04\u00a0\nAge\u00a0at\u00a0diagnosis\u00a0(years) \u00a0 31\u00b116\u00a0 51\u00b117\u00a0 25\u00b112\u00a0 31\u00b113\u00a0 25\u00b122\u00a0 29\u00b119\u00a0 29\u00b111\u00a0 NS\u00a0\nGender\u00a0(male/female)\u00a0 25/22\u00a0 3/1\u00a0 2/3\u00a0 8/7\u00a0 3/3\u00a0 5/2\u00a0 4/6\u00a0 NS\u00a0\nAffected\u00a0family\u00a0members\u00a0 19%\u00a0 0%\u00a0 0%\u00a0 25%\u00a0 17%\u00a0 33%\u00a0 23%\u00a0 NS\u00a0\nInfectious\u00a0diseases\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\n\u00a0 Respiratory\u00a0infections\u00a0 82%\u00a0 75%\u00a0 80%\u00a0 83%\u00a0 67%\u00a0 71%\u00a0 100%\u00a0 NS\u00a0\n\u00a0 Bronchiectasis\u00a0 33%\u00a0 75%\u00a0 40%\u00a0 25%\u00a0 33%\u00a0 14%\u00a0 80%c,e\u00a0<0.02\u00a0\n\u00a0 Other\u00a0infections\u00a0 71%\u00a0 50%\u00a0 60%\u00a0 58%\u00a0 67%\u00a0 86%\u00a0 90%\u00a0 NS\u00a0\n\u00a0T O T A L \u00a0 96%\u00a0 100%\u00a0 100%\u00a0 92%\u00a0 83%\u00a0 100%\u00a0 100%\u00a0 NS\u00a0\nAutoimmune\u00a0\ndiseases\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0\u00a0 \u00a0 \u00a0\n\u00a0Tissue\u2010specific\u00a0\nautoimmunity\u00a023%\u00a0 0%\u00a0 20%\u00a0 33%\u00a0 0%\u00a0 67%d\u00a0 10%e\u00a0<0.04\u00a0\n\u00a0 Systemic\u00a0autoimmunity\u00a0 18%\u00a0 25%\u00a0 0%\u00a0 17%\u00a0 50%\u00a0 0%\u00a0 20%\u00a0 NS\u00a0\n\u00a0 Cytopenias\u00a0 27%\u00a0 0%\u00a0 0%\u00a0 8%\u00a0 67%c\u00a029%\u00a0 50%c\u00a0<0.04\u00a0\n\u00a0 TOTAL\u00a0 63%\u00a0 25%\u00a0 25%\u00a0 58%\u00a0 100%a,b\u00a086%\u00a0 60%\u00a0 <0.03\u00a0\nOrganomegalies\u00a0\u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 N S \u00a0\n\u00a0 Splenomegaly\u00a0 50%\u00a050%\u00a0 20%\u00a0 50%\u00a0 50%\u00a0 57%\u00a0 67%\u00a0 <0.02\u00a0\n\u00a0 Hepatomegaly \u00a0 32%\u00a0 50%\u00a0 20%\u00a0 0%\u00a0 33%\u00a057%c\u00a0 56%c\u00a0<0.009\u00a0\n\u00a0 TOTAL\u00a0 52%\u00a0 50%\u00a0 40%\u00a0 50%\u00a0 50%\u00a0 57%\u00a0 67%\u00a0 NS\u00a0\nLymphadenopathy\u00a0 \u00a0 31%\u00a0 25%\u00a0 20%\u00a0 33%\u00a0 0%\u00a0 43%\u00a0 50%\u00a0 NS\u00a0\nEnteropathy \u00a0\u00a0 39%\u00a050%\u00a0 0%\u00a0 17%\u00a0 67%b\u00a029%\u00a0 78%b,c\u00a0<0.05\u00a0\nGranuloma\u00a0 \u00a0 7%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0 30%\u00a0 NS\u00a0\nSolid\u00a0tumors\u00a0\u00a0 \u00a0 11%\u00a0 50%\u00a0 20%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0 20%\u00a0NS\u00a0\nHematologic\u00a0tumors\u00a0 \u00a0 5%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0 14%\u00a0 11%\u00a0 NS\u00a0\nAllergy\u00a0 \u00a0 2%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0 0%\u00a0 10%\u00a0 NS\u00a0\n  \u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\n \n \n \n \nReferencias \nbibliogr\u00e1ficas \n\u00a0\n\u00a0\u00a0 \n\u00a0\n\u00a0\u00a0\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0229\u00a0\u2010\u00a0\n\u00a01\u00a0\u00a0 Abbas\u00a0A,\u00a0Lichtman\u00a0A,\u00a0Pillai\u00a0S.\u00a0 Cellular\u00a0and\u00a0Molecular\u00a0Immunology .\u00a08th\u00a0ed.\u00a0Elsevier\u00a0Saunders:\u00a0Philadelphia,\u00a0\nPA,\u00a02015.\u00a0\n2\u00a0\u00a0 Delves\u00a0P,\u00a0Martin\u00a0S.\u00a0Burton\u00a0D.\u00a0Roitt\u00a0I.\u00a0 Roitt\u2019s\u00a0Essential\u00a0Immunology .\u00a012th\u00a0ed.\u00a0Wiley\u2010Blackwell:\u00a0London,\u00a0UK,\u00a0\n2014.\u00a0\n3\u00a0\u00a0 Mix\u00a0E,\u00a0Goertsches\u00a0R,\u00a0Zett\u00a0UK.\u00a0 Immunoglobulins\u00a0\u2010\u00a0Basic\u00a0consid erations.\u00a0 J\u00a0Neurol\u00a02006;\u00a0253:\u00a09\u201317.\u00a0\n4\u00a0\u00a0 Hoffman\u00a0W,\u00a0Lakkis\u00a0FG,\u00a0Chalasani\u00a0G.\u00a0B\u00a0cells,\u00a0antibodies,\u00a0and\u00a0 more.\u00a0Clin\u00a0J\u00a0Am\u00a0Soc\u00a0Nephrol \u00a02016;\u00a011:\u00a0137\u2013154.\u00a0\n5\u00a0\u00a0 Schroeder\u00a0HWJ,\u00a0Cavacini\u00a0L.\u00a0Structure\u00a0and\u00a0Function\u00a0of\u00a0Immunog lobulins.\u00a0J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02010;\u00a0125:\u00a0\nS41\u2013S52.\u00a0\n6\u00a0\u00a0 Murphy\u00a0K,\u00a0Weaber\u00a0C.\u00a0 Janeway\u2019s\u00a0Immunobiology .\u00a09th\u00a0ed.\u00a0Garland\u00a0Science:\u00a0New\u00a0York,\u00a0NY,\u00a02017.\u00a0\n7\u00a0\u00a0 Hamilton\u00a0RG.\u00a0Human\u00a0IgG\u00a0subcla ss\u00a0measurements\u00a0in\u00a0the\u00a0clinical \u00a0laboratory.\u00a0 Clin\u00a0Chem \u00a01987;\u00a033:\u00a01707\u20131725.\u00a0\n8\u00a0\u00a0 Vidarsson\u00a0G,\u00a0Dekkers\u00a0G,\u00a0Rispens\u00a0T.\u00a0IgG\u00a0subclasses\u00a0and\u00a0alloty pes:\u00a0From\u00a0structure\u00a0to\u00a0effector\u00a0functions.\u00a0 Front\u00a0\nImmunol\u00a02014;\u00a05:\u00a01\u201317.\u00a0\n9\u00a0\u00a0 Normansell\u00a0DE.\u00a0Human\u00a0immunoglobulin\u00a0subclasses.\u00a0 Diagn\u00a0Clin\u00a0Immunol \u00a01987;\u00a05:\u00a0115\u2013128.\u00a0\n10\u00a0\u00a0 Kerr\u00a0M.\u00a0The\u00a0structure\u00a0and\u00a0function\u00a0of\u00a0human\u00a0IgA.\u00a0 Biochem\u00a0J \u00a01990;\u00a0271:\u00a0285\u201396.\u00a0\n11\u00a0\u00a0 Abinun\u00a0M,\u00a0Albert\u00a0M,\u00a0Buckland\u00a0SBCM,\u00a0Bustamante\u00a0J,\u00a0Cant\u00a0A,\u00a0Ca sanova\u00a0J\u2010L\u00a0 et\u00a0al.\u00a0ESID\u00a0Registry\u00a0\u2013\u00a0Working\u00a0\nDefinitions\u00a0for\u00a0Clinical\u00a0Diagnos is\u00a0of\u00a0PID.\u00a02017.\u00a0Disponible\u00a0en\u00a0 https://esid.org/Working\u2010Parties/Registry/New\u2010\nESID\u2010Registry.\u00a0\n12\u00a0\u00a0 Spickett\u00a0GP,\u00a0Misbah\u00a0SA,\u00a0Cha pel\u00a0HM.\u00a0Primary\u00a0antibody\u00a0deficie ncy\u00a0in\u00a0adults.\u00a0 Lancet\u00a01991;\u00a0337:\u00a0281\u20134.\u00a0\n13\u00a0\u00a0 Yazdani\u00a0R,\u00a0Azizi\u00a0G,\u00a0Abolhassa ni\u00a0H,\u00a0Aghamohammadi\u00a0A.\u00a0Selecti ve\u00a0IgA\u00a0Deficiency:\u00a0Epidemiology,\u00a0Pathogenesis,\u00a0\nClinical\u00a0Phenotype,\u00a0Diagnosi s,\u00a0Prognosis\u00a0and\u00a0Management.\u00a0 Scand\u00a0J\u00a0Immunol \u00a02017;\u00a085:\u00a03\u201312.\u00a0\n14\u00a0\u00a0 Vale\u00a0AM,\u00a0Schroeder\u00a0HW.\u00a0Clinical\u00a0consequences\u00a0of\u00a0defects\u00a0in\u00a0 B\u2010cell\u00a0development.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02010;\u00a0\n125:\u00a0778\u2013787.\u00a0\n15\u00a0\u00a0 Abramson\u00a0N,\u00a0Schur\u00a0PH.\u00a0The\u00a0IgG\u00a0subclasses\u00a0of\u00a0red\u00a0cell\u00a0antibo dies\u00a0and\u00a0relationship\u00a0to\u00a0monocyte\u00a0binding.\u00a0 Blood\u00a0\n1972;\u00a040:\u00a0500\u20138.\u00a0\n16\u00a0\u00a0 Meulenbroek\u00a0A.\u00a0 Useful\u00a0Diagnostic\u00a0Markers\u00a0for\u00a0Immunocompetence .\u00a03rd\u00a0ed.\u00a0Sanquin:\u00a0Amsterdam,\u00a0The\u00a0\nNetherlands,\u00a02008.\u00a0\n17\u00a0\u00a0 Aalberse\u00a0RC,\u00a0Van\u00a0Milligen\u00a0F,\u00a0Tan\u00a0KY,\u00a0Stapel\u00a0SO.\u00a0Allergen\u2010sp ecific\u00a0IgG4\u00a0in\u00a0atopic\u00a0disease.\u00a0 Allergy\u00a01993;\u00a048:\u00a0559\u2013\n69.\u00a0\n18\u00a0\u00a0 Shakib\u00a0F.\u00a0The\u00a0IgG4\u00a0subclass.\u00a0 Monogr\u00a0Allergy \u00a01986;\u00a019:\u00a0223\u2013226.\u00a0\n19\u00a0\u00a0 Manz\u00a0RA,\u00a0Hauser\u00a0AE,\u00a0Hiepe\u00a0F,\u00a0Radbruch\u00a0A.\u00a0Maintenance\u00a0of\u00a0ser um\u00a0antibody\u00a0levels.\u00a0 Annu\u00a0Rev\u00a0Immunol \u00a02005;\u00a0\n23:\u00a0367\u201386.\u00a0\n20\u00a0\u00a0 Vandermeulen\u00a0E,\u00a0Verleden\u00a0SE,\u00a0Bellon\u00a0H,\u00a0Ruttens\u00a0D,\u00a0Lammertyn \u00a0E,\u00a0Claes\u00a0S\u00a0 et\u00a0al.\u00a0Humoral\u00a0immunity\u00a0in\u00a0\nphenotypes\u00a0of\u00a0chronic\u00a0lung\u00a0allograft\u00a0dysfunction:\u00a0A\u00a0broncho\u2010alv eolar\u00a0lavage\u00a0fluid\u00a0analysis.\u00a0 Transpl\u00a0Immunol \u00a0\n2016;\u00a038:\u00a027\u201332.\u00a0\n21\u00a0\u00a0 Mestecky\u00a0J,\u00a0Strober\u00a0W,\u00a0Russe ll\u00a0M,\u00a0Cheroutre\u00a0H,\u00a0Lambrecht\u00a0BN \u00a0KB.\u00a0Mucosal\u00a0Immunology .\u00a03rd\u00a0ed.\u00a0Elsevier:\u00a0\nOxford,\u00a0UK,\u00a02005.\u00a0\n22\u00a0\u00a0 Reddy\u00a0PS,\u00a0Corley\u00a0RB.\u00a0The\u00a0cont ribution\u00a0of\u00a0ER\u00a0quality\u00a0control \u00a0to\u00a0the\u00a0biologic\u00a0functions\u00a0of\u00a0secretory\u00a0IgM.\u00a0\nImmunol\u00a0Today \u00a01999;\u00a020:\u00a0582\u20138.\u00a0\n23\u00a0\u00a0 McMillan\u00a0R,\u00a0Longmire\u00a0RL,\u00a0Yelenosky\u00a0R,\u00a0Lang\u00a0JE,\u00a0Heath\u00a0V,\u00a0Cra ddock\u00a0CG.\u00a0Immunoglobulin\u00a0synthesis\u00a0by\u00a0human\u00a0\nlymphoid\u00a0tissues:\u00a0normal\u00a0bone\u00a0ma rrow\u00a0as\u00a0a\u00a0major\u00a0site\u00a0of\u00a0IgG\u00a0pro duction.\u00a0J\u00a0Immunol \u00a01972;\u00a0109:\u00a01386\u20131394.\u00a0\n24\u00a0\u00a0 Burtis\u00a0CA,\u00a0Ashwood\u00a0ER,\u00a0Bruns\u00a0DE.\u00a0 Tietz\u00a0Textbook\u00a0of\u00a0Clinical\u00a0Chemistry\u00a0and\u00a0Molecular\u00a0Diagnostics .\u00a05th\u00a0ed.\u00a0\nElsevier\u00a0Saunders:\u00a0St.\u00a0Louis,\u00a0MO,\u00a02012.\u00a0\n25\u00a0\u00a0 van\u00a0de\u00a0Winkel\u00a0JG,\u00a0Anderson\u00a0CL.\u00a0Biology\u00a0of\u00a0human\u00a0immunoglobu lin\u00a0G\u00a0Fc\u00a0receptors.\u00a0 J\u00a0Leukoc\u00a0Biol \u00a01991;\u00a049:\u00a0\n511\u2013524.\u00a0\n26\u00a0\u00a0 Kim\u00a0K,\u00a0Keller\u00a0MA,\u00a0Heiner\u00a0DC.\u00a0Immunoglobulin\u00a0G\u00a0subclasses\u00a0in \u00a0human\u00a0colostrum,\u00a0milk\u00a0and\u00a0saliva.\u00a0 Acta\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0230\u00a0\u2010\u00a0\n\u00a0Paediatr\u00a01992;\u00a081:\u00a0113\u2013118.\u00a0\n27\u00a0\u00a0 Kasc hka\u00a0W P ,\u00a0Thei l kaes\u00a0L, \u00a0Eic khoff\u00a0K, \u00a0Skvari l \u00a0F.\u00a0Di sproporti onate\u00a0elevation\u00a0of\u00a0the\u00a0immunoglobulin\u00a0G1\u00a0\nconcentration\u00a0in\u00a0cerebrospinal\u00a0f luids\u00a0of\u00a0patients\u00a0with\u00a0multiple \u00a0sclerosis.\u00a0 Infect\u00a0Immun \u00a01979;\u00a026:\u00a0933\u2013941.\u00a0\n28\u00a0\u00a0 Aalberse\u00a0RC,\u00a0Stapel\u00a0SO,\u00a0Schuur man\u00a0J,\u00a0Rispens\u00a0T.\u00a0Immunoglobu lin\u00a0G4:\u00a0An\u00a0odd\u00a0antibody.\u00a0 Clin\u00a0Exp\u00a0Allergy \u00a02009;\u00a0\n39:\u00a0469\u2013477.\u00a0\n29\u00a0\u00a0 Woof\u00a0JM,\u00a0Ken\u00a0MA.\u00a0The\u00a0functio n\u00a0of\u00a0immunoglobulin\u00a0A\u00a0in\u00a0immuni ty.\u00a0J\u00a0Pathol\u00a02006;\u00a0208:\u00a0270\u2013282.\u00a0\n30\u00a0\u00a0 Woof\u00a0JM,\u00a0Russell\u00a0MW.\u00a0Structur e\u00a0and\u00a0function\u00a0relationships\u00a0i n\u00a0IgA.\u00a0Mucosal\u00a0Immunol \u00a02011;\u00a04:\u00a0590\u2013597.\u00a0\n31\u00a0\u00a0 Kazeeva\u00a0TN,\u00a0Shevelev\u00a0\u00a0a.\u00a0B.\u00a0U nknown\u00a0functions\u00a0of\u00a0immunoglob ulins\u00a0A.\u00a0Biochem\u00a02007;\u00a072:\u00a0485\u2013494.\u00a0\n32\u00a0\u00a0 Roberts\u2010Thomson\u00a0PJ,\u00a0Shepherd\u00a0K.\u00a0Molecular\u00a0size\u00a0heterogeneit y\u00a0of\u00a0immunoglobulins\u00a0in\u00a0health\u00a0and\u00a0disease.\u00a0\nClin\u00a0Exp\u00a0Immunol \u00a01990;\u00a079:\u00a0328\u2013334.\u00a0\n33\u00a0\u00a0 Danilova\u00a0N,\u00a0Amemiya\u00a0CT.\u00a0Going\u00a0 adaptive:\u00a0The\u00a0saga\u00a0of\u00a0antibod ies.\u00a0Ann\u00a0N\u00a0Y\u00a0Acad\u00a0Sci \u00a02009;\u00a01168:\u00a0130\u2013155.\u00a0\n34\u00a0\u00a0 Cerutti\u00a0A,\u00a0Cols\u00a0M,\u00a0Gentile\u00a0M,\u00a0Cassis\u00a0L,\u00a0Barra\u00a0CM,\u00a0He\u00a0B\u00a0 et\u00a0al.\u00a0Regulation\u00a0of\u00a0mucosal\u00a0IgA\u00a0responses:\u00a0Lessons\u00a0\nfrom\u00a0primary\u00a0immunodeficiencies.\u00a0 Ann\u00a0N\u00a0Y\u00a0Acad\u00a0Sci \u00a02011;\u00a01238:\u00a0132\u2013144.\u00a0\n35\u00a0\u00a0 Cerutti\u00a0A,\u00a0Chen\u00a0K,\u00a0Chorny\u00a0A.\u00a0Immunoglobulin\u00a0responses\u00a0at\u00a0th e\u00a0mucosal\u00a0interface.\u00a0 Annu\u00a0Rev\u00a0Immunol \u00a02011;\u00a0\n29:\u00a0273\u201393.\u00a0\n36\u00a0\u00a0 Monteiro\u00a0RC,\u00a0Van\u00a0De\u00a0Winke l\u00a0JGJ.\u00a0IgA\u00a0Fc\u00a0receptors.\u00a0 Annu\u00a0Rev\u00a0Immunol \u00a02003;\u00a021:\u00a0177\u2013204.\u00a0\n37\u00a0\u00a0 Hiemstra\u00a0PS,\u00a0Gorter\u00a0A,\u00a0Stuurman\u00a0ME,\u00a0Van\u00a0Es\u00a0LA,\u00a0Daha\u00a0MR.\u00a0Act ivation\u00a0of\u00a0the\u00a0alternative\u00a0pathway\u00a0of\u00a0\ncomplement\u00a0by\u00a0human\u00a0serum\u00a0IgA.\u00a0 Eur\u00a0J\u00a0Immunol \u00a01987;\u00a017:\u00a0321\u2013326.\u00a0\n38\u00a0\u00a0 Hiemstra\u00a0PS,\u00a0Biewenga\u00a0J,\u00a0Gorter\u00a0A,\u00a0Stuurman\u00a0ME,\u00a0Faber\u00a0A,\u00a0va n\u00a0Es\u00a0LA\u00a0et\u00a0al.\u00a0Activation\u00a0of\u00a0complement\u00a0by\u00a0\nhuman\u00a0serum\u00a0IgA,\u00a0secretory\u00a0IgA\u00a0and\u00a0IgA1\u00a0fragments.\u00a0 Mol\u00a0Immunol \u00a01988;\u00a025:\u00a0527\u2013533.\u00a0\n39\u00a0\u00a0 Schauer\u00a0U,\u00a0Stemberg\u00a0F,\u00a0Rieger\u00a0CHL,\u00a0Borte\u00a0M,\u00a0Schubert\u00a0S,\u00a0Rie del\u00a0F\u00a0et\u00a0al.\u00a0Establishment\u00a0of\u00a0age\u2010dependent\u00a0\nreference\u00a0values\u00a0for\u00a0IgA\u00a0subclasses.\u00a0 Clin\u00a0Chim\u00a0Acta \u00a02003;\u00a0328:\u00a0129\u2013133.\u00a0\n40\u00a0\u00a0 Woof\u00a0JM,\u00a0Mestecky\u00a0J.\u00a0Mucosal\u00a0immunoglobulins.\u00a0 Immunol\u00a0Rev \u00a02005;\u00a0206:\u00a064\u201382.\u00a0\n41\u00a0\u00a0 Mestecky\u00a0J,\u00a0Lue\u00a0C,\u00a0Tarkowski\u00a0A,\u00a0Ladjeva\u00a0I,\u00a0Peterman\u00a0JH,\u00a0Mol doveanu\u00a0Z\u00a0 et\u00a0al.\u00a0Comparative\u00a0Studies\u00a0of\u00a0the\u00a0\nBiological\u00a0Properties\u00a0of\u00a0Human\u00a0IgA\u00a0Subclasses.\u00a0In:\u00a0Poulik\u00a0MD\u00a0(e d).\u00a0Protides\u00a0of\u00a0the\u00a0Biological\u00a0Fluids .\u00a0Elsevier:\u00a0\nLondon,\u00a0UK,\u00a01989,\u00a0pp\u00a0173\u2013182.\u00a0\n42\u00a0\u00a0 Vladutiu\u00a0AO.\u00a0Immunoglobulin\u00a0D:\u00a0properties,\u00a0measurement,\u00a0and \u00a0clinical\u00a0relevance.\u00a0 Clin\u00a0Diagn\u00a0Lab\u00a0Immunol \u00a0\n2000;\u00a07:\u00a0131\u2013140.\u00a0\n43\u00a0\u00a0 Putnam\u00a0FW,\u00a0Takahashi\u00a0N,\u00a0Tetaert\u00a0D,\u00a0Debuire\u00a0B,\u00a0Lin\u00a0LC.\u00a0Amino \u00a0acid\u00a0sequence\u00a0of\u00a0the\u00a0first\u00a0constant\u00a0region\u00a0\ndomain\u00a0and\u00a0the\u00a0hinge\u00a0region\u00a0of\u00a0the\u00a0delta\u00a0heavy\u00a0chain\u00a0of\u00a0human\u00a0I gD.\u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A \u00a01981;\u00a078:\u00a06168\u2013\n6172.\u00a0\n44\u00a0\u00a0 Plebani\u00a0A,\u00a0Mira\u00a0E,\u00a0Mevio\u00a0E,\u00a0M onafo\u00a0V,\u00a0Notarangelo\u00a0LD,\u00a0Avanz ini\u00a0A\u00a0et\u00a0al.\u00a0IgM\u00a0and\u00a0IgD\u00a0concentrations\u00a0in\u00a0the\u00a0\nserum\u00a0and\u00a0secretions\u00a0of\u00a0children\u00a0 with\u00a0selective\u00a0IgA\u00a0deficiency. \u00a0Clin\u00a0Exp\u00a0Immunol \u00a01983;\u00a053:\u00a0689\u2013696.\u00a0\n45\u00a0\u00a0 Chen\u00a0K,\u00a0Xu\u00a0W,\u00a0Wilson\u00a0M,\u00a0He\u00a0B,\u00a0Miller\u00a0NW,\u00a0Bengt\u00e9n\u00a0E\u00a0 et\u00a0al.\u00a0Immunoglobulin\u00a0D\u00a0enhances\u00a0immune\u00a0surveillance\u00a0\nby\u00a0activating\u00a0antimicrobial,\u00a0proinflammatory\u00a0and\u00a0B\u00a0cell\u2010stimula ting\u00a0programs\u00a0in\u00a0basophils.\u00a0 Nat\u00a0Immunol \u00a0\n2009;\u00a010:\u00a0889\u201398.\u00a0\n46\u00a0\u00a0 Chen\u00a0K,\u00a0Cerutti\u00a0A.\u00a0The\u00a0functi on\u00a0and\u00a0regulation\u00a0of\u00a0immunoglo bulin\u00a0D.\u00a0Curr\u00a0Opin\u00a0Immunol \u00a02011;\u00a023:\u00a0345\u2013352.\u00a0\n47\u00a0\u00a0 Riesbeck\u00a0K,\u00a0Nordstrom\u00a0T.\u00a0Stru cture\u00a0and\u00a0immunological\u00a0action \u00a0of\u00a0the\u00a0human\u00a0pathogen\u00a0Moraxella\u00a0catarrhalis\u00a0\nIgD\u2010binding\u00a0protein.\u00a0 Crit\u00a0Rev\u00a0Immunol \u00a02006;\u00a026:\u00a0353\u201376.\u00a0\n48\u00a0\u00a0 Mimura\u00a0T,\u00a0Usui\u00a0T,\u00a0Mori\u00a0M,\u00a0Aixinjueluo\u00a0W,\u00a0Funatsu\u00a0H,\u00a0Noma\u00a0H\u00a0 et\u00a0al.\u00a0Immunochromatographic\u00a0assay\u00a0for\u00a0\nmeasurement\u00a0of\u00a0total\u00a0IgE\u00a0in\u00a0tear s,\u00a0nasal\u00a0mucus,\u00a0and\u00a0saliva\u00a0of\u00a0p atients\u00a0with\u00a0allergic\u00a0rhinoconjunctivitis.\u00a0 J\u00a0\nAsthma\u00a02010;\u00a047:\u00a01153\u20131160.\u00a0\n49\u00a0\u00a0 Poole\u00a0JA,\u00a0Matangkasombut\u00a0P,\u00a0Rosenwasser\u00a0LJ.\u00a0Targeting\u00a0the\u00a0I gE\u00a0molecule\u00a0in\u00a0allergic\u00a0and\u00a0asthmatic\u00a0diseases:\u00a0\nReview\u00a0of\u00a0the\u00a0IgE\u00a0molecule\u00a0and\u00a0clinical\u00a0efficacy.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02005;\u00a0115:\u00a0375\u2013385.\u00a0\n50\u00a0\u00a0 Stone\u00a0KD,\u00a0Prussin\u00a0C,\u00a0Metcalfe\u00a0DD.\u00a0IgE,\u00a0mast\u00a0cells,\u00a0basophil s,\u00a0and\u00a0eosinophils.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02010;\u00a0\n125:\u00a0S73\u201080.\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0231\u00a0\u2010\u00a0\n\u00a051\u00a0\u00a0 Lebien\u00a0TW,\u00a0Tedder\u00a0TF.\u00a0ASH\u00a050th\u00a0anniversary\u00a0review\u00a0B\u00a0lymphoc ytes\u202f:\u00a0how\u00a0they\u00a0develop\u00a0and\u00a0function.\u00a0 Am\u00a0Soc\u00a0\nHematol\u00a02008;\u00a0112:\u00a01570\u20131580.\u00a0\n52\u00a0\u00a0 Nagasawa\u00a0T.\u00a0Microenvironmenta l\u00a0niches\u00a0in\u00a0the\u00a0bone\u00a0marrow\u00a0re quired\u00a0for\u00a0B\u2010cell\u00a0development.\u00a0 Nat\u00a0Rev\u00a0\nImmunol\u00a02006;\u00a06:\u00a0107\u2013116.\u00a0\n53\u00a0\u00a0 Perez\u2010Andres\u00a0M,\u00a0Paiva\u00a0B,\u00a0Nieto\u00a0WG,\u00a0Caraux\u00a0A,\u00a0Schmitz\u00a0A,\u00a0Alm eida\u00a0J\u00a0et\u00a0al.\u00a0Human\u00a0peripheral\u00a0blood\u00a0B\u2010cell\u00a0\ncompartments:\u00a0a\u00a0crossroad\u00a0in\u00a0B\u2010cell\u00a0traffic.\u00a0 Cytometry\u00a0B\u00a0Clin\u00a0Cytom \u00a02010;\u00a078\u00a0Suppl\u00a01 :\u00a0S47\u201060.\u00a0\n54\u00a0\u00a0 Allen\u00a0CDC,\u00a0Okada\u00a0T,\u00a0Cyster\u00a0JG.\u00a0Germinal\u2010center\u00a0organization \u00a0and\u00a0cellular\u00a0dynamics.\u00a0 Immunity \u00a02007;\u00a027:\u00a0190\u2013\n202.\u00a0\n55\u00a0\u00a0 Tonegawa\u00a0S.\u00a0Somatic\u00a0generation\u00a0of\u00a0antibody\u00a0diversity.\u00a0 Nature\u00a01983;\u00a0302:\u00a0575\u2013581.\u00a0\n56\u00a0\u00a0 Pieper\u00a0K,\u00a0Grimbacher\u00a0B,\u00a0Eibel \u00a0H.\u00a0B\u2010cell\u00a0biology\u00a0and\u00a0develop ment.\u00a0J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02013;\u00a0131:\u00a0959\u2013971.\u00a0\n57\u00a0\u00a0 Ichii\u00a0M,\u00a0Oritani\u00a0K,\u00a0Kanakura\u00a0Y.\u00a0Early\u00a0B\u00a0lymphocyte\u00a0developm ent:\u00a0Similarities\u00a0and\u00a0differences\u00a0in\u00a0human\u00a0and\u00a0\nmouse.\u00a0World\u00a0J\u00a0Stem\u00a0Cells \u00a02014;\u00a06:\u00a0421\u201331.\u00a0\n58\u00a0\u00a0 Matarraz\u00a0S,\u00a0Lopez\u00a0A,\u00a0Barrena\u00a0S ,\u00a0Fernandez\u00a0C,\u00a0Jensen\u00a0E,\u00a0Flor es\u00a0J\u00a0et\u00a0al.\u00a0The\u00a0immunophenotype\u00a0of\u00a0different\u00a0\nimmature,\u00a0myeloid\u00a0and\u00a0B\u2010cell\u00a0lineage\u2010committed\u00a0CD34+\u00a0hematopoie tic\u00a0cells\u00a0allows\u00a0discrimination\u00a0between\u00a0\nnormal/reactive\u00a0and\u00a0myelodys plastic\u00a0syndrome\u00a0precursors.\u00a0 Leukemia \u00a02008;\u00a022:\u00a01175\u20131183.\u00a0\n59\u00a0\u00a0 van\u00a0Zelm\u00a0MC,\u00a0van\u00a0der\u00a0Burg\u00a0M,\u00a0de\u00a0Ridder\u00a0D,\u00a0Barendregt\u00a0BH,\u00a0de \u00a0Haas\u00a0EFE,\u00a0Reinders\u00a0MJT\u00a0 et\u00a0al.\u00a0Ig\u00a0gene\u00a0\nrearrangement\u00a0steps\u00a0are\u00a0initiate d\u00a0in\u00a0early\u00a0human\u00a0precursor\u00a0B\u00a0ce ll\u00a0subsets\u00a0and\u00a0correlate\u00a0with\u00a0specific\u00a0\ntranscription\u00a0factor\u00a0expression.\u00a0 J\u00a0Immunol \u00a02005;\u00a0175:\u00a05912\u20135922.\u00a0\n60\u00a0\u00a0 Lewis\u00a0SM.\u00a0The\u00a0mechanism\u00a0of\u00a0V(D)J\u00a0joining:\u00a0lessons\u00a0from\u00a0mole cular,\u00a0immunological,\u00a0and\u00a0comparative\u00a0\nanalyses.\u00a0 Adv\u00a0Immunol \u00a01994;\u00a056:\u00a027\u2013150.\u00a0\n61\u00a0\u00a0 Hardy\u00a0RR,\u00a0Hayakawa\u00a0K.\u00a0B\u00a0C ell\u00a0Development\u00a0Pathways.\u00a0 Annu\u00a0Rev\u00a0Immunol \u00a02001;\u00a019:\u00a0595\u2013621.\u00a0\n62\u00a0\u00a0 Berkowska\u00a0MA,\u00a0van\u00a0der\u00a0Burg\u00a0M,\u00a0van\u00a0Dongen\u00a0JJM,\u00a0van\u00a0Zelm\u00a0MC.\u00a0 Checkpoints\u00a0of\u00a0B\u00a0cell\u00a0differentiation:\u00a0\nVisualizing\u00a0Ig\u2010centric\u00a0processes.\u00a0 Ann\u00a0N\u00a0Y\u00a0Acad\u00a0Sci \u00a02011;\u00a01246:\u00a011\u201325.\u00a0\n63\u00a0\u00a0 Clavarino\u00a0G,\u00a0Delouche\u00a0N,\u00a0Vetti er\u00a0C,\u00a0Laurin\u00a0D,\u00a0Pernollet\u00a0M,\u00a0 Raskovalova\u00a0T\u00a0 et\u00a0al.\u00a0Novel\u00a0strategy\u00a0for\u00a0phenotypic\u00a0\ncharacterization\u00a0of\u00a0Human\u00a0B\u00a0lym phocytes\u00a0from\u00a0precursors\u00a0to\u00a0effe ctor\u00a0cells\u00a0by\u00a0flow\u00a0cytometry.\u00a0 PLoS\u00a0One \u00a0\n2016;\u00a011:\u00a01\u201316.\u00a0\n64\u00a0\u00a0 van\u00a0 Lochem\u00a0 EG,\u00a0 van\u00a0 der\u00a0 Velden\u00a0 VHJ,\u00a0 Wind\u00a0 HK,\u00a0 te\u00a0 Marvelde\u00a0 JG, \u00a0W e s t e r d a a l \u00a0N A C , \u00a0v a n \u00a0D on g e n \u00a0J J M . \u00a0\nImmunophenotypic\u00a0differentiation \u00a0patterns\u00a0of\u00a0normal\u00a0hematopoies is\u00a0in\u00a0human\u00a0bone\u00a0marrow:\u00a0reference\u00a0\npatterns\u00a0for\u00a0age\u2010related\u00a0change s\u00a0and\u00a0disease\u2010induced\u00a0shifts.\u00a0 Cytometry\u00a0B\u00a0Clin\u00a0Cytom \u00a02004;\u00a060:\u00a01\u201313.\u00a0\n65\u00a0\u00a0 Agrawal\u00a0S,\u00a0Smith\u00a0SABC,\u00a0Tangye\u00a0SG,\u00a0Sewell\u00a0WA.\u00a0Transitional\u00a0B \u00a0cell\u00a0subsets\u00a0in\u00a0human\u00a0bone\u00a0marrow.\u00a0 Clin\u00a0Exp\u00a0\nImmunol\u00a02013;\u00a0174:\u00a053\u201359.\u00a0\n66\u00a0\u00a0 Radic\u00a0MZ,\u00a0Zouali\u00a0M.\u00a0Receptor\u00a0editing,\u00a0immune\u00a0diversificatio n,\u00a0and\u00a0self\u2010tolerance.\u00a0 Immunity \u00a01996;\u00a05:\u00a0505\u2013\n511.\u00a0\n67\u00a0\u00a0 Chen\u00a0C,\u00a0Radic\u00a0MZ,\u00a0Erikson\u00a0J,\u00a0Camper\u00a0SA,\u00a0Litwin\u00a0S,\u00a0Hardy\u00a0RR\u00a0 et\u00a0al.\u00a0Deletion\u00a0and\u00a0editing\u00a0of \u00a0B\u00a0cells\u00a0that\u00a0express\u00a0\nantibodies\u00a0to\u00a0DNA.\u00a0 J\u00a0Immunol \u00a01994;\u00a0152:\u00a01970\u20131982.\u00a0\n68\u00a0\u00a0 Wang\u00a0LD,\u00a0Clark\u00a0MR.\u00a0B\u2010cell\u00a0antigen\u2010receptor\u00a0signalling\u00a0in\u00a0ly mphocyte\u00a0development.\u00a0 Immunology \u00a02003;\u00a0110:\u00a0\n411\u2013420.\u00a0\n69\u00a0\u00a0 Tangye\u00a0SG.\u00a0Thucydides\u00a0and\u00a0 longer\u2010lived\u00a0plasma\u00a0cells.\u00a0 Blood\u00a02015;\u00a0125:\u00a01684\u20135.\u00a0\n70\u00a0\u00a0 Lanzavecchia\u00a0A,\u00a0Sallusto\u00a0F.\u00a0Human\u00a0B\u00a0cell\u00a0memory.\u00a0 Curr\u00a0Opin\u00a0Immunol \u00a02009;\u00a021:\u00a0298\u2013304.\u00a0\n71\u00a0\u00a0 Tarlinton\u00a0D,\u00a0Good\u2010Jacobson\u00a0K.\u00a0Diversity\u00a0among\u00a0memory\u00a0B\u00a0cell s:\u00a0origin,\u00a0consequences,\u00a0and\u00a0utility.\u00a0 Science\u00a0\n2013;\u00a0341:\u00a01205\u20131211.\u00a0\n72\u00a0\u00a0 Sims\u00a0GP,\u00a0Ettinger\u00a0R,\u00a0Shirota\u00a0Y,\u00a0Yarboro\u00a0CH,\u00a0Illei\u00a0GG,\u00a0Lipsk y\u00a0PE.\u00a0Identification\u00a0and\u00a0characterization\u00a0of\u00a0circulating\u00a0\nhuman\u00a0transitional\u00a0B\u00a0cells.\u00a0 Blood\u00a02005;\u00a0105:\u00a04390\u20138.\u00a0\n73\u00a0\u00a0 Fearon\u00a0DT,\u00a0Carroll\u00a0MC.\u00a0Regulation\u00a0of\u00a0B\u00a0lymphocyte\u00a0responses \u00a0to\u00a0foreign\u00a0and\u00a0self\u2010antigens\u00a0by\u00a0the\u00a0CD19/CD21\u00a0\ncomplex.\u00a0 Annu\u00a0Rev\u00a0Immunol \u00a02000;\u00a018:\u00a0393\u2013422.\u00a0\n74\u00a0\u00a0 Carter\u00a0RH,\u00a0Fearon\u00a0DT.\u00a0CD19:\u00a0lowering\u00a0the\u00a0threshold\u00a0for\u00a0anti gen\u00a0receptor\u00a0stimulation\u00a0of\u00a0B\u00a0lymphocytes.\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0232\u00a0\u2010\u00a0\n\u00a0Science\u00a01992;\u00a0256:\u00a0105\u2013107.\u00a0\n75\u00a0\u00a0 Riley\u00a0JK,\u00a0Sliwkowski\u00a0MX.\u00a0CD 20:\u00a0a\u00a0gene\u00a0in\u00a0search\u00a0of\u00a0a\u00a0functi on.\u00a0Semin\u00a0Oncol \u00a02000;\u00a027:\u00a017\u201324.\u00a0\n76\u00a0\u00a0 Justement\u00a0LB,\u00a0Brown\u00a0VK,\u00a0Lin\u00a0J.\u00a0Regulation\u00a0of\u00a0B\u2010cell\u00a0activat ion\u00a0by\u00a0CD45:\u00a0a\u00a0question\u00a0of\u00a0mechanism.\u00a0 Immunol\u00a0\nToday\u00a01994;\u00a015:\u00a0399\u2013406.\u00a0\n77\u00a0\u00a0 Rhee\u00a0I,\u00a0Veillette\u00a0A.\u00a0Protein\u00a0 tyrosine\u00a0phospha tases\u00a0in\u00a0lymph ocyte\u00a0activation\u00a0and\u00a0autoimmunity.\u00a0 Nat\u00a0Immunol \u00a0\n2012;\u00a013:\u00a0439\u2013447.\u00a0\n78\u00a0\u00a0 Sen\u00a0G,\u00a0Bikah\u00a0G,\u00a0Venkataraman\u00a0C,\u00a0Bondada\u00a0S.\u00a0Negative\u00a0regulat ion\u00a0of\u00a0antigen\u00a0receptor\u2010mediated\u00a0signaling\u00a0by\u00a0\nconstitutive\u00a0association\u00a0of\u00a0CD5\u00a0w ith\u00a0the\u00a0SHP\u20101\u00a0protein\u00a0tyrosine \u00a0phosphatase\u00a0in\u00a0B\u20101\u00a0B\u00a0cells.\u00a0 Eur\u00a0J\u00a0Immunol \u00a0\n1999;\u00a029:\u00a03319\u20133328.\u00a0\n79\u00a0\u00a0 Gary\u2010Gouy\u00a0H,\u00a0Harriague\u00a0J,\u00a0Dalloul\u00a0A,\u00a0Donnadieu\u00a0E,\u00a0Bismuth\u00a0G .\u00a0CD5\u2010negative\u00a0regulation\u00a0of\u00a0B\u00a0cell\u00a0receptor\u00a0\nsignaling\u00a0 pathways\u00a0 originates\u00a0 from\u00a0 tyrosine\u00a0 residue\u00a0 Y429\u00a0 outsid e\u00a0 an\u00a0 immunoreceptor\u00a0 tyrosine\u2010based\u00a0\ninhibitory\u00a0motif.\u00a0 J\u00a0Immunol \u00a02002;\u00a0168:\u00a0232\u2013239.\u00a0\n80\u00a0\u00a0 Fujimoto\u00a0M,\u00a0Bradney\u00a0AP,\u00a0Poe\u00a0JC,\u00a0Steeber\u00a0DA,\u00a0Tedder\u00a0TF.\u00a0Modu lation\u00a0of\u00a0B\u00a0lymphocyte\u00a0antigen\u00a0receptor\u00a0signal\u00a0\ntransduction\u00a0by\u00a0a\u00a0CD19/CD22\u00a0regulatory\u00a0loop.\u00a0 Immunity \u00a01999;\u00a011:\u00a0191\u2013200.\u00a0\n81\u00a0\u00a0 Armitage\u00a0RJ,\u00a0Macduff\u00a0BM,\u00a0Spriggs\u00a0MK,\u00a0Fanslow\u00a0WC.\u00a0Human\u00a0B\u00a0ce ll\u00a0proliferation\u00a0and\u00a0Ig\u00a0secretion\u00a0induced\u00a0by\u00a0\nrecombinant\u00a0CD40\u00a0ligand\u00a0are\u00a0modulated\u00a0by\u00a0soluble\u00a0cytokines.\u00a0 J\u00a0Immunol \u00a01993;\u00a0150:\u00a03671\u20133680.\u00a0\n82\u00a0\u00a0 Good\u2010Jacobson\u00a0KL,\u00a0Shlomchik\u00a0 MJ.\u00a0Plasticity\u00a0and\u00a0heterogeneit y\u00a0in\u00a0the\u00a0generation\u00a0of\u00a0memory\u00a0B\u00a0cells\u00a0and\u00a0long\u2010\nlived\u00a0plasma\u00a0cells:\u00a0the\u00a0influence\u00a0of\u00a0germinal\u00a0center\u00a0interactio ns\u00a0and\u00a0dynamics.\u00a0 J\u00a0Immunol \u00a02010;\u00a0185:\u00a03117\u2013\n3125.\u00a0\n83\u00a0\u00a0 Shlomchik\u00a0MJ,\u00a0Weisel\u00a0F.\u00a0Germinal\u00a0center\u00a0selection\u00a0and\u00a0the\u00a0d evelopment\u00a0of\u00a0memory\u00a0B\u00a0and\u00a0plasma\u00a0cells.\u00a0\nImmunol\u00a0Rev \u00a02012;\u00a0247:\u00a052\u201363.\u00a0\n84\u00a0\u00a0 Victora\u00a0GD,\u00a0Dominguez\u2010Sola\u00a0D,\u00a0Holmes\u00a0AB,\u00a0Deroubaix\u00a0S,\u00a0Dalla \u2010Favera\u00a0R,\u00a0Nussenzweig\u00a0MC.\u00a0Identification\u00a0of\u00a0\nhuman\u00a0germinal\u00a0center\u00a0light\u00a0and\u00a0da rk\u00a0zone\u00a0cells\u00a0and\u00a0their\u00a0relat ionship\u00a0to\u00a0human\u00a0B\u2010cell\u00a0lymphomas.\u00a0 Blood\u00a0\n2012;\u00a0120:\u00a02240\u20132248.\u00a0\n85\u00a0\u00a0 Mesin\u00a0L,\u00a0Ersching\u00a0J,\u00a0Victora\u00a0GD.\u00a0Germinal\u00a0Center\u00a0B\u00a0Cell\u00a0Dyn amics.\u00a0Immunity \u00a02016;\u00a045:\u00a0471\u2013482.\u00a0\n86\u00a0\u00a0 Allen\u00a0CDC,\u00a0Ansel\u00a0KM,\u00a0Low\u00a0C,\u00a0Lesley\u00a0R,\u00a0Tamamura\u00a0H,\u00a0Fujii\u00a0N\u00a0 et\u00a0al.\u00a0Germinal\u00a0center\u00a0dark\u00a0and\u00a0light\u00a0zone\u00a0\norganization\u00a0is\u00a0mediated \u00a0by\u00a0CXCR4\u00a0and\u00a0CXCR5.\u00a0 Nat\u00a0Immunol \u00a02004;\u00a05:\u00a0943\u201352.\u00a0\n87\u00a0\u00a0 Zhang\u00a0Y,\u00a0Garcia\u2010Ibanez\u00a0L,\u00a0Toellner\u00a0KM.\u00a0Regulation\u00a0of\u00a0germin al\u00a0center\u00a0B\u2010cell\u00a0differentiation.\u00a0 Immunol\u00a0Rev \u00a0\n2016;\u00a0270:\u00a08\u201319.\u00a0\n88\u00a0\u00a0 Stavnezer\u00a0J,\u00a0Schrader\u00a0CE.\u00a0IgH\u00a0chain\u00a0class\u00a0switch\u00a0recombinat ion:\u00a0mechanism\u00a0and\u00a0regulation.\u00a0 J\u00a0Immunol \u00a02014;\u00a0\n193:\u00a05370\u20135378.\u00a0\n89\u00a0\u00a0 Xu\u00a0Z,\u00a0Zan\u00a0H,\u00a0Pone\u00a0EJ,\u00a0Mai\u00a0T,\u00a0Casali\u00a0P.\u00a0Immunoglobulin\u00a0class \u2010switch\u00a0DNA\u00a0recombination:\u00a0induction,\u00a0targeting\u00a0\nand\u00a0beyond.\u00a0 Nat\u00a0Rev\u00a0Immunol \u00a02012;\u00a012:\u00a0517\u2013531.\u00a0\n90\u00a0\u00a0 Muramatsu\u00a0M,\u00a0Kinoshita\u00a0K,\u00a0Fagarasan\u00a0S,\u00a0Yamada\u00a0S,\u00a0Shinkai\u00a0Y, \u00a0Honjo\u00a0T.\u00a0Class\u00a0switch\u00a0recombination\u00a0and\u00a0\nhypermutation\u00a0require\u00a0activation\u2010 induced\u00a0cytidine\u00a0deaminase\u00a0(AI D),\u00a0a\u00a0potential\u00a0RNA\u00a0editing\u00a0enzyme.\u00a0 Cell\u00a0\n2000;\u00a0102:\u00a0553\u201363.\u00a0\n91\u00a0\u00a0 Briere\u00a0F,\u00a0Servet\u2010Delprat\u00a0C,\u00a0B ridon\u00a0JM,\u00a0Saint\u2010Remy\u00a0JM,\u00a0Banch ereau\u00a0J.\u00a0Human\u00a0interleukin\u00a010\u00a0induces\u00a0naive\u00a0\nsurface\u00a0immunoglobulin\u00a0D+\u00a0(sIgD+ )\u00a0B\u00a0cells\u00a0to\u00a0secrete\u00a0IgG1\u00a0and\u00a0I gG3.\u00a0J\u00a0Exp\u00a0Med \u00a01994;\u00a0179:\u00a0757\u2013762.\u00a0\n92\u00a0\u00a0 Zan\u00a0H,\u00a0Cerutti\u00a0A,\u00a0Dramitinos\u00a0P,\u00a0Schaffer\u00a0A,\u00a0Casali\u00a0P.\u00a0CD40\u00a0 engagement\u00a0triggers\u00a0switching\u00a0to\u00a0IgA1\u00a0and\u00a0IgA2\u00a0in\u00a0\nhuman\u00a0B\u00a0cells\u00a0through\u00a0induction\u00a0of\u00a0endogenous\u00a0TGF\u2010beta:\u00a0evidenc e\u00a0for\u00a0TGF\u2010beta\u00a0but\u00a0not\u00a0IL\u201010\u2010dependent\u00a0\ndirect\u00a0S\u00a0mu\u2010\u2010>S\u00a0alpha\u00a0and\u00a0sequential\u00a0S\u00a0mu\u2010\u2010>S\u00a0gamma,\u00a0S\u00a0gamma\u2010\u2010> S\u00a0alpha\u00a0DNA\u00a0recombination.\u00a0 J\u00a0Immunol \u00a0\n1998;\u00a0161:\u00a05217\u20135225.\u00a0\n93\u00a0\u00a0 Punnonen\u00a0J,\u00a0Aversa\u00a0G,\u00a0Cocks\u00a0B G,\u00a0McKenzie\u00a0AN,\u00a0Menon\u00a0S,\u00a0Zuraw ski\u00a0G\u00a0et\u00a0al.\u00a0Interleukin\u00a013\u00a0induces\u00a0interleukin\u00a0\n4\u2010independent\u00a0IgG4\u00a0and\u00a0IgE\u00a0synthesis\u00a0and\u00a0CD23\u00a0\u00a0expression\u00a0by\u00a0hu man\u00a0B\u00a0cells.\u00a0 Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A \u00a01993;\u00a0\n90:\u00a03730\u20133734.\u00a0\n94\u00a0\u00a0 Horns\u00a0F,\u00a0Vollmers\u00a0C,\u00a0Croote\u00a0D,\u00a0Mackey\u00a0SF,\u00a0Swan\u00a0GE,\u00a0Dekker\u00a0C L\u00a0et\u00a0al.\u00a0Lineage\u00a0tracing\u00a0of\u00a0human\u00a0B\u00a0cells\u00a0reveals\u00a0\nthe\u00a0in\u00a0vivo\u00a0landscape\u00a0of\u00a0human \u00a0antibody\u00a0class\u00a0switching.\u00a0 Elife\u00a02016;\u00a05.\u00a0doi:10.7554/eLife.16578.\u00a0\n95\u00a0\u00a0 Collins\u00a0AM,\u00a0Jackson\u00a0KJL.\u00a0A\u00a0Temporal\u00a0Model\u00a0of\u00a0Human\u00a0IgE\u00a0and\u00a0 IgG\u00a0Antibody\u00a0Function.\u00a0 Front\u00a0Immunol \u00a02013;\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0233\u00a0\u2010\u00a0\n\u00a04:\u00a0235.\u00a0\n96\u00a0\u00a0 Jackson\u00a0KJL,\u00a0Wang\u00a0Y,\u00a0Collins\u00a0AM.\u00a0Human\u00a0immunoglobulin\u00a0class es\u00a0and\u00a0subclasses\u00a0show\u00a0variability\u00a0in\u00a0VDJ\u00a0gene\u00a0\nmutation\u00a0levels.\u00a0 Immunol\u00a0Cell\u00a0Biol \u00a02014;\u00a092:\u00a0729\u2013733.\u00a0\n97\u00a0\u00a0 de\u00a0Jong\u00a0BG,\u00a0IJspeert\u00a0H,\u00a0Marques\u00a0L,\u00a0van\u00a0der\u00a0Burg\u00a0M,\u00a0van\u00a0Dong en\u00a0JJ,\u00a0Loos\u00a0BG\u00a0 et\u00a0al.\u00a0Human\u00a0IgG2\u2010\u00a0and\u00a0IgG4\u2010\nexpressing\u00a0memory\u00a0B\u00a0cells\u00a0displ ay\u00a0enhanced\u00a0molecular\u00a0and\u00a0phenot ypic\u00a0signs\u00a0of\u00a0maturity\u00a0and\u00a0accumulate\u00a0\nwith\u00a0age.\u00a0 Immunol\u00a0Cell\u00a0Biol \u00a02017;\u00a095:\u00a0744\u2013752.\u00a0\n98\u00a0\u00a0 van\u00a0Zelm\u00a0MC.\u00a0B\u00a0cells\u00a0take\u00a0their\u00a0time:\u00a0sequential\u00a0IgG\u00a0class\u00a0 switching\u00a0over\u00a0the\u00a0course\u00a0of\u00a0an\u00a0immune\u00a0response?\u00a0\nImmunol\u00a0Cell\u00a0Biol \u00a02014;\u00a092:\u00a0645\u2013646.\u00a0\n99\u00a0\u00a0 Smith\u00a0KG,\u00a0Hewitson\u00a0TD,\u00a0Nossal\u00a0GJ,\u00a0Tarlinton\u00a0DM.\u00a0The\u00a0phenoty pe\u00a0and\u00a0fate\u00a0of\u00a0the\u00a0antibody\u2010forming\u00a0cells\u00a0of\u00a0\nthe\u00a0splenic\u00a0foci.\u00a0 Eur\u00a0J\u00a0Immunol \u00a01996;\u00a026:\u00a0444\u2013448.\u00a0\n100\u00a0\u00a0 Manz\u00a0RA,\u00a0Thiel\u00a0A,\u00a0Radbruch\u00a0 A.\u00a0Lifetime\u00a0of\u00a0plasma\u00a0cells\u00a0in\u00a0 the\u00a0bone\u00a0marrow.\u00a0 Nature\u00a01997;\u00a0388:\u00a0133\u2013134.\u00a0\n101\u00a0\u00a0 Mesin\u00a0L,\u00a0Di\u00a0Niro\u00a0R,\u00a0Thompson\u00a0KM,\u00a0Lundin\u00a0KEA,\u00a0Sollid\u00a0LM.\u00a0Lo ng\u2010lived\u00a0plasma\u00a0cells\u00a0from\u00a0human\u00a0small\u00a0intestine\u00a0\nbiopsies\u00a0secrete\u00a0immunoglobulin s\u00a0for\u00a0many\u00a0weeks\u00a0in\u00a0vitro.\u00a0 J\u00a0Immunol \u00a02011;\u00a0187:\u00a02867\u20132874.\u00a0\n102\u00a0\u00a0 Landsverk\u00a0OJB,\u00a0Snir\u00a0O,\u00a0Casado \u00a0RB,\u00a0Richter\u00a0L,\u00a0Mold\u00a0JE,\u00a0Reu\u00a0 P\u00a0et\u00a0al.\u00a0Antibody\u2010secreting\u00a0plasma\u00a0cells\u00a0persist\u00a0for\u00a0\ndecades\u00a0in\u00a0human\u00a0intestine.\u00a0 J\u00a0Exp\u00a0Med \u00a02017;\u00a0214:\u00a0309\u2013317.\u00a0\n103\u00a0\u00a0 Chu\u00a0VT,\u00a0Berek\u00a0C.\u00a0The\u00a0establis hment\u00a0of\u00a0the\u00a0plasma\u00a0cell\u00a0surv ival\u00a0niche\u00a0in\u00a0the\u00a0bone\u00a0marrow.\u00a0 Immunol\u00a0Rev \u00a02013;\u00a0\n251:\u00a0177\u2013188.\u00a0\n104\u00a0\u00a0 Yu\u00a0X,\u00a0Tsibane\u00a0T,\u00a0McGraw\u00a0PA, \u00a0House\u00a0FS,\u00a0Keefer\u00a0CJ,\u00a0Hicar\u00a0MD\u00a0 et\u00a0al.\u00a0Neutralizing\u00a0antibodies\u00a0derived\u00a0from\u00a0the\u00a0B\u00a0\ncells\u00a0of\u00a01918\u00a0influenza\u00a0pandemic\u00a0survivors.\u00a0 Nature\u00a02008;\u00a0455:\u00a0532\u2013536.\u00a0\n105\u00a0\u00a0 Crotty\u00a0S,\u00a0Felgner\u00a0P,\u00a0Davies\u00a0 H,\u00a0Glidewell\u00a0J,\u00a0Villarreal\u00a0L,\u00a0 Ahmed\u00a0R.\u00a0Cutting\u00a0edge:\u00a0long\u2010term\u00a0B\u00a0cell\u00a0memory\u00a0in\u00a0\nhumans\u00a0after\u00a0smallpox\u00a0vaccination.\u00a0 J\u00a0Immunol \u00a02003;\u00a0171:\u00a04969\u20134973.\u00a0\n106\u00a0\u00a0 Seifert\u00a0M,\u00a0Kuppers\u00a0R.\u00a0 Human\u00a0memory\u00a0B\u00a0cells.\u00a0 Leukemia \u00a02016;\u00a030:\u00a02283\u20132292.\u00a0\n107\u00a0\u00a0 Mond\u00a0JJ,\u00a0Vos\u00a0Q,\u00a0Lees\u00a0A,\u00a0Snapper\u00a0CM.\u00a0T\u00a0cell\u00a0independent\u00a0ant igens.\u00a0Curr\u00a0Opin\u00a0Immunol \u00a01995;\u00a07:\u00a0349\u2013354.\u00a0\n108\u00a0\u00a0 Vos\u00a0Q,\u00a0Lees\u00a0A,\u00a0Wu\u00a0ZQ,\u00a0Snappe r\u00a0CM,\u00a0Mond\u00a0JJ.\u00a0B\u2010cell\u00a0activati on\u00a0by\u00a0T\u2010cell\u2010independent\u00a0type\u00a02\u00a0antigens\u00a0as\u00a0an\u00a0\nintegral\u00a0part\u00a0of\u00a0the\u00a0humoral\u00a0immune\u00a0response\u00a0to\u00a0pathogenic\u00a0micr oorganisms.\u00a0 Immunol\u00a0Rev \u00a02000;\u00a0176:\u00a0154\u2013\n170.\u00a0\n109\u00a0\u00a0 Defrance\u00a0T,\u00a0Taillardet\u00a0M,\u00a0G enestier\u00a0L.\u00a0T\u00a0cell\u2010independent\u00a0 B\u00a0cell\u00a0memory.\u00a0 Curr\u00a0Opin\u00a0Immunol \u00a02011;\u00a023:\u00a0330\u2013\n336.\u00a0\n110\u00a0\u00a0 van\u00a0Zelm\u00a0MC,\u00a0Bartol\u00a0SJW,\u00a0Driessen\u00a0GJ,\u00a0Mascart\u00a0F,\u00a0Reisli\u00a0I, \u00a0Franco\u00a0JL\u00a0 et\u00a0al.\u00a0Human\u00a0CD19\u00a0and\u00a0CD40L\u00a0deficiencies\u00a0\nimpair\u00a0antibody\u00a0selection\u00a0and\u00a0 differentially\u00a0affect\u00a0somatic\u00a0hyp ermutation.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02014;\u00a0134:\u00a0\n135\u2013144.\u00a0\n111\u00a0\u00a0 Berkowska\u00a0MA,\u00a0Driessen\u00a0GJA,\u00a0B ikos\u00a0V,\u00a0Grosserichter\u2010Wagener \u00a0C,\u00a0Stamatopoulos\u00a0K,\u00a0Cerutti\u00a0A\u00a0 et\u00a0al.\u00a0Human\u00a0\nmemory\u00a0B\u00a0cells\u00a0originate\u00a0from\u00a0three\u00a0distinct\u00a0germinal\u00a0center\u2010de pendent\u00a0and\u00a0\u2010indepe ndent\u00a0maturation\u00a0\npathways.\u00a0 Blood\u00a02011;\u00a0118:\u00a02150\u20132158.\u00a0\n112\u00a0\u00a0 Maecker\u00a0HT,\u00a0McCoy\u00a0JP,\u00a0Nussenblatt\u00a0R.\u00a0Standardizing\u00a0immunop henotyping\u00a0for\u00a0the\u00a0Human\u00a0Immunology\u00a0\nProject.\u00a0Nat\u00a0Rev\u00a0Immunol \u00a02012;\u00a0257:\u00a02432\u20132437.\u00a0\n113\u00a0\u00a0 Cuss\u00a0AK,\u00a0Avery\u00a0DT,\u00a0Cannons\u00a0JL,\u00a0Yu\u00a0LJ,\u00a0Nichols\u00a0KE,\u00a0Shaw\u00a0PJ\u00a0 et\u00a0al.\u00a0Expansion\u00a0of\u00a0functionally\u00a0immature\u00a0\ntransitional\u00a0B\u00a0cells\u00a0is\u00a0associated\u00a0with\u00a0human\u2010immunodeficient\u00a0s tates\u00a0characterized\u00a0by\u00a0impaired\u00a0humoral\u00a0\nimmunity.\u00a0 J\u00a0Immunol \u00a02006;\u00a0176:\u00a01506\u20131516.\u00a0\n114\u00a0\u00a0 Lee\u00a0J,\u00a0Kuchen\u00a0S,\u00a0Fischer\u00a0R,\u00a0 Chang\u00a0S,\u00a0Lipsky\u00a0PE.\u00a0Identifica tion\u00a0and\u00a0characterization\u00a0of\u00a0a\u00a0human\u00a0CD5+\u00a0pre\u2010naive\u00a0\nB\u00a0cell\u00a0population.\u00a0 J\u00a0Immunol \u00a02009;\u00a0182:\u00a04116\u20134126.\u00a0\n115\u00a0\u00a0 Suryani\u00a0S,\u00a0Fulcher\u00a0DA,\u00a0Santner\u2010Nanan\u00a0B,\u00a0Nanan\u00a0R,\u00a0Wong\u00a0M,\u00a0S haw\u00a0PJ\u00a0et\u00a0al.\u00a0Differential\u00a0expression\u00a0of\u00a0CD21\u00a0\nidentifies\u00a0developmentally\u00a0and\u00a0f unctionally\u00a0distinct\u00a0subsets\u00a0of \u00a0human\u00a0transitional\u00a0B\u00a0cells.\u00a0 Blood\u00a02010;\u00a0115:\u00a0\n519\u2013529.\u00a0\n116\u00a0\u00a0 Said\u00a0JW,\u00a0Hoyer\u00a0KK,\u00a0French\u00a0SW, \u00a0Rosenfelt\u00a0L,\u00a0Garcia\u2010Lloret\u00a0M ,\u00a0Koh\u00a0PJ\u00a0et\u00a0al.\u00a0TCL1\u00a0oncogene\u00a0expression\u00a0in\u00a0B\u00a0cell\u00a0\nsubsets\u00a0from\u00a0lymphoid\u00a0hyperplas ia\u00a0and\u00a0distinct\u00a0classes\u00a0of\u00a0B\u00a0cel l\u00a0lymphoma.\u00a0 Lab\u00a0Invest \u00a02001;\u00a081:\u00a0555\u2013564.\u00a0\n117\u00a0\u00a0 Caraux\u00a0A,\u00a0Klein\u00a0B,\u00a0Paiva\u00a0B,\u00a0Bret\u00a0C,\u00a0Schmitz\u00a0A,\u00a0Fuhler\u00a0GM\u00a0 et\u00a0al.\u00a0Circulating\u00a0human\u00a0B\u00a0and\u00a0plasma\u00a0cells.\u00a0Age\u2010Referencias bibliogr\u00e1ficas  \n\u2010\u00a0234\u00a0\u2010\u00a0\n\u00a0associated\u00a0changes\u00a0in\u00a0counts\u00a0and\u00a0detailed\u00a0characterization\u00a0of\u00a0c irculating\u00a0normal\u00a0CD138\u2010\u00a0and\u00a0CD138+\u00a0plasma\u00a0\ncells.\u00a0Haematologica \u00a02010;\u00a095:\u00a01016\u201320.\u00a0\n118\u00a0\u00a0 Lee\u00a0J,\u00a0Sim\u00a0J\u2010H,\u00a0Kim\u00a0I\u2010J.\u00a0Peripheral\u00a0immature\u00a0B\u00a0cells:\u00a0modu lators\u00a0of\u00a0autoimmunity.\u00a0 Int\u00a0J\u00a0Rheum\u00a0Dis \u00a02015;\u00a018:\u00a0\n200\u2013207.\u00a0\n119\u00a0\u00a0 Isnardi\u00a0I,\u00a0Ng\u00a0Y,\u00a0Menard\u00a0L,\u00a0Me yers\u00a0G,\u00a0Saadoun\u00a0D,\u00a0Srdanovic\u00a0 I\u00a0et\u00a0al.\u00a0Complement\u00a0receptor\u00a02/CD21\u2010\u00a0human\u00a0\nnaive\u00a0B\u00a0cells\u00a0contain\u00a0mostly\u00a0auto reactive\u00a0unresponsive\u00a0clones.\u00a0 Blood\u00a02010;\u00a0115:\u00a05026\u201336.\u00a0\n120\u00a0\u00a0 Thorarinsdottir\u00a0K,\u00a0Camponesc hi\u00a0A,\u00a0Gjertsson\u00a0I,\u00a0M\u00e5rtensson\u00a0 I\u2010L.\u00a0CD21\u00a0\u2010/low\u00a0B\u00a0cells:\u00a0A\u00a0Snapshot\u00a0of\u00a0a\u00a0Unique\u00a0B\u00a0\nCell\u00a0Subset\u00a0in\u00a0Health\u00a0and\u00a0Disease.\u00a0 Scand\u00a0J\u00a0Immunol \u00a02015;\u00a082:\u00a0254\u201361.\u00a0\n121\u00a0\u00a0 Klein\u00a0U,\u00a0Rajewsky\u00a0K,\u00a0K\u00fcppers \u00a0R.\u00a0Human\u00a0immunoglobulin\u00a0(Ig)M +IgD+\u00a0peripheral\u00a0blood\u00a0B\u00a0cells\u00a0expressing\u00a0the\u00a0\nCD27\u00a0cell\u00a0surface\u00a0antigen\u00a0carry\u00a0somatically\u00a0mutated\u00a0variable\u00a0re gion\u00a0genes:\u00a0CD27\u00a0as\u00a0a\u00a0general\u00a0marker\u00a0for\u00a0\nsomatically\u00a0mutated\u00a0(memory)\u00a0B\u00a0cells.\u00a0 J\u00a0Exp\u00a0Med \u00a01998;\u00a0188:\u00a01679\u201389.\u00a0\n122\u00a0\u00a0 Tangye\u00a0SG,\u00a0Liu\u00a0YJ,\u00a0Aversa\u00a0G,\u00a0Phillips\u00a0JH,\u00a0de\u00a0Vries\u00a0JE.\u00a0Ide ntification\u00a0of\u00a0functional\u00a0human\u00a0splenic\u00a0memory\u00a0B\u00a0cells\u00a0\nby\u00a0expression\u00a0of\u00a0CD148\u00a0and\u00a0CD27.\u00a0 J\u00a0Exp\u00a0Med \u00a01998;\u00a0188:\u00a01691\u20131703.\u00a0\n123\u00a0\u00a0 Fecteau\u00a0JF,\u00a0C\u00f4t\u00e9\u00a0G,\u00a0N\u00e9ron\u00a0S.\u00a0 A\u00a0new\u00a0memory\u00a0CD27\u2010IgG+\u00a0B\u00a0cell \u00a0population\u00a0in\u00a0peripheral\u00a0blood\u00a0expressing\u00a0VH\u00a0\ngenes\u00a0with\u00a0low\u00a0frequency\u00a0of\u00a0somatic\u00a0mutation.\u00a0 J\u00a0Immunol \u00a02006;\u00a0177:\u00a03728\u20133736.\u00a0\n124\u00a0\u00a0 Wei\u00a0C,\u00a0Anolik\u00a0J,\u00a0Cappione\u00a0A,\u00a0Zheng\u00a0B,\u00a0Pugh\u2010Bernard\u00a0A,\u00a0Broo ks\u00a0J\u00a0et\u00a0al.\u00a0A\u00a0New\u00a0Population\u00a0of\u00a0Cells\u00a0Lacking\u00a0\nExpression\u00a0of\u00a0CD27\u00a0Represents\u00a0a\u00a0Notable\u00a0Component\u00a0of\u00a0the\u00a0B\u00a0Cell \u00a0Memory\u00a0Compartment\u00a0in\u00a0Systemic\u00a0Lupus\u00a0\nErythematosus.\u00a0 J\u00a0Immunol \u00a02007;\u00a0178:\u00a06624\u20136633.\u00a0\n125\u00a0\u00a0 Colonna\u2010Romano\u00a0G,\u00a0Bulati\u00a0M,\u00a0Aquino\u00a0A,\u00a0Pellicano\u00a0M,\u00a0Vitello \u00a0S,\u00a0Lio\u00a0D\u00a0et\u00a0al.\u00a0A\u00a0double\u2010negative\u00a0(IgD\u2010CD27\u2010)\u00a0B\u00a0\ncell\u00a0population\u00a0is\u00a0increased\u00a0in\u00a0 the\u00a0peripheral\u00a0blood\u00a0of\u00a0elderly \u00a0people.\u00a0Mech\u00a0Ageing\u00a0Dev \u00a02009;\u00a0130:\u00a0681\u2013690.\u00a0\n126\u00a0\u00a0 Moir\u00a0S,\u00a0Ho\u00a0J,\u00a0Malaspina\u00a0A,\u00a0Wang\u00a0W,\u00a0DiPoto\u00a0AC,\u00a0O\u2019Shea\u00a0MA\u00a0 et\u00a0al.\u00a0Evidence\u00a0for\u00a0HIV\u2010associated\u00a0B\u00a0cell\u00a0exhaustion\u00a0\nin\u00a0a\u00a0dysfunctional\u00a0memory\u00a0B\u00a0cell\u00a0compartment\u00a0in\u00a0HIV\u2010infected\u00a0vi remic\u00a0individuals.\u00a0 J\u00a0Exp\u00a0Med \u00a02008;\u00a0205:\u00a0\n1797\u20131805.\u00a0\n127\u00a0\u00a0 Thorarinsdottir\u00a0K,\u00a0Camponeschi\u00a0A,\u00a0Cavallini\u00a0N,\u00a0Grimsholm\u00a0O ,\u00a0Jacobsson\u00a0L,\u00a0Gjertsson\u00a0I\u00a0 et\u00a0al.\u00a0CD21(\u2010/low)\u00a0B\u00a0\ncells\u00a0in\u00a0human\u00a0blood\u00a0are\u00a0memory\u00a0cells.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a02016;\u00a0185:\u00a0252\u201362.\u00a0\n128\u00a0\u00a0 Portugal\u00a0S,\u00a0Obeng\u2010Adjei\u00a0N,\u00a0Moir\u00a0S,\u00a0Crompton\u00a0PD,\u00a0Pierce\u00a0SK. \u00a0Atypical\u00a0memory\u00a0B\u00a0cells\u00a0in\u00a0human\u00a0chronic\u00a0\ninfectious\u00a0diseases:\u00a0An\u00a0interim\u00a0report.\u00a0 Cell\u00a0Immunol \u00a02017;\u00a0321:\u00a018\u201325.\u00a0\n129\u00a0\u00a0 Pupovac\u00a0A,\u00a0Good\u2010Jacobson\u00a0KL.\u00a0An\u00a0antigen\u00a0to\u00a0remember:\u00a0regul ation\u00a0of\u00a0B\u00a0cell\u00a0memory\u00a0in\u00a0health\u00a0and\u00a0disease.\u00a0\nCurr\u00a0Opin\u00a0Immunol \u00a02017;\u00a045:\u00a089\u201396.\u00a0\n130\u00a0\u00a0 van\u00a0Zelm\u00a0MC.\u00a0Human\u00a0CD27+IgM+ IgD+\u00a0B\u00a0cells:\u00a0T\u2010cell\u00a0or\u00a0TLR\u2010de pendent?\u00a0 Blood\u00a02012;\u00a0120:\u00a04905\u20134906.\u00a0\n131\u00a0\u00a0 Wirths\u00a0 S,\u00a0 Lanzavecchia\u00a0 A.\u00a0 AB CB1\u00a0 transporter\u00a0 discriminates\u00a0 human\u00a0 resting\u00a0 naive\u00a0 B\u00a0 cells\u00a0 from\u00a0 cycling\u00a0\ntransitional\u00a0and\u00a0memory\u00a0B\u00a0cells.\u00a0 Eur\u00a0J\u00a0Immunol \u00a02005;\u00a035:\u00a03433\u20133441.\u00a0\n132\u00a0\u00a0 Martin\u00a0V,\u00a0Bryan\u00a0Wu\u00a0Y\u2010C,\u00a0Kipling\u00a0D,\u00a0Dunn\u2010Walters\u00a0D.\u00a0Ageing\u00a0 of\u00a0the\u00a0B\u2010cell\u00a0repertoire.\u00a0 Philos\u00a0Trans\u00a0R\u00a0Soc\u00a0Lond\u00a0\nB\u00a0Biol\u00a0Sci\u00a02015;\u00a0370:\u00a020140237.\u00a0\n133\u00a0\u00a0 Seifert\u00a0M,\u00a0Steimle\u2010Grauer\u00a0SA,\u00a0Goossens\u00a0T,\u00a0Hansmann\u00a0ML,\u00a0Br\u00e4 uninger\u00a0A,\u00a0K\u00fcppers\u00a0R.\u00a0A\u00a0model\u00a0for\u00a0the\u00a0\ndevelopment\u00a0of\u00a0human\u00a0IgD\u2010only\u00a0B\u00a0cells:\u00a0Genotypic\u00a0analyses\u00a0sugge st\u00a0their\u00a0generation\u00a0in\u00a0superantigen\u00a0driven\u00a0\nimmune\u00a0responses.\u00a0 Mol\u00a0Immunol \u00a02009;\u00a046:\u00a0630\u2013639.\u00a0\n134\u00a0\u00a0 Forsgren\u00a0A,\u00a0Grubb\u00a0AO.\u00a0Many\u00a0b acterial\u00a0species\u00a0bind\u00a0human\u00a0Ig D.\u00a0J\u00a0Immunol \u00a01979;\u00a0122:\u00a01468\u20131472.\u00a0\n135\u00a0\u00a0 Johansen\u00a0F\u2010E,\u00a0Baekkevold\u00a0ES, \u00a0Carlsen\u00a0HS,\u00a0Farstad\u00a0IN,\u00a0Soler \u00a0D,\u00a0Brandtzaeg\u00a0P.\u00a0Regional\u00a0induction\u00a0of\u00a0adhesion\u00a0\nmolecules\u00a0and\u00a0chemokine\u00a0receptors\u00a0explains\u00a0disparate\u00a0homing\u00a0of\u00a0 human\u00a0B\u00a0cells\u00a0to\u00a0systemic\u00a0and\u00a0mucosal\u00a0\neffector\u00a0sites:\u00a0dispersion\u00a0from\u00a0tonsils.\u00a0 Blood\u00a02005;\u00a0106:\u00a0593\u2013600.\u00a0\n136\u00a0\u00a0 Morbach\u00a0H,\u00a0Eichhorn\u00a0EM,\u00a0Liese \u00a0JG,\u00a0Girschick\u00a0HJ.\u00a0Reference\u00a0 values\u00a0for\u00a0B\u00a0cell\u00a0subpopulations\u00a0from\u00a0infancy\u00a0to\u00a0\nadulthood.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a02010;\u00a0162:\u00a0271\u20139.\u00a0\n137\u00a0\u00a0 Huck\u00a0K,\u00a0Feyen\u00a0O,\u00a0Ghosh\u00a0S,\u00a0Beltz\u00a0K,\u00a0Bellert\u00a0S,\u00a0Niehues\u00a0T.\u00a0M emory\u00a0B\u2010cells\u00a0in\u00a0healthy\u00a0and\u00a0antibody\u2010deficient\u00a0\nchildren.\u00a0 Clin\u00a0Immunol \u00a02009;\u00a0131:\u00a050\u201359.\u00a0\n138\u00a0\u00a0 Mei\u00a0HE,\u00a0Yoshida\u00a0T,\u00a0Sime\u00a0W,\u00a0 Hiepe\u00a0F,\u00a0Thiele\u00a0K,\u00a0Manz\u00a0R\u00a0a\u00a0 et\u00a0al.\u00a0Blood\u2010borne\u00a0human\u00a0plasma\u00a0cells\u00a0in\u00a0steady\u00a0state\u00a0\nare\u00a0derived\u00a0from\u00a0mucosal \u00a0immune\u00a0responses.\u00a02009;\u00a0 113:\u00a02461\u20132469.\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0235\u00a0\u2010\u00a0\n\u00a0139\u00a0\u00a0 Odendahl\u00a0M,\u00a0Mei\u00a0H,\u00a0Hoyer\u00a0BF, \u00a0Jacobi\u00a0AM,\u00a0Hansen\u00a0A,\u00a0Muehling haus\u00a0G\u00a0et\u00a0al.\u00a0Generation\u00a0of\u00a0migratory\u00a0antigen\u2010\nspecific\u00a0plasma\u00a0blasts\u00a0and\u00a0mobiliz ation\u00a0of\u00a0resident\u00a0plasma\u00a0cell s\u00a0in\u00a0a\u00a0secondary\u00a0immune\u00a0response.\u00a0 Blood\u00a02005;\u00a0\n105:\u00a01614\u20131621.\u00a0\n140\u00a0\u00a0 Medina\u00a0F,\u00a0Segundo\u00a0C,\u00a0Campos\u2010Caro\u00a0A,\u00a0Gonzalez\u2010Garcia\u00a0I,\u00a0Bri eva\u00a0JA.\u00a0The\u00a0heterogeneity\u00a0shown\u00a0by\u00a0human\u00a0\nplasma\u00a0cells\u00a0from\u00a0tonsil,\u00a0blood,\u00a0 and\u00a0bone\u00a0marrow\u00a0reveals\u00a0graded \u00a0stages\u00a0of\u00a0increasing\u00a0maturity,\u00a0but\u00a0local\u00a0\nprofiles\u00a0of\u00a0adhesion\u00a0molecule\u00a0expression.\u00a0 Blood\u00a02002;\u00a099:\u00a02154\u20132161.\u00a0\n141\u00a0\u00a0 Sundstrom\u00a0P,\u00a0Lundin\u00a0SB,\u00a0Nilsson\u00a0L\u2010A,\u00a0Quiding\u2010Jarbrink\u00a0M.\u00a0H uman\u00a0IgA\u2010secreting\u00a0cells\u00a0induced\u00a0by\u00a0intestinal,\u00a0\nbut\u00a0not\u00a0systemic,\u00a0immunization\u00a0respond\u00a0to\u00a0CCL25\u00a0(TECK)\u00a0and\u00a0CCL2 8\u00a0(MEC).\u00a0Eur\u00a0J\u00a0Immunol \u00a02008;\u00a038:\u00a03327\u2013\n3338.\u00a0\n142\u00a0\u00a0 Liston\u00a0A,\u00a0Carr\u00a0EJ,\u00a0Linterman\u00a0MA.\u00a0Shaping\u00a0Variation\u00a0in\u00a0the\u00a0 Human\u00a0Immune\u00a0System.\u00a0 Trends\u00a0Immunol \u00a02016;\u00a037:\u00a0\n637\u2013646.\u00a0\n143\u00a0\u00a0 Carr\u00a0EJ,\u00a0Dooley\u00a0J,\u00a0Garcia\u2010Perez\u00a0JE,\u00a0Lagou\u00a0V,\u00a0Lee\u00a0JC,\u00a0Woute rs\u00a0C\u00a0et\u00a0al.\u00a0The\u00a0cellular\u00a0composition\u00a0of\u00a0the\u00a0human\u00a0\nimmune\u00a0system\u00a0is\u00a0shaped\u00a0by\u00a0age\u00a0and\u00a0cohabitation.\u00a0 Nat\u00a0Immunol \u00a02016;\u00a017:\u00a0461\u2013468.\u00a0\n144\u00a0\u00a0 van\u00a0den\u00a0Heuvel\u00a0D,\u00a0Jansen\u00a0MAE,\u00a0Nasserinejad\u00a0K,\u00a0Dik\u00a0WA,\u00a0van\u00a0 Lochem\u00a0EG,\u00a0Bakker\u2010Jonges\u00a0LE\u00a0 et\u00a0al.\u00a0Effects\u00a0of\u00a0\nnongenetic\u00a0factors\u00a0on\u00a0immune\u00a0ce ll\u00a0dynamics\u00a0in\u00a0early\u00a0childhood:\u00a0 The\u00a0Generation\u00a0R\u00a0Study.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0\nImmunol\u00a02017;\u00a0139:\u00a01923\u20131934.e17.\u00a0\n145\u00a0\u00a0 Simon\u00a0AK,\u00a0Hollander\u00a0GA,\u00a0McMichael\u00a0A.\u00a0Evolution\u00a0of\u00a0the\u00a0immu ne\u00a0system\u00a0in\u00a0humans\u00a0from\u00a0infancy\u00a0to\u00a0old\u00a0age.\u00a0\nProceedings\u00a0Biol\u00a0Sci \u00a02015;\u00a0282:\u00a020143085.\u00a0\n146\u00a0\u00a0 Pawelec\u00a0G,\u00a0Derhovanessian\u00a0E ,\u00a0Larbi\u00a0A.\u00a0Immunosenescence\u00a0and \u00a0cancer.\u00a0Crit\u00a0Rev\u00a0Oncol\u00a0Hematol \u00a02010;\u00a075:\u00a0\n165\u2013172.\u00a0\n147\u00a0\u00a0 Yoshikawa\u00a0TT.\u00a0Epidemiology\u00a0and\u00a0unique\u00a0aspects\u00a0of\u00a0aging\u00a0and \u00a0infectious\u00a0diseases.\u00a0 Clin\u00a0Infect\u00a0Dis \u00a02000;\u00a030:\u00a0\n931\u2013933.\u00a0\n148\u00a0\u00a0 Cooper\u00a0MD.\u00a0Current\u00a0concepts. \u00a0B\u00a0lymphocytes.\u00a0Normal\u00a0develop ment\u00a0and\u00a0function.\u00a0 N\u00a0Engl\u00a0J\u00a0Med \u00a01987;\u00a0317:\u00a0\n1452\u20131456.\u00a0\n149\u00a0\u00a0 Zhang\u00a0X,\u00a0Zhivaki\u00a0D,\u00a0Lo\u2010Man\u00a0 R.\u00a0Unique\u00a0aspects\u00a0of\u00a0the\u00a0perina tal\u00a0immune\u00a0system.\u00a0 Nat\u00a0Rev\u00a0Immunol \u00a02017;\u00a017:\u00a0\n495\u2013507.\u00a0\n150\u00a0\u00a0 Taniguchi\u00a0H,\u00a0Toyoshima\u00a0T,\u00a0Fukao\u00a0K,\u00a0Nakauchi\u00a0H.\u00a0Evidence\u00a0fo r\u00a0the\u00a0presence\u00a0of\u00a0hematopoietic\u00a0stem\u00a0cells\u00a0in\u00a0the\u00a0\nadult\u00a0liver.\u00a0 Transplant\u00a0Proc \u00a01995;\u00a027:\u00a0196\u2013199.\u00a0\n151\u00a0\u00a0 Crosbie\u00a0OM,\u00a0Reynolds\u00a0M,\u00a0McEntee\u00a0G,\u00a0Traynor\u00a0O,\u00a0Hegarty\u00a0JE,\u00a0 O\u2019Farrelly\u00a0C.\u00a0In\u00a0vitro\u00a0evi dence\u00a0for\u00a0the\u00a0presence\u00a0\nof\u00a0hematopoietic\u00a0stem\u00a0cells \u00a0in\u00a0the\u00a0adult\u00a0human\u00a0liver.\u00a0 Hepatology \u00a01999;\u00a029:\u00a01193\u20131198.\u00a0\n152\u00a0\u00a0 Siegrist\u00a0C\u2010A,\u00a0Aspinall\u00a0R.\u00a0B\u2010c ell\u00a0responses\u00a0to\u00a0vaccination\u00a0 at\u00a0the\u00a0extremes\u00a0of\u00a0age.\u00a0 Nat\u00a0Rev\u00a0Immunol \u00a02009;\u00a09:\u00a0\n185\u2013194.\u00a0\n153\u00a0\u00a0 Kirkland\u00a0JL,\u00a0Tchkonia\u00a0T,\u00a0Pirtskhalava\u00a0T,\u00a0Han\u00a0J,\u00a0Karagianni des\u00a0I.\u00a0Adipogenesis\u00a0and\u00a0aging:\u00a0does\u00a0aging\u00a0make\u00a0fat\u00a0\ngo\u00a0MAD?\u00a0 Exp\u00a0Gerontol \u00a02002;\u00a037:\u00a0757\u2013767.\u00a0\n154\u00a0\u00a0 Jensen\u00a0K,\u00a0Schaffer\u00a0L,\u00a0Olsta d\u00a0OK,\u00a0Bechensteen\u00a0AG,\u00a0Hellebost ad\u00a0M,\u00a0Tjonnfjord\u00a0GE\u00a0 et\u00a0al.\u00a0Striking\u00a0decrease\u00a0in\u00a0the\u00a0\ntotal\u00a0precursor\u00a0B\u2010cell\u00a0compartment\u00a0during\u00a0early\u00a0childhood\u00a0as\u00a0ev idenced\u00a0by\u00a0flow\u00a0cytometry\u00a0and\u00a0gene\u00a0\nexpression\u00a0changes.\u00a0 Pediatr\u00a0Hematol\u00a0Oncol \u00a02010;\u00a027:\u00a031\u201345.\u00a0\n155\u00a0\u00a0 Pihlgren\u00a0M,\u00a0Friedli\u00a0M,\u00a0Tougn e\u00a0C,\u00a0Rochat\u00a0A\u2010F,\u00a0Lambert\u00a0P\u2010H,\u00a0 Siegrist\u00a0C\u2010A.\u00a0Reduced\u00a0ability\u00a0of\u00a0neonatal\u00a0and\u00a0early\u2010\nlife\u00a0bone\u00a0marrow\u00a0stromal\u00a0cells\u00a0t o\u00a0support\u00a0plasmablast\u00a0survival. \u00a0J\u00a0Immunol \u00a02006;\u00a0176:\u00a0165\u201372.\u00a0\n156\u00a0\u00a0 Pihlgren\u00a0M,\u00a0Schallert\u00a0N,\u00a0To ugne\u00a0C,\u00a0Bozzotti\u00a0P,\u00a0Kovarik\u00a0J,\u00a0 Fulurija\u00a0A\u00a0 et\u00a0al.\u00a0Delayed\u00a0and\u00a0deficient\u00a0establishment\u00a0\nof\u00a0the\u00a0long\u2010term\u00a0bone\u00a0marrow\u00a0plas ma\u00a0cell\u00a0pool\u00a0during\u00a0early\u00a0life .\u00a0Eur\u00a0J\u00a0Immunol \u00a02001;\u00a031:\u00a0939\u2013946.\u00a0\n157\u00a0\u00a0 Luscieti\u00a0P,\u00a0Hubschmid\u00a0T,\u00a0Co ttier\u00a0H,\u00a0Hess\u00a0MW,\u00a0Sobin\u00a0LH.\u00a0Hum an\u00a0lymph\u00a0node\u00a0morphology\u00a0as\u00a0a\u00a0function\u00a0of\u00a0age\u00a0\nand\u00a0site.\u00a0J\u00a0Clin\u00a0Pathol \u00a01980;\u00a033:\u00a0454\u2013461.\u00a0\n158\u00a0\u00a0 Barzanji\u00a0AJ,\u00a0Emery\u00a0JL.\u00a0Germinal\u00a0centers\u00a0in\u00a0the\u00a0spleens\u00a0of\u00a0 neonates\u00a0and\u00a0stillbirths.\u00a0 Early\u00a0Hum\u00a0Dev \u00a01978;\u00a01:\u00a0\n363\u2013369.\u00a0\n159\u00a0\u00a0 Ahmadi\u00a0 O,\u00a0 Mccall\u00a0 JL,\u00a0 Stringer \u00a0 MD.\u00a0 Does\u00a0 senescence\u00a0 affect\u00a0 l ymph\u00a0 node\u00a0 number\u00a0 and\u00a0 morphology?\u00a0 A\u00a0\nsystematic\u00a0review.\u00a0 ANZ\u00a0J\u00a0Surg \u00a02013;\u00a083:\u00a0612\u2013618.\u00a0\n160\u00a0\u00a0 Hadamitzky\u00a0C,\u00a0Spohr\u00a0H,\u00a0Debertin\u00a0AS,\u00a0Guddat\u00a0S,\u00a0Tsokos\u00a0M,\u00a0Pa bst\u00a0R.\u00a0Age\u2010dependent\u00a0histoarchitectural\u00a0changes\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0236\u00a0\u2010\u00a0\n\u00a0in\u00a0human\u00a0lymph\u00a0nodes:\u00a0an\u00a0underestimated\u00a0\u00a0process\u00a0with\u00a0clinical\u00a0 relevance?\u00a0 J\u00a0Anat\u00a02010;\u00a0216:\u00a0556\u2013562.\u00a0\n161\u00a0\u00a0 Tsakraklides\u00a0V,\u00a0Tsakraklides\u00a0E,\u00a0Good\u00a0RA.\u00a0An\u00a0autopsy\u00a0study\u00a0 of\u00a0human\u00a0axillary\u00a0lymph\u00a0node\u00a0histology.\u00a0 Am\u00a0J\u00a0\nPathol\u00a01975;\u00a078:\u00a07\u201322.\u00a0\n162\u00a0\u00a0 Sjogren\u00a0YM,\u00a0Tomicic\u00a0S,\u00a0Lundberg\u00a0A,\u00a0Bottcher\u00a0MF,\u00a0Bjorksten\u00a0 B,\u00a0Sverremark\u2010Ekstrom\u00a0E\u00a0 et\u00a0al.\u00a0Influence\u00a0of\u00a0early\u00a0\ngut\u00a0microbiota\u00a0on\u00a0the\u00a0maturation \u00a0of\u00a0childhood\u00a0mucosal\u00a0and\u00a0syste mic\u00a0immune\u00a0responses.\u00a0 Clin\u00a0Exp\u00a0Allergy \u00a0\n2009;\u00a039:\u00a01842\u20131851.\u00a0\n163\u00a0\u00a0 Gr\u00f6nlund\u00a0MM,\u00a0Arvilommi\u00a0H,\u00a0Kero\u00a0P,\u00a0Lehtonen\u00a0OP,\u00a0Isolauri\u00a0E. \u00a0Importance\u00a0of\u00a0intestinal\u00a0colonisation\u00a0in\u00a0the\u00a0\nmaturation\u00a0of\u00a0humoral\u00a0immunity\u00a0in\u00a0early\u00a0infancy:\u00a0a\u00a0prospective\u00a0 follow\u00a0up\u00a0study\u00a0of\u00a0healthy\u00a0infants\u00a0aged\u00a00\u20106\u00a0\nmonths.\u00a0Arch\u00a0Dis\u00a0Child\u00a0Fetal\u00a0Neonatal\u00a0Ed \u00a02000;\u00a083:\u00a0F186\u2013F192.\u00a0\n164\u00a0\u00a0 Gronlund\u00a0MM,\u00a0Lehtonen\u00a0OP,\u00a0Eero la\u00a0E,\u00a0Kero\u00a0P.\u00a0Fecal\u00a0microflo ra\u00a0in\u00a0healthy\u00a0infants\u00a0born\u00a0by\u00a0different\u00a0methods\u00a0\nof\u00a0delivery:\u00a0permanent\u00a0changes\u00a0in\u00a0intestinal\u00a0flora\u00a0after\u00a0cesare an\u00a0delivery.\u00a0 J\u00a0Pediatr\u00a0Gastroenterol\u00a0Nutr \u00a01999;\u00a0\n28:\u00a019\u201325.\u00a0\n165\u00a0\u00a0 Bennet\u00a0R,\u00a0Nord\u00a0CE.\u00a0Development\u00a0of\u00a0the\u00a0faecal\u00a0anaerobic\u00a0mic roflora\u00a0after\u00a0caesarean\u00a0section\u00a0and\u00a0treatment\u00a0\nwith\u00a0antibiotics\u00a0in\u00a0newborn\u00a0infants.\u00a0 Infection\u00a01987;\u00a015:\u00a0332\u2013336.\u00a0\n166\u00a0\u00a0 Penders\u00a0J,\u00a0Thijs\u00a0C,\u00a0Vink\u00a0C,\u00a0Stelma\u00a0FF,\u00a0Snijders\u00a0B,\u00a0Kummeli ng\u00a0I\u00a0et\u00a0al.\u00a0Factors\u00a0influencing\u00a0the\u00a0composition\u00a0of\u00a0the\u00a0\nintestinal\u00a0microbiota\u00a0in\u00a0early\u00a0infancy.\u00a0 Pediatrics \u00a02006;\u00a0118:\u00a0511\u2013521.\u00a0\n167\u00a0\u00a0 Wall\u00a0R,\u00a0Ross\u00a0RP,\u00a0Ryan\u00a0CA,\u00a0Hussey\u00a0S,\u00a0Murphy\u00a0B,\u00a0Fitzgerald\u00a0G F\u00a0et\u00a0al.\u00a0Role\u00a0of\u00a0gut\u00a0microbiota\u00a0in\u00a0early\u00a0infant\u00a0\ndevelopment.\u00a0 Clin\u00a0Med\u00a0Pediatr \u00a02009;\u00a03:\u00a045\u201354.\u00a0\n168\u00a0\u00a0 Alkan\u00a0Ozdemir\u00a0S,\u00a0Ozer\u00a0EA,\u00a0Kose\u00a0S,\u00a0Ilhan\u00a0O,\u00a0Ozturk\u00a0C,\u00a0Sutcu oglu\u00a0S.\u00a0Reference\u00a0values\u00a0of\u00a0serum\u00a0IgG\u00a0and\u00a0IgM\u00a0\nlevels\u00a0in\u00a0preterm\u00a0and\u00a0term\u00a0newborns.\u00a0 J\u00a0Matern\u00a0Fetal\u00a0Neonatal\u00a0Med \u00a02016;\u00a029:\u00a0972\u20136.\u00a0\n169\u00a0\u00a0 Hanson\u00a0LA,\u00a0Korotkova\u00a0M,\u00a0Lundin\u00a0S,\u00a0Haversen\u00a0L,\u00a0Silfverdal\u00a0S A,\u00a0Mattsby\u2010Baltzer\u00a0I\u00a0 et\u00a0al.\u00a0The\u00a0transfer\u00a0of\u00a0immunity\u00a0\nfrom\u00a0mother\u00a0to\u00a0child.\u00a0 Ann\u00a0N\u00a0Y\u00a0Acad\u00a0Sci \u00a02003;\u00a0987:\u00a0199\u2013206.\u00a0\n170\u00a0\u00a0 Allansmith\u00a0M,\u00a0McClellan\u00a0BH,\u00a0Butterworth\u00a0M,\u00a0Maloney\u00a0JR.\u00a0The \u00a0development\u00a0of\u00a0immunoglobulin\u00a0levels\u00a0in\u00a0man.\u00a0\nJ\u00a0Pediatr\u00a01968;\u00a072:\u00a0276\u2013290.\u00a0\n171\u00a0\u00a0 Vlug\u00a0A,\u00a0Nieuwenhuys\u00a0EJ,\u00a0van\u00a0Eijk\u00a0R\u00a0V,\u00a0Geertzen\u00a0HG,\u00a0van\u00a0Hou te\u00a0AJ.\u00a0Nephelometric\u00a0measurements\u00a0of\u00a0human\u00a0\nIgG\u00a0subclasses\u00a0and\u00a0thei r\u00a0reference\u00a0ranges.\u00a0 Ann\u00a0Biol\u00a0Clin\u00a0(Paris) \u00a01994;\u00a052:\u00a0561\u2013567.\u00a0\n172\u00a0\u00a0 Linder\u00a0N,\u00a0Waintraub\u00a0I,\u00a0Smetana\u00a0Z,\u00a0Barzilai\u00a0\u00a0a,\u00a0Lubin\u00a0D,\u00a0Me ndelson\u00a0E\u00a0 et\u00a0al.\u00a0Placental\u00a0transfer\u00a0and\u00a0decay\u00a0of\u00a0\nvaricella\u2010zoster\u00a0virus\u00a0antibodies\u00a0in\u00a0preterm\u00a0infants.\u00a0 J\u00a0Pediatr\u00a02000;\u00a0137:\u00a085\u20139.\u00a0\n173\u00a0\u00a0 Linder\u00a0 N,\u00a0 Tallen\u2010Gozani\u00a0 E,\u00a0 Ge rman\u00a0 B,\u00a0 Duvdevani\u00a0 P,\u00a0 Ferber\u00a0 A ,\u00a0 Sirota\u00a0 L.\u00a0 Placental\u00a0 transfer\u00a0 of\u00a0 measles\u00a0\nantibodies:\u00a0Effect\u00a0of\u00a0gestationa l\u00a0age\u00a0and\u00a0maternal\u00a0vaccination\u00a0 status.\u00a0Vaccine\u00a02004;\u00a022:\u00a01509\u20131514.\u00a0\n174\u00a0\u00a0 van\u00a0den\u00a0Berg\u00a0JP,\u00a0Westerbeek\u00a0E\u00a0a\u00a0M,\u00a0Berbers\u00a0G\u00a0a\u00a0M,\u00a0van\u00a0Gage ldonk\u00a0PGM,\u00a0van\u00a0der\u00a0Klis\u00a0FRM,\u00a0van\u00a0Elburg\u00a0RM.\u00a0\nTransplacental\u00a0transport\u00a0of\u00a0IgG\u00a0antibodies\u00a0specific\u00a0for\u00a0pertuss is,\u00a0diphtheria,\u00a0tetanus,\u00a0haemophilus\u00a0influenzae\u00a0\ntype\u00a0b,\u00a0and\u00a0Neisseria\u00a0meningitidis\u00a0serogroup\u00a0C\u00a0is\u00a0lower\u00a0in\u00a0pret erm\u00a0compared\u00a0with\u00a0term\u00a0infants.\u00a0 Pediatr\u00a0Infect\u00a0\nDis\u00a0J\u00a02010;\u00a029:\u00a0801\u2013805.\u00a0\n175\u00a0\u00a0 Ben\u2010Hur\u00a0 H,\u00a0 Gurevich\u00a0 P,\u00a0 Elhayany\u00a0 A,\u00a0 Avinoach\u00a0 I,\u00a0 Schneider\u00a0 D F,\u00a0 Zusman\u00a0 I.\u00a0 Transport\u00a0 of\u00a0 maternal\u00a0\nimmunoglobulins\u00a0through\u00a0the\u00a0huma n\u00a0placental\u00a0barrier\u00a0in\u00a0normal\u00a0p regnancy\u00a0and\u00a0during\u00a0inflammation.\u00a0 Int\u00a0J\u00a0\nMol\u00a0Med\u00a02005;\u00a016:\u00a0401\u2013407.\u00a0\n176\u00a0\u00a0 Borte\u00a0S,\u00a0Janzi\u00a0M,\u00a0Pan\u2010Hammars tr\u00f6m\u00a0Q,\u00a0von\u00a0D\u00f6beln\u00a0U,\u00a0Nordval l\u00a0L,\u00a0Winiarski\u00a0J\u00a0 et\u00a0al.\u00a0Placental\u00a0transfer\u00a0of\u00a0\nmaternally\u2010derived\u00a0 iga\u00a0 precludes\u00a0 the\u00a0 use\u00a0 of\u00a0 guthrie\u00a0 card\u00a0 eluate s \u00a0a s \u00a0a \u00a0s c r e e n i n g \u00a0t o o l \u00a0f o r \u00a0p r i m a r y \u00a0\nimmunodeficiency\u00a0diseases.\u00a0 PLoS\u00a0One \u00a02012;\u00a07:\u00a01\u20138.\u00a0\n177\u00a0\u00a0 Malek\u00a0A,\u00a0Sager\u00a0R,\u00a0Schneider\u00a0H.\u00a0Transport\u00a0of\u00a0proteins\u00a0acros s\u00a0the\u00a0human\u00a0placenta.\u00a0 Am\u00a0J\u00a0Reprod\u00a0Immunol \u00a01998;\u00a0\n40:\u00a0347\u201351.\u00a0\n178\u00a0\u00a0 Nathan\u00a0DG,\u00a0Oski\u00a0FA.\u00a0 Nathan\u00a0and\u00a0Oski\u2019s\u00a0Hematology\u00a0of\u00a0Infancy\u00a0and\u00a0Childhood .\u00a07th\u00a0ed.\u00a0Saunders:\u00a0Philadelphia,\u00a0\nPA,\u00a02008.\u00a0\n179\u00a0\u00a0 Gurevich\u00a0P,\u00a0Ben\u2010Hur\u00a0H,\u00a0Mold avsky\u00a0M,\u00a0Szvalb\u00a0S,\u00a0Shperling\u00a0I, \u00a0Zusman\u00a0I.\u00a0An\u00a0immunohistochemical\u00a0study\u00a0of\u00a0the\u00a0\nsecretory\u00a0immune\u00a0system\u00a0in\u00a0human \u00a0fetal\u00a0endocrine\u00a0glands\u00a0and\u00a0the ir\u00a0precursors.\u00a0 Early\u00a0Pregnancy \u00a02001;\u00a05:\u00a0\n191\u2013200.\u00a0\n180\u00a0\u00a0 Stiehm\u00a0ER,\u00a0Fudenberg\u00a0HH.\u00a0Serum\u00a0levels\u00a0of\u00a0immune\u00a0globulins\u00a0 in\u00a0health\u00a0and\u00a0disease:\u00a0a\u00a0survey.\u00a0 Pediatrics \u00a01966;\u00a0\n37:\u00a0715\u2013727.\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0237\u00a0\u2010\u00a0\n\u00a0181\u00a0\u00a0 van\u00a0der\u00a0Giessen\u00a0M,\u00a0Rossouw\u00a0E,\u00a0van\u00a0Veen\u00a0T,\u00a0van\u00a0Loghem\u00a0E,\u00a0Ze gers\u00a0BJ,\u00a0Sander\u00a0PC.\u00a0Quantification\u00a0of\u00a0IgG\u00a0\nsubclasses\u00a0in\u00a0sera\u00a0of\u00a0normal\u00a0adults\u00a0and\u00a0healthy\u00a0children\u00a0betwee n\u00a04\u00a0and\u00a012\u00a0years\u00a0of\u00a0age.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a0\n1975;\u00a021:\u00a0501\u2013509.\u00a0\n182\u00a0\u00a0 Bird\u00a0D,\u00a0Duffy\u00a0S,\u00a0Isaacs\u00a0D,\u00a0W ebster\u00a0ADB.\u00a0Reference\u00a0children \u00a0for\u00a0IgG\u00a0subclasses\u00a0in\u00a0 preschool.\u00a01985;\u00a0:\u00a0204\u2013207.\u00a0\n183\u00a0\u00a0 Berth\u00a0M,\u00a0Delanghe\u00a0J,\u00a0Langlois \u00a0M,\u00a0De\u00a0Buyzere\u00a0M.\u00a0Reference\u00a0v alues\u00a0of\u00a0serum\u00a0IgA\u00a0subclasses\u00a0in\u00a0caucasian\u00a0adults\u00a0\nby\u00a0immunonephelometry.\u00a0 Clin\u00a0Chem \u00a01999;\u00a045:\u00a0309\u2013310.\u00a0\n184\u00a0\u00a0 Haraldsson\u00a0 A,\u00a0 Weemaes\u00a0 CMR,\u00a0 J onasdottir\u00a0 S,\u00a0 Olafsson\u00a0 O,\u00a0 Van\u00a0 D e \u00a0W i e l \u00a0G , \u00a0G o e r t z \u00a0J \u00a0 et\u00a0 al.\u00a0S e r u m \u00a0\nimmunoglobulinD\u00a0in\u00a0infants\u00a0and\u00a0children.\u00a0 Scand\u00a0J\u00a0Immunol \u00a02000;\u00a051:\u00a0415\u2013418.\u00a0\n185\u00a0\u00a0 Martins\u00a0TB,\u00a0Bandhauer\u00a0ME,\u00a0Bunker\u00a0AM,\u00a0Roberts\u00a0WL,\u00a0Hill\u00a0HR.\u00a0 New\u00a0childhood\u00a0and\u00a0adult\u00a0reference\u00a0intervals\u00a0\nfor\u00a0total\u00a0IgE.\u00a0J.\u00a0Allerg y\u00a0Clin.\u00a0Immunol.\u00a02014;\u00a0 133:\u00a0589\u2013591.\u00a0\n186\u00a0\u00a0 French\u00a0MA,\u00a0Harrison\u00a0G.\u00a0Serum\u00a0IgG\u00a0subclass\u00a0concentrations\u00a0i n\u00a0healthy\u00a0adults:\u00a0a\u00a0study\u00a0using\u00a0monoclonal\u00a0\nantisera.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a01984;\u00a056:\u00a0473\u20135.\u00a0\n187\u00a0\u00a0 Plebani\u00a0A,\u00a0Ugazio\u00a0AG,\u00a0Avanzini\u00a0MA,\u00a0Massimi\u00a0P,\u00a0Zonta\u00a0L,\u00a0Mon afo\u00a0V\u00a0et\u00a0al.\u00a0Serum\u00a0IgG\u00a0subclass\u00a0concentrations\u00a0\nin\u00a0healthy\u00a0subjects\u00a0at\u00a0different\u00a0age:\u00a0age\u00a0normal\u00a0percentile\u00a0cha rts.\u00a0Eur\u00a0J\u00a0Pediatr \u00a01989;\u00a0149:\u00a0164\u2013167.\u00a0\n188\u00a0\u00a0 Duchamp\u00a0 M,\u00a0 Sterlin\u00a0 D,\u00a0 Diabate\u00a0 A,\u00a0 Uring\u2010Lambert\u00a0 B,\u00a0 Gu\u00e9rin\u2010E l\u00a0 Khourouj\u00a0 V,\u00a0 Le\u00a0 Mauff\u00a0 B\u00a0 et\u00a0 al.\u00a0 B\u2010cell\u00a0\nsubpopulations\u00a0in\u00a0children:\u00a0N ational\u00a0reference\u00a0values.\u00a0 Immunity,\u00a0Inflamm\u00a0Dis \u00a02014;\u00a02:\u00a0131\u201340.\u00a0\n189\u00a0\u00a0 Pi\u0105tosa\u00a0B,\u00a0Wolska\u2010Ku\u015bnierz\u00a0B ,\u00a0Pac\u00a0M,\u00a0Siewiera\u00a0K,\u00a0Ga\u0142kowska \u00a0E,\u00a0Bernatowska\u00a0E.\u00a0B\u00a0cell\u00a0subsets\u00a0in\u00a0healthy\u00a0\nchildren:\u00a0reference\u00a0values\u00a0for\u00a0evaluation\u00a0of\u00a0B\u00a0cell\u00a0maturation\u00a0 process\u00a0in\u00a0peripheral\u00a0blood.\u00a0 Cytometry\u00a0B\u00a0Clin\u00a0\nCytom\u00a02010;\u00a078:\u00a0372\u201381.\u00a0\n190\u00a0\u00a0 van\u00a0 Gent\u00a0 R,\u00a0 van\u00a0 Tilburg\u00a0 CM,\u00a0 Nibbelke\u00a0 EE,\u00a0 Otto\u00a0 SA,\u00a0 Gaiser\u00a0 J F,\u00a0 Janssens\u2010Korpela\u00a0 PL\u00a0 et\u00a0 al.\u00a0 Refined\u00a0\ncharacterization\u00a0and\u00a0reference\u00a0values\u00a0of\u00a0the\u00a0pediatric\u00a0T\u2010\u00a0and\u00a0B \u2010cell\u00a0compartments.\u00a0 Clin\u00a0Immunol \u00a02009;\u00a0133:\u00a0\n95\u2013107.\u00a0\n191\u00a0\u00a0 Comans\u2010Bitter\u00a0 WM,\u00a0 De\u00a0 Groot\u00a0 R,\u00a0 Van\u00a0 den\u00a0 Beemd\u00a0 R,\u00a0 Neijens\u00a0 HJ, \u00a0 Hop\u00a0 WCJ,\u00a0 Groeneveld\u00a0 K\u00a0 et\u00a0 al.\u00a0\nImmunophenotyping\u00a0of\u00a0blood\u00a0lymphocytes\u00a0in\u00a0childhood:\u00a0Reference\u00a0 values\u00a0for\u00a0lymphocyte\u00a0subpopulations.\u00a0\nJ\u00a0Pediatr\u00a01997;\u00a0130:\u00a0388\u2013393.\u00a0\n192\u00a0\u00a0 Schatorj\u00e9\u00a0EJH,\u00a0Gemen\u00a0EFA,\u00a0Dri essen\u00a0GJA,\u00a0Leuvenink\u00a0J,\u00a0van\u00a0H out\u00a0RWNM,\u00a0van\u00a0der\u00a0Burg\u00a0M\u00a0 et\u00a0al.\u00a0Age\u2010matched\u00a0\nReference\u00a0Values\u00a0for\u00a0B\u2010lymphocyte\u00a0Subpopulations\u00a0and\u00a0CVID\u00a0Class ifications\u00a0in\u00a0Children.\u00a0 Scand\u00a0J\u00a0Immunol \u00a0\n2011;\u00a074:\u00a0502\u2013510.\u00a0\n193\u00a0\u00a0 Walker\u00a0JC,\u00a0Smolders\u00a0MAJC,\u00a0Gem en\u00a0EFA,\u00a0Antonius\u00a0TAJ,\u00a0Leuveni nk\u00a0J,\u00a0de\u00a0Vries\u00a0E.\u00a0Development\u00a0of\u00a0lymphocyte\u00a0\nsubpopulations\u00a0in\u00a0preterm\u00a0infants.\u00a0 Scand\u00a0J\u00a0Immunol \u00a02011;\u00a073:\u00a053\u201358.\u00a0\n194\u00a0\u00a0 Kaur\u00a0K,\u00a0Chowdhury\u00a0S,\u00a0Greensp an\u00a0NS,\u00a0Schreiber\u00a0JR.\u00a0Decreased \u00a0expression\u00a0of\u00a0tumor\u00a0necrosis\u00a0factor\u00a0family\u00a0\nreceptors\u00a0involved\u00a0in\u00a0humoral\u00a0imm une\u00a0responses\u00a0in\u00a0preterm\u00a0neona tes.\u00a0Blood\u00a02007;\u00a0110:\u00a02948\u20132954.\u00a0\n195\u00a0\u00a0 Elliott\u00a0SR,\u00a0Roberton\u00a0DM,\u00a0Zola\u00a0H,\u00a0Macardle\u00a0PJ.\u00a0Expression\u00a0o f\u00a0the\u00a0costimulator\u00a0molecules,\u00a0CD40\u00a0and\u00a0CD154,\u00a0on\u00a0\nlymphocytes\u00a0from\u00a0neonates\u00a0and\u00a0young\u00a0children.\u00a0 Hum\u00a0Immunol \u00a02000;\u00a061:\u00a0378\u2013388.\u00a0\n196\u00a0\u00a0 Driessen\u00a0GJ,\u00a0Dalm\u00a0VASH,\u00a0van\u00a0Hagen\u00a0PM,\u00a0Grashoff\u00a0HA,\u00a0Hartwig \u00a0NG,\u00a0van\u00a0Rossum\u00a0AMC\u00a0 et\u00a0al.\u00a0Common\u00a0variable\u00a0\nimmunodeficiency\u00a0and\u00a0idiopathic\u00a0p rimary\u00a0hypogammaglobulinemia:\u00a0 two\u00a0different\u00a0conditions\u00a0within\u00a0the\u00a0\nsame\u00a0disease\u00a0spectrum.\u00a0 Haematologica \u00a02013;\u00a098:\u00a01617\u20131623.\u00a0\n197\u00a0\u00a0 Dunn\u2010Walters\u00a0DK.\u00a0The\u00a0ageing\u00a0human\u00a0B\u00a0cell\u00a0repertoire:\u00a0A\u00a0fai lure\u00a0of\u00a0selection?\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a02016;\u00a0183:\u00a0\n50\u201356.\u00a0\n198\u00a0\u00a0 Shearer\u00a0WT,\u00a0Rosenblatt\u00a0HM,\u00a0Gelman\u00a0RS,\u00a0Oyomopito\u00a0R,\u00a0Plaeger \u00a0S,\u00a0Stiehm\u00a0ER\u00a0 et\u00a0al.\u00a0Lymphocyte\u00a0subsets\u00a0in\u00a0\nhealthy\u00a0children\u00a0from\u00a0birth\u00a0through\u00a018\u00a0years\u00a0of\u00a0age:\u00a0the\u00a0Pediat ric\u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a0P1009\u00a0study.\u00a0 J\u00a0\nAllergy\u00a0Clin\u00a0Immunol \u00a02003;\u00a0112:\u00a0973\u201380.\u00a0\n199\u00a0\u00a0 Bisset\u00a0LR,\u00a0Lung\u00a0TL,\u00a0Kaelin\u00a0 M,\u00a0Ludwig\u00a0E,\u00a0Dubs\u00a0RW.\u00a0Reference \u00a0values\u00a0for\u00a0peripheral\u00a0blood\u00a0lymphocyte\u00a0\nphenotypes\u00a0applicable\u00a0to\u00a0the\u00a0heal thy\u00a0adult\u00a0population\u00a0in\u00a0Switze rland.\u00a0Eur\u00a0J\u00a0Haematol \u00a02004;\u00a072:\u00a0203\u2013212.\u00a0\n200\u00a0\u00a0 Rabe\u00a0H,\u00a0Lundell\u00a0A\u2010C,\u00a0Andersso n\u00a0K,\u00a0Adlerberth\u00a0I,\u00a0Wold\u00a0AE,\u00a0R udin\u00a0A.\u00a0Higher\u00a0proportion s\u00a0of\u00a0circulating\u00a0FOXP3+\u00a0\nand\u00a0CTLA\u20104+\u00a0regulatory\u00a0T\u00a0cells\u00a0are\u00a0associated\u00a0with\u00a0lower\u00a0fracti ons\u00a0of\u00a0memory\u00a0CD4+\u00a0T\u00a0cells\u00a0in\u00a0infants.\u00a0 J\u00a0Leukoc\u00a0\nBiol\u00a02011;\u00a090:\u00a01133\u20131140.\u00a0\n201\u00a0\u00a0 Cossarizza\u00a0A,\u00a0Ortolani\u00a0C,\u00a0Pa ganelli\u00a0R,\u00a0Barbieri\u00a0D,\u00a0Monti\u00a0D ,\u00a0Sansoni\u00a0P\u00a0 et\u00a0al.\u00a0CD45\u00a0isoforms\u00a0expression\u00a0on\u00a0CD4+\u00a0\nand\u00a0CD8+\u00a0T\u00a0cells\u00a0throughout\u00a0life,\u00a0from\u00a0newborns\u00a0\u00a0to\u00a0centenarian s:\u00a0implications\u00a0for\u00a0T\u00a0cell\u00a0memory.\u00a0 Mech\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0238\u00a0\u2010\u00a0\n\u00a0Ageing\u00a0Dev \u00a01996;\u00a086:\u00a0173\u2013195.\u00a0\n202\u00a0\u00a0 Erkeller\u2010Yuksel\u00a0FM,\u00a0Deneys\u00a0V,\u00a0Yuksel\u00a0B,\u00a0Hannet\u00a0I,\u00a0Hulstaer t\u00a0F,\u00a0Hamilton\u00a0C\u00a0 et\u00a0al.\u00a0Age\u2010related\u00a0changes\u00a0in\u00a0human\u00a0\nblood\u00a0lymphocyte\u00a0subpopulations.\u00a0 J\u00a0Pediatr\u00a01992;\u00a0120:\u00a0216\u2013222.\u00a0\n203\u00a0\u00a0 Gilmour\u00a0KC,\u00a0Walshe\u00a0D,\u00a0Heath\u00a0 S,\u00a0Monaghan\u00a0G,\u00a0Loughlin\u00a0S,\u00a0Les ter\u00a0T\u00a0et\u00a0al.\u00a0Immunological\u00a0and\u00a0genetic\u00a0analysis\u00a0\nof\u00a065\u00a0patients\u00a0with\u00a0a\u00a0clinical\u00a0s uspicion\u00a0of\u00a0X\u00a0\u00a0linked\u00a0hyper\u2010IgM .\u00a0Mol\u00a0Pathol \u00a02003;\u00a056:\u00a0256\u2013262.\u00a0\n204\u00a0\u00a0 Nonoyama\u00a0S,\u00a0Penix\u00a0LA,\u00a0Edwards\u00a0CP,\u00a0Lewis\u00a0DB,\u00a0Ito\u00a0S,\u00a0Aruffo\u00a0 A\u00a0et\u00a0al.\u00a0Diminished\u00a0expression\u00a0of\u00a0CD40\u00a0ligand\u00a0by\u00a0\nactivated\u00a0neonatal\u00a0T\u00a0cells.\u00a0 J\u00a0Clin\u00a0Invest \u00a01995;\u00a095:\u00a066\u201375.\u00a0\n205\u00a0\u00a0 McGreal\u00a0EP,\u00a0Hearne\u00a0K,\u00a0Spiller\u00a0OB.\u00a0Off\u00a0to\u00a0a\u00a0slow\u00a0start:\u00a0und er\u2010development\u00a0of\u00a0the\u00a0complement\u00a0system\u00a0in\u00a0term\u00a0\nnewborns\u00a0is\u00a0more\u00a0substantial \u00a0following\u00a0premature\u00a0birth.\u00a0 Immunobiology \u00a02012;\u00a0217:\u00a0176\u2013186.\u00a0\n206\u00a0\u00a0 Al\u2010Hertani\u00a0W,\u00a0Yan\u00a0SR,\u00a0Byers \u00a0DM,\u00a0Bortolussi\u00a0R.\u00a0Human\u00a0newbor n\u00a0polymorphonuclear\u00a0neutrophils\u00a0exhibit\u00a0\ndecreased\u00a0levels\u00a0of\u00a0MyD88\u00a0and\u00a0attenuated\u00a0p38\u00a0phosphorylation\u00a0in \u00a0response\u00a0to\u00a0lipopolysaccharide.\u00a0 Clin\u00a0\nInvest\u00a0Med \u00a02007;\u00a030:\u00a0E44\u201053.\u00a0\n207\u00a0\u00a0 Sadeghi\u00a0K,\u00a0Berger\u00a0A,\u00a0Langgart ner\u00a0M,\u00a0Prusa\u00a0A\u2010R,\u00a0Hayde\u00a0M,\u00a0He rkner\u00a0K\u00a0et\u00a0al.\u00a0Immaturity\u00a0of\u00a0infection\u00a0control\u00a0in\u00a0\npreterm\u00a0and\u00a0term\u00a0newborns\u00a0is\u00a0associated\u00a0with\u00a0impaired\u00a0toll\u2010like \u00a0receptor\u00a0signaling.\u00a0 J\u00a0Infect\u00a0Dis \u00a02007;\u00a0195:\u00a0\n296\u2013302.\u00a0\n208\u00a0\u00a0 Filias\u00a0A,\u00a0Theodorou\u00a0GL,\u00a0Mouzopoulou\u00a0S,\u00a0Varvarigou\u00a0AA,\u00a0Mant agos\u00a0S,\u00a0Karakantza\u00a0M.\u00a0Phagocytic\u00a0ability\u00a0of\u00a0\nneutrophils\u00a0and\u00a0monocytes\u00a0in\u00a0neonates.\u00a0 BMC\u00a0Pediatr \u00a02011;\u00a011:\u00a029.\u00a0\n209\u00a0\u00a0 Picard\u00a0C,\u00a0Bobby\u00a0Gaspar\u00a0H,\u00a0Al\u2010Herz\u00a0W,\u00a0Bousfiha\u00a0A,\u00a0Casanova\u00a0 J\u2010L,\u00a0Chatila\u00a0T\u00a0 et\u00a0al.\u00a0International\u00a0Union\u00a0of\u00a0\nImmunological\u00a0Societies:\u00a02017\u00a0Pr imary\u00a0Immunodeficiency\u00a0Diseases \u00a0Committee\u00a0Report\u00a0on\u00a0Inborn\u00a0Errors\u00a0of\u00a0\nImmunity.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02018;\u00a038:\u00a096\u2013128.\u00a0\n210\u00a0\u00a0 Notarangelo\u00a0LD,\u00a0Fischer\u00a0A,\u00a0Geha\u00a0RS,\u00a0Casanova\u00a0J\u2010L,\u00a0Chapel\u00a0H ,\u00a0Conley\u00a0ME\u00a0 et\u00a0al.\u00a0Primary\u00a0immunodeficiencies:\u00a0\n2009\u00a0update.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02009;\u00a0124:\u00a01161\u20131178.\u00a0\n211\u00a0\u00a0 Driessen\u00a0G,\u00a0van\u00a0der\u00a0Burg\u00a0M.\u00a0E ducational\u00a0paper:\u00a0primary\u00a0ant ibody\u00a0deficiencies.\u00a0 Eur\u00a0J\u00a0Pediatr \u00a02011;\u00a0170:\u00a0693\u2013\n702.\u00a0\n212\u00a0\u00a0 Wood\u00a0PM.\u00a0Primary\u00a0antibod y\u00a0deficiency\u00a0syndromes.\u00a0 Curr\u00a0Opin\u00a0Hematol \u00a02010;\u00a017:\u00a0356\u2013361.\u00a0\n213\u00a0\u00a0 Durandy\u00a0A,\u00a0Kracker\u00a0S,\u00a0Fisch er\u00a0A.\u00a0Primary\u00a0antibody\u00a0deficien cies.\u00a0Nat\u00a0Rev\u00a0Immunol \u00a02013;\u00a013:\u00a0519\u2013533.\u00a0\n214\u00a0\u00a0 Rezaei\u00a0N,\u00a0Aghamohammadi\u00a0A,\u00a0Notarangelo\u00a0LD\u00a0(eds.).\u00a0 Primary\u00a0Immunodeficiency\u00a0Diseases .\u00a0Springer:\u00a0Berlin,\u00a0\nHeidelberg,\u00a02008.\u00a0\n215\u00a0\u00a0 Winkelstein\u00a0 JA,\u00a0 Marino\u00a0 MC,\u00a0 Lederman\u00a0 HM,\u00a0 Jones\u00a0 SM,\u00a0 Sullivan \u00a0K , \u00a0B u r k s \u00a0A W \u00a0 et\u00a0 al.\u00a0 X\u2010linked\u00a0\nagammaglobulinemia:\u00a0report\u00a0on\u00a0a\u00a0United\u00a0States\u00a0registry\u00a0of\u00a0201\u00a0p atients.\u00a0Medicine\u00a0(Baltimore) \u00a02006;\u00a085:\u00a0193\u2013\n202.\u00a0\n216\u00a0\u00a0 Ochs\u00a0H,\u00a0Smith\u00a0C,\u00a0Puck,\u00a0JM\u00a0(eds.).\u00a0 Primary\u00a0Immunodeficiency\u00a0Diseases .\u00a03rd\u00a0ed.\u00a0Oxford\u00a0University\u00a0Press:\u00a0\nOxford,\u00a0UK,\u00a02013.\u00a0\n217\u00a0\u00a0 van\u00a0der\u00a0Burg\u00a0M,\u00a0van\u00a0Zelm\u00a0MC,\u00a0Driessen\u00a0GJA,\u00a0van\u00a0Dongen\u00a0JJM. \u00a0New\u00a0frontiers\u00a0of\u00a0primary\u00a0antibody\u00a0deficiencies.\u00a0\nCell\u00a0Mol\u00a0Life\u00a0Sci \u00a02012;\u00a069:\u00a059\u201373.\u00a0\n218\u00a0\u00a0 Tsukada\u00a0S,\u00a0Saffran\u00a0DC,\u00a0Raw lings\u00a0DJ,\u00a0Parolini\u00a0O,\u00a0Allen\u00a0RC,\u00a0 Klisak\u00a0I\u00a0et\u00a0al.\u00a0Deficient\u00a0expression\u00a0of\u00a0a\u00a0B\u00a0cell\u00a0\ncytoplasmic\u00a0tyrosine\u00a0kinase\u00a0in\u00a0h uman\u00a0X\u2010linked\u00a0agammaglobulinemi a.\u00a0Cell\u00a01993;\u00a072:\u00a0279\u2013290.\u00a0\n219\u00a0\u00a0 Vetrie\u00a0D,\u00a0Vorechovsky\u00a0I,\u00a0Si deras\u00a0P,\u00a0Holland\u00a0J,\u00a0Davies\u00a0A,\u00a0F linter\u00a0F\u00a0et\u00a0al.\u00a0The\u00a0gene\u00a0involved\u00a0in\u00a0X\u2010linked\u00a0\nagammaglobulinaemia\u00a0is\u00a0a\u00a0member\u00a0of\u00a0the\u00a0src\u00a0family\u00a0of\u00a0protein\u2010ty rosine\u00a0kinases.\u00a0 Nature\u00a01993;\u00a0361:\u00a0226\u2013233.\u00a0\n220\u00a0\u00a0 Yel\u00a0L,\u00a0Minegishi\u00a0Y,\u00a0Coustan\u2010Smith\u00a0E,\u00a0Buckley\u00a0RH,\u00a0Trubel\u00a0H, \u00a0Pachman\u00a0LM\u00a0 et\u00a0al.\u00a0Mutations\u00a0in\u00a0the\u00a0mu\u00a0heavy\u2010\nchain\u00a0gene\u00a0in\u00a0patients\u00a0with\u00a0agammaglobulinemia.\u00a0 N\u00a0Engl\u00a0J\u00a0Med \u00a01996;\u00a0335:\u00a01486\u20131493.\u00a0\n221\u00a0\u00a0 Minegishi\u00a0Y,\u00a0Coustan\u2010Smith\u00a0E,\u00a0Wang\u00a0YH,\u00a0Cooper\u00a0MD,\u00a0Campana\u00a0 D,\u00a0Conley\u00a0ME.\u00a0Mutations\u00a0in\u00a0the\u00a0human\u00a0\nlambda5/14.1\u00a0gene\u00a0result\u00a0in\u00a0B\u00a0ce ll\u00a0deficiency\u00a0and\u00a0agammaglobuli nemia.\u00a0J\u00a0Exp\u00a0Med \u00a01998;\u00a0187:\u00a071\u201377.\u00a0\n222\u00a0\u00a0 Minegishi\u00a0Y,\u00a0Coustan\u2010Smith\u00a0E,\u00a0Rapalus\u00a0L,\u00a0Ersoy\u00a0F,\u00a0Campana\u00a0 D,\u00a0Conley\u00a0ME.\u00a0Mutations\u00a0i n\u00a0Igalpha\u00a0(CD79a)\u00a0result\u00a0\nin\u00a0a\u00a0complete\u00a0block\u00a0in\u00a0B\u2010cell\u00a0development.\u00a0 J\u00a0Clin\u00a0Invest \u00a01999;\u00a0104:\u00a01115\u20131121.\u00a0\n223\u00a0\u00a0 Dobbs\u00a0AK,\u00a0Yang\u00a0T,\u00a0Farmer\u00a0D,\u00a0Kager\u00a0L,\u00a0Parolini\u00a0O,\u00a0Conley\u00a0ME .\u00a0Cutting\u00a0edge:\u00a0a\u00a0hypomorphic\u00a0mutation\u00a0in\u00a0Igbeta\u00a0\n(CD79b)\u00a0in\u00a0a\u00a0patient\u00a0with\u00a0immunodeficiency\u00a0and\u00a0a\u00a0leaky\u00a0defect\u00a0i n\u00a0B\u00a0cell\u00a0development.\u00a0 J\u00a0Immunol \u00a02007;\u00a0179:\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0239\u00a0\u2010\u00a0\n\u00a02055\u20132059.\u00a0\n224\u00a0\u00a0 Minegishi\u00a0Y,\u00a0Rohrer\u00a0J,\u00a0Coustan\u2010Smith\u00a0E,\u00a0Lederman\u00a0HM,\u00a0Pappu \u00a0R,\u00a0Campana\u00a0D\u00a0 et\u00a0al.\u00a0An\u00a0essential\u00a0role\u00a0for\u00a0BLNK\u00a0\nin\u00a0human\u00a0B\u00a0cell\u00a0development.\u00a0 Science\u00a01999;\u00a0286:\u00a01954\u20131957.\u00a0\n225\u00a0\u00a0 Lopez\u00a0Granados\u00a0E,\u00a0Porpiglia\u00a0AS,\u00a0Hogan\u00a0MB,\u00a0Matamoros\u00a0N,\u00a0Kra sovec\u00a0S,\u00a0Pignata\u00a0C\u00a0 et\u00a0al.\u00a0Clinical\u00a0and\u00a0molecular\u00a0\nanalysis\u00a0of\u00a0patients\u00a0with\u00a0defect s\u00a0in\u00a0micro\u00a0heavy\u00a0chain\u00a0gene.\u00a0 J\u00a0Clin\u00a0Invest \u00a02002;\u00a0110:\u00a01029\u20131035.\u00a0\n226\u00a0\u00a0 Sicherer\u00a0SH,\u00a0Winkelstein\u00a0JA .\u00a0Primary\u00a0immunodeficiency\u00a0dise ases\u00a0in\u00a0adults.\u00a0 JAMA\u00a01998;\u00a0279:\u00a058\u201361.\u00a0\n227\u00a0\u00a0 Stubbs\u00a0A,\u00a0Bangs\u00a0C,\u00a0Shillitoe\u00a0B ,\u00a0Edgar\u00a0JD,\u00a0Burns\u00a0SO,\u00a0Thomas \u00a0M\u00a0et\u00a0al.\u00a0Bronchiectasis\u00a0and\u00a0 deteriorating\u00a0lung\u00a0\nfunction\u00a0in\u00a0agammaglobulinaemia\u00a0 despite\u00a0immunoglobulin\u00a0replacem ent\u00a0therapy.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a02018;\u00a0\n191:\u00a0212\u2013219.\u00a0\n228\u00a0\u00a0 Abolhassani\u00a0H,\u00a0Hirbod\u2010Mobarakeh\u00a0A,\u00a0Shahinpour\u00a0S,\u00a0Panahi\u00a0M, \u00a0Mohammadinejad\u00a0P,\u00a0Mirminachi\u00a0B\u00a0 et\u00a0al.\u00a0\nMortality\u00a0and\u00a0morbidity\u00a0in\u00a0patients\u00a0with\u00a0X\u2010linked\u00a0agammaglobuli naemia.\u00a0Allergol\u00a0Immunopathol\u00a0(Madr) \u00a0\n2015;\u00a043:\u00a062\u201366.\u00a0\n229\u00a0\u00a0 Shillitoe\u00a0B,\u00a0Gennery\u00a0A.\u00a0X\u2010Li nked\u00a0Agammaglobulinaemia:\u00a0Outc omes\u00a0in\u00a0the\u00a0modern\u00a0era.\u00a0 Clin\u00a0Immunol \u00a02017;\u00a0\n183:\u00a054\u201362.\u00a0\n230\u00a0\u00a0 Cooper\u00a0 MD,\u00a0 Faulk\u00a0 WP,\u00a0 Fudenberg\u00a0 HH,\u00a0 Good\u00a0 RA,\u00a0 Hitzig\u00a0 W,\u00a0 Kunk el\u00a0 H\u00a0et\u00a0 al.\u00a0C l a s s i f i c a t i o n \u00a0o f \u00a0p r i m a r y \u00a0\nimmunodeficiencies.\u00a0 N\u00a0Engl\u00a0J\u00a0Med \u00a01973;\u00a0288:\u00a0966\u2013967.\u00a0\n231\u00a0\u00a0 Bonilla\u00a0 FA,\u00a0 Barlan\u00a0 I,\u00a0 Chapel\u00a0 H,\u00a0 Costa\u2010Carvalho\u00a0 BT,\u00a0 Cunning ham\u2010Rundles\u00a0 C,\u00a0 de\u00a0 la\u00a0 Morena\u00a0 MT\u00a0 et\u00a0 al.\u00a0\nInternational\u00a0Consensus\u00a0Document\u00a0(ICON):\u00a0Common\u00a0Variable\u00a0Immuno deficiency\u00a0Disorders.\u00a0 J\u00a0allergy\u00a0Clin\u00a0\nImmunol\u00a0Pract \u00a02016;\u00a04:\u00a038\u201359.\u00a0\n232\u00a0\u00a0 Ameratunga\u00a0R,\u00a0Brewerton\u00a0M,\u00a0 Slade\u00a0C,\u00a0Jordan\u00a0A,\u00a0Gillis\u00a0D,\u00a0St eele\u00a0R\u00a0et\u00a0al.\u00a0Comparison\u00a0of\u00a0diagnostic\u00a0criteria\u00a0for\u00a0\ncommon\u00a0variable\u00a0immunodeficiency\u00a0disorder.\u00a0 Front\u00a0Immunol \u00a02014;\u00a05:\u00a0415.\u00a0\n233\u00a0\u00a0 Bertinchamp\u00a0R,\u00a0G\u00e9rard\u00a0L,\u00a0Boutboul\u00a0D,\u00a0Malphettes\u00a0M,\u00a0Fieschi \u00a0C,\u00a0Oksenhendler\u00a0E\u00a0 et\u00a0al.\u00a0Exclusion\u00a0of\u00a0Patients\u00a0\nwith\u00a0a\u00a0Severe\u00a0T\u2010Cell\u00a0Defect\u00a0Improves\u00a0the\u00a0Definition\u00a0of\u00a0Common\u00a0V ariable\u00a0Immunodeficiency.\u00a0 J\u00a0allergy\u00a0Clin\u00a0\nImmunol\u00a0Pract \u00a02016;\u00a04:\u00a01147\u20131157.\u00a0\n234\u00a0\u00a0 Chapel\u00a0 H.\u00a0 Common\u00a0 Variable\u00a0 Immunodeficiency\u00a0 Disorders\u00a0 (CVID )\u00a0 \u2010\u00a0 Diagnoses\u00a0 of\u00a0 Exclusion,\u00a0 Especially\u00a0\nCombined\u00a0Immune\u00a0Defects.\u00a0 J\u00a0allergy\u00a0Clin\u00a0Immunol\u00a0Pract \u00a02016;\u00a04:\u00a01158\u20131159.\u00a0\n235\u00a0\u00a0 Chapel\u00a0H,\u00a0Cunningham\u2010Rundles \u00a0C.\u00a0Update\u00a0in\u00a0understanding\u00a0co mmon\u00a0variable\u00a0immunodeficiency\u00a0disorders\u00a0\n(CVIDs)\u00a0and\u00a0the\u00a0management\u00a0of\u00a0patients\u00a0with\u00a0these\u00a0conditions.\u00a0 Br\u00a0J\u00a0Haematol \u00a02009;\u00a0145:\u00a0709\u2013727.\u00a0\n236\u00a0\u00a0 Jolles\u00a0S.\u00a0The\u00a0variable\u00a0in\u00a0common\u00a0variable\u00a0immunodeficiency :\u00a0a\u00a0disease\u00a0of\u00a0complex\u00a0phenotypes.\u00a0 J\u00a0allergy\u00a0Clin\u00a0\nImmunol\u00a0Pract \u00a02013;\u00a01:\u00a0545\u201356.\u00a0\n237\u00a0\u00a0 Conley\u00a0ME,\u00a0Notarangelo\u00a0LD,\u00a0 Etzioni\u00a0A.\u00a0Diagnostic\u00a0criteria\u00a0 for\u00a0primary\u00a0immunodefici encies.\u00a0Representing\u00a0\nPAGID\u00a0(Pan\u2010American\u00a0Group\u00a0for\u00a0Immunodeficiency)\u00a0and\u00a0ESID\u00a0(Europ ean\u00a0Society\u00a0for\u00a0Immunodeficiencies).\u00a0\nClin\u00a0Immunol \u00a01999;\u00a093:\u00a0190\u20137.\u00a0\n238\u00a0\u00a0 Ameratunga\u00a0R,\u00a0Woon\u00a0S\u2010T,\u00a0Gill is\u00a0D,\u00a0Koopmans\u00a0W,\u00a0Steele\u00a0R.\u00a0Ne w\u00a0diagnostic\u00a0criteria\u00a0for\u00a0common\u00a0variable\u00a0\nimmune\u00a0deficiency\u00a0(CVID),\u00a0which\u00a0 may\u00a0assist\u00a0with\u00a0decisions\u00a0to\u00a0tr eat\u00a0with\u00a0intravenous\u00a0or\u00a0subcutaneous\u00a0\nimmunoglobulin.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a02013;\u00a0174:\u00a0203\u2013211.\u00a0\n239\u00a0\u00a0 Grimbacher\u00a0B,\u00a0ESID\u00a0Registry\u00a0W orking\u00a0Party.\u00a0The\u00a0European\u00a0So ciety\u00a0for\u00a0Immunodeficiencies\u00a0(ESID)\u00a0registry\u00a0\n2014.\u00a0C l i n \u00a0E x p \u00a0I m m u n o l \u00a0 2014;\u00a0 178\u00a0 Suppl :\u00a0 18\u201320.\u00a0 Disponible\u00a0 en\u00a0 https://esid.org/Working\u2010\nParties/Registry/New\u2010ESID\u2010Registry.\u00a0\n240\u00a0\u00a0 Sanchez\u2010Ramon\u00a0S,\u00a0de\u00a0Gracia\u00a0J, \u00a0Garcia\u2010Alonso\u00a0AM,\u00a0Rodriguez\u00a0 Molina\u00a0JJ,\u00a0Melero\u00a0J,\u00a0de\u00a0Andres\u00a0A\u00a0 et\u00a0al.\u00a0\nMulticenter\u00a0study\u00a0for\u00a0the\u00a0evalua tion\u00a0of\u00a0the\u00a0antibody\u00a0response\u00a0a gainst\u00a0salmonella\u00a0\u00a0typhi\u00a0Vi\u00a0vaccination\u00a0\n(EMPATHY)\u00a0for\u00a0the\u00a0diagnosis\u00a0of\u00a0A nti\u2010polysaccharide\u00a0antibody\u00a0pro duction\u00a0deficiency\u00a0in\u00a0patients\u00a0with\u00a0primary\u00a0\nimmunodeficiency.\u00a0 Clin\u00a0Immunol \u00a02016;\u00a0169:\u00a080\u201384.\u00a0\n241\u00a0\u00a0 Daly\u00a0TM,\u00a0Hill\u00a0HR.\u00a0Use\u00a0and\u00a0c linical\u00a0interpretation\u00a0of\u00a0pneum ococcal\u00a0antibody\u00a0measurements\u00a0in\u00a0the\u00a0evaluation\u00a0\nof\u00a0humoral\u00a0immune\u00a0function.\u00a0 Clin\u00a0Vaccine\u00a0Immunol \u00a02015;\u00a022:\u00a0148\u2013152.\u00a0\n242\u00a0\u00a0 Bonilla\u00a0FA,\u00a0Khan\u00a0DA,\u00a0Ballas\u00a0ZK,\u00a0Chinen\u00a0J,\u00a0Frank\u00a0MM,\u00a0Hsu\u00a0JT \u00a0et\u00a0al.\u00a0Practice\u00a0parameter\u00a0for\u00a0the\u00a0diagnosis\u00a0and\u00a0\nmanagement\u00a0of\u00a0primary\u00a0immunodeficiency.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02015;\u00a0136:\u00a01178\u20131186.\u00a0\n243\u00a0\u00a0 Dorsey\u00a0MJ,\u00a0Orange\u00a0JS.\u00a0Impaire d\u00a0specific\u00a0antibody\u00a0response\u00a0 and\u00a0increased\u00a0B\u2010cell\u00a0population\u00a0in\u00a0transient\u00a0\u00a0\nhypogammaglobulinemia\u00a0of\u00a0infancy.\u00a0 Ann\u00a0Allergy\u00a0Asthma\u00a0Immunol \u00a02006;\u00a097:\u00a0590\u2013595.\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0240\u00a0\u2010\u00a0\n\u00a0244\u00a0\u00a0 Gathmann\u00a0B,\u00a0Mahlaoui\u00a0N,\u00a0Gerard\u00a0L,\u00a0Oksenhendler\u00a0E,\u00a0Warnatz\u00a0 K,\u00a0Schulze\u00a0I\u00a0 et\u00a0al.\u00a0Clinical\u00a0picture\u00a0and\u00a0treatment\u00a0\nof\u00a02212\u00a0patients\u00a0with\u00a0common\u00a0 variable\u00a0immunodeficiency.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02014;\u00a0134:\u00a0116\u2013126.\u00a0\n245\u00a0\u00a0 Slade\u00a0CA,\u00a0Bosco\u00a0JJ,\u00a0Binh\u00a0Giang\u00a0T,\u00a0Kruse\u00a0E,\u00a0Stirling\u00a0RG,\u00a0Ca meron\u00a0PU\u00a0 et\u00a0al.\u00a0Delayed\u00a0Diagnosis\u00a0and\u00a0Complications\u00a0\nof\u00a0Predominantly\u00a0Antibody\u00a0Deficie ncies\u00a0in\u00a0a\u00a0Cohort\u00a0of\u00a0Australia n\u00a0Adults.\u00a0 Front\u00a0Immunol \u00a02018;\u00a09:\u00a0694.\u00a0\n246\u00a0\u00a0 Cunningham\u2010Rundles\u00a0C.\u00a0The\u00a0many\u00a0faces\u00a0of\u00a0common\u00a0variable\u00a0im munodeficiency.\u00a0 Hematol\u00a0Am\u00a0Soc\u00a0Hematol\u00a0\nEduc\u00a0Progr \u00a02012;\u00a02012:\u00a0301\u2013305.\u00a0\n247\u00a0\u00a0 Resnick\u00a0ES,\u00a0Moshier\u00a0EL,\u00a0Go dbold\u00a0JH,\u00a0Cunningham\u2010Rundles\u00a0C.\u00a0 Morbidity\u00a0and\u00a0mortality\u00a0in\u00a0common\u00a0variable\u00a0\nimmune\u00a0deficiency\u00a0over\u00a04\u00a0decades.\u00a0 Blood\u00a02012;\u00a0119:\u00a01650\u20131657.\u00a0\n248\u00a0\u00a0 Cunningham\u2010Rundles\u00a0C,\u00a0Bodian\u00a0C.\u00a0Common\u00a0variable\u00a0immunodefi ciency:\u00a0clinical\u00a0and\u00a0immunological\u00a0features\u00a0\nof\u00a0248\u00a0patients.\u00a0 Clin\u00a0Immunol \u00a01999;\u00a092:\u00a034\u201348.\u00a0\n249\u00a0\u00a0 Chapel\u00a0H,\u00a0Lucas\u00a0M,\u00a0Lee\u00a0M,\u00a0Bjorkander\u00a0J,\u00a0Webster\u00a0D,\u00a0Grimbac her\u00a0B\u00a0et\u00a0al.\u00a0Common\u00a0variable\u00a0immunodeficiency\u00a0\ndisorders:\u00a0division\u00a0into\u00a0distinct\u00a0clinical\u00a0phenotypes.\u00a0 Blood\u00a02008;\u00a0112:\u00a0277\u2013286.\u00a0\n250\u00a0\u00a0 Wehr\u00a0C,\u00a0Kivioja\u00a0T,\u00a0Schmitt\u00a0C,\u00a0Ferry\u00a0B,\u00a0Witte\u00a0T,\u00a0Eren\u00a0E\u00a0 et\u00a0al.\u00a0The\u00a0EUROclass\u00a0trial:\u00a0defining\u00a0subgroups\u00a0in\u00a0common\u00a0\nvariable\u00a0immunodeficiency.\u00a0 Blood\u00a02008;\u00a0111:\u00a077\u201385.\u00a0\n251\u00a0\u00a0 Quinti\u00a0I,\u00a0Soresina\u00a0A,\u00a0Spadaro\u00a0G,\u00a0Martino\u00a0S,\u00a0Donnanno\u00a0S,\u00a0Ag ostini\u00a0C\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0follow\u2010up\u00a0and\u00a0outcome\u00a0\nof\u00a0a\u00a0large\u00a0cohort\u00a0of\u00a0patients\u00a0wi th\u00a0common\u00a0variable\u00a0immunodefici ency.\u00a0J\u00a0Clin\u00a0Immunol \u00a02007;\u00a027:\u00a0308\u2013316.\u00a0\n252\u00a0\u00a0 Oksenhendler\u00a0E,\u00a0Gerard\u00a0L,\u00a0Fi eschi\u00a0C,\u00a0Malphettes\u00a0M,\u00a0Mouillo t\u00a0G,\u00a0Jaussaud\u00a0R\u00a0 et\u00a0al.\u00a0Infections\u00a0in\u00a0252\u00a0patients\u00a0\nwith\u00a0common\u00a0variable\u00a0immunodeficiency.\u00a0 Clin\u00a0Infect\u00a0Dis \u00a02008;\u00a046:\u00a01547\u20131554.\u00a0\n253\u00a0\u00a0 Mouillot\u00a0G,\u00a0Carmagnat\u00a0M,\u00a0Ger ard\u00a0L,\u00a0Garnier\u00a0J\u2010L,\u00a0Fieschi\u00a0C, \u00a0Vince\u00a0N\u00a0et\u00a0al.\u00a0B\u2010cell\u00a0and\u00a0T\u2010cell\u00a0phenotypes\u00a0in\u00a0CVID\u00a0\npatients\u00a0correlate\u00a0with\u00a0the\u00a0clin ical\u00a0phenotype\u00a0of\u00a0the\u00a0disease.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02010;\u00a030:\u00a0746\u2013755.\u00a0\n254\u00a0\u00a0 Bazregari\u00a0S,\u00a0Azizi\u00a0G,\u00a0Tavakol\u00a0M,\u00a0Asgardoon\u00a0MH,\u00a0Kiaee\u00a0F,\u00a0Ta vakolinia\u00a0N\u00a0 et\u00a0al.\u00a0Evaluation\u00a0of\u00a0infectious\u00a0and\u00a0non\u2010\ninfectious\u00a0complications\u00a0in\u00a0pati ents\u00a0with\u00a0primary\u00a0immunodeficie ncy.\u00a0Cent\u00a0J\u00a0Immunol \u00a02017;\u00a042:\u00a0336\u2013341.\u00a0\n255\u00a0\u00a0 Agarwal\u00a0 S,\u00a0 Mayer\u00a0 L.\u00a0 Pathogenesis\u00a0 and\u00a0 treatment\u00a0 of\u00a0 gastroin testinal\u00a0 disease\u00a0 in\u00a0 antibody\u00a0 deficiency\u00a0\nsyndromes.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02009;\u00a0124:\u00a0658\u2013664.\u00a0\n256\u00a0\u00a0 Chapel\u00a0H,\u00a0Lucas\u00a0M,\u00a0Patel\u00a0S,\u00a0Lee\u00a0M,\u00a0Cunningham\u2010Rundles\u00a0C,\u00a0R esnick\u00a0E\u00a0et\u00a0al.\u00a0Confirmation\u00a0and\u00a0improvement\u00a0\nof\u00a0criteria\u00a0for\u00a0clinical\u00a0phenoty ping\u00a0in\u00a0common\u00a0variable\u00a0immunod eficiency\u00a0disorders\u00a0in\u00a0replicate\u00a0cohorts.\u00a0 J\u00a0\nAllergy\u00a0Clin\u00a0Immunol \u00a02012;\u00a0130:\u00a01197\u20131198.\u00a0\n257\u00a0\u00a0 Feuille\u00a0EJ,\u00a0Anooshiravani\u00a0N,\u00a0 Sullivan\u00a0KE,\u00a0Fuleihan\u00a0RL,\u00a0Cun ningham\u2010Rundles\u00a0C.\u00a0Autoimmune\u00a0Cytopenias\u00a0and\u00a0\nAssociated\u00a0Conditions\u00a0in\u00a0CVID:\u00a0a \u00a0Report\u00a0From\u00a0the\u00a0USIDNET\u00a0Regist ry.\u00a0J\u00a0Clin\u00a0Immunol \u00a02018;\u00a038:\u00a028\u201334.\u00a0\n258\u00a0\u00a0 Jolles\u00a0S,\u00a0Chapel\u00a0H,\u00a0Litzman\u00a0J.\u00a0When\u00a0to\u00a0initiate\u00a0immunoglob ulin\u00a0replacement\u00a0therapy\u00a0(IGRT)\u00a0in\u00a0antibody\u00a0\ndeficiency:\u00a0a\u00a0practical\u00a0approach.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a02017;\u00a0188:\u00a0333\u2013341.\u00a0\n259\u00a0\u00a0 Busse\u00a0PJ,\u00a0Razvi\u00a0S,\u00a0Cunningha m\u2010Rundles\u00a0C.\u00a0Efficacy\u00a0of\u00a0intra venous\u00a0immunoglobulin\u00a0in\u00a0the\u00a0prevention\u00a0of\u00a0\npneumonia\u00a0in\u00a0patients\u00a0with\u00a0common\u00a0variable\u00a0immunodeficiency.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02002;\u00a0109:\u00a01001\u2013\n1004.\u00a0\n260\u00a0\u00a0 Berger\u00a0M,\u00a0Jolles\u00a0S,\u00a0Orange\u00a0JS ,\u00a0Sleasman\u00a0JW.\u00a0Bioavailabilit y\u00a0of\u00a0IgG\u00a0administered\u00a0by\u00a0the\u00a0subcutaneous\u00a0route.\u00a0 J\u00a0\nClin\u00a0Immunol \u00a02013;\u00a033:\u00a0984\u2013990.\u00a0\n261\u00a0\u00a0 Jolles\u00a0S,\u00a0Borte\u00a0M,\u00a0Nelson\u00a0RPJ,\u00a0Rojavin\u00a0M,\u00a0Bexon\u00a0M,\u00a0Lawo\u00a0J\u2010 P\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0efficacy,\u00a0safe ty,\u00a0and\u00a0tolerability\u00a0\nof\u00a0Hizentra(R)\u00a0for\u00a0treatment\u00a0of\u00a0 primary\u00a0immunodeficiency\u00a0diseas e.\u00a0Clin\u00a0Immunol \u00a02014;\u00a0150:\u00a0161\u2013169.\u00a0\n262\u00a0\u00a0 Haddad\u00a0E,\u00a0Berger\u00a0M,\u00a0Wang\u00a0EC Y,\u00a0Jones\u00a0CA,\u00a0Bexon\u00a0M,\u00a0Baggish\u00a0J S.\u00a0Higher\u00a0doses\u00a0of\u00a0subcutaneous\u00a0IgG\u00a0reduce\u00a0\nresource\u00a0utilization\u00a0in\u00a0patients\u00a0with\u00a0primary\u00a0immunodeficiency. \u00a0J\u00a0Clin\u00a0Immunol \u00a02012;\u00a032:\u00a0281\u2013289.\u00a0\n263\u00a0\u00a0 Hammarstrom\u00a0 L,\u00a0 Vorechovsky\u00a0 I ,\u00a0 Webster\u00a0 D.\u00a0 Selective\u00a0 IgA\u00a0 def iciency\u00a0 (SIgAD)\u00a0 and\u00a0 common\u00a0 variable\u00a0\nimmunodeficiency\u00a0(CVID).\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a02000;\u00a0120:\u00a0225\u2013231.\u00a0\n264\u00a0\u00a0 Ashman\u00a0RF,\u00a0Schaffer\u00a0FM,\u00a0Kemp\u00a0JD,\u00a0Yokoyama\u00a0WM,\u00a0Zhu\u00a0ZB,\u00a0Coop er\u00a0MD\u00a0et\u00a0al.\u00a0Genetic\u00a0and\u00a0immunologic\u00a0\nanalysis\u00a0of\u00a0a\u00a0family\u00a0containing\u00a0five\u00a0patients\u00a0with\u00a0common\u2010varia ble\u00a0immune\u00a0deficiency\u00a0or\u00a0selective\u00a0IgA\u00a0\ndeficiency.\u00a0 J\u00a0Clin\u00a0Immunol \u00a01992;\u00a012:\u00a0406\u2013414.\u00a0\n265\u00a0\u00a0 Bogaert\u00a0DJA,\u00a0Dullaers\u00a0M,\u00a0Lambrecht\u00a0BN,\u00a0Vermaelen\u00a0KY,\u00a0De\u00a0Ba ere\u00a0E,\u00a0Haerynck\u00a0F.\u00a0Genes\u00a0associated\u00a0with\u00a0\ncommon\u00a0variable\u00a0immunodeficiency:\u00a0 one\u00a0diagnosis\u00a0to\u00a0rule\u00a0them\u00a0al l?\u00a0J\u00a0Med\u00a0Genet \u00a02016;\u00a053:\u00a0575\u201390.\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0241\u00a0\u2010\u00a0\n\u00a0266\u00a0\u00a0 Kienzler\u00a0A\u2010K,\u00a0Hargreaves\u00a0CE,\u00a0Patel\u00a0SY.\u00a0The\u00a0role\u00a0of\u00a0genomic s\u00a0in\u00a0common\u00a0variable\u00a0immunodeficiency\u00a0disorders.\u00a0\nClin\u00a0Exp\u00a0Immunol \u00a02017;\u00a0188:\u00a0326\u2013332.\u00a0\n267\u00a0\u00a0 Flanagan\u00a0SE,\u00a0Haapaniemi\u00a0E,\u00a0Ru ssell\u00a0MA,\u00a0Caswell\u00a0R,\u00a0Allen\u00a0HL ,\u00a0De\u00a0Franco\u00a0E\u00a0 et\u00a0al.\u00a0Activating\u00a0germline\u00a0mutations\u00a0\nin\u00a0STAT3\u00a0cause\u00a0early\u2010onset\u00a0mul ti\u2010organ\u00a0autoimmune\u00a0disease.\u00a0 Nat\u00a0Genet \u00a02014;\u00a046:\u00a0812\u2013814.\u00a0\n268\u00a0\u00a0 Abolhassani\u00a0 H,\u00a0 Wang\u00a0 N,\u00a0 Agha mohammadi\u00a0 A,\u00a0 Rezaei\u00a0 N,\u00a0 Lee\u00a0 YN,\u00a0 Frugoni\u00a0 F\u00a0 et\u00a0 al.\u00a0A \u00a0h y p o m o r p h i c \u00a0\nrecombination\u2010activating\u00a0gene\u00a01\u00a0(RAG1)\u00a0mutation\u00a0resulting\u00a0in\u00a0a\u00a0 phenotype\u00a0resembling\u00a0common\u00a0variable\u00a0\nimmunodeficiency.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02014;\u00a0134:\u00a01375\u20131380.\u00a0\n269\u00a0\u00a0 Abolhassani\u00a0 H,\u00a0 Cheraghi\u00a0 T,\u00a0 Rezaei\u00a0 N,\u00a0 Aghamohammadi\u00a0 A,\u00a0 Hamm arstrom\u00a0 L.\u00a0 Common\u00a0 Variable\u00a0\nImmunodeficiency\u00a0or\u00a0Late\u2010Onset\u00a0C ombined\u00a0Immunodeficiency:\u00a0A\u00a0New \u00a0Hypomorphic\u00a0JAK3\u00a0Patient\u00a0and\u00a0\nReview\u00a0of\u00a0the\u00a0Literature.\u00a0 J\u00a0Investig\u00a0Allergol\u00a0Clin\u00a0Immunol \u00a02015;\u00a025:\u00a0218\u2013220.\u00a0\n270\u00a0\u00a0 Chandra\u00a0 A,\u00a0 Zhang\u00a0 F,\u00a0 Gilmour\u00a0 KC,\u00a0 Webster\u00a0 D,\u00a0 Plagnol\u00a0 V,\u00a0 Kuma raratne\u00a0 DS\u00a0 et\u00a0 al.\u00a0C o m m o n \u00a0v a r i a b l e \u00a0\nimmunodeficiency\u00a0and\u00a0natural\u00a0killer\u00a0cell\u00a0lymphopenia\u00a0caused\u00a0by\u00a0 Ets\u2010binding\u00a0site\u00a0mutation\u00a0in\u00a0the\u00a0IL\u20102\u00a0\nreceptor\u00a0\u03b3\u00a0(IL2RG)\u00a0gene\u00a0promoter.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02016;\u00a0137:\u00a0940\u2013942.\u00a0\n271\u00a0\u00a0 Volk\u00a0T,\u00a0Pannicke\u00a0U,\u00a0Reisli\u00a0I,\u00a0Bulashevska\u00a0A,\u00a0Ritter\u00a0J,\u00a0Bjo rkman\u00a0A\u00a0et\u00a0al.\u00a0DCLRE1C\u00a0(ARTEMIS)\u00a0mutations\u00a0causing\u00a0\nphenotypes\u00a0ranging\u00a0from\u00a0atypical\u00a0severe\u00a0combined\u00a0immunodeficien cy\u00a0to\u00a0mere\u00a0antibody\u00a0deficiency.\u00a0 Hum\u00a0\nMol\u00a0Genet \u00a02015;\u00a024:\u00a07361\u20137372.\u00a0\n272\u00a0\u00a0 Tuijnenburg\u00a0P,\u00a0Lango\u00a0Allen\u00a0H, \u00a0Burns\u00a0SO,\u00a0Greene\u00a0D,\u00a0Jansen\u00a0M H,\u00a0Staples\u00a0E\u00a0 et\u00a0al.\u00a0Loss\u2010of\u2010function\u00a0nuclear\u00a0factor\u00a0\n\u03baB\u00a0 subunit\u00a0 1\u00a0 (NFKB1)\u00a0 variants\u00a0 are\u00a0 the\u00a0 most\u00a0 common\u00a0 monogenic\u00a0 cau se\u00a0 of\u00a0 common\u00a0 variable\u00a0\nimmunodeficiency\u00a0 in\u00a0 Europeans.\u00a0 J\u00a0 Allergy\u00a0 Clin\u00a0 Immunol \u00a0 2018;\u00a0 En\u00a0 prensa\u00a0 desde\u00a0 Marzo\u00a0 de\u00a0 2018.\u00a0\ndoi:10.1016/j.jaci.2018.01.039.\u00a0\n273\u00a0\u00a0 Pan\u2010Hammarstrom\u00a0Q,\u00a0Salzer\u00a0U,\u00a0Du\u00a0L,\u00a0Bjorkander\u00a0J,\u00a0Cunningha m\u2010Rundles\u00a0C,\u00a0Nelson\u00a0DL\u00a0 et\u00a0al.\u00a0Reexamining\u00a0the\u00a0\nrole\u00a0of\u00a0TACI\u00a0coding\u00a0variants\u00a0in\u00a0common\u00a0variable\u00a0immunodeficienc y\u00a0\u00a0and\u00a0selective\u00a0IgA\u00a0deficiency.\u00a0Nat.\u00a0Genet.\u00a0\n2007;\u00a039:\u00a0429\u2013430.\u00a0\n274\u00a0\u00a0 Losi\u00a0CG,\u00a0Silini\u00a0A,\u00a0Fiorini\u00a0C ,\u00a0Soresina\u00a0A,\u00a0Meini\u00a0A,\u00a0Ferrari \u00a0S\u00a0et\u00a0al.\u00a0Mutational\u00a0analysis\u00a0of\u00a0human\u00a0BAFF\u00a0receptor\u00a0\nTNFRSF13C\u00a0(BAFF\u2010R)\u00a0in\u00a0patients\u00a0with\u00a0common\u00a0variable\u00a0immunodefic iency.\u00a0J\u00a0Clin\u00a0Immunol \u00a02005;\u00a025:\u00a0496\u2013\n502.\u00a0\n275\u00a0\u00a0 Orange\u00a0JS,\u00a0Glessner\u00a0JT,\u00a0Res nick\u00a0E,\u00a0Sullivan\u00a0KE,\u00a0Lucas\u00a0M,\u00a0F erry\u00a0B\u00a0et\u00a0al.\u00a0Genome\u2010wide\u00a0association\u00a0identifies\u00a0\ndiverse\u00a0causes\u00a0of\u00a0common\u00a0variable\u00a0immunodeficiency.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02011;\u00a0127:\u00a01360\u20137.e6.\u00a0\n276\u00a0\u00a0 Li\u00a0J,\u00a0J\u00f8rgensen\u00a0SF,\u00a0Maggadottir\u00a0SM,\u00a0Bakay\u00a0M,\u00a0Warnatz\u00a0K,\u00a0Gl essner\u00a0J\u00a0et\u00a0al.\u00a0Association\u00a0of\u00a0CLEC16A\u00a0with\u00a0human\u00a0\ncommon\u00a0variable\u00a0immunodeficiency\u00a0d isorder\u00a0and\u00a0role\u00a0in\u00a0murine\u00a0B\u00a0 cells.\u00a0Nat\u00a0Commun \u00a02015;\u00a06:\u00a06804.\u00a0\n277\u00a0\u00a0 van\u00a0Schouwenburg\u00a0PA,\u00a0Davenport\u00a0EE,\u00a0Kienzler\u00a0A\u2010K,\u00a0Marwah\u00a0I, \u00a0Wright\u00a0B,\u00a0Lucas\u00a0M\u00a0 et\u00a0al.\u00a0Application\u00a0of\u00a0whole\u00a0\ngenome\u00a0and\u00a0RNA\u00a0sequencing\u00a0to\u00a0investigate\u00a0the\u00a0genomic\u00a0landscape\u00a0 of\u00a0common\u00a0variable\u00a0immunodeficiency\u00a0\ndisorders.\u00a0 Clin\u00a0Immunol \u00a02015;\u00a0160:\u00a0301\u2013314.\u00a0\n278\u00a0\u00a0 Rodriguez\u2010Cortez\u00a0VC,\u00a0Del\u00a0Pino\u2010Molina\u00a0L,\u00a0Rodriguez\u2010Ubreva\u00a0J ,\u00a0Ciudad\u00a0L,\u00a0Gomez\u2010Cabrero\u00a0D,\u00a0Company\u00a0C\u00a0 et\u00a0al.\u00a0\nMonozygotic\u00a0twins\u00a0discordant\u00a0for \u00a0common\u00a0variable\u00a0immunodeficien cy\u00a0reveal\u00a0impaired\u00a0DNA\u00a0demethylation\u00a0\nduring\u00a0naive\u2010to\u2010memory\u00a0B\u2010cell\u00a0transition.\u00a0 Nat\u00a0Commun \u00a02015;\u00a06:\u00a07335.\u00a0\n279\u00a0\u00a0 Vlkova\u00a0M,\u00a0Thon\u00a0V,\u00a0Sarfyova\u00a0M,\u00a0Blaha\u00a0L,\u00a0Svobodnik\u00a0A,\u00a0Lokaj\u00a0 J\u00a0et\u00a0al.\u00a0Age\u00a0dependency\u00a0and\u00a0mutual\u00a0relations\u00a0in\u00a0T\u00a0\nand\u00a0B\u00a0lymphocyte\u00a0abnormalities\u00a0in\u00a0common\u00a0variable\u00a0immunodeficie ncy\u00a0patients.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a02006;\u00a0\n143:\u00a0373\u2013379.\u00a0\n280\u00a0\u00a0 Pia \u0327tosa\u00a0B,\u00a0Pac\u00a0M,\u00a0Siewiera\u00a0K,\u00a0Pietrucha\u00a0B,\u00a0Klaudel\u2010Dreszler\u00a0M,\u00a0Her opolita\u0144ska\u2010Pliszka\u00a0E\u00a0 et\u00a0al.\u00a0Common\u00a0\nvariable\u00a0immune\u00a0deficiency\u00a0in\u00a0ch ildren\u00a0\u2010\u00a0Clinical\u00a0characteristi cs\u00a0varies\u00a0depending\u00a0on\u00a0defect\u00a0in\u00a0peripheral\u00a0B\u00a0\ncell\u00a0maturation.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02013;\u00a033:\u00a0731\u2013741.\u00a0\n281\u00a0\u00a0 Al\u00a0Kindi\u00a0M,\u00a0Mundy\u00a0J,\u00a0Sullivan\u00a0T,\u00a0Smith\u00a0W,\u00a0Kette\u00a0F,\u00a0Smith\u00a0A \u00a0et\u00a0al.\u00a0Utility\u00a0of\u00a0peripheral\u00a0blood\u00a0B\u00a0cell\u00a0subsets\u00a0\nanalysis\u00a0in\u00a0common\u00a0variable\u00a0immunodeficiency.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a02012;\u00a0167:\u00a0275\u2013281.\u00a0\n282\u00a0\u00a0 Lougaris\u00a0V,\u00a0Baronio\u00a0M,\u00a0Masneri\u00a0S,\u00a0Lorenzini\u00a0T,\u00a0Cattivelli\u00a0 K,\u00a0Tampella\u00a0G\u00a0 et\u00a0al.\u00a0Correlation\u00a0of\u00a0bone\u00a0marrow\u00a0\nabnormalities,\u00a0peripheral\u00a0lymphocyte\u00a0subsets\u00a0and\u00a0clinical\u00a0featu res\u00a0in\u00a0uncomplicated\u00a0common\u00a0variable\u00a0\nimmunodeficiency\u00a0(CVID)\u00a0patients.\u00a0 Clin\u00a0Immunol \u00a02016;\u00a0163:\u00a010\u201313.\u00a0\n283\u00a0\u00a0 Ochtrop\u00a0MLG,\u00a0Goldacker\u00a0S,\u00a0May \u00a0AM,\u00a0Rizzi\u00a0M,\u00a0Draeger\u00a0R,\u00a0Haus chke\u00a0D\u00a0et\u00a0al.\u00a0T\u00a0and\u00a0B\u00a0lymphocyte\u00a0abnormalities\u00a0\nin\u00a0bone\u00a0marrow\u00a0biopsies\u00a0of\u00a0commo n\u00a0variable\u00a0immunodeficiency.\u00a0 Blood\u00a02011;\u00a0118:\u00a0309\u2013318.\u00a0\n284\u00a0\u00a0 Driessen\u00a0GJ,\u00a0van\u00a0Zelm\u00a0MC,\u00a0van\u00a0Hagen\u00a0PM,\u00a0Hartwig\u00a0NG,\u00a0Trip\u00a0M ,\u00a0Warris\u00a0A\u00a0 et\u00a0al.\u00a0B\u2010cell\u00a0replication\u00a0history\u00a0and\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0242\u00a0\u2010\u00a0\n\u00a0somatic\u00a0 hypermutation\u00a0 status\u00a0 ide ntify\u00a0 distinct\u00a0 pathophysiologic \u00a0 backgrounds\u00a0 in\u00a0 common\u00a0 variable\u00a0\nimmunodeficiency.\u00a0 Blood\u00a02011;\u00a0118:\u00a06814\u20136823.\u00a0\n285\u00a0\u00a0 Bogaert\u00a0DJA,\u00a0De\u00a0Bruyne\u00a0M,\u00a0Deb acker\u00a0V,\u00a0Depuydt\u00a0P,\u00a0De\u00a0Preter \u00a0K,\u00a0Bonroy\u00a0C\u00a0 et\u00a0al.\u00a0The\u00a0immunophenotypic\u00a0\nfingerprint\u00a0of\u00a0patients\u00a0with\u00a0primary\u00a0antibody\u00a0deficiencies\u00a0is\u00a0p artially\u00a0present\u00a0in\u00a0their\u00a0asymptomatic\u00a0first\u2010\ndegree\u00a0relatives.\u00a0 Haematologica \u00a02017;\u00a0102:\u00a0192\u2013202.\u00a0\n286\u00a0\u00a0 Warnatz\u00a0K,\u00a0Denz\u00a0A,\u00a0Drager\u00a0R,\u00a0Braun\u00a0M,\u00a0Groth\u00a0C,\u00a0Wolff\u2010Vorbe ck\u00a0G\u00a0et\u00a0al.\u00a0Severe\u00a0deficiency\u00a0of\u00a0switched\u00a0memory\u00a0\nB\u00a0cells\u00a0(CD27(+)IgM(\u2010)IgD(\u2010))\u00a0in\u00a0 subgroups\u00a0of\u00a0patients\u00a0with\u00a0com mon\u00a0variable\u00a0immunodeficiency:\u00a0a\u00a0new\u00a0\napproach\u00a0to\u00a0classify\u00a0a\u00a0heterogeneous\u00a0disease.\u00a0 Blood\u00a02002;\u00a099:\u00a01544\u20131551.\u00a0\n287\u00a0\u00a0 Piqueras\u00a0B,\u00a0Lavenu\u2010Bombled\u00a0C, \u00a0Galicier\u00a0L,\u00a0Bergeron\u2010van\u00a0der \u00a0Cruyssen\u00a0F,\u00a0Mouthon\u00a0L,\u00a0Chevret\u00a0S\u00a0 et\u00a0al.\u00a0Common\u00a0\nvariable\u00a0immunodeficiency\u00a0patient \u00a0classification\u00a0based\u00a0on\u00a0impai red\u00a0B\u00a0cell\u00a0\u00a0memory\u00a0differentiation\u00a0correlates\u00a0\nwith\u00a0clinical\u00a0aspects.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02003;\u00a023:\u00a0385\u2013400.\u00a0\n288\u00a0\u00a0 Alachkar\u00a0H,\u00a0Taubenheim\u00a0N,\u00a0Haeney\u00a0MR,\u00a0Durandy\u00a0A,\u00a0Arkwright\u00a0 PD.\u00a0Memory\u00a0switched\u00a0B\u00a0cell\u00a0percentage\u00a0and\u00a0\nnot\u00a0serum\u00a0immunoglobulin\u00a0concentration\u00a0is\u00a0associated\u00a0with\u00a0clini cal\u00a0complications\u00a0in\u00a0children\u00a0and\u00a0adults\u00a0with\u00a0\nspecific\u00a0antibody\u00a0deficiency\u00a0and\u00a0common\u00a0variable\u00a0immunodeficien cy.\u00a0Clin\u00a0Immunol \u00a02006;\u00a0120:\u00a0310\u2013318.\u00a0\n289\u00a0\u00a0 Detkova\u00a0 D,\u00a0 de\u00a0 Gracia\u00a0 J,\u00a0 Lopes \u2010da\u2010Silva\u00a0 S,\u00a0 Vendrell\u00a0 M,\u00a0 Alva rez\u00a0 A,\u00a0 Guarner\u00a0 L\u00a0 et\u00a0 al.\u00a0 Common\u00a0 variable\u00a0\nimmunodeficiency:\u00a0association\u00a0 between\u00a0memory\u00a0B\u00a0cells\u00a0and\u00a0lung\u00a0d iseases.\u00a0Chest\u00a02007;\u00a0131:\u00a01883\u20131889.\u00a0\n290\u00a0\u00a0 Ko\u00a0J,\u00a0Radigan\u00a0L,\u00a0Cunningham\u2010Rundles\u00a0C.\u00a0Immune\u00a0competence\u00a0a nd\u00a0switched\u00a0memory\u00a0B\u00a0cells\u00a0in\u00a0common\u00a0\nvariable\u00a0immunodeficiency.\u00a0 Clin\u00a0Immunol \u00a02005;\u00a0116:\u00a037\u201341.\u00a0\n291\u00a0\u00a0 van\u00a0de\u00a0Ven\u00a0AAJM,\u00a0van\u00a0Montfrans\u00a0JM.\u00a0Clinical\u00a0complications\u00a0 in\u00a0pediatric\u00a0CVID\u00a0are\u00a0not\u00a0restricted\u00a0to\u00a0patients\u00a0\nwith\u00a0severely\u00a0reduced\u00a0class\u2010switched\u00a0memory\u00a0B\u00a0cells.\u00a0 Pediatr\u00a0Allergy\u00a0Immunol \u00a02011;\u00a022:\u00a0347\u20138.\u00a0\n292\u00a0\u00a0 Yong\u00a0PL,\u00a0Orange\u00a0JS,\u00a0Sullivan\u00a0KE.\u00a0Pediatric\u00a0common\u00a0variable \u00a0immunodeficiency:\u00a0immunologic\u00a0and\u00a0phenotypic\u00a0\nassociations\u00a0with\u00a0switched\u00a0memory\u00a0B\u00a0cells.\u00a0 Pediatr\u00a0Allergy\u00a0Immunol \u00a02010;\u00a021:\u00a0852\u2013858.\u00a0\n293\u00a0\u00a0 Moratto\u00a0D,\u00a0Gulino\u00a0AV,\u00a0Fontana\u00a0S,\u00a0Mori\u00a0L,\u00a0Pirovano\u00a0S,\u00a0Sores ina\u00a0A\u00a0et\u00a0al.\u00a0Combined\u00a0decrease\u00a0of\u00a0defined\u00a0B\u00a0and\u00a0\nT\u00a0cell\u00a0subsets\u00a0in\u00a0a\u00a0group\u00a0of\u00a0com mon\u00a0variable\u00a0immunodeficiency\u00a0p atients.\u00a0Clin\u00a0Immunol \u00a02006;\u00a0121:\u00a0203\u2013214.\u00a0\n294\u00a0\u00a0 Yazdani\u00a0R,\u00a0Seify\u00a0R,\u00a0Ganjalikhani\u2010Hakemi\u00a0M,\u00a0Abolhassani\u00a0H,\u00a0 Eskandari\u00a0N,\u00a0Golsaz\u2010Shirazi\u00a0F\u00a0 et\u00a0al.\u00a0Comparison\u00a0of\u00a0\nvarious\u00a0classifications\u00a0for\u00a0pati ents\u00a0with\u00a0common\u00a0variable\u00a0immun odeficiency\u00a0(CVID)\u00a0using\u00a0measurement\u00a0of\u00a0B\u2010\ncell\u00a0subsets.\u00a0 Allergol\u00a0Immunopathol\u00a0(Madr) \u00a02017;\u00a045:\u00a0183\u2013192.\u00a0\n295\u00a0\u00a0 Westh\u00a0L,\u00a0Mogensen\u00a0TH,\u00a0Dalgaard\u00a0LS,\u00a0Bernth\u00a0Jensen\u00a0JM,\u00a0Katze nstein\u00a0T,\u00a0Hansen\u00a0A\u2010BE\u00a0 et\u00a0al.\u00a0Identification\u00a0and\u00a0\nCharacterization\u00a0of\u00a0a\u00a0Nationwide\u00a0Danish\u00a0Adult\u00a0Common\u00a0Variable\u00a0\u00a0 Immunodeficiency\u00a0Cohort.\u00a0 Scand\u00a0J\u00a0\nImmunol\u00a02017;\u00a085:\u00a0450\u2013461.\u00a0\n296\u00a0\u00a0 Boileau\u00a0J,\u00a0Mouillot\u00a0G,\u00a0Gerard \u00a0L,\u00a0Carmagnat\u00a0M,\u00a0Rabian\u00a0C,\u00a0Ok senhendler\u00a0E\u00a0 et\u00a0al.\u00a0Autoimmunity\u00a0in\u00a0common\u00a0\nvariable\u00a0immunodeficiency:\u00a0correl ation\u00a0with\u00a0lymphocyte\u00a0phenotyp e\u00a0in\u00a0the\u00a0French\u00a0DEFI\u00a0study.\u00a0 J\u00a0Autoimmun \u00a0\n2011;\u00a036:\u00a025\u201332.\u00a0\n297\u00a0\u00a0 Goldacker\u00a0S,\u00a0Draeger\u00a0R,\u00a0Warna tz\u00a0K,\u00a0Huzly\u00a0D,\u00a0Salzer\u00a0U,\u00a0Thie l\u00a0J\u00a0et\u00a0al.\u00a0Active\u00a0vaccination\u00a0in\u00a0patients\u00a0with\u00a0common\u00a0\nvariable\u00a0immunodeficiency\u00a0(CVID).\u00a0 Clin\u00a0Immunol \u00a02007;\u00a0124:\u00a0294\u2013303.\u00a0\n298\u00a0\u00a0 Unger\u00a0S,\u00a0Seidl\u00a0M,\u00a0Schmitt\u2010Gr aeff\u00a0A,\u00a0Bohm\u00a0J,\u00a0Schrenk\u00a0K,\u00a0Weh r\u00a0C\u00a0et\u00a0al.\u00a0Ill\u2010defined\u00a0germinal\u00a0centers\u00a0and\u00a0severely\u00a0\nreduced\u00a0plasma\u00a0cells\u00a0are\u00a0histolo gical\u00a0hallmarks\u00a0of\u00a0lymphadenopa thy\u00a0in\u00a0patients\u00a0with\u00a0common\u00a0variable\u00a0\nimmunodeficiency.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02014;\u00a034:\u00a0615\u2013626.\u00a0\n299\u00a0\u00a0 Giovannetti\u00a0A,\u00a0Pierdominici\u00a0M,\u00a0Mazzetta\u00a0F,\u00a0Marziali\u00a0M,\u00a0Ren zi\u00a0C,\u00a0Mileo\u00a0AM\u00a0 et\u00a0al.\u00a0Unravelling\u00a0the\u00a0complexity\u00a0\nof\u00a0T\u00a0cell\u00a0abnormalities\u00a0in\u00a0common\u00a0variable\u00a0immunodeficiency.\u00a0 J\u00a0Immunol \u00a02007;\u00a0178:\u00a03932\u20133943.\u00a0\n300\u00a0\u00a0 Nechvatalova\u00a0J,\u00a0Pavlik\u00a0T,\u00a0Li tzman\u00a0J,\u00a0Vlkova\u00a0M.\u00a0Terminally\u00a0 differentiated\u00a0memory\u00a0T\u00a0cells\u00a0are\u00a0increased\u00a0in\u00a0\npatients\u00a0with\u00a0common\u00a0variable\u00a0immunodeficiency\u00a0and\u00a0selective\u00a0Ig A\u00a0deficiency.\u00a0 Cent\u00a0J\u00a0Immunol \u00a02017;\u00a042:\u00a0\n244\u2013251.\u00a0\n301\u00a0\u00a0 Arumugakani\u00a0 G,\u00a0 Wood\u00a0 PMD,\u00a0 Carter\u00a0 CRD.\u00a0 Frequency\u00a0 of\u00a0 Treg\u00a0 cel ls\u00a0 is\u00a0 reduced\u00a0 in\u00a0 CVID\u00a0 patients\u00a0 with\u00a0\nautoimmunity\u00a0and\u00a0splenomegaly\u00a0and\u00a0is\u00a0associated\u00a0with\u00a0expanded\u00a0C D21lo\u00a0B\u00a0lymphocytes.\u00a0 J\u00a0Clin\u00a0Immunol \u00a0\n2010;\u00a030:\u00a0292\u2013300.\u00a0\n302\u00a0\u00a0 Unger\u00a0S,\u00a0Seidl\u00a0M,\u00a0van\u00a0Schou wenburg\u00a0P,\u00a0Rakhmanov\u00a0M,\u00a0Bulashe vska\u00a0A,\u00a0Frede\u00a0N\u00a0 et\u00a0al.\u00a0The\u00a0TH1\u00a0phenotype\u00a0of\u00a0\nfollicular\u00a0helper\u00a0T\u00a0cells\u00a0indica tes\u00a0an\u00a0IFN\u2010gamma\u2010associated\u00a0\u00a0im mune\u00a0dysregulation\u00a0in\u00a0patients\u00a0with\u00a0CD21low\u00a0\ncommon\u00a0variable\u00a0immunodeficiency.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02018;\u00a0141:\u00a0730\u2013740.\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0243\u00a0\u2010\u00a0\n\u00a0303\u00a0\u00a0 Ebbo\u00a0M,\u00a0Gerard\u00a0L,\u00a0Carpentier\u00a0S,\u00a0Vely\u00a0F,\u00a0Cypowyj\u00a0S,\u00a0Farnari er\u00a0C\u00a0et\u00a0al.\u00a0Low\u00a0Circulating\u00a0Natural\u00a0Killer\u00a0Cell\u00a0Counts\u00a0\nare\u00a0Associated\u00a0With\u00a0Severe\u00a0Disease\u00a0in\u00a0\u00a0Patients\u00a0With\u00a0Common\u00a0Var iable\u00a0Immunodeficiency.\u00a0 EBioMedicine \u00a0\n2016;\u00a06:\u00a0222\u2013230.\u00a0\n304\u00a0\u00a0 Bryant\u00a0A,\u00a0Calver\u00a0NC,\u00a0Toubi\u00a0E,\u00a0Webster\u00a0AD,\u00a0Farrant\u00a0J.\u00a0Class ification\u00a0of\u00a0patients\u00a0with\u00a0common\u00a0variable\u00a0\nimmunodeficiency\u00a0by\u00a0B\u00a0cell\u00a0secre tion\u00a0of\u00a0IgM\u00a0and\u00a0IgG\u00a0in\u00a0response \u00a0to\u00a0anti\u2010IgM\u00a0and\u00a0interleukin\u20102.\u00a0 Clin\u00a0Immunol\u00a0\nImmunopathol \u00a01990;\u00a056:\u00a0239\u2013248.\u00a0\n305\u00a0\u00a0 R\u00f6sel\u00a0AL,\u00a0Scheibenbogen\u00a0C,\u00a0Schliesser\u00a0U,\u00a0Sollwedel\u00a0A,\u00a0Hoff meister\u00a0B,\u00a0Hanitsch\u00a0L\u00a0 et\u00a0al.\u00a0Classification\u00a0of\u00a0\ncommon\u00a0variable\u00a0immunodeficiencies\u00a0using\u00a0flow\u00a0cytometry\u00a0and\u00a0a\u00a0m emory\u00a0B\u2010cell\u00a0functionality\u00a0assay.\u00a0 J\u00a0Allergy\u00a0\nClin\u00a0Immunol \u00a02015;\u00a0135:\u00a0198\u2013208.\u00a0\n306\u00a0\u00a0 Qamar\u00a0N,\u00a0Fuleihan\u00a0RL.\u00a0The\u00a0hyper\u00a0IgM\u00a0syndromes.\u00a0 Clin\u00a0Rev\u00a0Allergy\u00a0Immunol \u00a02014;\u00a046:\u00a0120\u2013130.\u00a0\n307\u00a0\u00a0 de\u00a0la\u00a0Morena\u00a0MT.\u00a0Clinical\u00a0Phe notypes\u00a0of\u00a0Hyper\u2010IgM\u00a0Syndrome s.\u00a0J\u00a0allergy\u00a0Clin\u00a0Immunol\u00a0Pract \u00a02016;\u00a04:\u00a01023\u2013\n1036.\u00a0\n308\u00a0\u00a0 Gardes\u00a0P,\u00a0Forveille\u00a0M,\u00a0Alyana kian\u00a0M\u2010A,\u00a0Aucouturier\u00a0P,\u00a0Ilen cikova\u00a0D,\u00a0Leroux\u00a0D\u00a0 et\u00a0al.\u00a0Human\u00a0MSH6\u00a0deficiency\u00a0\nis\u00a0associated\u00a0with\u00a0impaired\u00a0antibody\u00a0maturation.\u00a0 J\u00a0Immunol \u00a02012;\u00a0188:\u00a02023\u20132029.\u00a0\n309\u00a0\u00a0 Kracker\u00a0 S,\u00a0 Di\u00a0 Virgilio\u00a0 M,\u00a0 Sch wartzentruber\u00a0 J,\u00a0 Cuenin\u00a0 C,\u00a0 Fo rveille\u00a0 M,\u00a0 Deau\u00a0 M\u2010C\u00a0 et\u00a0 al.\u00a0 An\u00a0 inherited\u00a0\nimmunoglobulin\u00a0class\u2010switch\u00a0recombination\u00a0deficiency\u00a0associated \u00a0with\u00a0a\u00a0defect\u00a0in\u00a0the\u00a0INO80\u00a0chromatin\u00a0\nremodeling\u00a0complex.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02015;\u00a0135:\u00a0998\u20131007.e6.\u00a0\n310\u00a0\u00a0 Ramirez\u2010Alejo\u00a0N,\u00a0Alcantara\u2010Mo ntiel\u00a0JC,\u00a0Yamazaki\u2010Nakashimad a\u00a0M,\u00a0Duran\u2010McKinster\u00a0C,\u00a0Valenzuela\u2010Leon\u00a0P,\u00a0\nRivas\u2010Larrauri\u00a0 F\u00a0 et\u00a0 al.\u00a0 Novel\u00a0 hypomorphic\u00a0 mutation\u00a0 in\u00a0 IK BKG\u00a0 impairs\u00a0 NEMO\u2010ubiquitylatio n\u00a0 causing\u00a0\nectodermal\u00a0dysplasia,\u00a0immunodefi ciency,\u00a0incontinentia\u00a0pigmenti, \u00a0and\u00a0immune\u00a0thrombocytopenic\u00a0purpura.\u00a0\nClin\u00a0Immunol \u00a02015;\u00a0160:\u00a0163\u2013171.\u00a0\n311\u00a0\u00a0 Lopez\u2010Granados\u00a0E,\u00a0Keenan\u00a0JE,\u00a0Kinney\u00a0MC,\u00a0Leo\u00a0H,\u00a0Jain\u00a0N,\u00a0Ma\u00a0 CA\u00a0et\u00a0al.\u00a0A\u00a0novel\u00a0mutation\u00a0in\u00a0NFKBIA/IKBA\u00a0results\u00a0\ni n \u00a0a \u00a0d e g r a d a t i o n \u2010 r e s i s t a n t \u00a0N \u2010 t r u n c a t e d \u00a0p r o t e i n \u00a0a n d \u00a0i s \u00a0a s s o c i a t e d\u00a0 with\u00a0 ectodermal\u00a0 dysplasia\u00a0 with\u00a0\nimmunodeficiency.\u00a0 Hum\u00a0Mutat \u00a02008;\u00a029:\u00a0861\u2013868.\u00a0\n312\u00a0\u00a0 Minegishi\u00a0Y,\u00a0Lavoie\u00a0A,\u00a0Cunni ngham\u2010Rundles\u00a0C,\u00a0Bedard\u00a0PM,\u00a0He bert\u00a0J,\u00a0Cote\u00a0L\u00a0 et\u00a0al.\u00a0Mutations\u00a0in\u00a0activation\u2010\ninduced\u00a0cytidine\u00a0deaminase\u00a0in\u00a0pat ients\u00a0with\u00a0hyper\u00a0IgM\u00a0syndrome. \u00a0Clin\u00a0Immunol \u00a02000;\u00a097:\u00a0203\u2013210.\u00a0\n313\u00a0\u00a0 Revy\u00a0P,\u00a0Muto\u00a0T,\u00a0Levy\u00a0Y,\u00a0Geissmann\u00a0F,\u00a0Plebani\u00a0A,\u00a0Sanal\u00a0O\u00a0 et\u00a0al.\u00a0Activation\u2010induced\u00a0cytidine\u00a0deaminase\u00a0(AID)\u00a0\ndeficiency\u00a0causes\u00a0the\u00a0autosomal\u00a0recessive\u00a0form\u00a0of\u00a0the\u00a0Hyper\u2010IgM \u00a0syndrome\u00a0(HIGM2).\u00a0 Cell\u00a02000;\u00a0102:\u00a0565\u2013\n575.\u00a0\n314\u00a0\u00a0 Imai\u00a0K,\u00a0Slupphaug\u00a0G,\u00a0Lee\u00a0W\u2010I,\u00a0Revy\u00a0P,\u00a0Nonoyama\u00a0S,\u00a0Catalan\u00a0 N\u00a0et\u00a0al.\u00a0Human\u00a0uracil\u2010DNA\u00a0glycosylase\u00a0deficiency\u00a0\nassociated\u00a0with\u00a0profoundly\u00a0impaired\u00a0immunoglobulin\u00a0class\u2010switch \u00a0recombination.\u00a0 Nat\u00a0Immunol \u00a02003;\u00a04:\u00a0\n1023\u20131028.\u00a0\n315\u00a0\u00a0 Ferrari\u00a0S,\u00a0Giliani\u00a0S,\u00a0Insala co\u00a0A,\u00a0Al\u2010Ghonaium\u00a0A,\u00a0Soresina\u00a0 AR,\u00a0Loubser\u00a0M\u00a0 et\u00a0al.\u00a0Mutations\u00a0of\u00a0CD40\u00a0gene\u00a0cause\u00a0\nan\u00a0autosomal\u00a0recessive\u00a0form\u00a0of\u00a0immunodeficiency\u00a0with\u00a0hyper\u00a0IgM. \u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A \u00a02001;\u00a098:\u00a012614\u2013\n12619.\u00a0\n316\u00a0\u00a0 Boisson\u00a0B,\u00a0Puel\u00a0A,\u00a0Picard\u00a0C,\u00a0Casanova\u00a0J\u2010L.\u00a0Human\u00a0IkappaBal pha\u00a0Gain\u00a0of\u00a0Function:\u00a0a\u00a0Severe\u00a0and\u00a0Syndromic\u00a0\nImmunodeficiency.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02017;\u00a037:\u00a0397\u2013412.\u00a0\n317\u00a0\u00a0 Winkelstein\u00a0JA,\u00a0Marino\u00a0MC,\u00a0 Ochs\u00a0H,\u00a0Fuleihan\u00a0R,\u00a0Scholl\u00a0PR,\u00a0 Geha\u00a0R\u00a0et\u00a0al.\u00a0The\u00a0X\u2010linked\u00a0hyper\u2010IgM\u00a0syndrome:\u00a0\nclinical\u00a0and\u00a0immunologic\u00a0 features\u00a0of\u00a079\u00a0patients.\u00a0 Medicine\u00a0(Baltimore) \u00a02003;\u00a082:\u00a0373\u2013384.\u00a0\n318\u00a0\u00a0 Hanson\u00a0EP,\u00a0Monaco\u2010Shawver\u00a0L,\u00a0Solt\u00a0LA,\u00a0Madge\u00a0LA,\u00a0Banerjee\u00a0P P,\u00a0May\u00a0MJ\u00a0 et\u00a0al.\u00a0Hypomorphic\u00a0nuclear\u00a0factor\u2010\nkappaB\u00a0 essential\u00a0 modulator\u00a0 mutatio n\u00a0 database\u00a0 and\u00a0 reconstitution \u00a0 system\u00a0 identifies\u00a0 phenotypic\u00a0 and\u00a0\nimmunologic\u00a0diversity.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02008;\u00a0122:\u00a01169\u20131177.e16.\u00a0\n319\u00a0\u00a0 de\u00a0la\u00a0Morena\u00a0MT,\u00a0Leonard\u00a0D,\u00a0Torgerson\u00a0TR,\u00a0Cabral\u2010Marques\u00a0O ,\u00a0Slatter\u00a0M,\u00a0Aghamohammadi\u00a0A\u00a0 et\u00a0al.\u00a0Long\u2010\nterm\u00a0outcomes\u00a0of\u00a0176\u00a0patients\u00a0with\u00a0X\u2010linked\u00a0hyper\u2010IgM\u00a0syndrome\u00a0 treated\u00a0with\u00a0\u00a0or\u00a0without\u00a0hematopoietic\u00a0\ncell\u00a0transplantation.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02017;\u00a0139:\u00a01282\u20131292.\u00a0\n320\u00a0\u00a0 Quartier\u00a0P,\u00a0Bustamante\u00a0J,\u00a0Sanal\u00a0O,\u00a0Plebani\u00a0A,\u00a0Debre\u00a0M,\u00a0Dev ille\u00a0A\u00a0et\u00a0al.\u00a0Clinical,\u00a0immunologic\u00a0and\u00a0genetic\u00a0\nanalysis\u00a0of\u00a029\u00a0patients\u00a0with\u00a0autosomal\u00a0recessive\u00a0hyper\u2010IgM\u00a0synd rome\u00a0due\u00a0to\u00a0Activation\u2010Induced\u00a0Cytidine\u00a0\nDeaminase\u00a0deficiency.\u00a0 Clin\u00a0Immunol \u00a02004;\u00a0110:\u00a022\u201329.\u00a0\n321\u00a0\u00a0 Allewelt\u00a0H,\u00a0Martin\u00a0PL,\u00a0Szabolcs\u00a0P,\u00a0Chao\u00a0N,\u00a0Buckley\u00a0R,\u00a0Pari kh\u00a0S.\u00a0Hematopoietic\u00a0Stem\u00a0Cell\u00a0Transplantation\u00a0for\u00a0\nCD40\u00a0Ligand\u00a0Deficiency:\u00a0Single \u00a0Institution\u00a0Experience.\u00a0 Pediatr\u00a0Blood\u00a0Cancer \u00a02015;\u00a062:\u00a02216\u20132222.\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0244\u00a0\u2010\u00a0\n\u00a0322\u00a0\u00a0 Mitsui\u2010Sekinaka\u00a0K,\u00a0Imai\u00a0K,\u00a0Sato\u00a0H,\u00a0Tomizawa\u00a0D,\u00a0Kajiwara\u00a0M, \u00a0Nagasawa\u00a0M\u00a0 et\u00a0al.\u00a0Clinical\u00a0features\u00a0and\u00a0\nhematopoietic\u00a0stem\u00a0cell\u00a0transpla ntations\u00a0for\u00a0CD40\u00a0ligand\u00a0defici ency\u00a0in\u00a0Japan.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02015;\u00a0\n136:\u00a01018\u20131024.\u00a0\n323\u00a0\u00a0 Agematsu\u00a0K,\u00a0Nagumo\u00a0H,\u00a0Shinozaki\u00a0K,\u00a0Hokibara\u00a0S,\u00a0Yasui\u00a0K,\u00a0Te rada\u00a0K\u00a0et\u00a0al.\u00a0Absence\u00a0of\u00a0IgD\u2010CD27(+)\u00a0memory\u00a0B\u00a0\ncell\u00a0population\u00a0in\u00a0X\u2010linked\u00a0hyper\u2010IgM\u00a0syndrome.\u00a0 J\u00a0Clin\u00a0Invest \u00a01998;\u00a0102:\u00a0853\u2013860.\u00a0\n324\u00a0\u00a0 van\u00a0der\u00a0Burg,\u00a0M.,\u00a0Kalina\u00a0T,\u00a0P\u00e9rez\u2010Andr\u00e9s\u00a0M,\u00a0Vlkova\u00a0M,\u00a0L\u00f3pe z\u2010Granados\u00a0E.\u00a0The\u00a0EuroFlow\u00a0approach\u00a0to\u00a0flow\u00a0\ncytometry\u00a0in\u00a0patients\u00a0with\u00a0primary\u00a0immunodeficiencies.\u00a0 Prep\u00a02018.\u00a0\n325\u00a0\u00a0 Rockey\u00a0JH,\u00a0Hanson\u00a0LA,\u00a0Heremans\u00a0JF,\u00a0Kunkel\u00a0HG.\u00a0Beta\u20102A\u00a0aglo bulinemia\u00a0in\u00a0two\u00a0healthy\u00a0men.\u00a0 J\u00a0Lab\u00a0Clin\u00a0Med \u00a0\n1964;\u00a063:\u00a0205\u2013212.\u00a0\n326\u00a0\u00a0 Ammann\u00a0AJ,\u00a0Hong\u00a0R.\u00a0Selective\u00a0 IgA\u00a0deficiency:\u00a0presentation\u00a0 of\u00a030\u00a0cases\u00a0and\u00a0a\u00a0review\u00a0of\u00a0the\u00a0literature.\u00a0\nMedicine\u00a0(Baltimore) \u00a01971;\u00a050:\u00a0223\u2013236.\u00a0\n327\u00a0\u00a0 Ammann\u00a0AJ,\u00a0Hong\u00a0R.\u00a0Selective\u00a0 IgA\u00a0deficiency\u00a0and\u00a0autoimmuni ty.\u00a0N\u00a0Engl\u00a0J\u00a0Med \u00a01971;\u00a0284:\u00a0985\u2013986.\u00a0\n328\u00a0\u00a0 Yazdani\u00a0R,\u00a0Latif\u00a0A,\u00a0Tabasso mi\u00a0F,\u00a0Abolhassani\u00a0H,\u00a0Azizi\u00a0G,\u00a0R ezaei\u00a0N\u00a0et\u00a0al.\u00a0Clinical\u00a0phenotype\u00a0classification\u00a0for\u00a0\nselective\u00a0immunoglobulin\u00a0A\u00a0deficiency.\u00a0 Expert\u00a0Rev\u00a0Clin\u00a0Immunol \u00a02015;\u00a011:\u00a01245\u20131254.\u00a0\n329\u00a0\u00a0 Cunningham\u2010Rundles\u00a0C.\u00a0Physiology\u00a0of\u00a0IgA\u00a0and\u00a0IgA\u00a0deficiency .\u00a0J\u00a0Clin\u00a0Immunol \u00a02001;\u00a021:\u00a0303\u2013309.\u00a0\n330\u00a0\u00a0 Al\u2010Herz\u00a0 W,\u00a0 Bousfiha\u00a0 A,\u00a0 Casanova\u00a0 J\u2010L,\u00a0 Chatila\u00a0 T,\u00a0 Conley\u00a0 ME, \u00a0 Cunningham\u2010Rundles\u00a0 C\u00a0 et\u00a0 al.\u00a0 Primary\u00a0\nimmunodeficiency\u00a0diseases:\u00a0an\u00a0update\u00a0on\u00a0the\u00a0classification\u00a0from \u00a0the\u00a0international\u00a0union\u00a0of\u00a0immunological\u00a0\nsocieties\u00a0expert\u00a0committee\u00a0for\u00a0primary\u00a0immunodeficiency.\u00a0 Front\u00a0Immunol \u00a02014;\u00a05:\u00a0162.\u00a0\n331\u00a0\u00a0 Kanoh\u00a0T,\u00a0Mizumoto\u00a0T,\u00a0Yasuda\u00a0N,\u00a0Koya\u00a0M,\u00a0Ohno\u00a0Y,\u00a0Uchino\u00a0H\u00a0 et\u00a0al.\u00a0Selective\u00a0IgA\u00a0deficiency\u00a0in\u00a0Japanese\u00a0blood\u00a0\ndonors:\u00a0frequency\u00a0and\u00a0statistical\u00a0analysis.\u00a0 Vox\u00a0Sang\u00a01986;\u00a050:\u00a081\u201386.\u00a0\n332\u00a0\u00a0 Wang\u00a0N,\u00a0Hammarstrom\u00a0L.\u00a0Ig A\u00a0deficiency:\u00a0what\u00a0is\u00a0new?\u00a0 Curr\u00a0Opin\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02012;\u00a012:\u00a0602\u2013608.\u00a0\n333\u00a0\u00a0 Pereira\u00a0LF,\u00a0Sapina\u00a0AM,\u00a0Arroyo\u00a0J,\u00a0Vinuelas\u00a0J,\u00a0Bardaji\u00a0RM,\u00a0P rieto\u00a0L.\u00a0Prevalence\u00a0of\u00a0selective\u00a0IgA\u00a0deficiency\u00a0in\u00a0\nSpain:\u00a0more\u00a0than\u00a0we\u00a0thought.\u00a0Blood.\u00a01997;\u00a0 90:\u00a0893.\u00a0\n334\u00a0\u00a0 Brandtzaeg\u00a0P,\u00a0Guy\u2010Grand\u00a0D,\u00a0G riscelli\u00a0C.\u00a0Intestinal\u00a0salivar y,\u00a0and\u00a0tonsillar\u00a0IgA\u00a0and\u00a0J\u2010chain\u00a0production\u00a0in\u00a0a\u00a0patient\u00a0\nwith\u00a0severe\u00a0deficiency\u00a0of\u00a0serum\u00a0IgA.\u00a0 Scand\u00a0J\u00a0Immunol \u00a01981;\u00a013:\u00a0313\u2013325.\u00a0\n335\u00a0\u00a0 Klemola\u00a0T.\u00a0Immunohistochem ical\u00a0findings\u00a0in\u00a0the\u00a0intestine\u00a0o f\u00a0IgA\u2010deficient\u00a0persons:\u00a0number\u00a0of\u00a0intraepithelial\u00a0\nT\u00a0lymphocytes\u00a0is\u00a0increased.\u00a0 J\u00a0Pediatr\u00a0Gastroenterol\u00a0Nutr \u00a01988;\u00a07:\u00a0537\u2013543.\u00a0\n336\u00a0\u00a0 Nilssen\u00a0DE,\u00a0Friman\u00a0V,\u00a0Theman\u00a0K,\u00a0Bjorkander\u00a0J,\u00a0Kilander\u00a0A,\u00a0 Holmgren\u00a0J\u00a0 et\u00a0al.\u00a0B\u2010cell\u00a0activation\u00a0in\u00a0duodenal\u00a0\nmucosa\u00a0after\u00a0oral\u00a0cholera\u00a0vaccination\u00a0in\u00a0IgA\u00a0deficient\u00a0subjects \u00a0with\u00a0or\u00a0without\u00a0IgG\u00a0subclass\u00a0deficiency.\u00a0 Scand\u00a0\nJ\u00a0Immunol \u00a01993;\u00a038:\u00a0201\u2013208.\u00a0\n337\u00a0\u00a0 Nilssen\u00a0 DE,\u00a0 Brandtzaeg\u00a0 P,\u00a0 Froland\u00a0 SS,\u00a0 Fausa\u00a0 O.\u00a0 Subclass\u00a0 co mposition\u00a0 and\u00a0 J\u2010chain\u00a0 expression\u00a0 of\u00a0 the\u00a0\n\u2018compensatory\u2019\u00a0gastrointestinal\u00a0 IgG\u00a0cell\u00a0population\u00a0in\u00a0selectiv e\u00a0IgA\u00a0deficiency.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a01992;\u00a087:\u00a0\n237\u2013245.\u00a0\n338\u00a0\u00a0 Brandtzaeg\u00a0P,\u00a0Karlsson\u00a0G,\u00a0Han sson\u00a0G,\u00a0Petruson\u00a0B,\u00a0Bjorkande r\u00a0J,\u00a0Hanson\u00a0LA.\u00a0Immunohistochemical\u00a0study\u00a0of\u00a0\nnasal\u00a0mucosa\u00a0in\u00a0patients\u00a0wit h\u00a0selective\u00a0IgA\u00a0deficiency.\u00a0 Int\u00a0Arch\u00a0Allergy\u00a0Appl\u00a0Immunol \u00a01987;\u00a082:\u00a0483\u2013484.\u00a0\n339\u00a0\u00a0 Brandtzaeg\u00a0P,\u00a0Karlsson\u00a0G,\u00a0Hansson\u00a0G,\u00a0Petruson\u00a0B,\u00a0Bjorkande r\u00a0J,\u00a0Hanson\u00a0LA.\u00a0The\u00a0clinical\u00a0condition\u00a0of\u00a0IgA\u2010\ndeficient\u00a0patients\u00a0is\u00a0related\u00a0to\u00a0the\u00a0proportion\u00a0of\u00a0\u00a0IgD\u2010\u00a0and\u00a0Ig M\u2010producing\u00a0cells\u00a0in\u00a0their\u00a0nasal\u00a0mucosa.\u00a0 Clin\u00a0Exp\u00a0\nImmunol\u00a01987;\u00a067:\u00a0626\u2013636.\u00a0\n340\u00a0\u00a0 Norhagen\u00a0G,\u00a0Engstrom\u00a0PE,\u00a0Hamm arstrom\u00a0L,\u00a0Soder\u00a0PO,\u00a0Smith\u00a0CI .\u00a0Immunoglobulin\u00a0levels\u00a0in\u00a0saliva\u00a0in\u00a0individuals\u00a0\nwith\u00a0selective\u00a0IgA\u00a0deficiency:\u00a0c ompensatory\u00a0IgM\u00a0secretion\u00a0and\u00a0i ts\u00a0correlation\u00a0with\u00a0HLA\u00a0and\u00a0susceptibility\u00a0to\u00a0\ninfections.\u00a0 J\u00a0Clin\u00a0Immunol \u00a01989;\u00a09:\u00a0279\u2013286.\u00a0\n341\u00a0\u00a0 Barros\u00a0MD,\u00a0Porto\u00a0MH,\u00a0Leser\u00a0PG,\u00a0Grumach\u00a0AS,\u00a0Carneiro\u2010Sampai o\u00a0MM.\u00a0Study\u00a0of\u00a0colostrum\u00a0of\u00a0a\u00a0patient\u00a0with\u00a0\nselective\u00a0IgA\u00a0deficiency.\u00a0 Allergol\u00a0Immunopathol\u00a0(Madr) \u00a01985;\u00a013:\u00a0331\u2013334.\u00a0\n342\u00a0\u00a0 Latiff\u00a0AHA,\u00a0Kerr\u00a0MA.\u00a0The\u00a0c linical\u00a0significance\u00a0of\u00a0immunogl obulin\u00a0A\u00a0deficiency.\u00a0 Ann\u00a0Clin\u00a0Biochem \u00a02007;\u00a044:\u00a0\n131\u2013139.\u00a0\n343\u00a0\u00a0 Edwards\u00a0E,\u00a0Razvi\u00a0S,\u00a0Cunningha m\u2010Rundles\u00a0C.\u00a0IgA\u00a0deficiency:\u00a0 clinical\u00a0correlates\u00a0and\u00a0responses\u00a0to\u00a0pneumococcal\u00a0\nvaccine.\u00a0Clin\u00a0Immunol \u00a02004;\u00a0111:\u00a093\u201397.\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0245\u00a0\u2010\u00a0\n\u00a0344\u00a0\u00a0 Aytekin\u00a0C,\u00a0Tuygun\u00a0N,\u00a0Gokce\u00a0S,\u00a0Dogu\u00a0F,\u00a0Ikinciogullari\u00a0A.\u00a0Se lective\u00a0IgA\u00a0deficiency:\u00a0clinical\u00a0and\u00a0laboratory\u00a0\nfeatures\u00a0of\u00a0118\u00a0children\u00a0in\u00a0Turkey.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02012;\u00a032:\u00a0961\u2013966.\u00a0\n345\u00a0\u00a0 Shkalim\u00a0V,\u00a0Monselize\u00a0Y,\u00a0Segal\u00a0N,\u00a0Zan\u2010Bar\u00a0I,\u00a0Hoffer\u00a0V,\u00a0Gart y\u00a0BZ.\u00a0Selective\u00a0IgA\u00a0deficiency\u00a0in\u00a0children\u00a0in\u00a0Israel.\u00a0 J\u00a0\nClin\u00a0Immunol \u00a02010;\u00a030:\u00a0761\u2013765.\u00a0\n346\u00a0\u00a0 Dominguez\u00a0O,\u00a0Giner\u00a0MT,\u00a0Alsina \u00a0L,\u00a0Martin\u00a0MA,\u00a0Lozano\u00a0J,\u00a0Plaz a\u00a0AM.\u00a0[Clinical\u00a0phenotypes\u00a0associated\u00a0with\u00a0\nselective\u00a0IgA\u00a0deficiency:\u00a0a\u00a0review\u00a0of\u00a0330\u00a0cases\u00a0and\u00a0a\u00a0proposed\u00a0 follow\u2010up\u00a0protocol].\u00a0 An\u00a0Pediatr\u00a0(Barc) \u00a02012;\u00a0\n76:\u00a0261\u2013267.\u00a0\n347\u00a0\u00a0 Gomez\u2010Carrasco\u00a0JA,\u00a0Barrera\u2010Gomez\u00a0MJ,\u00a0Garcia\u2010Mourino\u00a0V,\u00a0Alv arez\u00a0de\u00a0Mon\u00a0M,\u00a0Garcia\u00a0de\u00a0Frias\u00a0E.\u00a0Selective\u00a0\nand\u00a0partial\u00a0IgA\u00a0deficiency\u00a0in\u00a0an \u00a0adolescent\u00a0male\u00a0with\u00a0bronchiec tasis.\u00a0Allergol\u00a0Immunopathol\u00a0(Madr) \u00a01994;\u00a0\n22:\u00a0261\u2013263.\u00a0\n348\u00a0\u00a0 Chipps\u00a0BE,\u00a0Talamo\u00a0RC,\u00a0Winkel stein\u00a0JA.\u00a0IgA\u00a0deficiency,\u00a0recu rrent\u00a0pneumonias,\u00a0and\u00a0bronchiectasis.\u00a0 Chest\u00a01978;\u00a0\n73:\u00a0519\u2013526.\u00a0\n349\u00a0\u00a0 Yel\u00a0L.\u00a0Selective\u00a0IgA\u00a0deficiency.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02010;\u00a030:\u00a010\u201316.\u00a0\n350\u00a0\u00a0 Zinneman\u00a0HH,\u00a0Kaplan\u00a0AP.\u00a0The\u00a0 association\u00a0of\u00a0giardiasis\u00a0with \u00a0reduced\u00a0intestinal\u00a0secretory\u00a0immunoglobulin\u00a0A.\u00a0\nAm\u00a0J\u00a0Dig\u00a0Dis \u00a01972;\u00a017:\u00a0793\u2013797.\u00a0\n351\u00a0\u00a0 Ludvigsson\u00a0JF,\u00a0Neovius\u00a0M,\u00a0Hammarstrom\u00a0L.\u00a0Risk\u00a0of\u00a0Infection s\u00a0Among\u00a02100\u00a0Individuals\u00a0with\u00a0IgA\u00a0Deficiency:\u00a0a\u00a0\nNationwide\u00a0Cohort\u00a0Study.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02016;\u00a036:\u00a0134\u2013140.\u00a0\n352\u00a0\u00a0 Aghamohammadi\u00a0A,\u00a0Cheraghi\u00a0T,\u00a0Gharagozlou\u00a0M,\u00a0Movahedi\u00a0M,\u00a0Re zaei\u00a0N,\u00a0Yeganeh\u00a0M\u00a0 et\u00a0al.\u00a0IgA\u00a0deficiency:\u00a0\ncorrelation\u00a0between\u00a0clinical\u00a0a nd\u00a0immunological\u00a0phenotypes.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02009;\u00a029:\u00a0130\u2013136.\u00a0\n353\u00a0\u00a0 Ludvigsson\u00a0JF,\u00a0Neovius\u00a0M,\u00a0Hammarstrom\u00a0L.\u00a0Association\u00a0betwe en\u00a0IgA\u00a0deficiency\u00a0&\u00a0other\u00a0autoimmune\u00a0\nconditions:\u00a0a\u00a0population\u2010ba sed\u00a0matched\u00a0cohort\u00a0study.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02014;\u00a034:\u00a0444\u2013451.\u00a0\n354\u00a0\u00a0 Aghamohammadi\u00a0A,\u00a0Mohammadi\u00a0J ,\u00a0Parvaneh\u00a0N,\u00a0Rezaei\u00a0N,\u00a0Moin\u00a0M ,\u00a0Espanol\u00a0T\u00a0 et\u00a0al.\u00a0Progression\u00a0of\u00a0selective\u00a0\nIgA\u00a0deficiency\u00a0to\u00a0common\u00a0va riable\u00a0immunodeficiency.\u00a0 Int\u00a0Arch\u00a0Allergy\u00a0Immunol \u00a02008;\u00a0147:\u00a087\u201392.\u00a0\n355\u00a0\u00a0 Espanol\u00a0 T,\u00a0 Catala\u00a0 M,\u00a0 Hernande z\u00a0 M,\u00a0 Caragol\u00a0 I,\u00a0 Bertran\u00a0 JM.\u00a0 D evelopment\u00a0 of\u00a0 a\u00a0 common\u00a0 variable\u00a0\nimmunodeficiency\u00a0in\u00a0Ig A\u2010deficient\u00a0patients.\u00a0 Clin\u00a0Immunol\u00a0Immunopathol \u00a01996;\u00a080:\u00a0333\u2013335.\u00a0\n356\u00a0\u00a0 Litzman\u00a0J,\u00a0Stikarovska\u00a0D,\u00a0Pikulova\u00a0Z,\u00a0Pavlik\u00a0T,\u00a0Pesak\u00a0S,\u00a0T hon\u00a0V\u00a0et\u00a0al.\u00a0Change\u00a0in\u00a0referral\u00a0diagnoses\u00a0and\u00a0\ndiagnostic\u00a0delay\u00a0in\u00a0hypogammaglo bulinaemic\u00a0patients\u00a0during\u00a028\u00a0y ears\u00a0in\u00a0a\u00a0single\u00a0referral\u00a0centre.\u00a0 Int\u00a0Arch\u00a0\nAllergy\u00a0Immunol \u00a02010;\u00a0153:\u00a095\u2013101.\u00a0\n357\u00a0\u00a0 Vo\u00a0Ngoc\u00a0DTL,\u00a0Krist\u00a0L,\u00a0van\u00a0Overveld\u00a0FJ,\u00a0Rijkers\u00a0GT.\u00a0The\u00a0lon g\u00a0and\u00a0winding\u00a0road\u00a0to\u00a0IgA\u00a0deficiency:\u00a0causes\u00a0and\u00a0\nconsequences.\u00a0 Expert\u00a0Rev\u00a0Clin\u00a0Immunol \u00a02017;\u00a013:\u00a0371\u2013382.\u00a0\n358\u00a0\u00a0 Aghamohammadi\u00a0A,\u00a0Sedighipour\u00a0L,\u00a0Saeed\u00a0SE,\u00a0Kouhkan\u00a0A,\u00a0Heyda rzadeh\u00a0M,\u00a0Pourpak\u00a0Z.\u00a0Alterations\u00a0in\u00a0humoral\u00a0\nimmunity\u00a0in\u00a0relatives\u00a0of\u00a0patient s\u00a0with\u00a0common\u00a0variable\u00a0immunode ficiency.\u00a0J\u00a0Investig\u00a0Allergol\u00a0Clin\u00a0Immunol \u00a0\n2008;\u00a018:\u00a0266\u2013271.\u00a0\n359\u00a0\u00a0 Soler\u2010Palac\u00edn\u00a0P,\u00a0Cobos\u2010Carra scosa\u00a0E,\u00a0Mart\u00edn\u2010Nalda\u00a0A,\u00a0Carac seghi\u00a0F,\u00a0Hern\u00e1ndez\u00a0M,\u00a0Figueras\u2010Nadal\u00a0C.\u00a0Is\u00a0familial\u00a0\nscreening\u00a0useful\u00a0in\u00a0selective\u00a0immunoglobulin\u00a0A\u00a0deficiency?\u00a0 An\u00a0Pediatr\u00a0(Barc) \u00a02016;\u00a084:\u00a070\u20138.\u00a0\n360\u00a0\u00a0 Koistinen\u00a0J.\u00a0Familial\u00a0cluste ring\u00a0of\u00a0selective\u00a0IgA\u00a0deficien cy.\u00a0Vox\u00a0Sang\u00a01976;\u00a030:\u00a0181\u2013190.\u00a0\n361\u00a0\u00a0 Oen\u00a0K,\u00a0Petty\u00a0RE,\u00a0Schroeder\u00a0ML.\u00a0Immunoglobulin\u00a0A\u00a0deficiency :\u00a0genetic\u00a0studies.\u00a0 Tissue\u00a0Antigens \u00a01982;\u00a019:\u00a0174\u2013\n182.\u00a0\n362\u00a0\u00a0 Kralovicova\u00a0J,\u00a0Hammarstrom\u00a0L ,\u00a0Plebani\u00a0A,\u00a0Webster\u00a0ADB,\u00a0Vore chovsky\u00a0I.\u00a0Fine\u2010scale\u00a0mapping\u00a0at\u00a0IGAD1\u00a0and\u00a0\ngenome\u2010wide\u00a0genetic\u00a0linkage\u00a0analysis\u00a0implicate\u00a0HLA\u2010DQ/DR\u00a0as\u00a0a\u00a0m ajor\u00a0susceptibility\u00a0locus\u00a0in\u00a0selective\u00a0IgA\u00a0\ndeficiency\u00a0and\u00a0common\u00a0variable\u00a0immunodeficiency.\u00a0 J\u00a0Immunol \u00a02003;\u00a0170:\u00a02765\u20132775.\u00a0\n363\u00a0\u00a0 De\u00a0la\u00a0Concha\u00a0EG,\u00a0Fernandez\u2010 Arquero\u00a0M,\u00a0Gual\u00a0L,\u00a0Vigil\u00a0P,\u00a0Mar tinez\u00a0A,\u00a0Urcelay\u00a0E\u00a0 et\u00a0al.\u00a0MHC\u00a0susceptibility\u00a0genes\u00a0\nto\u00a0IgA\u00a0deficiency\u00a0are\u00a0located\u00a0in\u00a0different\u00a0regions\u00a0on\u00a0different \u00a0HLA\u00a0haplotypes.\u00a0 J\u00a0Immunol \u00a02002;\u00a0169:\u00a04637\u2013\n4643.\u00a0\n364\u00a0\u00a0 Gual\u00a0 L,\u00a0 Martinez\u00a0 A,\u00a0 Fernande z\u2010Arquero\u00a0 M,\u00a0 Garcia\u2010Rodriguez\u00a0 MC,\u00a0 Ferreira\u00a0 A,\u00a0 Fontan\u00a0 G\u00a0 et\u00a0 al.\u00a0M a j o r \u00a0\nhistocompatibility\u00a0complex\u00a0haplo types\u00a0in\u00a0Spanish\u00a0immunoglobulin \u00a0A\u00a0deficiency\u00a0patients:\u00a0a\u00a0comparative\u00a0fine\u00a0\nmapping\u00a0microsatellite\u00a0study.\u00a0 Tissue\u00a0Antigens \u00a02004;\u00a064:\u00a0671\u2013677.\u00a0\n365\u00a0\u00a0 Ferreira\u00a0RC,\u00a0Pan\u2010Hammarstrom\u00a0Q,\u00a0Graham\u00a0RR,\u00a0Fontan\u00a0G,\u00a0Lee\u00a0A T,\u00a0Ortmann\u00a0W\u00a0 et\u00a0al.\u00a0High\u2010density\u00a0SNP\u00a0mapping\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0246\u00a0\u2010\u00a0\n\u00a0of\u00a0the\u00a0HLA\u00a0region\u00a0iden tifies\u00a0multiple\u00a0inde pendent\u00a0susceptibilit y\u00a0loci\u00a0associated\u00a0with\u00a0selective\u00a0IgA\u00a0deficiency.\u00a0\nPLoS\u00a0Genet \u00a02012;\u00a08:\u00a0e1002476.\u00a0\n366\u00a0\u00a0 Wang\u00a0N,\u00a0Shen\u00a0N,\u00a0Vyse\u00a0TJ,\u00a0Anand\u00a0V,\u00a0Gunnarson\u00a0I,\u00a0Sturfelt\u00a0G\u00a0 et\u00a0al.\u00a0Selective\u00a0IgA\u00a0deficiency\u00a0in\u00a0autoimmune\u00a0\ndiseases.\u00a0 Mol\u00a0Med\u00a02011;\u00a017:\u00a01383\u20131396.\u00a0\n367\u00a0\u00a0 Bronson\u00a0PG,\u00a0Chang\u00a0D,\u00a0Bhangale\u00a0T,\u00a0Seldin\u00a0MF,\u00a0Ortmann\u00a0W,\u00a0Fer reira\u00a0RC\u00a0et\u00a0al.\u00a0Common\u00a0variants\u00a0at\u00a0PVT1,\u00a0\nATG13\u2010AMBRA1,\u00a0AHI1\u00a0and\u00a0CLEC16A\u00a0are\u00a0associated\u00a0with\u00a0selective\u00a0Ig A\u00a0deficiency.\u00a0 Nat\u00a0Genet \u00a02016;\u00a048:\u00a01425\u2013\n1429.\u00a0\n368\u00a0\u00a0 Ferreira\u00a0RC,\u00a0Pan\u2010Hammarstrom \u00a0Q,\u00a0Graham\u00a0RR,\u00a0Gateva\u00a0V,\u00a0Fonta n\u00a0G,\u00a0Lee\u00a0AT\u00a0 et\u00a0al.\u00a0Association\u00a0of\u00a0IFIH1\u00a0and\u00a0\nother\u00a0autoimmunity\u00a0risk\u00a0alleles\u00a0with\u00a0selective\u00a0IgA\u00a0deficiency.\u00a0 Nat\u00a0Genet \u00a02010;\u00a042:\u00a0777\u2013780.\u00a0\n369\u00a0\u00a0 Pulvirenti\u00a0F,\u00a0Zuntini\u00a0R,\u00a0Milito\u00a0C,\u00a0Specchia\u00a0F,\u00a0Spadaro\u00a0G,\u00a0 Danieli\u00a0MG\u00a0 et\u00a0al.\u00a0Clinical\u00a0Associations\u00a0of\u00a0Biallelic\u00a0and\u00a0\nMonoallelic\u00a0TNFRSF13B\u00a0Variants\u00a0in\u00a0Italian\u00a0Primary\u00a0Antibody\u00a0Defi ciency\u00a0Syndromes.\u00a0 J\u00a0Immunol\u00a0Res \u00a02016;\u00a0\n2016:\u00a08390356.\u00a0\n370\u00a0\u00a0 Castigli\u00a0E,\u00a0Wilson\u00a0SA,\u00a0Garib yan\u00a0L,\u00a0Rachid\u00a0R,\u00a0Bonilla\u00a0F,\u00a0Sc hneider\u00a0L\u00a0 et\u00a0al.\u00a0TACI\u00a0is\u00a0mutant\u00a0in\u00a0common\u00a0variable\u00a0\nimmunodeficiency\u00a0and\u00a0IgA\u00a0deficiency.\u00a0 Nat\u00a0Genet \u00a02005;\u00a037:\u00a0829\u2013834.\u00a0\n371\u00a0\u00a0 Abolhassani\u00a0H,\u00a0Aghamohammadi\u00a0A,\u00a0Hammarstrom\u00a0L.\u00a0Monogenic\u00a0m utations\u00a0associated\u00a0with\u00a0IgA\u00a0deficiency.\u00a0\nExpert\u00a0Rev\u00a0Clin\u00a0Immunol \u00a02016;\u00a012:\u00a01321\u20131335.\u00a0\n372\u00a0\u00a0 Castigli\u00a0E,\u00a0Wilson\u00a0S,\u00a0Garib yan\u00a0L,\u00a0Rachid\u00a0R,\u00a0Bonilla\u00a0F,\u00a0Sch neider\u00a0L\u00a0et\u00a0al.\u00a0Reexamining\u00a0the\u00a0role\u00a0of\u00a0TACI\u00a0coding\u00a0\nvariants\u00a0in\u00a0common\u00a0variable\u00a0imm unodeficiency\u00a0and\u00a0selective\u00a0IgA\u00a0 deficiency.\u00a0 Nat\u00a0Genet \u00a02007;\u00a039:\u00a0430\u20131.\u00a0\n373\u00a0\u00a0 Kato\u00a0T,\u00a0Crestani\u00a0E,\u00a0Kamae\u00a0C,\u00a0Honma\u00a0K,\u00a0Yokosuka\u00a0T,\u00a0Ikegawa\u00a0 T\u00a0et\u00a0al.\u00a0RAG1\u00a0deficiency\u00a0may\u00a0present\u00a0clinically\u00a0as\u00a0\nselective\u00a0IgA\u00a0deficiency.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02015;\u00a035:\u00a0280\u2013288.\u00a0\n374\u00a0\u00a0 Azizi\u00a0G,\u00a0Abolhassani\u00a0H,\u00a0Habibi\u00a0S,\u00a0Rahamooz\u00a0T,\u00a0Mohammadi\u00a0H, \u00a0Jafarnezhad\u2010Ansariha\u00a0F\u00a0 et\u00a0al.\u00a0Two\u00a0Faces\u00a0of\u00a0\nLRBA\u00a0Deficiency\u00a0in\u00a0Siblings:\u00a0Hypogammaglobulinemia\u00a0and\u00a0Normal\u00a0I mmunoglobulin\u00a0Levels.\u00a0 J\u00a0Investig\u00a0Allergol\u00a0\nClin\u00a0Immunol \u00a02018;\u00a028:\u00a048\u201350.\u00a0\n375\u00a0\u00a0 Litzman\u00a0 J,\u00a0 Vlkova\u00a0 M,\u00a0 Pikulova\u00a0 Z,\u00a0 Stikarovska\u00a0 D,\u00a0 Lokaj\u00a0 J.\u00a0 T \u00a0 and\u00a0 B\u00a0 lymphocyte\u00a0 subpopulations\u00a0 and\u00a0\nactivation/differentiation\u00a0markers\u00a0in\u00a0patients\u00a0with\u00a0selective\u00a0I gA\u00a0deficiency.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a02007;\u00a0147:\u00a0249\u2013\n254.\u00a0\n376\u00a0\u00a0 Bukowska\u2010Strakova\u00a0K,\u00a0Kowalczyk\u00a0D,\u00a0Baran\u00a0J,\u00a0Siedlar\u00a0M,\u00a0Koby larz\u00a0K,\u00a0Zembala\u00a0M.\u00a0The\u00a0B\u2010cell\u00a0compartment\u00a0in\u00a0\nthe\u00a0peripheral\u00a0blood\u00a0of\u00a0children \u00a0with\u00a0different\u00a0types\u00a0of\u00a0primar y\u00a0humoral\u00a0immunodeficiency.\u00a0 Pediatr\u00a0Res \u00a0\n2009;\u00a066:\u00a028\u201334.\u00a0\n377\u00a0\u00a0 Cipe\u00a0FE,\u00a0Dogu\u00a0F,\u00a0Guloglu\u00a0D,\u00a0Aytekin\u00a0C,\u00a0Polat\u00a0M,\u00a0Biyikli\u00a0Z\u00a0 et\u00a0al.\u00a0B\u2010cell\u00a0subsets\u00a0in\u00a0patients\u00a0with\u00a0transient\u00a0\nhypogammaglobulinemia\u00a0of\u00a0infancy, \u00a0partial\u00a0IgA\u00a0deficiency,\u00a0and\u00a0s elective\u00a0IgM\u00a0deficiency.\u00a0 J\u00a0Investig\u00a0Allergol\u00a0\nClin\u00a0Immunol \u00a02013;\u00a023:\u00a094\u2013100.\u00a0\n378\u00a0\u00a0 Nechvatalova\u00a0J,\u00a0Pikulova\u00a0Z,\u00a0Stikarovska\u00a0D,\u00a0Pesak\u00a0S,\u00a0Vlkova \u00a0M,\u00a0Litzman\u00a0J.\u00a0B\u2010lymphocyte\u00a0subpopulations\u00a0in\u00a0\npatients\u00a0with\u00a0selective\u00a0IgA\u00a0deficiency.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02012;\u00a032:\u00a0441\u2013448.\u00a0\n379\u00a0\u00a0 Aghamohammadi\u00a0A,\u00a0Abolhassani\u00a0H,\u00a0Biglari\u00a0M,\u00a0Abolmaali\u00a0S,\u00a0Mo azzami\u00a0K,\u00a0Tabatabaeiyan\u00a0M\u00a0 et\u00a0al.\u00a0Analysis\u00a0of\u00a0\nswitched\u00a0memory\u00a0B\u00a0cells\u00a0in\u00a0patients\u00a0with\u00a0IgA\u00a0deficiency.\u00a0 Int\u00a0Arch\u00a0Allergy\u00a0Immunol \u00a02011;\u00a0156:\u00a0462\u2013468.\u00a0\n380\u00a0\u00a0 Marasco\u00a0E,\u00a0Farroni\u00a0C,\u00a0Cascio li\u00a0S,\u00a0Marcellini\u00a0 V,\u00a0Scarsella\u00a0 M,\u00a0Giorda\u00a0E\u00a0 et\u00a0al.\u00a0B\u2010cell\u00a0activation\u00a0with\u00a0CD40L\u00a0or\u00a0CpG\u00a0\nmeasures\u00a0the\u00a0function\u00a0of\u00a0B\u2010cell\u00a0subsets\u00a0and\u00a0identifies\u00a0specific \u00a0defects\u00a0in\u00a0immunodeficient\u00a0patients.\u00a0 Eur\u00a0J\u00a0\nImmunol\u00a02017;\u00a047:\u00a0131\u2013143.\u00a0\n381\u00a0\u00a0 Bateman\u00a0EAL,\u00a0Ayers\u00a0L,\u00a0Sadler\u00a0R,\u00a0Lucas\u00a0M,\u00a0Roberts\u00a0C,\u00a0Woods\u00a0 A\u00a0et\u00a0al.\u00a0T\u00a0cell\u00a0phenotypes\u00a0in\u00a0patients\u00a0with\u00a0\ncommon\u00a0variable\u00a0immunodeficiency \u00a0disorders:\u00a0associations\u00a0with\u00a0c linical\u00a0phenotypes\u00a0in\u00a0comparison\u00a0with\u00a0\nother\u00a0groups\u00a0with\u00a0recurrent\u00a0infections.\u00a0 Clin\u00a0Exp\u00a0Immunol \u00a02012;\u00a0170:\u00a0202\u2013211.\u00a0\n382\u00a0\u00a0 Soheili\u00a0H,\u00a0Abolhassani\u00a0H,\u00a0Arandi\u00a0N,\u00a0Khazaei\u00a0HA,\u00a0Shahinpour \u00a0S,\u00a0Hirbod\u2010Mobarakeh\u00a0A\u00a0 et\u00a0al.\u00a0Evaluation\u00a0of\u00a0\nnatural\u00a0regulatory\u00a0T\u00a0cells\u00a0in\u00a0subjects\u00a0with\u00a0selective\u00a0IgA\u00a0defic iency:\u00a0from\u00a0senior\u00a0idea\u00a0 to\u00a0novel\u00a0opportunities.\u00a0\nInt\u00a0Arch\u00a0Allergy\u00a0Immunol \u00a02013;\u00a0160:\u00a0208\u2013214.\u00a0\n383\u00a0\u00a0 Friman\u00a0 V,\u00a0 Hanson\u00a0 LA,\u00a0 Bridon\u00a0 JM,\u00a0 Tarkowski\u00a0 A,\u00a0 Banchereau\u00a0 J, \u00a0 Briere\u00a0 F.\u00a0 IL\u201010\u2010driven\u00a0 immunoglobulin\u00a0\nproduction\u00a0by\u00a0B\u00a0lymphocytes\u00a0from\u00a0IgA\u2010deficient\u00a0individuals\u00a0corr elates\u00a0to\u00a0infection\u00a0proneness.\u00a0 Clin\u00a0Exp\u00a0\nImmunol\u00a01996;\u00a0104:\u00a0432\u2013438.\u00a0\n384\u00a0\u00a0 Schur\u00a0PH,\u00a0Borel\u00a0H,\u00a0Gelfand\u00a0 EW,\u00a0Alper\u00a0CA,\u00a0Rosen\u00a0FS.\u00a0Selecti ve\u00a0gamma\u2010g\u00a0globulin\u00a0deficiencies\u00a0in\u00a0patients\u00a0with\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0247\u00a0\u2010\u00a0\n\u00a0recurrent\u00a0pyogenic\u00a0infections.\u00a0 N\u00a0Engl\u00a0J\u00a0Med \u00a01970;\u00a0283:\u00a0631\u2013634.\u00a0\n385\u00a0\u00a0 Buckley\u00a0RH.\u00a0Immunoglobulin\u00a0G\u00a0subclass\u00a0deficiency:\u00a0fact\u00a0or\u00a0 fancy?\u00a0Curr\u00a0Allergy\u00a0Asthma\u00a0Rep \u00a02002;\u00a02:\u00a0356\u2013360.\u00a0\n386\u00a0\u00a0 Wahn\u00a0V,\u00a0von\u00a0Bernuth\u00a0H.\u00a0IgG\u00a0s ubclass\u00a0deficiencies\u00a0in\u00a0childr en:\u00a0Facts\u00a0and\u00a0fiction.\u00a0 Pediatr\u00a0Allergy\u00a0Immunol \u00a02017;\u00a0\n28:\u00a0521\u2013524.\u00a0\n387\u00a0\u00a0 Plebani\u00a0A,\u00a0Monafo\u00a0V,\u00a0Avanzini \u00a0MA,\u00a0Ugazio\u00a0AG,\u00a0Burgio\u00a0GR.\u00a0Re lationship\u00a0between\u00a0IgA\u00a0and\u00a0IgG\u00a0subclass\u00a0\ndeficiencies:\u00a0a\u00a0reappraisal.\u00a0 Monogr\u00a0Allergy \u00a01986;\u00a020:\u00a0171\u2013178.\u00a0\n388\u00a0\u00a0 Ballow\u00a0M.\u00a0Primary\u00a0immunodeficiency\u00a0disorders:\u00a0antibody\u00a0def iciency.\u00a0J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02002;\u00a0109:\u00a0581\u2013\n591.\u00a0\n389\u00a0\u00a0 Hammarstrom\u00a0L,\u00a0Smith\u00a0CI.\u00a0Ig G\u00a0subclasses\u00a0in\u00a0bacterial\u00a0infec tions.\u00a0Monogr\u00a0Allergy \u00a01986;\u00a019:\u00a0122\u2013133.\u00a0\n390\u00a0\u00a0 Bass\u00a0JL,\u00a0Nuss\u00a0R,\u00a0Mehta\u00a0KA,\u00a0Morganelli\u00a0P,\u00a0Bennett\u00a0L.\u00a0Recurr ent\u00a0meningococcemia\u00a0associated\u00a0with\u00a0IgG2\u2010\nsubclass\u00a0deficiency.\u00a0N.\u00a0Engl.\u00a0J.\u00a0Med.\u00a01983;\u00a0 309:\u00a0430.\u00a0\n391\u00a0\u00a0 Hanson\u00a0LA,\u00a0S\u00f6derstr\u00f6m\u00a0R,\u00a0Nilssen\u00a0DE,\u00a0Theman\u00a0K,\u00a0Bj\u00f6rkander\u00a0 J,\u00a0S\u00f6derstr\u00f6m\u00a0T\u00a0 et\u00a0al.\u00a0IgG\u00a0subclass\u00a0deficiency\u00a0\nwith\u00a0or\u00a0without\u00a0IgA\u00a0deficiency.\u00a0 Clin\u00a0Immunol\u00a0Immunopathol \u00a01991;\u00a061:\u00a0S70\u20107.\u00a0\n392\u00a0\u00a0 Aucouturier\u00a0P,\u00a0Lacombe\u00a0C,\u00a0Bre mard\u00a0C,\u00a0Lebranchu\u00a0Y,\u00a0Seligman n\u00a0M,\u00a0Griscelli\u00a0C\u00a0 et\u00a0al.\u00a0Serum\u00a0IgG\u00a0subclass\u00a0levels\u00a0\nin\u00a0patients\u00a0with\u00a0primary\u00a0immunodeficiency\u00a0syndromes\u00a0or\u00a0\u00a0abnorma l\u00a0susceptibility\u00a0to\u00a0infections.\u00a0 Clin\u00a0Immunol\u00a0\nImmunopathol \u00a01989;\u00a051:\u00a022\u201337.\u00a0\n393\u00a0\u00a0 Morgan\u00a0G,\u00a0Levinsky\u00a0RJ.\u00a0Clin ical\u00a0significance\u00a0of\u00a0IgG\u00a0subcla ss\u00a0deficiency.\u00a0 Arch\u00a0Dis\u00a0Child \u00a01988;\u00a063:\u00a0771\u2013773.\u00a0\n394\u00a0\u00a0 Sarmiento\u00a0E,\u00a0Mora\u00a0R,\u00a0Rodrigue z\u2010Mahou\u00a0M,\u00a0Rodriguez\u2010Molina\u00a0J ,\u00a0Fernandez\u2010Cruz\u00a0E,\u00a0Carbone\u00a0J.\u00a0[Autoimmune\u00a0\ndisease\u00a0in\u00a0primary\u00a0antibody\u00a0deficiencies].\u00a0 Allergol\u00a0Immunopathol\u00a0(Madr) \u00a02005;\u00a033:\u00a069\u201373.\u00a0\n395\u00a0\u00a0 Barton\u00a0 JC,\u00a0 Bertoli\u00a0 LF,\u00a0 Barton\u00a0 JC.\u00a0 Comparisons\u00a0 of\u00a0 CVID\u00a0 and\u00a0 IgGSD:\u00a0 referring\u00a0 physicians,\u00a0 autoimmune\u00a0\nconditions,\u00a0pneumovax\u00a0reactivity, \u00a0immunoglobulin\u00a0levels,\u00a0blood\u00a0 lymphocyte\u00a0subsets,\u00a0and\u00a0HLA\u2010A\u00a0and\u00a0\u2010B\u00a0\ntyping\u00a0in\u00a0432\u00a0adult\u00a0index\u00a0patients.\u00a0 J\u00a0Immunol\u00a0Res \u00a02014;\u00a02014:\u00a0542706.\u00a0\n396\u00a0\u00a0 Depiero\u00a0A,\u00a0Kaminski\u00a0DA,\u00a0Halsey\u00a0JF,\u00a0Briles\u00a0D,\u00a0Burrows\u00a0PD,\u00a0H ostoffer\u00a0RW.\u00a0Immunologic\u00a0compensation\u00a0in\u00a0a\u00a0\npatient\u00a0with\u00a0a\u00a0large\u00a0IgH\u00a0c onstant\u00a0region\u00a0deletion.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02001;\u00a0107:\u00a01051\u20131055.\u00a0\n397\u00a0\u00a0 Pan\u00a0Q,\u00a0Hammarstrom\u00a0L.\u00a0Molecu lar\u00a0basis\u00a0of\u00a0IgG\u00a0subclass\u00a0defi ciency.\u00a0Immunol\u00a0Rev \u00a02000;\u00a0178:\u00a099\u2013110.\u00a0\n398\u00a0\u00a0 Stavnezer\u2010Nordgren\u00a0J,\u00a0Kekish\u00a0 O,\u00a0Zegers\u00a0BJ.\u00a0Molecular\u00a0defec ts\u00a0in\u00a0a\u00a0human\u00a0immunoglobulin\u00a0kappa\u00a0chain\u00a0\ndeficiency.\u00a0 Science\u00a01985;\u00a0230:\u00a0458\u2013461.\u00a0\n399\u00a0\u00a0 Bernier\u00a0GM,\u00a0Gunderman\u00a0JR,\u00a0R uymann\u00a0FB.\u00a0Kappa\u2010chain\u00a0deficien cy.\u00a0Blood\u00a01972;\u00a040:\u00a0795\u2013805.\u00a0\n400\u00a0\u00a0 Zegers\u00a0BJ,\u00a0Maertzdorf\u00a0WJ,\u00a0Van \u00a0Loghem\u00a0E,\u00a0Mul\u00a0NA,\u00a0Stoop\u00a0JW,\u00a0 Van\u00a0Der\u00a0Laag\u00a0J\u00a0 et\u00a0al.\u00a0Kappa\u2010chain\u00a0deficiency.\u00a0An\u00a0\nimmunoglobulin\u00a0disorder.\u00a0 N\u00a0Engl\u00a0J\u00a0Med \u00a01976;\u00a0294:\u00a01026\u20131030.\u00a0\n401\u00a0\u00a0 Wall\u00a0LA,\u00a0Dimitriades\u00a0VR,\u00a0Sore nsen\u00a0RU.\u00a0Specific\u00a0Antibody\u00a0De ficiencies.\u00a0 Immunol\u00a0Allergy\u00a0Clin\u00a0North\u00a0Am \u00a02015;\u00a0\n35:\u00a0659\u2013670.\u00a0\n402\u00a0\u00a0 Stiehm\u00a0ER.\u00a0The\u00a0four\u00a0most\u00a0co mmon\u00a0pediatric\u00a0immunodeficienci es.\u00a0J\u00a0Immunotoxicol \u00a02008;\u00a05:\u00a0227\u2013234.\u00a0\n403\u00a0\u00a0 Tiller\u00a0TLJ,\u00a0Buckley\u00a0RH.\u00a0Trans ient\u00a0hypogammaglobulinemia\u00a0of \u00a0infancy:\u00a0review\u00a0of\u00a0the\u00a0literature,\u00a0clinical\u00a0and\u00a0\nimmunologic\u00a0features\u00a0of\u00a011\u00a0new\u00a0 cases,\u00a0and\u00a0long\u2010term\u00a0follow\u2010up.\u00a0 J\u00a0Pediatr\u00a01978;\u00a092:\u00a0347\u2013353.\u00a0\n404\u00a0\u00a0 Chovancova\u00a0Z,\u00a0Kralickova\u00a0P,\u00a0Pejchalova\u00a0A,\u00a0Bloomfield\u00a0M,\u00a0Ne chvatalova\u00a0J,\u00a0Vlkova\u00a0M\u00a0 et\u00a0al.\u00a0Selective\u00a0IgM\u00a0\nDeficiency:\u00a0Clinical\u00a0and\u00a0Laborato ry\u00a0Features\u00a0of\u00a017\u00a0Patients\u00a0and \u00a0a\u00a0Review\u00a0of\u00a0the\u00a0Literature.\u00a0 J\u00a0Clin\u00a0Immunol \u00a0\n2017;\u00a037:\u00a0559\u2013574.\u00a0\n405\u00a0\u00a0 Goldstein\u00a0 MF,\u00a0 Goldstein\u00a0 AL, \u00a0 Dunsky\u00a0 EH,\u00a0 Dvorin\u00a0 DJ,\u00a0 Belecane c h \u00a0G A , \u00a0S h a m i r \u00a0K . \u00a0S e l e c t i v e \u00a0I g M \u00a0\nimmunodeficiency:\u00a0retrospective\u00a0 analysis\u00a0of\u00a036\u00a0adult\u00a0patients\u00a0w ith\u00a0\u00a0review\u00a0of\u00a0the\u00a0literature.\u00a0 Ann\u00a0Allergy\u00a0\nAsthma\u00a0Immunol \u00a02006;\u00a097:\u00a0717\u2013730.\u00a0\n406\u00a0\u00a0 Freeman\u00a0J\u00a0a,\u00a0Crassini\u00a0KR,\u00a0Best\u00a0OG,\u00a0Forsyth\u00a0CJ,\u00a0Mackinlay\u00a0N J,\u00a0Han\u00a0P\u00a0et\u00a0al.\u00a0Immunoglobulin\u00a0G\u00a0subclass\u00a0deficiency\u00a0\nand\u00a0infection\u00a0risk\u00a0in\u00a0150\u00a0patients \u00a0with\u00a0chronic\u00a0lymphocytic\u00a0leu kemia.\u00a0Leuk\u00a0Lymphoma \u00a02013;\u00a054:\u00a099\u2013104.\u00a0\n407\u00a0\u00a0 Zhang\u00a0H,\u00a0Li\u00a0P,\u00a0Wu\u00a0D,\u00a0Xu\u00a0D,\u00a0Hou\u00a0Y,\u00a0Wang\u00a0Q\u00a0 et\u00a0al.\u00a0Serum\u00a0IgG\u00a0subclasses\u00a0in\u00a0autoimmune\u00a0diseases.\u00a0 Medicine\u00a0\n(Baltimore) \u00a02015;\u00a094:\u00a0e387.\u00a0\n408\u00a0\u00a0 Manz\u00a0RA,\u00a0Radbruch\u00a0A.\u00a0Plasma\u00a0 cells\u00a0for\u00a0a\u00a0lifetime?\u00a0Eur.\u00a0J.\u00a0 Immunol.\u00a02002;\u00a0 32:\u00a0923\u2013927.\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0248\u00a0\u2010\u00a0\n\u00a0409\u00a0\u00a0 Tarlinton\u00a0D,\u00a0Radbruch\u00a0A,\u00a0Hiepe\u00a0F,\u00a0Dorner\u00a0T.\u00a0Plasma\u00a0cell\u00a0di fferentiation\u00a0and\u00a0survival.\u00a0 Curr\u00a0Opin\u00a0Immunol \u00a02008;\u00a0\n20:\u00a0162\u2013169.\u00a0\n410\u00a0\u00a0 Vlkova\u00a0M,\u00a0Fro\u0148kova\u00a0E,\u00a0Kanderova\u00a0V,\u00a0Janda\u00a0A,\u00a0Ruzickova\u00a0S,\u00a0L itzman\u00a0J\u00a0et\u00a0al.\u00a0Characterization\u00a0of\u00a0lymphocyte\u00a0\nsubsets\u00a0in\u00a0patients\u00a0with\u00a0common\u00a0 variable\u00a0immunodeficiency\u00a0(CVID )\u00a0reveals\u00a0novel\u00a0subsets\u00a0of\u00a0human\u00a0na\u00efve\u00a0B\u2010\ncells\u00a0marked\u00a0by\u00a0CD24\u00a0expression.\u00a0 J\u00a0Immunol \u00a02010;\u00a0in\u00a0press.\u00a0doi:10.4049/jimmunol.0903876.\u00a0\n411\u00a0\u00a0 Mestecky\u00a0J,\u00a0Hamilton\u00a0RG,\u00a0Magnusson\u00a0CGM,\u00a0Jefferis\u00a0R,\u00a0Vaerma n\u00a0JP,\u00a0Goodall\u00a0M\u00a0 et\u00a0al.\u00a0Evaluation\u00a0of\u00a0monoclonal\u00a0\nantibodies\u00a0with\u00a0specificity\u00a0for\u00a0human\u00a0IgA,\u00a0IgA\u00a0subclasses\u00a0and\u00a0a llotypes\u00a0and\u00a0secretory\u00a0component.\u00a0Results\u00a0of\u00a0\nan\u00a0IUIS/WHO\u00a0collaborative\u00a0study.\u00a0 J\u00a0Immunol\u00a0Methods \u00a01996;\u00a0193:\u00a0103\u2013148.\u00a0\n412\u00a0\u00a0 Jefferis\u00a0R,\u00a0Reimer\u00a0CB,\u00a0Skvar il\u00a0F,\u00a0de\u00a0Lange\u00a0G,\u00a0Ling\u00a0NR,\u00a0Low e\u00a0J\u00a0et\u00a0al.\u00a0Evaluation\u00a0of\u00a0monoclonal\u00a0antibodies\u00a0having\u00a0\nspecificity\u00a0for\u00a0human\u00a0IgG\u00a0sub\u2010classes:\u00a0results\u00a0of\u00a0an\u00a0IUIS/WHO\u00a0c ollaborative\u00a0study.\u00a0 Immunol\u00a0Lett \u00a01985;\u00a010:\u00a0\n223\u201352.\u00a0\n413\u00a0\u00a0 Jefferis\u00a0R,\u00a0Reimer\u00a0CB,\u00a0Skvaril\u00a0F,\u00a0de\u00a0Lange\u00a0GG,\u00a0Goodall\u00a0DM, \u00a0Bentley\u00a0TL\u00a0 et\u00a0al.\u00a0Evaluation\u00a0of\u00a0monoclonal\u00a0\nantibodies\u00a0having\u00a0specificity\u00a0for\u00a0human\u00a0IgG\u00a0subclasses:\u00a0results \u00a0of\u00a0the\u00a02nd\u00a0IUIS/WHO\u00a0collaborative\u00a0study.\u00a0\nImmunol\u00a0Lett \u00a01992;\u00a031:\u00a0143\u201368.\u00a0\n414\u00a0\u00a0 Avery\u00a0DT,\u00a0Bryant\u00a0VL,\u00a0Ma\u00a0CS,\u00a0de\u00a0Waal\u00a0Malefyt\u00a0R,\u00a0Tangye\u00a0SG.\u00a0 IL\u201021\u2010induced\u00a0isotype\u00a0switching\u00a0to\u00a0IgG\u00a0and\u00a0IgA\u00a0\nby\u00a0human\u00a0naive\u00a0B\u00a0cells\u00a0is\u00a0diffe rentially\u00a0regulated\u00a0by\u00a0IL\u20104.\u00a0 J\u00a0Immunol \u00a02008;\u00a0181:\u00a01767\u201379.\u00a0\n415\u00a0\u00a0 He\u00a0B,\u00a0Xu\u00a0W,\u00a0Santini\u00a0PA,\u00a0Polydorides\u00a0AD,\u00a0Chiu\u00a0A,\u00a0Estrella\u00a0J \u00a0et\u00a0al.\u00a0Intestinal\u00a0Bacteria\u00a0Trigger\u00a0T\u00a0Cell\u2010Independent\u00a0\nImmunoglobulin\u00a0A2\u00a0Class\u00a0Switching\u00a0by\u00a0Inducing\u00a0Epithelial\u2010Cell\u00a0S ecretion\u00a0of\u00a0the\u00a0Cytokine\u00a0APRIL.\u00a0 Immunity \u00a0\n2007;\u00a026:\u00a0812\u2013826.\u00a0\n416\u00a0\u00a0 Lighaam\u00a0LC,\u00a0Vermeulen\u00a0E,\u00a0de n\u00a0Bleker\u00a0T,\u00a0Meijlink\u00a0KJ,\u00a0Aalber se\u00a0RC,\u00a0Barnes\u00a0E\u00a0 et\u00a0al.\u00a0Phenotypic\u00a0differences\u00a0\nbetween\u00a0IgG4+\u00a0and\u00a0IgG1+\u00a0B\u00a0cells\u00a0point\u00a0to\u00a0distinct\u00a0regulation\u00a0of \u00a0the\u00a0IgG4\u00a0response.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a0\n2014;\u00a0133:\u00a0267\u2013270.e6.\u00a0\n417\u00a0\u00a0 Reimer\u00a0CB,\u00a0Phillips\u00a0DJ,\u00a0Alois io\u00a0CH,\u00a0Black\u00a0CM,\u00a0Wells\u00a0TW.\u00a0Sp ecificity\u00a0and\u00a0association\u00a0constants\u00a0of\u00a033\u00a0monoclonal\u00a0\nantibodies\u00a0to\u00a0human\u00a0IgA\u00a0epitopes.\u00a0 Immunol\u00a0Lett \u00a01989;\u00a021:\u00a0209\u2013215.\u00a0\n418\u00a0\u00a0 Reimer\u00a0CB,\u00a0Phillips\u00a0DJ,\u00a0Aloi sio\u00a0CH,\u00a0Moore\u00a0DD,\u00a0Galland\u00a0GG,\u00a0 Wells\u00a0TW\u00a0 et\u00a0al.\u00a0Evaluation\u00a0of\u00a0Thirty\u2010One\u00a0Mouse\u00a0\nMonoclonal\u00a0Antibodies\u00a0to\u00a0Human\u00a0IgG\u00a0Epitopes.\u00a0 Hybridoma \u00a01984;\u00a03:\u00a0263\u2013275.\u00a0\n419\u00a0\u00a0 Hamilton\u00a0 RG,\u00a0 Morrison\u00a0 SL.\u00a0 Ep itope\u00a0 mapping\u00a0 of\u00a0 human\u00a0 immunog lobulin\u2010specific\u00a0 murine\u00a0 monoclonal\u00a0\nantibodies\u00a0with\u00a0domain\u2010switched, \u00a0deleted\u00a0and\u00a0point\u2010mutated\u00a0chim eric\u00a0antibodies.\u00a0 J\u00a0Immunol\u00a0Methods \u00a01993;\u00a0\n158:\u00a0107\u2013122.\u00a0\n420\u00a0\u00a0 Harada\u00a0S,\u00a0Hata\u00a0S,\u00a0Kosada\u00a0Y,\u00a0K ondo\u00a0E.\u00a0Identification\u00a0of\u00a0epi topes\u00a0recognized\u00a0by\u00a0a\u00a0pane l\u00a0of\u00a0six\u00a0anti\u2010human\u00a0IgG2\u00a0\nmonoclonal\u00a0antibodies.\u00a0 J\u00a0Immunol\u00a0Methods \u00a01991;\u00a0141:\u00a089\u201396.\u00a0\n421\u00a0\u00a0 Partridge\u00a0LJ,\u00a0Lowe\u00a0J,\u00a0Hardi e\u00a0DL,\u00a0Ling\u00a0NR,\u00a0Jefferis\u00a0R.\u00a0Immu nogenic\u00a0and\u00a0antigenic\u00a0epitopes\u00a0of\u00a0immunoglobulins.\u00a0\nII.\u00a0Antigenic\u00a0differences\u00a0between\u00a0secreted\u00a0and\u00a0membrane\u00a0IgG\u00a0dem onstrated\u00a0using\u00a0monoclonal\u00a0antibodies.\u00a0 J\u00a0\nImmunol\u00a01982;\u00a0128:\u00a01\u20136.\u00a0\n422\u00a0\u00a0 Haralambidou\u00a0S,\u00a0Melo\u00a0J\u00a0V,\u00a0Cat ovsky\u00a0D.\u00a0Different\u00a0reactivity \u00a0of\u00a0monoclonal\u00a0antibodies\u00a0against\u00a0common\u00a0acute\u00a0\nlymphoblastic\u00a0leukaemia\u00a0antigen\u00a0(CD10).\u00a0 J\u00a0Clin\u00a0Pathol \u00a01987;\u00a040:\u00a0490\u2013493.\u00a0\n423\u00a0\u00a0 Lanza\u00a0F,\u00a0Healy\u00a0L,\u00a0Sutherla nd\u00a0DR.\u00a0Structural\u00a0and\u00a0functional \u00a0features\u00a0of\u00a0the\u00a0CD34\u00a0antigen:\u00a0an\u00a0update.\u00a0 J\u00a0Biol\u00a0\nRegul\u00a0Homeost\u00a0Agents \u00a02001;\u00a015:\u00a01\u201313.\u00a0\n424\u00a0\u00a0 Hodge\u00a0TW,\u00a0Sasso\u00a0DR,\u00a0McDougal\u00a0JS.\u00a0Humans\u00a0with\u00a0OKT4\u2010epitope\u00a0 deficiency\u00a0have\u00a0a\u00a0single\u00a0nucleotide\u00a0base\u00a0\nchange\u00a0in\u00a0the\u00a0CD4\u00a0gene,\u00a0resultin g\u00a0in\u00a0substitution\u00a0of\u00a0TRP240\u00a0for \u00a0ARG240.\u00a0 Hum\u00a0Immunol \u00a01991;\u00a030:\u00a099\u2013104.\u00a0\n425\u00a0\u00a0 Zapata\u00a0DA,\u00a0Pacheco\u2010Castro\u00a0A,\u00a0Torres\u00a0PS,\u00a0Ramiro\u00a0AR,\u00a0San\u00a0Jos \u00e9\u00a0E,\u00a0Alarc\u00f3n\u00a0B\u00a0 et\u00a0al.\u00a0Conformational\u00a0and\u00a0\nbiochemical\u00a0differences\u00a0in\u00a0the\u00a0TC R.CD3\u00a0complex\u00a0of\u00a0CD8(+)\u00a0versus \u00a0CD4(+)\u00a0mature\u00a0lymphocytes\u00a0revealed\u00a0in\u00a0\nthe\u00a0absence\u00a0of\u00a0CD3gamma.\u00a0 J\u00a0Biol\u00a0Chem \u00a01999;\u00a0274:\u00a035119\u201328.\u00a0\n426\u00a0\u00a0 Leino\u00a0L,\u00a0Sorvaj\u00e4rvi\u00a0K.\u00a0CD11b\u00a0is\u00a0a\u00a0calcium\u2010dependent\u00a0epitop e\u00a0in\u00a0human\u00a0neutrophils.\u00a0 Biochem\u00a0Biophys\u00a0Res\u00a0\nCommun\u00a01992;\u00a0187:\u00a0195\u2013200.\u00a0\n427\u00a0\u00a0 van\u00a0Dongen\u00a0JJ,\u00a0Krissansen\u00a0GW,\u00a0Wolvers\u2010Tettero\u00a0IL,\u00a0Comans\u2010B itter\u00a0WM,\u00a0Adriaansen\u00a0HJ,\u00a0Hooijkaas\u00a0H\u00a0 et\u00a0al.\u00a0\nCytoplasmic\u00a0expression\u00a0of\u00a0the\u00a0CD 3\u00a0antigen\u00a0as\u00a0a\u00a0diagnostic\u00a0marke r\u00a0for\u00a0immature\u00a0T\u2010cell\u00a0malignancies.\u00a0 Blood\u00a0\n1988;\u00a071:\u00a0603\u201312.\u00a0\n428\u00a0\u00a0 Bellido\u00a0M,\u00a0Rubiol\u00a0E,\u00a0Ubeda\u00a0J,\u00a0Estivill\u00a0C,\u00a0Lopez\u00a0O,\u00a0Manteig a\u00a0R\u00a0et\u00a0al.\u00a0Rapid\u00a0and\u00a0simple\u00a0immunophenotypic\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0249\u00a0\u2010\u00a0\n\u00a0characterization\u00a0of\u00a0lympho cytes\u00a0using\u00a0a\u00a0new\u00a0test.\u00a0 Haematologica \u00a01998;\u00a083:\u00a0681\u2013685.\u00a0\n429\u00a0\u00a0 Tembhare\u00a0P,\u00a0Yuan\u00a0CM,\u00a0Xi\u00a0L,\u00a0Morris\u00a0JC,\u00a0Liewehr\u00a0D,\u00a0Venzon\u00a0D\u00a0 et\u00a0al.\u00a0Flow\u00a0cytometric\u00a0immunophenotypic\u00a0\nassessment\u00a0of\u00a0T\u2010cell\u00a0clonality\u00a0by\u00a0Vbeta\u00a0repertoire\u00a0analysis:\u00a0de tection\u00a0of\u00a0T\u2010cell\u00a0clonality\u00a0at\u00a0diagnosis\u00a0and\u00a0\nmonitoring\u00a0of\u00a0minimal\u00a0residua l\u00a0disease\u00a0following\u00a0therapy.\u00a0 Am\u00a0J\u00a0Clin\u00a0Pathol \u00a02011;\u00a0135:\u00a0890\u2013900.\u00a0\n430\u00a0\u00a0 van\u00a0Dongen\u00a0JJM,\u00a0Lhermitte\u00a0L,\u00a0Bottcher\u00a0S,\u00a0Almeida\u00a0J,\u00a0van\u00a0de r\u00a0Velden\u00a0VHJ,\u00a0Flores\u2010Montero\u00a0J\u00a0 et\u00a0al.\u00a0EuroFlow\u00a0\nantibody\u00a0panels\u00a0for\u00a0standardized\u00a0n\u2010dimensional\u00a0flow\u00a0cytometric\u00a0 immunophenotyping\u00a0of\u00a0normal,\u00a0reactive\u00a0\nand\u00a0malignant\u00a0leukocytes.\u00a0 Leukemia \u00a02012;\u00a026:\u00a01908\u20131975.\u00a0\n431\u00a0\u00a0 Gao\u00a0B,\u00a0Moore\u00a0C,\u00a0Porcheray\u00a0F,\u00a0Rong\u00a0C,\u00a0Abidoglu\u00a0C,\u00a0DeVito\u00a0J\u00a0 et\u00a0al.\u00a0Pretransplant\u00a0IgG\u00a0reactivity\u00a0to\u00a0apoptotic\u00a0\ncells\u00a0correlates\u00a0with\u00a0late\u00a0kidney\u00a0allograft\u00a0loss.\u00a0 Am\u00a0J\u00a0Transplant \u00a02014;\u00a014:\u00a01581\u20131591.\u00a0\n432\u00a0\u00a0 Karnell\u00a0JL,\u00a0Dimasi\u00a0N,\u00a0Karne ll\u00a0FG,\u00a0Fleming\u00a0R,\u00a0Kuta\u00a0E,\u00a0Wilso n\u00a0M\u00a0et\u00a0al.\u00a0CD19\u00a0and\u00a0CD32b\u00a0differentially\u00a0regulate\u00a0\nhuman\u00a0B\u00a0cell\u00a0responsiveness.\u00a0 J\u00a0Immunol \u00a02014;\u00a0192:\u00a01480\u20131490.\u00a0\n433\u00a0\u00a0 Buckley\u00a0 RH,\u00a0 Dees\u00a0 SC,\u00a0 O\u2019Fallo n\u00a0 WM.\u00a0 Serum\u00a0 immunoglobulins.\u00a0 I .\u00a0 Levels\u00a0 in\u00a0 normal\u00a0 children\u00a0 and\u00a0 in\u00a0\nuncomplicated\u00a0childhood\u00a0allergy.\u00a0 Pediatrics \u00a01968;\u00a041:\u00a0600\u2013611.\u00a0\n434\u00a0\u00a0 Schauer\u00a0U,\u00a0Stemberg\u00a0F,\u00a0Rieger\u00a0CHL,\u00a0Borte\u00a0M,\u00a0Schubert\u00a0S,\u00a0Ri edel\u00a0F\u00a0et\u00a0al.\u00a0IgG\u00a0Subclass\u00a0Concentrations\u00a0in\u00a0\nCertified\u00a0Reference\u00a0Material\u00a0470 \u00a0and\u00a0Reference\u00a0Values\u00a0for\u00a0Child ren\u00a0and\u00a0Adults\u00a0Determi ned\u00a0with\u00a0the\u00a0Binding\u00a0\nSite\u00a0Reagents.\u00a0 Clin\u00a0Chem \u00a02003;\u00a049:\u00a01924\u20131929.\u00a0\n435\u00a0\u00a0 Blanchard\u00a0Rohner\u00a0G,\u00a0Snape\u00a0MD,\u00a0Kelly\u00a0DF,\u00a0John\u00a0T,\u00a0Morant\u00a0A,\u00a0 Yu\u00a0L\u2010M\u00a0et\u00a0al.\u00a0The\u00a0magnitude\u00a0of\u00a0the\u00a0antibody\u00a0and\u00a0\nmemory\u00a0B\u00a0cell\u00a0responses\u00a0during\u00a0priming\u00a0with\u00a0a\u00a0protein\u2010polysacch aride\u00a0conjugate\u00a0vaccine\u00a0in\u00a0human\u00a0infants\u00a0\nis\u00a0associated\u00a0with\u00a0the\u00a0persistenc e\u00a0of\u00a0antibody\u00a0and\u00a0the\u00a0intensit y\u00a0of\u00a0booster\u00a0response.\u00a0 J\u00a0Immunol \u00a02008;\u00a0180:\u00a0\n2165\u20132173.\u00a0\n436\u00a0\u00a0 Moller\u00a0G,\u00a0Wigzell\u00a0H.\u00a0Antibod y\u00a0synthesis\u00a0at\u00a0the\u00a0cellular\u00a0le vel.\u00a0Antibody\u2010induced\u00a0suppression\u00a0of\u00a019S\u00a0and\u00a07S\u00a0\nantibody\u00a0response.\u00a0 J\u00a0Exp\u00a0Med \u00a01965;\u00a0121:\u00a0969\u2013989.\u00a0\n437\u00a0\u00a0 Cerottini\u00a0JC,\u00a0McConahey\u00a0PJ, \u00a0Dixon\u00a0FJ.\u00a0The\u00a0immunosuppressiv e\u00a0effect\u00a0of\u00a0passively\u00a0administered\u00a0antibody\u00a0IgG\u00a0\nfragments.\u00a0 J\u00a0Immunol \u00a01969;\u00a0102:\u00a01008\u20131015.\u00a0\n438\u00a0\u00a0 Bergstr\u00f6m\u00a0JJE,\u00a0Xu\u00a0H,\u00a0Heyman \u00a0B.\u00a0Epitope\u2010Specific\u00a0Suppressio n\u00a0of\u00a0IgG\u00a0Responses\u00a0by\u00a0Passively\u00a0Administered\u00a0\nSpecific\u00a0IgG:\u00a0Evidence\u00a0of\u00a0Epitope\u00a0Masking.\u00a0 Front\u00a0Immunol \u00a02017;\u00a08:\u00a0238.\u00a0\n439\u00a0\u00a0 Criado\u00a0I,Blanco\u00a0E,\u00a0Rodr\u00edguez\u2010Caballero\u00a0A,\u00a0Alcoceba\u00a0M,\u00a0Cont reras\u00a0T,\u00a0Guti\u00e9rrez\u00a0ML,\u00a0Romero\u00a0A,\u00a0Fern\u00e1ndez\u2013\nNavarro\u00a0P,\u00a0Gonz\u00e1lez\u00a0M,\u00a0Solano\u00a0F,\u00a0G\u00f3mez\u00a0C,\u00a0P\u00e9rez\u2010Andr\u00e9s\u00a0M,\u00a0van\u00a0D ongen,\u00a0JJM\u00a0OA.\u00a0Residual\u00a0normal\u00a0B\u2010cell\u00a0\nprofiles\u00a0in\u00a0monoclonal\u00a0B\u2010cell\u00a0lym phocytosis\u00a0versus\u00a0chronic\u00a0lymp hocytic\u00a0leukemia.\u00a0 Leukemia \u00a02018;\u00a0En\u00a0prensa\u00a0\ndesde\u00a0Mayo\u00a0de\u00a02018.\u00a0\n440\u00a0\u00a0 Sanoja\u2010Flores\u00a0L,\u00a0Paiva\u00a0B,\u00a0Flo res\u2010Montero\u00a0J,\u00a0Puig\u00a0N,\u00a0Burgos \u00a0L,\u00a0Garc\u00eda\u00a0O,\u00a0Prosper\u00a0F,\u00a0Merino\u00a0J\u00a0Vidriales\u00a0MB,\u00a0\nMateos\u00a0MV,\u00a0Garcia\u00a0R,\u00a0Palomera\u00a0L,\u00a0Rios\u00a0R,\u00a0Ca\u00f1izo\u00a0MC,\u00a0Durie\u00a0B,\u00a0va n\u00a0Dongen\u00a0JJM,\u00a0San\u00a0Miguel\u00a0J\u00a0OA.\u00a0Next\u00a0\nGeneration\u00a0Flow\u00a0(NGF):\u00a0A\u00a0High\u00a0Se nsitive\u00a0Technique\u00a0to\u00a0Detect\u00a0Cir culating\u00a0Peripheral\u00a0Blood\u00a0(PB)\u00a0Clonal\u00a0Plasma\u00a0\nCells\u00a0(cPC)\u00a0in\u00a0Patients\u00a0with\u00a0Newly\u00a0Diagnosed\u00a0of\u00a0Plasma\u00a0Cell\u00a0Neo plasms\u00a0(PCN).\u00a0 Blood\u00a02015;\u00a0126:\u00a04180.\u00a0\n441\u00a0\u00a0 Hannoun\u00a0C,\u00a0Megas\u00a0F,\u00a0Piercy\u00a0J .\u00a0Immunogenicity\u00a0and\u00a0protectiv e\u00a0efficacy\u00a0of\u00a0influenza\u00a0vaccination.\u00a0 Virus\u00a0Res \u00a0\n2004;\u00a0103:\u00a0133\u2013138.\u00a0\n442\u00a0\u00a0 Goodwin\u00a0K,\u00a0Viboud\u00a0C,\u00a0Simonsen\u00a0L.\u00a0Antibody\u00a0response\u00a0to\u00a0infl uenza\u00a0vaccination\u00a0in\u00a0the\u00a0elderly:\u00a0a\u00a0quantitative\u00a0\nreview.\u00a0Vaccine\u00a02006;\u00a024:\u00a01159\u20131169.\u00a0\n443\u00a0\u00a0 Melegaro\u00a0A,\u00a0Edmunds\u00a0WJ.\u00a0The\u00a023\u2010valent\u00a0pneumococcal\u00a0polysac charide\u00a0vaccine.\u00a0Part\u00a0II.\u00a0A\u00a0cost\u2010effectiveness\u00a0\u00a0\nanalysis\u00a0for\u00a0invasive\u00a0disease\u00a0in\u00a0the\u00a0elderly\u00a0in\u00a0England\u00a0and\u00a0Wal es.\u00a0Eur\u00a0J\u00a0Epidemiol \u00a02004;\u00a019:\u00a0365\u2013375.\u00a0\n444\u00a0\u00a0 Weinberger\u00a0B,\u00a0Herndler\u2010Brands tetter\u00a0D,\u00a0Schwanninger\u00a0A,\u00a0Wei skopf\u00a0D,\u00a0Grubeck\u2010Loebenstein\u00a0B.\u00a0Biology\u00a0of\u00a0\nimmune\u00a0responses\u00a0to\u00a0vaccines\u00a0in\u00a0elderly\u00a0persons.\u00a0 Clin\u00a0Infect\u00a0Dis \u00a02008;\u00a046:\u00a01078\u20131084.\u00a0\n445\u00a0\u00a0 Westerga\u00a0J,\u00a0Timens\u00a0W.\u00a0Immuno histological\u00a0ana lysis\u00a0of\u00a0human \u00a0fetal\u00a0lymph\u00a0nodes.\u00a0 Scand\u00a0J\u00a0Immunol \u00a01989;\u00a029:\u00a0\n103\u2013112.\u00a0\n446\u00a0\u00a0 Griffioen\u00a0AW,\u00a0Rijkers\u00a0GT,\u00a0Ja nssens\u2010Korpela\u00a0P,\u00a0Zegers\u00a0BJM.\u00a0 Pneumococcal\u00a0polysaccharides\u00a0complexed\u00a0with\u00a0\nC3d\u00a0bind\u00a0to\u00a0human\u00a0B\u00a0lymphocytes\u00a0vi a\u00a0complement\u00a0receptor\u00a0type\u00a02. \u00a0Infect\u00a0Immun \u00a01991;\u00a059:\u00a01839\u20131845.\u00a0\n447\u00a0\u00a0 Thiel\u00a0J,\u00a0Kimmig\u00a0L,\u00a0Salzer\u00a0U, \u00a0Grudzien\u00a0M,\u00a0Lebrecht\u00a0D,\u00a0Hagen a\u00a0T\u00a0et\u00a0al.\u00a0Genetic\u00a0CD21\u00a0deficiency\u00a0is\u00a0associated\u00a0\nwith\u00a0hypogammaglobulinemia.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02012;\u00a0129:\u00a0801\u2013810.e6.\u00a0\n448\u00a0\u00a0 Halista\u00a0SM,\u00a0Johnson\u2010Robbins\u00a0LA,\u00a0El\u2010Mohandes\u00a0AE,\u00a0Lees\u00a0A,\u00a0Mo nd\u00a0JJ,\u00a0Katona\u00a0IM.\u00a0Characterization\u00a0of\u00a0early\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0250\u00a0\u2010\u00a0\n\u00a0activation\u00a0events\u00a0in\u00a0cord\u00a0blood\u00a0B\u00a0cells\u00a0after\u00a0stimulation\u00a0with\u00a0 T\u00a0cell\u2010independent\u00a0activators.\u00a0 Pediatr\u00a0Res \u00a01998;\u00a0\n43:\u00a0496\u2013503.\u00a0\n449\u00a0\u00a0 Pedraz\u00a0C,\u00a0Lorente\u00a0F,\u00a0Pedraz\u00a0MJ,\u00a0Salazar\u00a0Villalobos\u00a0V.\u00a0Deve lopment\u00a0of\u00a0the\u00a0serum\u00a0levels\u00a0of\u00a0complement\u00a0during\u00a0\nthe\u00a0first\u00a0year\u00a0of\u00a0life.\u00a0 An\u00a0Esp\u00a0Pediatr \u00a01980;\u00a013:\u00a0571\u2013576.\u00a0\n450\u00a0\u00a0 Naradikian\u00a0MS,\u00a0Hao\u00a0Y,\u00a0Cancro\u00a0MP.\u00a0Age\u2010associated\u00a0B\u00a0cells:\u00a0K ey\u00a0mediators\u00a0of\u00a0both\u00a0protective\u00a0and\u00a0autoreactive\u00a0\nhumoral\u00a0responses.\u00a0 Immunol\u00a0Rev \u00a02016;\u00a0269:\u00a0118\u2013129.\u00a0\n451\u00a0\u00a0 Wang\u00a0Z,\u00a0Yunis\u00a0D,\u00a0Irigoyen\u00a0M, \u00a0Kitchens\u00a0B,\u00a0Bottaro\u00a0A,\u00a0Alt\u00a0F. \u00a0Discordance\u00a0between\u00a0IgA\u00a0switching\u00a0at\u00a0the\u00a0DNA\u00a0\nlevel\u00a0and\u00a0IgA\u00a0expression\u00a0at\u00a0the\u00a0 mRNA\u00a0level\u00a0in\u00a0IgA\u2010deficient\u00a0pat ients.\u00a0Clin\u00a0Immunol \u00a01999;\u00a091:\u00a0263\u2013270.\u00a0\n452\u00a0\u00a0 Blanco\u00a0E,\u00a0P\u00e9rez\u2010Andr\u00e9s\u00a0M,\u00a0A rriba\u2010M\u00e9ndez\u00a0S,\u00a0Contreras\u2010Sanfe liciano\u00a0T,\u00a0Criado\u00a0I,\u00a0Pelak\u00a0O\u00a0 et\u00a0al.\u00a0Age\u2010associated\u00a0\ndistribution\u00a0of\u00a0normal\u00a0B\u2010cell\u00a0and\u00a0plasma\u00a0cell\u00a0subsets\u00a0in\u00a0periph eral\u00a0blood.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02018;\u00a0En\u00a0\nprensa\u00a0desde\u00a0Marzo\u00a0de\u00a02018.\u00a0doi:10.1016/j.jaci.2018.02.017.\u00a0\n453\u00a0\u00a0 Kuehn\u00a0HS,\u00a0Boisson\u00a0B,\u00a0Cunningham\u2010Rundles\u00a0C,\u00a0Reichenbach\u00a0J,\u00a0 Stray\u2010Pedersen\u00a0A,\u00a0Gelfand\u00a0EW\u00a0 et\u00a0al.\u00a0Loss\u00a0of\u00a0B\u00a0\nCells\u00a0in\u00a0Patients\u00a0with\u00a0Hetero zygous\u00a0Mutations\u00a0in\u00a0IKAROS.\u00a0 N\u00a0Engl\u00a0J\u00a0Med \u00a02016;\u00a0374:\u00a01032\u20131043.\u00a0\n454\u00a0\u00a0 Schubert\u00a0 D,\u00a0 Bode\u00a0 C,\u00a0 Kenefeck\u00a0 R,\u00a0 Hou\u00a0 TZ,\u00a0 Wing\u00a0 JB,\u00a0 Kennedy\u00a0 A \u00a0et\u00a0 al.\u00a0 Autosomal\u00a0 dominant\u00a0 immune\u00a0\ndysregulation\u00a0syndrome\u00a0in\u00a0humans\u00a0with\u00a0CTLA4\u00a0mutations.\u00a0 Nat\u00a0Med\u00a02014;\u00a020:\u00a01410\u20131416.\u00a0\n455\u00a0\u00a0 Fliegauf\u00a0M,\u00a0Bryant\u00a0VL,\u00a0Frede\u00a0N,\u00a0Slade\u00a0C,\u00a0Woon\u00a0S\u2010T,\u00a0Lehnert \u00a0K\u00a0et\u00a0al.\u00a0Haploinsufficiency\u00a0of\u00a0the\u00a0NF\u2010kappaB1\u00a0\nSubunit\u00a0p50\u00a0in\u00a0Common\u00a0Variable\u00a0Immunodeficiency.\u00a0 Am\u00a0J\u00a0Hum\u00a0Genet \u00a02015;\u00a097:\u00a0389\u2013403.\u00a0\n456\u00a0\u00a0 Leven\u00a0EA,\u00a0Maffucci\u00a0P,\u00a0Ochs\u00a0HD,\u00a0Scholl\u00a0PR,\u00a0Buckley\u00a0RH,\u00a0Fule ihan\u00a0RL\u00a0et\u00a0al.\u00a0Hyper\u00a0IgM\u00a0Syndrome:\u00a0a\u00a0Report\u00a0from\u00a0\nthe\u00a0USIDNET\u00a0Registry.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02016;\u00a036:\u00a0490\u2013501.\u00a0\n457\u00a0\u00a0 O\u2019Gorman\u00a0MR,\u00a0Zaas\u00a0D,\u00a0Paniag ua\u00a0M,\u00a0Corrochano\u00a0V,\u00a0Scholl\u00a0PR,\u00a0 Pachman\u00a0LM.\u00a0Development\u00a0of\u00a0a\u00a0rapid\u00a0whole\u00a0\nblood\u00a0flow\u00a0cytometry\u00a0procedure\u00a0fo r\u00a0the\u00a0diagnosis\u00a0of\u00a0\u00a0X\u2010linked\u00a0h yper\u2010IgM\u00a0syndrome\u00a0patients\u00a0and\u00a0carriers.\u00a0 Clin\u00a0\nImmunol\u00a0Immunopathol \u00a01997;\u00a085:\u00a0172\u2013181.\u00a0\n458\u00a0\u00a0 Lougaris\u00a0V,\u00a0Gallizzi\u00a0R,\u00a0Vitali\u00a0M,\u00a0Baronio\u00a0M,\u00a0Salpietro\u00a0A,\u00a0 Bergbreiter\u00a0A\u00a0 et\u00a0al.\u00a0A\u00a0novel\u00a0compound\u00a0heterozygous\u00a0\nTACI\u00a0mutation\u00a0in\u00a0an\u00a0autosomal\u00a0recessive\u00a0common\u00a0variable\u00a0immunod eficiency\u00a0(CVID)\u00a0family.\u00a0 Hum\u00a0Immunol \u00a0\n2012;\u00a073:\u00a0836\u2013839.\u00a0\n459\u00a0\u00a0 Martinez\u2010Pomar\u00a0N,\u00a0Detkova\u00a0D,\u00a0Arostegui\u00a0JI,\u00a0Alvarez\u00a0A,\u00a0Sole r\u2010Palacin\u00a0P,\u00a0Vidaller\u00a0A\u00a0 et\u00a0al.\u00a0Role\u00a0of\u00a0TNFRSF13B\u00a0\nvariants\u00a0in\u00a0patients\u00a0with\u00a0common\u00a0variable\u00a0immunodeficiency.\u00a0Blo od.\u00a02009;\u00a0 114:\u00a02846\u20132848.\u00a0\n460\u00a0\u00a0 Martinez\u2010Gallo\u00a0M,\u00a0Radigan\u00a0L,\u00a0Almejun\u00a0MB,\u00a0Martinez\u2010Pomar\u00a0N, \u00a0Matamoros\u00a0N,\u00a0Cunningham\u2010Rundles\u00a0C.\u00a0TACI\u00a0\nmutations\u00a0and\u00a0impaired\u00a0B\u2010cell\u00a0f unction\u00a0in\u00a0subjects\u00a0with\u00a0CVID\u00a0an d\u00a0healthy\u00a0heterozygotes.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0\nImmunol\u00a02013;\u00a0131:\u00a0468\u2013476.\u00a0\n461\u00a0\u00a0 Romberg\u00a0N,\u00a0Chamberlain\u00a0N,\u00a0Saadoun\u00a0D,\u00a0Gentile\u00a0M,\u00a0Kinnunen\u00a0T ,\u00a0Ng\u00a0YS\u00a0et\u00a0al.\u00a0CVID\u2010associated\u00a0TACI\u00a0mutations\u00a0\naffect\u00a0autoreactive\u00a0B\u00a0cell\u00a0selection\u00a0and\u00a0activation.\u00a0 J\u00a0Clin\u00a0Invest \u00a02013;\u00a0123:\u00a04283\u20134293.\u00a0\n462\u00a0\u00a0 Mohammadi\u00a0J,\u00a0Liu\u00a0C,\u00a0Aghamohammadi\u00a0A,\u00a0Bergbreiter\u00a0A,\u00a0Du\u00a0L,\u00a0 Lu\u00a0J\u00a0et\u00a0al.\u00a0Novel\u00a0mutations\u00a0in\u00a0TACI\u00a0(TNFRSF13B)\u00a0\ncausing\u00a0common\u00a0variable\u00a0immunodeficiency.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02009;\u00a029:\u00a0777\u2013785.\u00a0\n463\u00a0\u00a0 Almejun\u00a0MB,\u00a0Cols\u00a0M,\u00a0Zelazko\u00a0 M,\u00a0Oleastro\u00a0M,\u00a0Cerutti\u00a0A,\u00a0Oppe zzo\u00a0P\u00a0et\u00a0al.\u00a0Naturally\u00a0occurring\u00a0mutation\u00a0\naffecting\u00a0the\u00a0MyD88\u2010binding\u00a0site\u00a0of\u00a0TNFRSF13B\u00a0impairs\u00a0triggerin g\u00a0of\u00a0class\u00a0switch\u00a0recombination.\u00a0 Eur\u00a0J\u00a0\nImmunol\u00a02013;\u00a043:\u00a0805\u2013814.\u00a0\n464\u00a0\u00a0 Sathkumara\u00a0HD,\u00a0De\u00a0Silva\u00a0NR,\u00a0Handunnetti\u00a0S,\u00a0De\u00a0Silva\u00a0AD.\u00a0Ge netics\u00a0of\u00a0common\u00a0variable\u00a0immunodeficiency:\u00a0\nrole\u00a0of\u00a0transmembrane\u00a0activator\u00a0 and\u00a0calcium\u00a0modulator\u00a0and\u00a0cyclo philin\u00a0ligand\u00a0interactor.\u00a0 Int\u00a0J\u00a0Immunogenet \u00a0\n2015;\u00a042:\u00a0239\u2013253.\u00a0\n465\u00a0\u00a0 Kutukculer\u00a0 N,\u00a0 Gulez\u00a0 N,\u00a0 Karaca\u00a0 NE,\u00a0 Aksu\u00a0 G,\u00a0 Berdeli\u00a0 A.\u00a0 Three \u00a0 different\u00a0 classifications,\u00a0 B\u00a0 lymphocyte\u00a0\nsubpopulations,\u00a0TNFRSF13B\u00a0(TACI),\u00a0TNFRSF13C\u00a0(BAFF\u2010R),\u00a0TNFSF13\u00a0( APRIL)\u00a0gene\u00a0mutations,\u00a0CTLA\u20104\u00a0and\u00a0ICOS\u00a0\ngene\u00a0polymorphisms\u00a0in\u00a0Turkish\u00a0patients\u00a0with\u00a0common\u00a0variable\u00a0imm unodeficiency.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02012;\u00a032:\u00a0\n1165\u20131179.\u00a0\n466\u00a0\u00a0 Salzer\u00a0U,\u00a0Chapel\u00a0HM,\u00a0Webster\u00a0 ADB,\u00a0Pan\u2010Hammarstrom\u00a0Q,\u00a0Schmi tt\u2010Graeff\u00a0A,\u00a0Schlesier\u00a0M\u00a0 et\u00a0al.\u00a0Mutations\u00a0in\u00a0\nTNFRSF13B\u00a0encoding\u00a0TACI\u00a0are\u00a0associated\u00a0with\u00a0common\u00a0variable\u00a0imm unodeficiency\u00a0in\u00a0humans.\u00a0 Nat\u00a0Genet \u00a0\n2005;\u00a037:\u00a0820\u2013828.\u00a0\n467\u00a0\u00a0 Salzer\u00a0U,\u00a0Bacchelli\u00a0C,\u00a0Buckr idge\u00a0S,\u00a0Pan\u2010Hammarstrom\u00a0Q,\u00a0Jen nings\u00a0S,\u00a0Lougaris\u00a0V\u00a0 et\u00a0al.\u00a0Relevance\u00a0of\u00a0biallelic\u00a0\nversus\u00a0monoallelic\u00a0TNFRSF13B\u00a0mutat ions\u00a0in\u00a0distinguishing\u00a0diseas e\u2010causing\u00a0from\u00a0risk\u2010increasing\u00a0TNFRSF13B\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0251\u00a0\u2010\u00a0\n\u00a0variants\u00a0in\u00a0antibody\u00a0deficiency\u00a0syndromes.\u00a0 Blood\u00a02009;\u00a0113:\u00a01967\u20131976.\u00a0\n468\u00a0\u00a0 Germinaro\u00a0M,\u00a0Reynolds\u00a0P,\u00a0Kn ight\u00a0V,\u00a0Alam\u00a0R.\u00a0Association\u00a0of\u00a0 B\u2010cell\u00a0activating\u00a0factor\u00a0receptor\u00a0deficiency\u00a0with\u00a0\nthe\u00a0P21R\u00a0polymorphism\u00a0and\u00a0commo n\u00a0variable\u00a0immunodeficiency.\u00a0Ann .\u00a0Allergy.\u00a0Asthma\u00a0Immunol.\u00a02015;\u00a0 115:\u00a0\n82\u201383.\u00a0\n469\u00a0\u00a0 Warnatz\u00a0K,\u00a0Salzer\u00a0U,\u00a0Rizzi\u00a0M,\u00a0Fischer\u00a0B,\u00a0Gutenberger\u00a0S,\u00a0Bo hm\u00a0J\u00a0et\u00a0al.\u00a0B\u2010cell\u00a0activating\u00a0factor\u00a0receptor\u00a0\ndeficiency\u00a0is\u00a0associated\u00a0with\u00a0an\u00a0adult\u2010onset\u00a0antibody\u00a0deficienc y\u00a0syndrome\u00a0in\u00a0humans.\u00a0 Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0\nA\u00a02009;\u00a0106:\u00a013945\u201313950.\u00a0\n470\u00a0\u00a0 Lougaris\u00a0V,\u00a0Baronio\u00a0M,\u00a0Moratto\u00a0D,\u00a0Cardinale\u00a0F,\u00a0Plebani\u00a0A.\u00a0 Monoallelic\u00a0BAFFR\u00a0P21R/H159Y\u00a0Mutations\u00a0and\u00a0\nFamiliar\u00a0Primary\u00a0Antibody\u00a0Defic iencies.\u00a0J.\u00a0Clin.\u00a0Immunol.\u00a02016; \u00a036:\u00a01\u20133.\u00a0\n471\u00a0\u00a0 Pieper\u00a0K,\u00a0Rizzi\u00a0M,\u00a0Speletas\u00a0M,\u00a0Smulski\u00a0CR,\u00a0Sic\u00a0H,\u00a0Kraus\u00a0H\u00a0 et\u00a0al.\u00a0A\u00a0common\u00a0single\u00a0nucleotide\u00a0polymorphism\u00a0\nimpairs\u00a0 B\u2010cell\u00a0 activating\u00a0 factor\u00a0 receptor\u2019s\u00a0 multimerization,\u00a0 co ntributing\u00a0 to\u00a0 common\u00a0 variable\u00a0\nimmunodeficiency.\u00a0J.\u00a0Allergy\u00a0Clin.\u00a0Immunol.\u00a02014;\u00a0 133:\u00a01222\u20131225.\u00a0\n472\u00a0\u00a0 Wang\u00a0H\u2010Y,\u00a0Ma\u00a0CA,\u00a0Zhao\u00a0Y,\u00a0Fan\u00a0X,\u00a0Zhou\u00a0Q,\u00a0Edmonds\u00a0P\u00a0 et\u00a0al.\u00a0Antibody\u00a0deficiency\u00a0asso ciated\u00a0with\u00a0an\u00a0inherited\u00a0\nautosomal\u00a0dominant\u00a0mutation\u00a0in\u00a0TWEAK.\u00a0 Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A \u00a02013;\u00a0110:\u00a05127\u20135132.\u00a0\n473\u00a0\u00a0 Maffucci\u00a0P,\u00a0Filion\u00a0CA,\u00a0Boisson\u00a0B,\u00a0Itan\u00a0Y,\u00a0Shang\u00a0L,\u00a0Casanov a\u00a0J\u2010L\u00a0et\u00a0al.\u00a0Genetic\u00a0Diagnosis\u00a0Using\u00a0Whole\u00a0Exome\u00a0\nSequencing\u00a0in\u00a0Common\u00a0Variable\u00a0Immunodeficiency.\u00a0 Front\u00a0Immunol \u00a02016;\u00a07:\u00a0220.\u00a0\n474\u00a0\u00a0 Lougaris\u00a0V,\u00a0Moratto\u00a0D,\u00a0Baronio\u00a0M,\u00a0Tampella\u00a0G,\u00a0van\u00a0der\u00a0Meer \u00a0JWM,\u00a0Badolato\u00a0R\u00a0 et\u00a0al.\u00a0Early\u00a0and\u00a0late\u00a0B\u2010cell\u00a0\ndevelopmental\u00a0 impairment\u00a0 in\u00a0 nuc lear\u00a0 factor\u00a0 kappa\u00a0 B,\u00a0 subunit\u00a0 1\u2010m utated\u00a0 common\u00a0 variable\u00a0\nimmunodeficiency\u00a0disease.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02017;\u00a0139:\u00a0349\u2013352.e1.\u00a0\n475\u00a0\u00a0 Kaustio\u00a0M,\u00a0Haapaniemi\u00a0E,\u00a0Goos \u00a0H,\u00a0Hautala\u00a0T,\u00a0Park\u00a0G,\u00a0Syrjan en\u00a0J\u00a0et\u00a0al.\u00a0Damaging\u00a0heterozygous\u00a0mutations\u00a0in\u00a0\nNFKB1\u00a0lead\u00a0to\u00a0diverse\u00a0immunologic\u00a0phenotypes.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02017;\u00a0140:\u00a0782\u2013796.\u00a0\n476\u00a0\u00a0 Schipp\u00a0C,\u00a0Nabhani\u00a0S,\u00a0Bienemann\u00a0K,\u00a0Simanovsky\u00a0N,\u00a0Kfir\u2010Erenf eld\u00a0S,\u00a0Assayag\u2010Asherie\u00a0N\u00a0 et\u00a0al.\u00a0Specific\u00a0antibody\u00a0\ndeficiency\u00a0and\u00a0autoinflammatory\u00a0disease\u00a0extend\u00a0the\u00a0clinical\u00a0and \u00a0immunological\u00a0spectrum\u00a0of\u00a0heterozygous\u00a0\nNFKB1\u00a0loss\u2010of\u2010function\u00a0mutations\u00a0in\u00a0humans.\u00a0 Haematologica \u00a02016;\u00a0101:\u00a0e392\u2013e396.\u00a0\n477\u00a0\u00a0 Boztug\u00a0H,\u00a0Hirschmugl\u00a0T,\u00a0Holte r\u00a0W,\u00a0Lakatos\u00a0K,\u00a0Kager\u00a0L,\u00a0Trap in\u00a0D\u00a0et\u00a0al.\u00a0NF\u2010kappaB1\u00a0Haploinsufficiency\u00a0Causing\u00a0\nImmunodeficiency\u00a0and\u00a0EBV\u2010Driven\u00a0Lymphoproliferation.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02016;\u00a036:\u00a0533\u2013540.\u00a0\n478\u00a0\u00a0 Kuehn\u00a0HS,\u00a0Niemela\u00a0JE,\u00a0Sreedhara\u00a0K,\u00a0Stoddard\u00a0JL,\u00a0Grossman\u00a0J ,\u00a0Wysocki\u00a0CA\u00a0 et\u00a0al.\u00a0Novel\u00a0nonsense\u00a0gain\u2010of\u2010\nfunction\u00a0NFKB2\u00a0mutations\u00a0associat ed\u00a0with\u00a0a\u00a0combined\u00a0immunodefic iency\u00a0phenotype.\u00a0 Blood\u00a02017;\u00a0130:\u00a0\n1553\u20131564.\u00a0\n479\u00a0\u00a0 Lal\u00a0RA,\u00a0Bachrach\u00a0LK,\u00a0Hoffman \u00a0AR,\u00a0Inlora\u00a0J,\u00a0Rego\u00a0S,\u00a0Snyder\u00a0 MP\u00a0et\u00a0al.\u00a0A\u00a0Case\u00a0Report\u00a0of\u00a0Hypoglycemia\u00a0and\u00a0\nHypogammaglobulinemia:\u00a0DAVID\u00a0Syndrome\u00a0in\u00a0a\u00a0Patient\u00a0With\u00a0a\u00a0Novel \u00a0NFKB2\u00a0Mutation.\u00a0 J\u00a0Clin\u00a0Endocrinol\u00a0\nMetab\u00a02017;\u00a0102:\u00a02127\u20132130.\u00a0\n480\u00a0\u00a0 Shi\u00a0 C,\u00a0 Wang\u00a0 F,\u00a0 Tong\u00a0 A,\u00a0 Zhang\u00a0 X\u2010Q,\u00a0 Song\u00a0 H\u2010M,\u00a0 Liu\u00a0 Z\u2010Y\u00a0 et\u00a0 al.\u00a0 NFKB2\u00a0 mutation\u00a0 in\u00a0 common\u00a0 variable\u00a0\nimmunodeficiency\u00a0and\u00a0isolated\u00a0adr enocorticotropic\u00a0hormone\u00a0defic iency:\u00a0A\u00a0case\u00a0report\u00a0and\u00a0review\u00a0of\u00a0\nliterature.\u00a0 Medicine\u00a0(Baltimore) \u00a02016;\u00a095:\u00a0e5081.\u00a0\n481\u00a0\u00a0 Lee\u00a0CE,\u00a0Fulcher\u00a0DA,\u00a0Whittle\u00a0B,\u00a0Chand\u00a0R,\u00a0Fewings\u00a0N,\u00a0Field\u00a0M \u00a0et\u00a0al.\u00a0Autosomal\u2010dominant\u00a0B\u2010cell\u00a0deficiency\u00a0with\u00a0\nalopecia\u00a0due\u00a0to\u00a0a\u00a0mutation\u00a0in\u00a0N FKB2\u00a0that\u00a0results\u00a0in\u00a0nonprocessa ble\u00a0p100.\u00a0 Blood\u00a02014;\u00a0124:\u00a02964\u20132972.\u00a0\n482\u00a0\u00a0 Liu\u00a0Y,\u00a0Hanson\u00a0S,\u00a0Gurugama\u00a0P,\u00a0Jones\u00a0A,\u00a0Clark\u00a0B,\u00a0Ibrahim\u00a0MAA .\u00a0Novel\u00a0NFKB2\u00a0mutation\u00a0in\u00a0early\u2010onset\u00a0CVID.\u00a0 J\u00a0\nClin\u00a0Immunol \u00a02014;\u00a034:\u00a0686\u2013690.\u00a0\n483\u00a0\u00a0 Brue\u00a0T,\u00a0Quentien\u00a0M\u2010H,\u00a0Khetchoumian\u00a0K,\u00a0Bensa\u00a0M,\u00a0Capo\u2010Chichi \u00a0J\u2010M,\u00a0Delemer\u00a0B\u00a0 et\u00a0al.\u00a0Mutations\u00a0in\u00a0NFKB2\u00a0and\u00a0\npotential\u00a0genetic\u00a0heterogeneity\u00a0 in\u00a0patients\u00a0with\u00a0DAVID\u00a0syndrome ,\u00a0having\u00a0variable\u00a0endocrine\u00a0and\u00a0immune\u00a0\ndeficiencies.\u00a0 BMC\u00a0Med\u00a0Genet \u00a02014;\u00a015:\u00a0139.\u00a0\n484\u00a0\u00a0 Lindsley\u00a0AW,\u00a0Qian\u00a0Y,\u00a0Valencia \u00a0CA,\u00a0Shah\u00a0K,\u00a0Zhang\u00a0K,\u00a0Assa\u2019ad \u00a0A.\u00a0Combined\u00a0immune\u00a0deficiency\u00a0in\u00a0a\u00a0patient\u00a0with\u00a0\na\u00a0novel\u00a0NFKB2\u00a0mutation.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02014;\u00a034:\u00a0910\u2013915.\u00a0\n485\u00a0\u00a0 Chen\u00a0K,\u00a0Coonrod\u00a0EM,\u00a0Kumanovic s\u00a0A,\u00a0Franks\u00a0ZF,\u00a0Durtschi\u00a0JD,\u00a0 Margraf\u00a0RL\u00a0 et\u00a0al.\u00a0Germline\u00a0mutations\u00a0in\u00a0NFKB2\u00a0\nimplicate\u00a0the\u00a0noncanonical\u00a0NF\u2010kappaB\u00a0pathway\u00a0in\u00a0the\u00a0pathogenesi s\u00a0of\u00a0common\u00a0variable\u00a0immunodeficiency.\u00a0\nAm\u00a0J\u00a0Hum\u00a0Genet \u00a02013;\u00a093:\u00a0812\u2013824.\u00a0\n486\u00a0\u00a0 Lougaris\u00a0V,\u00a0Tabellini\u00a0G,\u00a0Vitali\u00a0M,\u00a0Baronio\u00a0M,\u00a0Patrizi\u00a0O,\u00a0T ampella\u00a0G\u00a0 et\u00a0al.\u00a0Defective\u00a0natural\u00a0killer\u2010cell\u00a0cytotoxic\u00a0\nactivity\u00a0in\u00a0NFKB2\u2010mutated\u00a0CVID\u2010like\u00a0disease.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02015;\u00a0135:\u00a01641\u20131643.\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0252\u00a0\u2010\u00a0\n\u00a0487\u00a0\u00a0 Carpier\u00a0 J\u2010M,\u00a0 Lucas\u00a0 CL.\u00a0 Epstein\u2010Barr\u00a0 Virus\u00a0 Susceptibility\u00a0 i n\u00a0 Activated\u00a0 PI3K\u03b4\u00a0 Syndrome\u00a0 (APDS)\u00a0\nImmunodeficiency.\u00a0 Front\u00a0Immunol \u00a02017;\u00a08:\u00a02005.\u00a0\n488\u00a0\u00a0 Maccari\u00a0ME,\u00a0Abolhassani\u00a0H,\u00a0Aghamohammadi\u00a0A,\u00a0Aiuti\u00a0A,\u00a0Alein ikova\u00a0O,\u00a0Bangs\u00a0C\u00a0 et\u00a0al.\u00a0Disease\u00a0Evolution\u00a0and\u00a0\nResponse\u00a0to\u00a0Rapamycin\u00a0in\u00a0Activat ed\u00a0Phosphoinositide\u00a03\u2010Kinase\u00a0de lta\u00a0Syndrome:\u00a0The\u00a0European\u00a0Society\u00a0for\u00a0\nImmunodeficiencies\u2010Activated\u00a0Pho sphoinositide\u00a03\u2010Kinase\u00a0delta\u00a0Sy ndrome\u00a0Registry.\u00a0 Front\u00a0Immunol \u00a02018;\u00a09:\u00a0\n543.\u00a0\n489\u00a0\u00a0 Coulter\u00a0TI,\u00a0Chandra\u00a0A,\u00a0Bacon\u00a0CM,\u00a0Babar\u00a0J,\u00a0Curtis\u00a0J,\u00a0Screat on\u00a0N\u00a0et\u00a0al.\u00a0Clinical\u00a0spectrum\u00a0and\u00a0features\u00a0of\u00a0\nactivated\u00a0phosphoinositide\u00a03\u2010kinase\u00a0delta\u00a0syndrome:\u00a0A\u00a0large\u00a0pat ient\u00a0cohort\u00a0study.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a0\n2017;\u00a0139:\u00a0597\u2013606.e4.\u00a0\n490\u00a0\u00a0 Elkaim\u00a0E,\u00a0Neven\u00a0B,\u00a0Bruneau\u00a0J ,\u00a0Mitsui\u2010Sekinaka\u00a0K,\u00a0Stanislas \u00a0A,\u00a0Heurtier\u00a0L\u00a0 et\u00a0al.\u00a0Clinical\u00a0and\u00a0immunologic\u00a0\nphenotype\u00a0associated\u00a0with\u00a0activated\u00a0phosphoinositide\u00a03\u2010kinase\u00a0d elta\u00a0syndrome\u00a02:\u00a0A\u00a0cohort\u00a0study.\u00a0 J\u00a0Allergy\u00a0\nClin\u00a0Immunol \u00a02016;\u00a0138:\u00a0210\u2013218.e9.\u00a0\n491\u00a0\u00a0 Kanegane\u00a0H,\u00a0Agematsu\u00a0K,\u00a0Futatani\u00a0T,\u00a0Sira\u00a0MM,\u00a0Suga\u00a0K,\u00a0Sekig uchi\u00a0T\u00a0et\u00a0al.\u00a0Novel\u00a0mutations\u00a0in\u00a0a\u00a0Japanese\u00a0\npatient\u00a0with\u00a0CD19\u00a0deficiency.\u00a0 Genes\u00a0Immun \u00a02007;\u00a08:\u00a0663\u2013670.\u00a0\n492\u00a0\u00a0 Vince\u00a0N,\u00a0Boutboul\u00a0D,\u00a0Mouillot\u00a0G,\u00a0Just\u00a0N,\u00a0Peralta\u00a0M,\u00a0Casano va\u00a0J\u2010L\u00a0et\u00a0al.\u00a0Defects\u00a0in\u00a0the\u00a0CD19\u00a0complex\u00a0\npredispose\u00a0to\u00a0glomerulonephritis ,\u00a0as\u00a0well\u00a0as\u00a0IgG1\u00a0subclass\u00a0defi ciency.\u00a0J.\u00a0Allergy\u00a0Clin.\u00a0Immunol.\u00a02011;\u00a0 127:\u00a0\n535\u2013538.\u00a0\n493\u00a0\u00a0 van\u00a0Zelm\u00a0MC,\u00a0Reisli\u00a0I,\u00a0van\u00a0der\u00a0Burg\u00a0M,\u00a0Castano\u00a0D,\u00a0van\u00a0Noes el\u00a0CJM,\u00a0van\u00a0Tol\u00a0MJD\u00a0 et\u00a0al.\u00a0An\u00a0antibody\u2010deficiency\u00a0\nsyndrome\u00a0due\u00a0to\u00a0mutations\u00a0in\u00a0the\u00a0CD19\u00a0gene.\u00a0 N\u00a0Engl\u00a0J\u00a0Med \u00a02006;\u00a0354:\u00a01901\u20131912.\u00a0\n494\u00a0\u00a0 van\u00a0Zelm\u00a0MC,\u00a0Smet\u00a0J,\u00a0van\u00a0der\u00a0Burg\u00a0M,\u00a0Ferster\u00a0A,\u00a0Le\u00a0PQ,\u00a0Sch andene\u00a0L\u00a0 et\u00a0al.\u00a0Antibody\u00a0deficiency\u00a0due\u00a0to\u00a0a\u00a0\nmissense\u00a0 mutation\u00a0 in\u00a0 CD19\u00a0 demonstr a t e s \u00a0t h e \u00a0i m p o r t a n c e \u00a0o f \u00a0t h e \u00a0c o nserved\u00a0 tryptophan\u00a0 41\u00a0 in\u00a0\nimmunoglobulin\u00a0superfamily\u00a0domain\u00a0formation.\u00a0 Hum\u00a0Mol\u00a0Genet \u00a02011;\u00a020:\u00a01854\u20131863.\u00a0\n495\u00a0\u00a0 Skendros\u00a0P,\u00a0Rondeau\u00a0S,\u00a0Chateil\u00a0J\u2010F,\u00a0Bui\u00a0S,\u00a0Bocly\u00a0V,\u00a0Moreau \u00a0J\u2010F\u00a0et\u00a0al.\u00a0Misdiagnosed\u00a0CD19\u00a0deficiency\u00a0leads\u00a0to\u00a0\nsevere\u00a0lung\u00a0disease.\u00a0 Pediatr\u00a0Allergy\u00a0Immunol \u00a02014;\u00a025:\u00a0603\u20136.\u00a0\n496\u00a0\u00a0 Wentink\u00a0MWJ,\u00a0Lambeck\u00a0AJA,\u00a0van\u00a0Zelm\u00a0MC,\u00a0Simons\u00a0E,\u00a0van\u00a0Donge n\u00a0JJM,\u00a0IJspeert\u00a0H\u00a0 et\u00a0al.\u00a0CD21\u00a0and\u00a0CD19\u00a0\ndeficiency:\u00a0Two\u00a0defects\u00a0in\u00a0the\u00a0same\u00a0complex\u00a0leading\u00a0to\u00a0differen t\u00a0disease\u00a0modalities.\u00a0 Clin\u00a0Immunol \u00a02015;\u00a0161:\u00a0\n120\u2013127.\u00a0\n497\u00a0\u00a0 Vences\u2010Catalan\u00a0F,\u00a0Kuo\u00a0C\u2010C,\u00a0Sa gi\u00a0Y,\u00a0Chen\u00a0H,\u00a0Kela\u2010Madar\u00a0N,\u00a0v an\u00a0Zelm\u00a0MC\u00a0 et\u00a0al.\u00a0A\u00a0mutation\u00a0in\u00a0the\u00a0human\u00a0\ntetraspanin\u00a0CD81\u00a0gene\u00a0is\u00a0expresse d\u00a0as\u00a0a\u00a0truncated\u00a0protein\u00a0but\u00a0d oes\u00a0not\u00a0enable\u00a0CD19\u00a0maturation\u00a0and\u00a0cell\u00a0\nsurface\u00a0expression.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02015;\u00a035:\u00a0254\u2013263.\u00a0\n498\u00a0\u00a0 Kuijpers\u00a0TW,\u00a0Bende\u00a0RJ,\u00a0Baars\u00a0PA,\u00a0Grummels\u00a0A,\u00a0Derks\u00a0IAM,\u00a0Do lman\u00a0KM\u00a0 et\u00a0al.\u00a0CD20\u00a0deficiency\u00a0in\u00a0humans\u00a0\nresults\u00a0in\u00a0impaired\u00a0T\u00a0cell\u2010inde pendent\u00a0antibody\u00a0responses.\u00a0 J\u00a0Clin\u00a0Invest \u00a02010;\u00a0120:\u00a0214\u2013222.\u00a0\n499\u00a0\u00a0 Capitani\u00a0N,\u00a0Ariani\u00a0F,\u00a0Amedei\u00a0A,\u00a0Pezzicoli\u00a0A,\u00a0Matucci\u00a0A,\u00a0Vu ltaggio\u00a0A\u00a0et\u00a0al.\u00a0Vav1\u00a0haploinsufficiency\u00a0in\u00a0a\u00a0common\u00a0\nvariable\u00a0immunodeficiency\u00a0patient \u00a0with\u00a0defective\u00a0T\u2010cell\u00a0functio n.\u00a0Int\u00a0J\u00a0Immunopathol\u00a0Pharmacol \u00a02012;\u00a025:\u00a0\n811\u2013817.\u00a0\n500\u00a0\u00a0 Alkhairy\u00a0OK,\u00a0Rezaei\u00a0N,\u00a0Graham\u00a0RR,\u00a0Abolhassani\u00a0H,\u00a0Borte\u00a0S,\u00a0 Hultenby\u00a0K\u00a0 et\u00a0al.\u00a0RAC2\u00a0loss\u2010of\u2010function\u00a0mutation\u00a0\nin\u00a02\u00a0siblings\u00a0with\u00a0characteristics\u00a0of\u00a0common\u00a0variable\u00a0immunodef iciency.\u00a0J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02015;\u00a0135:\u00a0\n1380\u20101384\u20135.\u00a0\n501\u00a0\u00a0 Compeer\u00a0EB,\u00a0Janssen\u00a0W,\u00a0van\u00a0R oyen\u2010Kerkhof\u00a0A,\u00a0van\u00a0Gijn\u00a0M,\u00a0va n\u00a0Montfrans\u00a0JM,\u00a0Boes\u00a0M.\u00a0Dysfunctional\u00a0BLK\u00a0in\u00a0\ncommon\u00a0variable\u00a0immunodeficiency\u00a0perturbs\u00a0B\u2010cell\u00a0proliferation\u00a0 and\u00a0ability\u00a0to\u00a0elicit\u00a0antigen\u2010specific\u00a0CD4+\u00a0\nT\u2010cell\u00a0help.\u00a0 Oncotarget \u00a02015;\u00a06:\u00a010759\u201310771.\u00a0\n502\u00a0\u00a0 Keller\u00a0MD,\u00a0Pandey\u00a0R,\u00a0Li\u00a0D,\u00a0Glessner\u00a0J,\u00a0Tian\u00a0L,\u00a0Henrickson\u00a0 SE\u00a0et\u00a0al.\u00a0Mutation\u00a0in\u00a0IRF2BP2\u00a0is\u00a0responsible\u00a0for\u00a0a\u00a0\nfamilial\u00a0form\u00a0of\u00a0common\u00a0variable\u00a0immunodeficiency\u00a0disorder.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02016;\u00a0138:\u00a0544\u2013550.e4.\u00a0\n503\u00a0\u00a0 Jansen\u00a0EJR,\u00a0Timal\u00a0S,\u00a0Ryan\u00a0M,\u00a0Ashikov\u00a0A,\u00a0van\u00a0Scherpenzeel\u00a0M ,\u00a0Graham\u00a0LA\u00a0 et\u00a0al.\u00a0ATP6AP1\u00a0deficiency\u00a0causes\u00a0an\u00a0\nimmunodeficiency\u00a0 with\u00a0 hepatopath y,\u00a0 cognitive\u00a0 impairment\u00a0 and\u00a0 abn ormal\u00a0 protein\u00a0 glycosylation.\u00a0 Nat\u00a0\nCommun\u00a02016;\u00a07:\u00a011600.\u00a0\n504\u00a0\u00a0 Chakraborty\u00a0PK,\u00a0Schmitz\u2010Abe \u00a0K,\u00a0Kennedy\u00a0EK,\u00a0Mamady\u00a0H,\u00a0Naas\u00a0 T,\u00a0Durie\u00a0D\u00a0 et\u00a0al.\u00a0Mutations\u00a0in\u00a0TRNT1\u00a0cause\u00a0\ncongenital\u00a0sideroblastic\u00a0anemia\u00a0with\u00a0immunodeficiency,\u00a0fevers,\u00a0 and\u00a0developmental\u00a0delay\u00a0(SIFD).\u00a0 Blood\u00a02014;\u00a0\n124:\u00a02867\u20132871.\u00a0\n505\u00a0\u00a0 Lougaris\u00a0V,\u00a0Chou\u00a0J,\u00a0Baronio\u00a0M,\u00a0Gazzurelli\u00a0L,\u00a0Lorenzini\u00a0T,\u00a0 Soresina\u00a0A\u00a0 et\u00a0al.\u00a0Novel\u00a0biallelic\u00a0TRNT1\u00a0mutations\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0253\u00a0\u2010\u00a0\n\u00a0resulting\u00a0 in\u00a0 sideroblastic\u00a0 anemia,\u00a0 combined\u00a0 B\u00a0 and\u00a0 T\u00a0 cell\u00a0 defect s,\u00a0 hypogammaglobulinemia,\u00a0 recurrent\u00a0\ninfections,\u00a0hypertrophic\u00a0cardiomy opathy\u00a0and\u00a0developmental\u00a0delay .\u00a0Clin.\u00a0Immunol.\u00a02018;\u00a0 188:\u00a020\u201322.\u00a0\n506\u00a0\u00a0 Wedatilake\u00a0Y,\u00a0Niazi\u00a0R,\u00a0Fasso ne\u00a0E,\u00a0Powell\u00a0CA,\u00a0Pearce\u00a0S,\u00a0Pla gnol\u00a0V\u00a0et\u00a0al.\u00a0TRNT1\u00a0deficiency:\u00a0clinical,\u00a0biochemical\u00a0\nand\u00a0molecular\u00a0genetic\u00a0features.\u00a0 Orphanet\u00a0J\u00a0Rare\u00a0Dis \u00a02016;\u00a011:\u00a090.\u00a0\n507\u00a0\u00a0 Barton\u00a0C,\u00a0Kausar\u00a0S,\u00a0Kerr\u00a0D,\u00a0Bitetti\u00a0S,\u00a0Wynn\u00a0R.\u00a0SIFD\u00a0as\u00a0a\u00a0n ovel\u00a0cause\u00a0of\u00a0severe\u00a0fetal\u00a0hydrops\u00a0and\u00a0neonatal\u00a0\nanaemia\u00a0with\u00a0iron\u00a0loading\u00a0and\u00a0marked\u00a0extramedullary\u00a0haemopoiesi s.\u00a0J\u00a0Clin\u00a0Pathol \u00a02018;\u00a071:\u00a0275\u2013278.\u00a0\n508\u00a0\u00a0 Hull\u00a0S,\u00a0Malik\u00a0ANJ,\u00a0Arno\u00a0G,\u00a0M ackay\u00a0DS,\u00a0Plagnol\u00a0V,\u00a0Michaelid es\u00a0M\u00a0et\u00a0al.\u00a0Expanding\u00a0the\u00a0Phenotype\u00a0of\u00a0TRNT1\u2010\nRelated\u00a0Immunodeficiency\u00a0to\u00a0Include\u00a0Childhood\u00a0Cataract\u00a0and\u00a0Inne r\u00a0Retinal\u00a0Dysfunction.\u00a0 JAMA\u00a0Ophthalmol \u00a0\n2016;\u00a0134:\u00a01049\u20131053.\u00a0\n509\u00a0\u00a0 Bourgeois\u00a0P,\u00a0Esteve\u00a0C,\u00a0Chaix\u00a0C,\u00a0B\u00e9roud\u00a0C,\u00a0L\u00e9vy\u00a0N,\u00a0THES\u00a0cli nical\u00a0consortium\u00a0 et\u00a0al.\u00a0Tricho\u2010Hepato\u2010Enteric\u00a0\nSyndrome\u00a0mutation\u00a0update:\u00a0Mutations\u00a0spectrum\u00a0of\u00a0TTC37\u00a0and\u00a0SKIV2 L,\u00a0clinical\u00a0analysis\u00a0and\u00a0future\u00a0prospects.\u00a0\nHum\u00a0Mutat \u00a02018;\u00a0En\u00a0prensa\u00a0desde\u00a0Marzo\u00a0de\u00a02018.\u00a0doi:10.1002/humu.23418.\u00a0\n510\u00a0\u00a0 Schubert\u00a0D,\u00a0Klein\u00a0M\u2010C,\u00a0Hassd enteufel\u00a0S,\u00a0Caballero\u2010Oteyza\u00a0A ,\u00a0Yang\u00a0L,\u00a0Proietti\u00a0M\u00a0 et\u00a0al.\u00a0Plasma\u00a0cell\u00a0deficiency\u00a0\nin\u00a0human\u00a0subjects\u00a0with\u00a0heterozygous\u00a0mutations\u00a0in\u00a0Sec61\u00a0transloc on\u00a0alpha\u00a01\u00a0subunit\u00a0(SEC61A1).\u00a0 J\u00a0Allergy\u00a0Clin\u00a0\nImmunol\u00a02018;\u00a0141:\u00a01427\u20131438.\u00a0\n511\u00a0\u00a0 Salzer\u00a0E,\u00a0Santos\u2010Valente\u00a0E,\u00a0Klaver\u00a0S,\u00a0Ban\u00a0SA,\u00a0Emminger\u00a0W,\u00a0 Prengemann\u00a0NK\u00a0 et\u00a0al.\u00a0B\u2010cell\u00a0deficiency\u00a0and\u00a0severe\u00a0\nautoimmunity\u00a0caused\u00a0by\u00a0deficienc y\u00a0of\u00a0protein\u00a0kinase\u00a0\u00a0C\u00a0delta.\u00a0 Blood\u00a02013;\u00a0121:\u00a03112\u20133116.\u00a0\n512\u00a0\u00a0 Kiykim\u00a0A,\u00a0Ogulur\u00a0I,\u00a0Baris\u00a0S,\u00a0Salzer\u00a0E,\u00a0Karakoc\u2010Aydiner\u00a0E,\u00a0 Ozen\u00a0AO\u00a0 et\u00a0al.\u00a0Potentially\u00a0Beneficial\u00a0Effect\u00a0of\u00a0\nHydroxychloroquine\u00a0in\u00a0a\u00a0Patient\u00a0 with\u00a0a\u00a0Novel\u00a0Mutation\u00a0in\u00a0Protei n\u00a0Kinase\u00a0Cdelta\u00a0Deficiency.\u00a0 J\u00a0Clin\u00a0Immunol \u00a0\n2015;\u00a035:\u00a0523\u2013526.\u00a0\n513\u00a0\u00a0 Belot\u00a0A,\u00a0Kasher\u00a0PR,\u00a0Trotter\u00a0EW,\u00a0Foray\u00a0A\u2010P,\u00a0Debaud\u00a0A\u2010L,\u00a0Ric e\u00a0GI\u00a0et\u00a0al.\u00a0Protein\u00a0kinase\u00a0cdelta\u00a0deficiency\u00a0causes\u00a0\nmendelian\u00a0systemic\u00a0lupus\u00a0erythematosus\u00a0with\u00a0B\u00a0cell\u2010defective\u00a0ap optosis\u00a0and\u00a0hyperproliferation.\u00a0 Arthritis\u00a0\nRheum\u00a02013;\u00a065:\u00a02161\u20132171.\u00a0\n514\u00a0\u00a0 Kuehn\u00a0HS,\u00a0Niemela\u00a0JE,\u00a0Rangel\u2010Santos\u00a0A,\u00a0Zhang\u00a0M,\u00a0Pittaluga\u00a0 S,\u00a0Stoddard\u00a0JL\u00a0 et\u00a0al.\u00a0Loss\u2010of\u2010function\u00a0of\u00a0the\u00a0\nprotein\u00a0kinase\u00a0C\u00a0delta\u00a0(PKCdelta )\u00a0causes\u00a0a\u00a0B\u2010cell\u00a0lymphoprolife rative\u00a0syndrome\u00a0in\u00a0humans.\u00a0 Blood\u00a02013;\u00a0121:\u00a0\n3117\u20133125.\u00a0\n515\u00a0\u00a0 Zhou\u00a0Q,\u00a0Lee\u00a0G\u2010S,\u00a0Brady\u00a0J,\u00a0Datta\u00a0S,\u00a0Katan\u00a0M,\u00a0Sheikh\u00a0A\u00a0 et\u00a0al.\u00a0A\u00a0hypermorphic\u00a0missense\u00a0mutation\u00a0in\u00a0PLCG2,\u00a0\nencoding\u00a0 phospholipase\u00a0 Cgamma2,\u00a0 causes\u00a0 a\u00a0 dominantly\u00a0 inherited\u00a0 a utoinflammatory\u00a0 disease\u00a0 with\u00a0\nimmunodeficiency.\u00a0 Am\u00a0J\u00a0Hum\u00a0Genet \u00a02012;\u00a091:\u00a0713\u2013720.\u00a0\n516\u00a0\u00a0 Ombrello\u00a0 MJ,\u00a0 Remmers\u00a0 EF,\u00a0 Sun\u00a0 G,\u00a0 Freeman\u00a0 AF,\u00a0 Datta\u00a0 S,\u00a0 Torab i\u2010Parizi\u00a0 P\u00a0 et\u00a0 al.\u00a0 Cold\u00a0 urticaria,\u00a0\nimmunodeficiency,\u00a0and\u00a0autoimmuni ty\u00a0related\u00a0to\u00a0PLCG2\u00a0deletions.\u00a0 N\u00a0Engl\u00a0J\u00a0Med \u00a02012;\u00a0366:\u00a0330\u2013338.\u00a0\n517\u00a0\u00a0 Kucuk\u00a0ZY,\u00a0Charbonnier\u00a0L\u2010M,\u00a0 McMasters\u00a0RL,\u00a0Chatila\u00a0T,\u00a0Bleesi ng\u00a0JJ.\u00a0CTLA\u20104\u00a0haploinsuffi ciency\u00a0in\u00a0a\u00a0patient\u00a0with\u00a0\nan\u00a0autoimmune\u00a0lymphoproliferative\u00a0disorder.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02017;\u00a0140:\u00a0862\u2013864.e4.\u00a0\n518\u00a0\u00a0 Slatter\u00a0MA,\u00a0Engelhardt\u00a0KR,\u00a0B urroughs\u00a0LM,\u00a0Arkwright\u00a0PD,\u00a0Nad emi\u00a0Z,\u00a0Skoda\u2010Smith\u00a0S\u00a0 et\u00a0al.\u00a0Hematopoietic\u00a0stem\u00a0\ncell\u00a0transplantation\u00a0for\u00a0CTLA4\u00a0deficiency.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02016;\u00a0138:\u00a0615\u2013619.e1.\u00a0\n519\u00a0\u00a0 Navarini\u00a0AA,\u00a0Hruz\u00a0P,\u00a0Berger\u00a0CT,\u00a0Hou\u00a0TZ,\u00a0Schwab\u00a0C,\u00a0Gabrysch \u00a0A\u00a0et\u00a0al.\u00a0Vedolizumab\u00a0as\u00a0a\u00a0successful\u00a0treatment\u00a0\nof\u00a0CTLA\u20104\u2010associated\u00a0autoimmune\u00a0enterocolitis.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02017;\u00a0139:\u00a01043\u20131046.e5.\u00a0\n520\u00a0\u00a0 Hayakawa\u00a0S,\u00a0Okada\u00a0S,\u00a0Tsumura\u00a0M,\u00a0Sakata\u00a0S,\u00a0Ueno\u00a0Y,\u00a0Imai\u00a0K\u00a0 et\u00a0al.\u00a0A\u00a0Patient\u00a0with\u00a0CTLA\u20104\u00a0Haploinsufficiency\u00a0\nPresenting\u00a0Gastric\u00a0Cancer.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02016;\u00a036:\u00a028\u201332.\u00a0\n521\u00a0\u00a0 Zeissig\u00a0S,\u00a0Petersen\u00a0B\u2010S,\u00a0Tom czak\u00a0M,\u00a0Melum\u00a0E,\u00a0Huc\u2010Claustre\u00a0 E,\u00a0Dougan\u00a0SK\u00a0 et\u00a0al.\u00a0Early\u2010onset\u00a0Crohn\u2019s\u00a0disease\u00a0\nand\u00a0autoimmunity\u00a0associated\u00a0with\u00a0a\u00a0variant\u00a0in\u00a0CTLA\u20104.\u00a0 Gut\u00a02015;\u00a064:\u00a01889\u20131897.\u00a0\n522\u00a0\u00a0 Kuehn\u00a0HS,\u00a0Ouyang\u00a0W,\u00a0Lo\u00a0B,\u00a0Deenick\u00a0EK,\u00a0Niemela\u00a0JE,\u00a0Avery\u00a0DT \u00a0et\u00a0al.\u00a0Immune\u00a0dysregulation\u00a0in\u00a0human\u00a0subjects\u00a0\nwith\u00a0heterozygous\u00a0germline\u00a0mutations\u00a0in\u00a0CTLA4.\u00a0 Science\u00a02014;\u00a0345:\u00a01623\u20131627.\u00a0\n523\u00a0\u00a0 Hou\u00a0TZ,\u00a0Olbrich\u00a0P,\u00a0Soto\u00a0JML,\u00a0Sanchez\u00a0B,\u00a0Moreno\u00a0PS,\u00a0Borte\u00a0S \u00a0et\u00a0al.\u00a0Study\u00a0of\u00a0an\u00a0extended\u00a0family\u00a0with\u00a0CTLA\u20104\u00a0\ndeficiency\u00a0 suggests\u00a0 a\u00a0 CD28/CTLA \u20104\u00a0 independent\u00a0 mechanism\u00a0 respons i b l e \u00a0f o r \u00a0d i f f e r e n c e s \u00a0i n \u00a0d i s e a s e \u00a0\nmanifestations\u00a0and\u00a0severity.\u00a0 Clin\u00a0Immunol \u00a02018;\u00a0188:\u00a094\u2013102.\u00a0\n524\u00a0\u00a0 Schwab\u00a0C,\u00a0Gabrysch\u00a0A,\u00a0Olbrich \u00a0P,\u00a0Pati\u00f1o\u00a0V,\u00a0Warnatz\u00a0K,\u00a0Wolf f\u00a0D\u00a0et\u00a0al.\u00a0Phenotype,\u00a0penetrance,\u00a0and\u00a0treatment\u00a0\nof\u00a0 133\u00a0 CTLA\u20104\u2010insufficient\u00a0 individuals.\u00a0 J\u00a0 Allergy\u00a0 Clin\u00a0 Immunol \u00a0 2018;\u00a0 En\u00a0 prensa\u00a0 desde\u00a0 Mayo\u00a0de\u00a0 2018.\u00a0\ndoi:10.1016/j.jaci.2018.02.055.\u00a0Referencias bibliogr\u00e1ficas  \n\u2010\u00a0254\u00a0\u2010\u00a0\n\u00a0525\u00a0\u00a0 Lopez\u2010Herrera\u00a0 G,\u00a0 Tampella\u00a0 G ,\u00a0 Pan\u2010Hammarstrom \u00a0 Q,\u00a0 Herholz\u00a0 P, \u00a0 Trujillo\u2010Vargas\u00a0 CM,\u00a0 Phadwal\u00a0 K\u00a0 et\u00a0 al.\u00a0\nDeleterious\u00a0mutations\u00a0in\u00a0LRBA\u00a0are\u00a0associated\u00a0with\u00a0a\u00a0syndrome\u00a0of \u00a0immune\u00a0deficiency\u00a0and\u00a0autoimmunity.\u00a0 Am\u00a0\nJ\u00a0Hum\u00a0Genet \u00a02012;\u00a090:\u00a0986\u20131001.\u00a0\n526\u00a0\u00a0 Alangari\u00a0A,\u00a0Alsultan\u00a0A,\u00a0Adly\u00a0 N,\u00a0Massaad\u00a0MJ,\u00a0Kiani\u00a0IS,\u00a0Alje breen\u00a0A\u00a0et\u00a0al.\u00a0LPS\u2010responsive\u00a0beige\u2010like\u00a0anchor\u00a0\n(LRBA)\u00a0gene\u00a0mutation\u00a0in\u00a0a\u00a0family\u00a0with\u00a0inflammatory\u00a0bowel\u00a0diseas e\u00a0and\u00a0combined\u00a0immunodeficiency.\u00a0 J\u00a0\nAllergy\u00a0Clin\u00a0Immunol \u00a02012;\u00a0130:\u00a0481\u2013488.e2.\u00a0\n527\u00a0\u00a0 Charbonnier\u00a0L\u2010M,\u00a0Janssen\u00a0E,\u00a0Chou\u00a0J,\u00a0Ohsumi\u00a0TK,\u00a0Keles\u00a0S,\u00a0Hs u\u00a0JT\u00a0et\u00a0al.\u00a0Regulatory\u00a0T\u2010cell\u00a0deficiency\u00a0and\u00a0immune\u00a0\ndysregulation,\u00a0polyendocrinopathy ,\u00a0enteropathy,\u00a0X\u2010linked\u2010like\u00a0d isorder\u00a0caused\u00a0by\u00a0loss\u2010of\u2010function\u00a0mutations\u00a0\nin\u00a0LRBA.\u00a0J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02015;\u00a0135:\u00a0217\u2013227.\u00a0\n528\u00a0\u00a0 Gamez\u2010Diaz\u00a0L,\u00a0August\u00a0D,\u00a0Stepe nsky\u00a0P,\u00a0Revel\u2010Vilk\u00a0S,\u00a0Seidel\u00a0 MG,\u00a0Noriko\u00a0M\u00a0 et\u00a0al.\u00a0The\u00a0extended\u00a0phenotype\u00a0of\u00a0\nLPS\u2010responsive\u00a0beige\u2010like\u00a0anchor\u00a0protein\u00a0(LRBA)\u00a0deficiency.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02016;\u00a0137:\u00a0223\u2013230.\u00a0\n529\u00a0\u00a0 Alroqi\u00a0FJ,\u00a0Charbonnier\u00a0L\u2010M,\u00a0Baris\u00a0S,\u00a0Kiykim\u00a0A,\u00a0Chou\u00a0J,\u00a0Pla tt\u00a0CD\u00a0et\u00a0al.\u00a0Exaggerated\u00a0follicular\u00a0helper\u00a0T\u2010cell\u00a0\nresponses\u00a0in\u00a0patients\u00a0with\u00a0LRBA\u00a0deficiency\u00a0caused\u00a0by\u00a0failure\u00a0of \u00a0CTLA4\u2010mediated\u00a0regulation.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0\nImmunol\u00a02018;\u00a0141:\u00a01050\u20131059.e10.\u00a0\n530\u00a0\u00a0 Seidel\u00a0MG,\u00a0Hirschmugl\u00a0T,\u00a0Game z\u2010Diaz\u00a0L,\u00a0Schwinger\u00a0W,\u00a0Serwas \u00a0N,\u00a0Deutschmann\u00a0A\u00a0 et\u00a0al.\u00a0Long\u2010term\u00a0remission\u00a0\nafter\u00a0 allogeneic\u00a0 hematopoietic\u00a0 stem\u00a0 cell\u00a0 transplantation\u00a0 in\u00a0 LPS \u2010responsive\u00a0 beige\u2010like\u00a0 anchor\u00a0 (LRBA)\u00a0\ndeficiency.\u00a0J.\u00a0Allergy\u00a0Clin.\u00a0Immunol.\u00a02015;\u00a0 135:\u00a01384\u20131388.\u00a0\n531\u00a0\u00a0 Kostel\u00a0Bal\u00a0S,\u00a0Haskologlu\u00a0S,\u00a0Serwas\u00a0NK,\u00a0Islamoglu\u00a0C,\u00a0Ayteki n\u00a0C,\u00a0Kendirli\u00a0T\u00a0 et\u00a0al.\u00a0Multiple\u00a0Presentations\u00a0of\u00a0LRBA\u00a0\nDeficiency:\u00a0a\u00a0Single\u2010Center\u00a0Experience.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02017;\u00a037:\u00a0790\u2013800.\u00a0\n532\u00a0\u00a0 Serwas\u00a0NK,\u00a0Kansu\u00a0A,\u00a0Santos\u2010Valente\u00a0E,\u00a0Kuloglu\u00a0Z,\u00a0Demir\u00a0A,\u00a0 Yaman\u00a0A\u00a0 et\u00a0al.\u00a0Atypical\u00a0manifestation\u00a0of\u00a0LRBA\u00a0\ndeficiency\u00a0with\u00a0predominant\u00a0IBD\u2010like\u00a0phenotype.\u00a0 Inflamm\u00a0Bowel\u00a0Dis \u00a02015;\u00a021:\u00a040\u201347.\u00a0\n533\u00a0\u00a0 Bakhtiar\u00a0S,\u00a0Gamez\u2010Diaz\u00a0L,\u00a0Jar isch\u00a0A,\u00a0Soerensen\u00a0J,\u00a0Grimbach er\u00a0B,\u00a0Belohradsky\u00a0B\u00a0 et\u00a0al.\u00a0Treatment\u00a0of\u00a0Infantile\u00a0\nInflammatory\u00a0Bowel\u00a0Disease\u00a0and\u00a0Autoimmunity\u00a0by\u00a0Allogeneic\u00a0\u00a0Stem \u00a0Cell\u00a0Transplantation\u00a0in\u00a0LPS\u2010Responsive\u00a0\nBeige\u2010Like\u00a0Anchor\u00a0Deficiency.\u00a0 Front\u00a0Immunol \u00a02017;\u00a08:\u00a052.\u00a0\n534\u00a0\u00a0 Sari\u00a0S,\u00a0Dogu\u00a0F,\u00a0Hwa\u00a0V,\u00a0Hask ologlu\u00a0S,\u00a0Dauber\u00a0A,\u00a0Rosenfeld\u00a0R \u00a0et\u00a0al.\u00a0A\u00a0Successful\u00a0HSCT\u00a0in\u00a0a\u00a0Girl\u00a0with\u00a0Novel\u00a0LRBA\u00a0\nMutation\u00a0with\u00a0Refractory\u00a0Celiac\u00a0 Disease.\u00a0J.\u00a0Clin.\u00a0Immunol.\u00a02016 ;\u00a036:\u00a08\u201311.\u00a0\n535\u00a0\u00a0 Alkhairy\u00a0OK,\u00a0Abolhassani\u00a0H,\u00a0Rezaei\u00a0N,\u00a0Fang\u00a0M,\u00a0Andersen\u00a0KK, \u00a0Chavoshzadeh\u00a0Z\u00a0 et\u00a0al.\u00a0Spectrum\u00a0of\u00a0Phenotypes\u00a0\nAssociated\u00a0with\u00a0Mutations\u00a0in\u00a0LRBA.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02016;\u00a036:\u00a033\u201345.\u00a0\n536\u00a0\u00a0 Revel\u2010Vilk\u00a0 S,\u00a0 Fischer\u00a0 U,\u00a0 Keller\u00a0 B,\u00a0 Nabhani\u00a0 S,\u00a0 Gamez\u2010Diaz\u00a0 L ,\u00a0 Rensing\u2010Ehl\u00a0 A\u00a0 et\u00a0 al.\u00a0 Autoimmune\u00a0\nlymphoproliferative\u00a0syndrome\u2010like\u00a0disease\u00a0in\u00a0patients\u00a0with\u00a0LRBA \u00a0mutation.\u00a0 Clin\u00a0Immunol \u00a02015;\u00a0159:\u00a084\u201392.\u00a0\n537\u00a0\u00a0 Lo\u00a0B,\u00a0Zhang\u00a0K,\u00a0Lu\u00a0W,\u00a0Zheng\u00a0L,\u00a0Zhang\u00a0Q,\u00a0Kanellopoulou\u00a0C\u00a0 et\u00a0al.\u00a0AUTOIMMUNE\u00a0DISEASE.\u00a0Patients\u00a0with\u00a0LRBA\u00a0\ndeficiency\u00a0show\u00a0CTLA4\u00a0loss\u00a0and\u00a0immune\u00a0dysregulation\u00a0responsive\u00a0 to\u00a0abatacept\u00a0therapy.\u00a0 Science\u00a02015;\u00a0349:\u00a0\n436\u201340.\u00a0\n538\u00a0\u00a0 Schreiner\u00a0F,\u00a0Plamper\u00a0M,\u00a0Due ker\u00a0G,\u00a0Schoenberger\u00a0S,\u00a0Gamez\u2010Di az\u00a0L,\u00a0Grimbacher\u00a0B\u00a0 et\u00a0al.\u00a0Infancy\u2010Onset\u00a0T1DM,\u00a0\nShort\u00a0Stature,\u00a0and\u00a0Severe\u00a0Immunod ysregulation\u00a0in\u00a0Two\u00a0Siblings\u00a0W ith\u00a0a\u00a0Homozygous\u00a0LRBA\u00a0Mutation.\u00a0 J\u00a0Clin\u00a0\nEndocrinol\u00a0Metab \u00a02016;\u00a0101:\u00a0898\u2013904.\u00a0\n539\u00a0\u00a0 Chou\u00a0J,\u00a0Massaad\u00a0MJ,\u00a0Cangemi\u00a0B,\u00a0Bainter\u00a0W,\u00a0Platt\u00a0C,\u00a0Badran\u00a0 YR\u00a0et\u00a0al.\u00a0A\u00a0novel\u00a0mutation\u00a0in\u00a0ICOS\u00a0presenting\u00a0as\u00a0\nhypogammaglobulinemia\u00a0with\u00a0susc eptibility\u00a0\u00a0to\u00a0opportunistic\u00a0pat hogens.\u00a0J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02015;\u00a0136:\u00a0\n794\u2013797.e1.\u00a0\n540\u00a0\u00a0 Robertson\u00a0N,\u00a0Engelhardt\u00a0KR,\u00a0M organ\u00a0N\u00a0V,\u00a0Barge\u00a0D,\u00a0Cant\u00a0AJ,\u00a0 Hughes\u00a0SM\u00a0 et\u00a0al.\u00a0Astute\u00a0Clinician\u00a0Report:\u00a0A\u00a0Novel\u00a0\n10\u00a0bp\u00a0Frameshift\u00a0Deletion\u00a0in\u00a0Exon\u00a0 2\u00a0of\u00a0ICOS\u00a0Causes\u00a0a\u00a0Combined\u00a0I mmunodeficiency\u00a0Associated\u00a0with\u00a0an\u00a0\nEnteritis\u00a0and\u00a0Hepatitis.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02015;\u00a035:\u00a0598\u2013603.\u00a0\n541\u00a0\u00a0 Takahashi\u00a0N,\u00a0Matsumoto\u00a0K,\u00a0Saito\u00a0H,\u00a0Nanki\u00a0T,\u00a0Miyasaka\u00a0N,\u00a0Ko bata\u00a0T\u00a0et\u00a0al.\u00a0Impaired\u00a0CD4\u00a0and\u00a0CD8\u00a0effector\u00a0\nfunction\u00a0and\u00a0decreased\u00a0memory\u00a0T\u00a0c ell\u00a0populations\u00a0in\u00a0ICOS\u2010defici ent\u00a0patients.\u00a0 J\u00a0Immunol \u00a02009;\u00a0182:\u00a05515\u2013\n5527.\u00a0\n542\u00a0\u00a0 Salzer\u00a0U,\u00a0Maul\u2010Pavicic\u00a0A,\u00a0C unningham\u2010Rundles\u00a0C,\u00a0Urschel\u00a0S, \u00a0Belohradsky\u00a0BH,\u00a0Litzman\u00a0J\u00a0 et\u00a0al.\u00a0ICOS\u00a0deficiency\u00a0\nin\u00a0patients\u00a0with\u00a0common\u00a0va riable\u00a0immunodeficiency.\u00a0 Clin\u00a0Immunol \u00a02004;\u00a0113:\u00a0234\u2013240.\u00a0\n543\u00a0\u00a0 Schepp\u00a0J,\u00a0Chou\u00a0J,\u00a0Skrabl\u2010Baum gartner\u00a0A,\u00a0Arkwright\u00a0PD,\u00a0Enge lhardt\u00a0KR,\u00a0Hambleton\u00a0S\u00a0 et\u00a0al.\u00a014\u00a0Years\u00a0after\u00a0\nDiscovery:\u00a0Clinical\u00a0Follow\u2010up\u00a0on\u00a015\u00a0Patients\u00a0with\u00a0Inducible\u00a0Co\u2010 Stimulator\u00a0Deficiency.\u00a0 Front\u00a0Immunol \u00a02017;\u00a08:\u00a0\n964.\u00a0Referencias bibliogr\u00e1ficas \u00a0\n\u2010\u00a0255\u00a0\u2010\u00a0\n\u00a0544\u00a0\u00a0 van\u00a0Montfrans\u00a0JM,\u00a0Hoepelman\u00a0AIM,\u00a0Otto\u00a0S,\u00a0van\u00a0Gijn\u00a0M,\u00a0van\u00a0d e\u00a0Corput\u00a0L,\u00a0de\u00a0Weger\u00a0RA\u00a0 et\u00a0al.\u00a0CD27\u00a0deficiency\u00a0\nis\u00a0associated\u00a0with\u00a0combined\u00a0immunodeficiency\u00a0and\u00a0persistent\u00a0sym ptomatic\u00a0EBV\u00a0viremia.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0\nImmunol\u00a02012;\u00a0129:\u00a0787\u2013793.e6.\u00a0\n545\u00a0\u00a0 Alkhairy\u00a0OK,\u00a0Perez\u2010Becker\u00a0R,\u00a0Driessen\u00a0GJ,\u00a0Abolhassani\u00a0H,\u00a0v an\u00a0Montfrans\u00a0J,\u00a0Borte\u00a0S\u00a0 et\u00a0al.\u00a0Novel\u00a0mutations\u00a0in\u00a0\nTNFRSF7/CD27:\u00a0Clinical,\u00a0immunologic,\u00a0and\u00a0genetic\u00a0characterizati on\u00a0of\u00a0human\u00a0CD27\u00a0deficiency.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0\nImmunol\u00a02015;\u00a0136:\u00a0703\u2013712.e10.\u00a0\n546\u00a0\u00a0 Salzer\u00a0E,\u00a0Daschkey\u00a0S,\u00a0Choo\u00a0S,\u00a0Gombert\u00a0M,\u00a0Santos\u2010Valente\u00a0E, \u00a0Ginzel\u00a0S\u00a0et\u00a0al.\u00a0Combined\u00a0immunodeficiency\u00a0with\u00a0\nlife\u2010threatening\u00a0 EBV\u2010associated\u00a0 lymphoproliferative\u00a0 disorder\u00a0 in \u00a0 patients\u00a0 lacking\u00a0 functional\u00a0 CD27.\u00a0\nHaematologica \u00a02013;\u00a098:\u00a0473\u2013478.\u00a0\n547\u00a0\u00a0 Kotlarz\u00a0D,\u00a0Zietara\u00a0N,\u00a0Milne r\u00a0JD,\u00a0Klein\u00a0C.\u00a0Human\u00a0IL\u201021\u00a0and\u00a0 IL\u201021R\u00a0deficiencies:\u00a0two\u00a0novel\u00a0entities\u00a0of\u00a0primary\u00a0\nimmunodeficiency.\u00a0 Curr\u00a0Opin\u00a0Pediatr \u00a02014;\u00a026:\u00a0704\u2013712.\u00a0\n548\u00a0\u00a0 Kotlarz\u00a0D,\u00a0Zietara\u00a0N,\u00a0Uzel\u00a0G,\u00a0Weidemann\u00a0T,\u00a0Braun\u00a0CJ,\u00a0Diest elhorst\u00a0J\u00a0et\u00a0al.\u00a0Loss\u2010of\u2010function\u00a0mutations\u00a0in\u00a0the\u00a0\nIL\u201021\u00a0receptor\u00a0gene\u00a0cause\u00a0a\u00a0prim ary\u00a0immunodeficiency\u00a0syndrome.\u00a0 J\u00a0Exp\u00a0Med \u00a02013;\u00a0210:\u00a0433\u2013443.\u00a0\n549\u00a0\u00a0 Stepensky\u00a0 P,\u00a0 Keller\u00a0 B,\u00a0 Abuzaitoun\u00a0 O,\u00a0 Shaag\u00a0 A,\u00a0 Yaacov\u00a0 B,\u00a0 Un ger\u00a0 S\u00a0et\u00a0 al.\u00a0 Extending\u00a0 the\u00a0 clinical\u00a0 and\u00a0\nimmunological\u00a0phenotype\u00a0of\u00a0human \u00a0interleukin\u201021\u00a0receptor\u00a0defici ency.\u00a0Haematologica \u00a02015;\u00a0100:\u00a0e72\u201076.\u00a0\n550\u00a0\u00a0 Erman\u00a0B,\u00a0Bilic\u00a0I,\u00a0Hirschmugl \u00a0T,\u00a0Salzer\u00a0E,\u00a0Cagdas\u00a0D,\u00a0Esenbo ga\u00a0S\u00a0et\u00a0al.\u00a0Combined\u00a0immunodeficiency\u00a0with\u00a0CD4\u00a0\nlymphopenia\u00a0 and\u00a0 sclerosing\u00a0 cholangitis\u00a0 caused\u00a0 by\u00a0 a\u00a0 novel\u00a0 loss\u2010o f\u2010function\u00a0 mutation\u00a0 affecting\u00a0 IL21R.\u00a0\nHaematologica.\u00a02015;\u00a0 100:\u00a0e216\u2010219.\u00a0\n551\u00a0\u00a0 Salzer\u00a0E,\u00a0Kansu\u00a0A,\u00a0Sic\u00a0H,\u00a0Majek\u00a0P,\u00a0Ikinciogullari\u00a0A,\u00a0Dogu\u00a0 FE\u00a0et\u00a0al.\u00a0Early\u2010onset\u00a0inflammatory\u00a0bowel\u00a0disease\u00a0and\u00a0\ncommon\u00a0variable\u00a0immunodeficiency\u2010like\u00a0disease\u00a0caused\u00a0by\u00a0IL\u201021\u00a0d eficiency.\u00a0 J\u00a0Allergy\u00a0Clin\u00a0Immunol \u00a02014;\u00a0\n133:\u00a01651\u20131659.e12.\u00a0\n552\u00a0\u00a0 Milner\u00a0JD,\u00a0Vogel\u00a0TP,\u00a0Forbes\u00a0 L,\u00a0Ma\u00a0CA,\u00a0Stray\u2010Pedersen\u00a0A,\u00a0Ni emela\u00a0JE\u00a0 et\u00a0al.\u00a0Early\u2010onset\u00a0lymphoproliferation\u00a0\nand\u00a0autoimmunity\u00a0caused\u00a0by\u00a0germline\u00a0STAT3\u00a0gain\u2010of\u2010function\u00a0muta tions.\u00a0Blood\u00a02015;\u00a0125:\u00a0591\u2013599.\u00a0\n553\u00a0\u00a0 Haapaniemi\u00a0EM,\u00a0Kaustio\u00a0M,\u00a0Rajala\u00a0HLM,\u00a0van\u00a0Adrichem\u00a0AJ,\u00a0Kai nulainen\u00a0L,\u00a0Glumoff\u00a0V\u00a0 et\u00a0al.\u00a0Autoimmunity,\u00a0\nhypogammaglobulinemia,\u00a0 lymphoproliferation,\u00a0 and\u00a0 mycobacterial\u00a0 d isease\u00a0 in\u00a0 patients\u00a0 with\u00a0 activating\u00a0\nmutations\u00a0in\u00a0STAT3.\u00a0 Blood\u00a02015;\u00a0125:\u00a0639\u2013648.\u00a0\n554\u00a0\u00a0 Russell\u00a0MA,\u00a0Pigors\u00a0M,\u00a0Houssen\u00a0ME,\u00a0Manson\u00a0A,\u00a0Kelsell\u00a0D,\u00a0Lon ghurst\u00a0H\u00a0 et\u00a0al.\u00a0A\u00a0novel\u00a0de\u00a0novo\u00a0activating\u00a0\nmutation\u00a0in\u00a0STAT3\u00a0identified\u00a0in\u00a0a\u00a0patient\u00a0with\u00a0common\u00a0\u00a0variable \u00a0immunodeficiency\u00a0(CVID).\u00a0 Clin\u00a0Immunol \u00a0\n2018;\u00a0187:\u00a0132\u2013136.\u00a0\n555\u00a0\u00a0 Buchbinder\u00a0D,\u00a0Baker\u00a0R,\u00a0Lee\u00a0YN,\u00a0Ravell\u00a0J,\u00a0Zhang\u00a0Y,\u00a0McElwee\u00a0 J\u00a0et\u00a0al.\u00a0Identification\u00a0of\u00a0patients\u00a0with\u00a0RAG\u00a0\nmutations\u00a0previously\u00a0diagnosed\u00a0with\u00a0common\u00a0variable\u00a0immunodefic iency\u00a0disorders.\u00a0 J\u00a0Clin\u00a0Immunol \u00a02015;\u00a0\n35:\u00a0119\u2013124.\u00a0\n\u00a0", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}